(lp0
(dp1
S'line'
p2
S'Using cDNA microarrays and quantitative real-time PCR, we previously discovered that NOR1 increases the expression of growth factor receptor-bound protein 2 (Grb2) mRNA by 4.8-fold in the human hepatocellular carcinoma cell line HepG2.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I158
sS'uniprot'
p8
VP62993
p9
sS'lengthInChars'
p10
I4
sS'name'
p11
VGrb2
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I85
sg8
S''
p15
sg10
I4
sg11
VNOR1
p16
sg13
I1
sa(dp17
g7
I118
sg8
VP62993
p18
sg10
I38
sg11
Vgrowth factor receptor-bound protein 2
p19
sg13
I5
sasS'diseases'
p20
(lp21
(dp22
g7
I194
sS'cui'
p23
VC1512411
p24
sg10
I24
sg11
Vhepatocellular carcinoma
p25
sg13
I2
sasa(dp26
g2
S'In addition, expression of human NOR1 protein in different normal and cancerous human tissues was analyzed via search of the human RNA and protein databases; the data showed that although most malignant cells weakly stained or were negative for NOR1 expression, the liver cancer cells displayed moderate to strong expression of NOR1.\n'
p27
sg4
(lp28
(dp29
g7
I33
sg8
g15
sg10
I4
sg11
VNOR1
p30
sg13
I1
sa(dp31
g7
I27
sg8
g15
sg10
I18
sg11
Vhuman NOR1 protein
p32
sg13
I3
sa(dp33
g7
I33
sg8
g15
sg10
I4
sg11
VNOR1
p34
sg13
I1
sasg20
(lp35
(dp36
g7
I266
sg23
VC0345904
p37
sg10
I12
sg11
Vliver cancer
p38
sg13
I2
sasa(dp39
g2
S'These data suggested that NOR1 might serve as a cancer/testis/brain antigen in cells, and that altered NOR1 expression in liver cancer may help us to elucidate the functions of NOR1 protein in liver carcinogenesis.\n'
p40
sg4
(lp41
(dp42
g7
I26
sg8
g15
sg10
I4
sg11
VNOR1
p43
sg13
I1
sa(dp44
g7
I26
sg8
g15
sg10
I4
sg11
VNOR1
p45
sg13
I1
sa(dp46
g7
I177
sg8
g15
sg10
I12
sg11
VNOR1 protein
p47
sg13
I2
sasg20
(lp48
(dp49
g7
I48
sg23
VC0006826
p50
sg10
I6
sg11
Vcancer
p51
sg13
I1
sa(dp52
g7
I122
sg23
VC0345904
p53
sg10
I12
sg11
Vliver cancer
p54
sg13
I2
sa(dp55
g7
I193
sg23
VC1512409
p56
sg10
I20
sg11
Vliver carcinogenesis
p57
sg13
I2
sasa(dp58
g2
S'Significant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta) = 6.6x10(-8), OR = 1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta) = 2.9x10(-7), OR = 1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E.\n'
p59
sg4
(lp60
(dp61
g7
I152
sg8
g15
sg10
I7
sg11
VCFH SNP
p62
sg13
I2
sa(dp63
g7
I249
sg8
g15
sg10
I5
sg11
VCFHR1
p64
sg13
I1
sa(dp65
g7
I259
sg8
g15
sg10
I5
sg11
VCFHR4
p66
sg13
I1
sasg20
(lp67
(dp68
g7
I38
sg23
VC0014060
p69
sg10
I3
sg11
VSLE
p70
sg13
I1
sasa(dp71
g2
S'Gastroschisis and omphalocele are the most common fetal abdominal wall defects (AWDs).\n'
p72
sg4
(lp73
sg20
(lp74
(dp75
g7
I0
sg23
VC0265706
p76
sg10
I13
sg11
VGastroschisis
p77
sg13
I1
sa(dp78
g7
I18
sg23
VC0795690
p79
sg10
I11
sg11
Vomphalocele
p80
sg13
I1
sasa(dp81
g2
S'AWDs were identified through gastroschisis and omphalocele checkboxes from publicly available US Natality data (2006 to 2010).\n'
p82
sg4
(lp83
sg20
(lp84
(dp85
g7
I47
sg23
VC0795690
p86
sg10
I11
sg11
Vomphalocele
p87
sg13
I1
sa(dp88
g7
I29
sg23
VC0265706
p89
sg10
I13
sg11
Vgastroschisis
p90
sg13
I1
sasa(dp91
g2
S'The angiogenic proteins vascular endothelial growth factor (VEGF) and prokineticin1 (PROK1) proteins are considered important in colorectal cancer, the relationship between their simultaneous expression and prognosis was investigated in the present study.\n'
p92
sg4
(lp93
(dp94
g7
I60
sg8
g15
sg10
I4
sg11
VVEGF
p95
sg13
I1
sa(dp96
g7
I24
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p97
sg13
I4
sa(dp98
g7
I70
sg8
VP58294
p99
sg10
I30
sg11
Vprokineticin1 (PROK1) proteins
p100
sg13
I3
sasg20
(lp101
(dp102
g7
I129
sg23
VC1527249
p103
sg10
I17
sg11
Vcolorectal cancer
p104
sg13
I2
sasa(dp105
g2
S'VEGF and PROK1 expression in 620 primary human colorectal cancer lesions was confirmed via immunohistochemical staining with anti-VEGF and anti-PROK1 antibodies, and the correlation between the expression of these 2 proteins and recurrence/prognosis were investigated.\n'
p106
sg4
(lp107
(dp108
g7
I139
sg8
VP58294
p109
sg10
I21
sg11
Vanti-PROK1 antibodies
p110
sg13
I2
sa(dp111
g7
I9
sg8
VP58294
p112
sg10
I5
sg11
VPROK1
p113
sg13
I1
sasg20
(lp114
(dp115
g7
I229
sg23
VC1458156
p116
sg10
I10
sg11
Vrecurrence
p117
sg13
I1
sa(dp118
g7
I47
sg23
VC1527249
p119
sg10
I17
sg11
Vcolorectal cancer
p120
sg13
I2
sasa(dp121
g2
S'The prognosis was poorer in colorectal cancers that expressed both PROK1 and VEGF relative to the cases that expressed only 1 protein, and the expression of both proteins was found to be an independent prognostic factor.\n'
p122
sg4
(lp123
(dp124
g7
I67
sg8
VP58294
p125
sg10
I5
sg11
VPROK1
p126
sg13
I1
sasg20
(lp127
(dp128
g7
I28
sg23
VC1527249
p129
sg10
I18
sg11
Vcolorectal cancers
p130
sg13
I2
sasa(dp131
g2
S'Two angiogenic growth factors, in particular, Vascular endothelial growth factor (VEGF) and Prokineticin1(PROK1), are considered to have an important role in hematogenous metastasis of colorectal cancer.\n'
p132
sg4
(lp133
(dp134
g7
I4
sg8
VP19883
p135
sg10
I25
sg11
Vangiogenic growth factors
p136
sg13
I3
sa(dp137
g7
I82
sg8
g15
sg10
I4
sg11
VVEGF
p138
sg13
I1
sa(dp139
g7
I46
sg8
g15
sg10
I34
sg11
VVascular endothelial growth factor
p140
sg13
I4
sa(dp141
g7
I106
sg8
VP58294
p142
sg10
I5
sg11
VPROK1
p143
sg13
I1
sasg20
(lp144
(dp145
g7
I185
sg23
VC1527249
p146
sg10
I17
sg11
Vcolorectal cancer
p147
sg13
I2
sa(dp148
g7
I171
sg23
VC0027627
p149
sg10
I10
sg11
Vmetastasis
p150
sg13
I1
sasa(dp151
g2
S'Accordingly, we report our findings on the importance of the anti-tumor efffect by inhibiting these two factors in human colorectal cancer.When the culture fluid of Colorectal cancer cell lines(DLD-1, HCT116, and LoVo) with high levels of VEGF/PROK1 expression was injected subcutaneously into mice, the culture fluid increased subcutaneous angiogenesis.\n'
p152
sg4
(lp153
(dp154
g7
I194
sg8
VP98173
p155
sg10
I5
sg11
VDLD-1
p156
sg13
I1
sa(dp157
g7
I244
sg8
VP58294
p158
sg10
I5
sg11
VPROK1
p159
sg13
I1
sasg20
(lp160
(dp161
g7
I66
sg23
VC0027651
p162
sg10
I5
sg11
Vtumor
p163
sg13
I1
sa(dp164
g7
I165
sg23
VC1527249
p165
sg10
I17
sg11
VColorectal cancer
p166
sg13
I2
sa(dp167
g7
I121
sg23
VC1527249
p168
sg10
I17
sg11
Vcolorectal cancer
p169
sg13
I2
sasa(dp170
g2
S'Also, tumor masses were produced in mice by subcutaneously embedding colorectal cancer cells with high levels VEGF/PROK1 expression.\n'
p171
sg4
(lp172
(dp173
g7
I115
sg8
VP58294
p174
sg10
I5
sg11
VPROK1
p175
sg13
I1
sasg20
(lp176
(dp177
g7
I6
sg23
VC0027651
p178
sg10
I5
sg11
Vtumor
p179
sg13
I1
sa(dp180
g7
I69
sg23
VC1527249
p181
sg10
I17
sg11
Vcolorectal cancer
p182
sg13
I2
sasa(dp183
g2
S'When both anti-PROK1 and anti-VEGF antibodies were simultaneously applied, tumor formation and peritumoral angiogenesis were strongly suppressed, compared with when either anti-PROK1 antibody or anti-VEGF antibody was applied alone.Simultaneous targeting of both angiogenic growth factors (VEGF/PROK1) may prove more useful in colorectal cancer.\n'
p184
sg4
(lp185
(dp186
g7
I15
sg8
VP58294
p187
sg10
I5
sg11
VPROK1
p188
sg13
I1
sa(dp189
g7
I172
sg8
VP58294
p190
sg10
I19
sg11
Vanti-PROK1 antibody
p191
sg13
I2
sa(dp192
g7
I10
sg8
VP58294
p193
sg10
I10
sg11
Vanti-PROK1
p194
sg13
I1
sa(dp195
g7
I263
sg8
VP19883
p196
sg10
I25
sg11
Vangiogenic growth factors
p197
sg13
I3
sasg20
(lp198
(dp199
g7
I327
sg23
VC1527249
p200
sg10
I17
sg11
Vcolorectal cancer
p201
sg13
I2
sa(dp202
g7
I75
sg23
VC0027651
p203
sg10
I5
sg11
Vtumor
p204
sg13
I1
sasa(dp205
g2
S'The current study established the anti-PROK1 monoclonal antibody (mAb) and examined the relationship between the expression of PROK1 protein and human colorectal cancer.\n'
p206
sg4
(lp207
(dp208
g7
I34
sg8
VP58294
p209
sg10
I30
sg11
Vanti-PROK1 monoclonal antibody
p210
sg13
I3
sa(dp211
g7
I127
sg8
VP58294
p212
sg10
I13
sg11
VPROK1 protein
p213
sg13
I2
sasg20
(lp214
(dp215
g7
I151
sg23
VC1527249
p216
sg10
I17
sg11
Vcolorectal cancer
p217
sg13
I2
sasa(dp218
g2
S'The expression of PROK1 protein was assessed in 620 resected sporadic colorectal cancer tissue samples by immunohistochemical staining with in-house-developed human PROK1 mAb to investigate the relationship of PROK1 expression to clinicopathologic factors, recurrence, and survival rate and to evaluate its prognostic significance.\n'
p219
sg4
(lp220
(dp221
g7
I18
sg8
VP58294
p222
sg10
I13
sg11
VPROK1 protein
p223
sg13
I2
sa(dp224
g7
I18
sg8
VP58294
p225
sg10
I5
sg11
VPROK1
p226
sg13
I1
sa(dp227
g7
I159
sg8
VP58294
p228
sg10
I15
sg11
Vhuman PROK1 mAb
p229
sg13
I3
sasg20
(lp230
(dp231
g7
I70
sg23
VC1527249
p232
sg10
I17
sg11
Vcolorectal cancer
p233
sg13
I2
sa(dp234
g7
I257
sg23
VC1458156
p235
sg10
I10
sg11
Vrecurrence
p236
sg13
I1
sasa(dp237
g2
S'The expression of PROK1 protein was detected in 36 % (223/620) of human primary colorectal cancer lesions but no in the healthy mucosa adjacent to the colorectal cancer lesions.\n'
p238
sg4
(lp239
(dp240
g7
I18
sg8
VP58294
p241
sg10
I13
sg11
VPROK1 protein
p242
sg13
I2
sasg20
(lp243
(dp244
g7
I80
sg23
VC1527249
p245
sg10
I17
sg11
Vcolorectal cancer
p246
sg13
I2
sa(dp247
g7
I80
sg23
VC1527249
p248
sg10
I17
sg11
Vcolorectal cancer
p249
sg13
I2
sasa(dp250
g2
S'The expression of PROK1 protein was identified for the first time as a new prognostic factor in colorectal cancer.\n'
p251
sg4
(lp252
(dp253
g7
I18
sg8
VP58294
p254
sg10
I13
sg11
VPROK1 protein
p255
sg13
I2
sasg20
(lp256
(dp257
g7
I96
sg23
VC1527249
p258
sg10
I17
sg11
Vcolorectal cancer
p259
sg13
I2
sasa(dp260
g2
S'Here we investigated how the anti-PROK1 monoclonal antibody (mAb; established by our department) would affect the high-PROK1-expressing colorectal cancer (CRC) cells in vitro and vivo.\n'
p261
sg4
(lp262
(dp263
g7
I29
sg8
VP58294
p264
sg10
I30
sg11
Vanti-PROK1 monoclonal antibody
p265
sg13
I3
sa(dp266
g7
I34
sg8
VP58294
p267
sg10
I5
sg11
VPROK1
p268
sg13
I1
sasg20
(lp269
(dp270
g7
I155
sg23
VC1527249
p271
sg10
I3
sg11
VCRC
p272
sg13
I1
sa(dp273
g7
I136
sg23
VC1527249
p274
sg10
I17
sg11
Vcolorectal cancer
p275
sg13
I2
sasa(dp276
g2
S'PROK1 expression was not observed in healthy gastrointestinal mucosa, but was observed in the primary lesions in 23 out of 98 (31.6%) patients with colorectal cancer, 19 out of 55 (34.5%) patients with gastric cancer, and 5 of 10 (50%) patients with cancer of the small intestine.\n'
p277
sg4
(lp278
(dp279
g7
I0
sg8
VP58294
p280
sg10
I5
sg11
VPROK1
p281
sg13
I1
sasg20
(lp282
(dp283
g7
I148
sg23
VC1527249
p284
sg10
I17
sg11
Vcolorectal cancer
p285
sg13
I2
sa(dp286
g7
I202
sg23
VC0024623
p287
sg10
I14
sg11
Vgastric cancer
p288
sg13
I2
sa(dp289
g7
I159
sg23
VC0006826
p290
sg10
I6
sg11
Vcancer
p291
sg13
I1
sasa(dp292
g2
S'Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) has             recently been identified as one of the vascular endothelial growth factors, and             it is considered that the overexpression of EG-VEGF in colon cancer is related             to hepatic metastasis.\n'
p293
sg4
(lp294
(dp295
g7
I60
sg8
VP58294
p296
sg10
I7
sg11
VEG-VEGF
p297
sg13
I1
sa(dp298
g7
I124
sg8
VP19883
p299
sg10
I35
sg11
Vvascular endothelial growth factors
p300
sg13
I4
sa(dp301
g7
I0
sg8
VP58294
p302
sg10
I58
sg11
VEndocrine gland-derived vascular endothelial growth factor
p303
sg13
I6
sa(dp304
g7
I60
sg8
VP58294
p305
sg10
I7
sg11
VEG-VEGF
p306
sg13
I1
sasg20
(lp307
(dp308
g7
I271
sg23
VC0494165
p309
sg10
I18
sg11
Vhepatic metastasis
p310
sg13
I2
sa(dp311
g7
I232
sg23
VC0699790
p312
sg10
I12
sg11
Vcolon cancer
p313
sg13
I2
sasa(dp314
g2
S'In this study, we report our recent novel findings of the             involvement of EG-VEGF in cell invasion of colon cancer cells.\n'
p315
sg4
(lp316
(dp317
g7
I85
sg8
VP58294
p318
sg10
I7
sg11
VEG-VEGF
p319
sg13
I1
sasg20
(lp320
(dp321
g7
I113
sg23
VC0699790
p322
sg10
I12
sg11
Vcolon cancer
p323
sg13
I2
sa(dp324
g7
I96
sg23
VC2699153
p325
sg10
I13
sg11
Vcell invasion
p326
sg13
I2
sasa(dp327
g2
S'Finally, the EG-VEGF receptor on the colon cancer cell membrane             was blocked by anti-PK-R1 and -PK-R2 antibodies to study whether cell invasion             ability would be altered.\n'
p328
sg4
(lp329
(dp330
g7
I13
sg8
VP58294
p331
sg10
I16
sg11
VEG-VEGF receptor
p332
sg13
I2
sa(dp333
g7
I91
sg8
g15
sg10
I32
sg11
Vanti-PK-R1 and -PK-R2 antibodies
p334
sg13
I4
sasg20
(lp335
(dp336
g7
I141
sg23
VC2699153
p337
sg10
I13
sg11
Vcell invasion
p338
sg13
I2
sa(dp339
g7
I37
sg23
VC0699790
p340
sg10
I12
sg11
Vcolon cancer
p341
sg13
I2
sasa(dp342
g2
S'In colon cancer cell lines where the expression of PK-R1             and 2 was confirmed, stimulation with EG-VEGF increased cell invasion a maximum             of ~3-5 times.\n'
p343
sg4
(lp344
(dp345
g7
I107
sg8
VP58294
p346
sg10
I7
sg11
VEG-VEGF
p347
sg13
I1
sasg20
(lp348
(dp349
g7
I3
sg23
VC0699790
p350
sg10
I12
sg11
Vcolon cancer
p351
sg13
I2
sa(dp352
g7
I125
sg23
VC2699153
p353
sg10
I13
sg11
Vcell invasion
p354
sg13
I2
sasa(dp355
g2
S'The study showed that the EG-VEGF             protein may act on MMP-2, -7 and -9 via PK-R2 to strengthen cell invasion ability             in colon cancer cell lines.\n'
p356
sg4
(lp357
(dp358
g7
I26
sg8
VP58294
p359
sg10
I7
sg11
VEG-VEGF
p360
sg13
I1
sa(dp361
g7
I65
sg8
VP08253
p362
sg10
I9
sg11
VMMP-2, -7
p363
sg13
I2
sasg20
(lp364
(dp365
g7
I143
sg23
VC0699790
p366
sg10
I12
sg11
Vcolon cancer
p367
sg13
I2
sa(dp368
g7
I106
sg23
VC2699153
p369
sg10
I13
sg11
Vcell invasion
p370
sg13
I2
sasa(dp371
g2
S'To study the implication of prokineticin 1 (PK1/EG-VEGF) and prokineticin 2 (PK2/Bv8) in hepatocellular carcinoma angiogenesis.\n'
p372
sg4
(lp373
(dp374
g7
I28
sg8
VP58294
p375
sg10
I14
sg11
Vprokineticin 1
p376
sg13
I2
sa(dp377
g7
I77
sg8
g15
sg10
I3
sg11
VPK2
p378
sg13
I1
sa(dp379
g7
I81
sg8
g15
sg10
I3
sg11
VBv8
p380
sg13
I1
sa(dp381
g7
I61
sg8
g15
sg10
I14
sg11
Vprokineticin 2
p382
sg13
I2
sa(dp383
g7
I44
sg8
VP58294
p384
sg10
I3
sg11
VPK1
p385
sg13
I1
sa(dp386
g7
I48
sg8
VP58294
p387
sg10
I7
sg11
VEG-VEGF
p388
sg13
I1
sasg20
(lp389
(dp390
g7
I89
sg23
VC1512411
p391
sg10
I24
sg11
Vhepatocellular carcinoma
p392
sg13
I2
sasa(dp393
g2
S'In this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants.\n'
p394
sg4
(lp395
(dp396
g7
I49
sg8
VP58294
p397
sg10
I7
sg11
VEG-VEGF
p398
sg13
I1
sa(dp399
g7
I49
sg8
VP58294
p400
sg10
I7
sg11
VEG-VEGF
p401
sg13
I1
sasg20
(lp402
(dp403
g7
I60
sg23
VC1527249
p404
sg10
I17
sg11
Vcolorectal cancer
p405
sg13
I2
sasa(dp406
g2
S'We determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses.\n'
p407
sg4
(lp408
(dp409
g7
I35
sg8
VP58294
p410
sg10
I7
sg11
VEG-VEGF
p411
sg13
I1
sasg20
(lp412
(dp413
g7
I59
sg23
VC1527249
p414
sg10
I18
sg11
Vcolorectal cancers
p415
sg13
I2
sasa(dp416
g2
S'We speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor.\n'
p417
sg4
(lp418
(dp419
g7
I46
sg8
VP58294
p420
sg10
I12
sg11
VEG-VEGF gene
p421
sg13
I2
sasg20
(lp422
(dp423
g7
I22
sg23
VC1527249
p424
sg10
I18
sg11
Vcolorectal cancers
p425
sg13
I2
sasa(dp426
g2
S'The aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).\n'
p427
sg4
(lp428
(dp429
g7
I128
sg8
g15
sg10
I14
sg11
Vangiopoietin 2
p430
sg13
I2
sa(dp431
g7
I85
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p432
sg13
I4
sa(dp433
g7
I151
sg8
VP52799
p434
sg10
I8
sg11
VephrinB2
p435
sg13
I1
sa(dp436
g7
I224
sg8
VP58294
p437
sg10
I7
sg11
VEG-VEGF
p438
sg13
I1
sa(dp439
g7
I164
sg8
VP58294
p440
sg10
I58
sg11
Vendocrine gland-derived vascular endothelial growth factor
p441
sg13
I6
sa(dp442
g7
I144
sg8
g15
sg10
I4
sg11
VAng2
p443
sg13
I1
sa(dp444
g7
I121
sg8
g15
sg10
I4
sg11
VVEGF
p445
sg13
I1
sasg20
(lp446
(dp447
g7
I334
sg23
VC2239176
p448
sg10
I3
sg11
VHCC
p449
sg13
I1
sa(dp450
g7
I237
sg23
VC0596263
p451
sg10
I14
sg11
Vcarcinogenesis
p452
sg13
I1
sa(dp453
g7
I267
sg23
VC3163918
p454
sg10
I14
sg11
Vtumor thrombus
p455
sg13
I2
sa(dp456
g7
I308
sg23
VC2239176
p457
sg10
I24
sg11
Vhepatocellular carcinoma
p458
sg13
I2
sasa(dp459
g2
S"A recent genome-wide association study (GWA) reported a significant association between single nucleotide polymorphisms (SNPs) at the PCDH11X gene and late-onset Alzheimer's disease (LOAD).\n"
p460
sg4
(lp461
sg20
(lp462
(dp463
g7
I162
sg23
VC1521724
p464
sg10
I19
sg11
VAlzheimer's disease
p465
sg13
I2
sasa(dp466
g2
S"Protocadherin 11X (Pcdh11X) has been suspected to be associated with Alzheimer's disease through participating in the metabolism of PP1Alfa and Beta-catenin or by altering the synaptic functions.\n"
p467
sg4
(lp468
(dp469
g7
I144
sg8
VP35222
p470
sg10
I12
sg11
VBeta-catenin
p471
sg13
I1
sa(dp472
g7
I0
sg8
g15
sg10
I17
sg11
VProtocadherin 11X
p473
sg13
I2
sa(dp474
g7
I19
sg8
g15
sg10
I7
sg11
VPcdh11X
p475
sg13
I1
sasg20
(lp476
(dp477
g7
I69
sg23
VC1521724
p478
sg10
I19
sg11
VAlzheimer's disease
p479
sg13
I2
sasa(dp480
g2
S"A recent genome-wide association study reported that a common single nucleotide polymorphism (SNP, rs5984894) in the gene encoding Pcdh11X was associated with susceptibility to late-onset Alzheimer's disease (LOAD) in Caucasians.\n"
p481
sg4
(lp482
sg20
(lp483
(dp484
g7
I188
sg23
VC1521724
p485
sg10
I19
sg11
VAlzheimer's disease
p486
sg13
I2
sasa(dp487
g2
S"A recent genome-wide study on late-onset Alzheimer's disease identified a SNP (rs5984894) on Xq21.3 in the PCDH11X gene strongly associated with LOAD individuals of European descent from the United States.\n"
p488
sg4
(lp489
sg20
(lp490
(dp491
g7
I41
sg23
VC1521724
p492
sg10
I19
sg11
VAlzheimer's disease
p493
sg13
I2
sasa(dp494
g2
S"By analyzing late-onset Alzheimer's disease (LOAD) in a genome-wide association study (313,504 SNPs, three series, 844 cases and 1,255 controls) and evaluating the 25 SNPs with the most significant allelic association in four additional series (1,547 cases and 1,209 controls), we identified a SNP (rs5984894) on Xq21.3 in PCDH11X that is strongly associated with LOAD in individuals of European descent from the United States.\n"
p495
sg4
(lp496
sg20
(lp497
(dp498
g7
I45
sg23
VC1521724
p499
sg10
I4
sg11
VLOAD
p500
sg13
I1
sa(dp501
g7
I13
sg23
VC1521724
p502
sg10
I30
sg11
Vlate-onset Alzheimer's disease
p503
sg13
I3
sa(dp504
g7
I45
sg23
VC1521724
p505
sg10
I4
sg11
VLOAD
p506
sg13
I1
sasa(dp507
g2
S'In this study, we investigated the effect of Bim-1 siRNA on cell proliferation, cell cycle, cell apoptosis and migration of human esophageal carcinoma EC9706 cells, and explored its potential mechanisms.\n'
p508
sg4
(lp509
sg20
(lp510
(dp511
g7
I65
sg23
VC0334094
p512
sg10
I13
sg11
Vproliferation
p513
sg13
I1
sa(dp514
g7
I130
sg23
VC0152018
p515
sg10
I20
sg11
Vesophageal carcinoma
p516
sg13
I2
sasa(dp517
g2
S'In the present study, 4-mm samples of BIM (n=31) and CIM (n=9) were selected from esophagectomy specimens that had been resected for esophageal cancer.\n'
p518
sg4
(lp519
(dp520
g7
I53
sg8
g15
sg10
I3
sg11
VCIM
p521
sg13
I1
sasg20
(lp522
(dp523
g7
I133
sg23
VC0014859
p524
sg10
I17
sg11
Vesophageal cancer
p525
sg13
I2
sasa(dp526
g2
S'Mechanistically, HCMV upregulated two specific cellular antiapoptotic proteins, myeloid leukemia sequence 1 (Mcl-1) and heat shock protein 27 (HSP27), to block the two proteolytic cleavages necessary for the formation of fully active caspase 3 and the subsequent initiation of apoptosis.\n'
p527
sg4
(lp528
(dp529
g7
I120
sg8
VP34931
p530
sg10
I21
sg11
Vheat shock protein 27
p531
sg13
I4
sa(dp532
g7
I109
sg8
VP07954
p533
sg10
I5
sg11
VMcl-1
p534
sg13
I1
sa(dp535
g7
I234
sg8
VP42574
p536
sg10
I9
sg11
Vcaspase 3
p537
sg13
I2
sa(dp538
g7
I143
sg8
g15
sg10
I5
sg11
VHSP27
p539
sg13
I1
sasg20
(lp540
(dp541
g7
I109
sg23
VC1708350
p542
sg10
I3
sg11
VMcl
p543
sg13
I1
sa(dp544
g7
I80
sg23
VC0023470
p545
sg10
I16
sg11
Vmyeloid leukemia
p546
sg13
I2
sasa(dp547
g2
S'Heat shock protein 27 (HSP27) has been reported to promote the development of leukemia by protecting tumor cells from apoptosis through various mechanisms.\n'
p548
sg4
(lp549
(dp550
g7
I0
sg8
VP34931
p551
sg10
I21
sg11
VHeat shock protein 27
p552
sg13
I4
sa(dp553
g7
I23
sg8
g15
sg10
I5
sg11
VHSP27
p554
sg13
I1
sasg20
(lp555
(dp556
g7
I101
sg23
VC0027651
p557
sg10
I5
sg11
Vtumor
p558
sg13
I1
sa(dp559
g7
I78
sg23
VC0023418
p560
sg10
I8
sg11
Vleukemia
p561
sg13
I1
sasa(dp562
g2
S'The present study investigated the effects of small hairpin (sh)RNA-mediated HSP27 knockdown on the anti-cancer effects of quercetin in U937 human leukemia cells.\n'
p563
sg4
(lp564
(dp565
g7
I77
sg8
g15
sg10
I5
sg11
VHSP27
p566
sg13
I1
sasg20
(lp567
(dp568
g7
I105
sg23
VC0006826
p569
sg10
I6
sg11
Vcancer
p570
sg13
I1
sa(dp571
g7
I147
sg23
VC0023418
p572
sg10
I8
sg11
Vleukemia
p573
sg13
I1
sasa(dp574
g2
S'Therefore, these findings collectively suggested that suppression of HSP27 expression amplified the anti-cancer effects of quercetin in U937 human leukemia cells, and that quercetin in combination with shHSP27 represents a promising therapeutic strategy for human leukemia.\n'
p575
sg4
(lp576
(dp577
g7
I69
sg8
g15
sg10
I5
sg11
VHSP27
p578
sg13
I1
sasg20
(lp579
(dp580
g7
I105
sg23
VC0006826
p581
sg10
I6
sg11
Vcancer
p582
sg13
I1
sa(dp583
g7
I147
sg23
VC0023418
p584
sg10
I8
sg11
Vleukemia
p585
sg13
I1
sa(dp586
g7
I54
sg23
VC0221103
p587
sg10
I11
sg11
Vsuppression
p588
sg13
I1
sa(dp589
g7
I147
sg23
VC0023418
p590
sg10
I8
sg11
Vleukemia
p591
sg13
I1
sasa(dp592
g2
S'Among these proteins, enolase, aldolase, HSP70 and sorcin were up-regulated in doxorubicin-resistant myelogenous leukemia cell line, whereas HSP27 was down-regulated.\n'
p593
sg4
(lp594
(dp595
g7
I22
sg8
VP13929
p596
sg10
I7
sg11
Venolase
p597
sg13
I1
sa(dp598
g7
I31
sg8
VP05062
p599
sg10
I8
sg11
Valdolase
p600
sg13
I1
sa(dp601
g7
I41
sg8
VP34932
p602
sg10
I5
sg11
VHSP70
p603
sg13
I1
sa(dp604
g7
I141
sg8
g15
sg10
I5
sg11
VHSP27
p605
sg13
I1
sa(dp606
g7
I51
sg8
VP30626
p607
sg10
I6
sg11
Vsorcin
p608
sg13
I1
sasg20
(lp609
(dp610
g7
I101
sg23
VC0023470
p611
sg10
I20
sg11
Vmyelogenous leukemia
p612
sg13
I2
sasa(dp613
g2
S'However, the role of Hsp27 in the pathogenesis of pediatric acute             leukemia (AL) remains unknown.\n'
p614
sg4
(lp615
(dp616
g7
I21
sg8
g15
sg10
I5
sg11
VHsp27
p617
sg13
I1
sasg20
(lp618
(dp619
g7
I78
sg23
VC0023418
p620
sg10
I8
sg11
Vleukemia
p621
sg13
I1
sa(dp622
g7
I34
sg23
VC0699748
p623
sg10
I12
sg11
Vpathogenesis
p624
sg13
I1
sasa(dp625
g2
S'In this study, we evaluated the expression levels             of Hsp27 in bone marrow samples from 94 children with newly diagnosed acute lymphoblastic             leukemia (ALL), acute myeloid leukemia (AML) and 5 leukemia cell lines.\n'
p626
sg4
(lp627
(dp628
g7
I65
sg8
g15
sg10
I5
sg11
VHsp27
p629
sg13
I1
sasg20
(lp630
(dp631
g7
I164
sg23
VC0023418
p632
sg10
I8
sg11
Vleukemia
p633
sg13
I1
sa(dp634
g7
I164
sg23
VC0023418
p635
sg10
I8
sg11
Vleukemia
p636
sg13
I1
sa(dp637
g7
I180
sg23
VC0023467
p638
sg10
I22
sg11
Vacute myeloid leukemia
p639
sg13
I3
sa(dp640
g7
I204
sg23
VC0023467
p641
sg10
I3
sg11
VAML
p642
sg13
I1
sasa(dp643
g2
S'Additionally,             we transfected a target-specific siRNA duplex against Hsp27 into leukemia cells,             and examined the chemosensitivity and cell apoptosis in the response to antitumor             drugs.\n'
p644
sg4
(lp645
(dp646
g7
I80
sg8
g15
sg10
I5
sg11
VHsp27
p647
sg13
I1
sasg20
(lp648
(dp649
g7
I91
sg23
VC0023418
p650
sg10
I8
sg11
Vleukemia
p651
sg13
I1
sasa(dp652
g2
S'Hsp27 was abundantly expressed in newly diagnosed AML-M4/M5 bone marrow             mononuclear cells (BMMCs) and THP-1, OCI/AML-3 leukemia cell lines.\n'
p653
sg4
(lp654
(dp655
g7
I50
sg8
VP41212
p656
sg10
I3
sg11
VAML
p657
sg13
I1
sa(dp658
g7
I0
sg8
g15
sg10
I5
sg11
VHsp27
p659
sg13
I1
sasg20
(lp660
(dp661
g7
I131
sg23
VC0023418
p662
sg10
I8
sg11
Vleukemia
p663
sg13
I1
sa(dp664
g7
I50
sg23
VC0023467
p665
sg10
I3
sg11
VAML
p666
sg13
I1
sa(dp667
g7
I50
sg23
VC0023467
p668
sg10
I3
sg11
VAML
p669
sg13
I1
sasa(dp670
g2
S'Knockdown of Hsp27 expression increased the chemosensitivity of             leukemia cells and the anticancer drug-induced apoptosis.\n'
p671
sg4
(lp672
(dp673
g7
I13
sg8
g15
sg10
I5
sg11
VHsp27
p674
sg13
I1
sasg20
(lp675
(dp676
g7
I76
sg23
VC0023418
p677
sg10
I8
sg11
Vleukemia
p678
sg13
I1
sasa(dp679
g2
S'Therefore, Hsp27 may be exploited as a new target for enhancing the             efficacy of chemotherapeutic drugs against leukemia.\n'
p680
sg4
(lp681
(dp682
g7
I11
sg8
g15
sg10
I5
sg11
VHsp27
p683
sg13
I1
sasg20
(lp684
(dp685
g7
I123
sg23
VC0023418
p686
sg10
I8
sg11
Vleukemia
p687
sg13
I1
sasa(dp688
g2
S'It was: xS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M-G-D-N-F-S-K-D-E-V-R-Q-T-W-K-E-A-P-I-A-G-G-K-V-D-Y-N-A-F-V-S-K-I- K- G-K-E-Q-D-D-A.\n'
p689
sg4
(lp690
(dp691
g7
I8
sg8
g15
sg10
I246
sg11
VxS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M
p692
sg13
I7
sasg20
(lp693
sa(dp694
g2
S"Integrin alpha 8 (ITGA8) encodes the alpha 8 subunit of the integrin alpha8beta1 protein and has recently been suggested as a new candidate gene for Parkinson's disease, an age related neurodegenerative disease with unknown etiology.\n"
p695
sg4
(lp696
(dp697
g7
I18
sg8
VP53708
p698
sg10
I5
sg11
VITGA8
p699
sg13
I1
sa(dp700
g7
I0
sg8
VP53708
p701
sg10
I16
sg11
VIntegrin alpha 8
p702
sg13
I3
sasg20
(lp703
(dp704
g7
I149
sg23
VC0030567
p705
sg10
I19
sg11
VParkinson's disease
p706
sg13
I2
sa(dp707
g7
I185
sg23
VC0524851
p708
sg10
I25
sg11
Vneurodegenerative disease
p709
sg13
I2
sasa(dp710
g2
S"Screen a Swedish case control material for rs7077361, a genetic variant in ITGA8, in order to investigate its possible implication in Parkinson's disease in Sweden.\n"
p711
sg4
(lp712
(dp713
g7
I75
sg8
VP53708
p714
sg10
I5
sg11
VITGA8
p715
sg13
I1
sasg20
(lp716
(dp717
g7
I134
sg23
VC0030567
p718
sg10
I19
sg11
VParkinson's disease
p719
sg13
I2
sasa(dp720
g2
S"Our results do not support the hypothesis of ITGA8 as a candidate gene for Parkinson's disease in Sweden.\n"
p721
sg4
(lp722
(dp723
g7
I45
sg8
VP53708
p724
sg10
I5
sg11
VITGA8
p725
sg13
I1
sasg20
(lp726
(dp727
g7
I75
sg23
VC0030567
p728
sg10
I19
sg11
VParkinson's disease
p729
sg13
I2
sasa(dp730
g2
S'CYFIP1 maps to the interval between proximal breakpoint 1 (BP1) and breakpoint 2 (BP2) of chromosomal 15q11-q13 deletions that are implicated in the Angelman (AS) and Prader-Willi syndrome (PWS).\n'
p731
sg4
(lp732
(dp733
g7
I82
sg8
VP18065
p734
sg10
I3
sg11
VBP2
p735
sg13
I1
sa(dp736
g7
I45
sg8
g15
sg10
I35
sg11
Vbreakpoint 1 (BP1) and breakpoint 2
p737
sg13
I6
sa(dp738
g7
I0
sg8
g15
sg10
I6
sg11
VCYFIP1
p739
sg13
I1
sasg20
(lp740
(dp741
g7
I167
sg23
VC0032897
p742
sg10
I21
sg11
VPrader-Willi syndrome
p743
sg13
I2
sa(dp744
g7
I190
sg23
VC0032897
p745
sg10
I3
sg11
VPWS
p746
sg13
I1
sasa(dp747
g2
S"We found copy number variants in PDE10A (phosphodiesterase 10A), CYFIP1 [cytoplasmic FMR1 (Fragile X mental retardation 1)-interacting protein 1], K(+) channel genes KCNE1 and KCNE2, the Down's syndrome critical region 1 gene RCAN1 (regulator of calcineurin 1), cell-recognition protein CHL1 (cell adhesion molecule with homology with L1CAM), the transcription factor SP4 (specificity protein 4) and histone deacetylase HDAC9, among others (see http://www.genes2cognition.org/SCZ-CNV).\n"
p748
sg4
(lp749
(dp750
g7
I335
sg8
VP32004
p751
sg10
I5
sg11
VL1CAM
p752
sg13
I1
sa(dp753
g7
I33
sg8
g15
sg10
I6
sg11
VPDE10A
p754
sg13
I1
sa(dp755
g7
I166
sg8
VP15382
p756
sg10
I5
sg11
VKCNE1
p757
sg13
I1
sa(dp758
g7
I176
sg8
g15
sg10
I5
sg11
VKCNE2
p759
sg13
I1
sa(dp760
g7
I41
sg8
g15
sg10
I21
sg11
Vphosphodiesterase 10A
p761
sg13
I2
sa(dp762
g7
I400
sg8
g15
sg10
I25
sg11
Vhistone deacetylase HDAC9
p763
sg13
I3
sa(dp764
g7
I287
sg8
g15
sg10
I28
sg11
VCHL1 (cell adhesion molecule
p765
sg13
I4
sasg20
(lp766
(dp767
g7
I298
sg23
VC0001511
p768
sg10
I8
sg11
Vadhesion
p769
sg13
I1
sa(dp770
g7
I187
sg23
VC0013080
p771
sg10
I15
sg11
VDown's syndrome
p772
sg13
I2
sa(dp773
g7
I101
sg23
VC0025362
p774
sg10
I18
sg11
Vmental retardation
p775
sg13
I2
sasa(dp776
g2
S'We describe nine cases with a microdeletion at 15q11.2 between BP1-BP2, thus having a haploinsufficiency for TUBGCP5, NIPA1, NIPA2, and CYFIP1 without Prader-Willi/Angelman syndrome.\n'
p777
sg4
(lp778
(dp779
g7
I63
sg8
g15
sg10
I7
sg11
VBP1-BP2
p780
sg13
I1
sa(dp781
g7
I118
sg8
g15
sg10
I5
sg11
VNIPA1
p782
sg13
I1
sa(dp783
g7
I109
sg8
g15
sg10
I7
sg11
VTUBGCP5
p784
sg13
I1
sa(dp785
g7
I136
sg8
g15
sg10
I6
sg11
VCYFIP1
p786
sg13
I1
sa(dp787
g7
I125
sg8
g15
sg10
I5
sg11
VNIPA2
p788
sg13
I1
sasg20
(lp789
(dp790
g7
I164
sg23
VC0162635
p791
sg10
I17
sg11
VAngelman syndrome
p792
sg13
I2
sasa(dp793
g2
S'Altered expression of CYFIP1 is seen in other developmental disabilities, including 15q disorders, and haploinsufficiency of CYFIP1 in Type I PWS cases may be associated with age-related phenotypic effects.\n'
p794
sg4
(lp795
(dp796
g7
I22
sg8
g15
sg10
I6
sg11
VCYFIP1
p797
sg13
I1
sa(dp798
g7
I22
sg8
g15
sg10
I6
sg11
VCYFIP1
p799
sg13
I1
sasg20
(lp800
(dp801
g7
I142
sg23
VC0032897
p802
sg10
I3
sg11
VPWS
p803
sg13
I1
sa(dp804
g7
I46
sg23
VC0008073
p805
sg10
I26
sg11
Vdevelopmental disabilities
p806
sg13
I2
sasa(dp807
g2
S'Expression analysis of cultured human cells and brain tissues from PWS patients indicates that CYFIP1 and NIPA2 are biallelically expressed.\n'
p808
sg4
(lp809
(dp810
g7
I95
sg8
g15
sg10
I6
sg11
VCYFIP1
p811
sg13
I1
sa(dp812
g7
I106
sg8
g15
sg10
I5
sg11
VNIPA2
p813
sg13
I1
sasg20
(lp814
(dp815
g7
I67
sg23
VC0032897
p816
sg10
I3
sg11
VPWS
p817
sg13
I1
sasa(dp818
g2
S'Four genes (NIPA1, NIPA2, CYFIP1, and GCP5) have been identified in the chromosomal region between breakpoints 1 and 2 and are implicated in compulsive behavior and lower intellectual ability observed in individuals with Prader-Willi syndrome with TI versus TII deletions.\n'
p819
sg4
(lp820
(dp821
g7
I38
sg8
g15
sg10
I4
sg11
VGCP5
p822
sg13
I1
sa(dp823
g7
I19
sg8
g15
sg10
I5
sg11
VNIPA2
p824
sg13
I1
sa(dp825
g7
I26
sg8
g15
sg10
I6
sg11
VCYFIP1
p826
sg13
I1
sa(dp827
g7
I12
sg8
g15
sg10
I5
sg11
VNIPA1
p828
sg13
I1
sasg20
(lp829
(dp830
g7
I141
sg23
VC0600104
p831
sg10
I19
sg11
Vcompulsive behavior
p832
sg13
I2
sa(dp833
g7
I221
sg23
VC0032897
p834
sg10
I21
sg11
VPrader-Willi syndrome
p835
sg13
I2
sasa(dp836
g2
S'Messenger RNA from NIPA1, NIPA2, CYFIP1, and GCP5 was reduced but detectable in the subjects with Prader-Willi syndrome with the TI deletion, supporting biallelic expression.\n'
p837
sg4
(lp838
(dp839
g7
I26
sg8
g15
sg10
I5
sg11
VNIPA2
p840
sg13
I1
sa(dp841
g7
I45
sg8
g15
sg10
I4
sg11
VGCP5
p842
sg13
I1
sa(dp843
g7
I33
sg8
g15
sg10
I6
sg11
VCYFIP1
p844
sg13
I1
sa(dp845
g7
I19
sg8
g15
sg10
I5
sg11
VNIPA1
p846
sg13
I1
sasg20
(lp847
(dp848
g7
I98
sg23
VC0032897
p849
sg10
I21
sg11
VPrader-Willi syndrome
p850
sg13
I2
sasa(dp851
g2
S'Therefore, we recruited 50 untreated house dust mite-sensitive allergic rhinitis patients and 29 non-atopic healthy individuals and performed comprehensive simultaneous flow cytometric analysis of mutual correlations between levels of CD14, CD16, CD163, CD206, CD124 (IL-4R), CD210 (IL-10R) and CD25, CD124, CD127 (IL-7R), CD210, ICOS expression on monocytes and CD4+ T cells, respectively.\n'
p852
sg4
(lp853
(dp854
g7
I254
sg8
VP22897
p855
sg10
I5
sg11
VCD206
p856
sg13
I1
sa(dp857
g7
I363
sg8
VP01730
p858
sg10
I4
sg11
VCD4+
p859
sg13
I1
sa(dp860
g7
I295
sg8
VP01589
p861
sg10
I4
sg11
VCD25
p862
sg13
I1
sa(dp863
g7
I283
sg8
g15
sg10
I6
sg11
VIL-10R
p864
sg13
I1
sa(dp865
g7
I247
sg8
g15
sg10
I5
sg11
VCD163
p866
sg13
I1
sa(dp867
g7
I235
sg8
VP08571
p868
sg10
I4
sg11
VCD14
p869
sg13
I1
sa(dp870
g7
I241
sg8
VP08637
p871
sg10
I4
sg11
VCD16
p872
sg13
I1
sasg20
(lp873
(dp874
g7
I63
sg23
VC2607914
p875
sg10
I17
sg11
Vallergic rhinitis
p876
sg13
I2
sa(dp877
g7
I101
sg23
VC0392707
p878
sg10
I6
sg11
Vatopic
p879
sg13
I1
sasa(dp880
g2
S'We did not observe any statistically significant differences between healthy and diabetic children in mRNA expression for FoxP3, IL-7R (CD127), IL-8RA, IL-10RA, IL-12A, IL-2RA (CD25), IL-21, STAT1, STAT3, SOCS2, SOCS3, TGF-beta1-R1, TGF-beta-R2 and TBX-21 genes.\n'
p881
sg4
(lp882
(dp883
g7
I191
sg8
VP42224
p884
sg10
I5
sg11
VSTAT1
p885
sg13
I1
sa(dp886
g7
I198
sg8
VP40763
p887
sg10
I5
sg11
VSTAT3
p888
sg13
I1
sa(dp889
g7
I184
sg8
g15
sg10
I5
sg11
VIL-21
p890
sg13
I1
sa(dp891
g7
I122
sg8
g15
sg10
I5
sg11
VFoxP3
p892
sg13
I1
sa(dp893
g7
I177
sg8
VP01589
p894
sg10
I4
sg11
VCD25
p895
sg13
I1
sa(dp896
g7
I205
sg8
g15
sg10
I5
sg11
VSOCS2
p897
sg13
I1
sa(dp898
g7
I161
sg8
VP29459
p899
sg10
I6
sg11
VIL-12A
p900
sg13
I1
sa(dp901
g7
I233
sg8
VP18075
p902
sg10
I11
sg11
VTGF-beta-R2
p903
sg13
I1
sa(dp904
g7
I212
sg8
g15
sg10
I5
sg11
VSOCS3
p905
sg13
I1
sa(dp906
g7
I219
sg8
VP01137
p907
sg10
I12
sg11
VTGF-beta1-R1
p908
sg13
I1
sasg20
(lp909
sa(dp910
g2
S'Expression of the Growth Hormone (GH)-stimulated gene Socs2 (Suppressor of Cytokine Signaling 2) is mediated by the transcription activator STAT5 (Signal Transducer and Activator of Transcription 5) and the transcription repressor BCL6 (B-Cell Lymphoma 6).\n'
p911
sg4
(lp912
(dp913
g7
I18
sg8
VP01242
p914
sg10
I14
sg11
VGrowth Hormone
p915
sg13
I2
sa(dp916
g7
I140
sg8
VP42229
p917
sg10
I5
sg11
VSTAT5
p918
sg13
I1
sa(dp919
g7
I34
sg8
VP01242
p920
sg10
I2
sg11
VGH
p921
sg13
I1
sa(dp922
g7
I54
sg8
g15
sg10
I5
sg11
VSocs2
p923
sg13
I1
sa(dp924
g7
I61
sg8
g15
sg10
I34
sg11
VSuppressor of Cytokine Signaling 2
p925
sg13
I5
sa(dp926
g7
I231
sg8
VP41182
p927
sg10
I4
sg11
VBCL6
p928
sg13
I1
sa(dp929
g7
I147
sg8
VP42229
p930
sg10
I50
sg11
VSignal Transducer and Activator of Transcription 5
p931
sg13
I7
sa(dp932
g7
I237
sg8
VP41182
p933
sg10
I17
sg11
VB-Cell Lymphoma 6
p934
sg13
I3
sasg20
(lp935
(dp936
g7
I237
sg23
VC0079731
p937
sg10
I15
sg11
VB-Cell Lymphoma
p938
sg13
I2
sasa(dp939
g2
S'Gene expression analysis revealed increased expression of MAPK1, AKT1, PRKCE, IL4R and DROSHA and decreased expression of CDKN1A/p21, SOCS2, CHEK1, RAD51, KLF4, BLIMP1 and IRF4 in follicular lymphoma.\n'
p940
sg4
(lp941
(dp942
g7
I141
sg8
g15
sg10
I5
sg11
VCHEK1
p943
sg13
I1
sa(dp944
g7
I129
sg8
VP42857
p945
sg10
I3
sg11
Vp21
p946
sg13
I1
sa(dp947
g7
I161
sg8
g15
sg10
I6
sg11
VBLIMP1
p948
sg13
I1
sa(dp949
g7
I155
sg8
g15
sg10
I4
sg11
VKLF4
p950
sg13
I1
sa(dp951
g7
I172
sg8
g15
sg10
I4
sg11
VIRF4
p952
sg13
I1
sa(dp953
g7
I87
sg8
g15
sg10
I6
sg11
VDROSHA
p954
sg13
I1
sa(dp955
g7
I122
sg8
VP38936
p956
sg10
I6
sg11
VCDKN1A
p957
sg13
I1
sa(dp958
g7
I148
sg8
g15
sg10
I5
sg11
VRAD51
p959
sg13
I1
sa(dp960
g7
I134
sg8
g15
sg10
I5
sg11
VSOCS2
p961
sg13
I1
sa(dp962
g7
I65
sg8
VP31749
p963
sg10
I4
sg11
VAKT1
p964
sg13
I1
sa(dp965
g7
I58
sg8
VP28482
p966
sg10
I5
sg11
VMAPK1
p967
sg13
I1
sa(dp968
g7
I71
sg8
g15
sg10
I5
sg11
VPRKCE
p969
sg13
I1
sasg20
(lp970
(dp971
g7
I180
sg23
VC0024301
p972
sg10
I19
sg11
Vfollicular lymphoma
p973
sg13
I2
sasa(dp974
g2
S'miR-20a/b and miR-194 target CDKN1A and SOCS2 in follicular lymphoma, potentially contributing to tumor cell proliferation and survival.\n'
p975
sg4
(lp976
(dp977
g7
I40
sg8
g15
sg10
I5
sg11
VSOCS2
p978
sg13
I1
sa(dp979
g7
I0
sg8
g15
sg10
I9
sg11
VmiR-20a/b
p980
sg13
I1
sa(dp981
g7
I29
sg8
VP38936
p982
sg10
I6
sg11
VCDKN1A
p983
sg13
I1
sa(dp984
g7
I14
sg8
g15
sg10
I7
sg11
VmiR-194
p985
sg13
I1
sasg20
(lp986
(dp987
g7
I98
sg23
VC0027651
p988
sg10
I5
sg11
Vtumor
p989
sg13
I1
sa(dp990
g7
I49
sg23
VC0024301
p991
sg10
I19
sg11
Vfollicular lymphoma
p992
sg13
I2
sa(dp993
g7
I109
sg23
VC0334094
p994
sg10
I13
sg11
Vproliferation
p995
sg13
I1
sasa(dp996
g2
S'Nuclear factors such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as transporters and conjugation enzymes involved in the detoxification of lithocholic acid (LCA), also showed higher expression in SPF mice.\n'
p997
sg4
(lp998
(dp999
g7
I24
sg8
g15
sg10
I19
sg11
Vpregnane X receptor
p1000
sg13
I3
sa(dp1001
g7
I45
sg8
g15
sg10
I3
sg11
VPXR
p1002
sg13
I1
sasg20
(lp1003
(dp1004
g7
I54
sg23
VC2607929
p1005
sg10
I32
sg11
Vconstitutive androstane receptor
p1006
sg13
I3
sa(dp1007
g7
I88
sg23
VC2607929
p1008
sg10
I3
sg11
VCAR
p1009
sg13
I1
sa(dp1010
g7
I176
sg23
VC0339527
p1011
sg10
I16
sg11
Vlithocholic acid
p1012
sg13
I2
sa(dp1013
g7
I194
sg23
VC0339527
p1014
sg10
I3
sg11
VLCA
p1015
sg13
I1
sasa(dp1016
g2
S'In this study, using transgenic mice bearing conditional expression of the activated constitutive androstane receptor (CAR), we demonstrate that activation of CAR is both necessary and sufficient to confer resistance to the hepatotoxicity of lithocholic acid (LCA).\n'
p1017
sg4
(lp1018
sg20
(lp1019
(dp1020
g7
I119
sg23
VC2607929
p1021
sg10
I3
sg11
VCAR
p1022
sg13
I1
sa(dp1023
g7
I260
sg23
VC0339527
p1024
sg10
I3
sg11
VLCA
p1025
sg13
I1
sa(dp1026
g7
I119
sg23
VC2607929
p1027
sg10
I3
sg11
VCAR
p1028
sg13
I1
sa(dp1029
g7
I85
sg23
VC2607929
p1030
sg10
I32
sg11
Vconstitutive androstane receptor
p1031
sg13
I3
sa(dp1032
g7
I242
sg23
VC0339527
p1033
sg10
I16
sg11
Vlithocholic acid
p1034
sg13
I2
sasa(dp1035
g2
S'These results support the conclusion that dental caries is highly affected by the activity of CA VI in saliva as well as by the salivary flow rate.\n'
p1036
sg4
(lp1037
(dp1038
g7
I94
sg8
VP23280
p1039
sg10
I5
sg11
VCA VI
p1040
sg13
I2
sasg20
(lp1041
(dp1042
g7
I42
sg23
VC0333519
p1043
sg10
I13
sg11
Vdental caries
p1044
sg13
I2
sasa(dp1045
g2
S'Eleven articles found a consistent association between salivary protein polymorphisms and risk of dental caries, for proteins related to antimicrobial activity (beta defensin 1 and lysozyme-like protein), pH control (carbonic anhydrase VI), and bacterial colonization/adhesion (lactotransferrin, mucin, and proline-rich protein Db).\n'
p1046
sg4
(lp1047
(dp1048
g7
I217
sg8
VP23280
p1049
sg10
I21
sg11
Vcarbonic anhydrase VI
p1050
sg13
I3
sa(dp1051
g7
I161
sg8
VP60022
p1052
sg10
I41
sg11
Vbeta defensin 1 and lysozyme-like protein
p1053
sg13
I6
sa(dp1054
g7
I296
sg8
g15
sg10
I5
sg11
Vmucin
p1055
sg13
I1
sasg20
(lp1056
(dp1057
g7
I268
sg23
VC0001511
p1058
sg10
I8
sg11
Vadhesion
p1059
sg13
I1
sa(dp1060
g7
I98
sg23
VC0333519
p1061
sg10
I13
sg11
Vdental caries
p1062
sg13
I2
sasa(dp1063
g2
S'The rs17032907 genetic variant and the haplotype (ACA) of CA VI may be associated with dental caries susceptibility.\n'
p1064
sg4
(lp1065
(dp1066
g7
I58
sg8
VP23280
p1067
sg10
I5
sg11
VCA VI
p1068
sg13
I2
sasg20
(lp1069
(dp1070
g7
I87
sg23
VC0333519
p1071
sg10
I13
sg11
Vdental caries
p1072
sg13
I2
sasa(dp1073
g2
S'The oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.\n'
p1074
sg4
(lp1075
(dp1076
g7
I110
sg8
VP35218
p1077
sg10
I18
sg11
Vcarbonic anhydrase
p1078
sg13
I2
sa(dp1079
g7
I130
sg8
VP35218
p1080
sg10
I2
sg11
VCA
p1081
sg13
I1
sasg20
(lp1082
(dp1083
g7
I48
sg23
VC0333519
p1084
sg10
I13
sg11
Vdental caries
p1085
sg13
I2
sasa(dp1086
g2
S'Streptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.\n'
p1087
sg4
(lp1088
(dp1089
g7
I101
sg8
VP35218
p1090
sg10
I29
sg11
VBeta-class carbonic anhydrase
p1091
sg13
I3
sasg20
(lp1092
(dp1093
g7
I62
sg23
VC0333519
p1094
sg10
I13
sg11
Vdental caries
p1095
sg13
I2
sasa(dp1096
g2
S'We used mice lacking the CNTNAP2 gene, which has been implicated in autism, and achieved a temporally precise reduction in E:I balance in the medial prefrontal cortex (mPFC) either by optogenetically increasing the excitability of inhibitory parvalbumin (PV) neurons or decreasing the excitability of excitatory pyramidal neurons.\n'
p1097
sg4
(lp1098
(dp1099
g7
I255
sg8
VP20472
p1100
sg10
I2
sg11
VPV
p1101
sg13
I1
sa(dp1102
g7
I242
sg8
VP20472
p1103
sg10
I11
sg11
Vparvalbumin
p1104
sg13
I1
sa(dp1105
g7
I25
sg8
g15
sg10
I12
sg11
VCNTNAP2 gene
p1106
sg13
I2
sasg20
(lp1107
(dp1108
g7
I215
sg23
VC0235169
p1109
sg10
I12
sg11
Vexcitability
p1110
sg13
I1
sa(dp1111
g7
I68
sg23
VC0004352
p1112
sg10
I6
sg11
Vautism
p1113
sg13
I1
sa(dp1114
g7
I215
sg23
VC0235169
p1115
sg10
I12
sg11
Vexcitability
p1116
sg13
I1
sasa(dp1117
g2
S'Post-mortem analyses have demonstrated a selective reduction in the expression of parvalbumin (PV) in GABAergic interneurons in the frontal rather than the sensory cortex of patients with neuropsychiatric disorders such as schizophrenia, autism spectrum disorders, and bipolar disorders.\n'
p1118
sg4
(lp1119
(dp1120
g7
I82
sg8
VP20472
p1121
sg10
I11
sg11
Vparvalbumin
p1122
sg13
I1
sa(dp1123
g7
I95
sg8
VP20472
p1124
sg10
I2
sg11
VPV
p1125
sg13
I1
sasg20
(lp1126
(dp1127
g7
I223
sg23
VC0036341
p1128
sg10
I13
sg11
Vschizophrenia
p1129
sg13
I1
sa(dp1130
g7
I269
sg23
VC0005586
p1131
sg10
I17
sg11
Vbipolar disorders
p1132
sg13
I2
sa(dp1133
g7
I238
sg23
VC1510586
p1134
sg10
I25
sg11
Vautism spectrum disorders
p1135
sg13
I3
sasa(dp1136
g2
S'Recent neuropathology studies in human brains indicate that several areas of the prefrontal cortex have decreased numbers of parvalbumin interneurons or decreased parvalbumin expression in Autism Spectrum disorders (ASD) [Hashemi, Ariza, Rogers, Noctor, &amp; Martinez-Cerdeno, 2017; Zikopoulos &amp; Barbas, ].\n'
p1137
sg4
(lp1138
(dp1139
g7
I125
sg8
VP20472
p1140
sg10
I11
sg11
Vparvalbumin
p1141
sg13
I1
sa(dp1142
g7
I125
sg8
VP20472
p1143
sg10
I11
sg11
Vparvalbumin
p1144
sg13
I1
sasg20
(lp1145
(dp1146
g7
I189
sg23
VC1510586
p1147
sg10
I25
sg11
VAutism Spectrum disorders
p1148
sg13
I3
sa(dp1149
g7
I216
sg23
VC1510586
p1150
sg10
I3
sg11
VASD
p1151
sg13
I1
sa(dp1152
g7
I7
sg23
VC1540677
p1153
sg10
I14
sg11
Vneuropathology
p1154
sg13
I1
sasa(dp1155
g2
S'In view of the documented association between parvalbumin-expressing neurons and autism, the objective of the present study was to determine if parvalbumin gene expression is also altered in Purkinje neurons of the cerebellum.\n'
p1156
sg4
(lp1157
(dp1158
g7
I46
sg8
VP20472
p1159
sg10
I11
sg11
Vparvalbumin
p1160
sg13
I1
sa(dp1161
g7
I144
sg8
VP20472
p1162
sg10
I16
sg11
Vparvalbumin gene
p1163
sg13
I2
sasg20
(lp1164
(dp1165
g7
I81
sg23
VC0004352
p1166
sg10
I6
sg11
Vautism
p1167
sg13
I1
sasa(dp1168
g2
S'Our hypothesis is that parvalbumin, a molecule that controls and coordinate many cellular brain functions, contributes to the excitatory/inhibitory imbalance in Autism.\n'
p1169
sg4
(lp1170
(dp1171
g7
I23
sg8
VP20472
p1172
sg10
I11
sg11
Vparvalbumin
p1173
sg13
I1
sasg20
(lp1174
(dp1175
g7
I148
sg23
VC1397014
p1176
sg10
I9
sg11
Vimbalance
p1177
sg13
I1
sa(dp1178
g7
I161
sg23
VC0004352
p1179
sg10
I6
sg11
VAutism
p1180
sg13
I1
sasa(dp1181
g2
S'We report that parvalbumin expression is depressed in Purkinje cells of the cerebellum in autism.\n'
p1182
sg4
(lp1183
(dp1184
g7
I15
sg8
VP20472
p1185
sg10
I11
sg11
Vparvalbumin
p1186
sg13
I1
sasg20
(lp1187
(dp1188
g7
I90
sg23
VC0004352
p1189
sg10
I6
sg11
Vautism
p1190
sg13
I1
sasa(dp1191
g2
S'For children less than 32 weeks, FVL homozygosity may be associated with an increase in the risk of developing quadriplegia (OR 9.12, 95% CI 0.86-53.71).\n'
p1192
sg4
(lp1193
sg20
(lp1194
(dp1195
g7
I111
sg23
VC0034372
p1196
sg10
I12
sg11
Vquadriplegia
p1197
sg13
I1
sasa(dp1198
g2
S'In the myocardium activation of NFATc3 down-regulates the expression of voltage-gated K(+) (Kv) channels after myocardial infarction (MI).\n'
p1199
sg4
(lp1200
(dp1201
g7
I32
sg8
g15
sg10
I6
sg11
VNFATc3
p1202
sg13
I1
sasg20
(lp1203
(dp1204
g7
I134
sg23
VC0027051
p1205
sg10
I2
sg11
VMI
p1206
sg13
I1
sa(dp1207
g7
I111
sg23
VC0027051
p1208
sg10
I21
sg11
Vmyocardial infarction
p1209
sg13
I2
sasa(dp1210
g2
S'Knockdown of NFAT4 suppresses mitochondrial fission and protects cardiomyocyte from apoptosis and myocardial infarction.\n'
p1211
sg4
(lp1212
(dp1213
g7
I13
sg8
g15
sg10
I5
sg11
VNFAT4
p1214
sg13
I1
sasg20
(lp1215
(dp1216
g7
I98
sg23
VC0027051
p1217
sg10
I21
sg11
Vmyocardial infarction
p1218
sg13
I2
sasa(dp1219
g2
S'The expression pattern of WNT3A is consistent with BRG1 in colon cancer tissues and WNT3A expression was inhibited in BRG1 knockdown cells.\n'
p1220
sg4
(lp1221
(dp1222
g7
I51
sg8
VP51532
p1223
sg10
I4
sg11
VBRG1
p1224
sg13
I1
sa(dp1225
g7
I26
sg8
VP56704
p1226
sg10
I5
sg11
VWNT3A
p1227
sg13
I1
sa(dp1228
g7
I51
sg8
VP51532
p1229
sg10
I28
sg11
VBRG1 in colon cancer tissues
p1230
sg13
I5
sa(dp1231
g7
I26
sg8
VP56704
p1232
sg10
I5
sg11
VWNT3A
p1233
sg13
I1
sasg20
(lp1234
(dp1235
g7
I59
sg23
VC0699790
p1236
sg10
I12
sg11
Vcolon cancer
p1237
sg13
I2
sasa(dp1238
g2
S'In this study, we demonstrate that BRG1 may contribute to colon cancer progression through upregulating WNT3A expression.\n'
p1239
sg4
(lp1240
(dp1241
g7
I104
sg8
VP56704
p1242
sg10
I5
sg11
VWNT3A
p1243
sg13
I1
sa(dp1244
g7
I35
sg8
VP51532
p1245
sg10
I4
sg11
VBRG1
p1246
sg13
I1
sasg20
(lp1247
(dp1248
g7
I64
sg23
VC0178874
p1249
sg10
I18
sg11
Vcancer progression
p1250
sg13
I2
sasa(dp1251
g2
S'VM-positive colon cancer samples showed increased Wnt3a expression (p &lt; 0.001) and Beta-catenin nuclear expression (p &lt; 0.001) compared with the VM-negative samples.\n'
p1252
sg4
(lp1253
(dp1254
g7
I50
sg8
VP56704
p1255
sg10
I5
sg11
VWnt3a
p1256
sg13
I1
sa(dp1257
g7
I86
sg8
VP35222
p1258
sg10
I12
sg11
VBeta-catenin
p1259
sg13
I1
sasg20
(lp1260
(dp1261
g7
I12
sg23
VC0699790
p1262
sg10
I12
sg11
Vcolon cancer
p1263
sg13
I2
sasa(dp1264
g2
S'In vitro, over-regulated Wnt3a expression in HT29 colon cancer cells promoted the capacity to form tube-like structures in the three-dimensional (3-D) culture together with increased expression of endothelial phenotype-associated proteins such as VEGFR2 and VE-cadherin.\n'
p1265
sg4
(lp1266
(dp1267
g7
I258
sg8
VP33151
p1268
sg10
I11
sg11
VVE-cadherin
p1269
sg13
I1
sa(dp1270
g7
I247
sg8
VP35968
p1271
sg10
I6
sg11
VVEGFR2
p1272
sg13
I1
sa(dp1273
g7
I25
sg8
VP56704
p1274
sg10
I5
sg11
VWnt3a
p1275
sg13
I1
sasg20
(lp1276
(dp1277
g7
I50
sg23
VC0699790
p1278
sg10
I12
sg11
Vcolon cancer
p1279
sg13
I2
sasa(dp1280
g2
S'However, the roles of Wnt3a, the representative canonical Wnt ligand, in EMT and colon cancer progression have not yet been fully explored.\n'
p1281
sg4
(lp1282
(dp1283
g7
I58
sg8
g15
sg10
I10
sg11
VWnt ligand
p1284
sg13
I2
sa(dp1285
g7
I22
sg8
VP56704
p1286
sg10
I5
sg11
VWnt3a
p1287
sg13
I1
sa(dp1288
g7
I73
sg8
g15
sg10
I3
sg11
VEMT
p1289
sg13
I1
sasg20
(lp1290
(dp1291
g7
I87
sg23
VC0178874
p1292
sg10
I18
sg11
Vcancer progression
p1293
sg13
I2
sasa(dp1294
g2
S'The expression levels of Wnt3a and EMT-associated proteins (E-cadherin, vimentin, and Beta-catenin) were assessed by immunohistochemistry in human colon cancer tissues to evaluate the clinicopathological significance of Wnt3a, as well as the correlation between Wnt3a and EMT.\n'
p1295
sg4
(lp1296
(dp1297
g7
I25
sg8
VP56704
p1298
sg10
I5
sg11
VWnt3a
p1299
sg13
I1
sa(dp1300
g7
I35
sg8
g15
sg10
I23
sg11
VEMT-associated proteins
p1301
sg13
I2
sa(dp1302
g7
I60
sg8
VP12830
p1303
sg10
I10
sg11
VE-cadherin
p1304
sg13
I1
sa(dp1305
g7
I86
sg8
VP35222
p1306
sg10
I12
sg11
VBeta-catenin
p1307
sg13
I1
sa(dp1308
g7
I35
sg8
g15
sg10
I3
sg11
VEMT
p1309
sg13
I1
sa(dp1310
g7
I25
sg8
VP56704
p1311
sg10
I5
sg11
VWnt3a
p1312
sg13
I1
sa(dp1313
g7
I25
sg8
VP56704
p1314
sg10
I5
sg11
VWnt3a
p1315
sg13
I1
sasg20
(lp1316
(dp1317
g7
I147
sg23
VC0699790
p1318
sg10
I12
sg11
Vcolon cancer
p1319
sg13
I2
sasa(dp1320
g2
S'We then upregulated Wnt3a expression in HCT116 colon cancer cells, established a nude mouse xenograft model, detected the expression of EMT and Wnt/Beta-catenin signaling-associated proteins, and observed invasion and clone-initiating abilities.\n'
p1321
sg4
(lp1322
(dp1323
g7
I20
sg8
VP56704
p1324
sg10
I5
sg11
VWnt3a
p1325
sg13
I1
sa(dp1326
g7
I136
sg8
g15
sg10
I3
sg11
VEMT
p1327
sg13
I1
sa(dp1328
g7
I148
sg8
VP35222
p1329
sg10
I12
sg11
VBeta-catenin
p1330
sg13
I1
sasg20
(lp1331
(dp1332
g7
I47
sg23
VC0699790
p1333
sg10
I12
sg11
Vcolon cancer
p1334
sg13
I2
sa(dp1335
g7
I205
sg23
VC2699153
p1336
sg10
I8
sg11
Vinvasion
p1337
sg13
I1
sasa(dp1338
g2
S'In 203 human colon cancer tissue samples, Wnt3a protein overexpression was related to colon cancer histological differentiation (P = 0.004), clinical stage (P = 0.008), presence of metastasis and recurrence (P = 0.036), and survival time (P = 0.007) of colon cancer patients.\n'
p1339
sg4
(lp1340
(dp1341
g7
I42
sg8
VP56704
p1342
sg10
I5
sg11
VWnt3a
p1343
sg13
I1
sasg20
(lp1344
(dp1345
g7
I181
sg23
VC0027627
p1346
sg10
I10
sg11
Vmetastasis
p1347
sg13
I1
sa(dp1348
g7
I13
sg23
VC0699790
p1349
sg10
I12
sg11
Vcolon cancer
p1350
sg13
I2
sa(dp1351
g7
I13
sg23
VC0699790
p1352
sg10
I12
sg11
Vcolon cancer
p1353
sg13
I2
sa(dp1354
g7
I13
sg23
VC0699790
p1355
sg10
I12
sg11
Vcolon cancer
p1356
sg13
I2
sa(dp1357
g7
I196
sg23
VC1458156
p1358
sg10
I10
sg11
Vrecurrence
p1359
sg13
I1
sasa(dp1360
g2
S'Wnt3a expression was associated with EMT and promoted colon cancer progression.\n'
p1361
sg4
(lp1362
(dp1363
g7
I37
sg8
g15
sg10
I3
sg11
VEMT
p1364
sg13
I1
sa(dp1365
g7
I0
sg8
VP56704
p1366
sg10
I5
sg11
VWnt3a
p1367
sg13
I1
sasg20
(lp1368
(dp1369
g7
I60
sg23
VC0178874
p1370
sg10
I18
sg11
Vcancer progression
p1371
sg13
I2
sasa(dp1372
g2
S'Disruption of 11-cis-RDHs causes a slowly developing cone dystrophy caused by inefficient cone pigment regeneration.\n'
p1373
sg4
(lp1374
(dp1375
g7
I14
sg8
g15
sg10
I11
sg11
V11-cis-RDHs
p1376
sg13
I1
sasg20
(lp1377
(dp1378
g7
I53
sg23
VC0730290
p1379
sg10
I14
sg11
Vcone dystrophy
p1380
sg13
I2
sa(dp1381
g7
I17
sg23
VC0007099
p1382
sg10
I3
sg11
Vcis
p1383
sg13
I1
sasa(dp1384
g2
S'To evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea.\n'
p1385
sg4
(lp1386
(dp1387
g7
I38
sg8
VP01286
p1388
sg10
I5
sg11
VGH-RH
p1389
sg13
I1
sa(dp1390
g7
I16
sg8
VP01286
p1391
sg10
I20
sg11
VGH-releasing hormone
p1392
sg13
I2
sasg20
(lp1393
(dp1394
g7
I92
sg23
VC0341862
p1395
sg10
I23
sg11
Vhypothalamic amenorrhea
p1396
sg13
I2
sasa(dp1397
g2
S'The amenorrheic condition associated with reduced BMI changes the GH-RH--induced GH response in hypothalamic amenorrhea, supporting a GH and a IGF-I disregulation in weight-loss--related amenorrhea.\n'
p1398
sg4
(lp1399
(dp1400
g7
I143
sg8
VP01343
p1401
sg10
I5
sg11
VIGF-I
p1402
sg13
I1
sasg20
(lp1403
(dp1404
g7
I109
sg23
VC0002453
p1405
sg10
I10
sg11
Vamenorrhea
p1406
sg13
I1
sa(dp1407
g7
I96
sg23
VC0341862
p1408
sg10
I23
sg11
Vhypothalamic amenorrhea
p1409
sg13
I2
sa(dp1410
g7
I16
sg23
VC0012634
p1411
sg10
I9
sg11
Vcondition
p1412
sg13
I1
sasa(dp1413
g2
S'We report the case of a 17-year-old girl presenting short stature (height 149 cm, below the 3rd percentile), obesity (weight 83.5 kg, body mass index 37 kg/m2) and secondary amenorrhea, in whom endocrinological evaluation disclosed an absolute lack of GH responsiveness to both suprapituitary challenges and repetitive growth hormone releasing hormone administration together with failure of plasma gonadotropins and PRL, low under basal conditions, to rise in response to GnRH and insulin-hypoglycemia, respectively.\n'
p1414
sg4
(lp1415
(dp1416
g7
I319
sg8
VP01242
p1417
sg10
I14
sg11
Vgrowth hormone
p1418
sg13
I2
sa(dp1419
g7
I482
sg8
VP01308
p1420
sg10
I7
sg11
Vinsulin
p1421
sg13
I1
sa(dp1422
g7
I417
sg8
VP01236
p1423
sg10
I3
sg11
VPRL
p1424
sg13
I1
sa(dp1425
g7
I473
sg8
VP01148
p1426
sg10
I4
sg11
VGnRH
p1427
sg13
I1
sasg20
(lp1428
(dp1429
g7
I164
sg23
VC0232940
p1430
sg10
I20
sg11
Vsecondary amenorrhea
p1431
sg13
I2
sa(dp1432
g7
I109
sg23
VC0028754
p1433
sg10
I7
sg11
Vobesity
p1434
sg13
I1
sa(dp1435
g7
I490
sg23
VC0020615
p1436
sg10
I12
sg11
Vhypoglycemia
p1437
sg13
I1
sa(dp1438
g7
I52
sg23
VC0013336
p1439
sg10
I13
sg11
Vshort stature
p1440
sg13
I2
sasa(dp1441
g2
S'Common genes include Jagged 1 (Jag1), Tetraspanin 2 (Tspan2), neuroblastoma, suppression of tumourigenicity 1 (Nbl1) and N-myc downstream regulated gene 2 (Ndrg2).\n'
p1442
sg4
(lp1443
(dp1444
g7
I21
sg8
VP78504
p1445
sg10
I8
sg11
VJagged 1
p1446
sg13
I2
sa(dp1447
g7
I121
sg8
VP04198
p1448
sg10
I5
sg11
VN-myc
p1449
sg13
I1
sa(dp1450
g7
I38
sg8
g15
sg10
I13
sg11
VTetraspanin 2
p1451
sg13
I2
sa(dp1452
g7
I31
sg8
VP78504
p1453
sg10
I4
sg11
VJag1
p1454
sg13
I1
sa(dp1455
g7
I53
sg8
g15
sg10
I6
sg11
VTspan2
p1456
sg13
I1
sasg20
(lp1457
(dp1458
g7
I62
sg23
VC0027819
p1459
sg10
I13
sg11
Vneuroblastoma
p1460
sg13
I1
sa(dp1461
g7
I77
sg23
VC0221103
p1462
sg10
I11
sg11
Vsuppression
p1463
sg13
I1
sasa(dp1464
g2
S'While vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used.\n'
p1465
sg4
(lp1466
sg20
(lp1467
(dp1468
g7
I48
sg23
VC0027819
p1469
sg10
I13
sg11
Vneuroblastoma
p1470
sg13
I1
sasa(dp1471
g2
S'The purpose of this study was to evaluate the correlation of somatostatin receptor-2 (SSTR2) expression with 68Ga-DOTA-TATE uptake and 177Lu-DOTA-TATE therapy in neuroblastoma (NB) xenograft models.\n'
p1472
sg4
(lp1473
(dp1474
g7
I86
sg8
VP30874
p1475
sg10
I5
sg11
VSSTR2
p1476
sg13
I1
sa(dp1477
g7
I61
sg8
VP61278
p1478
sg10
I23
sg11
Vsomatostatin receptor-2
p1479
sg13
I2
sasg20
(lp1480
(dp1481
g7
I177
sg23
VC0027819
p1482
sg10
I2
sg11
VNB
p1483
sg13
I1
sa(dp1484
g7
I162
sg23
VC0027819
p1485
sg10
I13
sg11
Vneuroblastoma
p1486
sg13
I1
sasa(dp1487
g2
S'Neuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively.\n'
p1488
sg4
(lp1489
(dp1490
g7
I225
sg8
VP30874
p1491
sg10
I5
sg11
VSSTR2
p1492
sg13
I1
sa(dp1493
g7
I202
sg8
VP61278
p1494
sg10
I21
sg11
VSomatostatin Receptor
p1495
sg13
I2
sasg20
(lp1496
(dp1497
g7
I0
sg23
VC0027819
p1498
sg10
I13
sg11
VNeuroblastoma
p1499
sg13
I1
sasa(dp1500
g2
S'Tissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from patients for whom clinical outcome data were available were sectioned and stained with haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2.\n'
p1501
sg4
(lp1502
(dp1503
g7
I244
sg8
VP30874
p1504
sg10
I5
sg11
VSSTR2
p1505
sg13
I1
sa(dp1506
g7
I236
sg8
VP18440
p1507
sg10
I3
sg11
VNAT
p1508
sg13
I1
sasg20
(lp1509
(dp1510
g7
I56
sg23
VC0027819
p1511
sg10
I13
sg11
Vneuroblastoma
p1512
sg13
I1
sasa(dp1513
g2
S'68Ga-DOTATATE PET/CT enables detection of meningioma tissue based on somatostatin receptor 2 expression.\n'
p1514
sg4
(lp1515
(dp1516
g7
I69
sg8
VP61278
p1517
sg10
I23
sg11
Vsomatostatin receptor 2
p1518
sg13
I3
sasg20
(lp1519
(dp1520
g7
I42
sg23
VC0025286
p1521
sg10
I10
sg11
Vmeningioma
p1522
sg13
I1
sasa(dp1523
g2
S'Immunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases.\n'
p1524
sg4
(lp1525
(dp1526
g7
I56
sg8
VP61278
p1527
sg10
I6
sg11
VSSTR2A
p1528
sg13
I1
sa(dp1529
g7
I162
sg8
VP12830
p1530
sg10
I27
sg11
Vepithelial membrane antigen
p1531
sg13
I3
sa(dp1532
g7
I48
sg8
VP13804
p1533
sg10
I3
sg11
VEMA
p1534
sg13
I1
sa(dp1535
g7
I56
sg8
VP30874
p1536
sg10
I5
sg11
VSSTR2
p1537
sg13
I1
sa(dp1538
g7
I56
sg8
VP61278
p1539
sg10
I6
sg11
VSSTR2A
p1540
sg13
I1
sa(dp1541
g7
I243
sg8
VP61278
p1542
sg10
I32
sg11
Vsomatostatin receptor subtype 2A
p1543
sg13
I4
sa(dp1544
g7
I48
sg8
VP12830
p1545
sg10
I3
sg11
VEMA
p1546
sg13
I1
sasg20
(lp1547
(dp1548
g7
I29
sg23
VC0025286
p1549
sg10
I10
sg11
Vmeningioma
p1550
sg13
I1
sa(dp1551
g7
I48
sg23
VC0268596
p1552
sg10
I3
sg11
VEMA
p1553
sg13
I1
sa(dp1554
g7
I29
sg23
VC0025286
p1555
sg10
I10
sg11
Vmeningioma
p1556
sg13
I1
sa(dp1557
g7
I48
sg23
VC0268596
p1558
sg10
I3
sg11
VEMA
p1559
sg13
I1
sa(dp1560
g7
I162
sg23
VC0268596
p1561
sg10
I27
sg11
Vepithelial membrane antigen
p1562
sg13
I3
sasa(dp1563
g2
S'Somatostatine receptors subtype 2 (SSTR2) are regarded as a potential target in neuroblastoma (NB) for imaging and promising therapeutic approaches.\n'
p1564
sg4
(lp1565
(dp1566
g7
I0
sg8
g15
sg10
I33
sg11
VSomatostatine receptors subtype 2
p1567
sg13
I4
sa(dp1568
g7
I35
sg8
VP30874
p1569
sg10
I5
sg11
VSSTR2
p1570
sg13
I1
sasg20
(lp1571
(dp1572
g7
I80
sg23
VC0027819
p1573
sg10
I13
sg11
Vneuroblastoma
p1574
sg13
I1
sa(dp1575
g7
I95
sg23
VC0027819
p1576
sg10
I2
sg11
VNB
p1577
sg13
I1
sasa(dp1578
g2
S'GaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging.\n'
p1579
sg4
(lp1580
(dp1581
g7
I105
sg8
VP31391
p1582
sg10
I6
sg11
VSSTR 2
p1583
sg13
I2
sasg20
(lp1584
(dp1585
g7
I73
sg23
VC0027819
p1586
sg10
I13
sg11
Vneuroblastoma
p1587
sg13
I1
sasa(dp1588
g2
S'PET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of meningiomas.\n'
p1589
sg4
(lp1590
(dp1591
g7
I14
sg8
VP30874
p1592
sg10
I5
sg11
VSSTR2
p1593
sg13
I1
sasg20
(lp1594
(dp1595
g7
I87
sg23
VC0025286
p1596
sg10
I11
sg11
Vmeningiomas
p1597
sg13
I1
sasa(dp1598
g2
S'(68)Ga-DOTATATE uptake correlates with SSTR2 expression and offers high diagnostic accuracy to delineate meningioma from tumor-free tissue even in recurrent tumors after previous therapy.\n'
p1599
sg4
(lp1600
(dp1601
g7
I39
sg8
VP30874
p1602
sg10
I5
sg11
VSSTR2
p1603
sg13
I1
sasg20
(lp1604
(dp1605
g7
I105
sg23
VC0025286
p1606
sg10
I10
sg11
Vmeningioma
p1607
sg13
I1
sa(dp1608
g7
I121
sg23
VC0027651
p1609
sg10
I5
sg11
Vtumor
p1610
sg13
I1
sa(dp1611
g7
I157
sg23
VC0027651
p1612
sg10
I6
sg11
Vtumors
p1613
sg13
I1
sasa(dp1614
g2
S'We aimed to compare the frequency of perineurial marker expression in these two entities, and to determine whether somatostatin receptor 2 (SSTR2) and progesterone receptor (PR), both expressed frequently in meningiomas, are also expressed in perineuriomas.\n'
p1615
sg4
(lp1616
(dp1617
g7
I115
sg8
VP61278
p1618
sg10
I23
sg11
Vsomatostatin receptor 2
p1619
sg13
I3
sa(dp1620
g7
I151
sg8
VP06401
p1621
sg10
I21
sg11
Vprogesterone receptor
p1622
sg13
I2
sa(dp1623
g7
I174
sg8
VP06401
p1624
sg10
I2
sg11
VPR
p1625
sg13
I1
sa(dp1626
g7
I140
sg8
VP30874
p1627
sg10
I5
sg11
VSSTR2
p1628
sg13
I1
sasg20
(lp1629
(dp1630
g7
I208
sg23
VC0025286
p1631
sg10
I11
sg11
Vmeningiomas
p1632
sg13
I1
sa(dp1633
g7
I243
sg23
VC0751691
p1634
sg10
I13
sg11
Vperineuriomas
p1635
sg13
I1
sasa(dp1636
g2
S'All tumours were stained using five antibodies against antigens that are known to be expressed in perineuriomas or meningiomas: epithelial membrane antigen (EMA), claudin-1, GLUT-1 (glucose transporter-1), SSTR2, and PR.\n'
p1637
sg4
(lp1638
(dp1639
g7
I174
sg8
VP11166
p1640
sg10
I6
sg11
VGLUT-1
p1641
sg13
I1
sa(dp1642
g7
I128
sg8
VP12830
p1643
sg10
I27
sg11
Vepithelial membrane antigen
p1644
sg13
I3
sa(dp1645
g7
I182
sg8
VP11166
p1646
sg10
I21
sg11
Vglucose transporter-1
p1647
sg13
I2
sa(dp1648
g7
I206
sg8
VP30874
p1649
sg10
I5
sg11
VSSTR2
p1650
sg13
I1
sa(dp1651
g7
I157
sg8
VP13804
p1652
sg10
I3
sg11
VEMA
p1653
sg13
I1
sa(dp1654
g7
I163
sg8
g15
sg10
I9
sg11
Vclaudin-1
p1655
sg13
I1
sasg20
(lp1656
(dp1657
g7
I98
sg23
VC0751691
p1658
sg10
I13
sg11
Vperineuriomas
p1659
sg13
I1
sa(dp1660
g7
I115
sg23
VC0025286
p1661
sg10
I11
sg11
Vmeningiomas
p1662
sg13
I1
sa(dp1663
g7
I128
sg23
VC0268596
p1664
sg10
I27
sg11
Vepithelial membrane antigen
p1665
sg13
I3
sa(dp1666
g7
I4
sg23
VC0027651
p1667
sg10
I7
sg11
Vtumours
p1668
sg13
I1
sa(dp1669
g7
I157
sg23
VC0268596
p1670
sg10
I3
sg11
VEMA
p1671
sg13
I1
sasa(dp1672
g2
S'Of the meningiomas, EMA was expressed in 59 of 61, claudin-1 in five of 63, GLUT-1 in 19 of 62, SSTR2 in 59 of 68, and PR in 44 of 62.\n'
p1673
sg4
(lp1674
(dp1675
g7
I51
sg8
g15
sg10
I9
sg11
Vclaudin-1
p1676
sg13
I1
sasg20
(lp1677
(dp1678
g7
I7
sg23
VC0025286
p1679
sg10
I11
sg11
Vmeningiomas
p1680
sg13
I1
sa(dp1681
g7
I20
sg23
VC0268596
p1682
sg10
I3
sg11
VEMA
p1683
sg13
I1
sasa(dp1684
g2
S'The SSTR2-positive/PR-positive phenotype was detected in 42 of 60 meningiomas, but in none of 20 perineuriomas.\n'
p1685
sg4
(lp1686
(dp1687
g7
I4
sg8
VP30874
p1688
sg10
I5
sg11
VSSTR2
p1689
sg13
I1
sasg20
(lp1690
(dp1691
g7
I66
sg23
VC0025286
p1692
sg10
I11
sg11
Vmeningiomas
p1693
sg13
I1
sa(dp1694
g7
I97
sg23
VC0751691
p1695
sg10
I13
sg11
Vperineuriomas
p1696
sg13
I1
sasa(dp1697
g2
S'SSTR2 and PR are highly sensitive and, in this context, specific meningioma markers.\n'
p1698
sg4
(lp1699
(dp1700
g7
I0
sg8
VP30874
p1701
sg10
I5
sg11
VSSTR2
p1702
sg13
I1
sasg20
(lp1703
(dp1704
g7
I65
sg23
VC0025286
p1705
sg10
I10
sg11
Vmeningioma
p1706
sg13
I1
sasa(dp1707
g2
S'We utilized inhibitors of cPLA2 alpha, COX-1/2 and 5-LO to determine the potential roles of these enzymes in development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).\n'
p1708
sg4
(lp1709
(dp1710
g7
I39
sg8
VP00395
p1711
sg10
I7
sg11
VCOX-1/2
p1712
sg13
I1
sa(dp1713
g7
I26
sg8
VP47712
p1714
sg10
I11
sg11
VcPLA2 alpha
p1715
sg13
I2
sasg20
(lp1716
(dp1717
g7
I167
sg23
VC0014070
p1718
sg10
I3
sg11
VEAE
p1719
sg13
I1
sa(dp1720
g7
I212
sg23
VC0026769
p1721
sg10
I2
sg11
VMS
p1722
sg13
I1
sa(dp1723
g7
I148
sg23
VC0014070
p1724
sg10
I17
sg11
Vencephalomyelitis
p1725
sg13
I1
sa(dp1726
g7
I192
sg23
VC0026769
p1727
sg10
I18
sg11
Vmultiple sclerosis
p1728
sg13
I2
sa(dp1729
g7
I137
sg23
VC0443146
p1730
sg10
I10
sg11
Vautoimmune
p1731
sg13
I1
sasa(dp1732
g2
S'This study aimed to better understand the role of miR-200a-3p and its correlation with HBx in HBV-induced hepatocellular carcinoma (HCC).\n'
p1733
sg4
(lp1734
(dp1735
g7
I87
sg8
VP24821
p1736
sg10
I3
sg11
VHBx
p1737
sg13
I1
sa(dp1738
g7
I50
sg8
g15
sg10
I11
sg11
VmiR-200a-3p
p1739
sg13
I1
sasg20
(lp1740
(dp1741
g7
I106
sg23
VC2239176
p1742
sg10
I24
sg11
Vhepatocellular carcinoma
p1743
sg13
I2
sa(dp1744
g7
I94
sg23
VC0019163
p1745
sg10
I3
sg11
VHBV
p1746
sg13
I1
sa(dp1747
g7
I132
sg23
VC2239176
p1748
sg10
I3
sg11
VHCC
p1749
sg13
I1
sasa(dp1750
g2
S'Further study suggested that lncRNA-PE downregulated miR-200a/b by repressing the primary transcript expression, enhanced ZEB1 expression, and promoted epithelial-mesenchymal transition of hepatocellular carcinoma cells.\n'
p1751
sg4
(lp1752
(dp1753
g7
I53
sg8
g15
sg10
I10
sg11
VmiR-200a/b
p1754
sg13
I1
sa(dp1755
g7
I29
sg8
VP48147
p1756
sg10
I9
sg11
VlncRNA-PE
p1757
sg13
I1
sa(dp1758
g7
I122
sg8
VP37275
p1759
sg10
I4
sg11
VZEB1
p1760
sg13
I1
sasg20
(lp1761
(dp1762
g7
I175
sg23
VC0599156
p1763
sg10
I10
sg11
Vtransition
p1764
sg13
I1
sa(dp1765
g7
I189
sg23
VC1512411
p1766
sg10
I24
sg11
Vhepatocellular carcinoma
p1767
sg13
I2
sasa(dp1768
g2
S'All these data imply that lncRNA-PE might play an important role in hepatocellular carcinoma development via the miR-200a/b-ZEB1 pathway.\n'
p1769
sg4
(lp1770
(dp1771
g7
I26
sg8
VP48147
p1772
sg10
I9
sg11
VlncRNA-PE
p1773
sg13
I1
sa(dp1774
g7
I124
sg8
VP37275
p1775
sg10
I4
sg11
VZEB1
p1776
sg13
I1
sa(dp1777
g7
I113
sg8
g15
sg10
I8
sg11
VmiR-200a
p1778
sg13
I1
sasg20
(lp1779
(dp1780
g7
I68
sg23
VC1512411
p1781
sg10
I24
sg11
Vhepatocellular carcinoma
p1782
sg13
I2
sasa(dp1783
g2
S'Herein, we found that hepatocellular carcinoma cells shed more microvesicles than normal hepatocytes and miR-200a were shown to inhibit the release of microvesicles in hepatocellular carcinoma cells.\n'
p1784
sg4
(lp1785
(dp1786
g7
I105
sg8
g15
sg10
I8
sg11
VmiR-200a
p1787
sg13
I1
sasg20
(lp1788
(dp1789
g7
I22
sg23
VC1512411
p1790
sg10
I24
sg11
Vhepatocellular carcinoma
p1791
sg13
I2
sa(dp1792
g7
I22
sg23
VC1512411
p1793
sg10
I24
sg11
Vhepatocellular carcinoma
p1794
sg13
I2
sasa(dp1795
g2
S'Collectively, our findings indicate that miR-200a regulated the microvesicle biogenesis involved in the hepatocellular carcinoma progression.\n'
p1796
sg4
(lp1797
(dp1798
g7
I41
sg8
g15
sg10
I8
sg11
VmiR-200a
p1799
sg13
I1
sasg20
(lp1800
(dp1801
g7
I104
sg23
VC1512411
p1802
sg10
I24
sg11
Vhepatocellular carcinoma
p1803
sg13
I2
sasa(dp1804
g2
S'Conclusions: These findings indicate that miR-200a regulates the proliferation, migration and invasion of HCC cells by targeting Foxa2, suggesting that miR-200a may function as a potential therapeutic molecular for the diagnosis and treatment of the liver cancer.\n'
p1805
sg4
(lp1806
(dp1807
g7
I129
sg8
g15
sg10
I5
sg11
VFoxa2
p1808
sg13
I1
sa(dp1809
g7
I42
sg8
g15
sg10
I8
sg11
VmiR-200a
p1810
sg13
I1
sa(dp1811
g7
I42
sg8
g15
sg10
I8
sg11
VmiR-200a
p1812
sg13
I1
sasg20
(lp1813
(dp1814
g7
I65
sg23
VC0334094
p1815
sg10
I13
sg11
Vproliferation
p1816
sg13
I1
sa(dp1817
g7
I94
sg23
VC2699153
p1818
sg10
I8
sg11
Vinvasion
p1819
sg13
I1
sa(dp1820
g7
I250
sg23
VC0345904
p1821
sg10
I12
sg11
Vliver cancer
p1822
sg13
I2
sa(dp1823
g7
I106
sg23
VC2239176
p1824
sg10
I3
sg11
VHCC
p1825
sg13
I1
sasa(dp1826
g2
S'Long noncoding RNAs (lncRNAs)-activated by transforming growth factor beta (lncRNA-ATB) is known to be involved in the invasion of hepatocellular carcinoma by regulating target genes of miR-200a.\n'
p1827
sg4
(lp1828
(dp1829
g7
I186
sg8
g15
sg10
I8
sg11
VmiR-200a
p1830
sg13
I1
sa(dp1831
g7
I76
sg8
VP00325
p1832
sg10
I10
sg11
VlncRNA-ATB
p1833
sg13
I1
sa(dp1834
g7
I43
sg8
VP18075
p1835
sg10
I31
sg11
Vtransforming growth factor beta
p1836
sg13
I4
sasg20
(lp1837
(dp1838
g7
I119
sg23
VC2699153
p1839
sg10
I8
sg11
Vinvasion
p1840
sg13
I1
sa(dp1841
g7
I131
sg23
VC1512411
p1842
sg10
I24
sg11
Vhepatocellular carcinoma
p1843
sg13
I2
sasa(dp1844
g2
S'In this study, we determined that miR-200a was downregulated in hepatocellular carcinoma (HCC) tissues and cell lines, consistent with the results of our previous study.\n'
p1845
sg4
(lp1846
(dp1847
g7
I34
sg8
g15
sg10
I8
sg11
VmiR-200a
p1848
sg13
I1
sasg20
(lp1849
(dp1850
g7
I90
sg23
VC2239176
p1851
sg10
I3
sg11
VHCC
p1852
sg13
I1
sa(dp1853
g7
I64
sg23
VC2239176
p1854
sg10
I24
sg11
Vhepatocellular carcinoma
p1855
sg13
I2
sasa(dp1856
g2
S'Our data indicate that nine distinct genes associated with multiple sclerosis risk, Bach2, Il2ra, Irf8, Mertk, Odf3b, Plek, Rgs1, Slc30a7 and Thada, can be confirmed to be differentially regulated in pathogenic CD4(+) T cells.\n'
p1857
sg4
(lp1858
(dp1859
g7
I111
sg8
g15
sg10
I5
sg11
VOdf3b
p1860
sg13
I1
sa(dp1861
g7
I98
sg8
g15
sg10
I4
sg11
VIrf8
p1862
sg13
I1
sa(dp1863
g7
I91
sg8
VP01589
p1864
sg10
I5
sg11
VIl2ra
p1865
sg13
I1
sa(dp1866
g7
I104
sg8
g15
sg10
I5
sg11
VMertk
p1867
sg13
I1
sa(dp1868
g7
I211
sg8
VP01730
p1869
sg10
I3
sg11
VCD4
p1870
sg13
I1
sa(dp1871
g7
I84
sg8
g15
sg10
I5
sg11
VBach2
p1872
sg13
I1
sa(dp1873
g7
I130
sg8
g15
sg10
I7
sg11
VSlc30a7
p1874
sg13
I1
sa(dp1875
g7
I124
sg8
g15
sg10
I4
sg11
VRgs1
p1876
sg13
I1
sa(dp1877
g7
I118
sg8
VP08567
p1878
sg10
I4
sg11
VPlek
p1879
sg13
I1
sasg20
(lp1880
(dp1881
g7
I59
sg23
VC0026769
p1882
sg10
I18
sg11
Vmultiple sclerosis
p1883
sg13
I2
sasa(dp1884
g2
S"Genetic polymorphisms within a single locus encoding the transcription factor BACH2 are associated with numerous autoimmune and allergic diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1 diabetes.\n"
p1885
sg4
(lp1886
(dp1887
g7
I57
sg8
VP35398
p1888
sg10
I26
sg11
Vtranscription factor BACH2
p1889
sg13
I3
sasg20
(lp1890
(dp1891
g7
I208
sg23
VC0026769
p1892
sg10
I18
sg11
Vmultiple sclerosis
p1893
sg13
I2
sa(dp1894
g7
I164
sg23
VC0010346
p1895
sg10
I15
sg11
VCrohn's disease
p1896
sg13
I2
sa(dp1897
g7
I113
sg23
VC0443146
p1898
sg10
I10
sg11
Vautoimmune
p1899
sg13
I1
sa(dp1900
g7
I181
sg23
VC0007570
p1901
sg10
I15
sg11
Vcoeliac disease
p1902
sg13
I2
sa(dp1903
g7
I231
sg23
VC0011854
p1904
sg10
I15
sg11
Vtype 1 diabetes
p1905
sg13
I3
sa(dp1906
g7
I198
sg23
VC0042900
p1907
sg10
I8
sg11
Vvitiligo
p1908
sg13
I1
sa(dp1909
g7
I156
sg23
VC0004096
p1910
sg10
I6
sg11
Vasthma
p1911
sg13
I1
sasa(dp1912
g2
S'However, array-based copy number analysis and qPCR were used to detect a hemizygous deletion in the PACD linkage interval containing 4 genes encoding small leucine-rich proteoglycans (SLRPs): KERA, LUM, DCN, and EPYC.\n'
p1913
sg4
(lp1914
(dp1915
g7
I192
sg8
g15
sg10
I4
sg11
VKERA
p1916
sg13
I1
sa(dp1917
g7
I212
sg8
g15
sg10
I4
sg11
VEPYC
p1918
sg13
I1
sa(dp1919
g7
I198
sg8
VP51884
p1920
sg10
I3
sg11
VLUM
p1921
sg13
I1
sa(dp1922
g7
I203
sg8
VP07585
p1923
sg10
I3
sg11
VDCN
p1924
sg13
I1
sa(dp1925
g7
I184
sg8
g15
sg10
I5
sg11
VSLRPs
p1926
sg13
I1
sa(dp1927
g7
I150
sg8
VP30740
p1928
sg10
I32
sg11
Vsmall leucine-rich proteoglycans
p1929
sg13
I3
sasg20
(lp1930
(dp1931
g7
I100
sg23
VC2748502
p1932
sg10
I4
sg11
VPACD
p1933
sg13
I1
sasa(dp1934
g2
S'The authors performed clinical evaluation of a previously unreported pedigree with PACD, light and electron microscopic examination of an excised corneal button, genomewide linkage analysis, fine mapping linkage and haplotype analysis, and screening of four candidate genes (KERA, LUM, DCN, and EPYC).\n'
p1935
sg4
(lp1936
(dp1937
g7
I295
sg8
g15
sg10
I4
sg11
VEPYC
p1938
sg13
I1
sa(dp1939
g7
I286
sg8
VP07585
p1940
sg10
I3
sg11
VDCN
p1941
sg13
I1
sa(dp1942
g7
I275
sg8
g15
sg10
I4
sg11
VKERA
p1943
sg13
I1
sa(dp1944
g7
I281
sg8
VP51884
p1945
sg10
I3
sg11
VLUM
p1946
sg13
I1
sasg20
(lp1947
(dp1948
g7
I83
sg23
VC2748502
p1949
sg10
I4
sg11
VPACD
p1950
sg13
I1
sasa(dp1951
g2
S'Emerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer.\n'
p1952
sg4
(lp1953
(dp1954
g7
I42
sg8
g15
sg10
I5
sg11
VCD164
p1955
sg13
I1
sasg20
(lp1956
(dp1957
g7
I150
sg23
VC0684249
p1958
sg10
I11
sg11
Vlung cancer
p1959
sg13
I2
sa(dp1960
g7
I89
sg23
VC0027627
p1961
sg10
I10
sg11
Vmetastasis
p1962
sg13
I1
sa(dp1963
g7
I78
sg23
VC0001807
p1964
sg10
I10
sg11
Vaggressive
p1965
sg13
I1
sasa(dp1966
g2
S'However, no data are available regarding the clinical significance of CD164 expression in lung cancer.\n'
p1967
sg4
(lp1968
(dp1969
g7
I70
sg8
g15
sg10
I5
sg11
VCD164
p1970
sg13
I1
sasg20
(lp1971
(dp1972
g7
I90
sg23
VC0684249
p1973
sg10
I11
sg11
Vlung cancer
p1974
sg13
I2
sasa(dp1975
g2
S'Using tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer.\n'
p1976
sg4
(lp1977
(dp1978
g7
I44
sg8
g15
sg10
I5
sg11
VCD164
p1979
sg13
I1
sasg20
(lp1980
(dp1981
g7
I125
sg23
VC0684249
p1982
sg10
I11
sg11
Vlung cancer
p1983
sg13
I2
sasa(dp1984
g2
S'Therefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.\n'
p1985
sg4
(lp1986
(dp1987
g7
I29
sg8
g15
sg10
I5
sg11
VCD164
p1988
sg13
I1
sasg20
(lp1989
(dp1990
g7
I40
sg23
VC0006826
p1991
sg10
I6
sg11
Vcancer
p1992
sg13
I1
sa(dp1993
g7
I141
sg23
VC0684249
p1994
sg10
I11
sg11
Vlung cancer
p1995
sg13
I2
sasa(dp1996
g2
S'Cluster of differentiation 164 (CD164), a sialomucin, has been demonstrated to be involved in the regulation of proliferation, apoptosis, adhesion and differentiation in multiple cancers.\n'
p1997
sg4
(lp1998
(dp1999
g7
I42
sg8
g15
sg10
I10
sg11
Vsialomucin
p2000
sg13
I1
sa(dp2001
g7
I0
sg8
g15
sg10
I30
sg11
VCluster of differentiation 164
p2002
sg13
I4
sa(dp2003
g7
I32
sg8
g15
sg10
I5
sg11
VCD164
p2004
sg13
I1
sasg20
(lp2005
(dp2006
g7
I138
sg23
VC0001511
p2007
sg10
I8
sg11
Vadhesion
p2008
sg13
I1
sa(dp2009
g7
I112
sg23
VC0334094
p2010
sg10
I13
sg11
Vproliferation
p2011
sg13
I1
sa(dp2012
g7
I179
sg23
VC0006826
p2013
sg10
I7
sg11
Vcancers
p2014
sg13
I1
sasa(dp2015
g2
S'However, the involvement of CD164 in human glioma proliferation and apoptosis remains unknown.\n'
p2016
sg4
(lp2017
(dp2018
g7
I28
sg8
g15
sg10
I5
sg11
VCD164
p2019
sg13
I1
sasg20
(lp2020
(dp2021
g7
I43
sg23
VC0017638
p2022
sg10
I6
sg11
Vglioma
p2023
sg13
I1
sa(dp2024
g7
I50
sg23
VC0334094
p2025
sg10
I13
sg11
Vproliferation
p2026
sg13
I1
sasa(dp2027
g2
S'The aim of the present study was to investigate the expression and oncogenic function of CD164 in normal human astrocytes (NHA) and glioma cells in vitro and in vivo.\n'
p2028
sg4
(lp2029
(dp2030
g7
I89
sg8
g15
sg10
I5
sg11
VCD164
p2031
sg13
I1
sasg20
(lp2032
(dp2033
g7
I132
sg23
VC0017638
p2034
sg10
I6
sg11
Vglioma
p2035
sg13
I1
sasa(dp2036
g2
S'The results of the present study demonstrated that CD164 mRNA and protein levels were significantly increased in human glioma cell lines and tissue samples.\n'
p2037
sg4
(lp2038
(dp2039
g7
I51
sg8
g15
sg10
I10
sg11
VCD164 mRNA
p2040
sg13
I2
sasg20
(lp2041
(dp2042
g7
I119
sg23
VC0017638
p2043
sg10
I6
sg11
Vglioma
p2044
sg13
I1
sasa(dp2045
g2
S'Knockdown of CD164 inhibited cell proliferation and promoted apoptosis of the U87 human glioma cell line in vitro and in vivo.\n'
p2046
sg4
(lp2047
(dp2048
g7
I13
sg8
g15
sg10
I5
sg11
VCD164
p2049
sg13
I1
sasg20
(lp2050
(dp2051
g7
I88
sg23
VC0017638
p2052
sg10
I6
sg11
Vglioma
p2053
sg13
I1
sa(dp2054
g7
I34
sg23
VC0334094
p2055
sg10
I13
sg11
Vproliferation
p2056
sg13
I1
sasa(dp2057
g2
S'The results suggest that CD164 expression may have affected the proliferation and apoptosis of human glioma cells via the PTEN/phosphoinositide 3-kinase/AKT pathway, and may therefore present a potential target for the diagnosis and treatment of glioma.\n'
p2058
sg4
(lp2059
(dp2060
g7
I127
sg8
g15
sg10
I25
sg11
Vphosphoinositide 3-kinase
p2061
sg13
I2
sa(dp2062
g7
I122
sg8
VP60484
p2063
sg10
I4
sg11
VPTEN
p2064
sg13
I1
sa(dp2065
g7
I153
sg8
g15
sg10
I3
sg11
VAKT
p2066
sg13
I1
sa(dp2067
g7
I25
sg8
g15
sg10
I5
sg11
VCD164
p2068
sg13
I1
sasg20
(lp2069
(dp2070
g7
I64
sg23
VC0334094
p2071
sg10
I13
sg11
Vproliferation
p2072
sg13
I1
sa(dp2073
g7
I101
sg23
VC0017638
p2074
sg10
I6
sg11
Vglioma
p2075
sg13
I1
sa(dp2076
g7
I101
sg23
VC0017638
p2077
sg10
I6
sg11
Vglioma
p2078
sg13
I1
sasa(dp2079
g2
S'We recently demonstrated the high expression of CD164 on CD4+ T cells from Sezary syndrome patients with a wide range of circulating tumor burdens.\n'
p2080
sg4
(lp2081
(dp2082
g7
I48
sg8
g15
sg10
I5
sg11
VCD164
p2083
sg13
I1
sa(dp2084
g7
I57
sg8
VP01730
p2085
sg10
I4
sg11
VCD4+
p2086
sg13
I1
sasg20
(lp2087
(dp2088
g7
I133
sg23
VC0027651
p2089
sg10
I5
sg11
Vtumor
p2090
sg13
I1
sa(dp2091
g7
I75
sg23
VC0036920
p2092
sg10
I15
sg11
VSezary syndrome
p2093
sg13
I2
sasa(dp2094
g2
S'Our results suggest that miR-124 function as a tumor suppressor miRNA and suppress tumor proliferation and aggression by directly targeting oncogenic CD164 signaling pathway in NSCLC.\n'
p2095
sg4
(lp2096
(dp2097
g7
I150
sg8
g15
sg10
I5
sg11
VCD164
p2098
sg13
I1
sasg20
(lp2099
(dp2100
g7
I47
sg23
VC0027651
p2101
sg10
I5
sg11
Vtumor
p2102
sg13
I1
sa(dp2103
g7
I47
sg23
VC0027651
p2104
sg10
I5
sg11
Vtumor
p2105
sg13
I1
sa(dp2106
g7
I177
sg23
VC0007131
p2107
sg10
I5
sg11
VNSCLC
p2108
sg13
I1
sa(dp2109
g7
I107
sg23
VC0001807
p2110
sg10
I10
sg11
Vaggression
p2111
sg13
I1
sa(dp2112
g7
I89
sg23
VC0334094
p2113
sg10
I13
sg11
Vproliferation
p2114
sg13
I1
sasa(dp2115
g2
S'In a cohort of patients with Sezary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls.\n'
p2116
sg4
(lp2117
(dp2118
g7
I72
sg8
VP01730
p2119
sg10
I4
sg11
VCD4+
p2120
sg13
I1
sa(dp2121
g7
I46
sg8
g15
sg10
I5
sg11
VCD164
p2122
sg13
I1
sasg20
(lp2123
(dp2124
g7
I29
sg23
VC0036920
p2125
sg10
I15
sg11
VSezary syndrome
p2126
sg13
I2
sasa(dp2127
g2
S'Increased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sezary syndrome.\n'
p2128
sg4
(lp2129
(dp2130
g7
I24
sg8
g15
sg10
I5
sg11
VCD164
p2131
sg13
I1
sa(dp2132
g7
I24
sg8
g15
sg10
I5
sg11
VCD164
p2133
sg13
I1
sasg20
(lp2134
(dp2135
g7
I136
sg23
VC0036920
p2136
sg10
I15
sg11
VSezary syndrome
p2137
sg13
I2
sasa(dp2138
g2
S'These results indicate that miR-219 suppresses the proliferation, migration and invasion of medulloblastoma cells by targeting CD164.\n'
p2139
sg4
(lp2140
(dp2141
g7
I127
sg8
g15
sg10
I5
sg11
VCD164
p2142
sg13
I1
sasg20
(lp2143
(dp2144
g7
I80
sg23
VC2699153
p2145
sg10
I8
sg11
Vinvasion
p2146
sg13
I1
sa(dp2147
g7
I51
sg23
VC0334094
p2148
sg10
I13
sg11
Vproliferation
p2149
sg13
I1
sa(dp2150
g7
I92
sg23
VC0025149
p2151
sg10
I15
sg11
Vmedulloblastoma
p2152
sg13
I1
sasa(dp2153
g2
S'Despite the known engagement of the AFAP1-AS in several human diseases, its biological function in Hirschsprung disease (HSCR) remains elusive.\n'
p2154
sg4
(lp2155
(dp2156
g7
I36
sg8
g15
sg10
I8
sg11
VAFAP1-AS
p2157
sg13
I1
sa(dp2158
g7
I121
sg8
VP14138
p2159
sg10
I4
sg11
VHSCR
p2160
sg13
I1
sa(dp2161
g7
I99
sg8
VP14138
p2162
sg10
I20
sg11
VHirschsprung disease
p2163
sg13
I2
sasg20
(lp2164
(dp2165
g7
I121
sg23
VC2931876
p2166
sg10
I4
sg11
VHSCR
p2167
sg13
I1
sa(dp2168
g7
I99
sg23
VC0019569
p2169
sg10
I20
sg11
VHirschsprung disease
p2170
sg13
I2
sasa(dp2171
g2
S'This prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients.\n'
p2172
sg4
(lp2173
(dp2174
g7
I304
sg8
g15
sg10
I37
sg11
Vprogressive myoclonic epilepsy type 1
p2175
sg13
I5
sa(dp2176
g7
I343
sg8
g15
sg10
I4
sg11
VPME1
p2177
sg13
I1
sasg20
(lp2178
(dp2179
g7
I115
sg23
VC0014548
p2180
sg10
I20
sg11
Vgeneralized epilepsy
p2181
sg13
I2
sa(dp2182
g7
I147
sg23
VC0270850
p2183
sg10
I32
sg11
Vidiopathic generalized syndromes
p2184
sg13
I3
sa(dp2185
g7
I393
sg23
VC0751122
p2186
sg10
I4
sg11
VSMEI
p2187
sg13
I1
sa(dp2188
g7
I304
sg23
VC0751778
p2189
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p2190
sg13
I3
sa(dp2191
g7
I234
sg23
VC0014553
p2192
sg10
I16
sg11
Vabsence epilepsy
p2193
sg13
I2
sa(dp2194
g7
I393
sg23
VC0751122
p2195
sg10
I4
sg11
VSMEI
p2196
sg13
I1
sa(dp2197
g7
I355
sg23
VC0751122
p2198
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p2199
sg13
I5
sa(dp2200
g7
I181
sg23
VC0270850
p2201
sg10
I3
sg11
VIGE
p2202
sg13
I1
sa(dp2203
g7
I475
sg23
VC0014544
p2204
sg10
I9
sg11
Vepileptic
p2205
sg13
I1
sa(dp2206
g7
I200
sg23
VC0270853
p2207
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p2208
sg13
I3
sa(dp2209
g7
I429
sg23
VC0238111
p2210
sg10
I23
sg11
VLennox-Gastaut syndrome
p2211
sg13
I2
sa(dp2212
g7
I181
sg23
VC0270850
p2213
sg10
I3
sg11
VIGE
p2214
sg13
I1
sa(dp2215
g7
I136
sg23
VC0039082
p2216
sg10
I9
sg11
Vsyndromes
p2217
sg13
I1
sasa(dp2218
g2
S'The International League Against Epilepsy (ILAE) classification recognizes 2 forms of myoclonic epilepsy with a good prognosis: benign myoclonic epilepsy of infancy (BMEI) and juvenile myoclonic epilepsy (JME); recent studies confirm the efficacy of levetiracetam (LEV) in treating idiopathic generalized epilepsies (IGE) in patients with myoclonic seizures.\n'
p2219
sg4
(lp2220
sg20
(lp2221
(dp2222
g7
I86
sg23
VC0014550
p2223
sg10
I18
sg11
Vmyoclonic epilepsy
p2224
sg13
I2
sa(dp2225
g7
I339
sg23
VC0014550
p2226
sg10
I18
sg11
Vmyoclonic seizures
p2227
sg13
I2
sa(dp2228
g7
I317
sg23
VC0270850
p2229
sg10
I3
sg11
VIGE
p2230
sg13
I1
sa(dp2231
g7
I86
sg23
VC0014550
p2232
sg10
I18
sg11
Vmyoclonic epilepsy
p2233
sg13
I2
sa(dp2234
g7
I205
sg23
VC0270853
p2235
sg10
I3
sg11
VJME
p2236
sg13
I1
sa(dp2237
g7
I33
sg23
VC0014544
p2238
sg10
I8
sg11
VEpilepsy
p2239
sg13
I1
sa(dp2240
g7
I176
sg23
VC0270853
p2241
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p2242
sg13
I3
sa(dp2243
g7
I282
sg23
VC0270850
p2244
sg10
I33
sg11
Vidiopathic generalized epilepsies
p2245
sg13
I3
sasa(dp2246
g2
S'We evaluated 35 patients (21 female, mean age 24.7 years) with different types of generalised epilepsies (juvenile myoclonic epilepsy (JME), severe myoclonic epilepsy of infancy (SMEI), Lennox-Gastaut syndrome (LGS), myoclonic-astatic epilepsy (MAE), myoclonic absences (MA), benign myoclonic epilepsy in infancy (BMEI) and 4 patients had unspecified epileptic syndromes).\n'
p2247
sg4
(lp2248
sg20
(lp2249
(dp2250
g7
I211
sg23
VC0023003
p2251
sg10
I3
sg11
VLGS
p2252
sg13
I1
sa(dp2253
g7
I125
sg23
VC0014544
p2254
sg10
I8
sg11
Vepilepsy
p2255
sg13
I1
sa(dp2256
g7
I314
sg23
VC0751120
p2257
sg10
I4
sg11
VBMEI
p2258
sg13
I1
sa(dp2259
g7
I135
sg23
VC0270853
p2260
sg10
I3
sg11
VJME
p2261
sg13
I1
sa(dp2262
g7
I276
sg23
VC0751120
p2263
sg10
I36
sg11
Vbenign myoclonic epilepsy in infancy
p2264
sg13
I5
sa(dp2265
g7
I179
sg23
VC0751122
p2266
sg10
I4
sg11
VSMEI
p2267
sg13
I1
sa(dp2268
g7
I361
sg23
VC0039082
p2269
sg10
I9
sg11
Vsyndromes
p2270
sg13
I1
sa(dp2271
g7
I141
sg23
VC0751122
p2272
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p2273
sg13
I5
sa(dp2274
g7
I186
sg23
VC0238111
p2275
sg10
I23
sg11
VLennox-Gastaut syndrome
p2276
sg13
I2
sa(dp2277
g7
I106
sg23
VC0270853
p2278
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p2279
sg13
I3
sa(dp2280
g7
I351
sg23
VC0014544
p2281
sg10
I9
sg11
Vepileptic
p2282
sg13
I1
sa(dp2283
g7
I94
sg23
VC0014544
p2284
sg10
I10
sg11
Vepilepsies
p2285
sg13
I1
sasa(dp2286
g2
S'The electroclinical features suggested juvenile myoclonic epilepsy in 14 patients, progressive myoclonus epilepsy in three, progressive familial cerebellar ataxia with myoclonus in two, and severe myoclonic epilepsy of infancy in one.\n'
p2287
sg4
(lp2288
sg20
(lp2289
(dp2290
g7
I83
sg23
VC0751778
p2291
sg10
I30
sg11
Vprogressive myoclonus epilepsy
p2292
sg13
I3
sa(dp2293
g7
I190
sg23
VC0751122
p2294
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p2295
sg13
I5
sa(dp2296
g7
I136
sg23
VC0270749
p2297
sg10
I26
sg11
Vfamilial cerebellar ataxia
p2298
sg13
I3
sa(dp2299
g7
I39
sg23
VC0270853
p2300
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p2301
sg13
I3
sa(dp2302
g7
I95
sg23
VC0027066
p2303
sg10
I9
sg11
Vmyoclonus
p2304
sg13
I1
sasa(dp2305
g2
S'In the idiopathic generalized epilepsies we consider the benign myoclonic epilepsy of infancy and its reflex variant, juvenile myoclonic epilepsy and palpebral myoclonias with absences.\n'
p2306
sg4
(lp2307
sg20
(lp2308
(dp2309
g7
I118
sg23
VC0270853
p2310
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p2311
sg13
I3
sa(dp2312
g7
I18
sg23
VC0014548
p2313
sg10
I22
sg11
Vgeneralized epilepsies
p2314
sg13
I2
sa(dp2315
g7
I64
sg23
VC0014550
p2316
sg10
I18
sg11
Vmyoclonic epilepsy
p2317
sg13
I2
sasa(dp2318
g2
S'Group 5 comprises the true myoclonic epilepsies, differentiating syndromes recognized as idiopathic--such as "Benign myoclonic epilepsy of infancy" and "Juvenile myoclonic epilepsy"--from those which are cryptogenic and carry a more cautious prognosis--as "Cryptogenic myoclonic and myoclonoastatic epilepsies" and "Severe myoclonic epilepsy of infancy".\n'
p2319
sg4
(lp2320
sg20
(lp2321
(dp2322
g7
I117
sg23
VC0014550
p2323
sg10
I18
sg11
Vmyoclonic epilepsy
p2324
sg13
I2
sa(dp2325
g7
I27
sg23
VC0014550
p2326
sg10
I20
sg11
Vmyoclonic epilepsies
p2327
sg13
I2
sa(dp2328
g7
I37
sg23
VC0014544
p2329
sg10
I10
sg11
Vepilepsies
p2330
sg13
I1
sa(dp2331
g7
I153
sg23
VC0270853
p2332
sg10
I27
sg11
VJuvenile myoclonic epilepsy
p2333
sg13
I3
sa(dp2334
g7
I316
sg23
VC0751122
p2335
sg10
I36
sg11
VSevere myoclonic epilepsy of infancy
p2336
sg13
I5
sa(dp2337
g7
I65
sg23
VC0039082
p2338
sg10
I9
sg11
Vsyndromes
p2339
sg13
I1
sasa(dp2340
g2
S'Interaction studies also showed that CEP78 binds to FAM161A, another ciliary protein associated with retinal degeneration.\n'
p2341
sg4
(lp2342
(dp2343
g7
I52
sg8
g15
sg10
I7
sg11
VFAM161A
p2344
sg13
I1
sa(dp2345
g7
I37
sg8
g15
sg10
I5
sg11
VCEP78
p2346
sg13
I1
sasg20
(lp2347
(dp2348
g7
I101
sg23
VC0035304
p2349
sg10
I20
sg11
Vretinal degeneration
p2350
sg13
I2
sasa(dp2351
g2
S'Altogether, our data strongly suggest that mutations in CEP78 cause a previously undescribed clinical entity of a ciliary nature characterized by blindness and deafness but clearly distinct from Usher syndrome, a condition for which visual impairment is due to retinitis pigmentosa.\n'
p2352
sg4
(lp2353
(dp2354
g7
I56
sg8
g15
sg10
I5
sg11
VCEP78
p2355
sg13
I1
sasg20
(lp2356
(dp2357
g7
I261
sg23
VC0035334
p2358
sg10
I20
sg11
Vretinitis pigmentosa
p2359
sg13
I2
sa(dp2360
g7
I195
sg23
VC0271097
p2361
sg10
I14
sg11
VUsher syndrome
p2362
sg13
I2
sa(dp2363
g7
I160
sg23
VC0011053
p2364
sg10
I8
sg11
Vdeafness
p2365
sg13
I1
sa(dp2366
g7
I233
sg23
VC3489703
p2367
sg10
I17
sg11
Vvisual impairment
p2368
sg13
I2
sa(dp2369
g7
I213
sg23
VC0012634
p2370
sg10
I9
sg11
Vcondition
p2371
sg13
I1
sa(dp2372
g7
I146
sg23
VC0456909
p2373
sg10
I9
sg11
Vblindness
p2374
sg13
I1
sasa(dp2375
g2
S'Methods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age &gt; 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening.\n'
p2376
sg4
(lp2377
sg20
(lp2378
(dp2379
g7
I49
sg23
VC1527249
p2380
sg10
I17
sg11
Vcolorectal cancer
p2381
sg13
I2
sa(dp2382
g7
I70
sg23
VC0025202
p2383
sg10
I8
sg11
Vmelanoma
p2384
sg13
I1
sasa(dp2385
g2
S'ConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P &lt; .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total).\n'
p2386
sg4
(lp2387
(dp2388
g7
I122
sg8
VP12314
p2389
sg10
I4
sg11
VFCRI
p2390
sg13
I1
sa(dp2391
g7
I122
sg8
VP12314
p2392
sg10
I4
sg11
VFCRI
p2393
sg13
I1
sasg20
(lp2394
(dp2395
g7
I353
sg23
VC0815107
p2396
sg10
I22
sg11
Vpsychological distress
p2397
sg13
I2
sa(dp2398
g7
I422
sg23
VC0006826
p2399
sg10
I6
sg11
Vcancer
p2400
sg13
I1
sasa(dp2401
g2
S'Differences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3.\n'
p2402
sg4
(lp2403
sg20
(lp2404
(dp2405
g7
I20
sg23
VC0815107
p2406
sg10
I22
sg11
Vpsychological distress
p2407
sg13
I2
sa(dp2408
g7
I47
sg23
VC0006826
p2409
sg10
I6
sg11
Vcancer
p2410
sg13
I1
sasa(dp2411
g2
S'Ganoderic acid interacts and modulates the signaling network in IR, IGFR-1, IGFR-2, VEGFR-1, VEFGR-2, and EGFR in cancer signaling pathways.\n'
p2412
sg4
(lp2413
(dp2414
g7
I68
sg8
VP08069
p2415
sg10
I6
sg11
VIGFR-1
p2416
sg13
I1
sa(dp2417
g7
I84
sg8
VP17948
p2418
sg10
I7
sg11
VVEGFR-1
p2419
sg13
I1
sa(dp2420
g7
I76
sg8
VP08069
p2421
sg10
I6
sg11
VIGFR-2
p2422
sg13
I1
sasg20
(lp2423
(dp2424
g7
I114
sg23
VC0006826
p2425
sg10
I6
sg11
Vcancer
p2426
sg13
I1
sasa(dp2427
g2
S'Sixty-four patients with hematological tumors were selected and divided into the group complicated with bacterial infection (infection group, 33 cases) and the non-infection group (31 cases), the flow cytometry was be used to detect the related peripheral blood markers CD64 and CD14, the nCD64 IND and CD14 IND were calculated, and the peripheral blood WBC count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined at the same time.\n'
p2428
sg4
(lp2429
(dp2430
g7
I406
sg8
VP02741
p2431
sg10
I18
sg11
VC-reactive protein
p2432
sg13
I2
sa(dp2433
g7
I279
sg8
VP08571
p2434
sg10
I4
sg11
VCD14
p2435
sg13
I1
sa(dp2436
g7
I426
sg8
VP02741
p2437
sg10
I3
sg11
VCRP
p2438
sg13
I1
sa(dp2439
g7
I270
sg8
VP12314
p2440
sg10
I4
sg11
VCD64
p2441
sg13
I1
sa(dp2442
g7
I303
sg8
VP08571
p2443
sg10
I8
sg11
VCD14 IND
p2444
sg13
I2
sasg20
(lp2445
(dp2446
g7
I25
sg23
VC0376545
p2447
sg10
I20
sg11
Vhematological tumors
p2448
sg13
I2
sa(dp2449
g7
I104
sg23
VC0004623
p2450
sg10
I19
sg11
Vbacterial infection
p2451
sg13
I2
sa(dp2452
g7
I114
sg23
VC0009450
p2453
sg10
I9
sg11
Vinfection
p2454
sg13
I1
sa(dp2455
g7
I114
sg23
VC0009450
p2456
sg10
I9
sg11
Vinfection
p2457
sg13
I1
sasa(dp2458
g2
S'The study objectives are to translate the FCRI in Dutch, and to explore the factor structure and the psychometric qualities of the Dutch translation of the Fear of Cancer Recurrence Inventory (FCRI-NL).\n'
p2459
sg4
(lp2460
sg20
(lp2461
(dp2462
g7
I164
sg23
VC0920420
p2463
sg10
I17
sg11
VCancer Recurrence
p2464
sg13
I2
sa(dp2465
g7
I156
sg23
VC0233705
p2466
sg10
I14
sg11
VFear of Cancer
p2467
sg13
I3
sasa(dp2468
g2
S'The Severity subscale (FCRI-SF-NL) may be a valuable screening tool for fear of cancer recurrence severity in clinical care.\n'
p2469
sg4
(lp2470
sg20
(lp2471
(dp2472
g7
I80
sg23
VC0920420
p2473
sg10
I17
sg11
Vcancer recurrence
p2474
sg13
I2
sa(dp2475
g7
I72
sg23
VC0233705
p2476
sg10
I14
sg11
Vfear of cancer
p2477
sg13
I3
sasa(dp2478
g2
S'FCI features, with single-tube 8-color combination using CD45, CD34, HAL-DR, CD11b, CD13, CD33, and CD117 and CD64, were compared for the 30 consecutive APL and 30 non-APL acute myeloid leukemia (AML) cases which morphologically mimicked an APL.\n'
p2479
sg4
(lp2480
(dp2481
g7
I100
sg8
VP10721
p2482
sg10
I5
sg11
VCD117
p2483
sg13
I1
sa(dp2484
g7
I57
sg8
VP08575
p2485
sg10
I4
sg11
VCD45
p2486
sg13
I1
sa(dp2487
g7
I90
sg8
VP20138
p2488
sg10
I4
sg11
VCD33
p2489
sg13
I1
sa(dp2490
g7
I84
sg8
VP15144
p2491
sg10
I4
sg11
VCD13
p2492
sg13
I1
sa(dp2493
g7
I77
sg8
VP11215
p2494
sg10
I5
sg11
VCD11b
p2495
sg13
I1
sa(dp2496
g7
I69
sg8
VP42357
p2497
sg10
I6
sg11
VHAL-DR
p2498
sg13
I1
sa(dp2499
g7
I110
sg8
VP12314
p2500
sg10
I4
sg11
VCD64
p2501
sg13
I1
sa(dp2502
g7
I63
sg8
VP28906
p2503
sg10
I4
sg11
VCD34
p2504
sg13
I1
sasg20
(lp2505
(dp2506
g7
I196
sg23
VC0023467
p2507
sg10
I3
sg11
VAML
p2508
sg13
I1
sa(dp2509
g7
I153
sg23
VC0023487
p2510
sg10
I3
sg11
VAPL
p2511
sg13
I1
sa(dp2512
g7
I172
sg23
VC0023467
p2513
sg10
I22
sg11
Vacute myeloid leukemia
p2514
sg13
I3
sa(dp2515
g7
I153
sg23
VC0023487
p2516
sg10
I3
sg11
VAPL
p2517
sg13
I1
sa(dp2518
g7
I153
sg23
VC0023487
p2519
sg10
I3
sg11
VAPL
p2520
sg13
I1
sasa(dp2521
g2
S'Recently, CLPB deficiency has been shown to cause a genetic syndrome with cataracts, neutropenia, and 3-methylglutaconic aciduria.\n'
p2522
sg4
(lp2523
(dp2524
g7
I10
sg8
g15
sg10
I4
sg11
VCLPB
p2525
sg13
I1
sasg20
(lp2526
(dp2527
g7
I102
sg23
VC0342727
p2528
sg10
I27
sg11
V3-methylglutaconic aciduria
p2529
sg13
I2
sa(dp2530
g7
I52
sg23
VC0567439
p2531
sg10
I16
sg11
Vgenetic syndrome
p2532
sg13
I2
sa(dp2533
g7
I74
sg23
VC0521707
p2534
sg10
I9
sg11
Vcataracts
p2535
sg13
I1
sasa(dp2536
g2
S'CLPB deficiency should be considered in neonates with absence of voluntary movements, respiratory insufficiency and swallowing problems, especially if associated with 3-methylglutaconic aciduria, neutropenia and cataracts.\n'
p2537
sg4
(lp2538
sg20
(lp2539
(dp2540
g7
I167
sg23
VC0342727
p2541
sg10
I27
sg11
V3-methylglutaconic aciduria
p2542
sg13
I2
sa(dp2543
g7
I86
sg23
VC0035229
p2544
sg10
I25
sg11
Vrespiratory insufficiency
p2545
sg13
I2
sa(dp2546
g7
I212
sg23
VC0521707
p2547
sg10
I9
sg11
Vcataracts
p2548
sg13
I1
sa(dp2549
g7
I116
sg23
VC0392678
p2550
sg10
I19
sg11
Vswallowing problems
p2551
sg13
I2
sasa(dp2552
g2
S'Mutations in CLPB, SERAC1, TAZ genes were identified in neonates with 3-methylglutaconic aciduria (3-MGA) as a discriminative feature.\n'
p2553
sg4
(lp2554
(dp2555
g7
I27
sg8
g15
sg10
I9
sg11
VTAZ genes
p2556
sg13
I2
sa(dp2557
g7
I19
sg8
g15
sg10
I6
sg11
VSERAC1
p2558
sg13
I1
sasg20
(lp2559
(dp2560
g7
I99
sg23
VC0342727
p2561
sg10
I5
sg11
V3-MGA
p2562
sg13
I1
sa(dp2563
g7
I70
sg23
VC0342727
p2564
sg10
I27
sg11
V3-methylglutaconic aciduria
p2565
sg13
I2
sasa(dp2566
g2
S'Altogether, our study suggests that disruption of CLPB causes a novel form of neonatal encephalopathy associated with 3-methylglutaconic aciduria.\n'
p2567
sg4
(lp2568
(dp2569
g7
I50
sg8
g15
sg10
I4
sg11
VCLPB
p2570
sg13
I1
sasg20
(lp2571
(dp2572
g7
I78
sg23
VC0235820
p2573
sg10
I23
sg11
Vneonatal encephalopathy
p2574
sg13
I2
sa(dp2575
g7
I118
sg23
VC0342727
p2576
sg10
I27
sg11
V3-methylglutaconic aciduria
p2577
sg13
I2
sasa(dp2578
g2
S'Taken together, mutations in CLPB define a syndrome with intellectual disability, congenital neutropenia, progressive brain atrophy, movement disorder, cataracts, and 3-methylglutaconic aciduria.\n'
p2579
sg4
(lp2580
sg20
(lp2581
(dp2582
g7
I152
sg23
VC0521707
p2583
sg10
I9
sg11
Vcataracts
p2584
sg13
I1
sa(dp2585
g7
I57
sg23
VC0025362
p2586
sg10
I23
sg11
Vintellectual disability
p2587
sg13
I2
sa(dp2588
g7
I167
sg23
VC0342727
p2589
sg10
I27
sg11
V3-methylglutaconic aciduria
p2590
sg13
I2
sa(dp2591
g7
I82
sg23
VC0340970
p2592
sg10
I22
sg11
Vcongenital neutropenia
p2593
sg13
I2
sa(dp2594
g7
I133
sg23
VC0026650
p2595
sg10
I17
sg11
Vmovement disorder
p2596
sg13
I2
sa(dp2597
g7
I43
sg23
VC0039082
p2598
sg10
I8
sg11
Vsyndrome
p2599
sg13
I1
sa(dp2600
g7
I118
sg23
VC0235946
p2601
sg10
I13
sg11
Vbrain atrophy
p2602
sg13
I2
sasa(dp2603
g2
S'We conclude that accumulation of protein aggregates underlies the development of cataracts and nephrocalcinosis in CLPB deficiency, which is a novel genetic cause of 3-methylglutaconic aciduria.\n'
p2604
sg4
(lp2605
sg20
(lp2606
(dp2607
g7
I95
sg23
VC0027709
p2608
sg10
I16
sg11
Vnephrocalcinosis
p2609
sg13
I1
sa(dp2610
g7
I81
sg23
VC0521707
p2611
sg10
I9
sg11
Vcataracts
p2612
sg13
I1
sa(dp2613
g7
I166
sg23
VC0342727
p2614
sg10
I27
sg11
V3-methylglutaconic aciduria
p2615
sg13
I2
sasa(dp2616
g2
S'We now propose that perturbation of the mitochondrial membranes by abnormal protein aggregates leads to 3-methylglutaconic aciduria in CLPB deficiency.\n'
p2617
sg4
(lp2618
sg20
(lp2619
(dp2620
g7
I104
sg23
VC0342727
p2621
sg10
I27
sg11
V3-methylglutaconic aciduria
p2622
sg13
I2
sasa(dp2623
g2
S'Here, we present mechanistic details about the Hsp100 chaperone inhibition by GdmCl using the Hsp104 homolog ClpB from Thermus thermophilus.\n'
p2624
sg4
(lp2625
(dp2626
g7
I94
sg8
g15
sg10
I19
sg11
VHsp104 homolog ClpB
p2627
sg13
I3
sasg20
(lp2628
sa(dp2629
g2
S'We present a crystal structure of ClpB NBD1 in complex with GdmCl and ADP, showing that the Gdm(+) ion binds specifically to the active site of NBD1.\n'
p2630
sg4
(lp2631
(dp2632
g7
I34
sg8
g15
sg10
I9
sg11
VClpB NBD1
p2633
sg13
I2
sasg20
(lp2634
(dp2635
g7
I60
sg23
VC0085207
p2636
sg10
I3
sg11
VGdm
p2637
sg13
I1
sasa(dp2638
g2
S'One patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia.\n'
p2639
sg4
(lp2640
(dp2641
g7
I53
sg8
VP09683
p2642
sg10
I8
sg11
Vsecretin
p2643
sg13
I1
sasg20
(lp2644
(dp2645
g7
I160
sg23
VC0020507
p2646
sg10
I11
sg11
Vhyperplasia
p2647
sg13
I1
sa(dp2648
g7
I17
sg23
VC0027773
p2649
sg10
I16
sg11
Vnesidioblastosis
p2650
sg13
I1
sasa(dp2651
g2
S'In addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia.\n'
p2652
sg4
(lp2653
(dp2654
g7
I39
sg8
VP09683
p2655
sg10
I8
sg11
Vsecretin
p2656
sg13
I1
sasg20
(lp2657
(dp2658
g7
I176
sg23
VC0020507
p2659
sg10
I11
sg11
Vhyperplasia
p2660
sg13
I1
sa(dp2661
g7
I91
sg23
VC0021670
p2662
sg10
I11
sg11
Vinsulinomas
p2663
sg13
I1
sa(dp2664
g7
I107
sg23
VC0027773
p2665
sg10
I16
sg11
Vnesidioblastosis
p2666
sg13
I1
sa(dp2667
g7
I163
sg23
VC0001430
p2668
sg10
I8
sg11
Vadenomas
p2669
sg13
I1
sasa(dp2670
g2
S'In addition, HLXB9 is recurrently rearranged in young children with acute myeloid leukemia characterized by a chromosomal translocation t(7;12)-HLXB9/TEL and concomitant high expression of the unrearranged, wild-type HLXB9 allele.\n'
p2671
sg4
(lp2672
(dp2673
g7
I13
sg8
VP50219
p2674
sg10
I5
sg11
VHLXB9
p2675
sg13
I1
sa(dp2676
g7
I207
sg8
VP50219
p2677
sg10
I22
sg11
Vwild-type HLXB9 allele
p2678
sg13
I3
sa(dp2679
g7
I150
sg8
VP41212
p2680
sg10
I3
sg11
VTEL
p2681
sg13
I1
sa(dp2682
g7
I13
sg8
VP50219
p2683
sg10
I5
sg11
VHLXB9
p2684
sg13
I1
sasg20
(lp2685
(dp2686
g7
I110
sg23
VC0040715
p2687
sg10
I25
sg11
Vchromosomal translocation
p2688
sg13
I2
sa(dp2689
g7
I68
sg23
VC0023467
p2690
sg10
I22
sg11
Vacute myeloid leukemia
p2691
sg13
I3
sasa(dp2692
g2
S'Herein, we report the clinical course of an 8-month-old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement.\n'
p2693
sg4
(lp2694
(dp2695
g7
I121
sg8
VP41212
p2696
sg10
I3
sg11
VTEL
p2697
sg13
I1
sa(dp2698
g7
I115
sg8
VP50219
p2699
sg10
I5
sg11
VHLXB9
p2700
sg13
I1
sasg20
(lp2701
(dp2702
g7
I69
sg23
VC0023467
p2703
sg10
I22
sg11
Vacute myeloid leukemia
p2704
sg13
I3
sasa(dp2705
g2
S'Using RT-PCR, we screened members of the EHG family of homeobox genes, comprising EN1 (at 2q14), GBX2 (at 2q36), and EN2, GBX1, and HLXB9 (at 7q36), for dysregulation in acute myeloid leukemia (AML) cell lines indicated by chromosomal breakpoints at these sites.\n'
p2706
sg4
(lp2707
(dp2708
g7
I55
sg8
VP52954
p2709
sg10
I14
sg11
Vhomeobox genes
p2710
sg13
I2
sa(dp2711
g7
I97
sg8
VP52951
p2712
sg10
I4
sg11
VGBX2
p2713
sg13
I1
sa(dp2714
g7
I122
sg8
g15
sg10
I4
sg11
VGBX1
p2715
sg13
I1
sa(dp2716
g7
I132
sg8
VP50219
p2717
sg10
I5
sg11
VHLXB9
p2718
sg13
I1
sa(dp2719
g7
I117
sg8
VP41208
p2720
sg10
I3
sg11
VEN2
p2721
sg13
I1
sasg20
(lp2722
(dp2723
g7
I194
sg23
VC0023467
p2724
sg10
I3
sg11
VAML
p2725
sg13
I1
sa(dp2726
g7
I170
sg23
VC0023467
p2727
sg10
I22
sg11
Vacute myeloid leukemia
p2728
sg13
I3
sasa(dp2729
g2
S'Previously, we showed that KLF5 is a mediator of RAS/MAPK and WNT signaling pathways under homeostatic conditions and that it promotes their tumorigenic functions during the development and progression of intestinal adenomas.\n'
p2730
sg4
(lp2731
(dp2732
g7
I27
sg8
g15
sg10
I4
sg11
VKLF5
p2733
sg13
I1
sa(dp2734
g7
I53
sg8
VP53779
p2735
sg10
I4
sg11
VMAPK
p2736
sg13
I1
sa(dp2737
g7
I49
sg8
VP01116
p2738
sg10
I3
sg11
VRAS
p2739
sg13
I1
sasg20
(lp2740
(dp2741
g7
I216
sg23
VC0001430
p2742
sg10
I8
sg11
Vadenomas
p2743
sg13
I1
sasa(dp2744
g2
S'Moreover, production of lethal adenomas and carcinomas by specific expression of an oncogenic mutant of Beta-catenin in Lgr5(+) stem cells was suppressed completely by Klf5 deletion in the same cells.\n'
p2745
sg4
(lp2746
(dp2747
g7
I168
sg8
g15
sg10
I13
sg11
VKlf5 deletion
p2748
sg13
I2
sa(dp2749
g7
I120
sg8
g15
sg10
I4
sg11
VLgr5
p2750
sg13
I1
sa(dp2751
g7
I104
sg8
VP35222
p2752
sg10
I12
sg11
VBeta-catenin
p2753
sg13
I1
sasg20
(lp2754
(dp2755
g7
I31
sg23
VC0001430
p2756
sg10
I8
sg11
Vadenomas
p2757
sg13
I1
sa(dp2758
g7
I44
sg23
VC0007097
p2759
sg10
I10
sg11
Vcarcinomas
p2760
sg13
I1
sa(dp2761
g7
I94
sg23
VC0596988
p2762
sg10
I6
sg11
Vmutant
p2763
sg13
I1
sasa(dp2764
g2
S'Elevated levels of two particular Fbxw7 substrates, Klf5 and Tgif1, were found in normal intestine and adenomas of R482Q/+, R482Q/R482Q and Fbxw7(-/-) mice, but not Fbxw7(+/-) animals.\n'
p2765
sg4
(lp2766
(dp2767
g7
I52
sg8
g15
sg10
I4
sg11
VKlf5
p2768
sg13
I1
sa(dp2769
g7
I61
sg8
g15
sg10
I5
sg11
VTgif1
p2770
sg13
I1
sa(dp2771
g7
I34
sg8
g15
sg10
I5
sg11
VFbxw7
p2772
sg13
I1
sa(dp2773
g7
I34
sg8
g15
sg10
I5
sg11
VFbxw7
p2774
sg13
I1
sa(dp2775
g7
I34
sg8
g15
sg10
I5
sg11
VFbxw7
p2776
sg13
I1
sasg20
(lp2777
(dp2778
g7
I103
sg23
VC0001430
p2779
sg10
I8
sg11
Vadenomas
p2780
sg13
I1
sasa(dp2781
g2
S'Here we investigated the in vivo effect of Klf5 heterozygosity on the propensity of ApcMin/KRASV12 double transgenic mice to develop intestinal tumors.\n'
p2782
sg4
(lp2783
(dp2784
g7
I43
sg8
g15
sg10
I4
sg11
VKlf5
p2785
sg13
I1
sasg20
(lp2786
(dp2787
g7
I133
sg23
VC0021841
p2788
sg10
I17
sg11
Vintestinal tumors
p2789
sg13
I2
sasa(dp2790
g2
S'To determine whether KLF5 contributes to intestinal adenoma formation, we examined tumor burdens in Apc(Min/+) mice and Apc(Min/+)/Klf5(+/-) mice.\n'
p2791
sg4
(lp2792
(dp2793
g7
I100
sg8
VP25054
p2794
sg10
I3
sg11
VApc
p2795
sg13
I1
sa(dp2796
g7
I100
sg8
VP25054
p2797
sg10
I3
sg11
VApc
p2798
sg13
I1
sa(dp2799
g7
I21
sg8
g15
sg10
I4
sg11
VKLF5
p2800
sg13
I1
sa(dp2801
g7
I131
sg8
g15
sg10
I4
sg11
VKlf5
p2802
sg13
I1
sasg20
(lp2803
(dp2804
g7
I41
sg23
VC1142339
p2805
sg10
I18
sg11
Vintestinal adenoma
p2806
sg13
I2
sa(dp2807
g7
I83
sg23
VC0027651
p2808
sg10
I5
sg11
Vtumor
p2809
sg13
I1
sa(dp2810
g7
I100
sg23
VC0033036
p2811
sg10
I3
sg11
VApc
p2812
sg13
I1
sa(dp2813
g7
I100
sg23
VC0033036
p2814
sg10
I3
sg11
VApc
p2815
sg13
I1
sasa(dp2816
g2
S'Compared with Apc(Min/+) mice, Apc(Min/+)/Klf5(+/-) mice had a 96% reduction in the number of intestinal adenomas.\n'
p2817
sg4
(lp2818
(dp2819
g7
I14
sg8
VP25054
p2820
sg10
I3
sg11
VApc
p2821
sg13
I1
sa(dp2822
g7
I42
sg8
g15
sg10
I4
sg11
VKlf5
p2823
sg13
I1
sa(dp2824
g7
I14
sg8
VP25054
p2825
sg10
I3
sg11
VApc
p2826
sg13
I1
sasg20
(lp2827
(dp2828
g7
I14
sg23
VC0033036
p2829
sg10
I3
sg11
VApc
p2830
sg13
I1
sa(dp2831
g7
I105
sg23
VC0001430
p2832
sg10
I8
sg11
Vadenomas
p2833
sg13
I1
sa(dp2834
g7
I14
sg23
VC0033036
p2835
sg10
I3
sg11
VApc
p2836
sg13
I1
sasa(dp2837
g2
S'Thus, KLF5 is necessary for the tumor-initiating activity of beta-catenin during intestinal adenoma formation in Apc(Min/+) mice, and reduced expression of KLF5 offsets the tumor-initiating activity of the Apc(Min) mutation by reducing the nuclear localization and activity of beta-catenin.\n'
p2838
sg4
(lp2839
(dp2840
g7
I6
sg8
g15
sg10
I4
sg11
VKLF5
p2841
sg13
I1
sa(dp2842
g7
I61
sg8
VP35222
p2843
sg10
I12
sg11
Vbeta-catenin
p2844
sg13
I1
sa(dp2845
g7
I113
sg8
VP25054
p2846
sg10
I3
sg11
VApc
p2847
sg13
I1
sa(dp2848
g7
I6
sg8
g15
sg10
I4
sg11
VKLF5
p2849
sg13
I1
sa(dp2850
g7
I61
sg8
VP35222
p2851
sg10
I12
sg11
Vbeta-catenin
p2852
sg13
I1
sa(dp2853
g7
I113
sg8
VP25054
p2854
sg10
I3
sg11
VApc
p2855
sg13
I1
sasg20
(lp2856
(dp2857
g7
I113
sg23
VC0033036
p2858
sg10
I3
sg11
VApc
p2859
sg13
I1
sa(dp2860
g7
I81
sg23
VC1142339
p2861
sg10
I18
sg11
Vintestinal adenoma
p2862
sg13
I2
sa(dp2863
g7
I32
sg23
VC0027651
p2864
sg10
I5
sg11
Vtumor
p2865
sg13
I1
sa(dp2866
g7
I113
sg23
VC0033036
p2867
sg10
I3
sg11
VApc
p2868
sg13
I1
sa(dp2869
g7
I32
sg23
VC0027651
p2870
sg10
I5
sg11
Vtumor
p2871
sg13
I1
sasa(dp2872
g2
S'KLF5 expression was examined in intestinal tumors derived from transgenic mice expressing KRAS(V12G) under villin promoter and in human colorectal cancers with mutated KRAS.\n'
p2873
sg4
(lp2874
(dp2875
g7
I90
sg8
VP01116
p2876
sg10
I4
sg11
VKRAS
p2877
sg13
I1
sa(dp2878
g7
I107
sg8
VP09327
p2879
sg10
I15
sg11
Vvillin promoter
p2880
sg13
I2
sa(dp2881
g7
I0
sg8
g15
sg10
I4
sg11
VKLF5
p2882
sg13
I1
sa(dp2883
g7
I90
sg8
VP01116
p2884
sg10
I4
sg11
VKRAS
p2885
sg13
I1
sasg20
(lp2886
(dp2887
g7
I32
sg23
VC0021841
p2888
sg10
I17
sg11
Vintestinal tumors
p2889
sg13
I2
sa(dp2890
g7
I136
sg23
VC1527249
p2891
sg10
I18
sg11
Vcolorectal cancers
p2892
sg13
I2
sasa(dp2893
g2
S'In vivo, both intestinal tumors derived from mice transgenic for villin-KRAS(V12G) and human primary colorectal cancers with mutated KRAS contained high levels of KLF5 and increased staining of the proliferative marker Ki67.\n'
p2894
sg4
(lp2895
(dp2896
g7
I65
sg8
VP09327
p2897
sg10
I6
sg11
Vvillin
p2898
sg13
I1
sa(dp2899
g7
I72
sg8
VP01116
p2900
sg10
I4
sg11
VKRAS
p2901
sg13
I1
sa(dp2902
g7
I72
sg8
VP01116
p2903
sg10
I4
sg11
VKRAS
p2904
sg13
I1
sa(dp2905
g7
I163
sg8
g15
sg10
I4
sg11
VKLF5
p2906
sg13
I1
sasg20
(lp2907
(dp2908
g7
I198
sg23
VC0334094
p2909
sg10
I13
sg11
Vproliferative
p2910
sg13
I1
sa(dp2911
g7
I14
sg23
VC0021841
p2912
sg10
I17
sg11
Vintestinal tumors
p2913
sg13
I2
sa(dp2914
g7
I101
sg23
VC1527249
p2915
sg10
I18
sg11
Vcolorectal cancers
p2916
sg13
I2
sasa(dp2917
g2
S'Elevated levels of KLF5 protein are strongly correlated with activating KRAS mutations in intestinal tumors in vitro and in vivo.\n'
p2918
sg4
(lp2919
(dp2920
g7
I19
sg8
g15
sg10
I12
sg11
VKLF5 protein
p2921
sg13
I2
sa(dp2922
g7
I72
sg8
VP01116
p2923
sg10
I4
sg11
VKRAS
p2924
sg13
I1
sasg20
(lp2925
(dp2926
g7
I90
sg23
VC0021841
p2927
sg10
I17
sg11
Vintestinal tumors
p2928
sg13
I2
sasa(dp2929
g2
S'Ras-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors.\n'
p2930
sg4
(lp2931
(dp2932
g7
I141
sg8
g15
sg10
I12
sg11
VKLF5 protein
p2933
sg13
I2
sa(dp2934
g7
I108
sg8
g15
sg10
I9
sg11
VKLF5 mRNA
p2935
sg13
I2
sa(dp2936
g7
I48
sg8
g15
sg10
I4
sg11
VKLF5
p2937
sg13
I1
sa(dp2938
g7
I0
sg8
VP01116
p2939
sg10
I3
sg11
VRas
p2940
sg13
I1
sasg20
(lp2941
(dp2942
g7
I163
sg23
VC0021841
p2943
sg10
I17
sg11
Vintestinal tumors
p2944
sg13
I2
sa(dp2945
g7
I4
sg23
VC1510411
p2946
sg10
I14
sg11
Vtransformation
p2947
sg13
I1
sasa(dp2948
g2
S'Reduced levels of KLF5 mRNA were also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with normal crypt epithelium, indicating that down-regulation of KLF5 is an early event in intestinal tumorigenesis in vivo.\n'
p2949
sg4
(lp2950
(dp2951
g7
I18
sg8
g15
sg10
I4
sg11
VKLF5
p2952
sg13
I1
sa(dp2953
g7
I18
sg8
g15
sg10
I9
sg11
VKLF5 mRNA
p2954
sg13
I2
sasg20
(lp2955
(dp2956
g7
I75
sg23
VC0032580
p2957
sg10
I30
sg11
Vfamilial adenomatous polyposis
p2958
sg13
I3
sa(dp2959
g7
I106
sg23
VC0001430
p2960
sg10
I8
sg11
Vadenomas
p2961
sg13
I1
sa(dp2962
g7
I226
sg23
VC0007621
p2963
sg10
I13
sg11
Vtumorigenesis
p2964
sg13
I1
sa(dp2965
g7
I50
sg23
VC0033036
p2966
sg10
I3
sg11
VAPC
p2967
sg13
I1
sasa(dp2968
g2
S'Collectively, these data indicate that intestinal tumor progression is associated with a change in the growth-related functions of KLF5 and that intestinal tumors down-regulate KLF5 expression by multiple mechanisms.\n'
p2969
sg4
(lp2970
(dp2971
g7
I131
sg8
g15
sg10
I4
sg11
VKLF5
p2972
sg13
I1
sa(dp2973
g7
I131
sg8
g15
sg10
I4
sg11
VKLF5
p2974
sg13
I1
sasg20
(lp2975
(dp2976
g7
I145
sg23
VC0021841
p2977
sg10
I17
sg11
Vintestinal tumors
p2978
sg13
I2
sa(dp2979
g7
I50
sg23
VC0178874
p2980
sg10
I17
sg11
Vtumor progression
p2981
sg13
I2
sasa(dp2982
g2
S'Variable major lipoprotein (Vmp) is a major tumor necrosis factor (TNF)-inducing component of Borrelia recurrentis, the agent of louse-borne relapsing fever.\n'
p2983
sg4
(lp2984
(dp2985
g7
I44
sg8
VP01375
p2986
sg10
I21
sg11
Vtumor necrosis factor
p2987
sg13
I3
sa(dp2988
g7
I67
sg8
VP01375
p2989
sg10
I3
sg11
VTNF
p2990
sg13
I1
sasg20
(lp2991
(dp2992
g7
I94
sg23
VC0024198
p2993
sg10
I8
sg11
VBorrelia
p2994
sg13
I1
sa(dp2995
g7
I129
sg23
VC0152061
p2996
sg10
I27
sg11
Vlouse-borne relapsing fever
p2997
sg13
I3
sa(dp2998
g7
I44
sg23
VC0333516
p2999
sg10
I14
sg11
Vtumor necrosis
p3000
sg13
I2
sasa(dp3001
g2
S'Louse-borne relapsing fever, caused by Borrelia recurrentis, provides one of the best documented examples of the causative role of tumor necrosis factor (TNF) in the pathology of severe infection in humans.\n'
p3002
sg4
(lp3003
(dp3004
g7
I154
sg8
VP01375
p3005
sg10
I3
sg11
VTNF
p3006
sg13
I1
sa(dp3007
g7
I131
sg8
VP01375
p3008
sg10
I21
sg11
Vtumor necrosis factor
p3009
sg13
I3
sasg20
(lp3010
(dp3011
g7
I186
sg23
VC0009450
p3012
sg10
I9
sg11
Vinfection
p3013
sg13
I1
sa(dp3014
g7
I166
sg23
VC0677042
p3015
sg10
I9
sg11
Vpathology
p3016
sg13
I1
sa(dp3017
g7
I0
sg23
VC0152061
p3018
sg10
I27
sg11
VLouse-borne relapsing fever
p3019
sg13
I3
sa(dp3020
g7
I131
sg23
VC0333516
p3021
sg10
I14
sg11
Vtumor necrosis
p3022
sg13
I2
sa(dp3023
g7
I39
sg23
VC0024198
p3024
sg10
I8
sg11
VBorrelia
p3025
sg13
I1
sasa(dp3026
g2
S'Severe Jarisch Herxheimer reaction (J-HR) precipitated by antibiotic treatment of louse-borne relapsing fever (LBRF) is associated with a transient, marked rise in circulating tumour necrosis factor alpha (TNF alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8).\n'
p3027
sg4
(lp3028
(dp3029
g7
I206
sg8
VP01375
p3030
sg10
I9
sg11
VTNF alpha
p3031
sg13
I2
sa(dp3032
g7
I258
sg8
VP60568
p3033
sg10
I4
sg11
VIL-8
p3034
sg13
I1
sa(dp3035
g7
I218
sg8
VP05231
p3036
sg10
I13
sg11
Vinterleukin 6
p3037
sg13
I2
sa(dp3038
g7
I233
sg8
VP05231
p3039
sg10
I4
sg11
VIL-6
p3040
sg13
I1
sa(dp3041
g7
I176
sg8
VP01375
p3042
sg10
I28
sg11
Vtumour necrosis factor alpha
p3043
sg13
I4
sa(dp3044
g7
I243
sg8
VP60568
p3045
sg10
I13
sg11
Vinterleukin 8
p3046
sg13
I2
sasg20
(lp3047
(dp3048
g7
I111
sg23
VC0152061
p3049
sg10
I4
sg11
VLBRF
p3050
sg13
I1
sa(dp3051
g7
I82
sg23
VC0152061
p3052
sg10
I27
sg11
Vlouse-borne relapsing fever
p3053
sg13
I3
sa(dp3054
g7
I176
sg23
VC0333516
p3055
sg10
I15
sg11
Vtumour necrosis
p3056
sg13
I2
sasa(dp3057
g2
S'In patients with louse-borne relapsing fever (Borrelia recurrentis infection), antimicrobial treatment is often followed by sudden fever, rigors, and persistent hypotension (Jarisch-Herxheimer reactions) that are associated with increases in plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interleukin-8.\n'
p3058
sg4
(lp3059
(dp3060
g7
I296
sg8
VP01375
p3061
sg10
I9
sg11
VTNF-alpha
p3062
sg13
I1
sa(dp3063
g7
I327
sg8
VP60568
p3064
sg10
I13
sg11
Vinterleukin-8
p3065
sg13
I1
sa(dp3066
g7
I308
sg8
VP05231
p3067
sg10
I13
sg11
Vinterleukin-6
p3068
sg13
I1
sa(dp3069
g7
I267
sg8
VP01375
p3070
sg10
I27
sg11
Vtumor necrosis factor alpha
p3071
sg13
I4
sasg20
(lp3072
(dp3073
g7
I267
sg23
VC0333516
p3074
sg10
I14
sg11
Vtumor necrosis
p3075
sg13
I2
sa(dp3076
g7
I17
sg23
VC0152061
p3077
sg10
I27
sg11
Vlouse-borne relapsing fever
p3078
sg13
I3
sa(dp3079
g7
I46
sg23
VC0857817
p3080
sg10
I30
sg11
VBorrelia recurrentis infection
p3081
sg13
I3
sa(dp3082
g7
I138
sg23
VC0424790
p3083
sg10
I6
sg11
Vrigors
p3084
sg13
I1
sasa(dp3085
g2
S'Pretreatment with sheep anti-TNF-alpha Fab suppresses Jarisch-Herxheimer reactions that occur after penicillin treatment for louse-borne relapsing fever, reduces the associated increases in plasma concentrations of interleukin-6 and interleukin-8, and may be useful in other forms of sepsis.\n'
p3086
sg4
(lp3087
(dp3088
g7
I233
sg8
VP60568
p3089
sg10
I13
sg11
Vinterleukin-8
p3090
sg13
I1
sa(dp3091
g7
I215
sg8
VP05231
p3092
sg10
I13
sg11
Vinterleukin-6
p3093
sg13
I1
sa(dp3094
g7
I24
sg8
VP01375
p3095
sg10
I18
sg11
Vanti-TNF-alpha Fab
p3096
sg13
I2
sasg20
(lp3097
(dp3098
g7
I125
sg23
VC0152061
p3099
sg10
I27
sg11
Vlouse-borne relapsing fever
p3100
sg13
I3
sa(dp3101
g7
I284
sg23
VC0243026
p3102
sg10
I6
sg11
Vsepsis
p3103
sg13
I1
sasa(dp3104
g2
S'A frail 84-year old lady with situs inversus totalis and symptomatic aortic stenosis underwent a successful transcatheter aortic valve implantation (TAVI) after extensive diagnostic work-up.\n'
p3105
sg4
(lp3106
sg20
(lp3107
(dp3108
g7
I57
sg23
VC0741183
p3109
sg10
I27
sg11
Vsymptomatic aortic stenosis
p3110
sg13
I3
sa(dp3111
g7
I30
sg23
VC0037221
p3112
sg10
I14
sg11
Vsitus inversus
p3113
sg13
I2
sasa(dp3114
g2
S"Here, we report the first known case of Marfan's syndrome, combined with situs inversus totalis with dextrocardia and discrete subaortic stenosis and aortic insufficiency in a 22-year-old woman.\n"
p3115
sg4
(lp3116
sg20
(lp3117
(dp3118
g7
I101
sg23
VC0011813
p3119
sg10
I12
sg11
Vdextrocardia
p3120
sg13
I1
sa(dp3121
g7
I118
sg23
VC0012628
p3122
sg10
I27
sg11
Vdiscrete subaortic stenosis
p3123
sg13
I3
sa(dp3124
g7
I73
sg23
VC0037221
p3125
sg10
I14
sg11
Vsitus inversus
p3126
sg13
I2
sa(dp3127
g7
I40
sg23
VC0024796
p3128
sg10
I17
sg11
VMarfan's syndrome
p3129
sg13
I2
sa(dp3130
g7
I150
sg23
VC0003504
p3131
sg10
I20
sg11
Vaortic insufficiency
p3132
sg13
I2
sasa(dp3133
g2
S'Low-frequency artifacts that plague traditional TIE methods can be suppressed without an excessive number of captured images.\n'
p3134
sg4
(lp3135
sg20
(lp3136
(dp3137
g7
I29
sg23
VC0032064
p3138
sg10
I6
sg11
Vplague
p3139
sg13
I1
sasa(dp3140
g2
S'The FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.\n'
p3141
sg4
(lp3142
(dp3143
g7
I4
sg8
VP31371
p3144
sg10
I14
sg11
VFGF9 subfamily
p3145
sg13
I2
sa(dp3146
g7
I4
sg8
VP31371
p3147
sg10
I4
sg11
VFGF9
p3148
sg13
I1
sa(dp3149
g7
I36
sg8
g15
sg10
I5
sg11
VFGF16
p3150
sg13
I1
sa(dp3151
g7
I47
sg8
g15
sg10
I5
sg11
VFGF20
p3152
sg13
I1
sasg20
(lp3153
(dp3154
g7
I169
sg23
VC2239176
p3155
sg10
I24
sg11
Vhepatocellular carcinoma
p3156
sg13
I2
sa(dp3157
g7
I195
sg23
VC2239176
p3158
sg10
I3
sg11
VHCC
p3159
sg13
I1
sa(dp3160
g7
I127
sg23
VC0334094
p3161
sg10
I13
sg11
Vproliferation
p3162
sg13
I1
sasa(dp3163
g2
S'FGF16 promoted proliferation and invasion behavior of SKOV-3 ovarian cancer cells, whose function may be similar in lung cancer.\n'
p3164
sg4
(lp3165
(dp3166
g7
I0
sg8
g15
sg10
I5
sg11
VFGF16
p3167
sg13
I1
sasg20
(lp3168
(dp3169
g7
I61
sg23
VC1140680
p3170
sg10
I14
sg11
Vovarian cancer
p3171
sg13
I2
sa(dp3172
g7
I33
sg23
VC2699153
p3173
sg10
I8
sg11
Vinvasion
p3174
sg13
I1
sa(dp3175
g7
I116
sg23
VC0684249
p3176
sg10
I11
sg11
Vlung cancer
p3177
sg13
I2
sa(dp3178
g7
I15
sg23
VC0334094
p3179
sg10
I13
sg11
Vproliferation
p3180
sg13
I1
sasa(dp3181
g2
S'This finding indicated possible involvement of FGF16 in ovarian cancer progression.\n'
p3182
sg4
(lp3183
(dp3184
g7
I47
sg8
g15
sg10
I5
sg11
VFGF16
p3185
sg13
I1
sasg20
(lp3186
(dp3187
g7
I64
sg23
VC0178874
p3188
sg10
I18
sg11
Vcancer progression
p3189
sg13
I2
sasa(dp3190
g2
S'We observed that FGF16 stimulates the proliferation of human ovarian adenocarcinoma cells, SKOV-3 and OAW-42.\n'
p3191
sg4
(lp3192
(dp3193
g7
I17
sg8
g15
sg10
I5
sg11
VFGF16
p3194
sg13
I1
sasg20
(lp3195
(dp3196
g7
I61
sg23
VC0948216
p3197
sg10
I22
sg11
Vovarian adenocarcinoma
p3198
sg13
I2
sa(dp3199
g7
I38
sg23
VC0334094
p3200
sg10
I13
sg11
Vproliferation
p3201
sg13
I1
sasa(dp3202
g2
S'Taken together, our findings indicate that FGF16 in conjunction with Wnt pathway contributes to the cancer phenotype of ovarian cells and suggests that modulation of its expression in ovarian cells might be a promising therapeutic strategy for the treatment of invasive ovarian cancers.\n'
p3203
sg4
(lp3204
(dp3205
g7
I43
sg8
g15
sg10
I5
sg11
VFGF16
p3206
sg13
I1
sasg20
(lp3207
(dp3208
g7
I270
sg23
VC1140680
p3209
sg10
I15
sg11
Vovarian cancers
p3210
sg13
I2
sa(dp3211
g7
I100
sg23
VC0006826
p3212
sg10
I6
sg11
Vcancer
p3213
sg13
I1
sasa(dp3214
g2
S'Loss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.\n'
p3215
sg4
(lp3216
(dp3217
g7
I34
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3218
sg13
I2
sasg20
(lp3219
(dp3220
g7
I50
sg23
VC0175692
p3221
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3222
sg13
I2
sasa(dp3223
g2
S'Johanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.\n'
p3224
sg4
(lp3225
sg20
(lp3226
(dp3227
g7
I336
sg23
VC0000768
p3228
sg10
I13
sg11
Vmalformations
p3229
sg13
I1
sa(dp3230
g7
I0
sg23
VC0175692
p3231
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3232
sg13
I2
sa(dp3233
g7
I300
sg23
VC0020676
p3234
sg10
I14
sg11
Vhypothyroidism
p3235
sg13
I1
sa(dp3236
g7
I28
sg23
VC0175692
p3237
sg10
I3
sg11
VJBS
p3238
sg13
I1
sa(dp3239
g7
I174
sg23
VC0267963
p3240
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3241
sg13
I3
sasa(dp3242
g2
S"There are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).\n"
p3243
sg4
(lp3244
sg20
(lp3245
(dp3246
g7
I199
sg23
VC1838348
p3247
sg10
I4
sg11
VOFCs
p3248
sg13
I1
sa(dp3249
g7
I176
sg23
VC1838348
p3250
sg10
I21
sg11
Voblique facial clefts
p3251
sg13
I3
sa(dp3252
g7
I39
sg23
VC0795841
p3253
sg10
I3
sg11
VJBS
p3254
sg13
I1
sasa(dp3255
g2
S'We describe the clinical aspects in four patients with JBS and extensive OFCs.\n'
p3256
sg4
(lp3257
sg20
(lp3258
(dp3259
g7
I55
sg23
VC0795841
p3260
sg10
I3
sg11
VJBS
p3261
sg13
I1
sasa(dp3262
g2
S'In all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.\n'
p3263
sg4
(lp3264
(dp3265
g7
I128
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3266
sg13
I2
sasg20
(lp3267
(dp3268
g7
I33
sg23
VC0795841
p3269
sg10
I3
sg11
VJBS
p3270
sg13
I1
sasa(dp3271
g2
S'Additionally, we review three previously reported cases of JBS with OFCs.\n'
p3272
sg4
(lp3273
sg20
(lp3274
(dp3275
g7
I59
sg23
VC0795841
p3276
sg10
I3
sg11
VJBS
p3277
sg13
I1
sasa(dp3278
g2
S'Taking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.\n'
p3279
sg4
(lp3280
sg20
(lp3281
(dp3282
g7
I74
sg23
VC0795841
p3283
sg10
I3
sg11
VJBS
p3284
sg13
I1
sa(dp3285
g7
I74
sg23
VC0795841
p3286
sg10
I3
sg11
VJBS
p3287
sg13
I1
sasa(dp3288
g2
S'This report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.\n'
p3289
sg4
(lp3290
sg20
(lp3291
(dp3292
g7
I84
sg23
VC0266617
p3293
sg10
I20
sg11
Vfacial malformations
p3294
sg13
I2
sa(dp3295
g7
I118
sg23
VC0795841
p3296
sg10
I3
sg11
VJBS
p3297
sg13
I1
sasa(dp3298
g2
S'Johanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.\n'
p3299
sg4
(lp3300
sg20
(lp3301
(dp3302
g7
I0
sg23
VC0175692
p3303
sg10
I26
sg11
VJohanson-Blizzard Syndrome
p3304
sg13
I2
sa(dp3305
g7
I77
sg23
VC0019247
p3306
sg10
I16
sg11
Vgenetic disorder
p3307
sg13
I2
sa(dp3308
g7
I28
sg23
VC0175692
p3309
sg10
I3
sg11
VJBS
p3310
sg13
I1
sa(dp3311
g7
I196
sg23
VC0025362
p3312
sg10
I18
sg11
Vmental retardation
p3313
sg13
I2
sa(dp3314
g7
I111
sg23
VC0267963
p3315
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3316
sg13
I3
sasa(dp3317
g2
S'Here, we report a 3 year-old mentally normal JBS girl.\n'
p3318
sg4
(lp3319
sg20
(lp3320
(dp3321
g7
I45
sg23
VC0795841
p3322
sg10
I3
sg11
VJBS
p3323
sg13
I1
sasa(dp3324
g2
S'With these findings, JBS diagnosis was established clinically.\n'
p3325
sg4
(lp3326
sg20
(lp3327
(dp3328
g7
I21
sg23
VC0795841
p3329
sg10
I3
sg11
VJBS
p3330
sg13
I1
sasa(dp3331
g2
S'Johanson-Blizzard syndrome (JBS) is a rare autosomal recessive syndrome characterized by dysmorphic nasal alae, ectodermal abnormalities, exocrine pancreatic insufficiency and early growth failure.\n'
p3332
sg4
(lp3333
sg20
(lp3334
(dp3335
g7
I138
sg23
VC0267963
p3336
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3337
sg13
I3
sa(dp3338
g7
I0
sg23
VC0175692
p3339
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3340
sg13
I2
sa(dp3341
g7
I28
sg23
VC0175692
p3342
sg10
I3
sg11
VJBS
p3343
sg13
I1
sa(dp3344
g7
I182
sg23
VC0878787
p3345
sg10
I14
sg11
Vgrowth failure
p3346
sg13
I2
sa(dp3347
g7
I18
sg23
VC0039082
p3348
sg10
I8
sg11
Vsyndrome
p3349
sg13
I1
sasa(dp3350
g2
S'Nonsense, frame shift and splice-site mutations of the ubiquitin ligase gene (UBR1) lead to early loss of acinar cells in individuals with JBS.\n'
p3351
sg4
(lp3352
(dp3353
g7
I55
sg8
g15
sg10
I21
sg11
Vubiquitin ligase gene
p3354
sg13
I3
sa(dp3355
g7
I78
sg8
g15
sg10
I4
sg11
VUBR1
p3356
sg13
I1
sasg20
(lp3357
(dp3358
g7
I139
sg23
VC0795841
p3359
sg10
I3
sg11
VJBS
p3360
sg13
I1
sasa(dp3361
g2
S'This case illustrates that the phenotypic variability of pancreatic involvement in JBS may be subtle and may not manifest until the second decade of life.\n'
p3362
sg4
(lp3363
(dp3364
g7
I83
sg8
g15
sg10
I3
sg11
VJBS
p3365
sg13
I1
sasg20
(lp3366
(dp3367
g7
I83
sg23
VC0795841
p3368
sg10
I3
sg11
VJBS
p3369
sg13
I1
sasa(dp3370
g2
S'Johanson-Blizzard syndrome (JBS) is a rare autosomal recessive disorder resulting from loss-of-function mutations in the UBR1 gene.\n'
p3371
sg4
(lp3372
(dp3373
g7
I121
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3374
sg13
I2
sasg20
(lp3375
(dp3376
g7
I0
sg23
VC0175692
p3377
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3378
sg13
I2
sa(dp3379
g7
I28
sg23
VC0175692
p3380
sg10
I3
sg11
VJBS
p3381
sg13
I1
sasa(dp3382
g2
S'JBS can be easily recognized by its unique clinical presentation (including exocrine pancreatic insufficiency, hypoplasia/aplasia of the alae nasi, congenital scalp defects, sensorineural hearing loss, growth retardation, psychomotor retardation, and anal and genitourinary anomalies).\n'
p3383
sg4
(lp3384
sg20
(lp3385
(dp3386
g7
I174
sg23
VC0018784
p3387
sg10
I26
sg11
Vsensorineural hearing loss
p3388
sg13
I3
sa(dp3389
g7
I76
sg23
VC0267963
p3390
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3391
sg13
I3
sa(dp3392
g7
I202
sg23
VC0151686
p3393
sg10
I18
sg11
Vgrowth retardation
p3394
sg13
I2
sa(dp3395
g7
I122
sg23
VC0243065
p3396
sg10
I7
sg11
Vaplasia
p3397
sg13
I1
sa(dp3398
g7
I0
sg23
VC0795841
p3399
sg10
I3
sg11
VJBS
p3400
sg13
I1
sa(dp3401
g7
I111
sg23
VC0243069
p3402
sg10
I10
sg11
Vhypoplasia
p3403
sg13
I1
sasa(dp3404
g2
S'The objective of this study is to report on the first familial case of gender-discordant twins presenting JBS and a novel mutation in the UBR1 gene.\n'
p3405
sg4
(lp3406
(dp3407
g7
I138
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3408
sg13
I2
sasg20
(lp3409
(dp3410
g7
I116
sg23
VC2985438
p3411
sg10
I14
sg11
Vnovel mutation
p3412
sg13
I2
sa(dp3413
g7
I106
sg23
VC0795841
p3414
sg10
I3
sg11
VJBS
p3415
sg13
I1
sasa(dp3416
g2
S'We also review literature describing molecularly confirmed cases of JBS.\n'
p3417
sg4
(lp3418
sg20
(lp3419
(dp3420
g7
I68
sg23
VC0795841
p3421
sg10
I3
sg11
VJBS
p3422
sg13
I1
sasa(dp3423
g2
S'Both patients presented typical clinical features of JBS.\n'
p3424
sg4
(lp3425
sg20
(lp3426
(dp3427
g7
I53
sg23
VC0795841
p3428
sg10
I3
sg11
VJBS
p3429
sg13
I1
sasa(dp3430
g2
S'Severe presentation of JBS usually involves deleterious (nonsense, frameshift, or splice-site) mutations in the UBR1 gene that are thought to completely abolish the expression of a functional protein product, as in this familial case; however, milder presentation of JBS has occasionally been observed with missense mutations in at least 1 of the 2 copies of UBR1, in which there may be residual activity of the product of this gene.\n'
p3431
sg4
(lp3432
(dp3433
g7
I112
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3434
sg13
I2
sa(dp3435
g7
I112
sg8
g15
sg10
I4
sg11
VUBR1
p3436
sg13
I1
sasg20
(lp3437
(dp3438
g7
I23
sg23
VC0795841
p3439
sg10
I3
sg11
VJBS
p3440
sg13
I1
sa(dp3441
g7
I23
sg23
VC0795841
p3442
sg10
I3
sg11
VJBS
p3443
sg13
I1
sa(dp3444
g7
I67
sg23
VC0079380
p3445
sg10
I10
sg11
Vframeshift
p3446
sg13
I1
sasa(dp3447
g2
S'Johanson-Blizzard syndrome (JBS) is a rare, autosomal recessive disorder characterized by exocrine pancreatic insufficiency, typical facial features, dental anomalies, hypothyroidism, sensorineural hearing loss, scalp defects, urogenital and anorectal anomalies, short stature, and cognitive impairment of variable degree.\n'
p3448
sg4
(lp3449
sg20
(lp3450
(dp3451
g7
I168
sg23
VC0020676
p3452
sg10
I14
sg11
Vhypothyroidism
p3453
sg13
I1
sa(dp3454
g7
I28
sg23
VC0175692
p3455
sg10
I3
sg11
VJBS
p3456
sg13
I1
sa(dp3457
g7
I0
sg23
VC0175692
p3458
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3459
sg13
I2
sa(dp3460
g7
I242
sg23
VC2974527
p3461
sg10
I19
sg11
Vanorectal anomalies
p3462
sg13
I2
sa(dp3463
g7
I282
sg23
VC0338656
p3464
sg10
I20
sg11
Vcognitive impairment
p3465
sg13
I2
sa(dp3466
g7
I90
sg23
VC0267963
p3467
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3468
sg13
I3
sa(dp3469
g7
I263
sg23
VC0013336
p3470
sg10
I13
sg11
Vshort stature
p3471
sg13
I2
sa(dp3472
g7
I184
sg23
VC0018784
p3473
sg10
I26
sg11
Vsensorineural hearing loss
p3474
sg13
I3
sasa(dp3475
g2
S'Mutation types include nonsense, frameshift, splice site, missense, and small in-frame deletions consistent with the hypothesis that loss of UBR1 protein function is the molecular basis of JBS.\n'
p3476
sg4
(lp3477
(dp3478
g7
I141
sg8
g15
sg10
I12
sg11
VUBR1 protein
p3479
sg13
I2
sasg20
(lp3480
(dp3481
g7
I33
sg23
VC0079380
p3482
sg10
I10
sg11
Vframeshift
p3483
sg13
I1
sa(dp3484
g7
I189
sg23
VC0795841
p3485
sg10
I3
sg11
VJBS
p3486
sg13
I1
sasa(dp3487
g2
S'The review of clinical data of a large number of molecularly confirmed JBS cases allows us to define minimal clinical criteria for the diagnosis of JBS.\n'
p3488
sg4
(lp3489
sg20
(lp3490
(dp3491
g7
I71
sg23
VC0795841
p3492
sg10
I3
sg11
VJBS
p3493
sg13
I1
sa(dp3494
g7
I71
sg23
VC0795841
p3495
sg10
I3
sg11
VJBS
p3496
sg13
I1
sasa(dp3497
g2
S'Johanson-Blizzard syndrome (JBS) is a rare autosomal recessive disease characterized by exocrine pancreatic insufficiency, hypoplastic or aplastic nasal alae, cutis aplasia on the scalp, and other features including developmental delay, failure to thrive, hearing loss, mental retardation, hypothyroidism, dental abnormalities, and anomalies in cardiac and genitourinary systems.\n'
p3498
sg4
(lp3499
sg20
(lp3500
(dp3501
g7
I159
sg23
VC0282160
p3502
sg10
I13
sg11
Vcutis aplasia
p3503
sg13
I2
sa(dp3504
g7
I256
sg23
VC0011053
p3505
sg10
I12
sg11
Vhearing loss
p3506
sg13
I2
sa(dp3507
g7
I88
sg23
VC0267963
p3508
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3509
sg13
I3
sa(dp3510
g7
I28
sg23
VC0175692
p3511
sg10
I3
sg11
VJBS
p3512
sg13
I1
sa(dp3513
g7
I0
sg23
VC0175692
p3514
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3515
sg13
I2
sa(dp3516
g7
I216
sg23
VC0424605
p3517
sg10
I19
sg11
Vdevelopmental delay
p3518
sg13
I2
sa(dp3519
g7
I237
sg23
VC0015544
p3520
sg10
I17
sg11
Vfailure to thrive
p3521
sg13
I3
sa(dp3522
g7
I270
sg23
VC0025362
p3523
sg10
I18
sg11
Vmental retardation
p3524
sg13
I2
sa(dp3525
g7
I290
sg23
VC0020676
p3526
sg10
I14
sg11
Vhypothyroidism
p3527
sg13
I1
sasa(dp3528
g2
S'We describe the case of a male infant with typical symptoms of JBS.\n'
p3529
sg4
(lp3530
sg20
(lp3531
(dp3532
g7
I63
sg23
VC0795841
p3533
sg10
I3
sg11
VJBS
p3534
sg13
I1
sasa(dp3535
g2
S'Johanson-Blizzard syndrome (JBS; OMIM 243800) is an autosomal recessive disorder that includes congenital exocrine pancreatic insufficiency, facial dysmorphism with the characteristic nasal wing hypoplasia, multiple malformations, and frequent mental retardation.\n'
p3536
sg4
(lp3537
sg20
(lp3538
(dp3539
g7
I216
sg23
VC0000768
p3540
sg10
I13
sg11
Vmalformations
p3541
sg13
I1
sa(dp3542
g7
I195
sg23
VC0243069
p3543
sg10
I10
sg11
Vhypoplasia
p3544
sg13
I1
sa(dp3545
g7
I28
sg23
VC0175692
p3546
sg10
I3
sg11
VJBS
p3547
sg13
I1
sa(dp3548
g7
I106
sg23
VC0267963
p3549
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3550
sg13
I3
sa(dp3551
g7
I244
sg23
VC0025362
p3552
sg10
I18
sg11
Vmental retardation
p3553
sg13
I2
sa(dp3554
g7
I0
sg23
VC0175692
p3555
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3556
sg13
I2
sa(dp3557
g7
I141
sg23
VC0266617
p3558
sg10
I18
sg11
Vfacial dysmorphism
p3559
sg13
I2
sasa(dp3560
g2
S'Our previous work has shown that JBS is caused by mutations in human UBR1, which encodes one of the E3 ubiquitin ligases of the N-end rule pathway.\n'
p3561
sg4
(lp3562
(dp3563
g7
I63
sg8
g15
sg10
I10
sg11
Vhuman UBR1
p3564
sg13
I2
sa(dp3565
g7
I33
sg8
g15
sg10
I3
sg11
VJBS
p3566
sg13
I1
sa(dp3567
g7
I100
sg8
VP62979
p3568
sg10
I20
sg11
VE3 ubiquitin ligases
p3569
sg13
I3
sasg20
(lp3570
(dp3571
g7
I33
sg23
VC0795841
p3572
sg10
I3
sg11
VJBS
p3573
sg13
I1
sasa(dp3574
g2
S'Most JBS-causing alterations of UBR1 are nonsense, frameshift or splice-site mutations that abolish UBR1 activity.\n'
p3575
sg4
(lp3576
(dp3577
g7
I32
sg8
g15
sg10
I4
sg11
VUBR1
p3578
sg13
I1
sa(dp3579
g7
I32
sg8
g15
sg10
I4
sg11
VUBR1
p3580
sg13
I1
sasg20
(lp3581
(dp3582
g7
I51
sg23
VC0079380
p3583
sg10
I10
sg11
Vframeshift
p3584
sg13
I1
sa(dp3585
g7
I5
sg23
VC0795841
p3586
sg10
I3
sg11
VJBS
p3587
sg13
I1
sasa(dp3588
g2
S'We report here missense mutations of human UBR1 in patients with milder variants of JBS.\n'
p3589
sg4
(lp3590
(dp3591
g7
I37
sg8
g15
sg10
I10
sg11
Vhuman UBR1
p3592
sg13
I2
sasg20
(lp3593
(dp3594
g7
I84
sg23
VC0795841
p3595
sg10
I3
sg11
VJBS
p3596
sg13
I1
sasa(dp3597
g2
S'Taking advantage of this conservation, we constructed alleles of the yeast Saccharomyces cerevisiae UBR1 that were counterparts of missense JBS-UBR1 alleles.\n'
p3598
sg4
(lp3599
(dp3600
g7
I140
sg8
g15
sg10
I3
sg11
VJBS
p3601
sg13
I1
sa(dp3602
g7
I69
sg8
g15
sg10
I35
sg11
Vyeast Saccharomyces cerevisiae UBR1
p3603
sg13
I4
sa(dp3604
g7
I100
sg8
g15
sg10
I4
sg11
VUBR1
p3605
sg13
I1
sasg20
(lp3606
(dp3607
g7
I140
sg23
VC0795841
p3608
sg10
I3
sg11
VJBS
p3609
sg13
I1
sasa(dp3610
g2
S'Among these yeast Ubr1 mutants, one of them (H160R) was inactive in yeast-based activity assays, the other one (Q1224E) had a detectable but weak activity, and the third one (V146L) exhibited a decreased but significant activity, in agreement with manifestations of JBS in the corresponding JBS patients.\n'
p3611
sg4
(lp3612
(dp3613
g7
I18
sg8
g15
sg10
I12
sg11
VUbr1 mutants
p3614
sg13
I2
sasg20
(lp3615
(dp3616
g7
I266
sg23
VC0795841
p3617
sg10
I3
sg11
VJBS
p3618
sg13
I1
sa(dp3619
g7
I266
sg23
VC0795841
p3620
sg10
I3
sg11
VJBS
p3621
sg13
I1
sasa(dp3622
g2
S'These results, made possible by modeling defects of a human ubiquitin ligase in its yeast counterpart, verified and confirmed the relevance of specific missense UBR1 alleles to JBS, and suggested that a residual activity of a missense allele is causally associated with milder variants of JBS.\n'
p3623
sg4
(lp3624
(dp3625
g7
I54
sg8
g15
sg10
I22
sg11
Vhuman ubiquitin ligase
p3626
sg13
I3
sa(dp3627
g7
I161
sg8
g15
sg10
I12
sg11
VUBR1 alleles
p3628
sg13
I2
sasg20
(lp3629
(dp3630
g7
I177
sg23
VC0795841
p3631
sg10
I3
sg11
VJBS
p3632
sg13
I1
sa(dp3633
g7
I177
sg23
VC0795841
p3634
sg10
I3
sg11
VJBS
p3635
sg13
I1
sasa(dp3636
g2
S'We report on a triplet pregnancy of consanguineous parents with one fetus being affected by recurrent Johanson-Blizzard syndrome (JBS).\n'
p3637
sg4
(lp3638
sg20
(lp3639
(dp3640
g7
I130
sg23
VC0175692
p3641
sg10
I3
sg11
VJBS
p3642
sg13
I1
sa(dp3643
g7
I15
sg23
VC0152151
p3644
sg10
I17
sg11
Vtriplet pregnancy
p3645
sg13
I2
sa(dp3646
g7
I102
sg23
VC0175692
p3647
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3648
sg13
I2
sasa(dp3649
g2
S'In addition to the lack of exocrine acini as the characteristic feature of JBS, the pancreas revealed a resorptive inflammatory reaction with infiltration by eosinophilic granulocytes that focally dispersed onto islets of Langerhans, thus favoring a progressive destructive rather than primary dysplastic process and possibly explaining the occurrence of diabetes mellitus in later life.\n'
p3650
sg4
(lp3651
sg20
(lp3652
(dp3653
g7
I142
sg23
VC0332448
p3654
sg10
I12
sg11
Vinfiltration
p3655
sg13
I1
sa(dp3656
g7
I355
sg23
VC0011849
p3657
sg10
I17
sg11
Vdiabetes mellitus
p3658
sg13
I2
sa(dp3659
g7
I115
sg23
VC0021368
p3660
sg10
I21
sg11
Vinflammatory reaction
p3661
sg13
I2
sa(dp3662
g7
I294
sg23
VC0334044
p3663
sg10
I10
sg11
Vdysplastic
p3664
sg13
I1
sa(dp3665
g7
I75
sg23
VC0795841
p3666
sg10
I3
sg11
VJBS
p3667
sg13
I1
sasa(dp3668
g2
S'JBS maps to chromosome 15q15-q21.1 and is associated with mutations in the UBR1 gene.\n'
p3669
sg4
(lp3670
(dp3671
g7
I0
sg8
g15
sg10
I3
sg11
VJBS
p3672
sg13
I1
sa(dp3673
g7
I75
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3674
sg13
I2
sasg20
(lp3675
(dp3676
g7
I0
sg23
VC0795841
p3677
sg10
I3
sg11
VJBS
p3678
sg13
I1
sasa(dp3679
g2
S'Johanson-Blizzard syndrome is a rare autosomal recessive multisystem disorder, it is characterized by the association of congenital exocrine pancreatic insufficiency and hypoplasia or aplasia of the nasal wings, and can be diagnosed by clinical characteristics and UBR1 gene analysis.\n'
p3680
sg4
(lp3681
(dp3682
g7
I265
sg8
g15
sg10
I9
sg11
VUBR1 gene
p3683
sg13
I2
sasg20
(lp3684
(dp3685
g7
I0
sg23
VC0175692
p3686
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3687
sg13
I2
sa(dp3688
g7
I57
sg23
VC0559758
p3689
sg10
I20
sg11
Vmultisystem disorder
p3690
sg13
I2
sa(dp3691
g7
I184
sg23
VC0243065
p3692
sg10
I7
sg11
Vaplasia
p3693
sg13
I1
sa(dp3694
g7
I170
sg23
VC0243069
p3695
sg10
I10
sg11
Vhypoplasia
p3696
sg13
I1
sa(dp3697
g7
I132
sg23
VC0267963
p3698
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3699
sg13
I3
sasa(dp3700
g2
S'* Sixteen distinct haplotypes were detected from 258 individuals in the C. conica complex inferred from the cpDNA sequences of intergenic spacer (IGS) between atpB and rbcL, IGS between trnT and trnL, trnL intron, and IGS between trnL and trnF.\n'
p3701
sg4
(lp3702
(dp3703
g7
I146
sg8
g15
sg10
I3
sg11
VIGS
p3704
sg13
I1
sa(dp3705
g7
I186
sg8
g15
sg10
I4
sg11
VtrnT
p3706
sg13
I1
sa(dp3707
g7
I201
sg8
VP49184
p3708
sg10
I11
sg11
VtrnL intron
p3709
sg13
I2
sa(dp3710
g7
I146
sg8
g15
sg10
I3
sg11
VIGS
p3711
sg13
I1
sa(dp3712
g7
I195
sg8
VP49184
p3713
sg10
I4
sg11
VtrnL
p3714
sg13
I1
sa(dp3715
g7
I159
sg8
VP05026
p3716
sg10
I4
sg11
VatpB
p3717
sg13
I1
sa(dp3718
g7
I195
sg8
VP49184
p3719
sg10
I4
sg11
VtrnL
p3720
sg13
I1
sasg20
(lp3721
(dp3722
g7
I146
sg23
VC1306856
p3723
sg10
I3
sg11
VIGS
p3724
sg13
I1
sa(dp3725
g7
I146
sg23
VC1306856
p3726
sg10
I3
sg11
VIGS
p3727
sg13
I1
sa(dp3728
g7
I146
sg23
VC1306856
p3729
sg10
I3
sg11
VIGS
p3730
sg13
I1
sasa(dp3731
g2
S'Maximum parsimony and Bayesian inference analyses of DNA sequence data of the plastid (the trnT-L igs, the trnL intron, two parts of the trnK intron, and the psbA-trnH igs) and nuclear genome (ITS1, 5.8S, and ITS2) showed these markers to be suitable to assess the species composition of sect.\n'
p3732
sg4
(lp3733
(dp3734
g7
I158
sg8
VP40306
p3735
sg10
I13
sg11
VpsbA-trnH igs
p3736
sg13
I2
sa(dp3737
g7
I107
sg8
VP49184
p3738
sg10
I11
sg11
VtrnL intron
p3739
sg13
I2
sa(dp3740
g7
I91
sg8
g15
sg10
I10
sg11
VtrnT-L igs
p3741
sg13
I2
sa(dp3742
g7
I137
sg8
g15
sg10
I11
sg11
VtrnK intron
p3743
sg13
I2
sasg20
(lp3744
(dp3745
g7
I98
sg23
VC1306856
p3746
sg10
I3
sg11
Vigs
p3747
sg13
I1
sa(dp3748
g7
I98
sg23
VC1306856
p3749
sg10
I3
sg11
Vigs
p3750
sg13
I1
sasa(dp3751
g2
S'However, the primers for amplification of chloroplast trnD-trnT intron and rRNA IGS failed to amplify the respective region in Elymus species.\n'
p3752
sg4
(lp3753
(dp3754
g7
I42
sg8
VP27708
p3755
sg10
I28
sg11
Vchloroplast trnD-trnT intron
p3756
sg13
I3
sasg20
(lp3757
(dp3758
g7
I25
sg23
VC1705759
p3759
sg10
I13
sg11
Vamplification
p3760
sg13
I1
sa(dp3761
g7
I80
sg23
VC1306856
p3762
sg10
I3
sg11
VIGS
p3763
sg13
I1
sasa(dp3764
g2
S'New primer pairs were designed and successfully amplified the cpDNA trnD-trnT intron and rRNA IGS region in Elymus species.\n'
p3765
sg4
(lp3766
(dp3767
g7
I73
sg8
g15
sg10
I4
sg11
VtrnT
p3768
sg13
I1
sasg20
(lp3769
(dp3770
g7
I94
sg23
VC1306856
p3771
sg10
I3
sg11
VIGS
p3772
sg13
I1
sasa(dp3773
g2
S'In the present study, we investigated the effect of taspine derivative 12k on human colorectal cancer targeted at EphrinB2 and its PDZ.\n'
p3774
sg4
(lp3775
(dp3776
g7
I114
sg8
VP52799
p3777
sg10
I8
sg11
VEphrinB2
p3778
sg13
I1
sasg20
(lp3779
(dp3780
g7
I84
sg23
VC1527249
p3781
sg10
I17
sg11
Vcolorectal cancer
p3782
sg13
I2
sasa(dp3783
g2
S'In this study, we investigated the mechanism of chemoresistance and epithelial-to-mesenchymal transition (EMT) in colorectal cancer involving the gain-of-function (GOF) mutant p53/ephrin-B2 signaling axis.\n'
p3784
sg4
(lp3785
(dp3786
g7
I176
sg8
VP42771
p3787
sg10
I3
sg11
Vp53
p3788
sg13
I1
sasg20
(lp3789
(dp3790
g7
I169
sg23
VC0596988
p3791
sg10
I6
sg11
Vmutant
p3792
sg13
I1
sa(dp3793
g7
I94
sg23
VC0599156
p3794
sg10
I10
sg11
Vtransition
p3795
sg13
I1
sa(dp3796
g7
I114
sg23
VC1527249
p3797
sg10
I17
sg11
Vcolorectal cancer
p3798
sg13
I2
sasa(dp3799
g2
S'Twenty proteins from different signaling pathways (epidermal growth factor receptor [EGFR], phosphorylated extracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility [RHAMM], Raf-1 kinase inhibitor protein [RKIP], Beta-catenin, E-cadherin, phosphorylated AK transforming [pAKT], p16, p21, Ki-67, B-cell Lymphoma-2 [BCL2], vascular endothelial growth factor, apoptosis protease activating factor 1 [APAF-1], mucin1 [MUC1], ephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7], phosphorylated mothers against decapentaplegic 2 [pSMAD2], caudal type homeobox transcription factor 2 [CDX2], Laminin5Gamma2, and mammalian sterile 20-like kinase 1 [MST1]) involved in colorectal cancer progression were studied immunohistochemically on 220 well-characterized patients using a multiple-punch tissue microarray including 437 and 430 samples from the tumor center and the invasive front, respectively.\n'
p3800
sg4
(lp3801
(dp3802
g7
I223
sg8
VP30086
p3803
sg10
I24
sg11
Vinhibitor protein [RKIP]
p3804
sg13
I3
sa(dp3805
g7
I210
sg8
VP04049
p3806
sg10
I12
sg11
VRaf-1 kinase
p3807
sg13
I2
sa(dp3808
g7
I51
sg8
VP01133
p3809
sg10
I32
sg11
Vepidermal growth factor receptor
p3810
sg13
I4
sa(dp3811
g7
I201
sg8
g15
sg10
I7
sg11
V[RHAMM]
p3812
sg13
I1
sa(dp3813
g7
I249
sg8
VP35222
p3814
sg10
I12
sg11
VBeta-catenin
p3815
sg13
I1
sa(dp3816
g7
I263
sg8
VP12830
p3817
sg10
I10
sg11
VE-cadherin
p3818
sg13
I1
sa(dp3819
g7
I579
sg8
g15
sg10
I50
sg11
Vcaudal type homeobox transcription factor 2 [CDX2]
p3820
sg13
I7
sa(dp3821
g7
I357
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p3822
sg13
I4
sa(dp3823
g7
I314
sg8
VP42771
p3824
sg10
I3
sg11
Vp16
p3825
sg13
I1
sa(dp3826
g7
I393
sg8
VP63123
p3827
sg10
I38
sg11
Vapoptosis protease activating factor 1
p3828
sg13
I5
sa(dp3829
g7
I324
sg8
VP46013
p3830
sg10
I5
sg11
VKi-67
p3831
sg13
I1
sa(dp3832
g7
I319
sg8
VP42857
p3833
sg10
I3
sg11
Vp21
p3834
sg13
I1
sa(dp3835
g7
I669
sg8
VP27361
p3836
sg10
I16
sg11
V20-like kinase 1
p3837
sg13
I3
sa(dp3838
g7
I275
sg8
VP55263
p3839
sg10
I17
sg11
Vphosphorylated AK
p3840
sg13
I2
sa(dp3841
g7
I457
sg8
VP52799
p3842
sg10
I61
sg11
Vephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7]
p3843
sg13
I8
sa(dp3844
g7
I331
sg8
VP10415
p3845
sg10
I24
sg11
VB-cell Lymphoma-2 [BCL2]
p3846
sg13
I3
sa(dp3847
g7
I687
sg8
VP26927
p3848
sg10
I4
sg11
VMST1
p3849
sg13
I1
sa(dp3850
g7
I107
sg8
VP53778
p3851
sg10
I93
sg11
Vextracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility
p3852
sg13
I11
sasg20
(lp3853
(dp3854
g7
I717
sg23
VC0178874
p3855
sg10
I18
sg11
Vcancer progression
p3856
sg13
I2
sa(dp3857
g7
I886
sg23
VC0027651
p3858
sg10
I5
sg11
Vtumor
p3859
sg13
I1
sa(dp3860
g7
I661
sg23
VC0678108
p3861
sg10
I7
sg11
Vsterile
p3862
sg13
I1
sa(dp3863
g7
I331
sg23
VC0079731
p3864
sg10
I15
sg11
VB-cell Lymphoma
p3865
sg13
I2
sasa(dp3866
g2
S'Abundant expression of IFN-Gamma-inducible protein 10 (IP-10) was observed on macrophages and in T cells in perimysial infiltrates of dermatomyositis (DM), and strong chemokine (C-X-C motif) receptor (CXCR)3 expression was observed on the majority of T cells in DM.\n'
p3867
sg4
(lp3868
(dp3869
g7
I23
sg8
VP01579
p3870
sg10
I9
sg11
VIFN-Gamma
p3871
sg13
I1
sasg20
(lp3872
(dp3873
g7
I151
sg23
VC0221056
p3874
sg10
I2
sg11
VDM
p3875
sg13
I1
sa(dp3876
g7
I119
sg23
VC0332448
p3877
sg10
I11
sg11
Vinfiltrates
p3878
sg13
I1
sa(dp3879
g7
I134
sg23
VC0221056
p3880
sg10
I15
sg11
Vdermatomyositis
p3881
sg13
I1
sa(dp3882
g7
I151
sg23
VC0221056
p3883
sg10
I2
sg11
VDM
p3884
sg13
I1
sasa(dp3885
g2
S'Abundant expression of IP-10 was observed on macrophages and T cells surrounding and invading non-necrotic muscle fibers in polymyositis and sporadic inclusion body myositis and in T cells in perimysial infiltrates of dermatomyositis.\n'
p3886
sg4
(lp3887
sg20
(lp3888
(dp3889
g7
I141
sg23
VC0751713
p3890
sg10
I32
sg11
Vsporadic inclusion body myositis
p3891
sg13
I4
sa(dp3892
g7
I218
sg23
VC0221056
p3893
sg10
I15
sg11
Vdermatomyositis
p3894
sg13
I1
sa(dp3895
g7
I203
sg23
VC0332448
p3896
sg10
I11
sg11
Vinfiltrates
p3897
sg13
I1
sa(dp3898
g7
I124
sg23
VC0085655
p3899
sg10
I12
sg11
Vpolymyositis
p3900
sg13
I1
sasa(dp3901
g2
S'DORs were colocalized in tissue slices and synaptosomes from the canine right atrium and SA node along with cholinergic and adrenergic markers, vesicular acetylcholine transporter (VAChT), and tyrosine hydroxylase (TH).\n'
p3902
sg4
(lp3903
(dp3904
g7
I144
sg8
g15
sg10
I35
sg11
Vvesicular acetylcholine transporter
p3905
sg13
I3
sa(dp3906
g7
I181
sg8
g15
sg10
I5
sg11
VVAChT
p3907
sg13
I1
sa(dp3908
g7
I193
sg8
VP07101
p3909
sg10
I20
sg11
Vtyrosine hydroxylase
p3910
sg13
I2
sa(dp3911
g7
I215
sg8
VP07101
p3912
sg10
I2
sg11
VTH
p3913
sg13
I1
sasg20
(lp3914
sa(dp3915
g2
S'Furthermore, the lack of interdigital programmed cell death and associated syndactyly was related to down-regulated gene expression of Bmp2, Bmp7, Msx1, and Msx2, which are known to promote apoptosis in the interdigital mesenchyme.\n'
p3916
sg4
(lp3917
(dp3918
g7
I135
sg8
VP12643
p3919
sg10
I4
sg11
VBmp2
p3920
sg13
I1
sa(dp3921
g7
I147
sg8
VP28360
p3922
sg10
I4
sg11
VMsx1
p3923
sg13
I1
sa(dp3924
g7
I141
sg8
VP18075
p3925
sg10
I4
sg11
VBmp7
p3926
sg13
I1
sa(dp3927
g7
I157
sg8
VP35548
p3928
sg10
I4
sg11
VMsx2
p3929
sg13
I1
sasg20
(lp3930
(dp3931
g7
I75
sg23
VC0039075
p3932
sg10
I10
sg11
Vsyndactyly
p3933
sg13
I1
sasa(dp3934
g2
S'In this context, ERdj3 suppression may eliminate the toxic gain of function associated with polymerization of ZAAT, thus providing a potential new therapeutic approach to the treatment of AATD-related liver disease.\n'
p3935
sg4
(lp3936
(dp3937
g7
I17
sg8
g15
sg10
I5
sg11
VERdj3
p3938
sg13
I1
sasg20
(lp3939
(dp3940
g7
I201
sg23
VC0023895
p3941
sg10
I13
sg11
Vliver disease
p3942
sg13
I2
sa(dp3943
g7
I23
sg23
VC0221103
p3944
sg10
I11
sg11
Vsuppression
p3945
sg13
I1
sa(dp3946
g7
I188
sg23
VC0221757
p3947
sg10
I4
sg11
VAATD
p3948
sg13
I1
sasa(dp3949
g2
S'The CPK, aldolase, GOT, GPT, and LDH concentrations in the serum and lumbar CSF of 80 patients with neuromuscular diseases and 20 controls were measured.\n'
p3950
sg4
(lp3951
(dp3952
g7
I33
sg8
g15
sg10
I3
sg11
VLDH
p3953
sg13
I1
sa(dp3954
g7
I9
sg8
VP05062
p3955
sg10
I8
sg11
Valdolase
p3956
sg13
I1
sa(dp3957
g7
I69
sg8
VP04141
p3958
sg10
I10
sg11
Vlumbar CSF
p3959
sg13
I2
sa(dp3960
g7
I4
sg8
g15
sg10
I3
sg11
VCPK
p3961
sg13
I1
sa(dp3962
g7
I24
sg8
VP24298
p3963
sg10
I3
sg11
VGPT
p3964
sg13
I1
sasg20
(lp3965
(dp3966
g7
I100
sg23
VC0027868
p3967
sg10
I22
sg11
Vneuromuscular diseases
p3968
sg13
I2
sasa(dp3969
g2
S'In 60 cases of various neuromuscular diseases, serum CA-III, CPK and aldolase were measured.\n'
p3970
sg4
(lp3971
(dp3972
g7
I53
sg8
VP07451
p3973
sg10
I6
sg11
VCA-III
p3974
sg13
I1
sa(dp3975
g7
I69
sg8
VP05062
p3976
sg10
I8
sg11
Valdolase
p3977
sg13
I1
sa(dp3978
g7
I61
sg8
g15
sg10
I3
sg11
VCPK
p3979
sg13
I1
sasg20
(lp3980
(dp3981
g7
I23
sg23
VC0027868
p3982
sg10
I22
sg11
Vneuromuscular diseases
p3983
sg13
I2
sasa(dp3984
g2
S'Together, our results show that P. gingivalis activates the ERK1/2-Ets1, p38/HSP27, and PAR2/NF-kB pathways to induce proMMP9 expression, after which the proenzyme is activated by gingipains to promote cellular invasion of OSCC cell lines.\n'
p3985
sg4
(lp3986
(dp3987
g7
I88
sg8
VP55085
p3988
sg10
I4
sg11
VPAR2
p3989
sg13
I1
sa(dp3990
g7
I60
sg8
VP27361
p3991
sg10
I6
sg11
VERK1/2
p3992
sg13
I1
sa(dp3993
g7
I77
sg8
g15
sg10
I5
sg11
VHSP27
p3994
sg13
I1
sa(dp3995
g7
I73
sg8
VP46108
p3996
sg10
I3
sg11
Vp38
p3997
sg13
I1
sa(dp3998
g7
I67
sg8
VP14921
p3999
sg10
I4
sg11
VEts1
p4000
sg13
I1
sasg20
(lp4001
(dp4002
g7
I211
sg23
VC2699153
p4003
sg10
I8
sg11
Vinvasion
p4004
sg13
I1
sasa(dp4005
g2
S'Tissue sections ranging from normal mucosa to moderately-differentiated oral squamous cell carcinoma were studied using monoclonal antibodies against N-ras and ets-1 proteins.\n'
p4006
sg4
(lp4007
(dp4008
g7
I152
sg8
VP01116
p4009
sg10
I3
sg11
Vras
p4010
sg13
I1
sa(dp4011
g7
I160
sg8
VP14921
p4012
sg10
I14
sg11
Vets-1 proteins
p4013
sg13
I2
sasg20
(lp4014
(dp4015
g7
I77
sg23
VC0007137
p4016
sg10
I23
sg11
Vsquamous cell carcinoma
p4017
sg13
I3
sasa(dp4018
g2
S'In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations.\n'
p4019
sg4
(lp4020
(dp4021
g7
I300
sg8
g15
sg10
I5
sg11
VFGF23
p4022
sg13
I1
sasg20
(lp4023
(dp4024
g7
I50
sg23
VC0242339
p4025
sg10
I12
sg11
Vdyslipidemia
p4026
sg13
I1
sasa(dp4027
g2
S'The use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D(2) (PGD(2)) with its G-protein coupled receptor, DP1 (Ptgdr).\n'
p4028
sg4
(lp4029
(dp4030
g7
I174
sg8
VP32247
p4031
sg10
I26
sg11
VG-protein coupled receptor
p4032
sg13
I3
sa(dp4033
g7
I202
sg8
g15
sg10
I3
sg11
VDP1
p4034
sg13
I1
sa(dp4035
g7
I207
sg8
g15
sg10
I5
sg11
VPtgdr
p4036
sg13
I1
sasg20
(lp4037
(dp4038
g7
I78
sg23
VC0016382
p4039
sg10
I8
sg11
Vflushing
p4040
sg13
I1
sa(dp4041
g7
I35
sg23
VC0242339
p4042
sg10
I12
sg11
Vdyslipidemia
p4043
sg13
I1
sasa(dp4044
g2
S'We performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268).\n'
p4045
sg4
(lp4046
sg20
(lp4047
(dp4048
g7
I180
sg23
VC0242339
p4049
sg10
I12
sg11
Vdyslipidemia
p4050
sg13
I1
sasa(dp4051
g2
S"Apart from primary aldosteronism, mineralocorticoid excess can be caused by congenital adrenal hyperplasia (CAH) due to mutations of the 11beta-hydroxylase and 17alpha-hydroxylase genes, by inactivating mutations of the glucocorticoid receptor gene (Chrousos syndrome), endogenous hypercortisolism (Cushing's syndrome), by mutations of the 11beta-hydroxysteroid dehydrogenase type 2 gene (apparent mineralocorticoid excess/AME) or licorice/carbenoxolone intake, mutations of the epithelial sodium channel genes (Liddle syndrome), mutations of the mineralocorticoid receptor gene (Geller syndrome), and by mutations in the WNK1, WNK4, KLHL3, CUL3 genes (pseudohypoaldosteronism type 2 or Gordon syndrome).\n"
p4052
sg4
(lp4053
(dp4054
g7
I340
sg8
VP49366
p4055
sg10
I47
sg11
V11beta-hydroxysteroid dehydrogenase type 2 gene
p4056
sg13
I5
sa(dp4057
g7
I220
sg8
VP04150
p4058
sg10
I28
sg11
Vglucocorticoid receptor gene
p4059
sg13
I3
sa(dp4060
g7
I641
sg8
g15
sg10
I10
sg11
VCUL3 genes
p4061
sg13
I2
sa(dp4062
g7
I622
sg8
g15
sg10
I4
sg11
VWNK1
p4063
sg13
I1
sa(dp4064
g7
I160
sg8
VP01893
p4065
sg10
I25
sg11
V17alpha-hydroxylase genes
p4066
sg13
I2
sa(dp4067
g7
I547
sg8
VP08235
p4068
sg10
I31
sg11
Vmineralocorticoid receptor gene
p4069
sg13
I3
sa(dp4070
g7
I634
sg8
g15
sg10
I5
sg11
VKLHL3
p4071
sg13
I1
sa(dp4072
g7
I628
sg8
g15
sg10
I4
sg11
VWNK4
p4073
sg13
I1
sa(dp4074
g7
I479
sg8
VP12830
p4075
sg10
I31
sg11
Vepithelial sodium channel genes
p4076
sg13
I4
sasg20
(lp4077
(dp4078
g7
I11
sg23
VC1384514
p4079
sg10
I21
sg11
Vprimary aldosteronism
p4080
sg13
I2
sa(dp4081
g7
I259
sg23
VC0039082
p4082
sg10
I8
sg11
Vsyndrome
p4083
sg13
I1
sa(dp4084
g7
I281
sg23
VC0010481
p4085
sg10
I16
sg11
Vhypercortisolism
p4086
sg13
I1
sa(dp4087
g7
I259
sg23
VC0039082
p4088
sg10
I8
sg11
Vsyndrome
p4089
sg13
I1
sa(dp4090
g7
I76
sg23
VC0001627
p4091
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p4092
sg13
I3
sa(dp4093
g7
I687
sg23
VC0220666
p4094
sg10
I15
sg11
VGordon syndrome
p4095
sg13
I2
sa(dp4096
g7
I299
sg23
VC0010481
p4097
sg10
I18
sg11
VCushing's syndrome
p4098
sg13
I2
sa(dp4099
g7
I108
sg23
VC0520463
p4100
sg10
I3
sg11
VCAH
p4101
sg13
I1
sa(dp4102
g7
I389
sg23
VC2936861
p4103
sg10
I33
sg11
Vapparent mineralocorticoid excess
p4104
sg13
I3
sa(dp4105
g7
I512
sg23
VC0221043
p4106
sg10
I15
sg11
VLiddle syndrome
p4107
sg13
I2
sa(dp4108
g7
I653
sg23
VC1449844
p4109
sg10
I30
sg11
Vpseudohypoaldosteronism type 2
p4110
sg13
I3
sasa(dp4111
g2
S"We provide an overview and diagnostic approach to apparent mineralocorticoid excess, glucocorticoid remediable aldosteronism, familial hyperaldosteronism type 2, Liddle's syndrome, Gordon's syndrome, activating mutations of the mineralocorticoid receptor, generalized glucocorticoid resistance and hypertensive forms of congenital adrenal hyperplasia.\n"
p4112
sg4
(lp4113
sg20
(lp4114
(dp4115
g7
I181
sg23
VC0220666
p4116
sg10
I17
sg11
VGordon's syndrome
p4117
sg13
I2
sa(dp4118
g7
I162
sg23
VC0221043
p4119
sg10
I17
sg11
VLiddle's syndrome
p4120
sg13
I2
sa(dp4121
g7
I320
sg23
VC0001627
p4122
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p4123
sg13
I3
sa(dp4124
g7
I135
sg23
VC0020428
p4125
sg10
I18
sg11
Vhyperaldosteronism
p4126
sg13
I1
sa(dp4127
g7
I268
sg23
VC1841971
p4128
sg10
I25
sg11
Vglucocorticoid resistance
p4129
sg13
I2
sa(dp4130
g7
I50
sg23
VC2936861
p4131
sg10
I33
sg11
Vapparent mineralocorticoid excess
p4132
sg13
I3
sa(dp4133
g7
I111
sg23
VC0020428
p4134
sg10
I13
sg11
Valdosteronism
p4135
sg13
I1
sasa(dp4136
g2
S'As chronic pancreatitis (CP) is characterized by tissue infiltration of inflammatory cells, fibrosis, pancreatic neuritis and severe pain, the roles of fractalkine and CX3CR1 were investigated in CP (n=61) and normal pancreas (NP, n=21) by QRT-PCR, western blot and immunohistochemistry analyses.\n'
p4137
sg4
(lp4138
sg20
(lp4139
(dp4140
g7
I49
sg23
VC0332448
p4141
sg10
I19
sg11
Vtissue infiltration
p4142
sg13
I2
sa(dp4143
g7
I92
sg23
VC0016059
p4144
sg10
I8
sg11
Vfibrosis
p4145
sg13
I1
sa(dp4146
g7
I126
sg23
VC0278140
p4147
sg10
I11
sg11
Vsevere pain
p4148
sg13
I2
sa(dp4149
g7
I113
sg23
VC0027813
p4150
sg10
I8
sg11
Vneuritis
p4151
sg13
I1
sa(dp4152
g7
I3
sg23
VC0149521
p4153
sg10
I20
sg11
Vchronic pancreatitis
p4154
sg13
I2
sa(dp4155
g7
I25
sg23
VC0149521
p4156
sg10
I2
sg11
VCP
p4157
sg13
I1
sa(dp4158
g7
I25
sg23
VC0149521
p4159
sg10
I2
sg11
VCP
p4160
sg13
I1
sasa(dp4161
g2
S'Neuro-immunoreactivity for fractalkine and CX3CR1 was strongest in patients suffering from severe pain and pancreatic neuritis.\n'
p4162
sg4
(lp4163
(dp4164
g7
I43
sg8
VP78423
p4165
sg10
I6
sg11
VCX3CR1
p4166
sg13
I1
sasg20
(lp4167
(dp4168
g7
I76
sg23
VC0683278
p4169
sg10
I9
sg11
Vsuffering
p4170
sg13
I1
sa(dp4171
g7
I91
sg23
VC0278140
p4172
sg10
I11
sg11
Vsevere pain
p4173
sg13
I2
sa(dp4174
g7
I118
sg23
VC0027813
p4175
sg10
I8
sg11
Vneuritis
p4176
sg13
I1
sasa(dp4177
g2
S'Our data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising treatment option for patients with retinitis pigmentosa.\n'
p4178
sg4
(lp4179
sg20
(lp4180
(dp4181
g7
I120
sg23
VC0035334
p4182
sg10
I20
sg11
Vretinitis pigmentosa
p4183
sg13
I2
sasa(dp4184
g2
S'The index patients were homozygotes for both a dominant mutation of the PABPN1 gene, (GCN)13, and a recessive mutation of the NRL gene, p.R31X, on chromosome 14q11.1, leading to early-onset OPMD accompanied by night blindness and reduced visual acuity.\n'
p4185
sg4
(lp4186
(dp4187
g7
I126
sg8
VP54845
p4188
sg10
I8
sg11
VNRL gene
p4189
sg13
I2
sa(dp4190
g7
I72
sg8
g15
sg10
I11
sg11
VPABPN1 gene
p4191
sg13
I2
sasg20
(lp4192
(dp4193
g7
I210
sg23
VC0028077
p4194
sg10
I15
sg11
Vnight blindness
p4195
sg13
I2
sa(dp4196
g7
I190
sg23
VC0270952
p4197
sg10
I4
sg11
VOPMD
p4198
sg13
I1
sasa(dp4199
g2
S'Homozygosity for the recessive NRL mutation described here appears to be associated with a distinct retinal phenotype, demonstrating ERG characteristics similar to those of ESCS patients.\n'
p4200
sg4
(lp4201
(dp4202
g7
I31
sg8
VP54845
p4203
sg10
I12
sg11
VNRL mutation
p4204
sg13
I2
sasg20
(lp4205
(dp4206
g7
I173
sg23
VC1849394
p4207
sg10
I4
sg11
VESCS
p4208
sg13
I1
sasa(dp4209
g2
S'This report expands the spectrum of NRL recessive mutations, as well as the genetic spectrum of ESCS, and indicates a new syndrome of OPMD with an ESCS-like phenotype.\n'
p4210
sg4
(lp4211
(dp4212
g7
I96
sg8
g15
sg10
I4
sg11
VESCS
p4213
sg13
I1
sa(dp4214
g7
I36
sg8
VP54845
p4215
sg10
I3
sg11
VNRL
p4216
sg13
I1
sa(dp4217
g7
I147
sg8
g15
sg10
I9
sg11
VESCS-like
p4218
sg13
I1
sasg20
(lp4219
(dp4220
g7
I96
sg23
VC1849394
p4221
sg10
I4
sg11
VESCS
p4222
sg13
I1
sa(dp4223
g7
I122
sg23
VC0039082
p4224
sg10
I8
sg11
Vsyndrome
p4225
sg13
I1
sa(dp4226
g7
I96
sg23
VC1849394
p4227
sg10
I4
sg11
VESCS
p4228
sg13
I1
sa(dp4229
g7
I134
sg23
VC0270952
p4230
sg10
I4
sg11
VOPMD
p4231
sg13
I1
sasa(dp4232
g2
S'Blue light exposure of the R91W;Nrl(-/-) mouse could therefore be used to study molecular events preceding edema formation in a cone-rich environment, and thus potentially help to develop treatment strategies for edema-based complications in macular degenerations.\n'
p4233
sg4
(lp4234
(dp4235
g7
I32
sg8
VP54845
p4236
sg10
I8
sg11
VNrl(-/-)
p4237
sg13
I1
sasg20
(lp4238
(dp4239
g7
I107
sg23
VC0013604
p4240
sg10
I5
sg11
Vedema
p4241
sg13
I1
sa(dp4242
g7
I242
sg23
VC0242383
p4243
sg10
I21
sg11
Vmacular degenerations
p4244
sg13
I2
sa(dp4245
g7
I107
sg23
VC0013604
p4246
sg10
I5
sg11
Vedema
p4247
sg13
I1
sasa(dp4248
g2
S'CXCL6 and CXCL2 enhanced angiogenesis by HUVECs when cultured with fibroblast cells and colon cancer cells (P &lt; 0.01).\n'
p4249
sg4
(lp4250
(dp4251
g7
I0
sg8
VP80162
p4252
sg10
I5
sg11
VCXCL6
p4253
sg13
I1
sa(dp4254
g7
I10
sg8
VP19875
p4255
sg10
I5
sg11
VCXCL2
p4256
sg13
I1
sasg20
(lp4257
(dp4258
g7
I88
sg23
VC0699790
p4259
sg10
I12
sg11
Vcolon cancer
p4260
sg13
I2
sasa(dp4261
g2
S'After quality and quantity measurements, gene expression analysis of a colorectal cancer-specific marker set with 11 genes (CA7, COL12A1, CXCL1, CXCL2, CHI3L1, GREM1, IL1B, IL1RN, IL8, MMP3, SLC5A7) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler480 System (Roche).\n'
p4262
sg4
(lp4263
(dp4264
g7
I167
sg8
VP01584
p4265
sg10
I4
sg11
VIL1B
p4266
sg13
I1
sa(dp4267
g7
I173
sg8
VP18510
p4268
sg10
I5
sg11
VIL1RN
p4269
sg13
I1
sa(dp4270
g7
I152
sg8
VP36222
p4271
sg10
I6
sg11
VCHI3L1
p4272
sg13
I1
sa(dp4273
g7
I160
sg8
g15
sg10
I5
sg11
VGREM1
p4274
sg13
I1
sa(dp4275
g7
I124
sg8
VP43166
p4276
sg10
I3
sg11
VCA7
p4277
sg13
I1
sa(dp4278
g7
I138
sg8
VP09341
p4279
sg10
I5
sg11
VCXCL1
p4280
sg13
I1
sa(dp4281
g7
I185
sg8
VP08254
p4282
sg10
I4
sg11
VMMP3
p4283
sg13
I1
sa(dp4284
g7
I145
sg8
VP19875
p4285
sg10
I5
sg11
VCXCL2
p4286
sg13
I1
sa(dp4287
g7
I129
sg8
g15
sg10
I7
sg11
VCOL12A1
p4288
sg13
I1
sa(dp4289
g7
I191
sg8
g15
sg10
I6
sg11
VSLC5A7
p4290
sg13
I1
sasg20
(lp4291
(dp4292
g7
I71
sg23
VC1527249
p4293
sg10
I17
sg11
Vcolorectal cancer
p4294
sg13
I2
sasa(dp4295
g2
S'These observations indicate a crucial role for TANs in the initiation and progression of CAC and suggest that the CXCL2-CXCR2 axis might be useful in reducing the risk of UC-associated colon cancer.\n'
p4296
sg4
(lp4297
(dp4298
g7
I120
sg8
VP25025
p4299
sg10
I5
sg11
VCXCR2
p4300
sg13
I1
sa(dp4301
g7
I114
sg8
VP19875
p4302
sg10
I5
sg11
VCXCL2
p4303
sg13
I1
sasg20
(lp4304
(dp4305
g7
I185
sg23
VC0699790
p4306
sg10
I12
sg11
Vcolon cancer
p4307
sg13
I2
sasa(dp4308
g2
S'Gene expression analysis of a colorectal cancer-specific marker set (with 7 genes: COL12A1, CXCL1, CXCL2, GREM1, IL1B, IL8, SLC7A5) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler(R) 480 System (Roche).\n'
p4309
sg4
(lp4310
(dp4311
g7
I99
sg8
VP19875
p4312
sg10
I5
sg11
VCXCL2
p4313
sg13
I1
sa(dp4314
g7
I83
sg8
g15
sg10
I7
sg11
VCOL12A1
p4315
sg13
I1
sa(dp4316
g7
I124
sg8
g15
sg10
I6
sg11
VSLC7A5
p4317
sg13
I1
sa(dp4318
g7
I113
sg8
VP01584
p4319
sg10
I4
sg11
VIL1B
p4320
sg13
I1
sa(dp4321
g7
I92
sg8
VP09341
p4322
sg10
I5
sg11
VCXCL1
p4323
sg13
I1
sa(dp4324
g7
I106
sg8
g15
sg10
I5
sg11
VGREM1
p4325
sg13
I1
sasg20
(lp4326
(dp4327
g7
I30
sg23
VC1527249
p4328
sg10
I17
sg11
Vcolorectal cancer
p4329
sg13
I2
sasa(dp4330
g2
S'It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis.\n'
p4331
sg4
(lp4332
sg20
(lp4333
(dp4334
g7
I211
sg23
VC3203547
p4335
sg10
I23
sg11
Vaxial spondyloarthritis
p4336
sg13
I2
sa(dp4337
g7
I236
sg23
VC0406317
p4338
sg10
I16
sg11
Vplaque psoriasis
p4339
sg13
I2
sa(dp4340
g7
I107
sg23
VC0003864
p4341
sg10
I9
sg11
Varthritis
p4342
sg13
I1
sa(dp4343
g7
I236
sg23
VC0406317
p4344
sg10
I16
sg11
Vplaque psoriasis
p4345
sg13
I2
sa(dp4346
g7
I107
sg23
VC0553662
p4347
sg10
I30
sg11
Varthritis, juvenile idiopathic
p4348
sg13
I3
sa(dp4349
g7
I138
sg23
VC0003872
p4350
sg10
I20
sg11
Varthritis, psoriatic
p4351
sg13
I2
sa(dp4352
g7
I170
sg23
VC0038013
p4353
sg10
I22
sg11
Vankylosing spondylitis
p4354
sg13
I2
sasa(dp4355
g2
S'We describe the case of a boy with a TUBA1A mutation presenting with microphthalmia and congenital cataracts in addition to microcephaly and severe brain malformation.\n'
p4356
sg4
(lp4357
(dp4358
g7
I37
sg8
g15
sg10
I6
sg11
VTUBA1A
p4359
sg13
I1
sasg20
(lp4360
(dp4361
g7
I69
sg23
VC0026010
p4362
sg10
I14
sg11
Vmicrophthalmia
p4363
sg13
I1
sa(dp4364
g7
I148
sg23
VC0266449
p4365
sg10
I18
sg11
Vbrain malformation
p4366
sg13
I2
sa(dp4367
g7
I88
sg23
VC0009691
p4368
sg10
I20
sg11
Vcongenital cataracts
p4369
sg13
I2
sa(dp4370
g7
I124
sg23
VC0025958
p4371
sg10
I12
sg11
Vmicrocephaly
p4372
sg13
I1
sasa(dp4373
g2
S"Recently, modifications of ABeta1-42 levels in CSF and plasma associated with improvement in memory and language functions have been observed in patients with mild-moderate Alzheimer's disease (AD) treated with plasma exchange (PE) with albumin replacement.\n"
p4374
sg4
(lp4375
(dp4376
g7
I237
sg8
VP00441
p4377
sg10
I7
sg11
Valbumin
p4378
sg13
I1
sasg20
(lp4379
(dp4380
g7
I173
sg23
VC1521724
p4381
sg10
I19
sg11
VAlzheimer's disease
p4382
sg13
I2
sa(dp4383
g7
I194
sg23
VC1521724
p4384
sg10
I2
sg11
VAD
p4385
sg13
I1
sasa(dp4386
g2
S'We previously showed that Decorin--a leucine-rich proteoglycan inhibiting the progression of glomerulonephritis and glomerular sclerosis--can be degraded by the ubiquitin-proteasome pathway and deubiquitinated and stabilized by ubiquitin-specific processing protease 2-69(Usp2-69).\n'
p4387
sg4
(lp4388
(dp4389
g7
I26
sg8
VP07585
p4390
sg10
I7
sg11
VDecorin
p4391
sg13
I1
sa(dp4392
g7
I161
sg8
VP62979
p4393
sg10
I9
sg11
Vubiquitin
p4394
sg13
I1
sa(dp4395
g7
I228
sg8
g15
sg10
I43
sg11
Vubiquitin-specific processing protease 2-69
p4396
sg13
I4
sa(dp4397
g7
I272
sg8
g15
sg10
I7
sg11
VUsp2-69
p4398
sg13
I1
sasg20
(lp4399
(dp4400
g7
I116
sg23
VC0178664
p4401
sg10
I20
sg11
Vglomerular sclerosis
p4402
sg13
I2
sa(dp4403
g7
I93
sg23
VC0017658
p4404
sg10
I18
sg11
Vglomerulonephritis
p4405
sg13
I1
sasa(dp4406
g2
S'Here, we explored the effect of Usp2-69 on MC proliferation and ECM deposition by transfecting Usp2-69 plasmid into rat anti-Thy1.1 nephritis model and into cultured MCs, as well as detected Usp2-69 and Decorin in rat anti-Thy1.1 nephritis model by western blot.\n'
p4407
sg4
(lp4408
(dp4409
g7
I32
sg8
g15
sg10
I7
sg11
VUsp2-69
p4410
sg13
I1
sa(dp4411
g7
I32
sg8
g15
sg10
I7
sg11
VUsp2-69
p4412
sg13
I1
sa(dp4413
g7
I116
sg8
VP04216
p4414
sg10
I13
sg11
Vrat anti-Thy1
p4415
sg13
I2
sa(dp4416
g7
I203
sg8
VP07585
p4417
sg10
I7
sg11
VDecorin
p4418
sg13
I1
sa(dp4419
g7
I32
sg8
g15
sg10
I7
sg11
VUsp2-69
p4420
sg13
I1
sasg20
(lp4421
(dp4422
g7
I166
sg23
VC0036221
p4423
sg10
I3
sg11
VMCs
p4424
sg13
I1
sa(dp4425
g7
I132
sg23
VC0027697
p4426
sg10
I9
sg11
Vnephritis
p4427
sg13
I1
sa(dp4428
g7
I46
sg23
VC0334094
p4429
sg10
I13
sg11
Vproliferation
p4430
sg13
I1
sa(dp4431
g7
I132
sg23
VC0027697
p4432
sg10
I9
sg11
Vnephritis
p4433
sg13
I1
sasa(dp4434
g2
S'Overexpressing Usp2-69 at the early stage, but not advanced stage, of anti-Thy1.1 nephritis alleviated cell proliferation and ECM deposition, which was shown by decreased Ki-67, Collagen IV and Fibronectin detected by immunohistochemistry.\n'
p4435
sg4
(lp4436
(dp4437
g7
I15
sg8
g15
sg10
I7
sg11
VUsp2-69
p4438
sg13
I1
sa(dp4439
g7
I171
sg8
VP46013
p4440
sg10
I5
sg11
VKi-67
p4441
sg13
I1
sa(dp4442
g7
I70
sg8
VP04216
p4443
sg10
I11
sg11
Vanti-Thy1.1
p4444
sg13
I1
sasg20
(lp4445
(dp4446
g7
I82
sg23
VC0027697
p4447
sg10
I9
sg11
Vnephritis
p4448
sg13
I1
sa(dp4449
g7
I108
sg23
VC0334094
p4450
sg10
I13
sg11
Vproliferation
p4451
sg13
I1
sasa(dp4452
g2
S'In conclusion, our findings suggest that Usp2-69 overexpression alleviates the progression of rat anti-Thy1.1 nephritis and, therefore, that exogenous plasmid injection via the renal artery enhanced by electrotransfer technology could be a promising avenue for glomerular disease research.\n'
p4453
sg4
(lp4454
(dp4455
g7
I94
sg8
VP04216
p4456
sg10
I15
sg11
Vrat anti-Thy1.1
p4457
sg13
I2
sa(dp4458
g7
I41
sg8
g15
sg10
I7
sg11
VUsp2-69
p4459
sg13
I1
sasg20
(lp4460
(dp4461
g7
I261
sg23
VC0268731
p4462
sg10
I18
sg11
Vglomerular disease
p4463
sg13
I2
sa(dp4464
g7
I110
sg23
VC0027697
p4465
sg10
I9
sg11
Vnephritis
p4466
sg13
I1
sasa(dp4467
g2
S'The proportion of USP2-69 positive area in the glomeruli was 3.90% in normal kidney, 4.96% in minimal change disease, and 4.39% in membranous glomerulonephritides, while it was 14.84% in IgA nephropathy (IgAN) (mesangial proliferative type), 16.18% in lupus nephritis (LN; diffuse proliferative type) and 15.54% in acute proliferative glomerulonephritides (APGN); the difference of the percentages between IgAN, LN (IV subtype) and APGN and normal kidney were statistically significant (P &lt; 0.05).\n'
p4468
sg4
(lp4469
(dp4470
g7
I187
sg8
VP11912
p4471
sg10
I15
sg11
VIgA nephropathy
p4472
sg13
I2
sa(dp4473
g7
I204
sg8
VP11912
p4474
sg10
I4
sg11
VIgAN
p4475
sg13
I1
sa(dp4476
g7
I18
sg8
g15
sg10
I7
sg11
VUSP2-69
p4477
sg13
I1
sa(dp4478
g7
I204
sg8
VP11912
p4479
sg10
I4
sg11
VIgAN
p4480
sg13
I1
sasg20
(lp4481
(dp4482
g7
I187
sg23
VC0017661
p4483
sg10
I15
sg11
VIgA nephropathy
p4484
sg13
I2
sa(dp4485
g7
I269
sg23
VC0024143
p4486
sg10
I2
sg11
VLN
p4487
sg13
I1
sa(dp4488
g7
I357
sg23
VC0017658
p4489
sg10
I4
sg11
VAPGN
p4490
sg13
I1
sa(dp4491
g7
I221
sg23
VC0334094
p4492
sg10
I13
sg11
Vproliferative
p4493
sg13
I1
sa(dp4494
g7
I269
sg23
VC0024143
p4495
sg10
I2
sg11
VLN
p4496
sg13
I1
sa(dp4497
g7
I131
sg23
VC0017665
p4498
sg10
I31
sg11
Vmembranous glomerulonephritides
p4499
sg13
I2
sa(dp4500
g7
I252
sg23
VC0024143
p4501
sg10
I15
sg11
Vlupus nephritis
p4502
sg13
I2
sa(dp4503
g7
I204
sg23
VC0017661
p4504
sg10
I4
sg11
VIgAN
p4505
sg13
I1
sa(dp4506
g7
I315
sg23
VC0017658
p4507
sg10
I40
sg11
Vacute proliferative glomerulonephritides
p4508
sg13
I3
sa(dp4509
g7
I357
sg23
VC0017658
p4510
sg10
I4
sg11
VAPGN
p4511
sg13
I1
sa(dp4512
g7
I221
sg23
VC0334094
p4513
sg10
I13
sg11
Vproliferative
p4514
sg13
I1
sa(dp4515
g7
I204
sg23
VC0017661
p4516
sg10
I4
sg11
VIgAN
p4517
sg13
I1
sa(dp4518
g7
I94
sg23
VC1704320
p4519
sg10
I22
sg11
Vminimal change disease
p4520
sg13
I3
sasa(dp4521
g2
S"We analysed surviving human SN DA neurons from patients with Parkinson's disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson's disease.\n"
p4522
sg4
(lp4523
(dp4524
g7
I167
sg8
VP48051
p4525
sg10
I5
sg11
VGIRK2
p4526
sg13
I1
sasg20
(lp4527
(dp4528
g7
I61
sg23
VC0030567
p4529
sg10
I19
sg11
VParkinson's disease
p4530
sg13
I2
sa(dp4531
g7
I61
sg23
VC0030567
p4532
sg10
I19
sg11
VParkinson's disease
p4533
sg13
I2
sasa(dp4534
g2
S"Thus, our findings provide a novel homeostatic functional link in SN DA neurons between Cav1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Cav1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson's disease pathology.\n"
p4535
sg4
(lp4536
(dp4537
g7
I88
sg8
g15
sg10
I9
sg11
VCav1.3- L
p4538
sg13
I2
sa(dp4539
g7
I222
sg8
VP62166
p4540
sg10
I12
sg11
VCav1.3/NCS-1
p4541
sg13
I1
sa(dp4542
g7
I238
sg8
VP48051
p4543
sg10
I5
sg11
VGIRK2
p4544
sg13
I1
sasg20
(lp4545
(dp4546
g7
I323
sg23
VC0677042
p4547
sg10
I9
sg11
Vpathology
p4548
sg13
I1
sa(dp4549
g7
I303
sg23
VC0030567
p4550
sg10
I19
sg11
VParkinson's disease
p4551
sg13
I2
sasa(dp4552
g2
S'In conclusion, sera from AIH-1 patients reacted with the amino acids in the sequence 33-37 (PQDGS) of the N-terminal of UGT1A6.\n'
p4553
sg4
(lp4554
(dp4555
g7
I120
sg8
VP35504
p4556
sg10
I6
sg11
VUGT1A6
p4557
sg13
I1
sasg20
(lp4558
sa(dp4559
g2
S'Several proapoptotic genes (AKT1 and AKT2) were down-regulated and antiapoptotic genes (APAF1 and BCL2L1) were up-regulated in multiple myeloma, both symptomatic and asymptomatic, compared to monoclonal gammopathy of undetermined significance.\n'
p4560
sg4
(lp4561
(dp4562
g7
I98
sg8
g15
sg10
I6
sg11
VBCL2L1
p4563
sg13
I1
sa(dp4564
g7
I37
sg8
VP31751
p4565
sg10
I4
sg11
VAKT2
p4566
sg13
I1
sa(dp4567
g7
I28
sg8
VP31749
p4568
sg10
I4
sg11
VAKT1
p4569
sg13
I1
sasg20
(lp4570
(dp4571
g7
I192
sg23
VC0026470
p4572
sg10
I50
sg11
Vmonoclonal gammopathy of undetermined significance
p4573
sg13
I5
sa(dp4574
g7
I127
sg23
VC0026764
p4575
sg10
I16
sg11
Vmultiple myeloma
p4576
sg13
I2
sasa(dp4577
g2
S'To study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM).\n'
p4578
sg4
(lp4579
(dp4580
g7
I155
sg8
VP42771
p4581
sg10
I3
sg11
Vp53
p4582
sg13
I1
sa(dp4583
g7
I134
sg8
VP51397
p4584
sg10
I3
sg11
VDAP
p4585
sg13
I1
sa(dp4586
g7
I108
sg8
VP51397
p4587
sg10
I24
sg11
Vdeath-associated protein
p4588
sg13
I2
sa(dp4589
g7
I146
sg8
VP03971
p4590
sg10
I3
sg11
Vp14
p4591
sg13
I1
sasg20
(lp4592
(dp4593
g7
I187
sg23
VC0026764
p4594
sg10
I16
sg11
Vmultiple myeloma
p4595
sg13
I2
sa(dp4596
g7
I68
sg23
VC0027651
p4597
sg10
I6
sg11
Vtumour
p4598
sg13
I1
sasa(dp4599
g2
S'The other was a spermatocytic seminoma with focal primitive neuroectodermal differentiation: formation of Homer-Wright rosettes and perivascular pseudorosettes, with immunoreactivity for S-100 protein, neuron-specific enolase, synaptophysin, neurofilament-68 kDa, microtubule-associated protein 2, and vimentin.\n'
p4600
sg4
(lp4601
(dp4602
g7
I264
sg8
VP11137
p4603
sg10
I32
sg11
Vmicrotubule-associated protein 2
p4604
sg13
I3
sa(dp4605
g7
I187
sg8
VP04271
p4606
sg10
I13
sg11
VS-100 protein
p4607
sg13
I2
sa(dp4608
g7
I202
sg8
VP09104
p4609
sg10
I23
sg11
Vneuron-specific enolase
p4610
sg13
I2
sa(dp4611
g7
I227
sg8
VP08247
p4612
sg10
I13
sg11
Vsynaptophysin
p4613
sg13
I1
sasg20
(lp4614
(dp4615
g7
I16
sg23
VC0334517
p4616
sg10
I22
sg11
Vspermatocytic seminoma
p4617
sg13
I2
sasa(dp4618
g2
S'In addition to Rett syndrome and breast/ovarian cancer observed in other studies, we report evidence for the first time, to our knowledge, that overexpression of ubiquinol-cytochrome c reductase core protein I might affect mitochondrial morphology and/or physiology and lead to development of obesity and related conditions.\n'
p4619
sg4
(lp4620
(dp4621
g7
I162
sg8
VP99999
p4622
sg10
I47
sg11
Vubiquinol-cytochrome c reductase core protein I
p4623
sg13
I6
sasg20
(lp4624
(dp4625
g7
I293
sg23
VC0028754
p4626
sg10
I7
sg11
Vobesity
p4627
sg13
I1
sa(dp4628
g7
I15
sg23
VC0035372
p4629
sg10
I13
sg11
VRett syndrome
p4630
sg13
I2
sa(dp4631
g7
I40
sg23
VC1140680
p4632
sg10
I14
sg11
Vovarian cancer
p4633
sg13
I2
sasa(dp4634
g2
S'From the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant.\n'
p4635
sg4
(lp4636
(dp4637
g7
I102
sg8
VP01116
p4638
sg10
I4
sg11
VKRAS
p4639
sg13
I1
sasg20
(lp4640
(dp4641
g7
I33
sg23
VC0009319
p4642
sg10
I7
sg11
Vcolitis
p4643
sg13
I1
sa(dp4644
g7
I52
sg23
VC0006826
p4645
sg10
I7
sg11
Vcancers
p4646
sg13
I1
sasa(dp4647
g2
S'In a murine acute systemic candidiasis model, C albicans strongly stimulated hepcidin, accompanied by a major reduction in transferrin saturation.\n'
p4648
sg4
(lp4649
(dp4650
g7
I123
sg8
VP02787
p4651
sg10
I11
sg11
Vtransferrin
p4652
sg13
I1
sasg20
(lp4653
(dp4654
g7
I18
sg23
VC0153252
p4655
sg10
I20
sg11
Vsystemic candidiasis
p4656
sg13
I2
sasa(dp4657
g2
S'On the other hand, iron overload (iron saturated transferrin) is a serious risk factor for candidiasis in newborn and in leukemic patients.\n'
p4658
sg4
(lp4659
(dp4660
g7
I49
sg8
VP02787
p4661
sg10
I11
sg11
Vtransferrin
p4662
sg13
I1
sasg20
(lp4663
(dp4664
g7
I19
sg23
VC0282193
p4665
sg10
I13
sg11
Viron overload
p4666
sg13
I2
sa(dp4667
g7
I91
sg23
VC0006840
p4668
sg10
I11
sg11
Vcandidiasis
p4669
sg13
I1
sasa(dp4670
g2
S'It has been suggested that blockade of the Na+/H+ exchanger (NHE1) can prevent atrial fibrillation (AF)-induced electrical remodeling and the development of AF.\n'
p4671
sg4
(lp4672
(dp4673
g7
I61
sg8
VP19634
p4674
sg10
I4
sg11
VNHE1
p4675
sg13
I1
sasg20
(lp4676
(dp4677
g7
I79
sg23
VC0004238
p4678
sg10
I19
sg11
Vatrial fibrillation
p4679
sg13
I2
sa(dp4680
g7
I100
sg23
VC0232197
p4681
sg10
I2
sg11
VAF
p4682
sg13
I1
sa(dp4683
g7
I100
sg23
VC0232197
p4684
sg10
I2
sg11
VAF
p4685
sg13
I1
sasa(dp4686
g2
S'The case of a 13-year-old boy is presented and the diagnostic process discussed especially the differentiation between trance states and epilepsy.\n'
p4687
sg4
(lp4688
sg20
(lp4689
(dp4690
g7
I137
sg23
VC0014544
p4691
sg10
I8
sg11
Vepilepsy
p4692
sg13
I1
sa(dp4693
g7
I119
sg23
VC0855240
p4694
sg10
I6
sg11
Vtrance
p4695
sg13
I1
sasa(dp4696
g2
S'The phenotype is usually T-B+NK+ SCID with lymphopenia where the clinical findings may be mild (CD3Gamma) or severe (CD3Delta, Epsilon, Zeta) owing to the underlying molecular defect.\n'
p4697
sg4
(lp4698
(dp4699
g7
I25
sg8
VP31785
p4700
sg10
I12
sg11
VT-B+NK+ SCID
p4701
sg13
I2
sasg20
(lp4702
(dp4703
g7
I43
sg23
VC0024312
p4704
sg10
I11
sg11
Vlymphopenia
p4705
sg13
I1
sa(dp4706
g7
I65
sg23
VC0037088
p4707
sg10
I17
sg11
Vclinical findings
p4708
sg13
I2
sa(dp4709
g7
I33
sg23
VC0085110
p4710
sg10
I4
sg11
VSCID
p4711
sg13
I1
sasa(dp4712
g2
S'In contrast, all reported human complete CD3delta (or CD3epsilon) deficiencies are in infants with life-threatening SCID and very severe alphabeta and gammadelta T lymphocytopenia.\n'
p4713
sg4
(lp4714
sg20
(lp4715
(dp4716
g7
I116
sg23
VC0085110
p4717
sg10
I4
sg11
VSCID
p4718
sg13
I1
sa(dp4719
g7
I164
sg23
VC0024312
p4720
sg10
I15
sg11
Vlymphocytopenia
p4721
sg13
I1
sasa(dp4722
g2
S'Although clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus.\n'
p4723
sg4
(lp4724
sg20
(lp4725
(dp4726
g7
I221
sg23
VC0011860
p4727
sg10
I24
sg11
Vtype 2 diabetes mellitus
p4728
sg13
I4
sa(dp4729
g7
I198
sg23
VC0311277
p4730
sg10
I17
sg11
Vabdominal obesity
p4731
sg13
I2
sasa(dp4732
g2
S'Given that most patients with mental disorders face chronic, even life-long, treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms are major considerations for APD maintenance treatment.\n'
p4733
sg4
(lp4734
sg20
(lp4735
(dp4736
g7
I141
sg23
VC0476237
p4737
sg10
I18
sg11
Vmetabolic symptoms
p4738
sg13
I2
sa(dp4739
g7
I47
sg23
VC3160739
p4740
sg10
I4
sg11
Vface
p4741
sg13
I1
sa(dp4742
g7
I30
sg23
VC0004936
p4743
sg10
I16
sg11
Vmental disorders
p4744
sg13
I2
sa(dp4745
g7
I123
sg23
VC0028754
p4746
sg10
I7
sg11
Vobesity
p4747
sg13
I1
sasa(dp4748
g2
S'Although offering many benefits for several psychiatric disorders, antipsychotic drugs (APDs) as a class have a major liability in their tendency to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population.\n'
p4749
sg4
(lp4750
sg20
(lp4751
(dp4752
g7
I168
sg23
VC0028754
p4753
sg10
I7
sg11
Vobesity
p4754
sg13
I1
sa(dp4755
g7
I44
sg23
VC0004936
p4756
sg10
I21
sg11
Vpsychiatric disorders
p4757
sg13
I2
sa(dp4758
g7
I157
sg23
VC0028754
p4759
sg10
I9
sg11
Vadiposity
p4760
sg13
I1
sasa(dp4761
g2
S'To describe the association between obesity and the use of antipsychotic drugs (APDs) in adult outpatients followed-up on in five Primary Care settings.\n'
p4762
sg4
(lp4763
sg20
(lp4764
(dp4765
g7
I36
sg23
VC0028754
p4766
sg10
I7
sg11
Vobesity
p4767
sg13
I1
sasa(dp4768
g2
S'Obesity was associated with the use of APDs [OR = 1.5 (CI: 1.3-1.8)], hypertension [OR = 2.4 (CI: 2.2-2.5)], diabetes [OR = 1.4 (CI: 1.3-1.5)] and dyslipidemia [OR = 1.3 (CI: 1.2-1.4)], p &lt; 0.0001 in all cases.\n'
p4769
sg4
(lp4770
sg20
(lp4771
(dp4772
g7
I0
sg23
VC0028754
p4773
sg10
I7
sg11
VObesity
p4774
sg13
I1
sa(dp4775
g7
I147
sg23
VC0242339
p4776
sg10
I12
sg11
Vdyslipidemia
p4777
sg13
I1
sa(dp4778
g7
I70
sg23
VC0020538
p4779
sg10
I12
sg11
Vhypertension
p4780
sg13
I1
sa(dp4781
g7
I109
sg23
VC0011849
p4782
sg10
I8
sg11
Vdiabetes
p4783
sg13
I1
sasa(dp4784
g2
S'Obesity was associated with the use of APDs, regardless of the type of drug, and with the presence of hypertension, diabetes and dyslipidemia.\n'
p4785
sg4
(lp4786
sg20
(lp4787
(dp4788
g7
I0
sg23
VC0028754
p4789
sg10
I7
sg11
VObesity
p4790
sg13
I1
sa(dp4791
g7
I116
sg23
VC0011849
p4792
sg10
I8
sg11
Vdiabetes
p4793
sg13
I1
sa(dp4794
g7
I129
sg23
VC0242339
p4795
sg10
I12
sg11
Vdyslipidemia
p4796
sg13
I1
sa(dp4797
g7
I102
sg23
VC0020538
p4798
sg10
I12
sg11
Vhypertension
p4799
sg13
I1
sasa(dp4800
g2
S'Higher DARs were associated with lower rates of moderate or severe paravalvular aortic regurgitation: DAR &lt;=10%, 17.6%; DAR 10% to 15%, 9.9%; DAR 15% to 20%, 6.3%; and DAR &gt;20%, 4.9%; P&lt;0.001.\n'
p4801
sg4
(lp4802
(dp4803
g7
I7
sg8
VP14868
p4804
sg10
I4
sg11
VDARs
p4805
sg13
I1
sasg20
(lp4806
(dp4807
g7
I7
sg23
VC0022595
p4808
sg10
I3
sg11
VDAR
p4809
sg13
I1
sa(dp4810
g7
I7
sg23
VC0022595
p4811
sg10
I3
sg11
VDAR
p4812
sg13
I1
sa(dp4813
g7
I80
sg23
VC0003504
p4814
sg10
I20
sg11
Vaortic regurgitation
p4815
sg13
I2
sa(dp4816
g7
I7
sg23
VC0022595
p4817
sg10
I3
sg11
VDAR
p4818
sg13
I1
sa(dp4819
g7
I7
sg23
VC0022595
p4820
sg10
I3
sg11
VDAR
p4821
sg13
I1
sasa(dp4822
g2
S'In 1990, Hopkins and Ruiz-Riben stated that the target date o f the end o f 1995 for the eradication of dracunculiasis is unrealistic only if it is judged to be unimportant.\n'
p4823
sg4
(lp4824
sg20
(lp4825
(dp4826
g7
I104
sg23
VC0013100
p4827
sg10
I14
sg11
Vdracunculiasis
p4828
sg13
I1
sasa(dp4829
g2
S'DLL1 influence drug resistance of small cell lung cancer through activating transcription of downstream genes HES1 and HEY1.\n'
p4830
sg4
(lp4831
(dp4832
g7
I119
sg8
g15
sg10
I4
sg11
VHEY1
p4833
sg13
I1
sa(dp4834
g7
I110
sg8
g15
sg10
I4
sg11
VHES1
p4835
sg13
I1
sa(dp4836
g7
I0
sg8
g15
sg10
I4
sg11
VDLL1
p4837
sg13
I1
sasg20
(lp4838
(dp4839
g7
I34
sg23
VC0149925
p4840
sg10
I22
sg11
Vsmall cell lung cancer
p4841
sg13
I4
sasa(dp4842
g2
S'In this study, we showed that a high percentage of lung cancer lines expressed Jagged1, Notch receptors, and their transcriptional target genes (HES1, Hey1), suggesting that the Notch pathway plays an important role in lung cancer biology.\n'
p4843
sg4
(lp4844
(dp4845
g7
I145
sg8
g15
sg10
I4
sg11
VHES1
p4846
sg13
I1
sa(dp4847
g7
I79
sg8
VP78504
p4848
sg10
I7
sg11
VJagged1
p4849
sg13
I1
sa(dp4850
g7
I151
sg8
g15
sg10
I4
sg11
VHey1
p4851
sg13
I1
sa(dp4852
g7
I88
sg8
g15
sg10
I15
sg11
VNotch receptors
p4853
sg13
I2
sasg20
(lp4854
(dp4855
g7
I51
sg23
VC0684249
p4856
sg10
I11
sg11
Vlung cancer
p4857
sg13
I2
sa(dp4858
g7
I51
sg23
VC0684249
p4859
sg10
I11
sg11
Vlung cancer
p4860
sg13
I2
sasa(dp4861
g2
S"ALPs easily insert in the outer leaflet of the plasma membrane and cross the membrane via an ATP-dependent CDC50a-containing 'flippase' complex (in carcinoma cells), or are internalized by lipid raft-dependent endocytosis (in lymphoma/leukemic cells).\n"
p4862
sg4
(lp4863
(dp4864
g7
I107
sg8
g15
sg10
I6
sg11
VCDC50a
p4865
sg13
I1
sa(dp4866
g7
I125
sg8
VP98196
p4867
sg10
I9
sg11
V'flippase
p4868
sg13
I1
sa(dp4869
g7
I0
sg8
VP03973
p4870
sg10
I4
sg11
VALPs
p4871
sg13
I1
sasg20
(lp4872
(dp4873
g7
I148
sg23
VC0007097
p4874
sg10
I9
sg11
Vcarcinoma
p4875
sg13
I1
sa(dp4876
g7
I226
sg23
VC0024299
p4877
sg10
I8
sg11
Vlymphoma
p4878
sg13
I1
sa(dp4879
g7
I0
sg23
VC1328840
p4880
sg10
I4
sg11
VALPs
p4881
sg13
I1
sasa(dp4882
g2
S'Levels of 27 transcripts were investigated as potential novel markers for prostate cancer, including genes encoding plasma membrane proteins (ADAM2, ELOVL5, MARCKSL1, RAMP1, TMEM30A, and TMEM66); secreted proteins (SPON2, TMEM30A, TMEM66, and truncated TMEFF2 (called POP4)); intracellular proteins (CAMK2N1, DHCR24, GLO1, NGFRAP1, PGK1, PSMA7, SBDS, and YWHAQ); and noncoding transcripts (POP1 (100 kb) from mRNA AK000023), POP2 (4 kb from mRNA AL832227), POP3 (50 kb from EST CFI40309), POP5 (intron of NCAM2, accession DO668384), POP6 (intron of FHIT), POP7 (intron of TNFAIP8), POP8 (intron of EFNA5), POP9 (intron of DSTN), POP10 (intron of ADAM2, accession DO668396), POP11 (87kb from EST BG194644), and POP12 (intron of EST BQ226050)).\n'
p4883
sg4
(lp4884
(dp4885
g7
I489
sg8
g15
sg10
I4
sg11
VPOP5
p4886
sg13
I1
sa(dp4887
g7
I149
sg8
g15
sg10
I6
sg11
VELOVL5
p4888
sg13
I1
sa(dp4889
g7
I332
sg8
VP00558
p4890
sg10
I4
sg11
VPGK1
p4891
sg13
I1
sa(dp4892
g7
I174
sg8
g15
sg10
I7
sg11
VTMEM30A
p4893
sg13
I1
sa(dp4894
g7
I582
sg8
VP52803
p4895
sg10
I22
sg11
VPOP8 (intron of EFNA5)
p4896
sg13
I4
sa(dp4897
g7
I157
sg8
VP49006
p4898
sg10
I8
sg11
VMARCKSL1
p4899
sg13
I1
sa(dp4900
g7
I142
sg8
g15
sg10
I5
sg11
VADAM2
p4901
sg13
I1
sa(dp4902
g7
I309
sg8
g15
sg10
I6
sg11
VDHCR24
p4903
sg13
I1
sa(dp4904
g7
I300
sg8
g15
sg10
I7
sg11
VCAMK2N1
p4905
sg13
I1
sa(dp4906
g7
I317
sg8
g15
sg10
I4
sg11
VGLO1
p4907
sg13
I1
sa(dp4908
g7
I142
sg8
g15
sg10
I5
sg11
VADAM2
p4909
sg13
I1
sa(dp4910
g7
I187
sg8
g15
sg10
I6
sg11
VTMEM66
p4911
sg13
I1
sa(dp4912
g7
I323
sg8
g15
sg10
I7
sg11
VNGFRAP1
p4913
sg13
I1
sa(dp4914
g7
I556
sg8
g15
sg10
I24
sg11
VPOP7 (intron of TNFAIP8)
p4915
sg13
I4
sa(dp4916
g7
I533
sg8
VP49789
p4917
sg10
I21
sg11
VPOP6 (intron of FHIT)
p4918
sg13
I4
sa(dp4919
g7
I505
sg8
g15
sg10
I5
sg11
VNCAM2
p4920
sg13
I1
sa(dp4921
g7
I167
sg8
g15
sg10
I5
sg11
VRAMP1
p4922
sg13
I1
sa(dp4923
g7
I268
sg8
g15
sg10
I4
sg11
VPOP4
p4924
sg13
I1
sa(dp4925
g7
I457
sg8
VP49888
p4926
sg10
I29
sg11
VPOP3 (50 kb from EST CFI40309
p4927
sg13
I6
sa(dp4928
g7
I174
sg8
g15
sg10
I7
sg11
VTMEM30A
p4929
sg13
I1
sa(dp4930
g7
I187
sg8
g15
sg10
I6
sg11
VTMEM66
p4931
sg13
I1
sa(dp4932
g7
I116
sg8
VP35968
p4933
sg10
I24
sg11
Vplasma membrane proteins
p4934
sg13
I3
sa(dp4935
g7
I338
sg8
g15
sg10
I5
sg11
VPSMA7
p4936
sg13
I1
sa(dp4937
g7
I215
sg8
g15
sg10
I5
sg11
VSPON2
p4938
sg13
I1
sa(dp4939
g7
I390
sg8
g15
sg10
I32
sg11
VPOP1 (100 kb) from mRNA AK000023
p4940
sg13
I6
sasg20
(lp4941
(dp4942
g7
I74
sg23
VC0600139
p4943
sg10
I15
sg11
Vprostate cancer
p4944
sg13
I2
sasa(dp4945
g2
S'Levels of CAMK2N1, GLO1, SDBS, and TMEM30A transcripts tended to be increased in primary prostate cancer from patients who later had biochemical failure.\n'
p4946
sg4
(lp4947
(dp4948
g7
I10
sg8
g15
sg10
I7
sg11
VCAMK2N1
p4949
sg13
I1
sa(dp4950
g7
I35
sg8
g15
sg10
I19
sg11
VTMEM30A transcripts
p4951
sg13
I2
sa(dp4952
g7
I19
sg8
g15
sg10
I4
sg11
VGLO1
p4953
sg13
I1
sasg20
(lp4954
(dp4955
g7
I89
sg23
VC0600139
p4956
sg10
I15
sg11
Vprostate cancer
p4957
sg13
I2
sasa(dp4958
g2
S'Human CDC50A mRNA was expressed in embryonic stem (ES) cells, placenta, brain and chondrosarcoma, while CDC50B mRNA was expressed in pancreatic islet, kidney, prostate as well as in lung carcinoid, parathyroid tumor, bladder tumor, meningioma and pancreatic cancer.\n'
p4959
sg4
(lp4960
(dp4961
g7
I0
sg8
g15
sg10
I17
sg11
VHuman CDC50A mRNA
p4962
sg13
I3
sa(dp4963
g7
I104
sg8
g15
sg10
I11
sg11
VCDC50B mRNA
p4964
sg13
I2
sasg20
(lp4965
(dp4966
g7
I198
sg23
VC0030521
p4967
sg10
I17
sg11
Vparathyroid tumor
p4968
sg13
I2
sa(dp4969
g7
I247
sg23
VC0235974
p4970
sg10
I17
sg11
Vpancreatic cancer
p4971
sg13
I2
sa(dp4972
g7
I232
sg23
VC0025286
p4973
sg10
I10
sg11
Vmeningioma
p4974
sg13
I1
sa(dp4975
g7
I217
sg23
VC0005695
p4976
sg10
I13
sg11
Vbladder tumor
p4977
sg13
I2
sa(dp4978
g7
I82
sg23
VC0008479
p4979
sg10
I14
sg11
Vchondrosarcoma
p4980
sg13
I1
sa(dp4981
g7
I187
sg23
VC0007095
p4982
sg10
I9
sg11
Vcarcinoid
p4983
sg13
I1
sasa(dp4984
g2
S'Finally, ephrin-B2/Fc promoted angiogenesis in vivo in corneal neovascularization and Matrigel plug assays in adult mice, whereas LY294002 reduced angiogenesis in Matrigel that was induced by ephrin-B2/Fc.\n'
p4985
sg4
(lp4986
(dp4987
g7
I9
sg8
VP52799
p4988
sg10
I9
sg11
Vephrin-B2
p4989
sg13
I1
sasg20
(lp4990
(dp4991
g7
I55
sg23
VC0085109
p4992
sg10
I26
sg11
Vcorneal neovascularization
p4993
sg13
I2
sasa(dp4994
g2
S'Mutations of SYNGAP1 have been frequently linked to brain disorders including intellectual disability, autisms, and seizure.\n'
p4995
sg4
(lp4996
(dp4997
g7
I13
sg8
g15
sg10
I7
sg11
VSYNGAP1
p4998
sg13
I1
sasg20
(lp4999
(dp5000
g7
I116
sg23
VC0036572
p5001
sg10
I7
sg11
Vseizure
p5002
sg13
I1
sa(dp5003
g7
I103
sg23
VC0004352
p5004
sg10
I7
sg11
Vautisms
p5005
sg13
I1
sa(dp5006
g7
I52
sg23
VC0006111
p5007
sg10
I15
sg11
Vbrain disorders
p5008
sg13
I2
sa(dp5009
g7
I78
sg23
VC0025362
p5010
sg10
I23
sg11
Vintellectual disability
p5011
sg13
I2
sasa(dp5012
g2
S'Furthermore, the LTP-regulated phosphoproteins, which included the scaffold proteins Shank3, Syngap1, Dlgap1, and Dlg4, represented the "PSD risk" for schizophrenia and autism spectrum disorder, such that without these proteins in the analysis, the association with the PSD and these two psychiatric diseases was not present.\n'
p5013
sg4
(lp5014
(dp5015
g7
I102
sg8
g15
sg10
I6
sg11
VDlgap1
p5016
sg13
I1
sa(dp5017
g7
I114
sg8
VP78352
p5018
sg10
I4
sg11
VDlg4
p5019
sg13
I1
sa(dp5020
g7
I137
sg8
g15
sg10
I3
sg11
VPSD
p5021
sg13
I1
sa(dp5022
g7
I85
sg8
g15
sg10
I6
sg11
VShank3
p5023
sg13
I1
sa(dp5024
g7
I93
sg8
g15
sg10
I7
sg11
VSyngap1
p5025
sg13
I1
sasg20
(lp5026
(dp5027
g7
I151
sg23
VC0036341
p5028
sg10
I13
sg11
Vschizophrenia
p5029
sg13
I1
sa(dp5030
g7
I169
sg23
VC1510586
p5031
sg10
I24
sg11
Vautism spectrum disorder
p5032
sg13
I3
sasa(dp5033
g2
S'Developmental delay was the first manifestation of SYNGAP1-related encephalopathy; intellectual disability became progressively obvious and was associated with autistic behaviours in eight patients.\n'
p5034
sg4
(lp5035
(dp5036
g7
I51
sg8
g15
sg10
I7
sg11
VSYNGAP1
p5037
sg13
I1
sasg20
(lp5038
(dp5039
g7
I0
sg23
VC0424605
p5040
sg10
I19
sg11
VDevelopmental delay
p5041
sg13
I2
sa(dp5042
g7
I83
sg23
VC0025362
p5043
sg10
I23
sg11
Vintellectual disability
p5044
sg13
I2
sa(dp5045
g7
I160
sg23
VC0004352
p5046
sg10
I8
sg11
Vautistic
p5047
sg13
I1
sa(dp5048
g7
I67
sg23
VC0085584
p5049
sg10
I14
sg11
Vencephalopathy
p5050
sg13
I1
sasa(dp5051
g2
S'The only two genes upregulated across all transcriptome-wide PE analyses to date (microarray, RNA-Seq and PAS-Seq) are NRIP1 (RIP140), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.\n'
p5052
sg4
(lp5053
(dp5054
g7
I126
sg8
VP48552
p5055
sg10
I6
sg11
VRIP140
p5056
sg13
I1
sa(dp5057
g7
I106
sg8
VP05165
p5058
sg10
I7
sg11
VPAS-Seq
p5059
sg13
I1
sa(dp5060
g7
I119
sg8
VP48552
p5061
sg10
I5
sg11
VNRIP1
p5062
sg13
I1
sa(dp5063
g7
I225
sg8
VP17948
p5064
sg10
I4
sg11
VFlt1
p5065
sg13
I1
sasg20
(lp5066
(dp5067
g7
I212
sg23
VC0028754
p5068
sg10
I7
sg11
Vobesity
p5069
sg13
I1
sa(dp5070
g7
I176
sg23
VC0524620
p5071
sg10
I19
sg11
Vmetabolic syndromes
p5072
sg13
I2
sasa(dp5073
g2
S'Furthermore, endothelial Flt1 gene deletion enhanced the effect of VEGFB, activating the thermogenic program in subcutaneous adipose tissue, which increased the basal metabolic rate, thus preventing diet-induced obesity and related metabolic complications.\n'
p5074
sg4
(lp5075
(dp5076
g7
I25
sg8
VP17948
p5077
sg10
I4
sg11
VFlt1
p5078
sg13
I1
sa(dp5079
g7
I67
sg8
VP49765
p5080
sg10
I5
sg11
VVEGFB
p5081
sg13
I1
sasg20
(lp5082
(dp5083
g7
I212
sg23
VC0028754
p5084
sg10
I7
sg11
Vobesity
p5085
sg13
I1
sa(dp5086
g7
I30
sg23
VC1442161
p5087
sg10
I13
sg11
Vgene deletion
p5088
sg13
I2
sasa(dp5089
g2
S'(2016) demonstrate that VEGF-B, by displacing VEGF-A from VEGFR1 and activating VEGFR2, increases adipose tissue vascularity, improves insulin sensitivity, diminishes obesity, and alleviates metabolic syndrome.\n'
p5090
sg4
(lp5091
(dp5092
g7
I135
sg8
VP01308
p5093
sg10
I7
sg11
Vinsulin
p5094
sg13
I1
sa(dp5095
g7
I58
sg8
VP17948
p5096
sg10
I6
sg11
VVEGFR1
p5097
sg13
I1
sa(dp5098
g7
I24
sg8
VP49765
p5099
sg10
I6
sg11
VVEGF-B
p5100
sg13
I1
sa(dp5101
g7
I69
sg8
VP35968
p5102
sg10
I17
sg11
Vactivating VEGFR2
p5103
sg13
I2
sasg20
(lp5104
(dp5105
g7
I135
sg23
VC0920563
p5106
sg10
I19
sg11
Vinsulin sensitivity
p5107
sg13
I2
sa(dp5108
g7
I191
sg23
VC0524620
p5109
sg10
I18
sg11
Vmetabolic syndrome
p5110
sg13
I2
sa(dp5111
g7
I167
sg23
VC0028754
p5112
sg10
I7
sg11
Vobesity
p5113
sg13
I1
sasa(dp5114
g2
S'Here, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity.\n'
p5115
sg4
(lp5116
(dp5117
g7
I49
sg8
VP49763
p5118
sg10
I4
sg11
VPlGF
p5119
sg13
I1
sa(dp5120
g7
I54
sg8
VP17948
p5121
sg10
I7
sg11
VVEGFR-1
p5122
sg13
I1
sasg20
(lp5123
(dp5124
g7
I81
sg23
VC0028754
p5125
sg10
I7
sg11
Vobesity
p5126
sg13
I1
sa(dp5127
g7
I156
sg23
VC0271510
p5128
sg10
I11
sg11
Vrecruitment
p5129
sg13
I1
sa(dp5130
g7
I97
sg23
VC0178874
p5131
sg10
I17
sg11
Vtumor progression
p5132
sg13
I2
sa(dp5133
g7
I129
sg23
VC1519670
p5134
sg10
I18
sg11
Vtumor angiogenesis
p5135
sg13
I2
sa(dp5136
g7
I152
sg23
VC1834582
p5137
sg10
I3
sg11
VTAM
p5138
sg13
I1
sasa(dp5139
g2
S'Ablation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype.\n'
p5140
sg4
(lp5141
(dp5142
g7
I12
sg8
VP17948
p5143
sg10
I7
sg11
VVEGFR-1
p5144
sg13
I1
sasg20
(lp5145
(dp5146
g7
I56
sg23
VC0027651
p5147
sg10
I5
sg11
Vtumor
p5148
sg13
I1
sa(dp5149
g7
I56
sg23
VC0178874
p5150
sg10
I17
sg11
Vtumor progression
p5151
sg13
I2
sa(dp5152
g7
I40
sg23
VC0028754
p5153
sg10
I7
sg11
Vobesity
p5154
sg13
I1
sasa(dp5155
g2
S'Targeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression.\n'
p5156
sg4
(lp5157
(dp5158
g7
I15
sg8
VP17948
p5159
sg10
I7
sg11
VVEGFR-1
p5160
sg13
I1
sa(dp5161
g7
I10
sg8
VP49763
p5162
sg10
I4
sg11
VPlGF
p5163
sg13
I1
sasg20
(lp5164
(dp5165
g7
I123
sg23
VC0178874
p5166
sg10
I17
sg11
Vtumor progression
p5167
sg13
I2
sa(dp5168
g7
I91
sg23
VC0028754
p5169
sg10
I7
sg11
Vobesity
p5170
sg13
I1
sa(dp5171
g7
I48
sg23
VC0027651
p5172
sg10
I5
sg11
Vtumor
p5173
sg13
I1
sasa(dp5174
g2
S'In a group of unmedicated patients with major depressive disorder matched for age with normal control group, we found a significant increase in 5-HT (100 microM)-induced accumulation of IP-1 (150 +/- 7% of basal for depressed patients, 132 +/- 3% for controls).\n'
p5175
sg4
(lp5176
sg20
(lp5177
(dp5178
g7
I40
sg23
VC1269683
p5179
sg10
I25
sg11
Vmajor depressive disorder
p5180
sg13
I3
sasa(dp5181
g2
S'It is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes).\n'
p5182
sg4
(lp5183
(dp5184
g7
I126
sg8
g15
sg10
I14
sg11
VJAK2 mutations
p5185
sg13
I2
sa(dp5186
g7
I302
sg8
VP10721
p5187
sg10
I13
sg11
VKIT mutations
p5188
sg13
I2
sa(dp5189
g7
I374
sg8
VP35637
p5190
sg10
I18
sg11
VFGFR1 fusion genes
p5191
sg13
I3
sa(dp5192
g7
I105
sg8
g15
sg10
I10
sg11
VJAK2 V617F
p5193
sg13
I2
sa(dp5194
g7
I105
sg8
g15
sg10
I10
sg11
VJAK2 V617F
p5195
sg13
I2
sa(dp5196
g7
I358
sg8
VP20930
p5197
sg10
I5
sg11
VFGFR1
p5198
sg13
I1
sasg20
(lp5199
(dp5200
g7
I321
sg23
VC1378511
p5201
sg10
I19
sg11
Vstem cell leukaemia
p5202
sg13
I3
sa(dp5203
g7
I203
sg23
VC0001815
p5204
sg10
I21
sg11
Vprimary myelofibrosis
p5205
sg13
I2
sa(dp5206
g7
I143
sg23
VC0040028
p5207
sg10
I25
sg11
Vessential thrombocythemia
p5208
sg13
I2
sa(dp5209
g7
I260
sg23
VC0221013
p5210
sg10
I21
sg11
Vsystemic mastocytosis
p5211
sg13
I2
sa(dp5212
g7
I86
sg23
VC0032463
p5213
sg10
I17
sg11
Vpolycythemia vera
p5214
sg13
I2
sa(dp5215
g7
I341
sg23
VC0024299
p5216
sg10
I8
sg11
Vlymphoma
p5217
sg13
I1
sasa(dp5218
g2
S'We show that stimulation of B-cells with the TLR9 ligands CpG-oligodeoxynucleotides (CpG-ODN) prevents spontaneous and irradiation-induced death of normal peripheral blood B-cells, and of B-cells from patients diagnosed with Common variable immunodeficiency (CVID).\n'
p5219
sg4
(lp5220
(dp5221
g7
I45
sg8
g15
sg10
I4
sg11
VTLR9
p5222
sg13
I1
sasg20
(lp5223
(dp5224
g7
I259
sg23
VC0009447
p5225
sg10
I4
sg11
VCVID
p5226
sg13
I1
sa(dp5227
g7
I225
sg23
VC0009447
p5228
sg10
I32
sg11
VCommon variable immunodeficiency
p5229
sg13
I3
sasa(dp5230
g2
S'Decreased IFN-Alfa secretion induced by TLR7/TLR8 activation was observed in CVID, which was recovered with TLR9 signaling.\n'
p5231
sg4
(lp5232
(dp5233
g7
I45
sg8
g15
sg10
I4
sg11
VTLR8
p5234
sg13
I1
sa(dp5235
g7
I108
sg8
g15
sg10
I4
sg11
VTLR9
p5236
sg13
I1
sa(dp5237
g7
I40
sg8
g15
sg10
I4
sg11
VTLR7
p5238
sg13
I1
sa(dp5239
g7
I10
sg8
VP01562
p5240
sg10
I8
sg11
VIFN-Alfa
p5241
sg13
I1
sasg20
(lp5242
(dp5243
g7
I77
sg23
VC0009447
p5244
sg10
I4
sg11
VCVID
p5245
sg13
I1
sasa(dp5246
g2
S'Our findings revealed that TLR9 activation has an adjuvant effect on the altered type I response in CVID.\n'
p5247
sg4
(lp5248
(dp5249
g7
I27
sg8
g15
sg10
I4
sg11
VTLR9
p5250
sg13
I1
sasg20
(lp5251
(dp5252
g7
I100
sg23
VC0009447
p5253
sg10
I4
sg11
VCVID
p5254
sg13
I1
sasa(dp5255
g2
S'We activated purified CVID B-cells with surrogate T-dependent (anti-CD40), T-independent (TLR-9 ligand) stimuli or through B-cell receptor engagement (anti-IgM) with or without IL-21.\n'
p5256
sg4
(lp5257
(dp5258
g7
I123
sg8
g15
sg10
I26
sg11
VB-cell receptor engagement
p5259
sg13
I3
sa(dp5260
g7
I151
sg8
VP29965
p5261
sg10
I8
sg11
Vanti-IgM
p5262
sg13
I1
sasg20
(lp5263
(dp5264
g7
I22
sg23
VC0009447
p5265
sg10
I4
sg11
VCVID
p5266
sg13
I1
sasa(dp5267
g2
S'Moreover, studies at the single cell level showed that DCs from CVID patients and healthy controls produced similar amounts of interferon-Alfa or interleukin-12 and expressed similar levels of activation markers in response to human cytomegalovirus and ligands for TLR-7 and TLR-9.\n'
p5268
sg4
(lp5269
(dp5270
g7
I127
sg8
VP01563
p5271
sg10
I15
sg11
Vinterferon-Alfa
p5272
sg13
I1
sa(dp5273
g7
I146
sg8
VP60568
p5274
sg10
I14
sg11
Vinterleukin-12
p5275
sg13
I1
sa(dp5276
g7
I265
sg8
g15
sg10
I5
sg11
VTLR-7
p5277
sg13
I1
sa(dp5278
g7
I275
sg8
g15
sg10
I5
sg11
VTLR-9
p5279
sg13
I1
sasg20
(lp5280
(dp5281
g7
I64
sg23
VC0009447
p5282
sg10
I4
sg11
VCVID
p5283
sg13
I1
sa(dp5284
g7
I55
sg23
VC0268238
p5285
sg10
I3
sg11
VDCs
p5286
sg13
I1
sasa(dp5287
g2
S'In conclusion, it seems unlikely that CVID is secondary to insufficient production of naturally occurring DCs or a defect in their signalling through TLR-7 or TLR-9.\n'
p5288
sg4
(lp5289
(dp5290
g7
I150
sg8
g15
sg10
I5
sg11
VTLR-7
p5291
sg13
I1
sa(dp5292
g7
I159
sg8
g15
sg10
I5
sg11
VTLR-9
p5293
sg13
I1
sasg20
(lp5294
(dp5295
g7
I38
sg23
VC0009447
p5296
sg10
I4
sg11
VCVID
p5297
sg13
I1
sa(dp5298
g7
I106
sg23
VC0268238
p5299
sg10
I3
sg11
VDCs
p5300
sg13
I1
sasa(dp5301
g2
S'Given the established link between vitamin A deficiency and increased susceptibility to infections, we investigated the ability of the vitamin A metabolite all-trans retinoic acid (RA) to restore the defective immune responses in CVID-derived B cells activated through the TLRs TLR9 and RP105.\n'
p5302
sg4
(lp5303
(dp5304
g7
I273
sg8
g15
sg10
I9
sg11
VTLRs TLR9
p5305
sg13
I2
sa(dp5306
g7
I287
sg8
g15
sg10
I5
sg11
VRP105
p5307
sg13
I1
sasg20
(lp5308
(dp5309
g7
I88
sg23
VC0021311
p5310
sg10
I10
sg11
Vinfections
p5311
sg13
I1
sa(dp5312
g7
I35
sg23
VC0042842
p5313
sg10
I20
sg11
Vvitamin A deficiency
p5314
sg13
I3
sa(dp5315
g7
I230
sg23
VC0009447
p5316
sg10
I4
sg11
VCVID
p5317
sg13
I1
sasa(dp5318
g2
S'This can be explained by impaired RA-mediated isotype switching in TLR9/RP105-stimulated CVID-derived B cells owing to reduced induction of activation-induced deaminase.\n'
p5319
sg4
(lp5320
(dp5321
g7
I72
sg8
g15
sg10
I5
sg11
VRP105
p5322
sg13
I1
sa(dp5323
g7
I67
sg8
g15
sg10
I4
sg11
VTLR9
p5324
sg13
I1
sasg20
(lp5325
(dp5326
g7
I89
sg23
VC0009447
p5327
sg10
I4
sg11
VCVID
p5328
sg13
I1
sa(dp5329
g7
I25
sg23
VC0684336
p5330
sg10
I8
sg11
Vimpaired
p5331
sg13
I1
sasa(dp5332
g2
S'The ability of RA to improve critical immune parameters in CVID-derived B cells stimulated through TLR9 and RP105 support the possibility of combining RA with TLR stimulation for the treatment of CVID.\n'
p5333
sg4
(lp5334
(dp5335
g7
I99
sg8
g15
sg10
I4
sg11
VTLR9
p5336
sg13
I1
sa(dp5337
g7
I108
sg8
g15
sg10
I5
sg11
VRP105
p5338
sg13
I1
sasg20
(lp5339
(dp5340
g7
I59
sg23
VC0009447
p5341
sg10
I4
sg11
VCVID
p5342
sg13
I1
sa(dp5343
g7
I59
sg23
VC0009447
p5344
sg10
I4
sg11
VCVID
p5345
sg13
I1
sasa(dp5346
g2
S'The CD21(low) V(H)1-69(+) B cells of MC patients, like those of CVID and HIV patients, are anergic to BCR and TLR9 stimulation and display deregulation of several anergy-related genes; proliferative anergy is also observed in CD21(high) MZ-like V(H)1-69(+) B cells, that over-express the antiproliferative transcriptional repressor Stra13.\n'
p5347
sg4
(lp5348
(dp5349
g7
I4
sg8
VP20023
p5350
sg10
I18
sg11
VCD21(low) V(H)1-69
p5351
sg13
I2
sa(dp5352
g7
I226
sg8
VP20023
p5353
sg10
I27
sg11
VCD21(high) MZ-like V(H)1-69
p5354
sg13
I3
sa(dp5355
g7
I332
sg8
g15
sg10
I6
sg11
VStra13
p5356
sg13
I1
sa(dp5357
g7
I102
sg8
VP11274
p5358
sg10
I3
sg11
VBCR
p5359
sg13
I1
sa(dp5360
g7
I110
sg8
g15
sg10
I4
sg11
VTLR9
p5361
sg13
I1
sasg20
(lp5362
(dp5363
g7
I185
sg23
VC0334094
p5364
sg10
I13
sg11
Vproliferative
p5365
sg13
I1
sa(dp5366
g7
I64
sg23
VC0009447
p5367
sg10
I4
sg11
VCVID
p5368
sg13
I1
sa(dp5369
g7
I73
sg23
VC0019693
p5370
sg10
I3
sg11
VHIV
p5371
sg13
I1
sasa(dp5372
g2
S'The secretion of glucagon by islet Alfa cells is normally suppressed by high blood glucose, but this suppressibility is impaired in patients with diabetes or cystic fibrosis (CF), a disease caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate-activated Cl- channel.\n'
p5373
sg4
(lp5374
(dp5375
g7
I17
sg8
VP01275
p5376
sg10
I8
sg11
Vglucagon
p5377
sg13
I1
sa(dp5378
g7
I231
sg8
g15
sg10
I38
sg11
VCF transmembrane conductance regulator
p5379
sg13
I4
sa(dp5380
g7
I271
sg8
VP13569
p5381
sg10
I4
sg11
VCFTR
p5382
sg13
I1
sasg20
(lp5383
(dp5384
g7
I175
sg23
VC0016059
p5385
sg10
I2
sg11
VCF
p5386
sg13
I1
sa(dp5387
g7
I158
sg23
VC0010674
p5388
sg10
I15
sg11
Vcystic fibrosis
p5389
sg13
I2
sa(dp5390
g7
I146
sg23
VC0011849
p5391
sg10
I8
sg11
Vdiabetes
p5392
sg13
I1
sa(dp5393
g7
I120
sg23
VC0684336
p5394
sg10
I8
sg11
Vimpaired
p5395
sg13
I1
sa(dp5396
g7
I175
sg23
VC0016059
p5397
sg10
I2
sg11
VCF
p5398
sg13
I1
sasa(dp5399
g2
S'The results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in Alfa cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.\n'
p5400
sg4
(lp5401
(dp5402
g7
I55
sg8
VP13569
p5403
sg10
I4
sg11
VCFTR
p5404
sg13
I1
sa(dp5405
g7
I108
sg8
VP01275
p5406
sg10
I8
sg11
Vglucagon
p5407
sg13
I1
sasg20
(lp5408
(dp5409
g7
I178
sg23
VC0271650
p5410
sg10
I19
sg11
Vglucose intolerance
p5411
sg13
I2
sa(dp5412
g7
I223
sg23
VC0011849
p5413
sg10
I8
sg11
Vdiabetes
p5414
sg13
I1
sasa(dp5415
g2
S'Although Beta-cell dysfunction in cystic fibrosis (CF) leads to diabetes, the mechanism by which the cystic fibrosis transmembrane conductance regulator (CFTR) channel influences islet insulin secretion remains debated.\n'
p5416
sg4
(lp5417
(dp5418
g7
I101
sg8
VP13569
p5419
sg10
I51
sg11
Vcystic fibrosis transmembrane conductance regulator
p5420
sg13
I5
sa(dp5421
g7
I9
sg8
VP13569
p5422
sg10
I45
sg11
VBeta-cell dysfunction in cystic fibrosis (CF)
p5423
sg13
I6
sa(dp5424
g7
I185
sg8
VP01308
p5425
sg10
I7
sg11
Vinsulin
p5426
sg13
I1
sa(dp5427
g7
I154
sg8
VP13569
p5428
sg10
I4
sg11
VCFTR
p5429
sg13
I1
sasg20
(lp5430
(dp5431
g7
I64
sg23
VC0011849
p5432
sg10
I8
sg11
Vdiabetes
p5433
sg13
I1
sa(dp5434
g7
I34
sg23
VC0010674
p5435
sg10
I15
sg11
Vcystic fibrosis
p5436
sg13
I2
sa(dp5437
g7
I34
sg23
VC0010674
p5438
sg10
I15
sg11
Vcystic fibrosis
p5439
sg13
I2
sa(dp5440
g7
I51
sg23
VC0010674
p5441
sg10
I2
sg11
VCF
p5442
sg13
I1
sasa(dp5443
g2
S'Baseline estimated cost in 2008 for a hypothetical underweight, homozygous F508del-CFTR 6-year-old female without chronic Pseudomonas aeruginosa/Staphylococcus aureus, CF-related diabetes (CFRD) or methicillin-resistant S. aureus (MRSA), and with a poor percent predicted forced expiratory volume in 1 s (ppFEV1) was Euro10,113, and was Euro21,082 in a 25-year-old with the same hypothetical profile.\n'
p5444
sg4
(lp5445
(dp5446
g7
I75
sg8
VP13569
p5447
sg10
I14
sg11
VF508del-CFTR 6
p5448
sg13
I2
sasg20
(lp5449
(dp5450
g7
I179
sg23
VC0011849
p5451
sg10
I8
sg11
Vdiabetes
p5452
sg13
I1
sa(dp5453
g7
I231
sg23
VC0343401
p5454
sg10
I4
sg11
VMRSA
p5455
sg13
I1
sasa(dp5456
g2
S'The goal of this work was to evaluate renal function and the expression of megalin, cubilin, CFTR (cystic fibrosis transmembrane conductance regulator), and ClC-5 in the proximal tubule and renal cortex of rats with type 1 diabetes.\n'
p5457
sg4
(lp5458
(dp5459
g7
I157
sg8
VP51795
p5460
sg10
I5
sg11
VClC-5
p5461
sg13
I1
sa(dp5462
g7
I84
sg8
g15
sg10
I7
sg11
Vcubilin
p5463
sg13
I1
sa(dp5464
g7
I75
sg8
VP54317
p5465
sg10
I7
sg11
Vmegalin
p5466
sg13
I1
sasg20
(lp5467
(dp5468
g7
I216
sg23
VC0011854
p5469
sg10
I15
sg11
Vtype 1 diabetes
p5470
sg13
I3
sa(dp5471
g7
I99
sg23
VC0010674
p5472
sg10
I15
sg11
Vcystic fibrosis
p5473
sg13
I2
sasa(dp5474
g2
S'Mean values in lichen ruber planus were Zn 784 micrograms/l, RBP 5.26 mg/dl and Vit A 656 ng/ml; in leukoplakia Zn 696 micrograms/l, RBP 5.30 mg/dl and Vit A 652 ng/ml; and in OSCC Zn 659 micrograms/l, RBP 5.00 mg/dl and Vit A 617 ng/ml.\n'
p5475
sg4
(lp5476
sg20
(lp5477
(dp5478
g7
I100
sg23
VC0023531
p5479
sg10
I11
sg11
Vleukoplakia
p5480
sg13
I1
sa(dp5481
g7
I15
sg23
VC0023646
p5482
sg10
I19
sg11
Vlichen ruber planus
p5483
sg13
I3
sasa(dp5484
g2
S'These observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.\n'
p5485
sg4
(lp5486
(dp5487
g7
I103
sg8
VP17931
p5488
sg10
I10
sg11
Vgalectin-3
p5489
sg13
I1
sasg20
(lp5490
(dp5491
g7
I73
sg23
VC0039103
p5492
sg10
I9
sg11
Vsynovitis
p5493
sg13
I1
sa(dp5494
g7
I83
sg23
VC0334094
p5495
sg10
I13
sg11
Vproliferation
p5496
sg13
I1
sa(dp5497
g7
I140
sg23
VC0004368
p5498
sg10
I12
sg11
Vautoimmunity
p5499
sg13
I1
sasa(dp5500
g2
S'In the entire UA cohort, galectin-3 correlated with the MRI bone marrow edema score, while PIIANP correlated with the MRI erosion score, and HYA with the synovitis and erosion scores.\n'
p5501
sg4
(lp5502
(dp5503
g7
I25
sg8
VP17931
p5504
sg10
I10
sg11
Vgalectin-3
p5505
sg13
I1
sasg20
(lp5506
(dp5507
g7
I122
sg23
VC1959609
p5508
sg10
I7
sg11
Verosion
p5509
sg13
I1
sa(dp5510
g7
I154
sg23
VC0039103
p5511
sg10
I9
sg11
Vsynovitis
p5512
sg13
I1
sa(dp5513
g7
I60
sg23
VC0948162
p5514
sg10
I17
sg11
Vbone marrow edema
p5515
sg13
I3
sa(dp5516
g7
I122
sg23
VC1959609
p5517
sg10
I7
sg11
Verosion
p5518
sg13
I1
sasa(dp5519
g2
S'Previous studies have reported overexpression of Galectin-3 in RA synovitis and increased levels in synovial fluid and serum in long-standing RA compared with osteoarthritis and healthy controls.\n'
p5520
sg4
(lp5521
(dp5522
g7
I49
sg8
VP17931
p5523
sg10
I10
sg11
VGalectin-3
p5524
sg13
I1
sasg20
(lp5525
(dp5526
g7
I159
sg23
VC0029408
p5527
sg10
I14
sg11
Vosteoarthritis
p5528
sg13
I1
sa(dp5529
g7
I66
sg23
VC0039103
p5530
sg10
I9
sg11
Vsynovitis
p5531
sg13
I1
sasa(dp5532
g2
S'We defined by immunohistology the infiltrating cells and examined the in situ expression of plausible protagonists in synovitis of FMF: myeloperoxidase, lysozyme, galectin 1, galectin 3, p65 (RelA)/nuclear factor KB, inducible nitric-oxide synthase, cyclooxygenase 2, and cleaved caspase 3.\n'
p5533
sg4
(lp5534
(dp5535
g7
I192
sg8
g15
sg10
I4
sg11
VRelA
p5536
sg13
I1
sa(dp5537
g7
I187
sg8
VP21579
p5538
sg10
I3
sg11
Vp65
p5539
sg13
I1
sa(dp5540
g7
I131
sg8
g15
sg10
I3
sg11
VFMF
p5541
sg13
I1
sa(dp5542
g7
I153
sg8
VP61626
p5543
sg10
I8
sg11
Vlysozyme
p5544
sg13
I1
sa(dp5545
g7
I280
sg8
VP42574
p5546
sg10
I9
sg11
Vcaspase 3
p5547
sg13
I2
sa(dp5548
g7
I163
sg8
VP09382
p5549
sg10
I10
sg11
Vgalectin 1
p5550
sg13
I2
sa(dp5551
g7
I198
sg8
VP01160
p5552
sg10
I17
sg11
Vnuclear factor KB
p5553
sg13
I3
sa(dp5554
g7
I175
sg8
VP17931
p5555
sg10
I10
sg11
Vgalectin 3
p5556
sg13
I2
sa(dp5557
g7
I250
sg8
VP35354
p5558
sg10
I16
sg11
Vcyclooxygenase 2
p5559
sg13
I2
sa(dp5560
g7
I227
sg8
VP29475
p5561
sg10
I21
sg11
Vnitric-oxide synthase
p5562
sg13
I2
sa(dp5563
g7
I136
sg8
VP05164
p5564
sg10
I15
sg11
Vmyeloperoxidase
p5565
sg13
I1
sasg20
(lp5566
(dp5567
g7
I131
sg23
VC0031069
p5568
sg10
I3
sg11
VFMF
p5569
sg13
I1
sa(dp5570
g7
I34
sg23
VC0332448
p5571
sg10
I12
sg11
Vinfiltrating
p5572
sg13
I1
sa(dp5573
g7
I118
sg23
VC0039103
p5574
sg10
I9
sg11
Vsynovitis
p5575
sg13
I1
sasa(dp5576
g2
S'Only one of these, pFLJ2, was mobilized by the IncP plasmids RP4, pRK231 and R702, but not by plasmids pSa, R40a, R387, pN3 or R16.\n'
p5577
sg4
(lp5578
sg20
(lp5579
(dp5580
g7
I103
sg23
VC1519176
p5581
sg10
I3
sg11
VpSa
p5582
sg13
I1
sa(dp5583
g7
I61
sg23
VC3151001
p5584
sg10
I3
sg11
VRP4
p5585
sg13
I1
sasa(dp5586
g2
S'Changes in the frequencies of genotypes and mutant alleles of ACE, AGTR1, AGT, and ITGB3 genes were analyzed in patients with arterial hypertension coupled with metabolic syndrome (N=15) and compared with population data and corresponding parameters in patients with isolated hypertension (N=15).\n'
p5587
sg4
(lp5588
(dp5589
g7
I67
sg8
VP30556
p5590
sg10
I5
sg11
VAGTR1
p5591
sg13
I1
sa(dp5592
g7
I62
sg8
VP12821
p5593
sg10
I3
sg11
VACE
p5594
sg13
I1
sa(dp5595
g7
I83
sg8
VP05106
p5596
sg10
I11
sg11
VITGB3 genes
p5597
sg13
I2
sa(dp5598
g7
I67
sg8
VP21549
p5599
sg10
I3
sg11
VAGT
p5600
sg13
I1
sasg20
(lp5601
(dp5602
g7
I126
sg23
VC0020538
p5603
sg10
I21
sg11
Varterial hypertension
p5604
sg13
I2
sa(dp5605
g7
I135
sg23
VC0020538
p5606
sg10
I12
sg11
Vhypertension
p5607
sg13
I1
sa(dp5608
g7
I44
sg23
VC0596988
p5609
sg10
I6
sg11
Vmutant
p5610
sg13
I1
sa(dp5611
g7
I161
sg23
VC0524620
p5612
sg10
I18
sg11
Vmetabolic syndrome
p5613
sg13
I2
sasa(dp5614
g2
S'We examined associations between 15 single nucleotide polymorphisms (SNPs) across ITGB3 and five CVD-related traits in the Hutterites: plasma levels of high density lipoprotein-cholesterol (HDL-c), triglycerides (TG), low density lipoprotein-cholesterol (LDL-c), and lipoprotein(a) [Lp(a)] and blood pressure or hypertension.\n'
p5615
sg4
(lp5616
(dp5617
g7
I218
sg8
VP02652
p5618
sg10
I35
sg11
Vlow density lipoprotein-cholesterol
p5619
sg13
I3
sa(dp5620
g7
I255
sg8
VP02652
p5621
sg10
I5
sg11
VLDL-c
p5622
sg13
I1
sa(dp5623
g7
I152
sg8
VP28845
p5624
sg10
I36
sg11
Vhigh density lipoprotein-cholesterol
p5625
sg13
I3
sa(dp5626
g7
I267
sg8
VP02652
p5627
sg10
I14
sg11
Vlipoprotein(a)
p5628
sg13
I1
sa(dp5629
g7
I190
sg8
VP28845
p5630
sg10
I5
sg11
VHDL-c
p5631
sg13
I1
sasg20
(lp5632
(dp5633
g7
I97
sg23
VC0007222
p5634
sg10
I3
sg11
VCVD
p5635
sg13
I1
sa(dp5636
g7
I312
sg23
VC0020538
p5637
sg10
I12
sg11
Vhypertension
p5638
sg13
I1
sasa(dp5639
g2
S'The present study was performed to investigate the expressions of transforming growth factor Beta1 (TGF-Beta1) and matrix metalloproteinase-9 (MMP-9) in an experimental model of tympanosclerosis and their possible roles in the formation of this disorder.\n'
p5640
sg4
(lp5641
(dp5642
g7
I66
sg8
VP01137
p5643
sg10
I32
sg11
Vtransforming growth factor Beta1
p5644
sg13
I4
sa(dp5645
g7
I100
sg8
VP01137
p5646
sg10
I9
sg11
VTGF-Beta1
p5647
sg13
I1
sa(dp5648
g7
I115
sg8
VP14780
p5649
sg10
I26
sg11
Vmatrix metalloproteinase-9
p5650
sg13
I2
sa(dp5651
g7
I143
sg8
VP14780
p5652
sg10
I5
sg11
VMMP-9
p5653
sg13
I1
sasg20
(lp5654
(dp5655
g7
I178
sg23
VC0395887
p5656
sg10
I16
sg11
Vtympanosclerosis
p5657
sg13
I1
sasa(dp5658
g2
S'RT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.\n'
p5659
sg4
(lp5660
(dp5661
g7
I157
sg8
g15
sg10
I6
sg11
VHS3ST2
p5662
sg13
I1
sa(dp5663
g7
I115
sg8
g15
sg10
I4
sg11
VEXT2
p5664
sg13
I1
sa(dp5665
g7
I195
sg8
g15
sg10
I4
sg11
VHPSE
p5666
sg13
I1
sa(dp5667
g7
I181
sg8
g15
sg10
I5
sg11
VSULF1
p5668
sg13
I1
sa(dp5669
g7
I128
sg8
VP52849
p5670
sg10
I5
sg11
VNDST2
p5671
sg13
I1
sa(dp5672
g7
I141
sg8
g15
sg10
I6
sg11
VHS2ST1
p5673
sg13
I1
sa(dp5674
g7
I121
sg8
VP52848
p5675
sg10
I5
sg11
VNDST1
p5676
sg13
I1
sa(dp5677
g7
I135
sg8
g15
sg10
I4
sg11
VGLCE
p5678
sg13
I1
sa(dp5679
g7
I109
sg8
g15
sg10
I4
sg11
VEXT1
p5680
sg13
I1
sa(dp5681
g7
I149
sg8
g15
sg10
I6
sg11
VHS3ST1
p5682
sg13
I1
sa(dp5683
g7
I165
sg8
g15
sg10
I6
sg11
VHS6ST1
p5684
sg13
I1
sa(dp5685
g7
I188
sg8
g15
sg10
I5
sg11
VSULF2
p5686
sg13
I1
sasg20
(lp5687
(dp5688
g7
I115
sg23
VC1851413
p5689
sg10
I4
sg11
VEXT2
p5690
sg13
I1
sa(dp5691
g7
I245
sg23
VC0017638
p5692
sg10
I6
sg11
Vglioma
p5693
sg13
I1
sa(dp5694
g7
I245
sg23
VC0017638
p5695
sg10
I6
sg11
Vglioma
p5696
sg13
I1
sa(dp5697
g7
I300
sg23
VC1621958
p5698
sg10
I23
sg11
Vglioblastoma multiforme
p5699
sg13
I2
sa(dp5700
g7
I109
sg23
VC0015306
p5701
sg10
I4
sg11
VEXT1
p5702
sg13
I1
sa(dp5703
g7
I325
sg23
VC1621958
p5704
sg10
I3
sg11
VGBM
p5705
sg13
I1
sasa(dp5706
g2
S'This study aimed to analyze the expression and function of HS6ST3 in breast cancer.\n'
p5707
sg4
(lp5708
(dp5709
g7
I59
sg8
g15
sg10
I6
sg11
VHS6ST3
p5710
sg13
I1
sasg20
(lp5711
(dp5712
g7
I69
sg23
VC0678222
p5713
sg10
I13
sg11
Vbreast cancer
p5714
sg13
I2
sasa(dp5715
g2
S'HS6ST3 was found up-regulated in T47D, MCF7 and MDA-MB231 breast cancer cell lines.\n'
p5716
sg4
(lp5717
(dp5718
g7
I0
sg8
g15
sg10
I6
sg11
VHS6ST3
p5719
sg13
I1
sasg20
(lp5720
(dp5721
g7
I58
sg23
VC0678222
p5722
sg10
I13
sg11
Vbreast cancer
p5723
sg13
I2
sasa(dp5724
g2
S'Silencing HS6ST3 diminished tumor cell growth, migration and invasion, but enhanced cell adhesion and apoptosis in breast cancer.\n'
p5725
sg4
(lp5726
sg20
(lp5727
(dp5728
g7
I28
sg23
VC0027651
p5729
sg10
I5
sg11
Vtumor
p5730
sg13
I1
sa(dp5731
g7
I115
sg23
VC0678222
p5732
sg10
I13
sg11
Vbreast cancer
p5733
sg13
I2
sa(dp5734
g7
I61
sg23
VC2699153
p5735
sg10
I8
sg11
Vinvasion
p5736
sg13
I1
sa(dp5737
g7
I89
sg23
VC0001511
p5738
sg10
I8
sg11
Vadhesion
p5739
sg13
I1
sasa(dp5740
g2
S'Gene microarray analysis revealed that silencing HS6ST3 significantly changed the expression of IGF1R and XAF1 in breast cancer cells.\n'
p5741
sg4
(lp5742
(dp5743
g7
I96
sg8
VP08069
p5744
sg10
I5
sg11
VIGF1R
p5745
sg13
I1
sa(dp5746
g7
I49
sg8
g15
sg10
I6
sg11
VHS6ST3
p5747
sg13
I1
sa(dp5748
g7
I106
sg8
g15
sg10
I4
sg11
VXAF1
p5749
sg13
I1
sasg20
(lp5750
(dp5751
g7
I114
sg23
VC0678222
p5752
sg10
I13
sg11
Vbreast cancer
p5753
sg13
I2
sasa(dp5754
g2
S'Further functional studies showed that the cellular processes were mediated by IGF1R and XAF1 after silencing HS6ST3 in breast cancer cells.\n'
p5755
sg4
(lp5756
(dp5757
g7
I89
sg8
g15
sg10
I4
sg11
VXAF1
p5758
sg13
I1
sa(dp5759
g7
I79
sg8
VP08069
p5760
sg10
I5
sg11
VIGF1R
p5761
sg13
I1
sa(dp5762
g7
I110
sg8
g15
sg10
I6
sg11
VHS6ST3
p5763
sg13
I1
sasg20
(lp5764
(dp5765
g7
I120
sg23
VC0678222
p5766
sg10
I13
sg11
Vbreast cancer
p5767
sg13
I2
sasa(dp5768
g2
S'Together these results indicate that HS6ST3 might be involved in the tumorigenesis of breast cancer and it could be a promising target in breast cancer therapy.\n'
p5769
sg4
(lp5770
(dp5771
g7
I37
sg8
g15
sg10
I6
sg11
VHS6ST3
p5772
sg13
I1
sasg20
(lp5773
(dp5774
g7
I86
sg23
VC0678222
p5775
sg10
I13
sg11
Vbreast cancer
p5776
sg13
I2
sa(dp5777
g7
I69
sg23
VC0007621
p5778
sg10
I13
sg11
Vtumorigenesis
p5779
sg13
I1
sa(dp5780
g7
I86
sg23
VC0678222
p5781
sg10
I13
sg11
Vbreast cancer
p5782
sg13
I2
sasa(dp5783
g2
S'We aimed to examine the relationship between the preoperative GSA index [uptake ratio of the liver to the liver plus heart at 15 min (LHL15) to uptake ratio of the heart at 15 min to that at 3 min (HH15) ratio] calculated from 99mTc-labeled diethylene triamine pentaacetate-galactosyl human serum albumin (99mTc-GSA) scintigraphy and background liver fibrosis and to investigate whether the GSA index can be a useful predictor in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) patients treated with surgical resection (SR).\n'
p5784
sg4
(lp5785
(dp5786
g7
I285
sg8
g15
sg10
I19
sg11
Vhuman serum albumin
p5787
sg13
I3
sasg20
(lp5788
(dp5789
g7
I462
sg23
VC2239176
p5790
sg10
I24
sg11
Vhepatocellular carcinoma
p5791
sg13
I2
sa(dp5792
g7
I345
sg23
VC0239946
p5793
sg10
I14
sg11
Vliver fibrosis
p5794
sg13
I2
sa(dp5795
g7
I430
sg23
VC0019196
p5796
sg10
I11
sg11
Vhepatitis C
p5797
sg13
I2
sa(dp5798
g7
I488
sg23
VC2239176
p5799
sg10
I3
sg11
VHCC
p5800
sg13
I1
sasa(dp5801
g2
S'Here we demonstrate that HS 6-O-sulfotransferases 1 and 2 (HS6ST-1 and HS6ST-2), which perform sulfation at 6-O position in glucosamine in HS, impact ovarian cancer angiogenesis through the HS-dependent HB-EGF/EGFR axis that subsequently modulates the expression of multiple angiogenic cytokines.\n'
p5802
sg4
(lp5803
(dp5804
g7
I190
sg8
VP19525
p5805
sg10
I19
sg11
VHS-dependent HB-EGF
p5806
sg13
I2
sa(dp5807
g7
I59
sg8
g15
sg10
I7
sg11
VHS6ST-1
p5808
sg13
I1
sa(dp5809
g7
I25
sg8
g15
sg10
I32
sg11
VHS 6-O-sulfotransferases 1 and 2
p5810
sg13
I5
sa(dp5811
g7
I71
sg8
g15
sg10
I7
sg11
VHS6ST-2
p5812
sg13
I1
sasg20
(lp5813
(dp5814
g7
I158
sg23
VC1536999
p5815
sg10
I19
sg11
Vcancer angiogenesis
p5816
sg13
I2
sasa(dp5817
g2
S'Down-regulation of HS6ST-1 or HS6ST-2 in human ovarian cancer cell lines results in 30-50% reduction in glucosamine 6-O-sulfate levels in HS, impairing HB-EGF-dependent EGFR signaling and diminishing FGF2, IL-6, and IL-8 mRNA and protein levels in cancer cells.\n'
p5818
sg4
(lp5819
(dp5820
g7
I19
sg8
g15
sg10
I7
sg11
VHS6ST-1
p5821
sg13
I1
sa(dp5822
g7
I30
sg8
g15
sg10
I7
sg11
VHS6ST-2
p5823
sg13
I1
sa(dp5824
g7
I152
sg8
g15
sg10
I21
sg11
VHB-EGF-dependent EGFR
p5825
sg13
I2
sa(dp5826
g7
I206
sg8
VP05231
p5827
sg10
I4
sg11
VIL-6
p5828
sg13
I1
sa(dp5829
g7
I200
sg8
g15
sg10
I4
sg11
VFGF2
p5830
sg13
I1
sasg20
(lp5831
(dp5832
g7
I55
sg23
VC0006826
p5833
sg10
I6
sg11
Vcancer
p5834
sg13
I1
sa(dp5835
g7
I47
sg23
VC1140680
p5836
sg10
I14
sg11
Vovarian cancer
p5837
sg13
I2
sasa(dp5838
g2
S'Our results show that in addition to the critical role that 6-O-sulfate moieties play in angiogenic cytokine activation, HS 6-O-sulfation level, determined by the expression of HS6ST isoforms in ovarian cancer cells, is a major regulator of angiogenic program in ovarian cancer cells impacting HB-EGF signaling and subsequent expression of angiogenic cytokines by cancer cells.\n'
p5839
sg4
(lp5840
(dp5841
g7
I340
sg8
VP01374
p5842
sg10
I20
sg11
Vangiogenic cytokines
p5843
sg13
I2
sa(dp5844
g7
I297
sg8
VP01133
p5845
sg10
I3
sg11
VEGF
p5846
sg13
I1
sa(dp5847
g7
I177
sg8
g15
sg10
I14
sg11
VHS6ST isoforms
p5848
sg13
I2
sasg20
(lp5849
(dp5850
g7
I195
sg23
VC1140680
p5851
sg10
I14
sg11
Vovarian cancer
p5852
sg13
I2
sa(dp5853
g7
I203
sg23
VC0006826
p5854
sg10
I6
sg11
Vcancer
p5855
sg13
I1
sa(dp5856
g7
I195
sg23
VC1140680
p5857
sg10
I14
sg11
Vovarian cancer
p5858
sg13
I2
sasa(dp5859
g2
S'We have investigated whether the expression of HS6STs and SULFs changes during chondrosarcoma progression and have determined 6O-sulphation levels in two chondrosarcoma cell lines.\n'
p5860
sg4
(lp5861
(dp5862
g7
I47
sg8
g15
sg10
I6
sg11
VHS6STs
p5863
sg13
I1
sasg20
(lp5864
(dp5865
g7
I79
sg23
VC0008479
p5866
sg10
I14
sg11
Vchondrosarcoma
p5867
sg13
I1
sa(dp5868
g7
I79
sg23
VC0008479
p5869
sg10
I14
sg11
Vchondrosarcoma
p5870
sg13
I1
sasa(dp5871
g2
S'Immunohistochemistry on tissue microarrays of chondrosarcomas showed that HS6ST3 and SULF1 were highly expressed in most chondrosarcomas, whereas SULF2 expression was absent in most cases.\n'
p5872
sg4
(lp5873
(dp5874
g7
I85
sg8
g15
sg10
I5
sg11
VSULF1
p5875
sg13
I1
sa(dp5876
g7
I74
sg8
g15
sg10
I6
sg11
VHS6ST3
p5877
sg13
I1
sa(dp5878
g7
I146
sg8
g15
sg10
I5
sg11
VSULF2
p5879
sg13
I1
sasg20
(lp5880
(dp5881
g7
I46
sg23
VC0008479
p5882
sg10
I15
sg11
Vchondrosarcomas
p5883
sg13
I1
sa(dp5884
g7
I46
sg23
VC0008479
p5885
sg10
I15
sg11
Vchondrosarcomas
p5886
sg13
I1
sasa(dp5887
g2
S'HS6ST1 and HS6ST2 expression are significantly increased during chondrosarcoma progression, which suggest that 6O-sulphation is increased during progression.\n'
p5888
sg4
(lp5889
(dp5890
g7
I0
sg8
g15
sg10
I6
sg11
VHS6ST1
p5891
sg13
I1
sasg20
(lp5892
(dp5893
g7
I64
sg23
VC0008479
p5894
sg10
I14
sg11
Vchondrosarcoma
p5895
sg13
I1
sasa(dp5896
g2
S'In conclusion, our results show increased HS6ST1 and HS6ST2 expression during chondrosarcoma progression and increased HS 6O-sulphation in vitro.\n'
p5897
sg4
(lp5898
(dp5899
g7
I42
sg8
g15
sg10
I6
sg11
VHS6ST1
p5900
sg13
I1
sasg20
(lp5901
(dp5902
g7
I78
sg23
VC0008479
p5903
sg10
I14
sg11
Vchondrosarcoma
p5904
sg13
I1
sasa(dp5905
g2
S'As 6O-sulphation plays an important role in signal transduction, altered HS6ST expression might be associated with changes in signal transduction pathways in chondrosarcoma progression.\n'
p5906
sg4
(lp5907
(dp5908
g7
I73
sg8
g15
sg10
I5
sg11
VHS6ST
p5909
sg13
I1
sasg20
(lp5910
(dp5911
g7
I158
sg23
VC0008479
p5912
sg10
I14
sg11
Vchondrosarcoma
p5913
sg13
I1
sasa(dp5914
g2
S'Thus, neutrophils and NK cells act as important disease-promoting immune cells in experimental osteoarthritis and their functional interaction is promoted by the CXCL10/CXCR3 axis.\n'
p5915
sg4
(lp5916
(dp5917
g7
I162
sg8
VP02778
p5918
sg10
I6
sg11
VCXCL10
p5919
sg13
I1
sa(dp5920
g7
I169
sg8
VP49682
p5921
sg10
I5
sg11
VCXCR3
p5922
sg13
I1
sasg20
(lp5923
(dp5924
g7
I95
sg23
VC0029408
p5925
sg10
I14
sg11
Vosteoarthritis
p5926
sg13
I1
sasa(dp5927
g2
S'Ovarian cancer cell line OC316 was reverse transfected with a miR-223 mimic and relative expression levels of miR-223 and SMARCD1 were quantified by RT-PCR; protein expression of SMARCD1 was evaluated by Western Blot.\n'
p5928
sg4
(lp5929
(dp5930
g7
I122
sg8
g15
sg10
I7
sg11
VSMARCD1
p5931
sg13
I1
sa(dp5932
g7
I122
sg8
g15
sg10
I7
sg11
VSMARCD1
p5933
sg13
I1
sa(dp5934
g7
I62
sg8
g15
sg10
I7
sg11
VmiR-223
p5935
sg13
I1
sasg20
(lp5936
(dp5937
g7
I0
sg23
VC1140680
p5938
sg10
I14
sg11
VOvarian cancer
p5939
sg13
I2
sasa(dp5940
g2
S'miR-223 expression was upregulated in high grade ovarian serous carcinoma samples (median RQ=4.8881, P=.0045), whilst SMARCD1 was down-regulated (median RQ=0.5107, P=.0492).\n'
p5941
sg4
(lp5942
(dp5943
g7
I118
sg8
g15
sg10
I7
sg11
VSMARCD1
p5944
sg13
I1
sasg20
(lp5945
(dp5946
g7
I49
sg23
VC1335177
p5947
sg10
I24
sg11
Vovarian serous carcinoma
p5948
sg13
I3
sasa(dp5949
g2
S'It was indicated that SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, dihydropyrimidinase-like 2, RMND5A and ANGPTL1 were potential prognostic markers in breast cancer, and the cell cycle may be involved in the regulation of breast cancer.\n'
p5950
sg4
(lp5951
(dp5952
g7
I186
sg8
g15
sg10
I60
sg11
Vchromatin, subfamily D, member 1, dihydropyrimidinase-like 2
p5953
sg13
I7
sa(dp5954
g7
I259
sg8
g15
sg10
I7
sg11
VANGPTL1
p5955
sg13
I1
sa(dp5956
g7
I248
sg8
g15
sg10
I6
sg11
VRMND5A
p5957
sg13
I1
sa(dp5958
g7
I22
sg8
VP28370
p5959
sg10
I3
sg11
VSWI
p5960
sg13
I1
sa(dp5961
g7
I26
sg8
g15
sg10
I3
sg11
VSNF
p5962
sg13
I1
sa(dp5963
g7
I26
sg8
g15
sg10
I3
sg11
VSNF
p5964
sg13
I1
sa(dp5965
g7
I87
sg8
g15
sg10
I32
sg11
Vchromatin, subfamily D, member 1
p5966
sg13
I5
sa(dp5967
g7
I22
sg8
VP28370
p5968
sg10
I3
sg11
VSWI
p5969
sg13
I1
sasg20
(lp5970
(dp5971
g7
I304
sg23
VC0678222
p5972
sg10
I13
sg11
Vbreast cancer
p5973
sg13
I2
sa(dp5974
g7
I304
sg23
VC0678222
p5975
sg10
I13
sg11
Vbreast cancer
p5976
sg13
I2
sasa(dp5977
g2
S'MiR-490-3p plays a tumour suppressor role in epithelial ovarian cancer by targeting CDK1 regulation and influencing SMARCD1 and cyclin D1 (CCND1) expressions.\n'
p5978
sg4
(lp5979
(dp5980
g7
I84
sg8
VP06493
p5981
sg10
I4
sg11
VCDK1
p5982
sg13
I1
sa(dp5983
g7
I139
sg8
VP24385
p5984
sg10
I5
sg11
VCCND1
p5985
sg13
I1
sa(dp5986
g7
I116
sg8
g15
sg10
I7
sg11
VSMARCD1
p5987
sg13
I1
sa(dp5988
g7
I0
sg8
g15
sg10
I10
sg11
VMiR-490-3p
p5989
sg13
I1
sa(dp5990
g7
I128
sg8
VP24385
p5991
sg10
I9
sg11
Vcyclin D1
p5992
sg13
I2
sasg20
(lp5993
(dp5994
g7
I19
sg23
VC0027651
p5995
sg10
I6
sg11
Vtumour
p5996
sg13
I1
sa(dp5997
g7
I45
sg23
VC0677886
p5998
sg10
I25
sg11
Vepithelial ovarian cancer
p5999
sg13
I3
sasa(dp6000
g2
S'Hepatocyte-specific inactivation of Baf60a reduced bile acid production and cholesterol absorption, and attenuated diet-induced hypercholesterolemia and atherosclerosis in mice.\n'
p6001
sg4
(lp6002
(dp6003
g7
I36
sg8
g15
sg10
I6
sg11
VBaf60a
p6004
sg13
I1
sasg20
(lp6005
(dp6006
g7
I128
sg23
VC0020443
p6007
sg10
I20
sg11
Vhypercholesterolemia
p6008
sg13
I1
sa(dp6009
g7
I153
sg23
VC0004153
p6010
sg10
I15
sg11
Vatherosclerosis
p6011
sg13
I1
sa(dp6012
g7
I20
sg23
VC0544461
p6013
sg10
I12
sg11
Vinactivation
p6014
sg13
I1
sasa(dp6015
g2
S'miR-7 expression reduced SMARCD1 protein expression in lung cancer cell lines.\n'
p6016
sg4
(lp6017
(dp6018
g7
I25
sg8
g15
sg10
I15
sg11
VSMARCD1 protein
p6019
sg13
I2
sa(dp6020
g7
I0
sg8
g15
sg10
I5
sg11
VmiR-7
p6021
sg13
I1
sasg20
(lp6022
(dp6023
g7
I55
sg23
VC0684249
p6024
sg10
I11
sg11
Vlung cancer
p6025
sg13
I2
sasa(dp6026
g2
S'We found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs.\n'
p6027
sg4
(lp6028
(dp6029
g7
I100
sg8
g15
sg10
I5
sg11
VmiR-7
p6030
sg13
I1
sa(dp6031
g7
I23
sg8
g15
sg10
I7
sg11
VSMARCD1
p6032
sg13
I1
sasg20
(lp6033
(dp6034
g7
I42
sg23
VC0684249
p6035
sg10
I11
sg11
Vlung cancer
p6036
sg13
I2
sa(dp6037
g7
I42
sg23
VC0684249
p6038
sg10
I11
sg11
Vlung cancer
p6039
sg13
I2
sasa(dp6040
g2
S'SMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell lines, and SMARCD1 and miR-7 expression levels were negatively correlated in clinical samples.\n'
p6041
sg4
(lp6042
(dp6043
g7
I0
sg8
g15
sg10
I7
sg11
VSMARCD1
p6044
sg13
I1
sa(dp6045
g7
I0
sg8
g15
sg10
I7
sg11
VSMARCD1
p6046
sg13
I1
sa(dp6047
g7
I123
sg8
g15
sg10
I5
sg11
VmiR-7
p6048
sg13
I1
sasg20
(lp6049
(dp6050
g7
I75
sg23
VC0152013
p6051
sg10
I19
sg11
Vlung adenocarcinoma
p6052
sg13
I2
sa(dp6053
g7
I44
sg23
VC0007131
p6054
sg10
I26
sg11
Vnon-small cell lung cancer
p6055
sg13
I4
sasa(dp6056
g2
S'Our investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.\n'
p6057
sg4
(lp6058
(dp6059
g7
I187
sg8
g15
sg10
I27
sg11
Vchromatin remodeling factor
p6060
sg13
I3
sa(dp6061
g7
I85
sg8
VP28370
p6062
sg10
I3
sg11
VSWI
p6063
sg13
I1
sa(dp6064
g7
I89
sg8
g15
sg10
I3
sg11
VSNF
p6065
sg13
I1
sa(dp6066
g7
I150
sg8
g15
sg10
I5
sg11
VmiR-7
p6067
sg13
I1
sa(dp6068
g7
I215
sg8
g15
sg10
I7
sg11
VSMARCD1
p6069
sg13
I1
sa(dp6070
g7
I228
sg8
VP42771
p6071
sg10
I3
sg11
Vp53
p6072
sg13
I1
sasg20
(lp6073
(dp6074
g7
I276
sg23
VC0684249
p6075
sg10
I11
sg11
Vlung cancer
p6076
sg13
I2
sasa(dp6077
g2
S'miR-490-3p exerted growth- and metastasis-suppressive effects on gastric cancer cells through directly targeting SMARCD1, a SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex subunit.\n'
p6078
sg4
(lp6079
(dp6080
g7
I159
sg8
g15
sg10
I3
sg11
VSNF
p6081
sg13
I1
sa(dp6082
g7
I124
sg8
VP28370
p6083
sg10
I3
sg11
VSWI
p6084
sg13
I1
sa(dp6085
g7
I0
sg8
g15
sg10
I10
sg11
VmiR-490-3p
p6086
sg13
I1
sa(dp6087
g7
I113
sg8
g15
sg10
I7
sg11
VSMARCD1
p6088
sg13
I1
sasg20
(lp6089
(dp6090
g7
I65
sg23
VC0024623
p6091
sg10
I14
sg11
Vgastric cancer
p6092
sg13
I2
sa(dp6093
g7
I31
sg23
VC0027627
p6094
sg10
I10
sg11
Vmetastasis
p6095
sg13
I1
sasa(dp6096
g2
S'Knockdown of SMARCD1 significantly attenuated the protumorigenic effects of miR-490-3p inhibitor, whereas enforced expression of SMARCD1 promoted in vitro and in vivo oncogenic phenotypes of gastric cancer cells.\n'
p6097
sg4
(lp6098
(dp6099
g7
I13
sg8
g15
sg10
I7
sg11
VSMARCD1
p6100
sg13
I1
sa(dp6101
g7
I13
sg8
g15
sg10
I7
sg11
VSMARCD1
p6102
sg13
I1
sa(dp6103
g7
I76
sg8
g15
sg10
I10
sg11
VmiR-490-3p
p6104
sg13
I1
sasg20
(lp6105
(dp6106
g7
I191
sg23
VC0024623
p6107
sg10
I14
sg11
Vgastric cancer
p6108
sg13
I2
sasa(dp6109
g2
S"SMARCD1 was markedly upregulated in gastric cancer in which its high expression was associated with shortened patients' survival independent of TNM staging.\n"
p6110
sg4
(lp6111
(dp6112
g7
I144
sg8
g15
sg10
I3
sg11
VTNM
p6113
sg13
I1
sa(dp6114
g7
I0
sg8
g15
sg10
I7
sg11
VSMARCD1
p6115
sg13
I1
sasg20
(lp6116
(dp6117
g7
I36
sg23
VC0024623
p6118
sg10
I14
sg11
Vgastric cancer
p6119
sg13
I2
sasa(dp6120
g2
S'iTD, nTD, and ECLNI were all significant independent adverse factors for RFS in rectal cancer, and were all associated with pT, pN, and LN ratio.\n'
p6121
sg4
(lp6122
(dp6123
g7
I5
sg8
g15
sg10
I3
sg11
VnTD
p6124
sg13
I1
sasg20
(lp6125
(dp6126
g7
I73
sg23
VC0015624
p6127
sg10
I3
sg11
VRFS
p6128
sg13
I1
sa(dp6129
g7
I80
sg23
VC0007113
p6130
sg10
I13
sg11
Vrectal cancer
p6131
sg13
I2
sasa(dp6132
g2
S'Silencing CCM3 by siRNA stimulated endothelial proliferation, migration and sprouting accompanied by significant downregulation of the core components of Notch signalling including DLL4, Notch4, HEY2 and HES1 and by activation of VEGF and Erk pathways.\n'
p6133
sg4
(lp6134
(dp6135
g7
I204
sg8
g15
sg10
I4
sg11
VHES1
p6136
sg13
I1
sa(dp6137
g7
I195
sg8
g15
sg10
I4
sg11
VHEY2
p6138
sg13
I1
sa(dp6139
g7
I181
sg8
g15
sg10
I4
sg11
VDLL4
p6140
sg13
I1
sa(dp6141
g7
I10
sg8
g15
sg10
I4
sg11
VCCM3
p6142
sg13
I1
sa(dp6143
g7
I239
sg8
VP29323
p6144
sg10
I3
sg11
VErk
p6145
sg13
I1
sa(dp6146
g7
I187
sg8
g15
sg10
I6
sg11
VNotch4
p6147
sg13
I1
sasg20
(lp6148
(dp6149
g7
I10
sg23
VC1864040
p6150
sg10
I4
sg11
VCCM3
p6151
sg13
I1
sa(dp6152
g7
I47
sg23
VC0334094
p6153
sg10
I13
sg11
Vproliferation
p6154
sg13
I1
sasa(dp6155
g2
S'The aim was to assess the efficacy of glucomannan (GNN) as a sole treatment for functional constipation.\n'
p6156
sg4
(lp6157
sg20
(lp6158
(dp6159
g7
I80
sg23
VC0401146
p6160
sg10
I23
sg11
Vfunctional constipation
p6161
sg13
I2
sasa(dp6162
g2
S'Children aged 3-16 years with functional constipation according to Rome III criteria were randomly assigned to receive GNN (2.52 g/d) or placebo for 4 weeks.\n'
p6163
sg4
(lp6164
sg20
(lp6165
(dp6166
g7
I30
sg23
VC0401146
p6167
sg10
I23
sg11
Vfunctional constipation
p6168
sg13
I2
sasa(dp6169
g2
S'Interestingly, using Affymetrix gene expression data of a cohort of 285 patients with acute myeloid leukemia (AML), we found that GNN/TU12B1-TY expression was specifically increased in two AML clusters.\n'
p6170
sg4
(lp6171
(dp6172
g7
I130
sg8
g15
sg10
I3
sg11
VGNN
p6173
sg13
I1
sasg20
(lp6174
(dp6175
g7
I110
sg23
VC0023467
p6176
sg10
I3
sg11
VAML
p6177
sg13
I1
sa(dp6178
g7
I110
sg23
VC0023467
p6179
sg10
I3
sg11
VAML
p6180
sg13
I1
sa(dp6181
g7
I86
sg23
VC0023467
p6182
sg10
I22
sg11
Vacute myeloid leukemia
p6183
sg13
I3
sasa(dp6184
g2
S'The present results indicate that reduced function of TU12B1-TY may contribute to the development and/or progression of human pancreatic cancer.\n'
p6185
sg4
(lp6186
(dp6187
g7
I54
sg8
g15
sg10
I9
sg11
VTU12B1-TY
p6188
sg13
I1
sasg20
(lp6189
(dp6190
g7
I126
sg23
VC0235974
p6191
sg10
I17
sg11
Vpancreatic cancer
p6192
sg13
I2
sasa(dp6193
g2
S'To characterize morphologic alterations in the retina of the visual mutant zebrafish gantenbein (gnn) and to examine whether these alterations correlate with those present in human hereditary eye diseases.\n'
p6194
sg4
(lp6195
(dp6196
g7
I61
sg8
g15
sg10
I34
sg11
Vvisual mutant zebrafish gantenbein
p6197
sg13
I4
sa(dp6198
g7
I97
sg8
g15
sg10
I3
sg11
Vgnn
p6199
sg13
I1
sasg20
(lp6200
(dp6201
g7
I181
sg23
VC0015398
p6202
sg10
I23
sg11
Vhereditary eye diseases
p6203
sg13
I3
sa(dp6204
g7
I68
sg23
VC0596988
p6205
sg10
I6
sg11
Vmutant
p6206
sg13
I1
sasa(dp6207
g2
S'Thus, the early developmental morphology of gnn exhibits similarities to cone dystrophies most commonly seen in age-related macular degeneration (AMD) among humans, whereas the later stages of degeneration in gnn resemble RPE alterations in retinitis pigmentosa (RP) in humans.\n'
p6208
sg4
(lp6209
(dp6210
g7
I44
sg8
g15
sg10
I3
sg11
Vgnn
p6211
sg13
I1
sasg20
(lp6212
(dp6213
g7
I78
sg23
VC0333606
p6214
sg10
I11
sg11
Vdystrophies
p6215
sg13
I1
sa(dp6216
g7
I132
sg23
VC0011164
p6217
sg10
I12
sg11
Vdegeneration
p6218
sg13
I1
sa(dp6219
g7
I222
sg23
VC0035334
p6220
sg10
I2
sg11
VRP
p6221
sg13
I1
sa(dp6222
g7
I112
sg23
VC0242383
p6223
sg10
I32
sg11
Vage-related macular degeneration
p6224
sg13
I3
sa(dp6225
g7
I241
sg23
VC0035334
p6226
sg10
I20
sg11
Vretinitis pigmentosa
p6227
sg13
I2
sa(dp6228
g7
I146
sg23
VC0242383
p6229
sg10
I3
sg11
VAMD
p6230
sg13
I1
sasa(dp6231
g2
S'The gnn zebrafish mutant may therefore be a useful model for examining the possible interplay and connection between cone dystrophy and RPE degeneration.\n'
p6232
sg4
(lp6233
(dp6234
g7
I4
sg8
g15
sg10
I20
sg11
Vgnn zebrafish mutant
p6235
sg13
I3
sasg20
(lp6236
(dp6237
g7
I117
sg23
VC0730290
p6238
sg10
I14
sg11
Vcone dystrophy
p6239
sg13
I2
sa(dp6240
g7
I18
sg23
VC0596988
p6241
sg10
I6
sg11
Vmutant
p6242
sg13
I1
sa(dp6243
g7
I140
sg23
VC0011164
p6244
sg10
I12
sg11
Vdegeneration
p6245
sg13
I1
sasa(dp6246
g2
S'Our goal was to assess the patterns of familial aggregation of three melanoma risk factors: great number of naevi (GNN), light phototype (LP) and high degree of sun exposure (HDSE).\n'
p6247
sg4
(lp6248
(dp6249
g7
I69
sg8
VP19883
p6250
sg10
I21
sg11
Vmelanoma risk factors
p6251
sg13
I3
sasg20
(lp6252
(dp6253
g7
I69
sg23
VC0025202
p6254
sg10
I8
sg11
Vmelanoma
p6255
sg13
I1
sasa(dp6256
g2
S'Twenty-five patients were divided into the following groups: (1) chronic glomerulonephritis with normal renal function (GNN) (2) chronic glomerulonephritis with moderate renal insufficiency (GNI) (3) severe chronic renal failure undergoing maintenance dialysis (CRF) (4) acute renal failure during oliguric phase (ARF) (5) normal control without renal suffering (NC).\n'
p6257
sg4
(lp6258
sg20
(lp6259
(dp6260
g7
I65
sg23
VC0152451
p6261
sg10
I26
sg11
Vchronic glomerulonephritis
p6262
sg13
I2
sa(dp6263
g7
I170
sg23
VC0035078
p6264
sg10
I19
sg11
Vrenal insufficiency
p6265
sg13
I2
sa(dp6266
g7
I271
sg23
VC0022660
p6267
sg10
I41
sg11
Vacute renal failure during oliguric phase
p6268
sg13
I6
sa(dp6269
g7
I262
sg23
VC0022661
p6270
sg10
I3
sg11
VCRF
p6271
sg13
I1
sa(dp6272
g7
I314
sg23
VC0022660
p6273
sg10
I3
sg11
VARF
p6274
sg13
I1
sa(dp6275
g7
I352
sg23
VC0683278
p6276
sg10
I9
sg11
Vsuffering
p6277
sg13
I1
sa(dp6278
g7
I207
sg23
VC0022661
p6279
sg10
I53
sg11
Vchronic renal failure undergoing maintenance dialysis
p6280
sg13
I6
sa(dp6281
g7
I65
sg23
VC0152451
p6282
sg10
I26
sg11
Vchronic glomerulonephritis
p6283
sg13
I2
sasa(dp6284
g2
S'The levels of PTH/PTHrP receptor mRNA (corrected by beta-actin mRNA) in the kidney of GNN, GNI, CRF and ARF patients was markedly decreased by up to 35.7%, 68.5%, 77.9% and 92.2%, respectively.\n'
p6285
sg4
(lp6286
(dp6287
g7
I86
sg8
g15
sg10
I3
sg11
VGNN
p6288
sg13
I1
sa(dp6289
g7
I96
sg8
VP06850
p6290
sg10
I3
sg11
VCRF
p6291
sg13
I1
sa(dp6292
g7
I14
sg8
VP01270
p6293
sg10
I3
sg11
VPTH
p6294
sg13
I1
sa(dp6295
g7
I18
sg8
VP12272
p6296
sg10
I19
sg11
VPTHrP receptor mRNA
p6297
sg13
I3
sa(dp6298
g7
I52
sg8
VP63261
p6299
sg10
I15
sg11
Vbeta-actin mRNA
p6300
sg13
I2
sa(dp6301
g7
I104
sg8
VP42771
p6302
sg10
I3
sg11
VARF
p6303
sg13
I1
sasg20
(lp6304
(dp6305
g7
I104
sg23
VC0264490
p6306
sg10
I3
sg11
VARF
p6307
sg13
I1
sa(dp6308
g7
I96
sg23
VC0022661
p6309
sg10
I3
sg11
VCRF
p6310
sg13
I1
sasa(dp6311
g2
S'Here, we tested whether rhMG53 protein can improve membrane repair in a dysferlin-deficient mouse model of LGMD2B (B6.129-Dysftm1Kcam/J).\n'
p6312
sg4
(lp6313
sg20
(lp6314
(dp6315
g7
I107
sg23
VC1850889
p6316
sg10
I6
sg11
VLGMD2B
p6317
sg13
I1
sasa(dp6318
g2
S'Three interacting partners of dysferlin are also implicated in membrane resealing: caveolin-3 (in limb girdle muscular dystrophy type 1C), annexin A1, and the newly identified protein mitsugumin 53 (MG53).\n'
p6319
sg4
(lp6320
(dp6321
g7
I139
sg8
VP04083
p6322
sg10
I10
sg11
Vannexin A1
p6323
sg13
I2
sa(dp6324
g7
I83
sg8
VP56539
p6325
sg10
I10
sg11
Vcaveolin-3
p6326
sg13
I1
sasg20
(lp6327
(dp6328
g7
I98
sg23
VC0686353
p6329
sg10
I30
sg11
Vlimb girdle muscular dystrophy
p6330
sg13
I4
sasa(dp6331
g2
S'Latency and amplitude of the visual P300 and N270 were examined in patients with transient ischemic attack (TIA) and in age-matched healthy control subjects to investigate the feasibility of N270 as a clinical examination method to evaluate the cognitive status of patients with TIA.\n'
p6332
sg4
(lp6333
sg20
(lp6334
(dp6335
g7
I81
sg23
VC0007787
p6336
sg10
I25
sg11
Vtransient ischemic attack
p6337
sg13
I3
sa(dp6338
g7
I108
sg23
VC0007787
p6339
sg10
I3
sg11
VTIA
p6340
sg13
I1
sa(dp6341
g7
I108
sg23
VC0007787
p6342
sg10
I3
sg11
VTIA
p6343
sg13
I1
sasa(dp6344
g2
S'We applied multichannel recording of P300 in 28 patients (68.3 +/- 8.1 years; 15 asymptomatic, 13 with a history of transient ischemic attack (TIA)) and compared them with an age- and sex-matched control group.\n'
p6345
sg4
(lp6346
sg20
(lp6347
(dp6348
g7
I116
sg23
VC0007787
p6349
sg10
I25
sg11
Vtransient ischemic attack
p6350
sg13
I3
sa(dp6351
g7
I143
sg23
VC0007787
p6352
sg10
I3
sg11
VTIA
p6353
sg13
I1
sasa(dp6354
g2
S'Previous studies have implicated the roles of NT and NTR1 in the etiology or expression of schizophrenia.\n'
p6355
sg4
(lp6356
(dp6357
g7
I53
sg8
g15
sg10
I4
sg11
VNTR1
p6358
sg13
I1
sasg20
(lp6359
(dp6360
g7
I91
sg23
VC0036341
p6361
sg10
I13
sg11
Vschizophrenia
p6362
sg13
I1
sasa(dp6363
g2
S'This case-control study examined the associations between schizophrenia and three NTR1 gene polymorphisms (rs6090453C/G, rs6011914C/G, and rs2427422A/G) previously linked to working memory performance in a Han Chinese population.\n'
p6364
sg4
(lp6365
(dp6366
g7
I82
sg8
g15
sg10
I9
sg11
VNTR1 gene
p6367
sg13
I2
sasg20
(lp6368
(dp6369
g7
I58
sg23
VC0036341
p6370
sg10
I13
sg11
Vschizophrenia
p6371
sg13
I1
sasa(dp6372
g2
S"This suggested that nonpeptide agonist mimetics acting at the NTR1 might be helpful in the treatment of Parkinson's disease and schizophrenia.\n"
p6373
sg4
(lp6374
(dp6375
g7
I62
sg8
g15
sg10
I4
sg11
VNTR1
p6376
sg13
I1
sasg20
(lp6377
(dp6378
g7
I104
sg23
VC0030567
p6379
sg10
I19
sg11
VParkinson's disease
p6380
sg13
I2
sa(dp6381
g7
I128
sg23
VC0036341
p6382
sg10
I13
sg11
Vschizophrenia
p6383
sg13
I1
sasa(dp6384
g2
S'The patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).\n'
p6385
sg4
(lp6386
(dp6387
g7
I164
sg8
VP01854
p6388
sg10
I3
sg11
VIgE
p6389
sg13
I1
sasg20
(lp6390
(dp6391
g7
I219
sg23
VC0004031
p6392
sg10
I4
sg11
VABPA
p6393
sg13
I1
sa(dp6394
g7
I144
sg23
VC0014457
p6395
sg10
I12
sg11
Veosinophilia
p6396
sg13
I1
sa(dp6397
g7
I164
sg23
VC0270850
p6398
sg10
I3
sg11
VIgE
p6399
sg13
I1
sasa(dp6400
g2
S'The patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).\n'
p6401
sg4
(lp6402
(dp6403
g7
I164
sg8
VP01854
p6404
sg10
I3
sg11
VIgE
p6405
sg13
I1
sasg20
(lp6406
(dp6407
g7
I219
sg23
VC0004031
p6408
sg10
I4
sg11
VABPA
p6409
sg13
I1
sa(dp6410
g7
I144
sg23
VC0014457
p6411
sg10
I12
sg11
Veosinophilia
p6412
sg13
I1
sa(dp6413
g7
I164
sg23
VC0270850
p6414
sg10
I3
sg11
VIgE
p6415
sg13
I1
sasa(dp6416
g2
S'sph1- and spa2-deleted cells possess defects in mating projection morphology and pseudohyphal growth.\n'
p6417
sg4
(lp6418
(dp6419
g7
I0
sg8
VP16157
p6420
sg10
I4
sg11
Vsph1
p6421
sg13
I1
sa(dp6422
g7
I10
sg8
g15
sg10
I4
sg11
Vspa2
p6423
sg13
I1
sasg20
(lp6424
(dp6425
g7
I29
sg23
VC0850310
p6426
sg10
I7
sg11
Vpossess
p6427
sg13
I1
sa(dp6428
g7
I0
sg23
VC2674218
p6429
sg10
I4
sg11
Vsph1
p6430
sg13
I1
sasa(dp6431
g2
S'sph1(Delta) spa2(Delta) double mutants also exhibit a strong haploid invasive growth defect and an exacerbated mating projection defect relative to either sph1(Delta) or spa2(Delta) single mutants.\n'
p6432
sg4
(lp6433
(dp6434
g7
I170
sg8
g15
sg10
I26
sg11
Vspa2(Delta) single mutants
p6435
sg13
I3
sa(dp6436
g7
I0
sg8
VP16157
p6437
sg10
I11
sg11
Vsph1(Delta)
p6438
sg13
I1
sa(dp6439
g7
I0
sg8
VP16157
p6440
sg10
I38
sg11
Vsph1(Delta) spa2(Delta) double mutants
p6441
sg13
I4
sasg20
(lp6442
(dp6443
g7
I0
sg23
VC2674218
p6444
sg10
I4
sg11
Vsph1
p6445
sg13
I1
sa(dp6446
g7
I0
sg23
VC2674218
p6447
sg10
I4
sg11
Vsph1
p6448
sg13
I1
sa(dp6449
g7
I69
sg23
VC1156244
p6450
sg10
I15
sg11
Vinvasive growth
p6451
sg13
I2
sasa(dp6452
g2
S'SPH1, which is similar to SPA2, is required for bipolar budding and plays a role in shmoo formation.\n'
p6453
sg4
(lp6454
(dp6455
g7
I0
sg8
VP16157
p6456
sg10
I4
sg11
VSPH1
p6457
sg13
I1
sa(dp6458
g7
I26
sg8
g15
sg10
I4
sg11
VSPA2
p6459
sg13
I1
sasg20
(lp6460
(dp6461
g7
I0
sg23
VC2674218
p6462
sg10
I4
sg11
VSPH1
p6463
sg13
I1
sasa(dp6464
g2
S'Outcomes were best in patients with ovarian cancer (MS 15.9 months) and colorectal cancer (MS 14.3 months) and worst in patients with lung (MS 2.4 months) and pancreas (MS 1.9 months) cancers.\n'
p6465
sg4
(lp6466
sg20
(lp6467
(dp6468
g7
I184
sg23
VC0006826
p6469
sg10
I7
sg11
Vcancers
p6470
sg13
I1
sa(dp6471
g7
I72
sg23
VC1527249
p6472
sg10
I17
sg11
Vcolorectal cancer
p6473
sg13
I2
sa(dp6474
g7
I36
sg23
VC1140680
p6475
sg10
I14
sg11
Vovarian cancer
p6476
sg13
I2
sasa(dp6477
g2
S'This study was undertaken to evaluate the effect of ADAM8 on the proliferation and apoptosis of hepatocytes and hepatoma carcinoma cells during hepatocellular carcinoma (HCC) progression.\n'
p6478
sg4
(lp6479
(dp6480
g7
I52
sg8
VP78325
p6481
sg10
I5
sg11
VADAM8
p6482
sg13
I1
sasg20
(lp6483
(dp6484
g7
I170
sg23
VC2239176
p6485
sg10
I3
sg11
VHCC
p6486
sg13
I1
sa(dp6487
g7
I65
sg23
VC0334094
p6488
sg10
I13
sg11
Vproliferation
p6489
sg13
I1
sa(dp6490
g7
I121
sg23
VC0007097
p6491
sg10
I9
sg11
Vcarcinoma
p6492
sg13
I1
sa(dp6493
g7
I144
sg23
VC2239176
p6494
sg10
I24
sg11
Vhepatocellular carcinoma
p6495
sg13
I2
sa(dp6496
g7
I112
sg23
VC2239176
p6497
sg10
I8
sg11
Vhepatoma
p6498
sg13
I1
sasa(dp6499
g2
S'In conclusion, our study suggested that ADAM8 could promote the proliferation of normal hepatocytes and render hepatoma carcinoma cells more resistant to apoptosis to play important roles during the progression of HCC.\n'
p6500
sg4
(lp6501
(dp6502
g7
I40
sg8
VP78325
p6503
sg10
I5
sg11
VADAM8
p6504
sg13
I1
sasg20
(lp6505
(dp6506
g7
I64
sg23
VC0334094
p6507
sg10
I13
sg11
Vproliferation
p6508
sg13
I1
sa(dp6509
g7
I111
sg23
VC2239176
p6510
sg10
I8
sg11
Vhepatoma
p6511
sg13
I1
sa(dp6512
g7
I120
sg23
VC0007097
p6513
sg10
I9
sg11
Vcarcinoma
p6514
sg13
I1
sa(dp6515
g7
I214
sg23
VC2239176
p6516
sg10
I3
sg11
VHCC
p6517
sg13
I1
sasa(dp6518
g2
S'Thus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.\n'
p6519
sg4
(lp6520
(dp6521
g7
I25
sg8
VP78325
p6522
sg10
I5
sg11
VADAM8
p6523
sg13
I1
sa(dp6524
g7
I25
sg8
VP78325
p6525
sg10
I5
sg11
VADAM8
p6526
sg13
I1
sasg20
(lp6527
(dp6528
g7
I34
sg23
VC0235974
p6529
sg10
I17
sg11
Vpancreatic cancer
p6530
sg13
I2
sasa(dp6531
g2
S'This study focuses on investigating the concrete role of a disintegrin and metalloproteinase 8 (ADAM8) in the progression of hepatocellular carcinoma (HCC).\n'
p6532
sg4
(lp6533
(dp6534
g7
I59
sg8
VP78325
p6535
sg10
I43
sg11
Vdisintegrin and metalloproteinase 8 (ADAM8)
p6536
sg13
I5
sasg20
(lp6537
(dp6538
g7
I125
sg23
VC2239176
p6539
sg10
I24
sg11
Vhepatocellular carcinoma
p6540
sg13
I2
sa(dp6541
g7
I151
sg23
VC2239176
p6542
sg10
I3
sg11
VHCC
p6543
sg13
I1
sasa(dp6544
g2
S'However, no studies have examined ADAM8 association in colorectal cancer (CRC).\n'
p6545
sg4
(lp6546
(dp6547
g7
I34
sg8
VP78325
p6548
sg10
I44
sg11
VADAM8 association in colorectal cancer (CRC)
p6549
sg13
I6
sasg20
(lp6550
(dp6551
g7
I74
sg23
VC1527249
p6552
sg10
I3
sg11
VCRC
p6553
sg13
I1
sa(dp6554
g7
I55
sg23
VC1527249
p6555
sg10
I17
sg11
Vcolorectal cancer
p6556
sg13
I2
sasa(dp6557
g2
S'Subgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).\n'
p6558
sg4
(lp6559
(dp6560
g7
I110
sg8
VP78325
p6561
sg10
I5
sg11
VADAM8
p6562
sg13
I1
sasg20
(lp6563
(dp6564
g7
I125
sg23
VC0027651
p6565
sg10
I6
sg11
Vtumors
p6566
sg13
I1
sa(dp6567
g7
I43
sg23
VC0699790
p6568
sg10
I12
sg11
Vcolon cancer
p6569
sg13
I2
sa(dp6570
g7
I125
sg23
VC0027651
p6571
sg10
I6
sg11
Vtumors
p6572
sg13
I1
sasa(dp6573
g2
S'The 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).\n'
p6574
sg4
(lp6575
(dp6576
g7
I170
sg8
VP78325
p6577
sg10
I5
sg11
VADAM8
p6578
sg13
I1
sa(dp6579
g7
I55
sg8
g15
sg10
I12
sg11
VTNM stage II
p6580
sg13
I3
sasg20
(lp6581
(dp6582
g7
I69
sg23
VC0001418
p6583
sg10
I14
sg11
Vadenocarcinoma
p6584
sg13
I1
sa(dp6585
g7
I18
sg23
VC0699790
p6586
sg10
I12
sg11
Vcolon cancer
p6587
sg13
I2
sa(dp6588
g7
I185
sg23
VC0027651
p6589
sg10
I6
sg11
Vtumors
p6590
sg13
I1
sa(dp6591
g7
I185
sg23
VC0027651
p6592
sg10
I6
sg11
Vtumors
p6593
sg13
I1
sasa(dp6594
g2
S'The aim of this study was to examine the role of the inflammatory cells in the invasion of pancreatic cancer cells, focusing on the involvement of a disintegrin and metalloproteinase 8 (ADAM8) and matrix metalloproteinase 9 (MMP9) proteins.\n'
p6595
sg4
(lp6596
(dp6597
g7
I197
sg8
VP14780
p6598
sg10
I42
sg11
Vmatrix metalloproteinase 9 (MMP9) proteins
p6599
sg13
I5
sa(dp6600
g7
I149
sg8
VP78325
p6601
sg10
I43
sg11
Vdisintegrin and metalloproteinase 8 (ADAM8)
p6602
sg13
I5
sasg20
(lp6603
(dp6604
g7
I91
sg23
VC0235974
p6605
sg10
I17
sg11
Vpancreatic cancer
p6606
sg13
I2
sa(dp6607
g7
I79
sg23
VC2699153
p6608
sg10
I8
sg11
Vinvasion
p6609
sg13
I1
sasa(dp6610
g2
S'ADAM8 expression is associated with worse survival of pancreatic cancer patients.\n'
p6611
sg4
(lp6612
(dp6613
g7
I0
sg8
VP78325
p6614
sg10
I5
sg11
VADAM8
p6615
sg13
I1
sasg20
(lp6616
(dp6617
g7
I54
sg23
VC0235974
p6618
sg10
I17
sg11
Vpancreatic cancer
p6619
sg13
I2
sasa(dp6620
g2
S'Anti-inflammatory macrophages increase pancreatic cancer cell migration rate in basement membrane matrix by inducing ADAM8 and MMP9 expression in cancer cells, thereby possibly enhancing the invasiveness of cancer.\n'
p6621
sg4
(lp6622
(dp6623
g7
I127
sg8
VP14780
p6624
sg10
I4
sg11
VMMP9
p6625
sg13
I1
sa(dp6626
g7
I117
sg8
VP78325
p6627
sg10
I5
sg11
VADAM8
p6628
sg13
I1
sasg20
(lp6629
(dp6630
g7
I39
sg23
VC0235974
p6631
sg10
I17
sg11
Vpancreatic cancer
p6632
sg13
I2
sa(dp6633
g7
I50
sg23
VC0006826
p6634
sg10
I6
sg11
Vcancer
p6635
sg13
I1
sa(dp6636
g7
I50
sg23
VC0006826
p6637
sg10
I6
sg11
Vcancer
p6638
sg13
I1
sasa(dp6639
g2
S'In this study,we investigated the ADAM8 expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features,including the survival of patients with HCC.\n'
p6640
sg4
(lp6641
(dp6642
g7
I34
sg8
VP78325
p6643
sg10
I5
sg11
VADAM8
p6644
sg13
I1
sasg20
(lp6645
(dp6646
g7
I54
sg23
VC2239176
p6647
sg10
I24
sg11
Vhepatocellular carcinoma
p6648
sg13
I2
sa(dp6649
g7
I80
sg23
VC2239176
p6650
sg10
I3
sg11
VHCC
p6651
sg13
I1
sa(dp6652
g7
I80
sg23
VC2239176
p6653
sg10
I3
sg11
VHCC
p6654
sg13
I1
sasa(dp6655
g2
S'Other studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients.\n'
p6656
sg4
(lp6657
(dp6658
g7
I55
sg8
VP02649
p6659
sg10
I20
sg11
VADAM family proteins
p6660
sg13
I3
sa(dp6661
g7
I161
sg8
VP78325
p6662
sg10
I5
sg11
VADAM8
p6663
sg13
I1
sasg20
(lp6664
(dp6665
g7
I98
sg23
VC0027651
p6666
sg10
I6
sg11
Vtumors
p6667
sg13
I1
sa(dp6668
g7
I265
sg23
VC2239176
p6669
sg10
I3
sg11
VHCC
p6670
sg13
I1
sa(dp6671
g7
I239
sg23
VC2239176
p6672
sg10
I24
sg11
Vhepatocellular carcinoma
p6673
sg13
I2
sasa(dp6674
g2
S'To evaluate the association between ADAM8 tissue expression and patient prognosis in hepatocellular carcinoma (HCC).\n'
p6675
sg4
(lp6676
(dp6677
g7
I36
sg8
VP78325
p6678
sg10
I5
sg11
VADAM8
p6679
sg13
I1
sasg20
(lp6680
(dp6681
g7
I111
sg23
VC2239176
p6682
sg10
I3
sg11
VHCC
p6683
sg13
I1
sa(dp6684
g7
I85
sg23
VC2239176
p6685
sg10
I24
sg11
Vhepatocellular carcinoma
p6686
sg13
I2
sasa(dp6687
g2
S'Some of the previously reported gout associated loci (except ALDH16A1), including ABCG2, SLC2A9, GCKR, ALDH2 and CNIH2, were replicated.\n'
p6688
sg4
(lp6689
(dp6690
g7
I113
sg8
g15
sg10
I5
sg11
VCNIH2
p6691
sg13
I1
sa(dp6692
g7
I89
sg8
g15
sg10
I6
sg11
VSLC2A9
p6693
sg13
I1
sa(dp6694
g7
I103
sg8
VP05091
p6695
sg10
I5
sg11
VALDH2
p6696
sg13
I1
sa(dp6697
g7
I61
sg8
g15
sg10
I8
sg11
VALDH16A1
p6698
sg13
I1
sa(dp6699
g7
I97
sg8
g15
sg10
I4
sg11
VGCKR
p6700
sg13
I1
sasg20
(lp6701
(dp6702
g7
I32
sg23
VC0018099
p6703
sg10
I4
sg11
Vgout
p6704
sg13
I1
sasa(dp6705
g2
S'The aim of this study was to examine the role of SLC2A9 and ABCG2 variants in tophaceous disease in people with gout.\n'
p6706
sg4
(lp6707
(dp6708
g7
I49
sg8
g15
sg10
I6
sg11
VSLC2A9
p6709
sg13
I1
sa(dp6710
g7
I60
sg8
VP26640
p6711
sg10
I14
sg11
VABCG2 variants
p6712
sg13
I2
sasg20
(lp6713
(dp6714
g7
I112
sg23
VC0018099
p6715
sg10
I4
sg11
Vgout
p6716
sg13
I1
sasa(dp6717
g2
S'The main objective of this study is to elucidate the clinical significance of the SLC2A9/GLUT9 rs11722228 polymorphism among male gout patients.\n'
p6718
sg4
(lp6719
(dp6720
g7
I89
sg8
g15
sg10
I5
sg11
VGLUT9
p6721
sg13
I1
sa(dp6722
g7
I82
sg8
g15
sg10
I6
sg11
VSLC2A9
p6723
sg13
I1
sasg20
(lp6724
(dp6725
g7
I130
sg23
VC0018099
p6726
sg10
I4
sg11
Vgout
p6727
sg13
I1
sasa(dp6728
g2
S'The genotypic frequencies of SLC2A9/GLUT9 rs1172228 did not differ significantly between the gout cases and the healthy controls.\n'
p6729
sg4
(lp6730
(dp6731
g7
I29
sg8
g15
sg10
I6
sg11
VSLC2A9
p6732
sg13
I1
sa(dp6733
g7
I36
sg8
g15
sg10
I5
sg11
VGLUT9
p6734
sg13
I1
sasg20
(lp6735
(dp6736
g7
I93
sg23
VC0018099
p6737
sg10
I4
sg11
Vgout
p6738
sg13
I1
sasa(dp6739
g2
S'The genotypic distribution of SLC2A9/GLUT9 rs1172228 in male gout patients did not differ significantly from that of healthy male controls.\n'
p6740
sg4
(lp6741
(dp6742
g7
I37
sg8
g15
sg10
I15
sg11
VGLUT9 rs1172228
p6743
sg13
I2
sa(dp6744
g7
I30
sg8
g15
sg10
I6
sg11
VSLC2A9
p6745
sg13
I1
sasg20
(lp6746
(dp6747
g7
I61
sg23
VC0018099
p6748
sg10
I4
sg11
Vgout
p6749
sg13
I1
sasa(dp6750
g2
S'The relationship between the SLC2A9 (solute carrier family 2, member 9) gene polymorphisms and gout was still inconsistent among the individual genetic association studies.\n'
p6751
sg4
(lp6752
(dp6753
g7
I37
sg8
g15
sg10
I23
sg11
Vsolute carrier family 2
p6754
sg13
I4
sa(dp6755
g7
I29
sg8
g15
sg10
I6
sg11
VSLC2A9
p6756
sg13
I1
sasg20
(lp6757
(dp6758
g7
I95
sg23
VC0018099
p6759
sg10
I4
sg11
Vgout
p6760
sg13
I1
sasa(dp6761
g2
S'Therefore, this present research was aimed to systematically evaluate the association between SLC2A9 gene polymorphisms and gout susceptibility.\n'
p6762
sg4
(lp6763
(dp6764
g7
I94
sg8
g15
sg10
I11
sg11
VSLC2A9 gene
p6765
sg13
I2
sasg20
(lp6766
(dp6767
g7
I124
sg23
VC0018099
p6768
sg10
I4
sg11
Vgout
p6769
sg13
I1
sasa(dp6770
g2
S'This study demonstrated that the genetic susceptibility for gout is associated with the SLC2A9 gene polymorphisms.\n'
p6771
sg4
(lp6772
(dp6773
g7
I88
sg8
g15
sg10
I11
sg11
VSLC2A9 gene
p6774
sg13
I2
sasg20
(lp6775
(dp6776
g7
I60
sg23
VC0018099
p6777
sg10
I4
sg11
Vgout
p6778
sg13
I1
sasa(dp6779
g2
S'Eight variants of ABCG2, SLC2A9, SLC22A12, SLC22A11 and SLC17A3 were genotyped in male individuals in a case-control study with 157 gout (33% tophi), 106 asymptomatic hyperuricaemia and 295 control subjects from Taiwan.\n'
p6780
sg4
(lp6781
(dp6782
g7
I33
sg8
g15
sg10
I8
sg11
VSLC22A12
p6783
sg13
I1
sa(dp6784
g7
I43
sg8
g15
sg10
I8
sg11
VSLC22A11
p6785
sg13
I1
sa(dp6786
g7
I25
sg8
g15
sg10
I6
sg11
VSLC2A9
p6787
sg13
I1
sa(dp6788
g7
I56
sg8
g15
sg10
I7
sg11
VSLC17A3
p6789
sg13
I1
sasg20
(lp6790
(dp6791
g7
I142
sg23
VC0221248
p6792
sg10
I5
sg11
Vtophi
p6793
sg13
I1
sa(dp6794
g7
I132
sg23
VC0018099
p6795
sg10
I4
sg11
Vgout
p6796
sg13
I1
sa(dp6797
g7
I167
sg23
VC0740394
p6798
sg10
I14
sg11
Vhyperuricaemia
p6799
sg13
I1
sasa(dp6800
g2
S'ABCG2 Q141K (T), SLC2A9 rs1014290 (A) and SLC22A12 rs475688 (C) under an additive model and alcohol use independently predicted the risk of gout (respective odds ratio for each factor=2.48, 2.03, 1.95 and 2.48).\n'
p6801
sg4
(lp6802
(dp6803
g7
I17
sg8
g15
sg10
I16
sg11
VSLC2A9 rs1014290
p6804
sg13
I2
sa(dp6805
g7
I42
sg8
g15
sg10
I8
sg11
VSLC22A12
p6806
sg13
I1
sasg20
(lp6807
(dp6808
g7
I140
sg23
VC0018099
p6809
sg10
I4
sg11
Vgout
p6810
sg13
I1
sasa(dp6811
g2
S'The aim of this study was to determine whether polymorphisms in solute carrier family 2 and facilitated glucose transporter member 9 (SLC2A9) are associated with susceptibility to gout.\n'
p6812
sg4
(lp6813
(dp6814
g7
I134
sg8
g15
sg10
I6
sg11
VSLC2A9
p6815
sg13
I1
sa(dp6816
g7
I64
sg8
g15
sg10
I68
sg11
Vsolute carrier family 2 and facilitated glucose transporter member 9
p6817
sg13
I10
sasg20
(lp6818
(dp6819
g7
I180
sg23
VC0018099
p6820
sg10
I4
sg11
Vgout
p6821
sg13
I1
sasa(dp6822
g2
S'A meta-analysis was conducted on associations between the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 and gout susceptibility using fixed and random effects models.\n'
p6823
sg4
(lp6824
(dp6825
g7
I113
sg8
g15
sg10
I6
sg11
VSLC2A9
p6826
sg13
I1
sasg20
(lp6827
(dp6828
g7
I124
sg23
VC0018099
p6829
sg10
I4
sg11
Vgout
p6830
sg13
I1
sasa(dp6831
g2
S'This meta-analysis shows that the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 protect against the development of gout in Caucasians and/or Asians.\n'
p6832
sg4
(lp6833
sg20
(lp6834
(dp6835
g7
I131
sg23
VC0018099
p6836
sg10
I4
sg11
Vgout
p6837
sg13
I1
sasa(dp6838
g2
S'We investigated the association of polymorphisms in the ABCG2 and SLC2A9 genes with gout in Korean patients and healthy individuals.\n'
p6839
sg4
(lp6840
(dp6841
g7
I66
sg8
g15
sg10
I12
sg11
VSLC2A9 genes
p6842
sg13
I2
sasg20
(lp6843
(dp6844
g7
I84
sg23
VC0018099
p6845
sg10
I4
sg11
Vgout
p6846
sg13
I1
sasa(dp6847
g2
S'We demonstrated a significant association between rs2231142 in the ABCG2 gene and gout and identified novel SNPs, c.881A&gt;G and c.1002+78G&gt;A, in the SLC2A9 gene that may be associated with gout in a Korean population.\n'
p6848
sg4
(lp6849
(dp6850
g7
I154
sg8
g15
sg10
I11
sg11
VSLC2A9 gene
p6851
sg13
I2
sasg20
(lp6852
(dp6853
g7
I82
sg23
VC0018099
p6854
sg10
I4
sg11
Vgout
p6855
sg13
I1
sa(dp6856
g7
I82
sg23
VC0018099
p6857
sg10
I4
sg11
Vgout
p6858
sg13
I1
sasa(dp6859
g2
S'SLC2A9 and ZNF518B may play a role in gout progression in different populations, but no studies have focused on the Tibetan Chinese population.\n'
p6860
sg4
(lp6861
(dp6862
g7
I11
sg8
g15
sg10
I7
sg11
VZNF518B
p6863
sg13
I1
sa(dp6864
g7
I0
sg8
g15
sg10
I6
sg11
VSLC2A9
p6865
sg13
I1
sasg20
(lp6866
(dp6867
g7
I38
sg23
VC0018099
p6868
sg10
I4
sg11
Vgout
p6869
sg13
I1
sasa(dp6870
g2
S'We detected 6 single nucleotide polymorphisms in SLC2A9 and ZNF518B in 319 Chinese Tibetan gout patients.\n'
p6871
sg4
(lp6872
(dp6873
g7
I49
sg8
g15
sg10
I6
sg11
VSLC2A9
p6874
sg13
I1
sa(dp6875
g7
I60
sg8
g15
sg10
I7
sg11
VZNF518B
p6876
sg13
I1
sasg20
(lp6877
(dp6878
g7
I91
sg23
VC0018099
p6879
sg10
I4
sg11
Vgout
p6880
sg13
I1
sasa(dp6881
g2
S'Polymorphisms in SLC2A9 and ZNF518B affected multiple risk factors related to gout development.\n'
p6882
sg4
(lp6883
(dp6884
g7
I17
sg8
g15
sg10
I6
sg11
VSLC2A9
p6885
sg13
I1
sa(dp6886
g7
I28
sg8
g15
sg10
I7
sg11
VZNF518B
p6887
sg13
I1
sasg20
(lp6888
(dp6889
g7
I78
sg23
VC0018099
p6890
sg10
I4
sg11
Vgout
p6891
sg13
I1
sasa(dp6892
g2
S'This study is the first to investigate and identify positive correlations between SLC2A9 and ZNF518B gene polymorphisms and metabolic indices in Tibetan gout patients.\n'
p6893
sg4
(lp6894
(dp6895
g7
I93
sg8
g15
sg10
I12
sg11
VZNF518B gene
p6896
sg13
I2
sa(dp6897
g7
I82
sg8
g15
sg10
I6
sg11
VSLC2A9
p6898
sg13
I1
sasg20
(lp6899
(dp6900
g7
I153
sg23
VC0018099
p6901
sg10
I4
sg11
Vgout
p6902
sg13
I1
sasa(dp6903
g2
S'In conclusion, two patients who developed hypercalcemia associated with bone metastasis after surgery for HCC were treated with alendronate and they experienced alleviation of the pain due to bone metastasis, improvement of their quality of life and a marked decrease in AFP levels with tumor regression.\n'
p6904
sg4
(lp6905
sg20
(lp6906
(dp6907
g7
I42
sg23
VC0020437
p6908
sg10
I13
sg11
Vhypercalcemia
p6909
sg13
I1
sa(dp6910
g7
I72
sg23
VC0153690
p6911
sg10
I15
sg11
Vbone metastasis
p6912
sg13
I2
sa(dp6913
g7
I287
sg23
VC0027651
p6914
sg10
I5
sg11
Vtumor
p6915
sg13
I1
sa(dp6916
g7
I106
sg23
VC2239176
p6917
sg10
I3
sg11
VHCC
p6918
sg13
I1
sa(dp6919
g7
I72
sg23
VC0153690
p6920
sg10
I15
sg11
Vbone metastasis
p6921
sg13
I2
sasa(dp6922
g2
S'Coloboma-like optic discs might be an additional feature observed in patients with SPTAN1 mutations.\n'
p6923
sg4
(lp6924
sg20
(lp6925
(dp6926
g7
I0
sg23
VC0009363
p6927
sg10
I8
sg11
VColoboma
p6928
sg13
I1
sasa(dp6929
g2
S"A newly described autoantibody to alpha-fodrin found in other neurodegenerative diseases such as Alzheimer's, further implicate a role for autoimmunity and the neurodegenerative processes in glaucoma.\n"
p6930
sg4
(lp6931
sg20
(lp6932
(dp6933
g7
I62
sg23
VC0524851
p6934
sg10
I26
sg11
Vneurodegenerative diseases
p6935
sg13
I2
sa(dp6936
g7
I191
sg23
VC0017601
p6937
sg10
I8
sg11
Vglaucoma
p6938
sg13
I1
sa(dp6939
g7
I139
sg23
VC0004368
p6940
sg10
I12
sg11
Vautoimmunity
p6941
sg13
I1
sasa(dp6942
g2
S'In a similar experiment, ocular hypertension was induced in four eyes pre-treated with an intravitreal injection of AAV-BIRC4 to assess alpha-fodrin cleavage.\n'
p6943
sg4
(lp6944
sg20
(lp6945
(dp6946
g7
I25
sg23
VC0028840
p6947
sg10
I19
sg11
Vocular hypertension
p6948
sg13
I2
sasa(dp6949
g2
S'Comparison of the Zrs z-scores between the healthy children and the health groups found significant differences in children with asthma, current wheeze and respiratory symptoms, but not in children born preterm or with early-life wheeze.\n'
p6950
sg4
(lp6951
sg20
(lp6952
(dp6953
g7
I156
sg23
VC0037090
p6954
sg10
I20
sg11
Vrespiratory symptoms
p6955
sg13
I2
sa(dp6956
g7
I145
sg23
VC0043144
p6957
sg10
I6
sg11
Vwheeze
p6958
sg13
I1
sa(dp6959
g7
I145
sg23
VC0043144
p6960
sg10
I6
sg11
Vwheeze
p6961
sg13
I1
sa(dp6962
g7
I129
sg23
VC0004096
p6963
sg10
I6
sg11
Vasthma
p6964
sg13
I1
sasa(dp6965
g2
S'The aim of this retrospective study was to assess responses to a bronchodilator by forced oscillation technique (FOT) and to relate the results of respiratory impedance (Zrs) to spirometric parameters in patients with chronic obstructive pulmonary disease (COPD).\n'
p6966
sg4
(lp6967
sg20
(lp6968
(dp6969
g7
I218
sg23
VC0024117
p6970
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p6971
sg13
I4
sa(dp6972
g7
I257
sg23
VC0024117
p6973
sg10
I4
sg11
VCOPD
p6974
sg13
I1
sasa(dp6975
g2
S'The diagnostic efficiency of Zrs, R5 and X35 when diagnosis asthma, expressed by ROC curve parameters, was as follows: AUC (0.721, 0.710, 0.695), sensitivity (62%, 72%, 53%) and specificity (72%, 61%, 76%), respectively.\n'
p6976
sg4
(lp6977
sg20
(lp6978
(dp6979
g7
I60
sg23
VC0004096
p6980
sg10
I6
sg11
Vasthma
p6981
sg13
I1
sasa(dp6982
g2
S'And R5, X35 and Zrs may provide useful IOS parameters for asthma.\n'
p6983
sg4
(lp6984
(dp6985
g7
I16
sg8
g15
sg10
I3
sg11
VZrs
p6986
sg13
I1
sasg20
(lp6987
(dp6988
g7
I58
sg23
VC0004096
p6989
sg10
I6
sg11
Vasthma
p6990
sg13
I1
sasa(dp6991
g2
S'Birth weight less than 3,000 g was associated with larger exercise-induced changes in Zrs and Rrs at 5 Hz, and in reactance (Xrs) at 5 Hz, than those with birth weight more than 3,000 g. Preliminary evidence was found that obesity may be associated with airway obstruction, but not with bronchial hyper-reactivity.\n'
p6992
sg4
(lp6993
sg20
(lp6994
(dp6995
g7
I223
sg23
VC0028754
p6996
sg10
I7
sg11
Vobesity
p6997
sg13
I1
sa(dp6998
g7
I94
sg23
VC1849334
p6999
sg10
I3
sg11
VRrs
p7000
sg13
I1
sa(dp7001
g7
I254
sg23
VC0001883
p7002
sg10
I18
sg11
Vairway obstruction
p7003
sg13
I2
sasa(dp7004
g2
S'To investigate the nature of mutations in exons 4 and 5 of the uromodulin (UM) gene, including in the area encoding the domain of 8 cysteines (D8C), in patients with multiple myeloma (MM) with the secretion of monoclonal light chains (LC) in cast nephropathy (CN) and without kidney injury.\n'
p7005
sg4
(lp7006
(dp7007
g7
I63
sg8
VP07911
p7008
sg10
I20
sg11
Vuromodulin (UM) gene
p7009
sg13
I3
sasg20
(lp7010
(dp7011
g7
I247
sg23
VC0022658
p7012
sg10
I11
sg11
Vnephropathy
p7013
sg13
I1
sa(dp7014
g7
I166
sg23
VC0026764
p7015
sg10
I16
sg11
Vmultiple myeloma
p7016
sg13
I2
sasa(dp7017
g2
S'The aim of the study was to investigate the association of the uromodulin (UMOD) genotype with patient health status and with renal cell carcinoma (RCC) aggressiveness.\n'
p7018
sg4
(lp7019
(dp7020
g7
I75
sg8
VP07911
p7021
sg10
I4
sg11
VUMOD
p7022
sg13
I1
sa(dp7023
g7
I63
sg8
VP07911
p7024
sg10
I10
sg11
Vuromodulin
p7025
sg13
I1
sasg20
(lp7026
(dp7027
g7
I148
sg23
VC0007134
p7028
sg10
I3
sg11
VRCC
p7029
sg13
I1
sa(dp7030
g7
I126
sg23
VC0007134
p7031
sg10
I20
sg11
Vrenal cell carcinoma
p7032
sg13
I3
sa(dp7033
g7
I153
sg23
VC0001807
p7034
sg10
I14
sg11
Vaggressiveness
p7035
sg13
I1
sasa(dp7036
g2
S'In patients diagnosed with renal cell carcinoma and treated with surgery, uromodulin homozygous genotype is associated with more aggressive renal cell carcinoma clinical and pathological characteristics.\n'
p7037
sg4
(lp7038
(dp7039
g7
I74
sg8
VP07911
p7040
sg10
I10
sg11
Vuromodulin
p7041
sg13
I1
sasg20
(lp7042
(dp7043
g7
I129
sg23
VC0001807
p7044
sg10
I10
sg11
Vaggressive
p7045
sg13
I1
sa(dp7046
g7
I27
sg23
VC0007134
p7047
sg10
I20
sg11
Vrenal cell carcinoma
p7048
sg13
I3
sa(dp7049
g7
I27
sg23
VC0007134
p7050
sg10
I20
sg11
Vrenal cell carcinoma
p7051
sg13
I3
sasa(dp7052
g2
S'CYP11B2 was sequenced if the aldosterone level was high (primary aldosteronism phenotype); SCNN1B, NEDD4L, GRK4, UMOD, and NPPA genes were sequenced if the aldosterone level was low (Liddle phenotype).\n'
p7053
sg4
(lp7054
(dp7055
g7
I91
sg8
VP51168
p7056
sg10
I6
sg11
VSCNN1B
p7057
sg13
I1
sa(dp7058
g7
I0
sg8
VP19099
p7059
sg10
I7
sg11
VCYP11B2
p7060
sg13
I1
sa(dp7061
g7
I123
sg8
VP01160
p7062
sg10
I10
sg11
VNPPA genes
p7063
sg13
I2
sa(dp7064
g7
I113
sg8
VP07911
p7065
sg10
I4
sg11
VUMOD
p7066
sg13
I1
sasg20
(lp7067
(dp7068
g7
I57
sg23
VC1384514
p7069
sg10
I21
sg11
Vprimary aldosteronism
p7070
sg13
I2
sasa(dp7071
g2
S'MT1F, MT1G, MT1X, and MT2A gene expression was significantly downregulated in colon cancer tissue (p&lt;0.05).\n'
p7072
sg4
(lp7073
(dp7074
g7
I12
sg8
VP80297
p7075
sg10
I4
sg11
VMT1X
p7076
sg13
I1
sa(dp7077
g7
I6
sg8
VP04733
p7078
sg10
I4
sg11
VMT1G
p7079
sg13
I1
sa(dp7080
g7
I0
sg8
VP04733
p7081
sg10
I4
sg11
VMT1F
p7082
sg13
I1
sa(dp7083
g7
I22
sg8
VP02795
p7084
sg10
I9
sg11
VMT2A gene
p7085
sg13
I2
sasg20
(lp7086
(dp7087
g7
I78
sg23
VC0699790
p7088
sg10
I12
sg11
Vcolon cancer
p7089
sg13
I2
sasa(dp7090
g2
S"Here, we describe the discovery of a new MSI marker for colorectal cancer located in the 3'-untranslated region (3'UTR, T20 mononucleotide repeat) of the metallothionein 1X gene (MT1XT20).\n"
p7091
sg4
(lp7092
(dp7093
g7
I154
sg8
VP80297
p7094
sg10
I23
sg11
Vmetallothionein 1X gene
p7095
sg13
I3
sasg20
(lp7096
(dp7097
g7
I41
sg23
VC0920269
p7098
sg10
I3
sg11
VMSI
p7099
sg13
I1
sa(dp7100
g7
I56
sg23
VC1527249
p7101
sg10
I17
sg11
Vcolorectal cancer
p7102
sg13
I2
sasa(dp7103
g2
S'Indeed, MT1XT20 instability was detected in 36 out of 37 cases (97.3%) of MSI-high colorectal cancers, whereas no MT1XT20 alterations were observed in 254 MSS or in 46 MSI-low cases.\n'
p7104
sg4
(lp7105
sg20
(lp7106
(dp7107
g7
I74
sg23
VC0920269
p7108
sg10
I3
sg11
VMSI
p7109
sg13
I1
sa(dp7110
g7
I155
sg23
VC0024814
p7111
sg10
I3
sg11
VMSS
p7112
sg13
I1
sa(dp7113
g7
I74
sg23
VC0920269
p7114
sg10
I3
sg11
VMSI
p7115
sg13
I1
sa(dp7116
g7
I83
sg23
VC1527249
p7117
sg10
I18
sg11
Vcolorectal cancers
p7118
sg13
I2
sasa(dp7119
g2
S'HNF-1Beta regulates tissue-specific gene expression in endometriosis, as well as the expression of several genes, including CD44v9, which binds several molecules, including hyaluronan, epidermal growth factor receptor (EGFR), leukemia-associated Rho-guanine nucleotide exchange factor (LARG), IQ motif containing GTPase activating protein 1 (IQGAP1), macrophage migration inhibitory factor (MIF), major histocompatibility complex, class II invariant chain (CD74), cystine transporter subunit (xCT), Fas and extracellular matrix (ECM) proteins.\n'
p7120
sg4
(lp7121
(dp7122
g7
I342
sg8
VP46940
p7123
sg10
I6
sg11
VIQGAP1
p7124
sg13
I1
sa(dp7125
g7
I286
sg8
g15
sg10
I4
sg11
VLARG
p7126
sg13
I1
sa(dp7127
g7
I0
sg8
g15
sg10
I9
sg11
VHNF-1Beta
p7128
sg13
I1
sa(dp7129
g7
I507
sg8
g15
sg10
I35
sg11
Vextracellular matrix (ECM) proteins
p7130
sg13
I4
sa(dp7131
g7
I293
sg8
VP46940
p7132
sg10
I47
sg11
VIQ motif containing GTPase activating protein 1
p7133
sg13
I7
sa(dp7134
g7
I226
sg8
g15
sg10
I58
sg11
Vleukemia-associated Rho-guanine nucleotide exchange factor
p7135
sg13
I5
sa(dp7136
g7
I219
sg8
VP01133
p7137
sg10
I4
sg11
VEGFR
p7138
sg13
I1
sa(dp7139
g7
I499
sg8
VP48023
p7140
sg10
I3
sg11
VFas
p7141
sg13
I1
sa(dp7142
g7
I457
sg8
VP04233
p7143
sg10
I4
sg11
VCD74
p7144
sg13
I1
sa(dp7145
g7
I397
sg8
VP18464
p7146
sg10
I58
sg11
Vmajor histocompatibility complex, class II invariant chain
p7147
sg13
I7
sa(dp7148
g7
I464
sg8
g15
sg10
I27
sg11
Vcystine transporter subunit
p7149
sg13
I3
sa(dp7150
g7
I185
sg8
VP01133
p7151
sg10
I32
sg11
Vepidermal growth factor receptor
p7152
sg13
I4
sa(dp7153
g7
I493
sg8
g15
sg10
I3
sg11
VxCT
p7154
sg13
I1
sasg20
(lp7155
(dp7156
g7
I226
sg23
VC0023418
p7157
sg10
I8
sg11
Vleukemia
p7158
sg13
I1
sa(dp7159
g7
I55
sg23
VC0014175
p7160
sg10
I13
sg11
Vendometriosis
p7161
sg13
I1
sa(dp7162
g7
I499
sg23
VC0015923
p7163
sg10
I3
sg11
VFas
p7164
sg13
I1
sasa(dp7165
g2
S'We sought to determine whether oxidative stress or a relative deficit of l-arginine plays a role in reducing cutaneous vasodilation in response to local heating in chronic kidney disease (CKD).\n'
p7166
sg4
(lp7167
sg20
(lp7168
(dp7169
g7
I62
sg23
VC0162429
p7170
sg10
I7
sg11
Vdeficit
p7171
sg13
I1
sa(dp7172
g7
I164
sg23
VC1561643
p7173
sg10
I22
sg11
Vchronic kidney disease
p7174
sg13
I3
sa(dp7175
g7
I188
sg23
VC1561643
p7176
sg10
I3
sg11
VCKD
p7177
sg13
I1
sa(dp7178
g7
I119
sg23
VC0595862
p7179
sg10
I12
sg11
Vvasodilation
p7180
sg13
I1
sa(dp7181
g7
I31
sg23
VC0242606
p7182
sg10
I16
sg11
Voxidative stress
p7183
sg13
I2
sasa(dp7184
g2
S'Eight patients with stage 3-4 CKD and eight age- and sex-matched healthy control (HC) subjects were instrumented with four microdialysis (MD) fibers for the local delivery of 1) Ringers solution (R), 2) 20 mM ascorbic acid (AA), 3) 10 mM l-arginine (l-Arg), and 4) 10 mM N(G)-nitro-l-arginine methyl ester (l-NAME).\n'
p7185
sg4
(lp7186
sg20
(lp7187
sa(dp7188
g2
S'The plateau %CVC(max) in the CKD group was significantly greater at the AA and l-Arg sites compared with R (AA: 89 +/- 2; l-Arg: 90 +/- 1; R: 76 +/- 4; P &lt; 0.05) and did not differ from HC.\n'
p7189
sg4
(lp7190
sg20
(lp7191
sa(dp7192
g2
S'Initial peak %CVC(max) was also significantly attenuated at the R and l-Arg sites in CKD (P &lt; 0.05) but did not differ at the AA site.\n'
p7193
sg4
(lp7194
sg20
(lp7195
sa(dp7196
g2
S'These results suggest that cutaneous microvascular function is impaired in stage 3-4 CKD and that oxidative stress and a deficit of l-arginine play a role in this impairment.\n'
p7197
sg4
(lp7198
sg20
(lp7199
(dp7200
g7
I163
sg23
VC0684336
p7201
sg10
I10
sg11
Vimpairment
p7202
sg13
I1
sa(dp7203
g7
I63
sg23
VC0684336
p7204
sg10
I8
sg11
Vimpaired
p7205
sg13
I1
sa(dp7206
g7
I121
sg23
VC0162429
p7207
sg10
I7
sg11
Vdeficit
p7208
sg13
I1
sa(dp7209
g7
I98
sg23
VC0242606
p7210
sg10
I16
sg11
Voxidative stress
p7211
sg13
I2
sasa(dp7212
g2
S'If true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF.\n'
p7213
sg4
(lp7214
(dp7215
g7
I75
sg8
VP06850
p7216
sg10
I3
sg11
VCRF
p7217
sg13
I1
sa(dp7218
g7
I52
sg8
VP06850
p7219
sg10
I21
sg11
Vchronic renal failure
p7220
sg13
I3
sasg20
(lp7221
(dp7222
g7
I75
sg23
VC0022661
p7223
sg10
I3
sg11
VCRF
p7224
sg13
I1
sa(dp7225
g7
I52
sg23
VC0022661
p7226
sg10
I21
sg11
Vchronic renal failure
p7227
sg13
I3
sa(dp7228
g7
I75
sg23
VC0022661
p7229
sg10
I3
sg11
VCRF
p7230
sg13
I1
sasa(dp7231
g2
S'l-arg, by its cytoprotective effect, maintained the thiol status, thereby preserving the activities of the membrane bound ATPases and preventing proteinuria and subsequent weight loss in EG-treated rats.\n'
p7232
sg4
(lp7233
(dp7234
g7
I122
sg8
VP05026
p7235
sg10
I7
sg11
VATPases
p7236
sg13
I1
sasg20
(lp7237
sa(dp7238
g2
S'As expected, a physiological analgesia is produced by administration of inhibitors, especially kelatorphan and analogues, demonstrating unambiguously the implication of enkephalinase and aminopeptidase M in enkephalin metabolism.\n'
p7239
sg4
(lp7240
(dp7241
g7
I187
sg8
VP15144
p7242
sg10
I16
sg11
Vaminopeptidase M
p7243
sg13
I2
sa(dp7244
g7
I169
sg8
VP08473
p7245
sg10
I13
sg11
Venkephalinase
p7246
sg13
I1
sasg20
(lp7247
(dp7248
g7
I29
sg23
VC0344307
p7249
sg10
I9
sg11
Vanalgesia
p7250
sg13
I1
sasa(dp7251
g2
S'Associated with antigliadin and anti-HSP antibodies, children with autism and patients with autoimmune disease developed anti-dipeptidylpeptidase I (DPP I), anti-dipeptidylpeptidase IV (DPP IV [or CD26]) and anti-aminopeptidase N (CD13) autoantibodies.\n'
p7252
sg4
(lp7253
(dp7254
g7
I32
sg8
g15
sg10
I19
sg11
Vanti-HSP antibodies
p7255
sg13
I2
sa(dp7256
g7
I149
sg8
g15
sg10
I5
sg11
VDPP I
p7257
sg13
I2
sa(dp7258
g7
I121
sg8
g15
sg10
I26
sg11
Vanti-dipeptidylpeptidase I
p7259
sg13
I2
sa(dp7260
g7
I208
sg8
VP15144
p7261
sg10
I21
sg11
Vanti-aminopeptidase N
p7262
sg13
I2
sa(dp7263
g7
I231
sg8
VP15144
p7264
sg10
I4
sg11
VCD13
p7265
sg13
I1
sa(dp7266
g7
I186
sg8
VP27487
p7267
sg10
I6
sg11
VDPP IV
p7268
sg13
I2
sa(dp7269
g7
I157
sg8
VP27487
p7270
sg10
I27
sg11
Vanti-dipeptidylpeptidase IV
p7271
sg13
I2
sasg20
(lp7272
(dp7273
g7
I92
sg23
VC0004364
p7274
sg10
I18
sg11
Vautoimmune disease
p7275
sg13
I2
sa(dp7276
g7
I37
sg23
VC0034152
p7277
sg10
I3
sg11
VHSP
p7278
sg13
I1
sa(dp7279
g7
I67
sg23
VC0004352
p7280
sg10
I6
sg11
Vautism
p7281
sg13
I1
sasa(dp7282
g2
S'We therefore investigated plasma ApN in anorexia nervosa (AN).\n'
p7283
sg4
(lp7284
sg20
(lp7285
(dp7286
g7
I58
sg23
VC0003125
p7287
sg10
I2
sg11
VAN
p7288
sg13
I1
sa(dp7289
g7
I40
sg23
VC0003125
p7290
sg10
I16
sg11
Vanorexia nervosa
p7291
sg13
I2
sasa(dp7292
g2
S'The observed ocular comorbidities included nystagmus (36.7%, 18/49), vitreous opacity (28.6%, 14/49), foveal hypoplasia (20.4%, 10/49), ametropia (12.2%, 6/49), exotropia (12.2%, 6/49), congenital glaucoma (12.2%, 6/49), esotropia (4.1%, 2/49), congenital ptosis (4.1%, 2/49), lens ectopia (4.1%, 2/49), scleral staphyloma (2.0%, 1/49) and pigmentary degeneration of retina (2.0%, 1/49).\n'
p7293
sg4
(lp7294
sg20
(lp7295
(dp7296
g7
I351
sg23
VC0035304
p7297
sg10
I22
sg11
Vdegeneration of retina
p7298
sg13
I3
sa(dp7299
g7
I186
sg23
VC0020302
p7300
sg10
I19
sg11
Vcongenital glaucoma
p7301
sg13
I2
sa(dp7302
g7
I340
sg23
VC0333446
p7303
sg10
I23
sg11
Vpigmentary degeneration
p7304
sg13
I2
sa(dp7305
g7
I245
sg23
VC0266573
p7306
sg10
I17
sg11
Vcongenital ptosis
p7307
sg13
I2
sa(dp7308
g7
I161
sg23
VC0015310
p7309
sg10
I9
sg11
Vexotropia
p7310
sg13
I1
sa(dp7311
g7
I109
sg23
VC0243069
p7312
sg10
I10
sg11
Vhypoplasia
p7313
sg13
I1
sa(dp7314
g7
I221
sg23
VC0014877
p7315
sg10
I9
sg11
Vesotropia
p7316
sg13
I1
sa(dp7317
g7
I136
sg23
VC1527310
p7318
sg10
I9
sg11
Vametropia
p7319
sg13
I1
sa(dp7320
g7
I43
sg23
VC0028738
p7321
sg10
I9
sg11
Vnystagmus
p7322
sg13
I1
sa(dp7323
g7
I78
sg23
VC1265876
p7324
sg10
I7
sg11
Vopacity
p7325
sg13
I1
sa(dp7326
g7
I304
sg23
VC0155359
p7327
sg10
I18
sg11
Vscleral staphyloma
p7328
sg13
I2
sa(dp7329
g7
I282
sg23
VC1562630
p7330
sg10
I7
sg11
Vectopia
p7331
sg13
I1
sasa(dp7332
g2
S'The common eye disorders for which genetic testing is commonly requested are briefly discussed - anophthalmia, microphthalmia, coloboma, anterior segment dysgenesis, corneal dystrophies, cataracts, optic atrophy, congenital glaucoma, congenital amaurosis, retinitis pigmentosa, color blindness, juvenile retinoshisis, retinoblastoma etc.\n'
p7333
sg4
(lp7334
(dp7335
g7
I318
sg8
g15
sg10
I18
sg11
Vretinoblastoma etc
p7336
sg13
I2
sasg20
(lp7337
(dp7338
g7
I97
sg23
VC0003119
p7339
sg10
I12
sg11
Vanophthalmia
p7340
sg13
I1
sa(dp7341
g7
I318
sg23
VC0035335
p7342
sg10
I14
sg11
Vretinoblastoma
p7343
sg13
I1
sa(dp7344
g7
I256
sg23
VC0035334
p7345
sg10
I20
sg11
Vretinitis pigmentosa
p7346
sg13
I2
sa(dp7347
g7
I137
sg23
VC0266525
p7348
sg10
I27
sg11
Vanterior segment dysgenesis
p7349
sg13
I3
sa(dp7350
g7
I245
sg23
VC0376288
p7351
sg10
I9
sg11
Vamaurosis
p7352
sg13
I1
sa(dp7353
g7
I166
sg23
VC0010036
p7354
sg10
I19
sg11
Vcorneal dystrophies
p7355
sg13
I2
sa(dp7356
g7
I187
sg23
VC0521707
p7357
sg10
I9
sg11
Vcataracts
p7358
sg13
I1
sa(dp7359
g7
I198
sg23
VC0029124
p7360
sg10
I13
sg11
Voptic atrophy
p7361
sg13
I2
sa(dp7362
g7
I224
sg23
VC0020302
p7363
sg10
I20
sg11
Vglaucoma, congenital
p7364
sg13
I2
sa(dp7365
g7
I111
sg23
VC0026010
p7366
sg10
I14
sg11
Vmicrophthalmia
p7367
sg13
I1
sa(dp7368
g7
I278
sg23
VC0242225
p7369
sg10
I15
sg11
Vcolor blindness
p7370
sg13
I2
sa(dp7371
g7
I127
sg23
VC0009363
p7372
sg10
I8
sg11
Vcoloboma
p7373
sg13
I1
sa(dp7374
g7
I11
sg23
VC0015397
p7375
sg10
I13
sg11
Veye disorders
p7376
sg13
I2
sasa(dp7377
g2
S'The anatomical causes of blindness include optic nerve disorders in 75 (24.8%) cases, retinal disorders in 55 (18.2%), corneal disorders in 47 (15.6%), lens-related disorders in 39 (12.9%), congenital anomalies in 11 (3.6%), and congenital glaucoma in 20 (6.6%) cases.\n'
p7378
sg4
(lp7379
sg20
(lp7380
(dp7381
g7
I86
sg23
VC0035309
p7382
sg10
I17
sg11
Vretinal disorders
p7383
sg13
I2
sa(dp7384
g7
I190
sg23
VC0000768
p7385
sg10
I20
sg11
Vcongenital anomalies
p7386
sg13
I2
sa(dp7387
g7
I119
sg23
VC0010034
p7388
sg10
I17
sg11
Vcorneal disorders
p7389
sg13
I2
sa(dp7390
g7
I229
sg23
VC0020302
p7391
sg10
I19
sg11
Vcongenital glaucoma
p7392
sg13
I2
sa(dp7393
g7
I25
sg23
VC0456909
p7394
sg10
I9
sg11
Vblindness
p7395
sg13
I1
sa(dp7396
g7
I43
sg23
VC0029132
p7397
sg10
I21
sg11
Voptic nerve disorders
p7398
sg13
I3
sasa(dp7399
g2
S'Among conditions causing blindness, optic atrophy seen in 73 (24.17%) cases was the most common, followed by retinal dystrophy in 44 (14.56%), corneal scarring in 35 (11.59%), cataract in 22 (7.28%), and congenital glaucoma in 20 (6.6%) cases.\n'
p7400
sg4
(lp7401
sg20
(lp7402
(dp7403
g7
I36
sg23
VC0029124
p7404
sg10
I13
sg11
Voptic atrophy
p7405
sg13
I2
sa(dp7406
g7
I151
sg23
VC0008767
p7407
sg10
I8
sg11
Vscarring
p7408
sg13
I1
sa(dp7409
g7
I204
sg23
VC0020302
p7410
sg10
I19
sg11
Vcongenital glaucoma
p7411
sg13
I2
sa(dp7412
g7
I176
sg23
VC0086543
p7413
sg10
I8
sg11
Vcataract
p7414
sg13
I1
sa(dp7415
g7
I109
sg23
VC0854723
p7416
sg10
I17
sg11
Vretinal dystrophy
p7417
sg13
I2
sa(dp7418
g7
I25
sg23
VC0456909
p7419
sg10
I9
sg11
Vblindness
p7420
sg13
I1
sasa(dp7421
g2
S'Other abnormalities included vitreous hemorrhage (n=1), congenital glaucoma (n=2), uveal coloboma (n=2), retinopathy mimicking retinopathy of prematurity (n=2), and cystic fovea (n=3).\n'
p7422
sg4
(lp7423
sg20
(lp7424
(dp7425
g7
I29
sg23
VC0042909
p7426
sg10
I19
sg11
Vvitreous hemorrhage
p7427
sg13
I2
sa(dp7428
g7
I89
sg23
VC0009363
p7429
sg10
I8
sg11
Vcoloboma
p7430
sg13
I1
sa(dp7431
g7
I105
sg23
VC0035309
p7432
sg10
I11
sg11
Vretinopathy
p7433
sg13
I1
sa(dp7434
g7
I56
sg23
VC0020302
p7435
sg10
I19
sg11
Vcongenital glaucoma
p7436
sg13
I2
sa(dp7437
g7
I127
sg23
VC0035344
p7438
sg10
I26
sg11
Vretinopathy of prematurity
p7439
sg13
I3
sasa(dp7440
g2
S'Primary congenital glaucoma (PCG) is isolated, non-syndromic glaucoma that occurs in the first three years of life and is a major cause of childhood blindness.\n'
p7441
sg4
(lp7442
sg20
(lp7443
(dp7444
g7
I19
sg23
VC0017601
p7445
sg10
I8
sg11
Vglaucoma
p7446
sg13
I1
sa(dp7447
g7
I149
sg23
VC0456909
p7448
sg10
I9
sg11
Vblindness
p7449
sg13
I1
sa(dp7450
g7
I0
sg23
VC1533041
p7451
sg10
I27
sg11
VPrimary congenital glaucoma
p7452
sg13
I3
sa(dp7453
g7
I29
sg23
VC1533041
p7454
sg10
I3
sg11
VPCG
p7455
sg13
I1
sasa(dp7456
g2
S'The purpose of the present study is to investigate the association between the polymorphisms in AXIN1 with susceptibility to clear cell renal cell carcinoma (ccRCC).\n'
p7457
sg4
(lp7458
(dp7459
g7
I96
sg8
g15
sg10
I5
sg11
VAXIN1
p7460
sg13
I1
sasg20
(lp7461
(dp7462
g7
I158
sg23
VC0279702
p7463
sg10
I5
sg11
VccRCC
p7464
sg13
I1
sa(dp7465
g7
I125
sg23
VC0279702
p7466
sg10
I31
sg11
Vclear cell renal cell carcinoma
p7467
sg13
I5
sasa(dp7468
g2
S'In both cultured melanoma cell lines and in vivo in melanoma cell-derived tumor xenografts, 1-benzyl-I3C disrupted canonical Wnt/Beta-catenin signaling that resulted in the down regulation of Beta-catenin protein levels with a concomitant increase in levels of the Beta-catenin destruction complex components GSK3Beta and Axin.\n'
p7469
sg4
(lp7470
(dp7471
g7
I192
sg8
VP35222
p7472
sg10
I20
sg11
VBeta-catenin protein
p7473
sg13
I2
sa(dp7474
g7
I129
sg8
VP35222
p7475
sg10
I12
sg11
VBeta-catenin
p7476
sg13
I1
sa(dp7477
g7
I322
sg8
g15
sg10
I4
sg11
VAxin
p7478
sg13
I1
sasg20
(lp7479
(dp7480
g7
I74
sg23
VC0027651
p7481
sg10
I5
sg11
Vtumor
p7482
sg13
I1
sa(dp7483
g7
I17
sg23
VC0025202
p7484
sg10
I8
sg11
Vmelanoma
p7485
sg13
I1
sa(dp7486
g7
I17
sg23
VC0025202
p7487
sg10
I8
sg11
Vmelanoma
p7488
sg13
I1
sasa(dp7489
g2
S'Here, we showed that SKL2001, which has been identified as an activator for Wnt signaling by disrupting the Axin/Beta-Catenin complex, negatively regulates growth of colon cancer spheroids cultured in the 3D condition that simulates tumor microenvironment in vivo.\n'
p7490
sg4
(lp7491
(dp7492
g7
I108
sg8
g15
sg10
I4
sg11
VAxin
p7493
sg13
I1
sasg20
(lp7494
(dp7495
g7
I233
sg23
VC0027651
p7496
sg10
I5
sg11
Vtumor
p7497
sg13
I1
sa(dp7498
g7
I166
sg23
VC0699790
p7499
sg10
I12
sg11
Vcolon cancer
p7500
sg13
I2
sa(dp7501
g7
I208
sg23
VC0012634
p7502
sg10
I9
sg11
Vcondition
p7503
sg13
I1
sasa(dp7504
g2
S"Defective lysosomal function defines many neurodegenerative diseases, such as neuronal ceroid lipofuscinoses (NCL) and Niemann-Pick type C (NPC), and is implicated in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD-TDP) with progranulin (PGRN) deficiency.\n"
p7505
sg4
(lp7506
(dp7507
g7
I140
sg8
g15
sg10
I3
sg11
VNPC
p7508
sg13
I1
sa(dp7509
g7
I119
sg8
g15
sg10
I19
sg11
VNiemann-Pick type C
p7510
sg13
I3
sasg20
(lp7511
(dp7512
g7
I231
sg23
VC0751072
p7513
sg10
I4
sg11
VFTLD
p7514
sg13
I1
sa(dp7515
g7
I167
sg23
VC1521724
p7516
sg10
I19
sg11
VAlzheimer's disease
p7517
sg13
I2
sa(dp7518
g7
I110
sg23
VC0027877
p7519
sg10
I3
sg11
VNCL
p7520
sg13
I1
sa(dp7521
g7
I140
sg23
VC2931822
p7522
sg10
I3
sg11
VNPC
p7523
sg13
I1
sa(dp7524
g7
I188
sg23
VC1521724
p7525
sg10
I2
sg11
VAD
p7526
sg13
I1
sa(dp7527
g7
I196
sg23
VC0751072
p7528
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p7529
sg13
I3
sa(dp7530
g7
I119
sg23
VC2931822
p7531
sg10
I19
sg11
VNiemann-Pick type C
p7532
sg13
I3
sa(dp7533
g7
I78
sg23
VC0027877
p7534
sg10
I30
sg11
Vneuronal ceroid lipofuscinoses
p7535
sg13
I3
sa(dp7536
g7
I42
sg23
VC0524851
p7537
sg10
I26
sg11
Vneurodegenerative diseases
p7538
sg13
I2
sasa(dp7539
g2
S"Moreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.\n"
p7540
sg4
(lp7541
sg20
(lp7542
(dp7543
g7
I117
sg23
VC0677042
p7544
sg10
I9
sg11
Vpathology
p7545
sg13
I1
sa(dp7546
g7
I80
sg23
VC0524851
p7547
sg10
I27
sg11
Vneurodegenerative disorders
p7548
sg13
I2
sa(dp7549
g7
I138
sg23
VC1521724
p7550
sg10
I19
sg11
VAlzheimer's disease
p7551
sg13
I2
sasa(dp7552
g2
S"Together, these critical roles in the CNS suggest that PGRN has the potential to be an important therapeutic target for the treatment of various neurodegenerative disorders, particularly Alzheimer's disease (AD).\n"
p7553
sg4
(lp7554
sg20
(lp7555
(dp7556
g7
I187
sg23
VC1521724
p7557
sg10
I19
sg11
VAlzheimer's disease
p7558
sg13
I2
sa(dp7559
g7
I145
sg23
VC0524851
p7560
sg10
I27
sg11
Vneurodegenerative disorders
p7561
sg13
I2
sa(dp7562
g7
I208
sg23
VC1521724
p7563
sg10
I2
sg11
VAD
p7564
sg13
I1
sasa(dp7565
g2
S"Pathological examination revealed Alzheimer's disease in three cases (all LPA), pathological PSP in two cases (one clinical PSP and one PNFA) and corticobasal degeneration in one case (PNFA).\n"
p7566
sg4
(lp7567
sg20
(lp7568
(dp7569
g7
I93
sg23
VC0038868
p7570
sg10
I3
sg11
VPSP
p7571
sg13
I1
sa(dp7572
g7
I34
sg23
VC1521724
p7573
sg10
I19
sg11
VAlzheimer's disease
p7574
sg13
I2
sa(dp7575
g7
I146
sg23
VC0393570
p7576
sg10
I25
sg11
Vcorticobasal degeneration
p7577
sg13
I2
sa(dp7578
g7
I93
sg23
VC0038868
p7579
sg10
I3
sg11
VPSP
p7580
sg13
I1
sasa(dp7581
g2
S"Granulin mutations were initially found in tau-negative patients, though recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease and corticobasal degeneration.\n"
p7582
sg4
(lp7583
sg20
(lp7584
(dp7585
g7
I182
sg23
VC0677042
p7586
sg10
I9
sg11
Vpathology
p7587
sg13
I1
sa(dp7588
g7
I227
sg23
VC0393570
p7589
sg10
I25
sg11
Vcorticobasal degeneration
p7590
sg13
I2
sa(dp7591
g7
I145
sg23
VC0524851
p7592
sg10
I27
sg11
Vneurodegenerative disorders
p7593
sg13
I2
sa(dp7594
g7
I203
sg23
VC1521724
p7595
sg10
I19
sg11
VAlzheimer's disease
p7596
sg13
I2
sasa(dp7597
g2
S'Inter-individual variation in CCAAT/enhancer binding protein gamma (CEBPG) transcript expression in normal human bronchial epithelial cells (NBEC) is associated with predisposition to lung cancer.\n'
p7598
sg4
(lp7599
(dp7600
g7
I30
sg8
g15
sg10
I36
sg11
VCCAAT/enhancer binding protein gamma
p7601
sg13
I4
sa(dp7602
g7
I68
sg8
VP53567
p7603
sg10
I5
sg11
VCEBPG
p7604
sg13
I1
sasg20
(lp7605
(dp7606
g7
I184
sg23
VC0684249
p7607
sg10
I11
sg11
Vlung cancer
p7608
sg13
I2
sasa(dp7609
g2
S'These data support the hypothesis that genetic variation in linkage disequilibrium with rs2772 influences regulation of CEBPG transcript expression through a trans-effect downstream of RNA polymerase II transcription and confirm that cis-acting genetic variation contributes to inter-individual variation in CEBPG transcript expression in NBEC, which is associated with variation in lung cancer risk.\n'
p7610
sg4
(lp7611
(dp7612
g7
I120
sg8
VP53567
p7613
sg10
I16
sg11
VCEBPG transcript
p7614
sg13
I2
sa(dp7615
g7
I120
sg8
VP53567
p7616
sg10
I16
sg11
VCEBPG transcript
p7617
sg13
I2
sa(dp7618
g7
I185
sg8
VP19388
p7619
sg10
I17
sg11
VRNA polymerase II
p7620
sg13
I3
sasg20
(lp7621
(dp7622
g7
I383
sg23
VC0684249
p7623
sg10
I11
sg11
Vlung cancer
p7624
sg13
I2
sa(dp7625
g7
I234
sg23
VC0007099
p7626
sg10
I3
sg11
Vcis
p7627
sg13
I1
sa(dp7628
g7
I68
sg23
VC0394006
p7629
sg10
I14
sg11
Vdisequilibrium
p7630
sg13
I1
sasa(dp7631
g2
S'In an effort to develop a biomarker for lung cancer risk, we evaluated the transcript expressions of 14 antioxidant, DNA repair, and transcription factor genes in normal bronchial epithelial cells (HUGO names CAT, CEBPG, E2F1, ERCC4, ERCC5, GPX1, GPX3, GSTM3, GSTP1, GSTT1, GSTZ1, MGST1, SOD1, and XRCC1).\n'
p7632
sg4
(lp7633
(dp7634
g7
I227
sg8
g15
sg10
I5
sg11
VERCC4
p7635
sg13
I1
sa(dp7636
g7
I209
sg8
VP04040
p7637
sg10
I3
sg11
VCAT
p7638
sg13
I1
sa(dp7639
g7
I234
sg8
VP28715
p7640
sg10
I5
sg11
VERCC5
p7641
sg13
I1
sa(dp7642
g7
I274
sg8
g15
sg10
I5
sg11
VGSTZ1
p7643
sg13
I1
sa(dp7644
g7
I214
sg8
VP53567
p7645
sg10
I5
sg11
VCEBPG
p7646
sg13
I1
sa(dp7647
g7
I221
sg8
g15
sg10
I4
sg11
VE2F1
p7648
sg13
I1
sa(dp7649
g7
I267
sg8
VP30711
p7650
sg10
I5
sg11
VGSTT1
p7651
sg13
I1
sa(dp7652
g7
I260
sg8
VP09211
p7653
sg10
I5
sg11
VGSTP1
p7654
sg13
I1
sa(dp7655
g7
I288
sg8
VP00441
p7656
sg10
I4
sg11
VSOD1
p7657
sg13
I1
sa(dp7658
g7
I298
sg8
VP18887
p7659
sg10
I5
sg11
VXRCC1
p7660
sg13
I1
sa(dp7661
g7
I253
sg8
VP21266
p7662
sg10
I5
sg11
VGSTM3
p7663
sg13
I1
sa(dp7664
g7
I281
sg8
VP10620
p7665
sg10
I5
sg11
VMGST1
p7666
sg13
I1
sa(dp7667
g7
I247
sg8
VP22352
p7668
sg10
I4
sg11
VGPX3
p7669
sg13
I1
sa(dp7670
g7
I241
sg8
VP07203
p7671
sg10
I4
sg11
VGPX1
p7672
sg13
I1
sasg20
(lp7673
(dp7674
g7
I40
sg23
VC0684249
p7675
sg10
I11
sg11
Vlung cancer
p7676
sg13
I2
sasa(dp7677
g2
S"We sought to review English language research articles examining the presence, clinical significance, and/or pathophysiology of MM in Parkinson's disease (PD), corticobasal syndrome (CBS), essential tremor (ET), focal hand dystonia, Creutzfeldt-Jakob's disease (CJD), and Huntington's disease.\n"
p7678
sg4
(lp7679
sg20
(lp7680
(dp7681
g7
I155
sg23
VC0030567
p7682
sg10
I2
sg11
VPD
p7683
sg13
I1
sa(dp7684
g7
I262
sg23
VC0022336
p7685
sg10
I3
sg11
VCJD
p7686
sg13
I1
sa(dp7687
g7
I207
sg23
VC0270736
p7688
sg10
I2
sg11
VET
p7689
sg13
I1
sa(dp7690
g7
I189
sg23
VC0270736
p7691
sg10
I16
sg11
Vessential tremor
p7692
sg13
I2
sa(dp7693
g7
I272
sg23
VC0020179
p7694
sg10
I20
sg11
VHuntington's disease
p7695
sg13
I2
sa(dp7696
g7
I173
sg23
VC0039082
p7697
sg10
I8
sg11
Vsyndrome
p7698
sg13
I1
sa(dp7699
g7
I212
sg23
VC3267192
p7700
sg10
I19
sg11
Vfocal hand dystonia
p7701
sg13
I3
sa(dp7702
g7
I134
sg23
VC0030567
p7703
sg10
I19
sg11
VParkinson's disease
p7704
sg13
I2
sa(dp7705
g7
I233
sg23
VC0022336
p7706
sg10
I27
sg11
VCreutzfeldt-Jakob's disease
p7707
sg13
I2
sasa(dp7708
g2
S'We report a patient that presented with the corticobasal syndrome (CBS), including progressive dementia, asymmetric parkinsonism associated with constructional and ideomotor apraxia, action myoclonus and focal hand dystonia.\n'
p7709
sg4
(lp7710
sg20
(lp7711
(dp7712
g7
I83
sg23
VC0743039
p7713
sg10
I20
sg11
Vprogressive dementia
p7714
sg13
I2
sa(dp7715
g7
I204
sg23
VC3267192
p7716
sg10
I19
sg11
Vfocal hand dystonia
p7717
sg13
I3
sa(dp7718
g7
I116
sg23
VC0242422
p7719
sg10
I12
sg11
Vparkinsonism
p7720
sg13
I1
sa(dp7721
g7
I183
sg23
VC0751354
p7722
sg10
I16
sg11
Vaction myoclonus
p7723
sg13
I2
sa(dp7724
g7
I164
sg23
VC0234523
p7725
sg10
I17
sg11
Videomotor apraxia
p7726
sg13
I2
sa(dp7727
g7
I57
sg23
VC0039082
p7728
sg10
I8
sg11
Vsyndrome
p7729
sg13
I1
sasa(dp7730
g2
S'Fifteen rearrangements detected in Sezary syndrome patients and SeAx resulted in an expression of new fusion transcripts, nine of them were in frame (EHD1-CAPN12, TMEM66-BAIAP2, MBD4-PTPRC, PTPRC-CPN2, MYB-MBNL1, TFG-GPR128, MAP4K3-FIGLA, DCP1A-CCL27, MBNL1-KIAA2018) and five resulted in ectopic expression of fragments of genes not expressed in normal T-cells (BAIAP2, CPN2, GPR128, CAPN12, FIGLA).\n'
p7731
sg4
(lp7732
(dp7733
g7
I150
sg8
g15
sg10
I4
sg11
VEHD1
p7734
sg13
I1
sa(dp7735
g7
I163
sg8
g15
sg10
I6
sg11
VTMEM66
p7736
sg13
I1
sa(dp7737
g7
I190
sg8
VP08575
p7738
sg10
I10
sg11
VPTPRC-CPN2
p7739
sg13
I1
sa(dp7740
g7
I232
sg8
g15
sg10
I5
sg11
VFIGLA
p7741
sg13
I1
sa(dp7742
g7
I217
sg8
g15
sg10
I6
sg11
VGPR128
p7743
sg13
I1
sa(dp7744
g7
I155
sg8
g15
sg10
I6
sg11
VCAPN12
p7745
sg13
I1
sa(dp7746
g7
I252
sg8
g15
sg10
I14
sg11
VMBNL1-KIAA2018
p7747
sg13
I1
sa(dp7748
g7
I217
sg8
g15
sg10
I6
sg11
VGPR128
p7749
sg13
I1
sa(dp7750
g7
I178
sg8
g15
sg10
I4
sg11
VMBD4
p7751
sg13
I1
sa(dp7752
g7
I232
sg8
g15
sg10
I5
sg11
VFIGLA
p7753
sg13
I1
sa(dp7754
g7
I155
sg8
g15
sg10
I6
sg11
VCAPN12
p7755
sg13
I1
sa(dp7756
g7
I225
sg8
g15
sg10
I6
sg11
VMAP4K3
p7757
sg13
I1
sa(dp7758
g7
I206
sg8
g15
sg10
I5
sg11
VMBNL1
p7759
sg13
I1
sa(dp7760
g7
I170
sg8
g15
sg10
I6
sg11
VBAIAP2
p7761
sg13
I1
sa(dp7762
g7
I213
sg8
g15
sg10
I3
sg11
VTFG
p7763
sg13
I1
sa(dp7764
g7
I170
sg8
g15
sg10
I6
sg11
VBAIAP2
p7765
sg13
I1
sa(dp7766
g7
I196
sg8
VP15538
p7767
sg10
I4
sg11
VCPN2
p7768
sg13
I1
sa(dp7769
g7
I202
sg8
VP10243
p7770
sg10
I3
sg11
VMYB
p7771
sg13
I1
sa(dp7772
g7
I239
sg8
g15
sg10
I5
sg11
VDCP1A
p7773
sg13
I1
sa(dp7774
g7
I245
sg8
g15
sg10
I5
sg11
VCCL27
p7775
sg13
I1
sa(dp7776
g7
I183
sg8
VP08575
p7777
sg10
I5
sg11
VPTPRC
p7778
sg13
I1
sasg20
(lp7779
(dp7780
g7
I35
sg23
VC0036920
p7781
sg10
I15
sg11
VSezary syndrome
p7782
sg13
I2
sasa(dp7783
g2
S'In addition, we found eleven potential cancer-related genes with mutations (EZH1, SPOP, NF1, TCF12, IGF2BP3, KMT2C, CNOT1, BRIP1, KDM5C, STAG2 and MAP4K3) that have not been reported in thyroid follicular tumors.\n'
p7784
sg4
(lp7785
(dp7786
g7
I123
sg8
g15
sg10
I5
sg11
VBRIP1
p7787
sg13
I1
sa(dp7788
g7
I82
sg8
g15
sg10
I4
sg11
VSPOP
p7789
sg13
I1
sa(dp7790
g7
I137
sg8
g15
sg10
I5
sg11
VSTAG2
p7791
sg13
I1
sa(dp7792
g7
I109
sg8
g15
sg10
I5
sg11
VKMT2C
p7793
sg13
I1
sa(dp7794
g7
I130
sg8
VP41229
p7795
sg10
I5
sg11
VKDM5C
p7796
sg13
I1
sa(dp7797
g7
I88
sg8
VP21359
p7798
sg10
I3
sg11
VNF1
p7799
sg13
I1
sa(dp7800
g7
I93
sg8
g15
sg10
I5
sg11
VTCF12
p7801
sg13
I1
sa(dp7802
g7
I76
sg8
g15
sg10
I4
sg11
VEZH1
p7803
sg13
I1
sa(dp7804
g7
I147
sg8
g15
sg10
I6
sg11
VMAP4K3
p7805
sg13
I1
sa(dp7806
g7
I100
sg8
g15
sg10
I7
sg11
VIGF2BP3
p7807
sg13
I1
sasg20
(lp7808
(dp7809
g7
I194
sg23
VC0474808
p7810
sg10
I17
sg11
Vfollicular tumors
p7811
sg13
I2
sa(dp7812
g7
I39
sg23
VC0006826
p7813
sg10
I6
sg11
Vcancer
p7814
sg13
I1
sa(dp7815
g7
I88
sg23
VC0027831
p7816
sg10
I3
sg11
VNF1
p7817
sg13
I1
sasa(dp7818
g2
S'Since GLK (also named MAP4K3) induces activation of NF-KB, which contributes to tumor progression, we investigated the role of GLK in NSCLC.\n'
p7819
sg4
(lp7820
(dp7821
g7
I6
sg8
VP35557
p7822
sg10
I3
sg11
VGLK
p7823
sg13
I1
sa(dp7824
g7
I22
sg8
g15
sg10
I6
sg11
VMAP4K3
p7825
sg13
I1
sa(dp7826
g7
I6
sg8
VP35557
p7827
sg10
I3
sg11
VGLK
p7828
sg13
I1
sasg20
(lp7829
(dp7830
g7
I80
sg23
VC0178874
p7831
sg10
I17
sg11
Vtumor progression
p7832
sg13
I2
sa(dp7833
g7
I134
sg23
VC0007131
p7834
sg10
I5
sg11
VNSCLC
p7835
sg13
I1
sasa(dp7836
g2
S'GLK protein levels of 190 samples from pulmonary tissue arrays and 58 pulmonary resection samples from stage I to stage III NSCLC patients were studied using immunohistochemistry or immunoblotting.\n'
p7837
sg4
(lp7838
(dp7839
g7
I0
sg8
VP35557
p7840
sg10
I3
sg11
VGLK
p7841
sg13
I1
sasg20
(lp7842
(dp7843
g7
I114
sg23
VC0278506
p7844
sg10
I15
sg11
Vstage III NSCLC
p7845
sg13
I3
sasa(dp7846
g2
S'High levels of GLK proteins were detected in pulmonary tissues from NSCLC patients.\n'
p7847
sg4
(lp7848
(dp7849
g7
I15
sg8
VP35557
p7850
sg10
I12
sg11
VGLK proteins
p7851
sg13
I2
sasg20
(lp7852
(dp7853
g7
I68
sg23
VC0007131
p7854
sg10
I5
sg11
VNSCLC
p7855
sg13
I1
sasa(dp7856
g2
S'Elevated GLK protein levels were correlated with increased recurrence risks and poor recurrence-free survival rates in NSCLC patients after adjusting for pathologic stage, smoking status, alcohol status, and EGFR levels.\n'
p7857
sg4
(lp7858
(dp7859
g7
I9
sg8
VP35557
p7860
sg10
I11
sg11
VGLK protein
p7861
sg13
I2
sasg20
(lp7862
(dp7863
g7
I59
sg23
VC1458156
p7864
sg10
I10
sg11
Vrecurrence
p7865
sg13
I1
sa(dp7866
g7
I59
sg23
VC1458156
p7867
sg10
I10
sg11
Vrecurrence
p7868
sg13
I1
sa(dp7869
g7
I119
sg23
VC0007131
p7870
sg10
I5
sg11
VNSCLC
p7871
sg13
I1
sasa(dp7872
g2
S'Thus, GLK is a novel prognostic biomarker for NSCLC recurrence.\n'
p7873
sg4
(lp7874
(dp7875
g7
I6
sg8
VP35557
p7876
sg10
I3
sg11
VGLK
p7877
sg13
I1
sasg20
(lp7878
(dp7879
g7
I46
sg23
VC0007131
p7880
sg10
I5
sg11
VNSCLC
p7881
sg13
I1
sa(dp7882
g7
I52
sg23
VC1458156
p7883
sg10
I10
sg11
Vrecurrence
p7884
sg13
I1
sasa(dp7885
g2
S'RNA fusion-based CISs were identified corresponding to both DNA-based CISs (Cdkn2a, Mycl1, Nf2, Pten, Sema6d, and Rere) and additional regions strongly associated with cancer that were not observed by LM-PCR (Myc, Akt1, Pth, Csf1r, Fgfr2, Wisp1, Map3k5, and Map4k3).\n'
p7886
sg4
(lp7887
(dp7888
g7
I84
sg8
VP12524
p7889
sg10
I3
sg11
VMyc
p7890
sg13
I1
sa(dp7891
g7
I258
sg8
g15
sg10
I6
sg11
VMap4k3
p7892
sg13
I1
sa(dp7893
g7
I84
sg8
VP12524
p7894
sg10
I5
sg11
VMycl1
p7895
sg13
I1
sa(dp7896
g7
I96
sg8
VP60484
p7897
sg10
I4
sg11
VPten
p7898
sg13
I1
sa(dp7899
g7
I225
sg8
VP09619
p7900
sg10
I5
sg11
VCsf1r
p7901
sg13
I1
sa(dp7902
g7
I220
sg8
VP01270
p7903
sg10
I3
sg11
VPth
p7904
sg13
I1
sa(dp7905
g7
I76
sg8
VP42771
p7906
sg10
I6
sg11
VCdkn2a
p7907
sg13
I1
sa(dp7908
g7
I239
sg8
g15
sg10
I5
sg11
VWisp1
p7909
sg13
I1
sa(dp7910
g7
I17
sg8
g15
sg10
I4
sg11
VCISs
p7911
sg13
I1
sa(dp7912
g7
I214
sg8
VP31749
p7913
sg10
I4
sg11
VAkt1
p7914
sg13
I1
sa(dp7915
g7
I246
sg8
g15
sg10
I6
sg11
VMap3k5
p7916
sg13
I1
sasg20
(lp7917
(dp7918
g7
I168
sg23
VC0006826
p7919
sg10
I6
sg11
Vcancer
p7920
sg13
I1
sa(dp7921
g7
I91
sg23
VC0027832
p7922
sg10
I3
sg11
VNf2
p7923
sg13
I1
sasa(dp7924
g2
S'Computationally, PTPRF, PRKAR2B, MAP4K3, and RICTOR were calculated as highly drug-targetable genes for breast cancer.\n'
p7925
sg4
(lp7926
(dp7927
g7
I24
sg8
VP31323
p7928
sg10
I7
sg11
VPRKAR2B
p7929
sg13
I1
sa(dp7930
g7
I33
sg8
g15
sg10
I6
sg11
VMAP4K3
p7931
sg13
I1
sa(dp7932
g7
I17
sg8
VP10586
p7933
sg10
I5
sg11
VPTPRF
p7934
sg13
I1
sa(dp7935
g7
I45
sg8
g15
sg10
I6
sg11
VRICTOR
p7936
sg13
I1
sasg20
(lp7937
(dp7938
g7
I104
sg23
VC0678222
p7939
sg10
I13
sg11
Vbreast cancer
p7940
sg13
I2
sasa(dp7941
g2
S'In the GeparTrio FFPE training cohort, a significant linear correlation between TMSB15A expression and pCR was apparent in triple-negative breast cancer (TNBC) (n=61, P=0.040).\n'
p7942
sg4
(lp7943
(dp7944
g7
I80
sg8
g15
sg10
I7
sg11
VTMSB15A
p7945
sg13
I1
sasg20
(lp7946
(dp7947
g7
I139
sg23
VC0678222
p7948
sg10
I13
sg11
Vbreast cancer
p7949
sg13
I2
sasa(dp7950
g2
S'In normal human prostate and prostate cancer tissues, TMSB15A was the predominant isoform expressed.\n'
p7951
sg4
(lp7952
sg20
(lp7953
(dp7954
g7
I29
sg23
VC0600139
p7955
sg10
I15
sg11
Vprostate cancer
p7956
sg13
I2
sasa(dp7957
g2
S'In contrast, normal colon and colon cancer tissue expressed predominantly TMSB15B.\n'
p7958
sg4
(lp7959
(dp7960
g7
I74
sg8
g15
sg10
I7
sg11
VTMSB15B
p7961
sg13
I1
sasg20
(lp7962
(dp7963
g7
I30
sg23
VC0699790
p7964
sg10
I12
sg11
Vcolon cancer
p7965
sg13
I2
sasa(dp7966
g2
S'Treatment of MCF-7 breast cancer cells with transforming growth factor beta 1 repressed TMSB15A expression but had no effect on TMSB15B.\n'
p7967
sg4
(lp7968
(dp7969
g7
I88
sg8
g15
sg10
I7
sg11
VTMSB15A
p7970
sg13
I1
sa(dp7971
g7
I128
sg8
g15
sg10
I7
sg11
VTMSB15B
p7972
sg13
I1
sa(dp7973
g7
I44
sg8
VP01137
p7974
sg10
I33
sg11
Vtransforming growth factor beta 1
p7975
sg13
I5
sasg20
(lp7976
(dp7977
g7
I19
sg23
VC0678222
p7978
sg10
I13
sg11
Vbreast cancer
p7979
sg13
I2
sasa(dp7980
g2
S'siRNA specific to the TMSB15B isoform suppressed cell migration of prostate cancer cells to epidermal growth factor, suggesting a functional role for this second isoform.\n'
p7981
sg4
(lp7982
(dp7983
g7
I92
sg8
VP01133
p7984
sg10
I23
sg11
Vepidermal growth factor
p7985
sg13
I3
sasg20
(lp7986
(dp7987
g7
I67
sg23
VC0600139
p7988
sg10
I15
sg11
Vprostate cancer
p7989
sg13
I2
sasa(dp7990
g2
S'We showed earlier that human beta-thymosin 15 (Tb15) is up-regulated in prostate cancer, confirming studies from others that propagated Tb15 as a prostate cancer biomarker.\n'
p7991
sg4
(lp7992
(dp7993
g7
I18
sg8
g15
sg10
I27
sg11
Vthat human beta-thymosin 15
p7994
sg13
I4
sa(dp7995
g7
I47
sg8
g15
sg10
I4
sg11
VTb15
p7996
sg13
I1
sa(dp7997
g7
I47
sg8
g15
sg10
I4
sg11
VTb15
p7998
sg13
I1
sasg20
(lp7999
(dp8000
g7
I72
sg23
VC0600139
p8001
sg10
I15
sg11
Vprostate cancer
p8002
sg13
I2
sa(dp8003
g7
I72
sg23
VC0600139
p8004
sg10
I15
sg11
Vprostate cancer
p8005
sg13
I2
sasa(dp8006
g2
S'Tb15r is present also in mouse prostate cancer cell lines.\n'
p8007
sg4
(lp8008
sg20
(lp8009
(dp8010
g7
I31
sg23
VC0600139
p8011
sg10
I15
sg11
Vprostate cancer
p8012
sg13
I2
sasa(dp8013
g2
S'In those patients with isolated adenopathy the following diagnoses were reached; sarcoidosis 23, TB 15, lymphoma 4, carcinoma 4, no diagnosis 1.\n'
p8014
sg4
(lp8015
sg20
(lp8016
(dp8017
g7
I81
sg23
VC0036202
p8018
sg10
I11
sg11
Vsarcoidosis
p8019
sg13
I1
sa(dp8020
g7
I116
sg23
VC0007097
p8021
sg10
I9
sg11
Vcarcinoma
p8022
sg13
I1
sa(dp8023
g7
I104
sg23
VC0024299
p8024
sg10
I8
sg11
Vlymphoma
p8025
sg13
I1
sasa(dp8026
g2
S'However, in this report we provide evidence that TbNB, initially identified in human neuroblastoma, is the only Tb isoform upregulated in human prostate cancer and that the Tb15 sequence is not present herein.\n'
p8027
sg4
(lp8028
(dp8029
g7
I49
sg8
g15
sg10
I4
sg11
VTbNB
p8030
sg13
I1
sa(dp8031
g7
I173
sg8
g15
sg10
I13
sg11
VTb15 sequence
p8032
sg13
I2
sasg20
(lp8033
(dp8034
g7
I144
sg23
VC0600139
p8035
sg10
I15
sg11
Vprostate cancer
p8036
sg13
I2
sa(dp8037
g7
I85
sg23
VC0027819
p8038
sg10
I13
sg11
Vneuroblastoma
p8039
sg13
I1
sasa(dp8040
g2
S'Human NB thymosin beta is a beta-thymosin originally found in neuroblastoma.\n'
p8041
sg4
(lp8042
(dp8043
g7
I0
sg8
VP20962
p8044
sg10
I22
sg11
VHuman NB thymosin beta
p8045
sg13
I4
sa(dp8046
g7
I28
sg8
VP20962
p8047
sg10
I13
sg11
Vbeta-thymosin
p8048
sg13
I1
sasg20
(lp8049
(dp8050
g7
I62
sg23
VC0027819
p8051
sg10
I13
sg11
Vneuroblastoma
p8052
sg13
I1
sasa(dp8053
g2
S'Our studies provide the first evidence that Upk1b is directly associated with the development of congenital anomalies of the urinary tract (CAKUT), spontaneous age-dependent hydronephrosis, and dysplastic urothelia.\n'
p8054
sg4
(lp8055
(dp8056
g7
I44
sg8
g15
sg10
I5
sg11
VUpk1b
p8057
sg13
I1
sasg20
(lp8058
(dp8059
g7
I97
sg23
VC0000768
p8060
sg10
I20
sg11
Vcongenital anomalies
p8061
sg13
I2
sa(dp8062
g7
I140
sg23
VC1968949
p8063
sg10
I5
sg11
VCAKUT
p8064
sg13
I1
sa(dp8065
g7
I194
sg23
VC0334044
p8066
sg10
I10
sg11
Vdysplastic
p8067
sg13
I1
sa(dp8068
g7
I174
sg23
VC0020295
p8069
sg10
I14
sg11
Vhydronephrosis
p8070
sg13
I1
sasa(dp8071
g2
S'Upk1b(RFP/RFP) mice developed age-dependent progressive hydronephrosis.\n'
p8072
sg4
(lp8073
(dp8074
g7
I0
sg8
g15
sg10
I5
sg11
VUpk1b
p8075
sg13
I1
sa(dp8076
g7
I6
sg8
VP25090
p8077
sg10
I3
sg11
VRFP
p8078
sg13
I1
sa(dp8079
g7
I6
sg8
VP25090
p8080
sg10
I3
sg11
VRFP
p8081
sg13
I1
sasg20
(lp8082
(dp8083
g7
I56
sg23
VC0020295
p8084
sg10
I14
sg11
Vhydronephrosis
p8085
sg13
I1
sasa(dp8086
g2
S"The aim of the present study was to investigate the role of serotonin (5-hydroxytryptamine) in the rostral ventromedial medulla (RVM) and spinal cord in pain sensory abnormalities in a 6-hydroxydopamine-treated rat model of Parkinson's disease.\n"
p8087
sg4
(lp8088
sg20
(lp8089
(dp8090
g7
I145
sg23
VC0035334
p8091
sg10
I4
sg11
Vcord
p8092
sg13
I1
sa(dp8093
g7
I224
sg23
VC0030567
p8094
sg10
I19
sg11
VParkinson's disease
p8095
sg13
I2
sasa(dp8096
g2
S"Conclusions These results suggest that the decreased 5-hydroxytryptamine contents in the rostral ventromedial medulla and spinal dorsal horn may be involved in hyperalgesia in the 6-hydroxydopamine-induced rat model of Parkinson's disease.\n"
p8097
sg4
(lp8098
sg20
(lp8099
(dp8100
g7
I219
sg23
VC0030567
p8101
sg10
I19
sg11
VParkinson's disease
p8102
sg13
I2
sa(dp8103
g7
I160
sg23
VC0020429
p8104
sg10
I12
sg11
Vhyperalgesia
p8105
sg13
I1
sasa(dp8106
g2
S"The role of serotonin7 (5-HT7) receptors in the regulation of depression is poorly understood, particularly in Parkinson's disease-associated depression.\n"
p8107
sg4
(lp8108
(dp8109
g7
I12
sg8
VP34969
p8110
sg10
I28
sg11
Vserotonin7 (5-HT7) receptors
p8111
sg13
I3
sasg20
(lp8112
(dp8113
g7
I62
sg23
VC0011581
p8114
sg10
I10
sg11
Vdepression
p8115
sg13
I1
sa(dp8116
g7
I111
sg23
VC0030567
p8117
sg10
I19
sg11
VParkinson's disease
p8118
sg13
I2
sa(dp8119
g7
I62
sg23
VC0011581
p8120
sg10
I10
sg11
Vdepression
p8121
sg13
I1
sasa(dp8122
g2
S'The expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4).\n'
p8123
sg4
(lp8124
(dp8125
g7
I75
sg8
g15
sg10
I7
sg11
VmiR-27a
p8126
sg13
I1
sa(dp8127
g7
I148
sg8
g15
sg10
I7
sg11
VmiR-221
p8128
sg13
I1
sa(dp8129
g7
I67
sg8
g15
sg10
I6
sg11
VmiR-21
p8130
sg13
I1
sa(dp8131
g7
I58
sg8
g15
sg10
I7
sg11
VmiR-20a
p8132
sg13
I1
sa(dp8133
g7
I139
sg8
g15
sg10
I7
sg11
VmiR-155
p8134
sg13
I1
sa(dp8135
g7
I102
sg8
g15
sg10
I7
sg11
VmiR-29c
p8136
sg13
I1
sa(dp8137
g7
I93
sg8
g15
sg10
I7
sg11
VmiR-29a
p8138
sg13
I1
sa(dp8139
g7
I111
sg8
g15
sg10
I7
sg11
VmiR-92a
p8140
sg13
I1
sa(dp8141
g7
I157
sg8
g15
sg10
I7
sg11
VmiR-222
p8142
sg13
I1
sa(dp8143
g7
I129
sg8
g15
sg10
I8
sg11
VmiR-146a
p8144
sg13
I1
sa(dp8145
g7
I84
sg8
g15
sg10
I7
sg11
VmiR-27b
p8146
sg13
I1
sa(dp8147
g7
I120
sg8
g15
sg10
I7
sg11
VmiR-122
p8148
sg13
I1
sasg20
(lp8149
(dp8150
g7
I21
sg23
VC0016059
p8151
sg10
I8
sg11
Vfibrosis
p8152
sg13
I1
sa(dp8153
g7
I253
sg23
VC0151517
p8154
sg10
I3
sg11
VCHB
p8155
sg13
I1
sa(dp8156
g7
I21
sg23
VC0016059
p8157
sg10
I8
sg11
Vfibrosis
p8158
sg13
I1
sa(dp8159
g7
I316
sg23
VC0023890
p8160
sg10
I9
sg11
Vcirrhosis
p8161
sg13
I1
sasa(dp8162
g2
S'For this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples.\n'
p8163
sg4
(lp8164
(dp8165
g7
I60
sg8
g15
sg10
I10
sg11
VmiR-92a-3p
p8166
sg13
I1
sasg20
(lp8167
(dp8168
g7
I359
sg23
VC2239176
p8169
sg10
I3
sg11
VHCC
p8170
sg13
I1
sa(dp8171
g7
I319
sg23
VC0019163
p8172
sg10
I3
sg11
VHBV
p8173
sg13
I1
sa(dp8174
g7
I319
sg23
VC0019163
p8175
sg10
I3
sg11
VHBV
p8176
sg13
I1
sa(dp8177
g7
I298
sg23
VC0524909
p8178
sg10
I19
sg11
Vchronic hepatitis B
p8179
sg13
I3
sa(dp8180
g7
I332
sg23
VC0023890
p8181
sg10
I9
sg11
Vcirrhosis
p8182
sg13
I1
sasa(dp8183
g2
S'Consistently, Bhlhb2 expression was significantly higher in PFC of ADHD model SHR than control.\n'
p8184
sg4
(lp8185
(dp8186
g7
I67
sg8
g15
sg10
I14
sg11
VADHD model SHR
p8187
sg13
I3
sa(dp8188
g7
I14
sg8
g15
sg10
I6
sg11
VBhlhb2
p8189
sg13
I1
sa(dp8190
g7
I60
sg8
VP27918
p8191
sg10
I3
sg11
VPFC
p8192
sg13
I1
sasg20
(lp8193
(dp8194
g7
I67
sg23
VC1263846
p8195
sg10
I4
sg11
VADHD
p8196
sg13
I1
sasa(dp8197
g2
S'We examined ANG expression in WTs, human fetal kidney (FK) and childhood kidney (NK) samples and studied its relationship with microvascular density (MVD) and with three other hypoxia-induced angiogenic factors: lactate dehydrogenase A (LDHA), vascular endothelial growth factor (VEGFA) and BHLHE40 (basic helix-loop-helix transcription factor E40).\n'
p8198
sg4
(lp8199
(dp8200
g7
I244
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p8201
sg13
I4
sa(dp8202
g7
I291
sg8
g15
sg10
I7
sg11
VBHLHE40
p8203
sg13
I1
sa(dp8204
g7
I280
sg8
g15
sg10
I5
sg11
VVEGFA
p8205
sg13
I1
sa(dp8206
g7
I212
sg8
VP49366
p8207
sg10
I23
sg11
Vlactate dehydrogenase A
p8208
sg13
I3
sa(dp8209
g7
I237
sg8
VP00338
p8210
sg10
I4
sg11
VLDHA
p8211
sg13
I1
sa(dp8212
g7
I300
sg8
g15
sg10
I47
sg11
Vbasic helix-loop-helix transcription factor E40
p8213
sg13
I5
sasg20
(lp8214
(dp8215
g7
I176
sg23
VC0242184
p8216
sg10
I7
sg11
Vhypoxia
p8217
sg13
I1
sa(dp8218
g7
I30
sg23
VC1839736
p8219
sg10
I3
sg11
VWTs
p8220
sg13
I1
sasa(dp8221
g2
S'ANG, CD31, VEGFA and BHLHE40 mRNA levels were significantly lower in 15 WTs compared with matched-paired NKs.\n'
p8222
sg4
(lp8223
(dp8224
g7
I0
sg8
VP03950
p8225
sg10
I3
sg11
VANG
p8226
sg13
I1
sa(dp8227
g7
I5
sg8
VP69905
p8228
sg10
I4
sg11
VCD31
p8229
sg13
I1
sa(dp8230
g7
I21
sg8
g15
sg10
I12
sg11
VBHLHE40 mRNA
p8231
sg13
I2
sasg20
(lp8232
(dp8233
g7
I72
sg23
VC1839736
p8234
sg10
I3
sg11
VWTs
p8235
sg13
I1
sasa(dp8236
g2
S'Mutations in the SLC5A5 gene encoding NIS that result in a non-functional protein lead to congenital hypothyroidism due to I- transport defect (ITD).\n'
p8237
sg4
(lp8238
(dp8239
g7
I17
sg8
g15
sg10
I24
sg11
VSLC5A5 gene encoding NIS
p8240
sg13
I4
sasg20
(lp8241
(dp8242
g7
I90
sg23
VC0342200
p8243
sg10
I25
sg11
Vcongenital hypothyroidism
p8244
sg13
I2
sasa(dp8245
g2
S'Thyroid concentrates radioactive iodine by sodium-iodide symporter; this is used for treating hyperthyroidism and thyroid cancer.\n'
p8246
sg4
(lp8247
sg20
(lp8248
(dp8249
g7
I94
sg23
VC0020550
p8250
sg10
I15
sg11
Vhyperthyroidism
p8251
sg13
I1
sa(dp8252
g7
I114
sg23
VC0007115
p8253
sg10
I14
sg11
Vthyroid cancer
p8254
sg13
I2
sasa(dp8255
g2
S'In this study, we investigated the relationship between iodine content and sodium iodide symporter (NIS) expression by using the clinical specimens from patients with nodular goiter and explored the pathogenesis triggered by iodine deficiency in nodular goiter.\n'
p8256
sg4
(lp8257
(dp8258
g7
I100
sg8
g15
sg10
I3
sg11
VNIS
p8259
sg13
I1
sa(dp8260
g7
I75
sg8
g15
sg10
I23
sg11
Vsodium iodide symporter
p8261
sg13
I3
sasg20
(lp8262
(dp8263
g7
I167
sg23
VC1318500
p8264
sg10
I14
sg11
Vnodular goiter
p8265
sg13
I2
sa(dp8266
g7
I167
sg23
VC1318500
p8267
sg10
I14
sg11
Vnodular goiter
p8268
sg13
I2
sa(dp8269
g7
I225
sg23
VC0342199
p8270
sg10
I17
sg11
Viodine deficiency
p8271
sg13
I2
sa(dp8272
g7
I199
sg23
VC0699748
p8273
sg10
I12
sg11
Vpathogenesis
p8274
sg13
I1
sasa(dp8275
g2
S'The same technique was used for the assays of the hepatic levels of FGF-21, silent information regulator (SIRT1), malondialdehyde (MDA),IL-10, tumor necrosis factor-Alfa (TNF-Alfa) as well as the apoptotic markers; caspase-3 and B-cell lymphoma (Bcl-2).\n'
p8276
sg4
(lp8277
(dp8278
g7
I68
sg8
g15
sg10
I6
sg11
VFGF-21
p8279
sg13
I1
sa(dp8280
g7
I171
sg8
VP01375
p8281
sg10
I8
sg11
VTNF-Alfa
p8282
sg13
I1
sa(dp8283
g7
I215
sg8
VP42574
p8284
sg10
I9
sg11
Vcaspase-3
p8285
sg13
I1
sa(dp8286
g7
I106
sg8
g15
sg10
I5
sg11
VSIRT1
p8287
sg13
I1
sa(dp8288
g7
I143
sg8
VP01375
p8289
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p8290
sg13
I3
sasg20
(lp8291
(dp8292
g7
I229
sg23
VC0079731
p8293
sg10
I15
sg11
VB-cell lymphoma
p8294
sg13
I2
sa(dp8295
g7
I143
sg23
VC0333516
p8296
sg10
I14
sg11
Vtumor necrosis
p8297
sg13
I2
sasa(dp8298
g2
S'We report here the case of a 25-year-old woman with a bulbar onset ALS that progressed in less than 12 months to invasive ventilation due to respiratory failure; Genetic screening identified a new mutation in the FUS gene that lies within the last codon.\n'
p8299
sg4
(lp8300
(dp8301
g7
I213
sg8
VP35637
p8302
sg10
I8
sg11
VFUS gene
p8303
sg13
I2
sasg20
(lp8304
(dp8305
g7
I141
sg23
VC1145670
p8306
sg10
I19
sg11
Vrespiratory failure
p8307
sg13
I2
sa(dp8308
g7
I193
sg23
VC2985439
p8309
sg10
I12
sg11
Vnew mutation
p8310
sg13
I2
sa(dp8311
g7
I67
sg23
VC0002736
p8312
sg10
I3
sg11
VALS
p8313
sg13
I1
sasa(dp8314
g2
S'The expression and biological function of Grb2-associated binding 2 (Gab2) in renal cell carcinoma (RCC) cells was tested here.\n'
p8315
sg4
(lp8316
(dp8317
g7
I69
sg8
g15
sg10
I4
sg11
VGab2
p8318
sg13
I1
sa(dp8319
g7
I42
sg8
VP62993
p8320
sg10
I25
sg11
VGrb2-associated binding 2
p8321
sg13
I3
sasg20
(lp8322
(dp8323
g7
I78
sg23
VC0007134
p8324
sg10
I20
sg11
Vrenal cell carcinoma
p8325
sg13
I3
sa(dp8326
g7
I100
sg23
VC0007134
p8327
sg10
I3
sg11
VRCC
p8328
sg13
I1
sasa(dp8329
g2
S'However, the significance of Grb2 and Sos proteins, which is related to EGF-triggered Ras activation, has not been elucidated in human bladder cancer.\n'
p8330
sg4
(lp8331
(dp8332
g7
I72
sg8
VP01133
p8333
sg10
I3
sg11
VEGF
p8334
sg13
I1
sa(dp8335
g7
I29
sg8
VP62993
p8336
sg10
I4
sg11
VGrb2
p8337
sg13
I1
sa(dp8338
g7
I86
sg8
VP01116
p8339
sg10
I3
sg11
VRas
p8340
sg13
I1
sa(dp8341
g7
I38
sg8
g15
sg10
I12
sg11
VSos proteins
p8342
sg13
I2
sasg20
(lp8343
(dp8344
g7
I135
sg23
VC0699885
p8345
sg10
I14
sg11
Vbladder cancer
p8346
sg13
I2
sasa(dp8347
g2
S'On the other hand, expression of Grb2 and Sos proteins was substantially increased in all human bladder cancer cell lines examined in comparison with cultured normal urothelial cells, whether codon 12 of H-ras was mutated or not.\n'
p8348
sg4
(lp8349
(dp8350
g7
I42
sg8
g15
sg10
I12
sg11
VSos proteins
p8351
sg13
I2
sa(dp8352
g7
I204
sg8
VP01112
p8353
sg10
I5
sg11
VH-ras
p8354
sg13
I1
sa(dp8355
g7
I33
sg8
VP62993
p8356
sg10
I4
sg11
VGrb2
p8357
sg13
I1
sasg20
(lp8358
(dp8359
g7
I96
sg23
VC0699885
p8360
sg10
I14
sg11
Vbladder cancer
p8361
sg13
I2
sasa(dp8362
g2
S'These results suggest that the amplification of both Grb2 and SOS proteins plays an important role in the carcinogenesis of human bladder cancer.\n'
p8363
sg4
(lp8364
(dp8365
g7
I62
sg8
g15
sg10
I12
sg11
VSOS proteins
p8366
sg13
I2
sa(dp8367
g7
I53
sg8
VP62993
p8368
sg10
I4
sg11
VGrb2
p8369
sg13
I1
sasg20
(lp8370
(dp8371
g7
I31
sg23
VC1705759
p8372
sg10
I13
sg11
Vamplification
p8373
sg13
I1
sa(dp8374
g7
I130
sg23
VC0699885
p8375
sg10
I14
sg11
Vbladder cancer
p8376
sg13
I2
sa(dp8377
g7
I106
sg23
VC0596263
p8378
sg10
I14
sg11
Vcarcinogenesis
p8379
sg13
I1
sasa(dp8380
g2
S'In the 32 patients studied, bladder cancer was diagnosed as pTaG1-2 in 8 cases, pT1G2 in 6, pT1G3 in 7, pT2G2-3 in 7, pT3G2-3 in 3 and pT4 in 1 patient.\n'
p8381
sg4
(lp8382
sg20
(lp8383
(dp8384
g7
I28
sg23
VC0699885
p8385
sg10
I14
sg11
Vbladder cancer
p8386
sg13
I2
sasa(dp8387
g2
S'In this study, we investigated whether silencing Wnt2B expression could inhibit the invasiveness of ovarian cancer cells and reduce drug resistance.\n'
p8388
sg4
(lp8389
(dp8390
g7
I49
sg8
g15
sg10
I5
sg11
VWnt2B
p8391
sg13
I1
sasg20
(lp8392
(dp8393
g7
I100
sg23
VC1140680
p8394
sg10
I14
sg11
Vovarian cancer
p8395
sg13
I2
sasa(dp8396
g2
S'These data suggest that Wnt2B indeed plays an important role in ovarian cancer metastasis and drug resistance.\n'
p8397
sg4
(lp8398
(dp8399
g7
I24
sg8
g15
sg10
I5
sg11
VWnt2B
p8400
sg13
I1
sasg20
(lp8401
(dp8402
g7
I64
sg23
VC1140680
p8403
sg10
I14
sg11
Vovarian cancer
p8404
sg13
I2
sa(dp8405
g7
I79
sg23
VC0027627
p8406
sg10
I10
sg11
Vmetastasis
p8407
sg13
I1
sasa(dp8408
g2
S'WNT2B is expressed in several types of human cancer, such as basal cell carcinoma, gastric cancer, breast cancer, head/neck squamous cell carcinoma, cervical cancer and leukemia.\n'
p8409
sg4
(lp8410
(dp8411
g7
I0
sg8
g15
sg10
I5
sg11
VWNT2B
p8412
sg13
I1
sasg20
(lp8413
(dp8414
g7
I45
sg23
VC0006826
p8415
sg10
I6
sg11
Vcancer
p8416
sg13
I1
sa(dp8417
g7
I149
sg23
VC0302592
p8418
sg10
I15
sg11
Vcervical cancer
p8419
sg13
I2
sa(dp8420
g7
I91
sg23
VC0006142
p8421
sg10
I14
sg11
Vcancer, breast
p8422
sg13
I2
sa(dp8423
g7
I124
sg23
VC0007137
p8424
sg10
I23
sg11
Vsquamous cell carcinoma
p8425
sg13
I3
sa(dp8426
g7
I45
sg23
VC0006826
p8427
sg10
I6
sg11
Vcancer
p8428
sg13
I1
sa(dp8429
g7
I61
sg23
VC0007117
p8430
sg10
I20
sg11
Vbasal cell carcinoma
p8431
sg13
I3
sa(dp8432
g7
I169
sg23
VC0023418
p8433
sg10
I8
sg11
Vleukemia
p8434
sg13
I1
sasa(dp8435
g2
S'Among various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer).\n'
p8436
sg4
(lp8437
(dp8438
g7
I37
sg8
g15
sg10
I11
sg11
VWnt-13 mRNA
p8439
sg13
I2
sasg20
(lp8440
(dp8441
g7
I14
sg23
VC0006826
p8442
sg10
I6
sg11
Vcancer
p8443
sg13
I1
sa(dp8444
g7
I71
sg23
VC0302592
p8445
sg10
I15
sg11
Vcervical cancer
p8446
sg13
I2
sa(dp8447
g7
I106
sg23
VC0024623
p8448
sg10
I14
sg11
Vgastric cancer
p8449
sg13
I2
sasa(dp8450
g2
S'The receptor protein tyrosine phosphatase PTPRG has been genetically associated with psychiatric disorders and is a ligand for members of the contactin family, which are themselves linked to autism spectrum disorders.\n'
p8451
sg4
(lp8452
(dp8453
g7
I142
sg8
g15
sg10
I16
sg11
Vcontactin family
p8454
sg13
I2
sa(dp8455
g7
I4
sg8
g15
sg10
I43
sg11
Vreceptor protein tyrosine phosphatase PTPRG
p8456
sg13
I5
sasg20
(lp8457
(dp8458
g7
I191
sg23
VC1510586
p8459
sg10
I25
sg11
Vautism spectrum disorders
p8460
sg13
I3
sa(dp8461
g7
I85
sg23
VC0004936
p8462
sg10
I21
sg11
Vpsychiatric disorders
p8463
sg13
I2
sasa(dp8464
g2
S'Based on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation.\n'
p8465
sg4
(lp8466
(dp8467
g7
I63
sg8
VP23470
p8468
sg10
I5
sg11
VPTPRG
p8469
sg13
I1
sasg20
(lp8470
(dp8471
g7
I43
sg23
VC2985439
p8472
sg10
I16
sg11
Vde novo mutation
p8473
sg13
I3
sa(dp8474
g7
I104
sg23
VC0036341
p8475
sg10
I13
sg11
Vschizophrenia
p8476
sg13
I1
sasa(dp8477
g2
S'The most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia.\n'
p8478
sg4
(lp8479
(dp8480
g7
I44
sg8
VP23470
p8481
sg10
I10
sg11
VPTPRG gene
p8482
sg13
I2
sasg20
(lp8483
(dp8484
g7
I161
sg23
VC0036341
p8485
sg10
I13
sg11
Vschizophrenia
p8486
sg13
I1
sa(dp8487
g7
I55
sg23
VC0544461
p8488
sg10
I12
sg11
Vinactivation
p8489
sg13
I1
sasa(dp8490
g2
S'The subgroups significantly differed in important features, including specific working memory deficits for PTPRG (n=5); severe negative symptoms, global cognitive deficits and poor educational attainment, suggesting a developmental disorder, for SLC39A13 (n=4); slow processing speed, childhood attention deficit disorder and milder symptoms for TGM5 (n=4); and global cognitive deficits with good educational attainment suggesting neurodegeneration for ARMS/KIDINS220 (n=5).\n'
p8491
sg4
(lp8492
(dp8493
g7
I246
sg8
g15
sg10
I8
sg11
VSLC39A13
p8494
sg13
I1
sa(dp8495
g7
I346
sg8
g15
sg10
I4
sg11
VTGM5
p8496
sg13
I1
sa(dp8497
g7
I107
sg8
VP23470
p8498
sg10
I5
sg11
VPTPRG
p8499
sg13
I1
sa(dp8500
g7
I459
sg8
g15
sg10
I9
sg11
VKIDINS220
p8501
sg13
I1
sasg20
(lp8502
(dp8503
g7
I432
sg23
VC0027746
p8504
sg10
I17
sg11
Vneurodegeneration
p8505
sg13
I1
sa(dp8506
g7
I153
sg23
VC0679466
p8507
sg10
I18
sg11
Vcognitive deficits
p8508
sg13
I2
sa(dp8509
g7
I87
sg23
VC0233794
p8510
sg10
I15
sg11
Vmemory deficits
p8511
sg13
I2
sa(dp8512
g7
I295
sg23
VC0339002
p8513
sg10
I26
sg11
Vattention deficit disorder
p8514
sg13
I3
sa(dp8515
g7
I153
sg23
VC0679466
p8516
sg10
I18
sg11
Vcognitive deficits
p8517
sg13
I2
sa(dp8518
g7
I218
sg23
VC0008073
p8519
sg10
I22
sg11
Vdevelopmental disorder
p8520
sg13
I2
sa(dp8521
g7
I454
sg23
VC0206655
p8522
sg10
I4
sg11
VARMS
p8523
sg13
I1
sasa(dp8524
g2
S'First, whole exome sequencing was conducted to identify disruptive de novo mutations in 14 complete parent-offspring trios with sporadic schizophrenia from Jerusalem, which identified 5 sporadic cases with de novo gene mutations in 5 different genes (PTPRG, TGM5, SLC39A13, BTK, CDKN3).\n'
p8525
sg4
(lp8526
(dp8527
g7
I258
sg8
g15
sg10
I4
sg11
VTGM5
p8528
sg13
I1
sa(dp8529
g7
I264
sg8
g15
sg10
I8
sg11
VSLC39A13
p8530
sg13
I1
sa(dp8531
g7
I251
sg8
VP23470
p8532
sg10
I5
sg11
VPTPRG
p8533
sg13
I1
sa(dp8534
g7
I274
sg8
g15
sg10
I3
sg11
VBTK
p8535
sg13
I1
sasg20
(lp8536
(dp8537
g7
I137
sg23
VC0036341
p8538
sg10
I13
sg11
Vschizophrenia
p8539
sg13
I1
sasa(dp8540
g2
S'Next, targeted exome capture of these genes was conducted in 48 well-characterized, unrelated, ethnically diverse schizophrenia cases, recruited and characterized by the same research team in New York (NY sample), which demonstrated extremely rare and potentially damaging variants in three of the five genes (MAF&lt;0.01) in 12/48 cases (25%); including PTPRG (5 cases), SCL39A13 (4 cases) and TGM5 (4 cases), a higher number than usually identified by whole exome sequencing.\n'
p8541
sg4
(lp8542
sg20
(lp8543
(dp8544
g7
I114
sg23
VC0036341
p8545
sg10
I13
sg11
Vschizophrenia
p8546
sg13
I1
sasa(dp8547
g2
S"Activated astrocytes were found to be strongly positive for RPTPGamma also in a mice model of Alzheimer's disease.\n"
p8548
sg4
(lp8549
(dp8550
g7
I60
sg8
VP23470
p8551
sg10
I9
sg11
VRPTPGamma
p8552
sg13
I1
sasg20
(lp8553
(dp8554
g7
I94
sg23
VC1521724
p8555
sg10
I19
sg11
VAlzheimer's disease
p8556
sg13
I2
sasa(dp8557
g2
S'Aqueous humor (AH) samples from 14 patients with presumed tuberculous uveitis (PTU), and 30 control patients were assayed for the proinflammatory cytokines interleukin IL-4, IL-12, IL-15, IL-17, interferon (IFN)-Gamma, and tumor necrosis factor (TNF)-Alfa, the immunosuppressive cytokine IL-10, and the chemokines GRO-Alfa/CXCL1, IL-8/CXCL8, MIG/CXCL9, IP-10/CXCL10 and SDF-1/CXCL12 with the use of a multiplex assay.\n'
p8558
sg4
(lp8559
(dp8560
g7
I342
sg8
g15
sg10
I3
sg11
VMIG
p8561
sg13
I1
sa(dp8562
g7
I353
sg8
VP02778
p8563
sg10
I5
sg11
VIP-10
p8564
sg13
I1
sa(dp8565
g7
I370
sg8
VP48061
p8566
sg10
I5
sg11
VSDF-1
p8567
sg13
I1
sa(dp8568
g7
I314
sg8
VP09341
p8569
sg10
I3
sg11
VGRO
p8570
sg13
I1
sa(dp8571
g7
I207
sg8
VP01562
p8572
sg10
I3
sg11
VIFN
p8573
sg13
I1
sa(dp8574
g7
I195
sg8
VP01563
p8575
sg10
I10
sg11
Vinterferon
p8576
sg13
I1
sa(dp8577
g7
I346
sg8
g15
sg10
I5
sg11
VCXCL9
p8578
sg13
I1
sa(dp8579
g7
I156
sg8
VP05112
p8580
sg10
I16
sg11
Vinterleukin IL-4
p8581
sg13
I2
sa(dp8582
g7
I223
sg8
VP01375
p8583
sg10
I32
sg11
Vtumor necrosis factor (TNF)-Alfa
p8584
sg13
I4
sa(dp8585
g7
I181
sg8
VP40933
p8586
sg10
I5
sg11
VIL-15
p8587
sg13
I1
sa(dp8588
g7
I359
sg8
VP02778
p8589
sg10
I6
sg11
VCXCL10
p8590
sg13
I1
sa(dp8591
g7
I323
sg8
VP09341
p8592
sg10
I5
sg11
VCXCL1
p8593
sg13
I1
sa(dp8594
g7
I376
sg8
VP48061
p8595
sg10
I6
sg11
VCXCL12
p8596
sg13
I1
sasg20
(lp8597
(dp8598
g7
I0
sg23
VC0595936
p8599
sg10
I13
sg11
VAqueous humor
p8600
sg13
I2
sa(dp8601
g7
I15
sg23
VC0595936
p8602
sg10
I2
sg11
VAH
p8603
sg13
I1
sa(dp8604
g7
I58
sg23
VC1281935
p8605
sg10
I19
sg11
Vtuberculous uveitis
p8606
sg13
I2
sa(dp8607
g7
I223
sg23
VC0333516
p8608
sg10
I14
sg11
Vtumor necrosis
p8609
sg13
I2
sasa(dp8610
g2
S"Aqueous humor (AH) samples from patients with Behcet's disease (BD) (n=29), Vogt-Koyanagi-Harada (VKH) disease (n=21), and HLA-B27-associated uveitis (n=8), and 42 control patients were assayed for the neutrophil chemoattractants CXCL1/GRO-Alfa and CXCL8/IL-8 and the lymphocyte chemoattractants CXCL9/MIG, CXCL10/IP-10 and CXCL12/SDF-1 with the use of a multiplex chemokine assay.\n"
p8611
sg4
(lp8612
(dp8613
g7
I331
sg8
VP48061
p8614
sg10
I5
sg11
VSDF-1
p8615
sg13
I1
sa(dp8616
g7
I236
sg8
VP09341
p8617
sg10
I3
sg11
VGRO
p8618
sg13
I1
sa(dp8619
g7
I314
sg8
VP02778
p8620
sg10
I5
sg11
VIP-10
p8621
sg13
I1
sa(dp8622
g7
I296
sg8
g15
sg10
I5
sg11
VCXCL9
p8623
sg13
I1
sa(dp8624
g7
I324
sg8
VP48061
p8625
sg10
I6
sg11
VCXCL12
p8626
sg13
I1
sa(dp8627
g7
I123
sg8
VP30486
p8628
sg10
I7
sg11
VHLA-B27
p8629
sg13
I1
sa(dp8630
g7
I302
sg8
g15
sg10
I3
sg11
VMIG
p8631
sg13
I1
sa(dp8632
g7
I230
sg8
VP09341
p8633
sg10
I5
sg11
VCXCL1
p8634
sg13
I1
sa(dp8635
g7
I307
sg8
VP02778
p8636
sg10
I6
sg11
VCXCL10
p8637
sg13
I1
sasg20
(lp8638
(dp8639
g7
I0
sg23
VC0595936
p8640
sg10
I13
sg11
VAqueous humor
p8641
sg13
I2
sa(dp8642
g7
I15
sg23
VC0595936
p8643
sg10
I2
sg11
VAH
p8644
sg13
I1
sa(dp8645
g7
I46
sg23
VC0004943
p8646
sg10
I16
sg11
VBehcet's disease
p8647
sg13
I2
sa(dp8648
g7
I142
sg23
VC0042164
p8649
sg10
I7
sg11
Vuveitis
p8650
sg13
I1
sa(dp8651
g7
I64
sg23
VC0004943
p8652
sg10
I2
sg11
VBD
p8653
sg13
I1
sasa(dp8654
g2
S'In patients with the same disease activity, AH levels of GRO-Alfa and IP-10 were significantly higher in patients with BD than in patients with VKH disease and HLA-B27-associated uveitis (p=0.0474; p&lt;0.001, respectively).\n'
p8655
sg4
(lp8656
(dp8657
g7
I160
sg8
VP30486
p8658
sg10
I7
sg11
VHLA-B27
p8659
sg13
I1
sa(dp8660
g7
I70
sg8
VP02778
p8661
sg10
I5
sg11
VIP-10
p8662
sg13
I1
sa(dp8663
g7
I57
sg8
VP09341
p8664
sg10
I8
sg11
VGRO-Alfa
p8665
sg13
I1
sasg20
(lp8666
(dp8667
g7
I179
sg23
VC0042164
p8668
sg10
I7
sg11
Vuveitis
p8669
sg13
I1
sasa(dp8670
g2
S'These data suggest that GRO-Alfa and IP-10 are the predominant CXC chemokines involved in neutrophil and activated T lymphocyte chemoattraction in endogenous uveitis, particularly in BD.\n'
p8671
sg4
(lp8672
(dp8673
g7
I24
sg8
VP09341
p8674
sg10
I3
sg11
VGRO
p8675
sg13
I1
sa(dp8676
g7
I37
sg8
VP02778
p8677
sg10
I5
sg11
VIP-10
p8678
sg13
I1
sasg20
(lp8679
(dp8680
g7
I158
sg23
VC0042164
p8681
sg10
I7
sg11
Vuveitis
p8682
sg13
I1
sasa(dp8683
g2
S'The purpose of this study was to investigate the role and regulation of the CXC chemokine GRO and the interaction between GRO and IL-8 in LPS-induced uveitis in rabbits.\n'
p8684
sg4
(lp8685
(dp8686
g7
I90
sg8
VP09341
p8687
sg10
I3
sg11
VGRO
p8688
sg13
I1
sasg20
(lp8689
(dp8690
g7
I138
sg23
VC0175697
p8691
sg10
I3
sg11
VLPS
p8692
sg13
I1
sa(dp8693
g7
I150
sg23
VC0042164
p8694
sg10
I7
sg11
Vuveitis
p8695
sg13
I1
sasa(dp8696
g2
S'Taken together, our results suggest that GRO is an essential mediator for neutrophil infiltration in LPS-induced uveitis in rabbits.\n'
p8697
sg4
(lp8698
(dp8699
g7
I41
sg8
VP09341
p8700
sg10
I3
sg11
VGRO
p8701
sg13
I1
sasg20
(lp8702
(dp8703
g7
I113
sg23
VC0042164
p8704
sg10
I7
sg11
Vuveitis
p8705
sg13
I1
sa(dp8706
g7
I101
sg23
VC0175697
p8707
sg10
I3
sg11
VLPS
p8708
sg13
I1
sa(dp8709
g7
I85
sg23
VC0332448
p8710
sg10
I12
sg11
Vinfiltration
p8711
sg13
I1
sasa(dp8712
g2
S"Na(+)K(+)ATPase, NKCC1, and alpha-syntrophin were expressed within sensory epithelia and were unaltered in Meniere's disease specimens.\n"
p8713
sg4
(lp8714
(dp8715
g7
I17
sg8
VP55011
p8716
sg10
I5
sg11
VNKCC1
p8717
sg13
I1
sa(dp8718
g7
I28
sg8
g15
sg10
I16
sg11
Valpha-syntrophin
p8719
sg13
I1
sa(dp8720
g7
I0
sg8
VP38606
p8721
sg10
I15
sg11
VNa(+)K(+)ATPase
p8722
sg13
I1
sasg20
(lp8723
(dp8724
g7
I107
sg23
VC0025281
p8725
sg10
I17
sg11
VMeniere's disease
p8726
sg13
I2
sasa(dp8727
g2
S'Although an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed.\n'
p8728
sg4
(lp8729
(dp8730
g7
I37
sg8
VP40145
p8731
sg10
I5
sg11
VHbAc1
p8732
sg13
I1
sa(dp8733
g7
I21
sg8
g15
sg10
I14
sg11
Vhemoglobin A1c
p8734
sg13
I2
sasg20
(lp8735
(dp8736
g7
I139
sg23
VC0011849
p8737
sg10
I17
sg11
Vdiabetes mellitus
p8738
sg13
I2
sa(dp8739
g7
I118
sg23
VC0685938
p8740
sg10
I16
sg11
Vdigestive cancer
p8741
sg13
I2
sasa(dp8742
g2
S'We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.\n'
p8743
sg4
(lp8744
(dp8745
g7
I163
sg8
VP25391
p8746
sg10
I5
sg11
VLAMA1
p8747
sg13
I1
sa(dp8748
g7
I175
sg8
g15
sg10
I3
sg11
VAkt
p8749
sg13
I1
sa(dp8750
g7
I112
sg8
g15
sg10
I4
sg11
VGPCR
p8751
sg13
I1
sa(dp8752
g7
I170
sg8
VP42336
p8753
sg10
I4
sg11
VPI3K
p8754
sg13
I1
sa(dp8755
g7
I105
sg8
g15
sg10
I5
sg11
VOR1B1
p8756
sg13
I1
sa(dp8757
g7
I237
sg8
VP31749
p8758
sg10
I3
sg11
VCRC
p8759
sg13
I1
sa(dp8760
g7
I202
sg8
VP40145
p8761
sg10
I5
sg11
VADCY3
p8762
sg13
I1
sasg20
(lp8763
(dp8764
g7
I59
sg23
VC0001430
p8765
sg10
I7
sg11
Vadenoma
p8766
sg13
I1
sa(dp8767
g7
I237
sg23
VC1527249
p8768
sg10
I3
sg11
VCRC
p8769
sg13
I1
sa(dp8770
g7
I59
sg23
VC0001430
p8771
sg10
I7
sg11
Vadenoma
p8772
sg13
I1
sa(dp8773
g7
I71
sg23
VC0006826
p8774
sg10
I6
sg11
Vcancer
p8775
sg13
I1
sasa(dp8776
g2
S'Recently, we provided human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma (brain tumor) risk in individuals with Neurofibromatosis type 1 (NF1).\n'
p8777
sg4
(lp8778
(dp8779
g7
I230
sg8
VP21359
p8780
sg10
I3
sg11
VNF1
p8781
sg13
I1
sa(dp8782
g7
I131
sg8
VP40145
p8783
sg10
I5
sg11
VADCY8
p8784
sg13
I1
sa(dp8785
g7
I204
sg8
VP21359
p8786
sg10
I24
sg11
VNeurofibromatosis type 1
p8787
sg13
I3
sasg20
(lp8788
(dp8789
g7
I230
sg23
VC0027831
p8790
sg10
I3
sg11
VNF1
p8791
sg13
I1
sa(dp8792
g7
I84
sg23
VC0006118
p8793
sg10
I11
sg11
Vbrain tumor
p8794
sg13
I2
sa(dp8795
g7
I204
sg23
VC0027831
p8796
sg10
I24
sg11
VNeurofibromatosis type 1
p8797
sg13
I3
sa(dp8798
g7
I84
sg23
VC0006118
p8799
sg10
I80
sg11
Vbrain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma
p8800
sg13
I13
sasa(dp8801
g2
S'However, the cAMP pathway is well-known to be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion, elevating the risk for females while protecting males.\n'
p8802
sg4
(lp8803
(dp8804
g7
I78
sg8
VP40145
p8805
sg10
I5
sg11
VADCY8
p8806
sg13
I1
sasg20
(lp8807
(dp8808
g7
I93
sg23
VC0017638
p8809
sg10
I6
sg11
Vglioma
p8810
sg13
I1
sasa(dp8811
g2
S'Here, we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma risk in NF1 in a sex-specific manner, elevating risk in females while reducing risk in males.\n'
p8812
sg4
(lp8813
(dp8814
g7
I95
sg8
VP40145
p8815
sg10
I5
sg11
VADCY8
p8816
sg13
I1
sa(dp8817
g7
I45
sg8
g15
sg10
I48
sg11
Vhuman adenylate cyclase gene adenylate cyclase 8
p8818
sg13
I7
sa(dp8819
g7
I137
sg8
VP21359
p8820
sg10
I3
sg11
VNF1
p8821
sg13
I1
sasg20
(lp8822
(dp8823
g7
I122
sg23
VC0017638
p8824
sg10
I6
sg11
Vglioma
p8825
sg13
I1
sa(dp8826
g7
I137
sg23
VC0027831
p8827
sg10
I3
sg11
VNF1
p8828
sg13
I1
sasa(dp8829
g2
S'Overall, our results establish a sex-specific role for cAMP regulation in human gliomagenesis, specifically identifying ADCY8 as a modifier of glioma risk in NF1.\n'
p8830
sg4
(lp8831
(dp8832
g7
I158
sg8
VP21359
p8833
sg10
I3
sg11
VNF1
p8834
sg13
I1
sa(dp8835
g7
I120
sg8
VP40145
p8836
sg10
I5
sg11
VADCY8
p8837
sg13
I1
sasg20
(lp8838
(dp8839
g7
I158
sg23
VC0027831
p8840
sg10
I3
sg11
VNF1
p8841
sg13
I1
sa(dp8842
g7
I80
sg23
VC0017638
p8843
sg10
I6
sg11
Vglioma
p8844
sg13
I1
sasa(dp8845
g2
S'The effect of insulin on the oxidative desaturation of 1-14C palmitic acid to palmitoleic acid (delta 9 desaturase) 1-14C linoleic acid to alpha-linolenic acid (delta 6 desaturase) on rat liver microsomes and 1-14C eicosa-8,11,14-trienoic acid to arachidonic acid (delta 5 desaturase) on rat liver microsomes and hepatoma tissue culture (HTC) cells was studied.\n'
p8846
sg4
(lp8847
(dp8848
g7
I265
sg8
VP28072
p8849
sg10
I18
sg11
Vdelta 5 desaturase
p8850
sg13
I3
sa(dp8851
g7
I161
sg8
VP28072
p8852
sg10
I18
sg11
Vdelta 6 desaturase
p8853
sg13
I3
sa(dp8854
g7
I14
sg8
VP01308
p8855
sg10
I7
sg11
Vinsulin
p8856
sg13
I1
sasg20
(lp8857
(dp8858
g7
I313
sg23
VC0023903
p8859
sg10
I8
sg11
Vhepatoma
p8860
sg13
I1
sasa(dp8861
g2
S'Methylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC).\n'
p8862
sg4
(lp8863
(dp8864
g7
I39
sg8
VP55085
p8865
sg10
I4
sg11
VEVX2
p8866
sg13
I1
sa(dp8867
g7
I22
sg8
VP12830
p8868
sg10
I4
sg11
VCDH1
p8869
sg13
I1
sa(dp8870
g7
I28
sg8
VP53355
p8871
sg10
I5
sg11
VDAPK1
p8872
sg13
I1
sasg20
(lp8873
(dp8874
g7
I89
sg23
VC0007137
p8875
sg10
I3
sg11
VSCC
p8876
sg13
I1
sa(dp8877
g7
I63
sg23
VC0007137
p8878
sg10
I24
sg11
Vsquamous cell carcinomas
p8879
sg13
I3
sa(dp8880
g7
I106
sg23
VC0001418
p8881
sg10
I15
sg11
Vadenocarcinomas
p8882
sg13
I1
sa(dp8883
g7
I123
sg23
VC0001418
p8884
sg10
I3
sg11
VADC
p8885
sg13
I1
sasa(dp8886
g2
S'Overall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters.\n'
p8887
sg4
(lp8888
(dp8889
g7
I28
sg8
VP35625
p8890
sg10
I5
sg11
VTIMP3
p8891
sg13
I1
sa(dp8892
g7
I35
sg8
VP25054
p8893
sg10
I3
sg11
VAPC
p8894
sg13
I1
sa(dp8895
g7
I9
sg8
VP06881
p8896
sg10
I5
sg11
VCALCA
p8897
sg13
I1
sa(dp8898
g7
I16
sg8
VP53355
p8899
sg10
I4
sg11
VDAPK
p8900
sg13
I1
sa(dp8901
g7
I22
sg8
VP03372
p8902
sg10
I4
sg11
VESR1
p8903
sg13
I1
sa(dp8904
g7
I43
sg8
VP10276
p8905
sg10
I19
sg11
VRAR-beta2 promoters
p8906
sg13
I2
sa(dp8907
g7
I35
sg8
VP25054
p8908
sg10
I3
sg11
VAPC
p8909
sg13
I1
sa(dp8910
g7
I28
sg8
VP35625
p8911
sg10
I5
sg11
VTIMP3
p8912
sg13
I1
sasg20
(lp8913
(dp8914
g7
I112
sg23
VC0006826
p8915
sg10
I7
sg11
Vcancers
p8916
sg13
I1
sa(dp8917
g7
I144
sg23
VC0001418
p8918
sg10
I15
sg11
Vadenocarcinomas
p8919
sg13
I1
sa(dp8920
g7
I35
sg23
VC0033036
p8921
sg10
I3
sg11
VAPC
p8922
sg13
I1
sa(dp8923
g7
I35
sg23
VC0033036
p8924
sg10
I3
sg11
VAPC
p8925
sg13
I1
sasa(dp8926
g2
S'Combining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).\n'
p8927
sg4
(lp8928
(dp8929
g7
I26
sg8
VP53355
p8930
sg10
I4
sg11
VDAPK
p8931
sg13
I1
sa(dp8932
g7
I19
sg8
VP06881
p8933
sg10
I5
sg11
VCALCA
p8934
sg13
I1
sa(dp8935
g7
I0
sg8
VP01893
p8936
sg10
I17
sg11
VCombining 4 genes
p8937
sg13
I3
sa(dp8938
g7
I41
sg8
VP25054
p8939
sg10
I3
sg11
VAPC
p8940
sg13
I1
sa(dp8941
g7
I32
sg8
VP03372
p8942
sg10
I4
sg11
VESR1
p8943
sg13
I1
sasg20
(lp8944
(dp8945
g7
I41
sg23
VC0033036
p8946
sg10
I3
sg11
VAPC
p8947
sg13
I1
sa(dp8948
g7
I85
sg23
VC0001418
p8949
sg10
I15
sg11
Vadenocarcinomas
p8950
sg13
I1
sa(dp8951
g7
I164
sg23
VC0030354
p8952
sg10
I9
sg11
Vpapilloma
p8953
sg13
I1
sasa(dp8954
g2
S'The thyroid tumor was diagnosed as metastasis to the thyroid from lung adenocarcinoma, because it showed mucin production, positive immunoreactivity for carcinoembryonic antigen and negative immunoreactivities for thyroglobulin and calcitonin.\n'
p8955
sg4
(lp8956
(dp8957
g7
I153
sg8
VP40198
p8958
sg10
I24
sg11
Vcarcinoembryonic antigen
p8959
sg13
I2
sa(dp8960
g7
I214
sg8
g15
sg10
I13
sg11
Vthyroglobulin
p8961
sg13
I1
sa(dp8962
g7
I105
sg8
g15
sg10
I5
sg11
Vmucin
p8963
sg13
I1
sa(dp8964
g7
I232
sg8
VP06881
p8965
sg10
I10
sg11
Vcalcitonin
p8966
sg13
I1
sasg20
(lp8967
(dp8968
g7
I66
sg23
VC0152013
p8969
sg10
I19
sg11
Vlung adenocarcinoma
p8970
sg13
I2
sa(dp8971
g7
I4
sg23
VC0040136
p8972
sg10
I13
sg11
Vthyroid tumor
p8973
sg13
I2
sa(dp8974
g7
I35
sg23
VC0347023
p8975
sg10
I25
sg11
Vmetastasis to the thyroid
p8976
sg13
I4
sasa(dp8977
g2
S'We searched Medline for clinical trials that assessed disease-modifying drugs for relapsing-remitting multiple sclerosis published from Sept 1, 2008, to Oct 31, 2012.\n'
p8978
sg4
(lp8979
(dp8980
g7
I153
sg8
VP00480
p8981
sg10
I6
sg11
VOct 31
p8982
sg13
I2
sasg20
(lp8983
(dp8984
g7
I82
sg23
VC0751967
p8985
sg10
I38
sg11
Vrelapsing-remitting multiple sclerosis
p8986
sg13
I3
sasa(dp8987
g2
S"SEPT1, SEPT4, and SEPT2 have been found in deposits known as neurofibrillary tangles and glial fibrils in Alzheimer's disease.\n"
p8988
sg4
(lp8989
(dp8990
g7
I7
sg8
g15
sg10
I5
sg11
VSEPT4
p8991
sg13
I1
sa(dp8992
g7
I0
sg8
g15
sg10
I5
sg11
VSEPT1
p8993
sg13
I1
sa(dp8994
g7
I18
sg8
g15
sg10
I5
sg11
VSEPT2
p8995
sg13
I1
sasg20
(lp8996
(dp8997
g7
I61
sg23
VC0085400
p8998
sg10
I23
sg11
Vneurofibrillary tangles
p8999
sg13
I2
sa(dp9000
g7
I106
sg23
VC1521724
p9001
sg10
I19
sg11
VAlzheimer's disease
p9002
sg13
I2
sasa(dp9003
g2
S'Finally, we evaluated the effect of the pro-arousal neuropeptides CRF and Hcrt-1/Ox-A in NPSR-deficient mice.\n'
p9004
sg4
(lp9005
(dp9006
g7
I74
sg8
VP50336
p9007
sg10
I6
sg11
VHcrt-1
p9008
sg13
I1
sasg20
(lp9009
(dp9010
g7
I66
sg23
VC0022661
p9011
sg10
I3
sg11
VCRF
p9012
sg13
I1
sasa(dp9013
g2
S'The administration of CRF and Hcrt-1/Ox-A, two classic pro-arousal peptides, elicited the same effects in both NPSR(-/-) and wild type mice, ruling out the possibility that adaptive mechanisms occurring at the level of these two systems could have occurred during NPSR(-/-) development to compensate for the lack of NPSR receptors.\n'
p9014
sg4
(lp9015
(dp9016
g7
I30
sg8
VP50336
p9017
sg10
I6
sg11
VHcrt-1
p9018
sg13
I1
sa(dp9019
g7
I316
sg8
g15
sg10
I14
sg11
VNPSR receptors
p9020
sg13
I2
sa(dp9021
g7
I22
sg8
VP06850
p9022
sg10
I3
sg11
VCRF
p9023
sg13
I1
sasg20
(lp9024
(dp9025
g7
I22
sg23
VC0022661
p9026
sg10
I3
sg11
VCRF
p9027
sg13
I1
sasa(dp9028
g2
S'Moreover, we demonstrated that the deletion of NPSR did not lead to compensatory changes in the vigilance-promoting effects of the CRF and Hcrt-1/Ox-A systems.\n'
p9029
sg4
(lp9030
(dp9031
g7
I131
sg8
VP06850
p9032
sg10
I3
sg11
VCRF
p9033
sg13
I1
sa(dp9034
g7
I139
sg8
VP50336
p9035
sg10
I6
sg11
VHcrt-1
p9036
sg13
I1
sasg20
(lp9037
(dp9038
g7
I131
sg23
VC0022661
p9039
sg10
I3
sg11
VCRF
p9040
sg13
I1
sasa(dp9041
g2
S'We included all RCTs of any calcimimetic agent, cinacalcet HCl (AMG-073, Sensipar), NPS R-467 or NPS R-568 administered to patients with CKD for the treatment of SHPT.\n'
p9042
sg4
(lp9043
sg20
(lp9044
(dp9045
g7
I84
sg23
VC0027341
p9046
sg10
I3
sg11
VNPS
p9047
sg13
I1
sa(dp9048
g7
I84
sg23
VC0027341
p9049
sg10
I3
sg11
VNPS
p9050
sg13
I1
sasa(dp9051
g2
S'Renal osteodystrophy (RO) due to secondary hyperparathyroidism (HPT) in chronic renal failure was an obvious target for studying the effects of NPS R-568.\n'
p9052
sg4
(lp9053
sg20
(lp9054
(dp9055
g7
I33
sg23
VC0020503
p9056
sg10
I29
sg11
Vsecondary hyperparathyroidism
p9057
sg13
I2
sa(dp9058
g7
I22
sg23
VC0035086
p9059
sg10
I2
sg11
VRO
p9060
sg13
I1
sa(dp9061
g7
I144
sg23
VC0027341
p9062
sg10
I3
sg11
VNPS
p9063
sg13
I1
sa(dp9064
g7
I0
sg23
VC0035086
p9065
sg10
I20
sg11
VRenal osteodystrophy
p9066
sg13
I2
sa(dp9067
g7
I72
sg23
VC0022661
p9068
sg10
I21
sg11
Vchronic renal failure
p9069
sg13
I3
sasa(dp9070
g2
S'Changes in BIS (bispectral index) VISTA bilateral monitoring system associated with intraoperative episodes of generalized and focal seizures, during total intravenous anesthesia for resection of a left frontal parasagittal meningioma, are herein described.\n'
p9071
sg4
(lp9072
sg20
(lp9073
(dp9074
g7
I211
sg23
VC0751304
p9075
sg10
I23
sg11
Vparasagittal meningioma
p9076
sg13
I2
sa(dp9077
g7
I127
sg23
VC0751495
p9078
sg10
I14
sg11
Vfocal seizures
p9079
sg13
I2
sa(dp9080
g7
I168
sg23
VC0278134
p9081
sg10
I10
sg11
Vanesthesia
p9082
sg13
I1
sasa(dp9083
g2
S"Previous studies identified a variety of putative target genes from several pathways associated with DNA damage repair, chromatin remodeling complex, PI3K-AKT-mTOR signaling, Notch signaling, cell cycle checkpoint signaling, BRCA-associated complex and Fanconi's anemia susceptibility genes that could be used as biomarkers or therapeutic targets for PARP inhibition.\n"
p9084
sg4
(lp9085
(dp9086
g7
I155
sg8
g15
sg10
I3
sg11
VAKT
p9087
sg13
I1
sa(dp9088
g7
I351
sg8
VP09874
p9089
sg10
I4
sg11
VPARP
p9090
sg13
I1
sa(dp9091
g7
I150
sg8
VP42336
p9092
sg10
I4
sg11
VPI3K
p9093
sg13
I1
sa(dp9094
g7
I159
sg8
VP42345
p9095
sg10
I4
sg11
VmTOR
p9096
sg13
I1
sasg20
(lp9097
(dp9098
g7
I101
sg23
VC0012860
p9099
sg10
I10
sg11
VDNA damage
p9100
sg13
I2
sa(dp9101
g7
I253
sg23
VC0015625
p9102
sg10
I16
sg11
VFanconi's anemia
p9103
sg13
I2
sasa(dp9104
g2
S'Hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied.\n'
p9105
sg4
(lp9106
(dp9107
g7
I106
sg8
VP09874
p9108
sg10
I4
sg11
VPARP
p9109
sg13
I1
sasg20
(lp9110
(dp9111
g7
I69
sg23
VC0002871
p9112
sg10
I6
sg11
Vanemia
p9113
sg13
I1
sa(dp9114
g7
I87
sg23
VC0879626
p9115
sg10
I15
sg11
Vadverse effects
p9116
sg13
I2
sasa(dp9117
g2
S'A total of 2,479 patients from 12 RCTs revealed that the incidence of PARPi-associated severe hematologic toxicities was, respectively: neutropenia: 32.9% (95% CI, 20.5%-48.3%); thrombocytopenia: 15.9% (95% CI, 9.5%-25.4%), and anemia: 9.1% (95% CI, 5.1%-15.7%).\n'
p9118
sg4
(lp9119
sg20
(lp9120
(dp9121
g7
I228
sg23
VC0002871
p9122
sg10
I6
sg11
Vanemia
p9123
sg13
I1
sasa(dp9124
g2
S"Examples of endocrine syndromes are classical carcinoid syndrome caused by serotonin (measured in the urine as its metabolite 5-HIAA), insulinoma syndrome caused by insulin or proinsulin, Zollinger-Ellison syndrome resulting from gastrin secretion, glucagonoma syndrome caused by glucagon, WDHA syndrome caused by vasoactive intestinal peptide, or Cushing's syndrome resulting from ectopic production of adrenocorticotropic hormone or corticotropin-releasing hormone.\n"
p9125
sg4
(lp9126
(dp9127
g7
I230
sg8
VP01350
p9128
sg10
I7
sg11
Vgastrin
p9129
sg13
I1
sa(dp9130
g7
I176
sg8
VP01308
p9131
sg10
I10
sg11
Vproinsulin
p9132
sg13
I1
sa(dp9133
g7
I435
sg8
VP06850
p9134
sg10
I31
sg11
Vcorticotropin-releasing hormone
p9135
sg13
I2
sa(dp9136
g7
I135
sg8
VP01308
p9137
sg10
I7
sg11
Vinsulin
p9138
sg13
I1
sa(dp9139
g7
I249
sg8
VP01275
p9140
sg10
I8
sg11
Vglucagon
p9141
sg13
I1
sa(dp9142
g7
I404
sg8
VP01189
p9143
sg10
I27
sg11
Vadrenocorticotropic hormone
p9144
sg13
I2
sasg20
(lp9145
(dp9146
g7
I135
sg23
VC0021670
p9147
sg10
I10
sg11
Vinsulinoma
p9148
sg13
I1
sa(dp9149
g7
I22
sg23
VC0039082
p9150
sg10
I8
sg11
Vsyndrome
p9151
sg13
I1
sa(dp9152
g7
I188
sg23
VC0043515
p9153
sg10
I26
sg11
VZollinger-Ellison syndrome
p9154
sg13
I2
sa(dp9155
g7
I22
sg23
VC0039082
p9156
sg10
I9
sg11
Vsyndromes
p9157
sg13
I1
sa(dp9158
g7
I46
sg23
VC0024586
p9159
sg10
I18
sg11
Vcarcinoid syndrome
p9160
sg13
I2
sa(dp9161
g7
I249
sg23
VC0017689
p9162
sg10
I20
sg11
Vglucagonoma syndrome
p9163
sg13
I2
sa(dp9164
g7
I290
sg23
VC0086768
p9165
sg10
I13
sg11
VWDHA syndrome
p9166
sg13
I2
sa(dp9167
g7
I348
sg23
VC0010481
p9168
sg10
I18
sg11
VCushing's syndrome
p9169
sg13
I2
sasa(dp9170
g2
S"We have previously reported and confirmed that vasoactive intestinal peptide (VIP) is a significant stimulator of ACTH and cortisol secretion in at least some patients with Cushing's disease.\n"
p9171
sg4
(lp9172
(dp9173
g7
I78
sg8
VP01282
p9174
sg10
I3
sg11
VVIP
p9175
sg13
I1
sa(dp9176
g7
I114
sg8
VP01189
p9177
sg10
I4
sg11
VACTH
p9178
sg13
I1
sa(dp9179
g7
I47
sg8
VP01282
p9180
sg10
I29
sg11
Vvasoactive intestinal peptide
p9181
sg13
I3
sasg20
(lp9182
(dp9183
g7
I173
sg23
VC0221406
p9184
sg10
I17
sg11
VCushing's disease
p9185
sg13
I2
sasa(dp9186
g2
S"We have also found that the hormonal responses to corticotropin-releasing hormone (CRH) in VIP-responsive patients with Cushing's disease were higher than those in VIP non-responders, which suggested a linkage between the actions of CRH and VIP in this disorder.\n"
p9187
sg4
(lp9188
(dp9189
g7
I83
sg8
VP06850
p9190
sg10
I3
sg11
VCRH
p9191
sg13
I1
sa(dp9192
g7
I50
sg8
VP06850
p9193
sg10
I31
sg11
Vcorticotropin-releasing hormone
p9194
sg13
I2
sa(dp9195
g7
I83
sg8
VP06850
p9196
sg10
I3
sg11
VCRH
p9197
sg13
I1
sa(dp9198
g7
I91
sg8
VP01282
p9199
sg10
I3
sg11
VVIP
p9200
sg13
I1
sasg20
(lp9201
(dp9202
g7
I120
sg23
VC0221406
p9203
sg10
I17
sg11
VCushing's disease
p9204
sg13
I2
sasa(dp9205
g2
S"This study is the first to demonstrate the parallel inhibition by DEX of ACTH and cortisol responses to CRH and VIP in Cushing's disease.\n"
p9206
sg4
(lp9207
(dp9208
g7
I73
sg8
VP01189
p9209
sg10
I4
sg11
VACTH
p9210
sg13
I1
sa(dp9211
g7
I112
sg8
VP01282
p9212
sg10
I3
sg11
VVIP
p9213
sg13
I1
sa(dp9214
g7
I104
sg8
VP06850
p9215
sg10
I3
sg11
VCRH
p9216
sg13
I1
sasg20
(lp9217
(dp9218
g7
I119
sg23
VC0221406
p9219
sg10
I17
sg11
VCushing's disease
p9220
sg13
I2
sasa(dp9221
g2
S"Of the patients with Cushing's disease, 9 (75%) were responsive to hCRH, 5 (42%) were to VIP, and 3 (25%) were to PHM, showing significant increases in both ACTH and cortisol.\n"
p9222
sg4
(lp9223
(dp9224
g7
I89
sg8
VP01282
p9225
sg10
I3
sg11
VVIP
p9226
sg13
I1
sa(dp9227
g7
I157
sg8
VP01189
p9228
sg10
I4
sg11
VACTH
p9229
sg13
I1
sasg20
(lp9230
(dp9231
g7
I21
sg23
VC0221406
p9232
sg10
I17
sg11
VCushing's disease
p9233
sg13
I2
sasa(dp9234
g2
S"In addition, in the patients with Cushing's disease the coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.\n"
p9235
sg4
(lp9236
(dp9237
g7
I93
sg8
VP01282
p9238
sg10
I3
sg11
VVIP
p9239
sg13
I1
sa(dp9240
g7
I133
sg8
VP01189
p9241
sg10
I4
sg11
VACTH
p9242
sg13
I1
sasg20
(lp9243
(dp9244
g7
I34
sg23
VC0221406
p9245
sg10
I17
sg11
VCushing's disease
p9246
sg13
I2
sasa(dp9247
g2
S"Abnormalities in hypothalamic-pituitary adrenal axis function were demonstrated by measuring plasma adrenocorticotropin abnormal concentrations following Vasoactive Intestinal Peptide (VIP) and Corticotropin Releasing Hormone (CRH) administration during a phase of remission of Cushing's disease in a 45-year-old female patient.\n"
p9248
sg4
(lp9249
(dp9250
g7
I194
sg8
VP06850
p9251
sg10
I31
sg11
VCorticotropin Releasing Hormone
p9252
sg13
I3
sa(dp9253
g7
I100
sg8
VP01189
p9254
sg10
I19
sg11
Vadrenocorticotropin
p9255
sg13
I1
sa(dp9256
g7
I185
sg8
VP01282
p9257
sg10
I3
sg11
VVIP
p9258
sg13
I1
sa(dp9259
g7
I154
sg8
VP01282
p9260
sg10
I29
sg11
VVasoactive Intestinal Peptide
p9261
sg13
I3
sa(dp9262
g7
I227
sg8
VP06850
p9263
sg10
I3
sg11
VCRH
p9264
sg13
I1
sasg20
(lp9265
(dp9266
g7
I278
sg23
VC0221406
p9267
sg10
I17
sg11
VCushing's disease
p9268
sg13
I2
sa(dp9269
g7
I265
sg23
VC0687702
p9270
sg10
I9
sg11
Vremission
p9271
sg13
I1
sasa(dp9272
g2
S"We conclude that the study of ACTH and cortisol response to VIP and CRH may be useful in revealing Cushing's disease even during a remission phase of the disorder.\n"
p9273
sg4
(lp9274
(dp9275
g7
I68
sg8
VP06850
p9276
sg10
I3
sg11
VCRH
p9277
sg13
I1
sa(dp9278
g7
I30
sg8
VP01189
p9279
sg10
I4
sg11
VACTH
p9280
sg13
I1
sa(dp9281
g7
I60
sg8
VP01282
p9282
sg10
I3
sg11
VVIP
p9283
sg13
I1
sasg20
(lp9284
(dp9285
g7
I131
sg23
VC0687702
p9286
sg10
I9
sg11
Vremission
p9287
sg13
I1
sa(dp9288
g7
I99
sg23
VC0221406
p9289
sg10
I17
sg11
VCushing's disease
p9290
sg13
I2
sasa(dp9291
g2
S'Here we introduce a cell culture model of EAD propagation consisting of monolayers of cultured neonatal rat ventricular myocytes treated with anthopleurin-A (AP-A).\n'
p9292
sg4
(lp9293
(dp9294
g7
I142
sg8
g15
sg10
I14
sg11
Vanthopleurin-A
p9295
sg13
I1
sa(dp9296
g7
I158
sg8
g15
sg10
I4
sg11
VAP-A
p9297
sg13
I1
sasg20
(lp9298
(dp9299
g7
I42
sg23
VC1864233
p9300
sg10
I3
sg11
VEAD
p9301
sg13
I1
sasa(dp9302
g2
S'The present study provides evidence in support of the hypothesis that AP-A-induced ventricular tachyarrhythmias are due to bradycardia-dependent EAD and triggered activity.\n'
p9303
sg4
(lp9304
(dp9305
g7
I70
sg8
g15
sg10
I4
sg11
VAP-A
p9306
sg13
I1
sasg20
(lp9307
(dp9308
g7
I145
sg23
VC1864233
p9309
sg10
I3
sg11
VEAD
p9310
sg13
I1
sa(dp9311
g7
I123
sg23
VC0428977
p9312
sg10
I11
sg11
Vbradycardia
p9313
sg13
I1
sasa(dp9314
g2
S'TU alternans was investigated by MAP recordings in six normal dogs, following the administration of anthopleurin-A (AP-A), a drug shown to delay sodium inactivation and to induce bradycardia dependent long QTU, EADs, and TdP.\n'
p9315
sg4
(lp9316
(dp9317
g7
I179
sg8
VP19525
p9318
sg10
I36
sg11
Vbradycardia dependent long QTU, EADs
p9319
sg13
I5
sa(dp9320
g7
I100
sg8
g15
sg10
I14
sg11
Vanthopleurin-A
p9321
sg13
I1
sa(dp9322
g7
I116
sg8
g15
sg10
I4
sg11
VAP-A
p9323
sg13
I1
sasg20
(lp9324
(dp9325
g7
I179
sg23
VC0428977
p9326
sg10
I11
sg11
Vbradycardia
p9327
sg13
I1
sa(dp9328
g7
I152
sg23
VC0544461
p9329
sg10
I12
sg11
Vinactivation
p9330
sg13
I1
sasa(dp9331
g2
S"Moreover, a series of recent studies have genetically and functionally linked kalirin signaling to several disorders, including schizophrenia and Alzheimer's disease.\n"
p9332
sg4
(lp9333
(dp9334
g7
I78
sg8
g15
sg10
I7
sg11
Vkalirin
p9335
sg13
I1
sasg20
(lp9336
(dp9337
g7
I128
sg23
VC0036341
p9338
sg10
I13
sg11
Vschizophrenia
p9339
sg13
I1
sa(dp9340
g7
I146
sg23
VC1521724
p9341
sg10
I19
sg11
VAlzheimer's disease
p9342
sg13
I2
sasa(dp9343
g2
S"A series of recent studies has improved our understanding of spine dynamics by establishing kalirin-7 as an important regulator of dendritic spine development as well as structural and functional plasticity, providing a model for the molecular control of structural plasticity and implicating kalirin-7 in synaptic pathology in several disorders including schizophrenia and Alzheimer's disease.\n"
p9344
sg4
(lp9345
(dp9346
g7
I92
sg8
g15
sg10
I9
sg11
Vkalirin-7
p9347
sg13
I1
sa(dp9348
g7
I92
sg8
g15
sg10
I9
sg11
Vkalirin-7
p9349
sg13
I1
sasg20
(lp9350
(dp9351
g7
I356
sg23
VC0036341
p9352
sg10
I13
sg11
Vschizophrenia
p9353
sg13
I1
sa(dp9354
g7
I374
sg23
VC1521724
p9355
sg10
I19
sg11
VAlzheimer's disease
p9356
sg13
I2
sa(dp9357
g7
I315
sg23
VC0677042
p9358
sg10
I9
sg11
Vpathology
p9359
sg13
I1
sasa(dp9360
g2
S'Here, we report that inhibition of the cell cycle-dependent kinase 9 (Cdk9) by RNA interference, or the compound flavopiridol, blocked infections with HAdV-C2/5, EKC-causing HAdV-D8/37, and progeny formation in human corneal epithelial and cancer cells.\n'
p9361
sg4
(lp9362
(dp9363
g7
I44
sg8
VP19525
p9364
sg10
I24
sg11
Vcycle-dependent kinase 9
p9365
sg13
I3
sa(dp9366
g7
I70
sg8
VP50750
p9367
sg10
I4
sg11
VCdk9
p9368
sg13
I1
sasg20
(lp9369
(dp9370
g7
I240
sg23
VC0006826
p9371
sg10
I6
sg11
Vcancer
p9372
sg13
I1
sa(dp9373
g7
I135
sg23
VC0021311
p9374
sg10
I10
sg11
Vinfections
p9375
sg13
I1
sa(dp9376
g7
I162
sg23
VC0014493
p9377
sg10
I3
sg11
VEKC
p9378
sg13
I1
sasa(dp9379
g2
S'The study identifies Cdk9 as a postexposure drug target against adenovirus infections in vitro and suggests that the clinically tested anticancer drug flavopiridol is a candidate for treating adenoviral EKC or adenovirus emergence upon immune suppression.\n'
p9380
sg4
(lp9381
(dp9382
g7
I21
sg8
VP50750
p9383
sg10
I4
sg11
VCdk9
p9384
sg13
I1
sasg20
(lp9385
(dp9386
g7
I64
sg23
VC0001486
p9387
sg10
I21
sg11
Vadenovirus infections
p9388
sg13
I2
sa(dp9389
g7
I236
sg23
VC1840264
p9390
sg10
I18
sg11
Vimmune suppression
p9391
sg13
I2
sa(dp9392
g7
I203
sg23
VC0014493
p9393
sg10
I3
sg11
VEKC
p9394
sg13
I1
sa(dp9395
g7
I64
sg23
VC0001486
p9396
sg10
I10
sg11
Vadenovirus
p9397
sg13
I1
sasa(dp9398
g2
S'We conclude that: 1) synthetic non-thiazolidinediones can serve as ligands of PPARgamma and PPARdelta; 2) ligand-dependent activation of PPARdelta involves an apparent conformational change and association of the receptor ligand binding domain with CREB-binding protein; 3) PPARgamma activation (but not PPARdelta or PPARalpha activation) is sufficient to potentiate preadipocyte differentiation; 4) non-thiazolidinedione PPARgamma agonists improve hyperglycemia and hypertriglyceridemia in vivo; 5) although PPARalpha activation is sufficient to affect triglyceride metabolism, PPARdelta activation does not appear to modulate glucose or triglyceride levels.\n'
p9399
sg4
(lp9400
(dp9401
g7
I92
sg8
g15
sg10
I9
sg11
VPPARdelta
p9402
sg13
I1
sa(dp9403
g7
I92
sg8
g15
sg10
I9
sg11
VPPARdelta
p9404
sg13
I1
sa(dp9405
g7
I92
sg8
g15
sg10
I9
sg11
VPPARdelta
p9406
sg13
I1
sa(dp9407
g7
I317
sg8
g15
sg10
I9
sg11
VPPARalpha
p9408
sg13
I1
sa(dp9409
g7
I249
sg8
g15
sg10
I20
sg11
VCREB-binding protein
p9410
sg13
I2
sa(dp9411
g7
I92
sg8
g15
sg10
I9
sg11
VPPARdelta
p9412
sg13
I1
sa(dp9413
g7
I317
sg8
g15
sg10
I9
sg11
VPPARalpha
p9414
sg13
I1
sa(dp9415
g7
I213
sg8
g15
sg10
I30
sg11
Vreceptor ligand binding domain
p9416
sg13
I4
sasg20
(lp9417
(dp9418
g7
I449
sg23
VC0020456
p9419
sg10
I13
sg11
Vhyperglycemia
p9420
sg13
I1
sasa(dp9421
g2
S'At present, four loci associated with non-syndromic auditory neuropathy have been mapped: Autosomal recessive deafness-9 [DFNB9; the otoferlin (OTOF) gene] and autosomal recessive deafness-59 [DFNB59; the pejvakin (PJVK) gene], associated with autosomal recessive inheritance; the autosomal dominant auditory neuropathy gene [AUNA1; the diaphanous-3 (DIAPH3) gene]; and AUNX1, linked to chromosome X.\n'
p9422
sg4
(lp9423
(dp9424
g7
I122
sg8
g15
sg10
I5
sg11
VDFNB9
p9425
sg13
I1
sasg20
(lp9426
(dp9427
g7
I370
sg23
VC1845095
p9428
sg10
I5
sg11
VAUNX1
p9429
sg13
I1
sa(dp9430
g7
I110
sg23
VC0011053
p9431
sg10
I8
sg11
Vdeafness
p9432
sg13
I1
sa(dp9433
g7
I122
sg23
VC1832828
p9434
sg10
I5
sg11
VDFNB9
p9435
sg13
I1
sa(dp9436
g7
I110
sg23
VC0011053
p9437
sg10
I8
sg11
Vdeafness
p9438
sg13
I1
sa(dp9439
g7
I193
sg23
VC1857744
p9440
sg10
I6
sg11
VDFNB59
p9441
sg13
I1
sa(dp9442
g7
I326
sg23
VC1836743
p9443
sg10
I5
sg11
VAUNA1
p9444
sg13
I1
sa(dp9445
g7
I52
sg23
VC1852271
p9446
sg10
I19
sg11
Vauditory neuropathy
p9447
sg13
I2
sa(dp9448
g7
I52
sg23
VC1852271
p9449
sg10
I19
sg11
Vauditory neuropathy
p9450
sg13
I2
sasa(dp9451
g2
S'Presence of antibodies to carbamylated fetal calf serum (CarP-FCS) and fibrinogen (CarP-Fib) was determined by inhouse ELISAs among RA cases in the Leiden Early Arthritis Clinic (n=846) and in the Swedish Epidemiological Investigation of Rheumatoid Arthritis (n=1985) cohorts.\n'
p9452
sg4
(lp9453
(dp9454
g7
I57
sg8
VP35219
p9455
sg10
I8
sg11
VCarP-FCS
p9456
sg13
I1
sa(dp9457
g7
I71
sg8
VP22087
p9458
sg10
I10
sg11
Vfibrinogen
p9459
sg13
I1
sa(dp9460
g7
I83
sg8
VP35219
p9461
sg10
I8
sg11
VCarP-Fib
p9462
sg13
I1
sasg20
(lp9463
(dp9464
g7
I57
sg23
VC0263385
p9465
sg10
I4
sg11
VCarP
p9466
sg13
I1
sa(dp9467
g7
I238
sg23
VC0003873
p9468
sg10
I20
sg11
VRheumatoid Arthritis
p9469
sg13
I2
sa(dp9470
g7
I57
sg23
VC0263385
p9471
sg10
I4
sg11
VCarP
p9472
sg13
I1
sa(dp9473
g7
I161
sg23
VC0003864
p9474
sg10
I9
sg11
VArthritis
p9475
sg13
I1
sasa(dp9476
g2
S'To detect the antibodies against human fibrinogen (FIB) Beta67-77 peptide and citrullinated human FIB Beta67-77 peptide in rheumatoid arthritis (RA) and examine their diagnostic values in RA.\n'
p9477
sg4
(lp9478
(dp9479
g7
I92
sg8
VP22087
p9480
sg10
I27
sg11
Vhuman FIB Beta67-77 peptide
p9481
sg13
I4
sa(dp9482
g7
I51
sg8
VP22087
p9483
sg10
I3
sg11
VFIB
p9484
sg13
I1
sa(dp9485
g7
I56
sg8
g15
sg10
I17
sg11
VBeta67-77 peptide
p9486
sg13
I2
sa(dp9487
g7
I33
sg8
VP22087
p9488
sg10
I16
sg11
Vhuman fibrinogen
p9489
sg13
I2
sasg20
(lp9490
(dp9491
g7
I123
sg23
VC0003873
p9492
sg10
I20
sg11
Vrheumatoid arthritis
p9493
sg13
I2
sa(dp9494
g7
I145
sg23
VC0003873
p9495
sg10
I2
sg11
VRA
p9496
sg13
I1
sa(dp9497
g7
I145
sg23
VC0003873
p9498
sg10
I2
sg11
VRA
p9499
sg13
I1
sasa(dp9500
g2
S"Polymyositis/dermatomyositis, systemic lupus erythematosus and Addison's disease, three conditions regulated by the HLA-B8-DR3 haplotype, were most strongly associated with MG, especially early-onset disease.\n"
p9501
sg4
(lp9502
(dp9503
g7
I116
sg8
VP30486
p9504
sg10
I20
sg11
VHLA-B8-DR3 haplotype
p9505
sg13
I2
sasg20
(lp9506
(dp9507
g7
I30
sg23
VC0024141
p9508
sg10
I28
sg11
Vsystemic lupus erythematosus
p9509
sg13
I3
sa(dp9510
g7
I63
sg23
VC0001403
p9511
sg10
I17
sg11
VAddison's disease
p9512
sg13
I2
sa(dp9513
g7
I0
sg23
VC0085655
p9514
sg10
I12
sg11
VPolymyositis
p9515
sg13
I1
sa(dp9516
g7
I13
sg23
VC0221056
p9517
sg10
I15
sg11
Vdermatomyositis
p9518
sg13
I1
sasa(dp9519
g2
S'The prevalence of sporadic inclusion body myositis (sIBM) was correlated with the frequency of HLA-DR3.\n'
p9520
sg4
(lp9521
(dp9522
g7
I95
sg8
VP30486
p9523
sg10
I7
sg11
VHLA-DR3
p9524
sg13
I1
sasg20
(lp9525
(dp9526
g7
I18
sg23
VC0751713
p9527
sg10
I32
sg11
Vsporadic inclusion body myositis
p9528
sg13
I4
sa(dp9529
g7
I52
sg23
VC0751713
p9530
sg10
I4
sg11
VsIBM
p9531
sg13
I1
sasa(dp9532
g2
S'The B8-DR3 haplotype fragment conferred the strongest susceptibility (OR 2.9, 95% CI 1.8-4.6), and the B-DR region of other ancestral haplotypes was associated with myositis subgroups.\n'
p9533
sg4
(lp9534
sg20
(lp9535
(dp9536
g7
I165
sg23
VC0027121
p9537
sg10
I8
sg11
Vmyositis
p9538
sg13
I1
sasa(dp9539
g2
S'Most gastric IFPs were associated with chronic atrophic gastritis while only one ileal polyp was associated with Meckels diverticulum.\n'
p9540
sg4
(lp9541
(dp9542
g7
I13
sg8
g15
sg10
I4
sg11
VIFPs
p9543
sg13
I1
sasg20
(lp9544
(dp9545
g7
I87
sg23
VC0032584
p9546
sg10
I5
sg11
Vpolyp
p9547
sg13
I1
sa(dp9548
g7
I113
sg23
VC0025037
p9549
sg10
I20
sg11
VMeckels diverticulum
p9550
sg13
I2
sa(dp9551
g7
I39
sg23
VC0017154
p9552
sg10
I26
sg11
Vchronic atrophic gastritis
p9553
sg13
I3
sasa(dp9554
g2
S'CBR1, DYRK1A, HMGN1, ITSN1, RCAN1, SON, TMEM50B, and TTC3 were each up-regulated two-fold in Down syndrome samples compared to normal samples; of these, SON and TTC3 were newly reported.\n'
p9555
sg4
(lp9556
(dp9557
g7
I21
sg8
g15
sg10
I5
sg11
VITSN1
p9558
sg13
I1
sa(dp9559
g7
I40
sg8
VP56557
p9560
sg10
I7
sg11
VTMEM50B
p9561
sg13
I1
sa(dp9562
g7
I0
sg8
VP16152
p9563
sg10
I4
sg11
VCBR1
p9564
sg13
I1
sa(dp9565
g7
I6
sg8
g15
sg10
I6
sg11
VDYRK1A
p9566
sg13
I1
sa(dp9567
g7
I14
sg8
VP05114
p9568
sg10
I5
sg11
VHMGN1
p9569
sg13
I1
sasg20
(lp9570
(dp9571
g7
I93
sg23
VC0013080
p9572
sg10
I13
sg11
VDown syndrome
p9573
sg13
I2
sasa(dp9574
g2
S'In this report we show that high levels of the TTC3 protein, encoded by one of the genes of the Down Syndrome Critical Region (DCR), prevent neurite extension and disrupt Golgi compactness in differentiating primary neurons.\n'
p9575
sg4
(lp9576
sg20
(lp9577
(dp9578
g7
I96
sg23
VC1860787
p9579
sg10
I29
sg11
VDown Syndrome Critical Region
p9580
sg13
I4
sa(dp9581
g7
I127
sg23
VC1860787
p9582
sg10
I3
sg11
VDCR
p9583
sg13
I1
sasa(dp9584
g2
S'TTC3 contains a canonical RING finger motif, a pair of tetratricopeptide motifs, a putative Akt phosphorylation site, and nuclear localization signals, and is encoded by a gene within the Down syndrome (DS) critical region on chromosome 21.\n'
p9585
sg4
(lp9586
(dp9587
g7
I92
sg8
g15
sg10
I3
sg11
VAkt
p9588
sg13
I1
sasg20
(lp9589
(dp9590
g7
I203
sg23
VC0013080
p9591
sg10
I2
sg11
VDS
p9592
sg13
I1
sa(dp9593
g7
I188
sg23
VC0013080
p9594
sg10
I13
sg11
VDown syndrome
p9595
sg13
I2
sasa(dp9596
g2
S'Nonchimeric polytransgenic 152F7 mice encompassing four human chromosome 21 genes (DSCR3, DSCR5, TTC3, and DYRK1A) within the Down syndrome critical region present with learning and memory impairment.\n'
p9597
sg4
(lp9598
(dp9599
g7
I90
sg8
VP57054
p9600
sg10
I5
sg11
VDSCR5
p9601
sg13
I1
sa(dp9602
g7
I107
sg8
g15
sg10
I6
sg11
VDYRK1A
p9603
sg13
I1
sa(dp9604
g7
I83
sg8
g15
sg10
I5
sg11
VDSCR3
p9605
sg13
I1
sasg20
(lp9606
(dp9607
g7
I126
sg23
VC1860787
p9608
sg10
I29
sg11
VDown syndrome critical region
p9609
sg13
I4
sa(dp9610
g7
I182
sg23
VC0233794
p9611
sg10
I17
sg11
Vmemory impairment
p9612
sg13
I2
sasa(dp9613
g2
S'Multivariate regression analysis revealed that plasma VWF Ag level is an independent predictor of mortality in ARDS pediatric patients.\n'
p9614
sg4
(lp9615
(dp9616
g7
I47
sg8
VP04275
p9617
sg10
I13
sg11
Vplasma VWF Ag
p9618
sg13
I3
sasg20
(lp9619
(dp9620
g7
I111
sg23
VC0035222
p9621
sg10
I4
sg11
VARDS
p9622
sg13
I1
sasa(dp9623
g2
S'Plasma VWF Ag level is an excellent predictive marker for outcome in children with ALI/ARDS.\n'
p9624
sg4
(lp9625
(dp9626
g7
I0
sg8
VP04275
p9627
sg10
I13
sg11
VPlasma VWF Ag
p9628
sg13
I3
sasg20
(lp9629
(dp9630
g7
I87
sg23
VC0035222
p9631
sg10
I4
sg11
VARDS
p9632
sg13
I1
sasa(dp9633
g2
S'In the multicenter study, patients with direct ARDS also had lower levels of von Willebrand factor antigen and IL-6 and IL-8, markers of endothelial injury and inflammation, respectively.\n'
p9634
sg4
(lp9635
(dp9636
g7
I111
sg8
VP05231
p9637
sg10
I4
sg11
VIL-6
p9638
sg13
I1
sa(dp9639
g7
I77
sg8
VP04275
p9640
sg10
I29
sg11
Vvon Willebrand factor antigen
p9641
sg13
I4
sasg20
(lp9642
(dp9643
g7
I47
sg23
VC0035222
p9644
sg10
I4
sg11
VARDS
p9645
sg13
I1
sa(dp9646
g7
I160
sg23
VC0021368
p9647
sg10
I12
sg11
Vinflammation
p9648
sg13
I1
sasa(dp9649
g2
S'To investigate the role of endothelial cell mediators, E-selectin (ES), intercellular adhesion molecule-1 (ICAM-1), tissue factor (TF), and von Willebrand factor (vWF), in the early phase of severe acute pancreatitis (SAP) complicated with respiratory failure [pancreatitis-associated lung injury (PALI)].\n'
p9650
sg4
(lp9651
(dp9652
g7
I72
sg8
VP05362
p9653
sg10
I33
sg11
Vintercellular adhesion molecule-1
p9654
sg13
I3
sa(dp9655
g7
I140
sg8
VP04275
p9656
sg10
I21
sg11
Vvon Willebrand factor
p9657
sg13
I3
sa(dp9658
g7
I163
sg8
VP04275
p9659
sg10
I3
sg11
VvWF
p9660
sg13
I1
sa(dp9661
g7
I107
sg8
VP05362
p9662
sg10
I6
sg11
VICAM-1
p9663
sg13
I1
sa(dp9664
g7
I27
sg8
VP16581
p9665
sg10
I38
sg11
Vendothelial cell mediators, E-selectin
p9666
sg13
I4
sasg20
(lp9667
(dp9668
g7
I86
sg23
VC0001511
p9669
sg10
I8
sg11
Vadhesion
p9670
sg13
I1
sa(dp9671
g7
I240
sg23
VC1145670
p9672
sg10
I19
sg11
Vrespiratory failure
p9673
sg13
I2
sa(dp9674
g7
I204
sg23
VC0030305
p9675
sg10
I12
sg11
Vpancreatitis
p9676
sg13
I1
sa(dp9677
g7
I198
sg23
VC0001339
p9678
sg10
I18
sg11
Vacute pancreatitis
p9679
sg13
I2
sasa(dp9680
g2
S'Thus, CLC-2 may be a promising and potential novel therapeutic strategy for combating primary open-angle glaucoma.\n'
p9681
sg4
(lp9682
(dp9683
g7
I6
sg8
VP51788
p9684
sg10
I5
sg11
VCLC-2
p9685
sg13
I1
sasg20
(lp9686
(dp9687
g7
I86
sg23
VC0339573
p9688
sg10
I27
sg11
Vprimary open-angle glaucoma
p9689
sg13
I3
sasa(dp9690
g2
S'To determine the effects of bariatric surgery on albuminuria in obese patients with type 2 diabetes mellitus.\n'
p9691
sg4
(lp9692
sg20
(lp9693
(dp9694
g7
I84
sg23
VC0011860
p9695
sg10
I24
sg11
Vtype 2 diabetes mellitus
p9696
sg13
I4
sa(dp9697
g7
I64
sg23
VC0028754
p9698
sg10
I5
sg11
Vobese
p9699
sg13
I1
sasa(dp9700
g2
S'Retrospective analyses of clinical records of obese patients with type 2 diabetes mellitus who had either micro- or macroalbuminuria and had undergone various bariatric surgery were retrieved from a local hospital database.\n'
p9701
sg4
(lp9702
sg20
(lp9703
(dp9704
g7
I66
sg23
VC0011860
p9705
sg10
I24
sg11
Vtype 2 diabetes mellitus
p9706
sg13
I4
sa(dp9707
g7
I46
sg23
VC0028754
p9708
sg10
I5
sg11
Vobese
p9709
sg13
I1
sasa(dp9710
g2
S'Of the 46 subjects with type 2 diabetes mellitus, 15 subjects had diabetic nephropathy and had pre- and post-bariatric surgery urine albumin-to-creatinine ratio or urine protein-to-creatinine ratio data available for analysis; 13 out of the 15 subjects (86.7%) showed improvement of urine albumin-to-creatinine ratio or urine protein-to-creatinine ratio after surgery; 2 showed equivocal results; 9 of 13 subjects (69.2%) showed remission of diabetic nephropathy; 7 of these 9 patients had microalbuminuria before surgery, 2 had macroalbuminuria before surgery.\n'
p9711
sg4
(lp9712
(dp9713
g7
I127
sg8
VP11172
p9714
sg10
I13
sg11
Vurine albumin
p9715
sg13
I2
sasg20
(lp9716
(dp9717
g7
I429
sg23
VC0687702
p9718
sg10
I9
sg11
Vremission
p9719
sg13
I1
sa(dp9720
g7
I66
sg23
VC0011881
p9721
sg10
I20
sg11
Vdiabetic nephropathy
p9722
sg13
I2
sa(dp9723
g7
I490
sg23
VC0730345
p9724
sg10
I16
sg11
Vmicroalbuminuria
p9725
sg13
I1
sa(dp9726
g7
I66
sg23
VC0011881
p9727
sg10
I20
sg11
Vdiabetic nephropathy
p9728
sg13
I2
sa(dp9729
g7
I24
sg23
VC0011860
p9730
sg10
I24
sg11
Vtype 2 diabetes mellitus
p9731
sg13
I4
sasa(dp9732
g2
S'In type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate.\n'
p9733
sg4
(lp9734
(dp9735
g7
I134
sg8
VP00441
p9736
sg10
I7
sg11
Valbumin
p9737
sg13
I1
sasg20
(lp9738
(dp9739
g7
I45
sg23
VC1561643
p9740
sg10
I22
sg11
Vchronic kidney disease
p9741
sg13
I3
sa(dp9742
g7
I3
sg23
VC0011860
p9743
sg10
I24
sg11
Vtype 2 diabetes mellitus
p9744
sg13
I4
sa(dp9745
g7
I29
sg23
VC0011860
p9746
sg10
I4
sg11
VT2DM
p9747
sg13
I1
sa(dp9748
g7
I69
sg23
VC1561643
p9749
sg10
I3
sg11
VCKD
p9750
sg13
I1
sasa(dp9751
g2
S'To investigate, for the first time, the impact of systolic pulmonary arterial pressure (PASP) on maximal exercise capacity in adults with mild-to-moderate cystic fibrosis, without PH at rest.\n'
p9752
sg4
(lp9753
sg20
(lp9754
(dp9755
g7
I155
sg23
VC0010674
p9756
sg10
I15
sg11
Vcystic fibrosis
p9757
sg13
I2
sasa(dp9758
g2
S'Assays of carboxypeptidase B-like activity and C3 in serum from patients with cystic fibrosis and appropriate control subjects failed to demonstrate a deficiency of carboxypeptidase B-like activity or a consistent increase in C3, as was suggested by Conover and associates.\n'
p9759
sg4
(lp9760
(dp9761
g7
I10
sg8
VP15086
p9762
sg10
I23
sg11
Vcarboxypeptidase B-like
p9763
sg13
I2
sa(dp9764
g7
I10
sg8
VP15086
p9765
sg10
I23
sg11
Vcarboxypeptidase B-like
p9766
sg13
I2
sasg20
(lp9767
(dp9768
g7
I78
sg23
VC0010674
p9769
sg10
I15
sg11
Vcystic fibrosis
p9770
sg13
I2
sa(dp9771
g7
I151
sg23
VC0398782
p9772
sg10
I32
sg11
Vdeficiency of carboxypeptidase B
p9773
sg13
I4
sasa(dp9774
g2
S'Differences between men and women with cystic fibrosis were apparent, in that women with cystic fibrosis had higher concentrations of both serum carboxypeptidase B-like activity and C3 than either men with cystic fibrosis or control subjects.\n'
p9775
sg4
(lp9776
(dp9777
g7
I139
sg8
VP15086
p9778
sg10
I24
sg11
Vserum carboxypeptidase B
p9779
sg13
I3
sasg20
(lp9780
(dp9781
g7
I39
sg23
VC0010674
p9782
sg10
I15
sg11
Vcystic fibrosis
p9783
sg13
I2
sa(dp9784
g7
I39
sg23
VC0010674
p9785
sg10
I15
sg11
Vcystic fibrosis
p9786
sg13
I2
sa(dp9787
g7
I39
sg23
VC0010674
p9788
sg10
I15
sg11
Vcystic fibrosis
p9789
sg13
I2
sasa(dp9790
g2
S'The properties and lysosomal distribution of the enzyme indicated that it was a carboxypeptidase B. Substrate affinity, thermolability, pH stability, the fall and rise in activity with subculture, the cyclical pattern of activity through serial passage and the level of activity were similar for the control and cystic fibrosis enzyme.\n'
p9791
sg4
(lp9792
(dp9793
g7
I80
sg8
VP15086
p9794
sg10
I18
sg11
Vcarboxypeptidase B
p9795
sg13
I2
sa(dp9796
g7
I312
sg8
VP13569
p9797
sg10
I22
sg11
Vcystic fibrosis enzyme
p9798
sg13
I3
sasg20
(lp9799
(dp9800
g7
I312
sg23
VC0010674
p9801
sg10
I15
sg11
Vcystic fibrosis
p9802
sg13
I2
sasa(dp9803
g2
S'In this review the roles identified for different selenoproteins in these steps and how they may promote or inhibit metastatic cancers is discussed.\n'
p9804
sg4
(lp9805
sg20
(lp9806
(dp9807
g7
I127
sg23
VC0006826
p9808
sg10
I7
sg11
Vcancers
p9809
sg13
I1
sasa(dp9810
g2
S'Indeed, many selenoproteins have antioxidant activity which can attenuate cancer development by minimizing oxidative insult and resultant DNA damage.\n'
p9811
sg4
(lp9812
(dp9813
g7
I13
sg8
VP55073
p9814
sg10
I14
sg11
Vselenoproteins
p9815
sg13
I1
sasg20
(lp9816
(dp9817
g7
I138
sg23
VC0012860
p9818
sg10
I10
sg11
VDNA damage
p9819
sg13
I2
sa(dp9820
g7
I74
sg23
VC0006826
p9821
sg10
I6
sg11
Vcancer
p9822
sg13
I1
sasa(dp9823
g2
S'In this review, we discuss what is currently known about selenoproteins in tumorigenesis with a focus on their contextual roles in cancer development, growth, and progression.\n'
p9824
sg4
(lp9825
(dp9826
g7
I57
sg8
VP55073
p9827
sg10
I14
sg11
Vselenoproteins
p9828
sg13
I1
sasg20
(lp9829
(dp9830
g7
I75
sg23
VC0007621
p9831
sg10
I13
sg11
Vtumorigenesis
p9832
sg13
I1
sa(dp9833
g7
I131
sg23
VC0006826
p9834
sg10
I6
sg11
Vcancer
p9835
sg13
I1
sasa(dp9836
g2
S'New aspects of Se actions in breast cancer have emerged such as the impact of genetic polymorphisms on Se metabolism and response, new functions of selenoproteins, epigenetic modulation of gene expression, and long-term influence of early-life exposure on disease risk.\n'
p9837
sg4
(lp9838
(dp9839
g7
I148
sg8
VP55073
p9840
sg10
I14
sg11
Vselenoproteins
p9841
sg13
I1
sasg20
(lp9842
(dp9843
g7
I29
sg23
VC0678222
p9844
sg10
I13
sg11
Vbreast cancer
p9845
sg13
I2
sasa(dp9846
g2
S'We observed that both SelS and C99 were colocalized in the membrane fraction of mouse neuroblastoma Neuro2a (N2a) cells.\n'
p9847
sg4
(lp9848
(dp9849
g7
I22
sg8
g15
sg10
I4
sg11
VSelS
p9850
sg13
I1
sasg20
(lp9851
(dp9852
g7
I80
sg23
VC1524043
p9853
sg10
I19
sg11
Vmouse neuroblastoma
p9854
sg13
I2
sasa(dp9855
g2
S'The results suggest that decreased NPY expression in the extended amygdala might be causally linked with the depression induced following type 2 diabetes and that the antidepressant action of imipramine in diabetic mice might be mediated by NPY-NPY Y1 receptor system.\n'
p9856
sg4
(lp9857
(dp9858
g7
I35
sg8
VP25929
p9859
sg10
I3
sg11
VNPY
p9860
sg13
I1
sa(dp9861
g7
I241
sg8
VP25929
p9862
sg10
I19
sg11
VNPY-NPY Y1 receptor
p9863
sg13
I3
sasg20
(lp9864
(dp9865
g7
I138
sg23
VC0011860
p9866
sg10
I15
sg11
Vtype 2 diabetes
p9867
sg13
I3
sa(dp9868
g7
I109
sg23
VC0011581
p9869
sg10
I10
sg11
Vdepression
p9870
sg13
I1
sasa(dp9871
g2
S'Numerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor.\n'
p9872
sg4
(lp9873
(dp9874
g7
I301
sg8
VP25929
p9875
sg10
I19
sg11
VCNS NPY Y1 receptor
p9876
sg13
I4
sa(dp9877
g7
I116
sg8
VP25929
p9878
sg10
I3
sg11
VNPY
p9879
sg13
I1
sa(dp9880
g7
I116
sg8
VP25929
p9881
sg10
I3
sg11
VNPY
p9882
sg13
I1
sa(dp9883
g7
I100
sg8
VP01303
p9884
sg10
I14
sg11
Vneuropeptide Y
p9885
sg13
I2
sasg20
(lp9886
(dp9887
g7
I31
sg23
VC0011849
p9888
sg10
I8
sg11
Vdiabetes
p9889
sg13
I1
sa(dp9890
g7
I19
sg23
VC0028754
p9891
sg10
I7
sg11
Vobesity
p9892
sg13
I1
sa(dp9893
g7
I79
sg23
VC0027769
p9894
sg10
I7
sg11
Vnervous
p9895
sg13
I1
sasa(dp9896
g2
S'We investigated whether annexin A8 (A-A8), a Ca-binding protein overexpressed in pancreatic cancer, plays a role in cell growth and migration and investigated its association with pancreatic cancer prognosis.\n'
p9897
sg4
(lp9898
(dp9899
g7
I45
sg8
g15
sg10
I18
sg11
VCa-binding protein
p9900
sg13
I2
sasg20
(lp9901
(dp9902
g7
I81
sg23
VC0235974
p9903
sg10
I17
sg11
Vpancreatic cancer
p9904
sg13
I2
sa(dp9905
g7
I81
sg23
VC0235974
p9906
sg10
I17
sg11
Vpancreatic cancer
p9907
sg13
I2
sasa(dp9908
g2
S'Although Annexin A8 (ANXA8), a member of a superfamily of calcium and phospholipid binding proteins, is physiologically expressed in a tissue-specific manner, recent microarray studies reported that ANXA8 was also ectopically expressed in pancreatic cancers.\n'
p9909
sg4
(lp9910
(dp9911
g7
I21
sg8
VP13928
p9912
sg10
I5
sg11
VANXA8
p9913
sg13
I1
sa(dp9914
g7
I21
sg8
VP13928
p9915
sg10
I5
sg11
VANXA8
p9916
sg13
I1
sa(dp9917
g7
I9
sg8
VP13928
p9918
sg10
I10
sg11
VAnnexin A8
p9919
sg13
I2
sasg20
(lp9920
(dp9921
g7
I239
sg23
VC0346647
p9922
sg10
I18
sg11
Vpancreatic cancers
p9923
sg13
I2
sasa(dp9924
g2
S'We investigated the molecular mechanism of expression of ANXA8 in cancer cells and its functional role in pancreatic cancer cells.\n'
p9925
sg4
(lp9926
(dp9927
g7
I57
sg8
VP13928
p9928
sg10
I5
sg11
VANXA8
p9929
sg13
I1
sasg20
(lp9930
(dp9931
g7
I66
sg23
VC0006826
p9932
sg10
I6
sg11
Vcancer
p9933
sg13
I1
sa(dp9934
g7
I106
sg23
VC0235974
p9935
sg10
I17
sg11
Vpancreatic cancer
p9936
sg13
I2
sasa(dp9937
g2
S'To investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.\n'
p9938
sg4
(lp9939
(dp9940
g7
I135
sg8
g15
sg10
I4
sg11
VMUC6
p9941
sg13
I1
sa(dp9942
g7
I220
sg8
VP25815
p9943
sg10
I5
sg11
VS100P
p9944
sg13
I1
sa(dp9945
g7
I328
sg8
VP56856
p9946
sg10
I10
sg11
Vclaudin 18
p9947
sg13
I2
sa(dp9948
g7
I91
sg8
VP35900
p9949
sg10
I4
sg11
VCK20
p9950
sg13
I1
sa(dp9951
g7
I151
sg8
g15
sg10
I5
sg11
VSMAD4
p9952
sg13
I1
sa(dp9953
g7
I158
sg8
g15
sg10
I4
sg11
VCDX2
p9954
sg13
I1
sa(dp9955
g7
I317
sg8
g15
sg10
I9
sg11
Vclaudin 4
p9956
sg13
I2
sa(dp9957
g7
I227
sg8
g15
sg10
I5
sg11
VIMP-3
p9958
sg13
I1
sa(dp9959
g7
I115
sg8
g15
sg10
I4
sg11
VMUC2
p9960
sg13
I1
sa(dp9961
g7
I164
sg8
VP40337
p9962
sg10
I4
sg11
VpVHL
p9963
sg13
I1
sa(dp9964
g7
I402
sg8
VP40198
p9965
sg10
I3
sg11
VCEA
p9966
sg13
I1
sa(dp9967
g7
I352
sg8
g15
sg10
I6
sg11
Vfascin
p9968
sg13
I1
sa(dp9969
g7
I395
sg8
VP16422
p9970
sg10
I5
sg11
VMOC31
p9971
sg13
I1
sa(dp9972
g7
I340
sg8
VP13928
p9973
sg10
I10
sg11
Vannexin A8
p9974
sg13
I2
sa(dp9975
g7
I360
sg8
g15
sg10
I4
sg11
VPSCA
p9976
sg13
I1
sa(dp9977
g7
I62
sg8
VP01768
p9978
sg10
I7
sg11
VCAM 5.2
p9979
sg13
I2
sa(dp9980
g7
I297
sg8
VP36952
p9981
sg10
I6
sg11
Vmaspin
p9982
sg13
I1
sa(dp9983
g7
I141
sg8
VP42771
p9984
sg10
I3
sg11
Vp53
p9985
sg13
I1
sa(dp9986
g7
I234
sg8
VP01308
p9987
sg10
I60
sg11
Vinsulin-like growth factor 2 messenger RNA binding protein 3
p9988
sg13
I9
sa(dp9989
g7
I71
sg8
g15
sg10
I18
sg11
VCK [cytokeratin] 7
p9990
sg13
I3
sa(dp9991
g7
I146
sg8
g15
sg10
I4
sg11
VDPC4
p9992
sg13
I1
sasg20
(lp9993
(dp9994
g7
I446
sg23
VC0006826
p9995
sg10
I6
sg11
Vcancer
p9996
sg13
I1
sa(dp9997
g7
I62
sg23
VC1861821
p9998
sg10
I3
sg11
VCAM
p9999
sg13
I1
sa(dp10000
g7
I488
sg23
VC1335302
p10001
sg10
I37
sg11
Vductal adenocarcinoma of the pancreas
p10002
sg13
I5
sa(dp10003
g7
I188
sg23
VC0027651
p10004
sg10
I5
sg11
Vtumor
p10005
sg13
I1
sasa(dp10006
g2
S'Claudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas.\n'
p10007
sg4
(lp10008
(dp10009
g7
I15
sg8
VP13928
p10010
sg10
I10
sg11
Vannexin A8
p10011
sg13
I2
sa(dp10012
g7
I0
sg8
VP56856
p10013
sg10
I10
sg11
VClaudin 18
p10014
sg13
I2
sasg20
(lp10015
(dp10016
g7
I85
sg23
VC0001418
p10017
sg10
I15
sg11
Vadenocarcinomas
p10018
sg13
I1
sa(dp10019
g7
I85
sg23
VC0001418
p10020
sg10
I15
sg11
Vadenocarcinomas
p10021
sg13
I1
sa(dp10022
g7
I65
sg23
VC0332448
p10023
sg10
I12
sg11
Vinfiltrating
p10024
sg13
I1
sasa(dp10025
g2
S'Multivariate analysis further confirmed that miR-340-low/ROCK1-high expression was an independent prognostic factor of unfavorable survival in pediatric osteosarcoma (for overall survival: p = 0.006, for progression-free survival: p = 0.008).\n'
p10026
sg4
(lp10027
(dp10028
g7
I57
sg8
g15
sg10
I5
sg11
VROCK1
p10029
sg13
I1
sa(dp10030
g7
I45
sg8
g15
sg10
I11
sg11
VmiR-340-low
p10031
sg13
I1
sasg20
(lp10032
(dp10033
g7
I143
sg23
VC1332986
p10034
sg10
I22
sg11
Vpediatric osteosarcoma
p10035
sg13
I2
sasa(dp10036
g2
S'Our data offer convincing evidence, for the first time, that the combined miR-340 downregulation and ROCK1 upregulation may be linked to tumor progression and adverse prognosis in pediatric osteosarcoma.\n'
p10037
sg4
(lp10038
(dp10039
g7
I101
sg8
g15
sg10
I5
sg11
VROCK1
p10040
sg13
I1
sasg20
(lp10041
(dp10042
g7
I180
sg23
VC1332986
p10043
sg10
I22
sg11
Vpediatric osteosarcoma
p10044
sg13
I2
sa(dp10045
g7
I137
sg23
VC0178874
p10046
sg10
I17
sg11
Vtumor progression
p10047
sg13
I2
sasa(dp10048
g2
S'We analyzed the effects of 3 war components-combat exposure (CES), observation of abusive violence (OBS), and participation in abusive violence (PARTC)-and sense of coherence (SOC) on the development of both posttraumatic stress disorder (PTSD) and depression among a sample of war veterans.\n'
p10049
sg4
(lp10050
sg20
(lp10051
(dp10052
g7
I61
sg23
VC0265493
p10053
sg10
I3
sg11
VCES
p10054
sg13
I1
sa(dp10055
g7
I90
sg23
VC0042693
p10056
sg10
I8
sg11
Vviolence
p10057
sg13
I1
sa(dp10058
g7
I208
sg23
VC0038436
p10059
sg10
I29
sg11
Vposttraumatic stress disorder
p10060
sg13
I3
sa(dp10061
g7
I249
sg23
VC0011581
p10062
sg10
I10
sg11
Vdepression
p10063
sg13
I1
sa(dp10064
g7
I90
sg23
VC0042693
p10065
sg10
I8
sg11
Vviolence
p10066
sg13
I1
sa(dp10067
g7
I239
sg23
VC0038436
p10068
sg10
I4
sg11
VPTSD
p10069
sg13
I1
sa(dp10070
g7
I33
sg23
VC0265493
p10071
sg10
I26
sg11
Vcomponents-combat exposure
p10072
sg13
I2
sasa(dp10073
g2
S'The expression levels of miR-155 in 38 pairs of cancer tissues and adjacent normal tissues from breast cancer patients were detected using quantitative real-time PCR.\n'
p10074
sg4
(lp10075
sg20
(lp10076
(dp10077
g7
I48
sg23
VC0006826
p10078
sg10
I6
sg11
Vcancer
p10079
sg13
I1
sa(dp10080
g7
I96
sg23
VC0678222
p10081
sg10
I13
sg11
Vbreast cancer
p10082
sg13
I2
sasa(dp10083
g2
S'Soft agar colony formation assay and tumor xenografts showed inhibition of miR-155 could significantly reduce proliferation of cancer cells in vivo and vitro, which confirmed that miR-155 is an effective therapeutic target of breast cancer.\n'
p10084
sg4
(lp10085
(dp10086
g7
I75
sg8
g15
sg10
I7
sg11
VmiR-155
p10087
sg13
I1
sa(dp10088
g7
I75
sg8
g15
sg10
I7
sg11
VmiR-155
p10089
sg13
I1
sasg20
(lp10090
(dp10091
g7
I37
sg23
VC0027651
p10092
sg10
I5
sg11
Vtumor
p10093
sg13
I1
sa(dp10094
g7
I127
sg23
VC0006826
p10095
sg10
I6
sg11
Vcancer
p10096
sg13
I1
sa(dp10097
g7
I226
sg23
VC0678222
p10098
sg10
I13
sg11
Vbreast cancer
p10099
sg13
I2
sa(dp10100
g7
I110
sg23
VC0334094
p10101
sg10
I13
sg11
Vproliferation
p10102
sg13
I1
sasa(dp10103
g2
S'Our results underscore the importance of miR-155 as a therapeutic target and combination of Doxorubicinol and miR-155-silencing would be a potential way to cure breast cancer.\n'
p10104
sg4
(lp10105
sg20
(lp10106
(dp10107
g7
I161
sg23
VC0678222
p10108
sg10
I13
sg11
Vbreast cancer
p10109
sg13
I2
sasa(dp10110
g2
S'We have quantified expression of seven oncomiRs, namely miR-17/92 cluster (miR-17, miR-18a, miR-19a and miR-20a), miR-21, miR-27a and miR-155, in plasma of 137 breast cancer (BC) patients.\n'
p10111
sg4
(lp10112
(dp10113
g7
I134
sg8
g15
sg10
I7
sg11
VmiR-155
p10114
sg13
I1
sa(dp10115
g7
I92
sg8
g15
sg10
I7
sg11
VmiR-19a
p10116
sg13
I1
sa(dp10117
g7
I56
sg8
g15
sg10
I6
sg11
VmiR-17
p10118
sg13
I1
sa(dp10119
g7
I83
sg8
g15
sg10
I7
sg11
VmiR-18a
p10120
sg13
I1
sa(dp10121
g7
I104
sg8
g15
sg10
I7
sg11
VmiR-20a
p10122
sg13
I1
sa(dp10123
g7
I122
sg8
g15
sg10
I7
sg11
VmiR-27a
p10124
sg13
I1
sa(dp10125
g7
I56
sg8
g15
sg10
I17
sg11
VmiR-17/92 cluster
p10126
sg13
I2
sasg20
(lp10127
(dp10128
g7
I175
sg23
VC0678222
p10129
sg10
I2
sg11
VBC
p10130
sg13
I1
sa(dp10131
g7
I160
sg23
VC0678222
p10132
sg10
I13
sg11
Vbreast cancer
p10133
sg13
I2
sasa(dp10134
g2
S'Our results suggested that MIAT acted as a competing endogenous RNA (ceRNA) to regulate the expression of dual specificity phosphatase 7 (DUSP7) by taking up miR-155-5p in breast cancer.\n'
p10135
sg4
(lp10136
(dp10137
g7
I158
sg8
g15
sg10
I10
sg11
VmiR-155-5p
p10138
sg13
I1
sa(dp10139
g7
I138
sg8
g15
sg10
I5
sg11
VDUSP7
p10140
sg13
I1
sa(dp10141
g7
I106
sg8
g15
sg10
I30
sg11
Vdual specificity phosphatase 7
p10142
sg13
I4
sasg20
(lp10143
(dp10144
g7
I172
sg23
VC0678222
p10145
sg10
I13
sg11
Vbreast cancer
p10146
sg13
I2
sasa(dp10147
g2
S'We conclude that MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p in breast cancer.\n'
p10148
sg4
(lp10149
(dp10150
g7
I92
sg8
g15
sg10
I5
sg11
VDUSP7
p10151
sg13
I1
sa(dp10152
g7
I121
sg8
g15
sg10
I10
sg11
VmiR-155-5p
p10153
sg13
I1
sasg20
(lp10154
(dp10155
g7
I31
sg23
VC0678222
p10156
sg10
I13
sg11
Vbreast cancer
p10157
sg13
I2
sa(dp10158
g7
I38
sg23
VC0178874
p10159
sg10
I18
sg11
Vcancer progression
p10160
sg13
I2
sasa(dp10161
g2
S'Four oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy.\n'
p10162
sg4
(lp10163
(dp10164
g7
I35
sg8
g15
sg10
I7
sg11
VmiR-19a
p10165
sg13
I1
sa(dp10166
g7
I44
sg8
g15
sg10
I8
sg11
VmiR-181b
p10167
sg13
I1
sa(dp10168
g7
I58
sg8
g15
sg10
I6
sg11
VmiR-24
p10169
sg13
I1
sasg20
(lp10170
(dp10171
g7
I170
sg23
VC0678222
p10172
sg10
I13
sg11
Vbreast cancer
p10173
sg13
I2
sa(dp10174
g7
I74
sg23
VC0027651
p10175
sg10
I5
sg11
Vtumor
p10176
sg13
I1
sa(dp10177
g7
I74
sg23
VC0027651
p10178
sg10
I5
sg11
Vtumor
p10179
sg13
I1
sasa(dp10180
g2
S'The present study determined the role of postoperative wound fluids (WFs) from patients diagnosed with breast cancer subsequent to breast conserving surgery or breast conserving surgery followed by IORT on the expression of three microRNAs (miRNAs), consisting of miR-21, miR-155 and miR-221, in distinct breast cancer cell lines that represent the general subtypes of breast cancer.\n'
p10181
sg4
(lp10182
sg20
(lp10183
(dp10184
g7
I103
sg23
VC0678222
p10185
sg10
I13
sg11
Vbreast cancer
p10186
sg13
I2
sa(dp10187
g7
I103
sg23
VC0678222
p10188
sg10
I13
sg11
Vbreast cancer
p10189
sg13
I2
sa(dp10190
g7
I55
sg23
VC0043207
p10191
sg10
I12
sg11
Vwound fluids
p10192
sg13
I2
sa(dp10193
g7
I103
sg23
VC0678222
p10194
sg10
I13
sg11
Vbreast cancer
p10195
sg13
I2
sa(dp10196
g7
I69
sg23
VC0043207
p10197
sg10
I3
sg11
VWFs
p10198
sg13
I1
sasa(dp10199
g2
S'Additionally, it was indicated that both WFs and RT-WF strongly downregulated the expression of miR-21, miR-155 and miR-221 in basal/epithelial and luminal subtypes of breast cancer.\n'
p10200
sg4
(lp10201
(dp10202
g7
I41
sg8
g15
sg10
I3
sg11
VWFs
p10203
sg13
I1
sasg20
(lp10204
(dp10205
g7
I41
sg23
VC0043207
p10206
sg10
I3
sg11
VWFs
p10207
sg13
I1
sa(dp10208
g7
I168
sg23
VC0678222
p10209
sg10
I13
sg11
Vbreast cancer
p10210
sg13
I2
sasa(dp10211
g2
S'The expression of three different microRNAs (miR-9, miR-21, and miR-155) in 52 formalin-fixed paraffin-embedded (FFPE) primary cervical cancer tissue samples and 50 FFPE normal cervical tissue samples were evaluated.\n'
p10212
sg4
(lp10213
sg20
(lp10214
(dp10215
g7
I127
sg23
VC0302592
p10216
sg10
I15
sg11
Vcervical cancer
p10217
sg13
I2
sasa(dp10218
g2
S'MiR-9, miR-21, and miR-155 were significantly overexpressed in cervical cancer tissues compared to normal tissues (P &lt; 0.001).\n'
p10219
sg4
(lp10220
(dp10221
g7
I0
sg8
g15
sg10
I5
sg11
VMiR-9
p10222
sg13
I1
sasg20
(lp10223
(dp10224
g7
I63
sg23
VC0302592
p10225
sg10
I15
sg11
Vcervical cancer
p10226
sg13
I2
sasa(dp10227
g2
S'MiR-21 and miR-155 expression combined with the HPV E6/E7 mRNA assay in HPV E6/E7 negative cervical cancer showed increased AUC of 0.7267 and 0.7000, respectively (P = 0.01, P = 0.04), demonstrating their potential as diagnostic tools.\n'
p10228
sg4
(lp10229
sg20
(lp10230
(dp10231
g7
I91
sg23
VC0302592
p10232
sg10
I15
sg11
Vcervical cancer
p10233
sg13
I2
sasa(dp10234
g2
S'Moreover, miR-21 and miR-155 were predictors showing a 7 fold and 10.3 fold higher risk for HPV E6/E7 negative patients with cervical cancer (P = 0.024 and P = 0.017, respectively) while miR-155 was a predictor showing a 27.9 fold higher risk for HPV E6/E7 positive patients with cervical cancer (P &lt; 0.0001).\n'
p10235
sg4
(lp10236
sg20
(lp10237
(dp10238
g7
I125
sg23
VC0302592
p10239
sg10
I15
sg11
Vcervical cancer
p10240
sg13
I2
sa(dp10241
g7
I125
sg23
VC0302592
p10242
sg10
I15
sg11
Vcervical cancer
p10243
sg13
I2
sasa(dp10244
g2
S'MiR-21 and miR-155 may be helpful in the prediction of both HPV positive and HPV negative cases of cervical cancer.\n'
p10245
sg4
(lp10246
(dp10247
g7
I0
sg8
g15
sg10
I6
sg11
VMiR-21
p10248
sg13
I1
sa(dp10249
g7
I11
sg8
g15
sg10
I7
sg11
VmiR-155
p10250
sg13
I1
sasg20
(lp10251
(dp10252
g7
I99
sg23
VC0302592
p10253
sg10
I15
sg11
Vcervical cancer
p10254
sg13
I2
sasa(dp10255
g2
S'The purpose of this study was to analyze the clinicopathologic significance of expression of EMT-related miRNAs, miR-9 and miR-155, in triple-negative breast cancers (TNBCs).\n'
p10256
sg4
(lp10257
(dp10258
g7
I113
sg8
g15
sg10
I5
sg11
VmiR-9
p10259
sg13
I1
sa(dp10260
g7
I123
sg8
g15
sg10
I7
sg11
VmiR-155
p10261
sg13
I1
sa(dp10262
g7
I93
sg8
g15
sg10
I18
sg11
VEMT-related miRNAs
p10263
sg13
I2
sasg20
(lp10264
(dp10265
g7
I151
sg23
VC0006142
p10266
sg10
I14
sg11
Vbreast cancers
p10267
sg13
I2
sasa(dp10268
g2
S'Then, based on the experimentally validated miRNA regulations to target genes, 4 candidate miRNAs (miR-24-3p, miR-192-5p, miR-139-5p and miR-155-5p) were identified to potentially contribute to ovarian cancer cell chemoresistance to CDDP through mediating OVCAR-8R cell CDDP resistance-related gene modules, which participated in functions that were closely related to "apoptosis", "cell cycle" and "adhesion".\n'
p10269
sg4
(lp10270
(dp10271
g7
I137
sg8
g15
sg10
I10
sg11
VmiR-155-5p
p10272
sg13
I1
sa(dp10273
g7
I122
sg8
g15
sg10
I10
sg11
VmiR-139-5p
p10274
sg13
I1
sa(dp10275
g7
I99
sg8
g15
sg10
I9
sg11
VmiR-24-3p
p10276
sg13
I1
sa(dp10277
g7
I110
sg8
g15
sg10
I10
sg11
VmiR-192-5p
p10278
sg13
I1
sasg20
(lp10279
(dp10280
g7
I400
sg23
VC0001511
p10281
sg10
I8
sg11
Vadhesion
p10282
sg13
I1
sa(dp10283
g7
I194
sg23
VC1140680
p10284
sg10
I14
sg11
Vovarian cancer
p10285
sg13
I2
sasa(dp10286
g2
S'The renal involvement may present with symptoms arising from interstitial nephritis, mainly distal renal tubular acidosis.\n'
p10287
sg4
(lp10288
sg20
(lp10289
(dp10290
g7
I92
sg23
VC1704380
p10291
sg10
I29
sg11
Vdistal renal tubular acidosis
p10292
sg13
I4
sa(dp10293
g7
I61
sg23
VC0027707
p10294
sg10
I22
sg11
Vinterstitial nephritis
p10295
sg13
I2
sasa(dp10296
g2
S"In a 29-year-old female patient, with bilateral nephrolithiasis, the diagnosis of primary Sjoegren's syndrome, tubulo-interstitial nephritis, distal renal tubular acidosis, and hypokalemia were established.\n"
p10297
sg4
(lp10298
sg20
(lp10299
(dp10300
g7
I90
sg23
VC1527336
p10301
sg10
I19
sg11
VSjoegren's syndrome
p10302
sg13
I2
sa(dp10303
g7
I48
sg23
VC0392525
p10304
sg10
I15
sg11
Vnephrolithiasis
p10305
sg13
I1
sa(dp10306
g7
I111
sg23
VC0041349
p10307
sg10
I29
sg11
Vtubulo-interstitial nephritis
p10308
sg13
I2
sa(dp10309
g7
I142
sg23
VC1704380
p10310
sg10
I29
sg11
Vdistal renal tubular acidosis
p10311
sg13
I4
sasa(dp10312
g2
S'Tubulo-interstitial nephritis constitutes the most frequent renal lesion and distal tubular acidosis (Type 1) is the most important clinical manifestation of this tubular dysfunction, although the occurrence of chronic renal insufficiency is not an uncommon finding in the presence of distal renal tubular acidosis.\n'
p10313
sg4
(lp10314
sg20
(lp10315
(dp10316
g7
I211
sg23
VC0022661
p10317
sg10
I27
sg11
Vchronic renal insufficiency
p10318
sg13
I3
sa(dp10319
g7
I0
sg23
VC0041349
p10320
sg10
I29
sg11
VTubulo-interstitial nephritis
p10321
sg13
I2
sa(dp10322
g7
I92
sg23
VC0001122
p10323
sg10
I8
sg11
Vacidosis
p10324
sg13
I1
sa(dp10325
g7
I285
sg23
VC1704380
p10326
sg10
I29
sg11
Vdistal renal tubular acidosis
p10327
sg13
I4
sasa(dp10328
g2
S'Right atrial thrombosis is classified as two type: A (mobile, thin) and B (non mobile and attached to atrial wall) that they are probably of cardiac origin due to local pathology, indwelling catheter, atrial fibrillation, stasis, rheumatological or hematological disease like protein C or S deficiency.\n'
p10329
sg4
(lp10330
(dp10331
g7
I276
sg8
VP02810
p10332
sg10
I9
sg11
Vprotein C
p10333
sg13
I2
sasg20
(lp10334
(dp10335
g7
I169
sg23
VC0677042
p10336
sg10
I9
sg11
Vpathology
p10337
sg13
I1
sa(dp10338
g7
I222
sg23
VC0333138
p10339
sg10
I6
sg11
Vstasis
p10340
sg13
I1
sa(dp10341
g7
I6
sg23
VC0340517
p10342
sg10
I17
sg11
Vatrial thrombosis
p10343
sg13
I2
sa(dp10344
g7
I201
sg23
VC0004238
p10345
sg10
I19
sg11
Vatrial fibrillation
p10346
sg13
I2
sa(dp10347
g7
I249
sg23
VC0018939
p10348
sg10
I21
sg11
Vhematological disease
p10349
sg13
I2
sasa(dp10350
g2
S'Venous stasis (e.g., immobilization, congestive heart failure, acute myocardial infarction, obesity), hypercoagulability (e.g., malignancy, inflammatory bowel disease, hyperhomocysteinemia, protein C resistance, antithrombin III, protein C or S deficiency) and endothelial trauma (e.g., surgical trauma, venous trauma, in-dwelling venous instrumentation) are risk factors.\n'
p10351
sg4
(lp10352
(dp10353
g7
I212
sg8
VP05546
p10354
sg10
I16
sg11
Vantithrombin III
p10355
sg13
I2
sa(dp10356
g7
I190
sg8
VP02810
p10357
sg10
I9
sg11
Vprotein C
p10358
sg13
I2
sasg20
(lp10359
(dp10360
g7
I0
sg23
VC0277919
p10361
sg10
I13
sg11
VVenous stasis
p10362
sg13
I2
sa(dp10363
g7
I140
sg23
VC0021390
p10364
sg10
I26
sg11
Vinflammatory bowel disease
p10365
sg13
I3
sa(dp10366
g7
I168
sg23
VC0598608
p10367
sg10
I20
sg11
Vhyperhomocysteinemia
p10368
sg13
I1
sa(dp10369
g7
I37
sg23
VC0018802
p10370
sg10
I24
sg11
Vcongestive heart failure
p10371
sg13
I3
sa(dp10372
g7
I92
sg23
VC0028754
p10373
sg10
I7
sg11
Vobesity
p10374
sg13
I1
sa(dp10375
g7
I63
sg23
VC0155626
p10376
sg10
I27
sg11
Vacute myocardial infarction
p10377
sg13
I3
sa(dp10378
g7
I128
sg23
VC0006826
p10379
sg10
I10
sg11
Vmalignancy
p10380
sg13
I1
sa(dp10381
g7
I102
sg23
VC0398623
p10382
sg10
I18
sg11
Vhypercoagulability
p10383
sg13
I1
sasa(dp10384
g2
S'To evaluate the use of selective vs. non-selective cyclo-oxygenase inhibitors (COXIs) for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.\n'
p10385
sg4
(lp10386
(dp10387
g7
I51
sg8
VP23219
p10388
sg10
I15
sg11
Vcyclo-oxygenase
p10389
sg13
I1
sasg20
(lp10390
(dp10391
g7
I147
sg23
VC1971635
p10392
sg10
I26
sg11
Vscleritis and episcleritis
p10393
sg13
I3
sa(dp10394
g7
I119
sg23
VC0009450
p10395
sg10
I10
sg11
Vinfectious
p10396
sg13
I1
sasa(dp10397
g2
S'Sixty-nine patients with scleritis and episcleritis treated for &gt;=2 months with COXIs were included.\n'
p10398
sg4
(lp10399
sg20
(lp10400
(dp10401
g7
I25
sg23
VC1971635
p10402
sg10
I26
sg11
Vscleritis and episcleritis
p10403
sg13
I3
sasa(dp10404
g2
S'Initial inflammation control was achieved in 78-81% of scleritis patients and 73-80% episcleritis patients on COXIs (p &gt; .05).\n'
p10405
sg4
(lp10406
sg20
(lp10407
(dp10408
g7
I8
sg23
VC0021368
p10409
sg10
I12
sg11
Vinflammation
p10410
sg13
I1
sa(dp10411
g7
I85
sg23
VC0014583
p10412
sg10
I12
sg11
Vepiscleritis
p10413
sg13
I1
sa(dp10414
g7
I55
sg23
VC0036416
p10415
sg10
I9
sg11
Vscleritis
p10416
sg13
I1
sasa(dp10417
g2
S'Selective vs. non-selective COXIs were equally efficacious for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.\n'
p10418
sg4
(lp10419
sg20
(lp10420
(dp10421
g7
I92
sg23
VC0009450
p10422
sg10
I10
sg11
Vinfectious
p10423
sg13
I1
sa(dp10424
g7
I120
sg23
VC1971635
p10425
sg10
I26
sg11
Vscleritis and episcleritis
p10426
sg13
I3
sasa(dp10427
g2
S'Here we show that KIAA0793, containing substantial sequence homology with the catalytic Dbl homology domain of the faciogenital dysplasia gene product (FGD1), is a specific GEF for Cdc42.\n'
p10428
sg4
(lp10429
(dp10430
g7
I181
sg8
VP60953
p10431
sg10
I5
sg11
VCdc42
p10432
sg13
I1
sa(dp10433
g7
I152
sg8
VP98174
p10434
sg10
I4
sg11
VFGD1
p10435
sg13
I1
sa(dp10436
g7
I173
sg8
VP10911
p10437
sg10
I3
sg11
VGEF
p10438
sg13
I1
sa(dp10439
g7
I78
sg8
g15
sg10
I29
sg11
Vcatalytic Dbl homology domain
p10440
sg13
I4
sasg20
(lp10441
(dp10442
g7
I152
sg23
VC1859974
p10443
sg10
I4
sg11
VFGD1
p10444
sg13
I1
sa(dp10445
g7
I115
sg23
VC0175701
p10446
sg10
I22
sg11
Vfaciogenital dysplasia
p10447
sg13
I2
sasa(dp10448
g2
S'The faciogenital dysplasia gene product, FGD1, is a Dbl family member that has recently been shown to function as a CDC42-specific GEF.\n'
p10449
sg4
(lp10450
(dp10451
g7
I52
sg8
VP10911
p10452
sg10
I17
sg11
VDbl family member
p10453
sg13
I3
sa(dp10454
g7
I41
sg8
VP98174
p10455
sg10
I4
sg11
VFGD1
p10456
sg13
I1
sa(dp10457
g7
I116
sg8
VP60953
p10458
sg10
I18
sg11
VCDC42-specific GEF
p10459
sg13
I2
sasg20
(lp10460
(dp10461
g7
I41
sg23
VC1859974
p10462
sg10
I4
sg11
VFGD1
p10463
sg13
I1
sa(dp10464
g7
I4
sg23
VC0175701
p10465
sg10
I22
sg11
Vfaciogenital dysplasia
p10466
sg13
I2
sasa(dp10467
g2
S'The majority of proteins that contain a DH (Dbl homology) domain were isolated as oncogenes in transfection assays, but two members of the DH family, FGD1 (the product of the faciogenital dysplasia or Aarskog-Scott syndrome locus) and Vav, have been shown to be essential for normal embryonic development.\n'
p10468
sg4
(lp10469
(dp10470
g7
I44
sg8
VP10911
p10471
sg10
I3
sg11
VDbl
p10472
sg13
I1
sa(dp10473
g7
I235
sg8
VP15498
p10474
sg10
I3
sg11
VVav
p10475
sg13
I1
sa(dp10476
g7
I150
sg8
VP98174
p10477
sg10
I4
sg11
VFGD1
p10478
sg13
I1
sasg20
(lp10479
(dp10480
g7
I201
sg23
VC0175701
p10481
sg10
I22
sg11
VAarskog-Scott syndrome
p10482
sg13
I2
sa(dp10483
g7
I175
sg23
VC0175701
p10484
sg10
I22
sg11
Vfaciogenital dysplasia
p10485
sg13
I2
sa(dp10486
g7
I150
sg23
VC1859974
p10487
sg10
I4
sg11
VFGD1
p10488
sg13
I1
sasa(dp10489
g2
S'Here we have examined the role of a Dbl-like molecule, the faciogenital dysplasia gene product (FGD1), which when mutated in its Dbl homology domain, cosegregates with the developmental disease Aarskog-Scott syndrome.\n'
p10490
sg4
(lp10491
(dp10492
g7
I129
sg8
VP10911
p10493
sg10
I19
sg11
VDbl homology domain
p10494
sg13
I3
sa(dp10495
g7
I36
sg8
VP10911
p10496
sg10
I17
sg11
VDbl-like molecule
p10497
sg13
I2
sa(dp10498
g7
I96
sg8
VP98174
p10499
sg10
I4
sg11
VFGD1
p10500
sg13
I1
sasg20
(lp10501
(dp10502
g7
I59
sg23
VC0175701
p10503
sg10
I22
sg11
Vfaciogenital dysplasia
p10504
sg13
I2
sa(dp10505
g7
I96
sg23
VC1859974
p10506
sg10
I4
sg11
VFGD1
p10507
sg13
I1
sa(dp10508
g7
I194
sg23
VC0175701
p10509
sg10
I22
sg11
VAarskog-Scott syndrome
p10510
sg13
I2
sasa(dp10511
g2
S"Non-survivors (n=29) versus survivors (n=46) were: older (77+/-9.8 vs 68+/-14, p=0.006), had higher New York Heart Association (NYHA) class (2.7+/-0.8 vs 2.3+/-0.8, p=0.037), higher brain natriuretic peptide (1157+/-717 vs 427+/-502 pg/mL, p=0.024, n=18), more coronary artery disease (61% vs 35%, p=0.031), more frequent left ventricular ejection fraction &lt;50% (20.7% vs 4.3%, p=0.026), more functional MR (41% vs 22%, p=0.069), higher mitral E/E(') (12.7+/-4.6 vs 9.8+/-4, p=0.008), higher pulmonary artery systolic pressure (PASP; 52.6+/-18.7 vs 36.7+/-14, p &lt;0.001), more &gt;=3+ tricuspid regurgitation (28% vs 4%, p=0.005) and more right ventricular dysfunction (26% vs 6%, p=0.035).\n"
p10512
sg4
(lp10513
sg20
(lp10514
(dp10515
g7
I261
sg23
VC1956346
p10516
sg10
I23
sg11
Vcoronary artery disease
p10517
sg13
I3
sa(dp10518
g7
I644
sg23
VC0242707
p10519
sg10
I29
sg11
Vright ventricular dysfunction
p10520
sg13
I3
sa(dp10521
g7
I590
sg23
VC0040961
p10522
sg10
I23
sg11
Vtricuspid regurgitation
p10523
sg13
I2
sasa(dp10524
g2
S'The presence of RBBB, IVCD, PASP &gt;= 40 mmHg, left atrium diameter and NYHA functional class were independent predictors of all-cause mortality in DCM patients.\n'
p10525
sg4
(lp10526
sg20
(lp10527
(dp10528
g7
I16
sg23
VC0085615
p10529
sg10
I4
sg11
VRBBB
p10530
sg13
I1
sa(dp10531
g7
I22
sg23
VC1882112
p10532
sg10
I4
sg11
VIVCD
p10533
sg13
I1
sasa(dp10534
g2
S'The goals of therapy, which should be highlighted in follow-up imaging, include not only reduction of PASP, decrease in pulmonary vascular resistance, and improvements in right ventricular function, cardiac output, and tricuspid regurgitation.\n'
p10535
sg4
(lp10536
sg20
(lp10537
(dp10538
g7
I219
sg23
VC0040961
p10539
sg10
I23
sg11
Vtricuspid regurgitation
p10540
sg13
I2
sasa(dp10541
g2
S'The objective of this study was to determine the prognostic significance of CD163(+) cells, interleukin-10 (IL-10), and interferon-gamma (IFN-Gamma) in oral lesions associated with oral squamous cell carcinoma (OSCC).\n'
p10542
sg4
(lp10543
(dp10544
g7
I92
sg8
VP22301
p10545
sg10
I14
sg11
Vinterleukin-10
p10546
sg13
I1
sa(dp10547
g7
I120
sg8
VP01579
p10548
sg10
I16
sg11
Vinterferon-gamma
p10549
sg13
I1
sa(dp10550
g7
I76
sg8
g15
sg10
I5
sg11
VCD163
p10551
sg13
I1
sa(dp10552
g7
I138
sg8
VP01579
p10553
sg10
I9
sg11
VIFN-Gamma
p10554
sg13
I1
sa(dp10555
g7
I108
sg8
VP22301
p10556
sg10
I5
sg11
VIL-10
p10557
sg13
I1
sasg20
(lp10558
(dp10559
g7
I186
sg23
VC0007137
p10560
sg10
I23
sg11
Vsquamous cell carcinoma
p10561
sg13
I3
sasa(dp10562
g2
S'beta-defensin expression was quantitatively assessed using real-time polymerase chain reactions in OSCC and control cell lines after exposure to interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma.\n'
p10563
sg4
(lp10564
(dp10565
g7
I0
sg8
VP59861
p10566
sg10
I13
sg11
Vbeta-defensin
p10567
sg13
I1
sa(dp10568
g7
I145
sg8
VP01584
p10569
sg10
I17
sg11
Vinterleukin-1beta
p10570
sg13
I1
sa(dp10571
g7
I164
sg8
VP01375
p10572
sg10
I27
sg11
Vtumor necrosis factor-alpha
p10573
sg13
I3
sa(dp10574
g7
I197
sg8
VP01579
p10575
sg10
I16
sg11
Vinterferon-gamma
p10576
sg13
I1
sasg20
(lp10577
(dp10578
g7
I164
sg23
VC0333516
p10579
sg10
I14
sg11
Vtumor necrosis
p10580
sg13
I2
sasa(dp10581
g2
S'We investigated the utility of J chain and myocyte enhancer factor 2B (MEF2B) in the diagnosis of CHL; NLPHL; PMBL; T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL); and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL, compared with OCT-2 and BOB.1.\n'
p10582
sg4
(lp10583
(dp10584
g7
I296
sg8
VP09086
p10585
sg10
I5
sg11
VOCT-2
p10586
sg13
I1
sa(dp10587
g7
I43
sg8
g15
sg10
I26
sg11
Vmyocyte enhancer factor 2B
p10588
sg13
I4
sa(dp10589
g7
I71
sg8
g15
sg10
I5
sg11
VMEF2B
p10590
sg13
I1
sa(dp10591
g7
I306
sg8
VP49685
p10592
sg10
I5
sg11
VBOB.1
p10593
sg13
I1
sasg20
(lp10594
(dp10595
g7
I162
sg23
VC1321547
p10596
sg10
I6
sg11
VTCRLBL
p10597
sg13
I1
sa(dp10598
g7
I103
sg23
VC1334968
p10599
sg10
I5
sg11
VNLPHL
p10600
sg13
I1
sa(dp10601
g7
I116
sg23
VC1321547
p10602
sg10
I44
sg11
VT-cell/histiocyte-rich large B-cell lymphoma
p10603
sg13
I4
sa(dp10604
g7
I145
sg23
VC0079731
p10605
sg10
I15
sg11
VB-cell lymphoma
p10606
sg13
I2
sa(dp10607
g7
I243
sg23
VC0079744
p10608
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p10609
sg13
I4
sasa(dp10610
g2
S'Three of 3 B-cell lymphomas, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL, were negative for J chain and MEF2B.\n'
p10611
sg4
(lp10612
sg20
(lp10613
(dp10614
g7
I11
sg23
VC0079731
p10615
sg10
I16
sg11
VB-cell lymphomas
p10616
sg13
I2
sa(dp10617
g7
I80
sg23
VC0079744
p10618
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p10619
sg13
I4
sasa(dp10620
g2
S'J chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL; are particularly useful in highlighting LP cells; and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas.\n'
p10621
sg4
(lp10622
(dp10623
g7
I12
sg8
g15
sg10
I5
sg11
VMEF2B
p10624
sg13
I1
sa(dp10625
g7
I195
sg8
VP49685
p10626
sg10
I5
sg11
VBOB.1
p10627
sg13
I1
sa(dp10628
g7
I185
sg8
VP09086
p10629
sg10
I5
sg11
VOCT-2
p10630
sg13
I1
sasg20
(lp10631
(dp10632
g7
I251
sg23
VC0079731
p10633
sg10
I16
sg11
VB-cell lymphomas
p10634
sg13
I2
sa(dp10635
g7
I63
sg23
VC1334968
p10636
sg10
I5
sg11
VNLPHL
p10637
sg13
I1
sa(dp10638
g7
I63
sg23
VC1334968
p10639
sg10
I5
sg11
VNLPHL
p10640
sg13
I1
sasa(dp10641
g2
S'We identified several consensus differentially expressed genes and these genes were further confirmed with literature mining; at last, two genes, that is, immunoglobulin J chain and C-X-C motif chemokine ligand 17, were screened as novel gastric cancer associated genes.\n'
p10642
sg4
(lp10643
(dp10644
g7
I155
sg8
VP01591
p10645
sg10
I22
sg11
Vimmunoglobulin J chain
p10646
sg13
I3
sa(dp10647
g7
I182
sg8
VP55773
p10648
sg10
I31
sg11
VC-X-C motif chemokine ligand 17
p10649
sg13
I5
sasg20
(lp10650
(dp10651
g7
I238
sg23
VC0024623
p10652
sg10
I14
sg11
Vgastric cancer
p10653
sg13
I2
sasa(dp10654
g2
S'A discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100Beta.\n'
p10655
sg4
(lp10656
(dp10657
g7
I143
sg8
g15
sg10
I5
sg11
VIL5RA
p10658
sg13
I1
sa(dp10659
g7
I168
sg8
VP04271
p10660
sg10
I8
sg11
VS100Beta
p10661
sg13
I1
sa(dp10662
g7
I150
sg8
VP22894
p10663
sg10
I4
sg11
VMMP8
p10664
sg13
I1
sa(dp10665
g7
I138
sg8
VP01591
p10666
sg10
I3
sg11
VIGJ
p10667
sg13
I1
sa(dp10668
g7
I131
sg8
g15
sg10
I5
sg11
VCD177
p10669
sg13
I1
sa(dp10670
g7
I124
sg8
VP05106
p10671
sg10
I5
sg11
VITGB3
p10672
sg13
I1
sa(dp10673
g7
I116
sg8
VP08514
p10674
sg10
I6
sg11
VITGA2B
p10675
sg13
I1
sa(dp10676
g7
I156
sg8
g15
sg10
I6
sg11
VP2RY12
p10677
sg13
I1
sasg20
(lp10678
sa(dp10679
g2
S"For the transcriptome analysis, we found some genes related to Alzheimer's disease (LRP1), an insulin-like growth factor receptor (IGF2R), immunity genes (IGL family and IGJ), two genes related to inflammatory reaction (CXCL5 and CCL3), one gene related to maintenance of cellular morphology (NHS), one gene considered to be a strong apoptosis inductor (LGALS14), and several transcripts of the neuroblastoma breakpoint family (NBPF).\n"
p10680
sg4
(lp10681
(dp10682
g7
I220
sg8
VP42830
p10683
sg10
I5
sg11
VCXCL5
p10684
sg13
I1
sa(dp10685
g7
I170
sg8
VP01591
p10686
sg10
I3
sg11
VIGJ
p10687
sg13
I1
sa(dp10688
g7
I230
sg8
VP10147
p10689
sg10
I4
sg11
VCCL3
p10690
sg13
I1
sa(dp10691
g7
I428
sg8
g15
sg10
I4
sg11
VNBPF
p10692
sg13
I1
sa(dp10693
g7
I395
sg8
g15
sg10
I31
sg11
Vneuroblastoma breakpoint family
p10694
sg13
I3
sa(dp10695
g7
I131
sg8
VP11717
p10696
sg10
I5
sg11
VIGF2R
p10697
sg13
I1
sa(dp10698
g7
I94
sg8
VP01308
p10699
sg10
I35
sg11
Vinsulin-like growth factor receptor
p10700
sg13
I4
sa(dp10701
g7
I84
sg8
g15
sg10
I4
sg11
VLRP1
p10702
sg13
I1
sa(dp10703
g7
I155
sg8
VP15814
p10704
sg10
I10
sg11
VIGL family
p10705
sg13
I2
sasg20
(lp10706
(dp10707
g7
I63
sg23
VC1521724
p10708
sg10
I19
sg11
VAlzheimer's disease
p10709
sg13
I2
sa(dp10710
g7
I197
sg23
VC0021368
p10711
sg10
I21
sg11
Vinflammatory reaction
p10712
sg13
I2
sa(dp10713
g7
I293
sg23
VC0796085
p10714
sg10
I3
sg11
VNHS
p10715
sg13
I1
sa(dp10716
g7
I395
sg23
VC0027819
p10717
sg10
I13
sg11
Vneuroblastoma
p10718
sg13
I1
sasa(dp10719
g2
S'Using principal components analysis, spots containing immunoglobulin J chain, apolipoprotein A-I, procollagen C-endopeptidase enhancer-1 and complement C4-A were associated with lymphoma development (P &lt; 0.0001).\n'
p10720
sg4
(lp10721
(dp10722
g7
I54
sg8
VP01591
p10723
sg10
I22
sg11
Vimmunoglobulin J chain
p10724
sg13
I3
sa(dp10725
g7
I98
sg8
g15
sg10
I38
sg11
Vprocollagen C-endopeptidase enhancer-1
p10726
sg13
I3
sa(dp10727
g7
I141
sg8
g15
sg10
I15
sg11
Vcomplement C4-A
p10728
sg13
I2
sa(dp10729
g7
I78
sg8
VP02647
p10730
sg10
I18
sg11
Vapolipoprotein A-I
p10731
sg13
I2
sasg20
(lp10732
(dp10733
g7
I37
sg23
VC0015230
p10734
sg10
I5
sg11
Vspots
p10735
sg13
I1
sa(dp10736
g7
I178
sg23
VC0024299
p10737
sg10
I8
sg11
Vlymphoma
p10738
sg13
I1
sasa(dp10739
g2
S'The relationship between combined temperature factors showed a linear impact until reaching high temperatures limiting malaria incidence, with a lag 3.25 months.\n'
p10740
sg4
(lp10741
sg20
(lp10742
(dp10743
g7
I119
sg23
VC0024530
p10744
sg10
I7
sg11
Vmalaria
p10745
sg13
I1
sasa(dp10746
g2
S'Experimental models of malaria have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), and programmed death-1 (PD-1) are involved in the functional impairment of T cells during infection.\n'
p10747
sg4
(lp10748
(dp10749
g7
I119
sg8
VP05154
p10750
sg10
I28
sg11
Vlymphocyte activation gene-3
p10751
sg13
I3
sa(dp10752
g7
I110
sg8
VP16410
p10753
sg10
I6
sg11
VCTLA-4
p10754
sg13
I1
sa(dp10755
g7
I149
sg8
VP16949
p10756
sg10
I5
sg11
VLAG-3
p10757
sg13
I1
sa(dp10758
g7
I161
sg8
VP18621
p10759
sg10
I18
sg11
Vprogrammed death-1
p10760
sg13
I2
sa(dp10761
g7
I73
sg8
VP16410
p10762
sg10
I35
sg11
Vcytotoxic T-lymphocyte attenuator-4
p10763
sg13
I3
sa(dp10764
g7
I181
sg8
VP18621
p10765
sg10
I4
sg11
VPD-1
p10766
sg13
I1
sasg20
(lp10767
(dp10768
g7
I23
sg23
VC0024530
p10769
sg10
I7
sg11
Vmalaria
p10770
sg13
I1
sa(dp10771
g7
I218
sg23
VC0684336
p10772
sg10
I10
sg11
Vimpairment
p10773
sg13
I1
sa(dp10774
g7
I247
sg23
VC0009450
p10775
sg10
I9
sg11
Vinfection
p10776
sg13
I1
sasa(dp10777
g2
S'We studied the arthritis association and the spliceo-transcriptome of four different Ltab-Ncr3 haplotypes and showed that higher Ltb and Ncr3 expression, lower Lst1 expression, and the expression of a shorter splice variant of Lst1 correlate with reduced arthritis severity in rats.\n'
p10778
sg4
(lp10779
(dp10780
g7
I160
sg8
g15
sg10
I4
sg11
VLst1
p10781
sg13
I1
sa(dp10782
g7
I129
sg8
g15
sg10
I3
sg11
VLtb
p10783
sg13
I1
sa(dp10784
g7
I160
sg8
g15
sg10
I4
sg11
VLst1
p10785
sg13
I1
sasg20
(lp10786
(dp10787
g7
I15
sg23
VC0003864
p10788
sg10
I9
sg11
Varthritis
p10789
sg13
I1
sa(dp10790
g7
I15
sg23
VC0003864
p10791
sg10
I9
sg11
Varthritis
p10792
sg13
I1
sasa(dp10793
g2
S'The C825T polymorphism (rs5443) of the Guanine Nucleotide-Binding protein subunit Beta3 (GNB3) gene has been associated with obesity, essential hypertension, atherosclerosis, coronary diseases, and cerebrovascular events, but with some sex-specific effects.\n'
p10794
sg4
(lp10795
(dp10796
g7
I39
sg8
VP09471
p10797
sg10
I48
sg11
VGuanine Nucleotide-Binding protein subunit Beta3
p10798
sg13
I5
sa(dp10799
g7
I89
sg8
VP16520
p10800
sg10
I4
sg11
VGNB3
p10801
sg13
I1
sasg20
(lp10802
(dp10803
g7
I125
sg23
VC0028754
p10804
sg10
I7
sg11
Vobesity
p10805
sg13
I1
sa(dp10806
g7
I158
sg23
VC0010054
p10807
sg10
I25
sg11
Vatherosclerosis, coronary
p10808
sg13
I2
sa(dp10809
g7
I134
sg23
VC0085580
p10810
sg10
I22
sg11
Vessential hypertension
p10811
sg13
I2
sasa(dp10812
g2
S'The guanine nucleotide-binding protein beta polypeptide 3 (GNB3) 825T allele encodes a product that enhances the activation of heterotrimeric G proteins, which is associated with the occurrence of the splice variant GBeta3 s that could play a role in vascular reactivity and hyperproliferation of smooth muscle cells, that makes such proteins attractive candidate gene products for susceptibility to essential hypertension (EH).\n'
p10813
sg4
(lp10814
(dp10815
g7
I201
sg8
VP26640
p10816
sg10
I23
sg11
Vsplice variant GBeta3 s
p10817
sg13
I4
sa(dp10818
g7
I4
sg8
VP09471
p10819
sg10
I53
sg11
Vguanine nucleotide-binding protein beta polypeptide 3
p10820
sg13
I6
sa(dp10821
g7
I127
sg8
g15
sg10
I25
sg11
Vheterotrimeric G proteins
p10822
sg13
I3
sa(dp10823
g7
I59
sg8
VP16520
p10824
sg10
I4
sg11
VGNB3
p10825
sg13
I1
sasg20
(lp10826
(dp10827
g7
I400
sg23
VC0085580
p10828
sg10
I22
sg11
Vessential hypertension
p10829
sg13
I2
sa(dp10830
g7
I424
sg23
VC0085580
p10831
sg10
I2
sg11
VEH
p10832
sg13
I1
sasa(dp10833
g2
S'In our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y6 receptor (P2Y6R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR), promoted Ang II-induced hypertension in mice.\n'
p10834
sg4
(lp10835
(dp10836
g7
I28
sg8
VP01019
p10837
sg10
I6
sg11
VAng II
p10838
sg13
I2
sa(dp10839
g7
I64
sg8
VP30556
p10840
sg10
I4
sg11
VAT1R
p10841
sg13
I1
sa(dp10842
g7
I271
sg8
g15
sg10
I4
sg11
VGPCR
p10843
sg13
I1
sa(dp10844
g7
I28
sg8
VP01019
p10845
sg10
I6
sg11
VAng II
p10846
sg13
I2
sa(dp10847
g7
I131
sg8
g15
sg10
I24
sg11
Vpurinergic P2Y6 receptor
p10848
sg13
I3
sa(dp10849
g7
I191
sg8
g15
sg10
I9
sg11
VG protein
p10850
sg13
I2
sasg20
(lp10851
(dp10852
g7
I302
sg23
VC0020538
p10853
sg10
I12
sg11
Vhypertension
p10854
sg13
I1
sa(dp10855
g7
I168
sg23
VC0021368
p10856
sg10
I12
sg11
Vinflammation
p10857
sg13
I1
sasa(dp10858
g2
S'We identified the role of regulator of G protein (heterotrimeric guanine nucleotide-binding protein) signaling 5 (RGS5) in blood pressure regulation during pregnancy and preeclampsia.\n'
p10859
sg4
(lp10860
(dp10861
g7
I114
sg8
g15
sg10
I4
sg11
VRGS5
p10862
sg13
I1
sa(dp10863
g7
I39
sg8
g15
sg10
I9
sg11
VG protein
p10864
sg13
I2
sa(dp10865
g7
I50
sg8
VP09471
p10866
sg10
I49
sg11
Vheterotrimeric guanine nucleotide-binding protein
p10867
sg13
I4
sasg20
(lp10868
(dp10869
g7
I170
sg23
VC0032914
p10870
sg10
I12
sg11
Vpreeclampsia
p10871
sg13
I1
sasa(dp10872
g2
S'Here, we investigated the expression and function of NR6A1 and its underlying mechanisms in prostate cancer (PCa) patients who underwent radical prostatectomy.\n'
p10873
sg4
(lp10874
(dp10875
g7
I53
sg8
g15
sg10
I5
sg11
VNR6A1
p10876
sg13
I1
sasg20
(lp10877
(dp10878
g7
I92
sg23
VC0600139
p10879
sg10
I15
sg11
Vprostate cancer
p10880
sg13
I2
sa(dp10881
g7
I109
sg23
VC0268398
p10882
sg10
I3
sg11
VPCa
p10883
sg13
I1
sasa(dp10884
g2
S'A total of 303 cases of prostate cancer after radical prostatectomy were analysed in a tissue microarray (TMA) for NR6A1 immunohistochemistry-based protein expression.\n'
p10885
sg4
(lp10886
(dp10887
g7
I115
sg8
g15
sg10
I40
sg11
VNR6A1 immunohistochemistry-based protein
p10888
sg13
I3
sasg20
(lp10889
(dp10890
g7
I24
sg23
VC0600139
p10891
sg10
I15
sg11
Vprostate cancer
p10892
sg13
I2
sasa(dp10893
g2
S'Knockdown of NR6A1 by small interfering RNA mediated gene silencing and overexpression of NR6A1 through lentivirus were utilized to investigate its potential role in prostate cancer cells.\n'
p10894
sg4
(lp10895
(dp10896
g7
I13
sg8
g15
sg10
I5
sg11
VNR6A1
p10897
sg13
I1
sa(dp10898
g7
I13
sg8
g15
sg10
I5
sg11
VNR6A1
p10899
sg13
I1
sasg20
(lp10900
(dp10901
g7
I166
sg23
VC0600139
p10902
sg10
I15
sg11
Vprostate cancer
p10903
sg13
I2
sasa(dp10904
g2
S'In addition, gene silencing of NR6A1 resulted in G0/G1 phase cell cycle arrest, and decreased metastatic and invasive potential of prostate cancer cells DU145 and PC3.\n'
p10905
sg4
(lp10906
(dp10907
g7
I31
sg8
g15
sg10
I5
sg11
VNR6A1
p10908
sg13
I1
sasg20
(lp10909
(dp10910
g7
I131
sg23
VC0600139
p10911
sg10
I15
sg11
Vprostate cancer
p10912
sg13
I2
sasa(dp10913
g2
S'In contrast, overexpression of NR6A1 reduced G0/G1 phase cell cycle arrest, and promoted metastatic and invasive potential of prostate cancer cells 22RV1.\n'
p10914
sg4
(lp10915
(dp10916
g7
I31
sg8
g15
sg10
I5
sg11
VNR6A1
p10917
sg13
I1
sasg20
(lp10918
(dp10919
g7
I126
sg23
VC0600139
p10920
sg10
I15
sg11
Vprostate cancer
p10921
sg13
I2
sasa(dp10922
g2
S'The aim of this review was to summarize the current evidence and to highlight the main issues future research needs to address regarding prostate cancer (PCa) treatment in renal transpant recipients (RTRs).\n'
p10923
sg4
(lp10924
sg20
(lp10925
(dp10926
g7
I137
sg23
VC0600139
p10927
sg10
I15
sg11
Vprostate cancer
p10928
sg13
I2
sa(dp10929
g7
I154
sg23
VC0268398
p10930
sg10
I3
sg11
VPCa
p10931
sg13
I1
sasa(dp10932
g2
S'We conducted a multicenter retrospective study and reviewed the charts and records of 20 RTRs who had undergone RRP for localized prostate cancer at four French renal transplant centers belonging to the Renal Transplantation Committee of the French Urological Association from April 1996 to April 2007.\n'
p10933
sg4
(lp10934
(dp10935
g7
I112
sg8
g15
sg10
I3
sg11
VRRP
p10936
sg13
I1
sasg20
(lp10937
(dp10938
g7
I130
sg23
VC0600139
p10939
sg10
I15
sg11
Vprostate cancer
p10940
sg13
I2
sasa(dp10941
g2
S'In our study, RRP was a safe procedure to treat localized prostate cancer in RTRs.\n'
p10942
sg4
(lp10943
sg20
(lp10944
(dp10945
g7
I58
sg23
VC0600139
p10946
sg10
I15
sg11
Vprostate cancer
p10947
sg13
I2
sasa(dp10948
g2
S'In this study, we examine the expression of RTR in murine placenta and several human placental choriocarcinoma cell lines.\n'
p10949
sg4
(lp10950
(dp10951
g7
I44
sg8
g15
sg10
I3
sg11
VRTR
p10952
sg13
I1
sasg20
(lp10953
(dp10954
g7
I85
sg23
VC0855173
p10955
sg10
I25
sg11
Vplacental choriocarcinoma
p10956
sg13
I2
sasa(dp10957
g2
S'RTR mRNA was also expressed in rat choriocarcinoma Rcho-1 cells and in the human placental choriocarcinoma cell lines BeWo, JAR, and JEG-3.\n'
p10958
sg4
(lp10959
(dp10960
g7
I0
sg8
g15
sg10
I8
sg11
VRTR mRNA
p10961
sg13
I2
sasg20
(lp10962
(dp10963
g7
I31
sg23
VC1882624
p10964
sg10
I19
sg11
Vrat choriocarcinoma
p10965
sg13
I2
sa(dp10966
g7
I81
sg23
VC0855173
p10967
sg10
I25
sg11
Vplacental choriocarcinoma
p10968
sg13
I2
sasa(dp10969
g2
S'To evaluate the prognostic significance of PSA nadir (nPSA) and the time to nadir in disease free of recurrence (DFR) in localized carcinoma of prostate treated with radical radiotherapy (RTR).\n'
p10970
sg4
(lp10971
(dp10972
g7
I43
sg8
VP55786
p10973
sg10
I9
sg11
VPSA nadir
p10974
sg13
I2
sasg20
(lp10975
(dp10976
g7
I101
sg23
VC1458156
p10977
sg10
I10
sg11
Vrecurrence
p10978
sg13
I1
sa(dp10979
g7
I131
sg23
VC0600139
p10980
sg10
I21
sg11
Vcarcinoma of prostate
p10981
sg13
I3
sa(dp10982
g7
I43
sg23
VC1519176
p10983
sg10
I3
sg11
VPSA
p10984
sg13
I1
sasa(dp10985
g2
S'The present study was aimed to determine the effect of steviol on PC1, CFTR, and Beta-catenin levels in renal epithelial cells with defective PC1 biogenesis and expression (Prkcsh-/- cell) and postnatal Pkd1 homozygous cell (Pkd1-/- cells).\n'
p10986
sg4
(lp10987
(dp10988
g7
I71
sg8
VP13569
p10989
sg10
I4
sg11
VCFTR
p10990
sg13
I1
sa(dp10991
g7
I203
sg8
VP98161
p10992
sg10
I20
sg11
VPkd1 homozygous cell
p10993
sg13
I3
sa(dp10994
g7
I203
sg8
VP98161
p10995
sg10
I4
sg11
VPkd1
p10996
sg13
I1
sa(dp10997
g7
I81
sg8
VP35222
p10998
sg10
I12
sg11
VBeta-catenin
p10999
sg13
I1
sa(dp11000
g7
I66
sg8
VP98161
p11001
sg10
I3
sg11
VPC1
p11002
sg13
I1
sasg20
(lp11003
(dp11004
g7
I203
sg23
VC3149841
p11005
sg10
I4
sg11
VPkd1
p11006
sg13
I1
sa(dp11007
g7
I203
sg23
VC3149841
p11008
sg10
I4
sg11
VPkd1
p11009
sg13
I1
sa(dp11010
g7
I66
sg23
VC1706595
p11011
sg10
I3
sg11
VPC1
p11012
sg13
I1
sa(dp11013
g7
I66
sg23
VC1706595
p11014
sg10
I3
sg11
VPC1
p11015
sg13
I1
sasa(dp11016
g2
S'Using western blot analysis, it was found that steviol treatment at 100myM for 24-48h substantially enhanced and stabilized PC1 C-terminal expression, while decreasing CFTR and Beta-catenin protein expression in both Prkcsh-/- and Pkd1-/- cells.\n'
p11017
sg4
(lp11018
(dp11019
g7
I231
sg8
VP98161
p11020
sg10
I4
sg11
VPkd1
p11021
sg13
I1
sa(dp11022
g7
I124
sg8
VP98161
p11023
sg10
I5
sg11
VPC1 C
p11024
sg13
I2
sa(dp11025
g7
I168
sg8
VP13569
p11026
sg10
I4
sg11
VCFTR
p11027
sg13
I1
sa(dp11028
g7
I177
sg8
VP35222
p11029
sg10
I20
sg11
VBeta-catenin protein
p11030
sg13
I2
sasg20
(lp11031
(dp11032
g7
I231
sg23
VC3149841
p11033
sg10
I4
sg11
VPkd1
p11034
sg13
I1
sa(dp11035
g7
I124
sg23
VC1706595
p11036
sg10
I3
sg11
VPC1
p11037
sg13
I1
sasa(dp11038
g2
S'KPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and Beta-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells.\n'
p11039
sg4
(lp11040
(dp11041
g7
I130
sg8
VP35222
p11042
sg10
I12
sg11
VBeta-catenin
p11043
sg13
I1
sa(dp11044
g7
I121
sg8
g15
sg10
I4
sg11
VPAK4
p11045
sg13
I1
sa(dp11046
g7
I154
sg8
VP98161
p11047
sg10
I9
sg11
VPkd1-null
p11048
sg13
I1
sasg20
(lp11049
(dp11050
g7
I154
sg23
VC3149841
p11051
sg10
I4
sg11
VPkd1
p11052
sg13
I1
sa(dp11053
g7
I23
sg23
VC0020507
p11054
sg10
I22
sg11
Vcellular proliferation
p11055
sg13
I2
sasa(dp11056
g2
S'Given the fundamental role of Beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with Beta-catenin signaling.\n'
p11057
sg4
(lp11058
(dp11059
g7
I134
sg8
g15
sg10
I17
sg11
Vprotein kinase D1
p11060
sg13
I3
sa(dp11061
g7
I30
sg8
VP35222
p11062
sg10
I12
sg11
VBeta-catenin
p11063
sg13
I1
sa(dp11064
g7
I196
sg8
g15
sg10
I4
sg11
VPKDs
p11065
sg13
I1
sa(dp11066
g7
I30
sg8
VP35222
p11067
sg10
I12
sg11
VBeta-catenin
p11068
sg13
I1
sa(dp11069
g7
I153
sg8
VP98161
p11070
sg10
I4
sg11
VPKD1
p11071
sg13
I1
sasg20
(lp11072
(dp11073
g7
I134
sg23
VC3149841
p11074
sg10
I17
sg11
Vprotein kinase D1
p11075
sg13
I3
sa(dp11076
g7
I83
sg23
VC0334094
p11077
sg10
I13
sg11
Vproliferation
p11078
sg13
I1
sa(dp11079
g7
I153
sg23
VC3149841
p11080
sg10
I4
sg11
VPKD1
p11081
sg13
I1
sasa(dp11082
g2
S'GPCR stimulation also induced the formation of a complex between PKD1 and Beta-catenin, as shown by coimmunoprecipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors.\n'
p11083
sg4
(lp11084
(dp11085
g7
I74
sg8
VP35222
p11086
sg10
I12
sg11
VBeta-catenin
p11087
sg13
I1
sa(dp11088
g7
I209
sg8
VP98161
p11089
sg10
I10
sg11
VPKD family
p11090
sg13
I2
sa(dp11091
g7
I0
sg8
g15
sg10
I4
sg11
VGPCR
p11092
sg13
I1
sa(dp11093
g7
I65
sg8
VP98161
p11094
sg10
I4
sg11
VPKD1
p11095
sg13
I1
sa(dp11096
g7
I65
sg8
VP98161
p11097
sg10
I4
sg11
VPKD1
p11098
sg13
I1
sasg20
(lp11099
(dp11100
g7
I65
sg23
VC1868682
p11101
sg10
I3
sg11
VPKD
p11102
sg13
I1
sa(dp11103
g7
I65
sg23
VC3149841
p11104
sg10
I4
sg11
VPKD1
p11105
sg13
I1
sa(dp11106
g7
I65
sg23
VC3149841
p11107
sg10
I4
sg11
VPKD1
p11108
sg13
I1
sasa(dp11109
g2
S'Using transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of Beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates.\n'
p11110
sg4
(lp11111
(dp11112
g7
I44
sg8
VP98161
p11113
sg10
I4
sg11
VPKD1
p11114
sg13
I1
sa(dp11115
g7
I140
sg8
VP35222
p11116
sg10
I12
sg11
VBeta-catenin
p11117
sg13
I1
sa(dp11118
g7
I44
sg8
VP98161
p11119
sg10
I12
sg11
VPKD1 protein
p11120
sg13
I2
sasg20
(lp11121
(dp11122
g7
I44
sg23
VC3149841
p11123
sg10
I4
sg11
VPKD1
p11124
sg13
I1
sa(dp11125
g7
I44
sg23
VC3149841
p11126
sg10
I4
sg11
VPKD1
p11127
sg13
I1
sasa(dp11128
g2
S'Pachyonychia congenita subjects were sampled who exhibited a mutation in KRT6A, KRT6B, KRT6C, KRT16 or KRT17, and the proteins were digested and analyzed by tandem mass spectrometry.\n'
p11129
sg4
(lp11130
(dp11131
g7
I73
sg8
VP02538
p11132
sg10
I5
sg11
VKRT6A
p11133
sg13
I1
sa(dp11134
g7
I94
sg8
VP08779
p11135
sg10
I5
sg11
VKRT16
p11136
sg13
I1
sa(dp11137
g7
I87
sg8
VP48668
p11138
sg10
I5
sg11
VKRT6C
p11139
sg13
I1
sa(dp11140
g7
I80
sg8
VP08779
p11141
sg10
I5
sg11
VKRT6B
p11142
sg13
I1
sasg20
(lp11143
(dp11144
g7
I0
sg23
VC0265334
p11145
sg10
I22
sg11
VPachyonychia congenita
p11146
sg13
I2
sasa(dp11147
g2
S'We thus performed extensive biomarker measures in these compartments using univariate and multivariate approaches to correlate disease biomarkers with SCORAD and with a combined hyperplasia score [thickness and keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD patients.\n'
p11148
sg4
(lp11149
(dp11150
g7
I223
sg8
VP04264
p11151
sg10
I3
sg11
VK16
p11152
sg13
I1
sa(dp11153
g7
I211
sg8
VP04264
p11154
sg10
I10
sg11
Vkeratin 16
p11155
sg13
I2
sasg20
(lp11156
(dp11157
g7
I178
sg23
VC0020507
p11158
sg10
I11
sg11
Vhyperplasia
p11159
sg13
I1
sasa(dp11160
g2
S'In addition to increased abundance, KRT16 demonstrated autoantigenicity, since sera from both fracture mice and CRPS patients showed increased autoantibody binding to recombinant kRT16 protein.\n'
p11161
sg4
(lp11162
(dp11163
g7
I167
sg8
VP08779
p11164
sg10
I25
sg11
Vrecombinant kRT16 protein
p11165
sg13
I3
sa(dp11166
g7
I36
sg8
VP08779
p11167
sg10
I5
sg11
VKRT16
p11168
sg13
I1
sasg20
(lp11169
(dp11170
g7
I112
sg23
VC0458219
p11171
sg10
I4
sg11
VCRPS
p11172
sg13
I1
sasa(dp11173
g2
S'The identification of autoantibodies against KRT16 as a biomarker in mice and in humans is a critical step towards these goals, and towards redefining CRPS as having an autoimmune etiology.\n'
p11174
sg4
(lp11175
(dp11176
g7
I45
sg8
VP08779
p11177
sg10
I5
sg11
VKRT16
p11178
sg13
I1
sasg20
(lp11179
(dp11180
g7
I169
sg23
VC0443146
p11181
sg10
I10
sg11
Vautoimmune
p11182
sg13
I1
sa(dp11183
g7
I151
sg23
VC0458219
p11184
sg10
I4
sg11
VCRPS
p11185
sg13
I1
sasa(dp11186
g2
S'These findings were associated with upregulation of mitochondrial Bak and Bcl-2/Bcl-xL, proapoptotic and prosurvival members in the Bcl-2 family, respectively, as well as increased mitochondrial cytochrome c release, caspase activation, and apoptosis in pancreatitis in PKCEpsilon knockout mice.\n'
p11187
sg4
(lp11188
(dp11189
g7
I181
sg8
VP99999
p11190
sg10
I34
sg11
Vmitochondrial cytochrome c release
p11191
sg13
I4
sa(dp11192
g7
I66
sg8
g15
sg10
I3
sg11
VBak
p11193
sg13
I1
sa(dp11194
g7
I80
sg8
g15
sg10
I6
sg11
VBcl-xL
p11195
sg13
I1
sa(dp11196
g7
I74
sg8
VP10415
p11197
sg10
I5
sg11
VBcl-2
p11198
sg13
I1
sa(dp11199
g7
I217
sg8
VP39880
p11200
sg10
I7
sg11
Vcaspase
p11201
sg13
I1
sa(dp11202
g7
I132
sg8
VP10415
p11203
sg10
I12
sg11
VBcl-2 family
p11204
sg13
I2
sasg20
(lp11205
(dp11206
g7
I254
sg23
VC0030305
p11207
sg10
I12
sg11
Vpancreatitis
p11208
sg13
I1
sasa(dp11209
g2
S'We then microinjected a GABAA receptor antagonist, an inhibitor of lactate transport (4CIN), or an inhibitor of lactate dehydrogenase, oxamate (OX), into the VMH prior to inducing hypoglycemia.\n'
p11210
sg4
(lp11211
(dp11212
g7
I24
sg8
g15
sg10
I14
sg11
VGABAA receptor
p11213
sg13
I2
sa(dp11214
g7
I112
sg8
VP49366
p11215
sg10
I21
sg11
Vlactate dehydrogenase
p11216
sg13
I2
sasg20
(lp11217
(dp11218
g7
I180
sg23
VC0020615
p11219
sg10
I12
sg11
Vhypoglycemia
p11220
sg13
I1
sasa(dp11221
g2
S'To assess whether lactate contributes to raising GABA in RH and diabetes, we injected 4CIN or OX into the VMH of RH and diabetic rats before inducing hypoglycemia.\n'
p11222
sg4
(lp11223
sg20
(lp11224
(dp11225
g7
I64
sg23
VC0011849
p11226
sg10
I8
sg11
Vdiabetes
p11227
sg13
I1
sa(dp11228
g7
I150
sg23
VC0020615
p11229
sg10
I12
sg11
Vhypoglycemia
p11230
sg13
I1
sasa(dp11231
g2
S'Mechanistically, we show that the protective effect of IL-22 on pancreatitis was mediated via the induction of Bcl-2 and Bcl-X(L), which bind to Beclin-1 and subsequently inhibit autophagosome formation to ameliorate pancreatitis.\n'
p11232
sg4
(lp11233
(dp11234
g7
I111
sg8
VP10415
p11235
sg10
I5
sg11
VBcl-2
p11236
sg13
I1
sa(dp11237
g7
I55
sg8
g15
sg10
I5
sg11
VIL-22
p11238
sg13
I1
sa(dp11239
g7
I145
sg8
g15
sg10
I8
sg11
VBeclin-1
p11240
sg13
I1
sa(dp11241
g7
I121
sg8
g15
sg10
I8
sg11
VBcl-X(L)
p11242
sg13
I1
sasg20
(lp11243
(dp11244
g7
I64
sg23
VC0030305
p11245
sg10
I12
sg11
Vpancreatitis
p11246
sg13
I1
sa(dp11247
g7
I64
sg23
VC0030305
p11248
sg10
I12
sg11
Vpancreatitis
p11249
sg13
I1
sasa(dp11250
g2
S'We used genetically modified rat models to investigate the role of MYL4 in atrial cardiomyopathy.\n'
p11251
sg4
(lp11252
(dp11253
g7
I67
sg8
VP12829
p11254
sg10
I4
sg11
VMYL4
p11255
sg13
I1
sasg20
(lp11256
(dp11257
g7
I82
sg23
VC0878544
p11258
sg10
I14
sg11
Vcardiomyopathy
p11259
sg13
I1
sasa(dp11260
g2
S'Exome sequencing and systematic bioinformatic analyses identified a rare missense variant of MYL4 (c.31G&gt;A [p.E11K]) in a large multiplex atrial cardiomyopathy family pedigree.\n'
p11261
sg4
(lp11262
(dp11263
g7
I93
sg8
VP12829
p11264
sg10
I4
sg11
VMYL4
p11265
sg13
I1
sasg20
(lp11266
(dp11267
g7
I148
sg23
VC0878544
p11268
sg10
I14
sg11
Vcardiomyopathy
p11269
sg13
I1
sasa(dp11270
g2
S'MYL4 knockout rats showed a similar atrial cardiomyopathy phenotype, whereas rats with an adjacent 4-amino-acid deletion showed no phenotype.\n'
p11271
sg4
(lp11272
(dp11273
g7
I0
sg8
VP12829
p11274
sg10
I4
sg11
VMYL4
p11275
sg13
I1
sasg20
(lp11276
(dp11277
g7
I43
sg23
VC0878544
p11278
sg10
I14
sg11
Vcardiomyopathy
p11279
sg13
I1
sasa(dp11280
g2
S'Loss-of-function MYL4 gene variants cause progressive atrial cardiomyopathy in humans and rats.\n'
p11281
sg4
(lp11282
(dp11283
g7
I17
sg8
VP12829
p11284
sg10
I18
sg11
VMYL4 gene variants
p11285
sg13
I3
sasg20
(lp11286
(dp11287
g7
I61
sg23
VC0878544
p11288
sg10
I14
sg11
Vcardiomyopathy
p11289
sg13
I1
sasa(dp11290
g2
S'Genome-wide association studies (GWAS) have yielded variants at &gt;30 loci that associate with atrial fibrillation (AF), including rare coding mutations in the sarcomere genes MYH6 and MYL4.\n'
p11291
sg4
(lp11292
(dp11293
g7
I186
sg8
VP12829
p11294
sg10
I4
sg11
VMYL4
p11295
sg13
I1
sa(dp11296
g7
I177
sg8
VP13533
p11297
sg10
I4
sg11
VMYH6
p11298
sg13
I1
sasg20
(lp11299
(dp11300
g7
I96
sg23
VC0004238
p11301
sg10
I19
sg11
Vatrial fibrillation
p11302
sg13
I2
sa(dp11303
g7
I117
sg23
VC0004238
p11304
sg10
I2
sg11
VAF
p11305
sg13
I1
sasa(dp11306
g2
S'We imputed these variants into 104,220 individuals down to a minor allele frequency of 0.1% and found a recessive frameshift mutation in MYL4 that causes early-onset atrial fibrillation, several mutations in ABCB4 that increase risk of liver diseases and an intronic variant in GNAS associating with increased thyroid-stimulating hormone levels when maternally inherited.\n'
p11307
sg4
(lp11308
(dp11309
g7
I137
sg8
VP12829
p11310
sg10
I4
sg11
VMYL4
p11311
sg13
I1
sa(dp11312
g7
I208
sg8
VP21439
p11313
sg10
I5
sg11
VABCB4
p11314
sg13
I1
sa(dp11315
g7
I310
sg8
VP01222
p11316
sg10
I27
sg11
Vthyroid-stimulating hormone
p11317
sg13
I2
sasg20
(lp11318
(dp11319
g7
I166
sg23
VC0004238
p11320
sg10
I19
sg11
Vatrial fibrillation
p11321
sg13
I2
sa(dp11322
g7
I236
sg23
VC0023895
p11323
sg10
I14
sg11
Vliver diseases
p11324
sg13
I2
sa(dp11325
g7
I114
sg23
VC0079380
p11326
sg10
I19
sg11
Vframeshift mutation
p11327
sg13
I2
sasa(dp11328
g2
S'The aim of this study is to examine the mitochondrial targeting of NDUFV2 and dissect the pathogenetic mechanism of one human deletion mutation present in patients with early-onset hypertrophic cardiomyopathy and encephalopathy.\n'
p11329
sg4
(lp11330
(dp11331
g7
I67
sg8
VP19404
p11332
sg10
I6
sg11
VNDUFV2
p11333
sg13
I1
sasg20
(lp11334
(dp11335
g7
I181
sg23
VC0007194
p11336
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p11337
sg13
I2
sa(dp11338
g7
I213
sg23
VC0085584
p11339
sg10
I14
sg11
Vencephalopathy
p11340
sg13
I1
sasa(dp11341
g2
S'The deletion mutant mimicking the human early-onset hypertrophic cardiomyopathy and encephalopathy lacked 19-40 residues in NDUFV2 and exhibited a significant reduction in its mitochondrial targeting ability.\n'
p11342
sg4
(lp11343
(dp11344
g7
I124
sg8
VP19404
p11345
sg10
I6
sg11
VNDUFV2
p11346
sg13
I1
sasg20
(lp11347
(dp11348
g7
I13
sg23
VC0596988
p11349
sg10
I6
sg11
Vmutant
p11350
sg13
I1
sa(dp11351
g7
I52
sg23
VC0007194
p11352
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p11353
sg13
I2
sa(dp11354
g7
I84
sg23
VC0085584
p11355
sg10
I14
sg11
Vencephalopathy
p11356
sg13
I1
sasa(dp11357
g2
S'The results of human disease cell model established that the impairment of mitochondrial localization of NDUFV2 as a mechanistic basis for early-onset hypertrophic cardiomyopathy and encephalopathy.\n'
p11358
sg4
(lp11359
(dp11360
g7
I105
sg8
VP19404
p11361
sg10
I6
sg11
VNDUFV2
p11362
sg13
I1
sasg20
(lp11363
(dp11364
g7
I61
sg23
VC0684336
p11365
sg10
I10
sg11
Vimpairment
p11366
sg13
I1
sa(dp11367
g7
I183
sg23
VC0085584
p11368
sg10
I14
sg11
Vencephalopathy
p11369
sg13
I1
sa(dp11370
g7
I151
sg23
VC0007194
p11371
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p11372
sg13
I2
sasa(dp11373
g2
S'A small deletion in the second intron of human NDUFV2 (IVS2+5_+8delGTAA) has been shown to cause hypertrophic cardiomyopathy and encephalomyopathy [Benit, P., Beugnot, R., Chretien, D., Giurgea, I., de Lonlay-Debeney, P., Issartel, J.P., Kerscher, S., Rustin, P., Roetig, A.\n'
p11374
sg4
(lp11375
(dp11376
g7
I41
sg8
VP19404
p11377
sg10
I31
sg11
Vhuman NDUFV2 (IVS2+5_+8delGTAA)
p11378
sg13
I3
sasg20
(lp11379
(dp11380
g7
I97
sg23
VC0007194
p11381
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p11382
sg13
I2
sasa(dp11383
g2
S'While mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.\n'
p11384
sg4
(lp11385
(dp11386
g7
I141
sg8
g15
sg10
I12
sg11
VNDUFS2 genes
p11387
sg13
I2
sa(dp11388
g7
I130
sg8
VP19404
p11389
sg10
I6
sg11
VNDUFV2
p11390
sg13
I1
sa(dp11391
g7
I23
sg8
g15
sg10
I11
sg11
VNDUFS3 gene
p11392
sg13
I2
sasg20
(lp11393
(dp11394
g7
I50
sg23
VC0023264
p11395
sg10
I14
sg11
VLeigh syndrome
p11396
sg13
I2
sa(dp11397
g7
I190
sg23
VC0878544
p11398
sg10
I14
sg11
Vcardiomyopathy
p11399
sg13
I1
sasa(dp11400
g2
S'Combination of denaturing high performance liquid chromatography and sequence analysis allowed us to show that a 4-bp deletion in intron 2 (IVS2+5_+8delGTAA) of the NDUFV2 gene (encoding NADH dehydrogenase ubiquinone flavoprotein 2) causes complex I deficiency and early onset hypertrophic cardiomyopathy with trunk hypotonia in three affected sibs of a consanguineous family.\n'
p11401
sg4
(lp11402
(dp11403
g7
I187
sg8
VP49366
p11404
sg10
I44
sg11
VNADH dehydrogenase ubiquinone flavoprotein 2
p11405
sg13
I5
sa(dp11406
g7
I165
sg8
VP19404
p11407
sg10
I11
sg11
VNDUFV2 gene
p11408
sg13
I2
sasg20
(lp11409
(dp11410
g7
I316
sg23
VC0026827
p11411
sg10
I9
sg11
Vhypotonia
p11412
sg13
I1
sa(dp11413
g7
I277
sg23
VC0007194
p11414
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p11415
sg13
I2
sa(dp11416
g7
I240
sg23
VC0342776
p11417
sg10
I20
sg11
Vcomplex I deficiency
p11418
sg13
I3
sasa(dp11419
g2
S'While mutation in a number of genes encoding complex I subunits essentially result in neurological symptoms, this first mutation in NDUFV2 is strikingly associated with cardiomyopathy, as previously observed in the unique case of NDFUS2 mutations.\n'
p11420
sg4
(lp11421
(dp11422
g7
I132
sg8
VP19404
p11423
sg10
I6
sg11
VNDUFV2
p11424
sg13
I1
sasg20
(lp11425
(dp11426
g7
I86
sg23
VC0235031
p11427
sg10
I21
sg11
Vneurological symptoms
p11428
sg13
I2
sa(dp11429
g7
I169
sg23
VC0878544
p11430
sg10
I14
sg11
Vcardiomyopathy
p11431
sg13
I1
sasa(dp11432
g2
S'Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control).\n'
p11433
sg4
(lp11434
sg20
(lp11435
(dp11436
g7
I52
sg23
VC0028754
p11437
sg10
I7
sg11
Vobesity
p11438
sg13
I1
sasa(dp11439
g2
S'GAL and GALP concentrations may be taken as potential biomarkers to predict development of obesity.\n'
p11440
sg4
(lp11441
(dp11442
g7
I0
sg8
VP16278
p11443
sg10
I3
sg11
VGAL
p11444
sg13
I1
sa(dp11445
g7
I8
sg8
g15
sg10
I4
sg11
VGALP
p11446
sg13
I1
sasg20
(lp11447
(dp11448
g7
I91
sg23
VC0028754
p11449
sg10
I7
sg11
Vobesity
p11450
sg13
I1
sasa(dp11451
g2
S'Galanin-like peptide (GALP) has an anti-obesity effect in rats and mice.\n'
p11452
sg4
(lp11453
(dp11454
g7
I0
sg8
g15
sg10
I20
sg11
VGalanin-like peptide
p11455
sg13
I2
sa(dp11456
g7
I22
sg8
g15
sg10
I4
sg11
VGALP
p11457
sg13
I1
sasg20
(lp11458
(dp11459
g7
I40
sg23
VC0028754
p11460
sg10
I7
sg11
Vobesity
p11461
sg13
I1
sasa(dp11462
g2
S'These results suggest that intranasal administration is an effective route whereby GALP can exert its effect as an anti-obesity drug.\n'
p11463
sg4
(lp11464
sg20
(lp11465
(dp11466
g7
I120
sg23
VC0028754
p11467
sg10
I7
sg11
Vobesity
p11468
sg13
I1
sasa(dp11469
g2
S'These results show that GALP stimulates fatty acid Beta-oxidation in liver and lipolysis in adipose tissue, and suggest that the anti-obesity effect of GALP may be due to anorexigenic actions and improvement of lipid metabolism in peripheral tissues via the sympathetic nervous system.\n'
p11470
sg4
(lp11471
(dp11472
g7
I24
sg8
g15
sg10
I4
sg11
VGALP
p11473
sg13
I1
sa(dp11474
g7
I24
sg8
g15
sg10
I4
sg11
VGALP
p11475
sg13
I1
sasg20
(lp11476
(dp11477
g7
I270
sg23
VC0027769
p11478
sg10
I7
sg11
Vnervous
p11479
sg13
I1
sa(dp11480
g7
I134
sg23
VC0028754
p11481
sg10
I7
sg11
Vobesity
p11482
sg13
I1
sasa(dp11483
g2
S'We conclude that GALP may be of therapeutic value for obesity and life-style-related diseases in the near future.\n'
p11484
sg4
(lp11485
(dp11486
g7
I17
sg8
g15
sg10
I4
sg11
VGALP
p11487
sg13
I1
sasg20
(lp11488
(dp11489
g7
I54
sg23
VC0028754
p11490
sg10
I7
sg11
Vobesity
p11491
sg13
I1
sasa(dp11492
g2
S'Galanin-like peptide (GALP) shows potential as a therapeutic in the treatment of obesity and related conditions.\n'
p11493
sg4
(lp11494
(dp11495
g7
I0
sg8
g15
sg10
I20
sg11
VGalanin-like peptide
p11496
sg13
I2
sa(dp11497
g7
I22
sg8
g15
sg10
I4
sg11
VGALP
p11498
sg13
I1
sasg20
(lp11499
(dp11500
g7
I81
sg23
VC0028754
p11501
sg10
I7
sg11
Vobesity
p11502
sg13
I1
sasa(dp11503
g2
S'Variations within the gene locus encoding SHP-2 have been associated with increased susceptibility to develop ulcerative colitis and gastric atrophy.\n'
p11504
sg4
(lp11505
(dp11506
g7
I42
sg8
g15
sg10
I5
sg11
VSHP-2
p11507
sg13
I1
sasg20
(lp11508
(dp11509
g7
I133
sg23
VC0017154
p11510
sg10
I15
sg11
Vgastric atrophy
p11511
sg13
I2
sa(dp11512
g7
I110
sg23
VC0009324
p11513
sg10
I18
sg11
Vulcerative colitis
p11514
sg13
I2
sasa(dp11515
g2
S'When we considered the host genetic effects alone, gene-gene interactions consistently decreased the risks of gastric cancer and/or atrophic gastritis, including three two-way interactions: PGC rs6912200-PTPN11 rs12229892, PGC rs4711690-IL1B rs1143623 and PTPN11 rs12229892-IL1B rs1143623 and a three-way interaction: PGC rs4711690-PGC rs6912200-PTPN11 rs12229892.\n'
p11516
sg4
(lp11517
(dp11518
g7
I190
sg8
VP20142
p11519
sg10
I31
sg11
VPGC rs6912200-PTPN11 rs12229892
p11520
sg13
I3
sa(dp11521
g7
I223
sg8
VP20142
p11522
sg10
I28
sg11
VPGC rs4711690-IL1B rs1143623
p11523
sg13
I3
sa(dp11524
g7
I318
sg8
VP20142
p11525
sg10
I45
sg11
VPGC rs4711690-PGC rs6912200-PTPN11 rs12229892
p11526
sg13
I4
sa(dp11527
g7
I256
sg8
g15
sg10
I32
sg11
VPTPN11 rs12229892-IL1B rs1143623
p11528
sg13
I3
sasg20
(lp11529
(dp11530
g7
I132
sg23
VC0017154
p11531
sg10
I18
sg11
Vatrophic gastritis
p11532
sg13
I2
sa(dp11533
g7
I110
sg23
VC0024623
p11534
sg10
I14
sg11
Vgastric cancer
p11535
sg13
I2
sasa(dp11536
g2
S'Inconsistency of reported associations of the G/A polymorphism (rs2301756) in the PTPN11 gene and gastric atrophy prompted us to undertake a meta-analysis.\n'
p11537
sg4
(lp11538
(dp11539
g7
I82
sg8
g15
sg10
I11
sg11
VPTPN11 gene
p11540
sg13
I2
sasg20
(lp11541
(dp11542
g7
I98
sg23
VC0017154
p11543
sg10
I15
sg11
Vgastric atrophy
p11544
sg13
I2
sasa(dp11545
g2
S'Associations of PTPN11 polymorphism with gastric atrophy in H. pylori (-) and (+) subjects are more readily interpreted in the homozygous and recessive models given that the dominant codominant effects skirted null associations.\n'
p11546
sg4
(lp11547
(dp11548
g7
I16
sg8
g15
sg10
I6
sg11
VPTPN11
p11549
sg13
I1
sasg20
(lp11550
(dp11551
g7
I41
sg23
VC0017154
p11552
sg10
I15
sg11
Vgastric atrophy
p11553
sg13
I2
sasa(dp11554
g2
S'Evidence of overall and subgroup decreased risks, strong in seropositive subjects, demonstrates protective effects of the PTPN11 G/A polymorphism from gastric atrophy.\n'
p11555
sg4
(lp11556
(dp11557
g7
I122
sg8
g15
sg10
I10
sg11
VPTPN11 G/A
p11558
sg13
I2
sasg20
(lp11559
(dp11560
g7
I151
sg23
VC0017154
p11561
sg10
I15
sg11
Vgastric atrophy
p11562
sg13
I2
sasa(dp11563
g2
S'The interaction between Src homology 2 domain-containing protein tyrosine phosphatase (SHP-2) of gastric epithelial cells and cagA from H. pylori plays a crucial role in developments of gastric atrophy and gastric cancer.\n'
p11564
sg4
(lp11565
(dp11566
g7
I24
sg8
VP12931
p11567
sg10
I61
sg11
VSrc homology 2 domain-containing protein tyrosine phosphatase
p11568
sg13
I7
sa(dp11569
g7
I126
sg8
VP05109
p11570
sg10
I4
sg11
VcagA
p11571
sg13
I1
sa(dp11572
g7
I87
sg8
g15
sg10
I5
sg11
VSHP-2
p11573
sg13
I1
sasg20
(lp11574
(dp11575
g7
I186
sg23
VC0017154
p11576
sg10
I15
sg11
Vgastric atrophy
p11577
sg13
I2
sa(dp11578
g7
I206
sg23
VC0024623
p11579
sg10
I14
sg11
Vgastric cancer
p11580
sg13
I2
sasa(dp11581
g2
S'This study aimed to investigate the association of haplotype tagging SNPs (htSNPs) in the PTPN11 gene encoding SHP-2 with gastric atrophy and gastric cancer in Chinese population.\n'
p11582
sg4
(lp11583
(dp11584
g7
I111
sg8
g15
sg10
I5
sg11
VSHP-2
p11585
sg13
I1
sa(dp11586
g7
I90
sg8
g15
sg10
I11
sg11
VPTPN11 gene
p11587
sg13
I2
sasg20
(lp11588
(dp11589
g7
I122
sg23
VC0017154
p11590
sg10
I15
sg11
Vgastric atrophy
p11591
sg13
I2
sa(dp11592
g7
I142
sg23
VC0024623
p11593
sg10
I14
sg11
Vgastric cancer
p11594
sg13
I2
sasa(dp11595
g2
S'Our study provides the first evidence that rs12423190 polymorphism of the PTPN11 gene is significantly associated with an increased risk of gastric atrophy in H. pylori infected Chinese Han population, suggesting that rs12423190 polymorphism could be used as a useful marker of genetic susceptibility to gastric atrophy among H. pylori infected subjects.\n'
p11596
sg4
(lp11597
(dp11598
g7
I74
sg8
g15
sg10
I11
sg11
VPTPN11 gene
p11599
sg13
I2
sasg20
(lp11600
(dp11601
g7
I140
sg23
VC0017154
p11602
sg10
I15
sg11
Vgastric atrophy
p11603
sg13
I2
sa(dp11604
g7
I140
sg23
VC0017154
p11605
sg10
I15
sg11
Vgastric atrophy
p11606
sg13
I2
sasa(dp11607
g2
S'The present study indicated that overexpression of GRP78 in colon cancer cells could promote cell-matrix adhesion through the upregulation of fibronectin, integrin-Beta1 and phosphorylated FAK.\n'
p11608
sg4
(lp11609
(dp11610
g7
I189
sg8
g15
sg10
I3
sg11
VFAK
p11611
sg13
I1
sa(dp11612
g7
I51
sg8
VP11021
p11613
sg10
I5
sg11
VGRP78
p11614
sg13
I1
sasg20
(lp11615
(dp11616
g7
I60
sg23
VC0699790
p11617
sg10
I12
sg11
Vcolon cancer
p11618
sg13
I2
sa(dp11619
g7
I105
sg23
VC0001511
p11620
sg10
I8
sg11
Vadhesion
p11621
sg13
I1
sasa(dp11622
g2
S'Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin Beta1 protein levels and downstream signaling.\n'
p11623
sg4
(lp11624
(dp11625
g7
I57
sg8
VP54646
p11626
sg10
I4
sg11
VAMPK
p11627
sg13
I1
sasg20
(lp11628
(dp11629
g7
I110
sg23
VC0699790
p11630
sg10
I12
sg11
Vcolon cancer
p11631
sg13
I2
sasa(dp11632
g2
S'On multivariate analysis, the independent predictors of gene expression were hepatitis C (Mx1, OAS2, PKR and IFI16), donor age (IFI16) and recipient gender (IRF7A) (P &lt; .05 for all).\n'
p11633
sg4
(lp11634
(dp11635
g7
I101
sg8
g15
sg10
I3
sg11
VPKR
p11636
sg13
I1
sa(dp11637
g7
I95
sg8
VP29728
p11638
sg10
I4
sg11
VOAS2
p11639
sg13
I1
sa(dp11640
g7
I90
sg8
VP20591
p11641
sg10
I3
sg11
VMx1
p11642
sg13
I1
sa(dp11643
g7
I157
sg8
g15
sg10
I5
sg11
VIRF7A
p11644
sg13
I1
sasg20
(lp11645
(dp11646
g7
I77
sg23
VC0019196
p11647
sg10
I11
sg11
Vhepatitis C
p11648
sg13
I2
sasa(dp11649
g2
S'No significant difference was observed in the expression of ERRbeta mRNA between endometrial carcinoma (23%, 0.21 +/- 0.16) and normal endometrium (22%, 0.27 +/- 0.15; P &gt; 0.05).\n'
p11650
sg4
(lp11651
(dp11652
g7
I60
sg8
g15
sg10
I12
sg11
VERRbeta mRNA
p11653
sg13
I2
sasg20
(lp11654
(dp11655
g7
I81
sg23
VC0476089
p11656
sg10
I21
sg11
Vendometrial carcinoma
p11657
sg13
I2
sasa(dp11658
g2
S'Patients undergoing major open vascular surgery (open abdominal aortic aneurysm [oAAA] repair, aortofemoral bypass, and lower extremity infrainguinal bypass [LEB]) were identified using the Michigan Surgical Quality Collaborative (MSQC) between July 2012 and June 2015.\n'
p11659
sg4
(lp11660
sg20
(lp11661
(dp11662
g7
I54
sg23
VC0162871
p11663
sg10
I25
sg11
Vabdominal aortic aneurysm
p11664
sg13
I3
sasa(dp11665
g2
S'Beta blocker utilization (&lt;1 month preoperative versus chronic) and POMI rates were prospectively collected for patients undergoing open abdominal aortic aneurysm (AAA) repair (n = 926) and lower extremity bypass (LEB; n = 2,123) from 2003 through 2008.\n'
p11666
sg4
(lp11667
sg20
(lp11668
(dp11669
g7
I167
sg23
VC0162871
p11670
sg10
I3
sg11
VAAA
p11671
sg13
I1
sa(dp11672
g7
I140
sg23
VC0162871
p11673
sg10
I25
sg11
Vabdominal aortic aneurysm
p11674
sg13
I3
sasa(dp11675
g2
S'We studied 10,081 patients who underwent nonemergent carotid endarterectomy (CEA; n = 5293), lower extremity bypass (LEB; n = 2673), endovascular abdominal aortic aneurysm repair (EVAR; n = 1005), and open infrarenal abdominal aortic aneurysm repair (OAAA; n = 1,110) within the VSGNE from 2003 to 2008.\n'
p11676
sg4
(lp11677
sg20
(lp11678
(dp11679
g7
I146
sg23
VC0162871
p11680
sg10
I25
sg11
Vabdominal aortic aneurysm
p11681
sg13
I3
sa(dp11682
g7
I146
sg23
VC0162871
p11683
sg10
I25
sg11
Vabdominal aortic aneurysm
p11684
sg13
I3
sasa(dp11685
g2
S'We mailed a survey to the directors of the 8 Canadian vascular surgery training programs, to ascertain the yearly operative volumes of their 3 most recent trainees with respect to 6 index operations: carotid endarterectomy (CEA), types I-IV thoracoabdominal aortic aneurysm (TAA) repair, elective open infrarenal aortic aneurysm (eAAA) repair, ruptured abdominal aortic aneurysm (rAAA) repair, endovascular abdominal aortic aneurysm repair (EVAR) and lower extremity arterial bypass (LEB).\n'
p11686
sg4
(lp11687
sg20
(lp11688
(dp11689
g7
I380
sg23
VC0265012
p11690
sg10
I4
sg11
VrAAA
p11691
sg13
I1
sa(dp11692
g7
I344
sg23
VC0265012
p11693
sg10
I34
sg11
Vruptured abdominal aortic aneurysm
p11694
sg13
I4
sa(dp11695
g7
I248
sg23
VC0162871
p11696
sg10
I25
sg11
Vabdominal aortic aneurysm
p11697
sg13
I3
sa(dp11698
g7
I241
sg23
VC0340630
p11699
sg10
I32
sg11
Vthoracoabdominal aortic aneurysm
p11700
sg13
I3
sa(dp11701
g7
I258
sg23
VC0003486
p11702
sg10
I15
sg11
Vaortic aneurysm
p11703
sg13
I2
sa(dp11704
g7
I275
sg23
VC0162872
p11705
sg10
I3
sg11
VTAA
p11706
sg13
I1
sasa(dp11707
g2
S'Between 1999 and 2002, vascular surgery trainees in Canadian training programs were exposed to the following yearly clinical volumes (expressed as mean [and standard deviation]): CEA 55.4 (33.9), TAA 6.2 (3.8), eAAA 63.8 (30.0), rAAA 13.5 (9.4), EVAR 14.9 (9.6) and LEB 74.5 (34.5).\n'
p11708
sg4
(lp11709
sg20
(lp11710
(dp11711
g7
I196
sg23
VC0162872
p11712
sg10
I3
sg11
VTAA
p11713
sg13
I1
sasa(dp11714
g2
S'The range of yearly clinical volumes were: CEA 21-124, TAA 1-18, eAAA 30-133, rAAA 3-45, EVAR 0-34 and LEB 20-143.\n'
p11715
sg4
(lp11716
sg20
(lp11717
(dp11718
g7
I55
sg23
VC0162872
p11719
sg10
I3
sg11
VTAA
p11720
sg13
I1
sasa(dp11721
g2
S'Risk-adjustment models have not been developed for elective abdominal aortic aneurysm repair (AAA), lower extremity bypass revascularization (LEB), or lower extremity amputation (AMP).\n'
p11722
sg4
(lp11723
sg20
(lp11724
(dp11725
g7
I60
sg23
VC0162871
p11726
sg10
I25
sg11
Vabdominal aortic aneurysm
p11727
sg13
I3
sa(dp11728
g7
I94
sg23
VC0162871
p11729
sg10
I3
sg11
VAAA
p11730
sg13
I1
sa(dp11731
g7
I70
sg23
VC0162871
p11732
sg10
I22
sg11
Vaortic aneurysm repair
p11733
sg13
I3
sasa(dp11734
g2
S'Postoperative ileus is accompanied by activation of CGRP, NGF-TrkA, and PAR-2 in DRGs.\n'
p11735
sg4
(lp11736
(dp11737
g7
I72
sg8
VP55085
p11738
sg10
I5
sg11
VPAR-2
p11739
sg13
I1
sa(dp11740
g7
I58
sg8
VP01138
p11741
sg10
I3
sg11
VNGF
p11742
sg13
I1
sa(dp11743
g7
I52
sg8
VP80511
p11744
sg10
I4
sg11
VCGRP
p11745
sg13
I1
sa(dp11746
g7
I62
sg8
VP06753
p11747
sg10
I4
sg11
VTrkA
p11748
sg13
I1
sasg20
(lp11749
(dp11750
g7
I0
sg23
VC0400877
p11751
sg10
I19
sg11
VPostoperative ileus
p11752
sg13
I2
sasa(dp11753
g2
S'The present study by examining the mRNA and/or protein levels of TrkA and TrkB in the distal colon and in colonic primary afferent neurons in the dorsal root ganglia (DRG) during colitis demonstrated that colitis elicited location-specific changes in the mRNA and protein levels of TrkA and TrkB in colonic primary sensory pathways.\n'
p11754
sg4
(lp11755
(dp11756
g7
I65
sg8
VP06753
p11757
sg10
I4
sg11
VTrkA
p11758
sg13
I1
sa(dp11759
g7
I74
sg8
g15
sg10
I4
sg11
VTrkB
p11760
sg13
I1
sa(dp11761
g7
I65
sg8
VP06753
p11762
sg10
I4
sg11
VTrkA
p11763
sg13
I1
sa(dp11764
g7
I74
sg8
g15
sg10
I4
sg11
VTrkB
p11765
sg13
I1
sasg20
(lp11766
(dp11767
g7
I179
sg23
VC0009319
p11768
sg10
I7
sg11
Vcolitis
p11769
sg13
I1
sa(dp11770
g7
I179
sg23
VC0009319
p11771
sg10
I7
sg11
Vcolitis
p11772
sg13
I1
sasa(dp11773
g2
S'In colitis both the TrkA and TrkB protein levels were increased in the L1 and S1 DRGs in a time-dependent manner; however, the level of TrkB mRNA but not TrkA mRNA was increased in these DRGs.\n'
p11774
sg4
(lp11775
(dp11776
g7
I29
sg8
g15
sg10
I12
sg11
VTrkB protein
p11777
sg13
I2
sa(dp11778
g7
I154
sg8
VP06753
p11779
sg10
I9
sg11
VTrkA mRNA
p11780
sg13
I2
sa(dp11781
g7
I136
sg8
g15
sg10
I9
sg11
VTrkB mRNA
p11782
sg13
I2
sa(dp11783
g7
I20
sg8
VP06753
p11784
sg10
I4
sg11
VTrkA
p11785
sg13
I1
sa(dp11786
g7
I78
sg8
g15
sg10
I7
sg11
VS1 DRGs
p11787
sg13
I2
sasg20
(lp11788
(dp11789
g7
I3
sg23
VC0009319
p11790
sg10
I7
sg11
Vcolitis
p11791
sg13
I1
sasa(dp11792
g2
S'Further experiments showed that colitis facilitated a retrograde transport of TrkA protein toward and an anterograde transport of TrkA mRNA away from the DRG, which may contribute to the increased TrkA mRNA level in the distal colon during colitis.\n'
p11793
sg4
(lp11794
(dp11795
g7
I130
sg8
VP06753
p11796
sg10
I9
sg11
VTrkA mRNA
p11797
sg13
I2
sa(dp11798
g7
I130
sg8
VP06753
p11799
sg10
I9
sg11
VTrkA mRNA
p11800
sg13
I2
sa(dp11801
g7
I78
sg8
VP06753
p11802
sg10
I12
sg11
VTrkA protein
p11803
sg13
I2
sasg20
(lp11804
(dp11805
g7
I32
sg23
VC0009319
p11806
sg10
I7
sg11
Vcolitis
p11807
sg13
I1
sa(dp11808
g7
I32
sg23
VC0009319
p11809
sg10
I7
sg11
Vcolitis
p11810
sg13
I1
sasa(dp11811
g2
S'Double staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.\n'
p11812
sg4
(lp11813
(dp11814
g7
I46
sg8
VP06753
p11815
sg10
I4
sg11
VTrkA
p11816
sg13
I1
sa(dp11817
g7
I145
sg8
g15
sg10
I7
sg11
VS1 DRGs
p11818
sg13
I2
sa(dp11819
g7
I59
sg8
g15
sg10
I4
sg11
VTrkB
p11820
sg13
I1
sa(dp11821
g7
I46
sg8
VP06753
p11822
sg10
I4
sg11
VTrkA
p11823
sg13
I1
sasg20
(lp11824
(dp11825
g7
I160
sg23
VC0009319
p11826
sg10
I7
sg11
Vcolitis
p11827
sg13
I1
sasa(dp11828
g2
S'These results suggested that colitis-induced primary afferent activation involved retrograde transport of TrkA but not TrkB from the distal colon to primary afferent neurons in DRG.\n'
p11829
sg4
(lp11830
(dp11831
g7
I106
sg8
VP06753
p11832
sg10
I4
sg11
VTrkA
p11833
sg13
I1
sa(dp11834
g7
I119
sg8
g15
sg10
I4
sg11
VTrkB
p11835
sg13
I1
sasg20
(lp11836
(dp11837
g7
I29
sg23
VC0009319
p11838
sg10
I7
sg11
Vcolitis
p11839
sg13
I1
sasa(dp11840
g2
S"In fact, receptor rearrangements or point mutations convert RET and NTRK1 in dominantly acting transforming genes leading to thyroid tumors, whereas inactivating mutations, associated with Hirschsprung's disease (HSCR) and congenital insensitivity to pain with anhidrosis (CIPA), impair RET and NTRK1 functions, respectively.\n"
p11841
sg4
(lp11842
(dp11843
g7
I60
sg8
VP07949
p11844
sg10
I3
sg11
VRET
p11845
sg13
I1
sa(dp11846
g7
I60
sg8
VP07949
p11847
sg10
I3
sg11
VRET
p11848
sg13
I1
sa(dp11849
g7
I189
sg8
VP14138
p11850
sg10
I22
sg11
VHirschsprung's disease
p11851
sg13
I2
sa(dp11852
g7
I213
sg8
VP14138
p11853
sg10
I4
sg11
VHSCR
p11854
sg13
I1
sasg20
(lp11855
(dp11856
g7
I223
sg23
VC0020074
p11857
sg10
I48
sg11
Vcongenital insensitivity to pain with anhidrosis
p11858
sg13
I6
sa(dp11859
g7
I189
sg23
VC0019569
p11860
sg10
I22
sg11
VHirschsprung's disease
p11861
sg13
I2
sa(dp11862
g7
I125
sg23
VC0040136
p11863
sg10
I14
sg11
Vthyroid tumors
p11864
sg13
I2
sa(dp11865
g7
I213
sg23
VC2931876
p11866
sg10
I4
sg11
VHSCR
p11867
sg13
I1
sa(dp11868
g7
I273
sg23
VC0020074
p11869
sg10
I4
sg11
VCIPA
p11870
sg13
I1
sasa(dp11871
g2
S'Thus, our results corroborate that therapeutic strategies based on the modulation of CCR1/CCR5-mediated cell migration and/or effector function may contribute to cardiac tissue damage limitation during chronic Chagas disease.\n'
p11872
sg4
(lp11873
(dp11874
g7
I85
sg8
VP32246
p11875
sg10
I4
sg11
VCCR1
p11876
sg13
I1
sa(dp11877
g7
I90
sg8
VP32302
p11878
sg10
I4
sg11
VCCR5
p11879
sg13
I1
sasg20
(lp11880
(dp11881
g7
I210
sg23
VC0041234
p11882
sg10
I14
sg11
VChagas disease
p11883
sg13
I2
sasa(dp11884
g2
S'The results of integrated analysis explored 3 OA-related pathways (rheumatoid arthritis, osteoclast differentiation and ECM-receptor interaction) and 4 candidate genes of OA (BST2, HDAC4, ITGB2 and VCAM1) that may be therapeutic targets.\n'
p11885
sg4
(lp11886
(dp11887
g7
I188
sg8
VP05107
p11888
sg10
I5
sg11
VITGB2
p11889
sg13
I1
sa(dp11890
g7
I175
sg8
g15
sg10
I4
sg11
VBST2
p11891
sg13
I1
sa(dp11892
g7
I198
sg8
VP19320
p11893
sg10
I5
sg11
VVCAM1
p11894
sg13
I1
sa(dp11895
g7
I120
sg8
g15
sg10
I12
sg11
VECM-receptor
p11896
sg13
I1
sa(dp11897
g7
I181
sg8
VP56524
p11898
sg10
I5
sg11
VHDAC4
p11899
sg13
I1
sasg20
(lp11900
(dp11901
g7
I67
sg23
VC0003873
p11902
sg10
I20
sg11
Vrheumatoid arthritis
p11903
sg13
I2
sasa(dp11904
g2
S'The patient showed moderate expression of CD18 in neutrophils with a homozygous splice mutation with c.41_c.58+2dup20 of ITGB2 and experienced recurrent severe infections complicated with systemic lupus erythematosus.\n'
p11905
sg4
(lp11906
(dp11907
g7
I101
sg8
VP05107
p11908
sg10
I25
sg11
Vc.41_c.58+2dup20 of ITGB2
p11909
sg13
I3
sa(dp11910
g7
I42
sg8
VP05107
p11911
sg10
I4
sg11
VCD18
p11912
sg13
I1
sasg20
(lp11913
(dp11914
g7
I188
sg23
VC0024141
p11915
sg10
I28
sg11
Vsystemic lupus erythematosus
p11916
sg13
I3
sa(dp11917
g7
I160
sg23
VC0021311
p11918
sg10
I10
sg11
Vinfections
p11919
sg13
I1
sasa(dp11920
g2
S'She received hematopoietic stem cell transplantation from a matched elder brother with heterozygous mutation of ITGB2, and has since remained free of infection and systemic lupus erythematosus symptoms without immunosuppression therapy.\n'
p11921
sg4
(lp11922
(dp11923
g7
I100
sg8
VP05107
p11924
sg10
I17
sg11
Vmutation of ITGB2
p11925
sg13
I3
sasg20
(lp11926
(dp11927
g7
I150
sg23
VC0009450
p11928
sg10
I9
sg11
Vinfection
p11929
sg13
I1
sa(dp11930
g7
I164
sg23
VC0024141
p11931
sg10
I28
sg11
Vsystemic lupus erythematosus
p11932
sg13
I3
sasa(dp11933
g2
S'Using mice deficient in all beta2 integrins (CD18 null mice), we demonstrate that expression of these heterodimeric adhesion molecules is critical for arthritis induction in the K/B x N serum transfer model.\n'
p11934
sg4
(lp11935
(dp11936
g7
I45
sg8
VP05107
p11937
sg10
I9
sg11
VCD18 null
p11938
sg13
I2
sa(dp11939
g7
I102
sg8
VP01185
p11940
sg10
I32
sg11
Vheterodimeric adhesion molecules
p11941
sg13
I3
sasg20
(lp11942
(dp11943
g7
I151
sg23
VC0003864
p11944
sg10
I9
sg11
Varthritis
p11945
sg13
I1
sa(dp11946
g7
I116
sg23
VC0001511
p11947
sg10
I8
sg11
Vadhesion
p11948
sg13
I1
sasa(dp11949
g2
S'Using null-allele mice and blocking mAbs, we demonstrate specifically that CD11a/CD18 (LFA-1) is absolutely required for the development of arthritis in this model.\n'
p11950
sg4
(lp11951
(dp11952
g7
I87
sg8
VP20701
p11953
sg10
I5
sg11
VLFA-1
p11954
sg13
I1
sa(dp11955
g7
I81
sg8
VP05107
p11956
sg10
I4
sg11
VCD18
p11957
sg13
I1
sa(dp11958
g7
I75
sg8
VP20701
p11959
sg10
I5
sg11
VCD11a
p11960
sg13
I1
sasg20
(lp11961
(dp11962
g7
I27
sg23
VC0233660
p11963
sg10
I8
sg11
Vblocking
p11964
sg13
I1
sa(dp11965
g7
I140
sg23
VC0003864
p11966
sg10
I9
sg11
Varthritis
p11967
sg13
I1
sasa(dp11968
g2
S'Thus, key proteins in Alzheimer Disease and Amyotrophic lateral sclerosis (ALS), including amyloid-Beta precursor protein, Tau and superoxide dismutase 1 (SOD1), spread to adjacent cells in their misfolded aggregated forms and exhibit template-directed misfolding to induce further misfolding, disruptions to proteostasis and toxicity.\n'
p11969
sg4
(lp11970
(dp11971
g7
I155
sg8
VP00441
p11972
sg10
I4
sg11
VSOD1
p11973
sg13
I1
sa(dp11974
g7
I91
sg8
VP17342
p11975
sg10
I30
sg11
Vamyloid-Beta precursor protein
p11976
sg13
I3
sa(dp11977
g7
I131
sg8
VP00441
p11978
sg10
I22
sg11
Vsuperoxide dismutase 1
p11979
sg13
I3
sa(dp11980
g7
I123
sg8
VP49768
p11981
sg10
I3
sg11
VTau
p11982
sg13
I1
sasg20
(lp11983
(dp11984
g7
I44
sg23
VC0002736
p11985
sg10
I29
sg11
VAmyotrophic lateral sclerosis
p11986
sg13
I3
sa(dp11987
g7
I75
sg23
VC0002736
p11988
sg10
I3
sg11
VALS
p11989
sg13
I1
sa(dp11990
g7
I22
sg23
VC0002395
p11991
sg10
I17
sg11
VAlzheimer Disease
p11992
sg13
I2
sa(dp11993
g7
I91
sg23
VC0011560
p11994
sg10
I7
sg11
Vamyloid
p11995
sg13
I1
sasa(dp11996
g2
S"The method is useful for identifying the defective APP-mRNA isoform in LND patients, and in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease, and may pave the way for new strategies applicable to rational antisense drugs design.\n"
p11997
sg4
(lp11998
(dp11999
g7
I156
sg8
g15
sg10
I8
sg11
VAPP gene
p12000
sg13
I2
sa(dp12001
g7
I51
sg8
g15
sg10
I8
sg11
VAPP-mRNA
p12002
sg13
I1
sasg20
(lp12003
(dp12004
g7
I245
sg23
VC0002736
p12005
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p12006
sg13
I3
sa(dp12007
g7
I184
sg23
VC0699748
p12008
sg10
I12
sg11
Vpathogenesis
p12009
sg13
I1
sa(dp12010
g7
I225
sg23
VC0016667
p12011
sg10
I18
sg11
Vfragile X syndrome
p12012
sg13
I3
sa(dp12013
g7
I280
sg23
VC1521724
p12014
sg10
I19
sg11
VAlzheimer's disease
p12015
sg13
I2
sa(dp12016
g7
I217
sg23
VC0004352
p12017
sg10
I6
sg11
Vautism
p12018
sg13
I1
sa(dp12019
g7
I115
sg23
VC0524851
p12020
sg10
I27
sg11
Vneurodegenerative disorders
p12021
sg13
I2
sasa(dp12022
g2
S'Several findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND).\n'
p12023
sg4
(lp12024
(dp12025
g7
I34
sg8
VP17342
p12026
sg10
I25
sg11
Vamyloid precursor protein
p12027
sg13
I3
sa(dp12028
g7
I61
sg8
g15
sg10
I3
sg11
VAPP
p12029
sg13
I1
sasg20
(lp12030
(dp12031
g7
I131
sg23
VC0085084
p12032
sg10
I3
sg11
VMND
p12033
sg13
I1
sa(dp12034
g7
I34
sg23
VC0011560
p12035
sg10
I7
sg11
Vamyloid
p12036
sg13
I1
sa(dp12037
g7
I109
sg23
VC0085084
p12038
sg10
I20
sg11
Vmotor neuron disease
p12039
sg13
I3
sa(dp12040
g7
I34
sg23
VC0011560
p12041
sg10
I7
sg11
Vamyloid
p12042
sg13
I1
sasa(dp12043
g2
S'Considering that dementia is one of the most frequent non-motor symptoms in amyotrophic lateral sclerosis (ALS) and that hippocampus is one of the brain areas with greater presence of amyloid-related changes in neurodegenerative diseases, our aim was to analyze the molecular markers of the amyloid cascade of APP in pathology studies of the hippocampus of autopsied patients with ALS and ALS-frontotemporal dementia (FTD).\n'
p12044
sg4
(lp12045
sg20
(lp12046
(dp12047
g7
I76
sg23
VC0002736
p12048
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p12049
sg13
I3
sa(dp12050
g7
I184
sg23
VC0011560
p12051
sg10
I7
sg11
Vamyloid
p12052
sg13
I1
sa(dp12053
g7
I17
sg23
VC0497327
p12054
sg10
I8
sg11
Vdementia
p12055
sg13
I1
sa(dp12056
g7
I107
sg23
VC0002736
p12057
sg10
I3
sg11
VALS
p12058
sg13
I1
sa(dp12059
g7
I58
sg23
VC0426980
p12060
sg10
I14
sg11
Vmotor symptoms
p12061
sg13
I2
sa(dp12062
g7
I389
sg23
VC0338451
p12063
sg10
I27
sg11
VALS-frontotemporal dementia
p12064
sg13
I2
sa(dp12065
g7
I418
sg23
VC0338451
p12066
sg10
I3
sg11
VFTD
p12067
sg13
I1
sa(dp12068
g7
I184
sg23
VC0011560
p12069
sg10
I7
sg11
Vamyloid
p12070
sg13
I1
sa(dp12071
g7
I317
sg23
VC0677042
p12072
sg10
I9
sg11
Vpathology
p12073
sg13
I1
sa(dp12074
g7
I211
sg23
VC0524851
p12075
sg10
I26
sg11
Vneurodegenerative diseases
p12076
sg13
I2
sa(dp12077
g7
I107
sg23
VC0002736
p12078
sg10
I3
sg11
VALS
p12079
sg13
I1
sasa(dp12080
g2
S'Immunohistochemical studies and confocal microscopy were used to analyze the expression of APP, TDP-43, pho-TDP-43, ABeta, APP intracellular cytoplasmatic domain (AICD) peptide, Fe65 protein, and pho-TAU in the hippocampus of seven patients with ALS, two patients with ALS-FTD, and four controls.\n'
p12081
sg4
(lp12082
(dp12083
g7
I104
sg8
g15
sg10
I10
sg11
Vpho-TDP-43
p12084
sg13
I1
sa(dp12085
g7
I196
sg8
VP49768
p12086
sg10
I7
sg11
Vpho-TAU
p12087
sg13
I1
sa(dp12088
g7
I91
sg8
g15
sg10
I3
sg11
VAPP
p12089
sg13
I1
sa(dp12090
g7
I141
sg8
g15
sg10
I35
sg11
Vcytoplasmatic domain (AICD) peptide
p12091
sg13
I4
sa(dp12092
g7
I91
sg8
g15
sg10
I3
sg11
VAPP
p12093
sg13
I1
sa(dp12094
g7
I178
sg8
g15
sg10
I12
sg11
VFe65 protein
p12095
sg13
I2
sa(dp12096
g7
I96
sg8
g15
sg10
I6
sg11
VTDP-43
p12097
sg13
I1
sa(dp12098
g7
I116
sg8
g15
sg10
I5
sg11
VABeta
p12099
sg13
I1
sasg20
(lp12100
(dp12101
g7
I273
sg23
VC0338451
p12102
sg10
I3
sg11
VFTD
p12103
sg13
I1
sa(dp12104
g7
I246
sg23
VC0002736
p12105
sg10
I3
sg11
VALS
p12106
sg13
I1
sa(dp12107
g7
I246
sg23
VC0002736
p12108
sg10
I3
sg11
VALS
p12109
sg13
I1
sasa(dp12110
g2
S'These results suggest that Sidt2(-/-) mice had spontaneous nonalcoholic fatty liver disease (NAFLD) accompanied by ERS.\n'
p12111
sg4
(lp12112
sg20
(lp12113
(dp12114
g7
I115
sg23
VC0403549
p12115
sg10
I3
sg11
VERS
p12116
sg13
I1
sa(dp12117
g7
I59
sg23
VC0400966
p12118
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p12119
sg13
I4
sa(dp12120
g7
I93
sg23
VC0400966
p12121
sg10
I5
sg11
VNAFLD
p12122
sg13
I1
sasa(dp12123
g2
S'Intraperitoneal and oral glucose tolerance tests in Sidt2 knockout mice indicated glucose intolerance and decreased serum insulin level.\n'
p12124
sg4
(lp12125
(dp12126
g7
I116
sg8
VP01308
p12127
sg10
I13
sg11
Vserum insulin
p12128
sg13
I2
sasg20
(lp12129
(dp12130
g7
I33
sg23
VC0020963
p12131
sg10
I9
sg11
Vtolerance
p12132
sg13
I1
sa(dp12133
g7
I82
sg23
VC0271650
p12134
sg10
I19
sg11
Vglucose intolerance
p12135
sg13
I2
sasa(dp12136
g2
S'For example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.\n'
p12137
sg4
(lp12138
(dp12139
g7
I13
sg8
VP55291
p12140
sg10
I5
sg11
VCDH15
p12141
sg13
I1
sa(dp12142
g7
I90
sg8
g15
sg10
I5
sg11
VCDH10
p12143
sg13
I1
sa(dp12144
g7
I78
sg8
VP55286
p12145
sg10
I4
sg11
VCDH8
p12146
sg13
I1
sa(dp12147
g7
I130
sg8
g15
sg10
I6
sg11
VPCDHb4
p12148
sg13
I1
sa(dp12149
g7
I229
sg8
VP55287
p12150
sg10
I5
sg11
VCDH11
p12151
sg13
I1
sa(dp12152
g7
I156
sg8
VP55289
p12153
sg10
I5
sg11
VCDH12
p12154
sg13
I1
sa(dp12155
g7
I156
sg8
VP55289
p12156
sg10
I5
sg11
VCDH12
p12157
sg13
I1
sa(dp12158
g7
I163
sg8
g15
sg10
I5
sg11
VCDH18
p12159
sg13
I1
sa(dp12160
g7
I23
sg8
g15
sg10
I6
sg11
VPCDH19
p12161
sg13
I1
sa(dp12162
g7
I170
sg8
g15
sg10
I6
sg11
VPCDH12
p12163
sg13
I1
sa(dp12164
g7
I97
sg8
VP55290
p12165
sg10
I5
sg11
VCDH13
p12166
sg13
I1
sa(dp12167
g7
I23
sg8
g15
sg10
I6
sg11
VPCDH19
p12168
sg13
I1
sa(dp12169
g7
I72
sg8
VP33151
p12170
sg10
I4
sg11
VCDH5
p12171
sg13
I1
sa(dp12172
g7
I150
sg8
g15
sg10
I4
sg11
VCDH7
p12173
sg13
I1
sa(dp12174
g7
I97
sg8
VP55290
p12175
sg10
I5
sg11
VCDH13
p12176
sg13
I1
sa(dp12177
g7
I84
sg8
g15
sg10
I4
sg11
VCDH9
p12178
sg13
I1
sa(dp12179
g7
I111
sg8
g15
sg10
I6
sg11
VPCDH10
p12180
sg13
I1
sa(dp12181
g7
I13
sg8
VP55291
p12182
sg10
I5
sg11
VCDH15
p12183
sg13
I1
sasg20
(lp12184
(dp12185
g7
I142
sg23
VC0004352
p12186
sg10
I6
sg11
Vautism
p12187
sg13
I1
sa(dp12188
g7
I277
sg23
VC0001973
p12189
sg10
I18
sg11
Valcohol dependency
p12190
sg13
I2
sa(dp12191
g7
I50
sg23
VC0338656
p12192
sg10
I20
sg11
Vcognitive impairment
p12193
sg13
I2
sa(dp12194
g7
I210
sg23
VC0036341
p12195
sg10
I13
sg11
Vschizophrenia
p12196
sg13
I1
sasa(dp12197
g2
S'The UCNs emitting UV/blue and green/red multiband light were used to activate the photoresponsive Azo and photosensitizer RB molecules; The mesoporous silica shell offered the possibilities to load anticancer drug and conjugate the light triggers; As there are strong charge interaction and hydrogen bonds between Dox and surface silanols of mesoporous silica, the azobenzene molecules worked as "gatekeeper" and "molecular stirrer" to precisely trap and propel the release of Dox under the external stimuli.\n'
p12198
sg4
(lp12199
sg20
(lp12200
sa(dp12201
g2
S'UCN1 is significantly reduced in endometrial adenocarcinoma compared to healthy controls.\n'
p12202
sg4
(lp12203
(dp12204
g7
I0
sg8
g15
sg10
I4
sg11
VUCN1
p12205
sg13
I1
sasg20
(lp12206
(dp12207
g7
I33
sg23
VC1153706
p12208
sg10
I26
sg11
Vendometrial adenocarcinoma
p12209
sg13
I2
sasa(dp12210
g2
S'UCN1 suppressed migration of endometrial cancer cells in vitro.\n'
p12211
sg4
(lp12212
sg20
(lp12213
(dp12214
g7
I29
sg23
VC0476089
p12215
sg10
I18
sg11
Vendometrial cancer
p12216
sg13
I2
sasa(dp12217
g2
S'We demonstrate that UCN1 significantly suppresses the migration of endometrial cancer cells but has no effect on their proliferation.\n'
p12218
sg4
(lp12219
(dp12220
g7
I20
sg8
g15
sg10
I4
sg11
VUCN1
p12221
sg13
I1
sasg20
(lp12222
(dp12223
g7
I119
sg23
VC0334094
p12224
sg10
I13
sg11
Vproliferation
p12225
sg13
I1
sa(dp12226
g7
I67
sg23
VC0476089
p12227
sg10
I18
sg11
Vendometrial cancer
p12228
sg13
I2
sasa(dp12229
g2
S'Thus, loss of UCN1 in endometrial cancer may promote invasion and metastatic spread.\n'
p12230
sg4
(lp12231
(dp12232
g7
I14
sg8
g15
sg10
I4
sg11
VUCN1
p12233
sg13
I1
sasg20
(lp12234
(dp12235
g7
I53
sg23
VC2699153
p12236
sg10
I8
sg11
Vinvasion
p12237
sg13
I1
sa(dp12238
g7
I22
sg23
VC0476089
p12239
sg10
I18
sg11
Vendometrial cancer
p12240
sg13
I2
sasa(dp12241
g2
S'Seven pathogenic variants leading to NSHL have so far been reported on two mitochondrial genes: MT-RNR1 encoding 12SrRNA and MT-TS1 encoding tRNA for Ser((UCN)) .\n'
p12242
sg4
(lp12243
(dp12244
g7
I96
sg8
VP43354
p12245
sg10
I24
sg11
VMT-RNR1 encoding 12SrRNA
p12246
sg13
I3
sasg20
(lp12247
sa(dp12248
g2
S'This study examines the role of FcgammaRIIB in the initiation of allergic rhinitis in mice.\n'
p12249
sg4
(lp12250
(dp12251
g7
I32
sg8
VP31994
p12252
sg10
I11
sg11
VFcgammaRIIB
p12253
sg13
I1
sasg20
(lp12254
(dp12255
g7
I65
sg23
VC2607914
p12256
sg10
I17
sg11
Vallergic rhinitis
p12257
sg13
I2
sasa(dp12258
g2
S'These results suggest that FcgammaRIIB plays a regulatory role in the initiation of allergic rhinitis that is independent of either mouse strain or type of sensitization.\n'
p12259
sg4
(lp12260
(dp12261
g7
I27
sg8
VP31994
p12262
sg10
I11
sg11
VFcgammaRIIB
p12263
sg13
I1
sasg20
(lp12264
(dp12265
g7
I84
sg23
VC2607914
p12266
sg10
I17
sg11
Vallergic rhinitis
p12267
sg13
I2
sasa(dp12268
g2
S'This study evaluated the interaction of radiation therapy (RT) and radiofrequency kyphoplasty (RFK) in the treatment of myeloma associated VCF.\n'
p12269
sg4
(lp12270
sg20
(lp12271
(dp12272
g7
I120
sg23
VC0026764
p12273
sg10
I7
sg11
Vmyeloma
p12274
sg13
I1
sasa(dp12275
g2
S'Eighty-six myeloma patients with VCF were treated with RFK followed by radiation therapy (RFK group) or vice versa (RT group).\n'
p12276
sg4
(lp12277
sg20
(lp12278
(dp12279
g7
I11
sg23
VC0026764
p12280
sg10
I7
sg11
Vmyeloma
p12281
sg13
I1
sasa(dp12282
g2
S'RFK is an effective method for treating VCF in myeloma patients independent of treatment order with regard to radiation therapy.\n'
p12283
sg4
(lp12284
(dp12285
g7
I0
sg8
g15
sg10
I3
sg11
VRFK
p12286
sg13
I1
sasg20
(lp12287
(dp12288
g7
I47
sg23
VC0026764
p12289
sg10
I7
sg11
Vmyeloma
p12290
sg13
I1
sasa(dp12291
g2
S'We investigated the involvement of RFK in cisplatin resistance using human prostate cancer PC3 cells.\n'
p12292
sg4
(lp12293
(dp12294
g7
I35
sg8
g15
sg10
I3
sg11
VRFK
p12295
sg13
I1
sasg20
(lp12296
(dp12297
g7
I75
sg23
VC0600139
p12298
sg10
I15
sg11
Vprostate cancer
p12299
sg13
I2
sasa(dp12300
g2
S'The present study suggests that RFK expression is involved not only in cellular protection from oxidative stress but also in malignant progression of prostate cancer.\n'
p12301
sg4
(lp12302
(dp12303
g7
I32
sg8
g15
sg10
I3
sg11
VRFK
p12304
sg13
I1
sasg20
(lp12305
(dp12306
g7
I135
sg23
VC1739135
p12307
sg10
I30
sg11
Vprogression of prostate cancer
p12308
sg13
I4
sa(dp12309
g7
I96
sg23
VC0242606
p12310
sg10
I16
sg11
Voxidative stress
p12311
sg13
I2
sasa(dp12312
g2
S'The anti-cancer effect of ATF-Fc (alone and in combination with trastuzumab) on tumor cells and in a nude mouse tumor model was evaluated by detecting the expression of uPA, urokinase plasminogen activator receptor (uPAR) and HER-2.\n'
p12313
sg4
(lp12314
(dp12315
g7
I169
sg8
VP00749
p12316
sg10
I3
sg11
VuPA
p12317
sg13
I1
sa(dp12318
g7
I226
sg8
VP04626
p12319
sg10
I5
sg11
VHER-2
p12320
sg13
I1
sa(dp12321
g7
I174
sg8
VP00747
p12322
sg10
I40
sg11
Vurokinase plasminogen activator receptor
p12323
sg13
I4
sa(dp12324
g7
I216
sg8
VP00747
p12325
sg10
I4
sg11
VuPAR
p12326
sg13
I1
sa(dp12327
g7
I26
sg8
VP00749
p12328
sg10
I3
sg11
VATF
p12329
sg13
I1
sasg20
(lp12330
(dp12331
g7
I80
sg23
VC0027651
p12332
sg10
I5
sg11
Vtumor
p12333
sg13
I1
sa(dp12334
g7
I80
sg23
VC0027651
p12335
sg10
I5
sg11
Vtumor
p12336
sg13
I1
sa(dp12337
g7
I9
sg23
VC0006826
p12338
sg10
I6
sg11
Vcancer
p12339
sg13
I1
sasa(dp12340
g2
S'To analyze the association of genotype combinations of the polymorphic markers G276T in the ADIPOQ gene, Glu23Lys in the KCNJ11 gene, and IVS3C&gt;T in the TCF7L2 gene with the development of type 2 diabetes mellitus (T2DM) in the Kyrgyz population.\n'
p12341
sg4
(lp12342
(dp12343
g7
I92
sg8
g15
sg10
I11
sg11
VADIPOQ gene
p12344
sg13
I2
sa(dp12345
g7
I121
sg8
g15
sg10
I11
sg11
VKCNJ11 gene
p12346
sg13
I2
sasg20
(lp12347
(dp12348
g7
I218
sg23
VC0011860
p12349
sg10
I4
sg11
VT2DM
p12350
sg13
I1
sa(dp12351
g7
I192
sg23
VC0011860
p12352
sg10
I24
sg11
Vtype 2 diabetes mellitus
p12353
sg13
I4
sasa(dp12354
g2
S'KCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes.\n'
p12355
sg4
(lp12356
(dp12357
g7
I0
sg8
VP48048
p12358
sg10
I5
sg11
VKCNJ1
p12359
sg13
I1
sasg20
(lp12360
(dp12361
g7
I72
sg23
VC0004775
p12362
sg10
I16
sg11
VBartter syndrome
p12363
sg13
I2
sa(dp12364
g7
I93
sg23
VC0011849
p12365
sg10
I8
sg11
Vdiabetes
p12366
sg13
I1
sasa(dp12367
g2
S'Neither diabetes mellitus nor Tempol altered Kir1.1, Kir2.1, Kir6.1, or SUR2B protein levels in renal cortical microvessels.\n'
p12368
sg4
(lp12369
(dp12370
g7
I53
sg8
VP63252
p12371
sg10
I6
sg11
VKir2.1
p12372
sg13
I1
sa(dp12373
g7
I72
sg8
g15
sg10
I13
sg11
VSUR2B protein
p12374
sg13
I2
sa(dp12375
g7
I61
sg8
g15
sg10
I6
sg11
VKir6.1
p12376
sg13
I1
sa(dp12377
g7
I45
sg8
VP48048
p12378
sg10
I6
sg11
VKir1.1
p12379
sg13
I1
sasg20
(lp12380
(dp12381
g7
I8
sg23
VC0011849
p12382
sg10
I17
sg11
Vdiabetes mellitus
p12383
sg13
I2
sasa(dp12384
g2
S'To the extent that the effects of Tempol reflect its antioxidant actions, our observations indicate that oxidative stress contributes to the exaggerated impact of Kir1.1, Kir2.1, and K(ATP) channels on afferent arteriolar tone during diabetes mellitus and that this phenomenon involves posttranslational modulation of channel function.\n'
p12385
sg4
(lp12386
(dp12387
g7
I171
sg8
VP63252
p12388
sg10
I6
sg11
VKir2.1
p12389
sg13
I1
sa(dp12390
g7
I163
sg8
VP48048
p12391
sg10
I6
sg11
VKir1.1
p12392
sg13
I1
sasg20
(lp12393
(dp12394
g7
I234
sg23
VC0011849
p12395
sg10
I17
sg11
Vdiabetes mellitus
p12396
sg13
I2
sa(dp12397
g7
I105
sg23
VC0242606
p12398
sg10
I16
sg11
Voxidative stress
p12399
sg13
I2
sasa(dp12400
g2
S'Furthermore, results suggested that co-exposure exacerbated the activation of TRPV1 signal pathways, with an enhancement in substance P and calcitonin gene-related peptide production, which contributed to inflammation in asthma by neurogenic inflammation.\n'
p12401
sg4
(lp12402
(dp12403
g7
I140
sg8
VP06881
p12404
sg10
I15
sg11
Vcalcitonin gene
p12405
sg13
I2
sa(dp12406
g7
I78
sg8
g15
sg10
I5
sg11
VTRPV1
p12407
sg13
I1
sasg20
(lp12408
(dp12409
g7
I221
sg23
VC0004096
p12410
sg10
I6
sg11
Vasthma
p12411
sg13
I1
sa(dp12412
g7
I205
sg23
VC0021368
p12413
sg10
I12
sg11
Vinflammation
p12414
sg13
I1
sa(dp12415
g7
I205
sg23
VC0021368
p12416
sg10
I12
sg11
Vinflammation
p12417
sg13
I1
sasa(dp12418
g2
S'It is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.\n'
p12419
sg4
(lp12420
(dp12421
g7
I115
sg8
g15
sg10
I5
sg11
VTRPV1
p12422
sg13
I1
sasg20
(lp12423
(dp12424
g7
I85
sg23
VC0242606
p12425
sg10
I16
sg11
Voxidative stress
p12426
sg13
I2
sa(dp12427
g7
I61
sg23
VC0155877
p12428
sg10
I15
sg11
Vallergic asthma
p12429
sg13
I2
sasa(dp12430
g2
S'In this review we will summarize recent evidence for an involvement of TRP channels (TRPA1, TRPC4, TRPC6, TRPV1, TRPV4, TRPM2 and TRPM8) expressed in the lung in pathways of toxin sensing and as mediators of lung inflammation and associated diseases like asthma, COPD, lung fibrosis and edema formation.\n'
p12431
sg4
(lp12432
(dp12433
g7
I71
sg8
VP13686
p12434
sg10
I12
sg11
VTRP channels
p12435
sg13
I2
sa(dp12436
g7
I120
sg8
VP10909
p12437
sg10
I5
sg11
VTRPM2
p12438
sg13
I1
sa(dp12439
g7
I130
sg8
g15
sg10
I5
sg11
VTRPM8
p12440
sg13
I1
sa(dp12441
g7
I99
sg8
g15
sg10
I5
sg11
VTRPC6
p12442
sg13
I1
sa(dp12443
g7
I92
sg8
g15
sg10
I5
sg11
VTRPC4
p12444
sg13
I1
sa(dp12445
g7
I106
sg8
g15
sg10
I5
sg11
VTRPV1
p12446
sg13
I1
sa(dp12447
g7
I85
sg8
g15
sg10
I5
sg11
VTRPA1
p12448
sg13
I1
sasg20
(lp12449
(dp12450
g7
I208
sg23
VC0032285
p12451
sg10
I17
sg11
Vlung inflammation
p12452
sg13
I2
sa(dp12453
g7
I255
sg23
VC0004096
p12454
sg10
I6
sg11
Vasthma
p12455
sg13
I1
sa(dp12456
g7
I263
sg23
VC0024117
p12457
sg10
I4
sg11
VCOPD
p12458
sg13
I1
sa(dp12459
g7
I287
sg23
VC0013604
p12460
sg10
I5
sg11
Vedema
p12461
sg13
I1
sa(dp12462
g7
I269
sg23
VC0034069
p12463
sg10
I13
sg11
Vlung fibrosis
p12464
sg13
I2
sasa(dp12465
g2
S'Our purpose was to investigate the regulatory mechanism of TRPV1 and related cytokines on children bronchial asthma.\n'
p12466
sg4
(lp12467
(dp12468
g7
I59
sg8
g15
sg10
I5
sg11
VTRPV1
p12469
sg13
I1
sasg20
(lp12470
(dp12471
g7
I99
sg23
VC0004096
p12472
sg10
I16
sg11
Vbronchial asthma
p12473
sg13
I2
sasa(dp12474
g2
S'Logistic regression analysis further demonstrated that TRPV1 mRNA level, EOS, IL-4 and IL-5 may be risk factors for children bronchial asthma.\n'
p12475
sg4
(lp12476
(dp12477
g7
I78
sg8
VP05112
p12478
sg10
I4
sg11
VIL-4
p12479
sg13
I1
sa(dp12480
g7
I87
sg8
VP05113
p12481
sg10
I4
sg11
VIL-5
p12482
sg13
I1
sa(dp12483
g7
I55
sg8
g15
sg10
I10
sg11
VTRPV1 mRNA
p12484
sg13
I2
sa(dp12485
g7
I73
sg8
g15
sg10
I3
sg11
VEOS
p12486
sg13
I1
sasg20
(lp12487
(dp12488
g7
I125
sg23
VC0004096
p12489
sg10
I16
sg11
Vbronchial asthma
p12490
sg13
I2
sa(dp12491
g7
I73
sg23
VC1836122
p12492
sg10
I3
sg11
VEOS
p12493
sg13
I1
sasa(dp12494
g2
S'The preliminary regulatory network of TRPV1 and related cytokines on children bronchial asthma established in this study provides certain theoretical basis for pathogenesis and treatment of children bronchial asthma.\n'
p12495
sg4
(lp12496
(dp12497
g7
I38
sg8
g15
sg10
I5
sg11
VTRPV1
p12498
sg13
I1
sasg20
(lp12499
(dp12500
g7
I78
sg23
VC0004096
p12501
sg10
I16
sg11
Vbronchial asthma
p12502
sg13
I2
sa(dp12503
g7
I160
sg23
VC0699748
p12504
sg10
I12
sg11
Vpathogenesis
p12505
sg13
I1
sa(dp12506
g7
I78
sg23
VC0004096
p12507
sg10
I16
sg11
Vbronchial asthma
p12508
sg13
I2
sasa(dp12509
g2
S'oleoylethanolamide, sphingosine-1-phosphate, N-palmitoyltaurine) were postulated to be involved in activating the transient receptor potential vanilloid type 1 (TRPV1) receptor, driving TRPV1-dependent pathogenesis in asthma.Our findings suggest that asthma is characterised by a modest systemic metabolic shift in a disease severity-dependent manner, and that steroid treatment significantly affects metabolism.\n'
p12510
sg4
(lp12511
(dp12512
g7
I161
sg8
g15
sg10
I5
sg11
VTRPV1
p12513
sg13
I1
sa(dp12514
g7
I114
sg8
g15
sg10
I62
sg11
Vtransient receptor potential vanilloid type 1 (TRPV1) receptor
p12515
sg13
I8
sasg20
(lp12516
(dp12517
g7
I218
sg23
VC0004096
p12518
sg10
I6
sg11
Vasthma
p12519
sg13
I1
sa(dp12520
g7
I218
sg23
VC0004096
p12521
sg10
I6
sg11
Vasthma
p12522
sg13
I1
sa(dp12523
g7
I202
sg23
VC0699748
p12524
sg10
I12
sg11
Vpathogenesis
p12525
sg13
I1
sasa(dp12526
g2
S'To investigate the effects of particulate matter &lt;= 2.5 microns (PM2.5) on asthma-related phenotypes and on lung expression of TRPA1 and TRPV1 proteins in a mouse model of asthma.\n'
p12527
sg4
(lp12528
(dp12529
g7
I140
sg8
g15
sg10
I14
sg11
VTRPV1 proteins
p12530
sg13
I2
sa(dp12531
g7
I130
sg8
g15
sg10
I5
sg11
VTRPA1
p12532
sg13
I1
sasg20
(lp12533
(dp12534
g7
I78
sg23
VC0004096
p12535
sg10
I6
sg11
Vasthma
p12536
sg13
I1
sa(dp12537
g7
I78
sg23
VC0004096
p12538
sg10
I6
sg11
Vasthma
p12539
sg13
I1
sasa(dp12540
g2
S'PM2.5 exacerbates effects of asthma in this model, possibly by regulating TRPA1 and TRPV1 and the relevant neurokines.\n'
p12541
sg4
(lp12542
(dp12543
g7
I74
sg8
g15
sg10
I5
sg11
VTRPA1
p12544
sg13
I1
sa(dp12545
g7
I84
sg8
g15
sg10
I5
sg11
VTRPV1
p12546
sg13
I1
sasg20
(lp12547
(dp12548
g7
I29
sg23
VC0004096
p12549
sg10
I6
sg11
Vasthma
p12550
sg13
I1
sasa(dp12551
g2
S'Our results show that CM Tln2 is essential for proper Beta1D-integrin expression and that Tln1 can substitute for Tln2 in preserving heart function, but that loss of all Tln forms from the heart-muscle cell leads to myocyte instability and a dilated cardiomyopathy.\n'
p12552
sg4
(lp12553
(dp12554
g7
I25
sg8
g15
sg10
I4
sg11
VTln2
p12555
sg13
I1
sa(dp12556
g7
I90
sg8
g15
sg10
I4
sg11
VTln1
p12557
sg13
I1
sa(dp12558
g7
I22
sg8
g15
sg10
I7
sg11
VCM Tln2
p12559
sg13
I2
sasg20
(lp12560
(dp12561
g7
I242
sg23
VC0007193
p12562
sg10
I22
sg11
Vdilated cardiomyopathy
p12563
sg13
I2
sasa(dp12564
g2
S'The levels of two miRNAs, hsa-miR-132-5p and hsa-miR-221-5p, were inversely correlated with the expression of CYP1A2 mRNA transcripts in normal human liver tissue samples represented in The Cancer Genome Atlas (TCGA) dataset.\n'
p12565
sg4
(lp12566
(dp12567
g7
I26
sg8
g15
sg10
I14
sg11
Vhsa-miR-132-5p
p12568
sg13
I1
sa(dp12569
g7
I110
sg8
VP05177
p12570
sg10
I23
sg11
VCYP1A2 mRNA transcripts
p12571
sg13
I3
sa(dp12572
g7
I45
sg8
g15
sg10
I14
sg11
Vhsa-miR-221-5p
p12573
sg13
I1
sasg20
(lp12574
(dp12575
g7
I190
sg23
VC0006826
p12576
sg10
I6
sg11
VCancer
p12577
sg13
I1
sa(dp12578
g7
I26
sg23
VC0393754
p12579
sg10
I3
sg11
Vhsa
p12580
sg13
I1
sa(dp12581
g7
I26
sg23
VC0393754
p12582
sg10
I3
sg11
Vhsa
p12583
sg13
I1
sasa(dp12584
g2
S'In situ hybridization and functional experiments in a panel of colorectal cancer cell lines and xenografts further clarified the role of clinical relevant miRNAs.Results: Six miRNAs (miR-92b-3p, miR-188-3p, miR-221-5p, miR-331-3p, miR-425-3p, and miR-497-5p) were identified as strong predictors of survival in the screening cohort.\n'
p12585
sg4
(lp12586
(dp12587
g7
I195
sg8
g15
sg10
I10
sg11
VmiR-188-3p
p12588
sg13
I1
sa(dp12589
g7
I231
sg8
g15
sg10
I10
sg11
VmiR-425-3p
p12590
sg13
I1
sa(dp12591
g7
I183
sg8
g15
sg10
I10
sg11
VmiR-92b-3p
p12592
sg13
I1
sa(dp12593
g7
I247
sg8
g15
sg10
I10
sg11
VmiR-497-5p
p12594
sg13
I1
sa(dp12595
g7
I219
sg8
g15
sg10
I10
sg11
VmiR-331-3p
p12596
sg13
I1
sa(dp12597
g7
I207
sg8
g15
sg10
I10
sg11
VmiR-221-5p
p12598
sg13
I1
sasg20
(lp12599
(dp12600
g7
I63
sg23
VC1527249
p12601
sg10
I17
sg11
Vcolorectal cancer
p12602
sg13
I2
sasa(dp12603
g2
S'Particularly, CLN1, CLN2 and CLN3 were obtained by adding derivatives C1, C2 or C3 during nanoparticles preparation, while CLN2-Pt were obtained by treating preformed CLN2 with Pt(II).\n'
p12604
sg4
(lp12605
(dp12606
g7
I20
sg8
g15
sg10
I4
sg11
VCLN2
p12607
sg13
I1
sa(dp12608
g7
I20
sg8
g15
sg10
I4
sg11
VCLN2
p12609
sg13
I1
sa(dp12610
g7
I29
sg8
g15
sg10
I4
sg11
VCLN3
p12611
sg13
I1
sa(dp12612
g7
I123
sg8
g15
sg10
I7
sg11
VCLN2-Pt
p12613
sg13
I1
sa(dp12614
g7
I14
sg8
VP50897
p12615
sg10
I4
sg11
VCLN1
p12616
sg13
I1
sasg20
(lp12617
(dp12618
g7
I20
sg23
VC1876161
p12619
sg10
I4
sg11
VCLN2
p12620
sg13
I1
sa(dp12621
g7
I20
sg23
VC1876161
p12622
sg10
I4
sg11
VCLN2
p12623
sg13
I1
sa(dp12624
g7
I29
sg23
VC2931674
p12625
sg10
I4
sg11
VCLN3
p12626
sg13
I1
sa(dp12627
g7
I14
sg23
VC1850451
p12628
sg10
I4
sg11
VCLN1
p12629
sg13
I1
sa(dp12630
g7
I20
sg23
VC1876161
p12631
sg10
I4
sg11
VCLN2
p12632
sg13
I1
sasa(dp12633
g2
S'As determined by ICP-OES, a content of P and Pt 2.2-fold and 2.5-fold higher in CLN2-Pt than in CLN3 was evidenced.\n'
p12634
sg4
(lp12635
(dp12636
g7
I80
sg8
g15
sg10
I7
sg11
VCLN2-Pt
p12637
sg13
I1
sa(dp12638
g7
I96
sg8
g15
sg10
I4
sg11
VCLN3
p12639
sg13
I1
sa(dp12640
g7
I17
sg8
g15
sg10
I7
sg11
VICP-OES
p12641
sg13
I1
sasg20
(lp12642
(dp12643
g7
I21
sg23
VC1838329
p12644
sg10
I3
sg11
VOES
p12645
sg13
I1
sa(dp12646
g7
I80
sg23
VC1876161
p12647
sg10
I4
sg11
VCLN2
p12648
sg13
I1
sa(dp12649
g7
I96
sg23
VC2931674
p12650
sg10
I4
sg11
VCLN3
p12651
sg13
I1
sa(dp12652
g7
I17
sg23
VC0268318
p12653
sg10
I3
sg11
VICP
p12654
sg13
I1
sasa(dp12655
g2
S'In fact, the antiproliferative activity shown by CLN3, CLN2-Pt on the three model cancer cell lines was substantially similar and comparable to that of complex C3 in dmso solution.\n'
p12656
sg4
(lp12657
(dp12658
g7
I55
sg8
g15
sg10
I7
sg11
VCLN2-Pt
p12659
sg13
I1
sa(dp12660
g7
I49
sg8
g15
sg10
I4
sg11
VCLN3
p12661
sg13
I1
sasg20
(lp12662
(dp12663
g7
I55
sg23
VC1876161
p12664
sg10
I4
sg11
VCLN2
p12665
sg13
I1
sa(dp12666
g7
I49
sg23
VC2931674
p12667
sg10
I4
sg11
VCLN3
p12668
sg13
I1
sa(dp12669
g7
I82
sg23
VC0006826
p12670
sg10
I6
sg11
Vcancer
p12671
sg13
I1
sasa(dp12672
g2
S'Separate prediction models which could predict consumption of each blood component in intra and postoperative phase of LDLT were derived from among the preoperative Hb, Hct, model for end-stage liver disease (MELD) score, body surface area (BSA), Plt, T. proteins, S. creatinine, B. urea, INR, and serum sodium and chloride.\n'
p12673
sg4
(lp12674
(dp12675
g7
I247
sg8
g15
sg10
I3
sg11
VPlt
p12676
sg13
I1
sasg20
(lp12677
(dp12678
g7
I194
sg23
VC0023895
p12679
sg10
I13
sg11
Vliver disease
p12680
sg13
I2
sasa(dp12681
g2
S'No association with vitiligo was found for the MECL1 gene, which encodes a third immunoproteasome subunit and is unlinked to the MHC class II region.\n'
p12682
sg4
(lp12683
(dp12684
g7
I129
sg8
VP13747
p12685
sg10
I19
sg11
VMHC class II region
p12686
sg13
I4
sa(dp12687
g7
I47
sg8
VP40313
p12688
sg10
I10
sg11
VMECL1 gene
p12689
sg13
I2
sasg20
(lp12690
(dp12691
g7
I20
sg23
VC0042900
p12692
sg10
I8
sg11
Vvitiligo
p12693
sg13
I1
sasa(dp12694
g2
S'We report a novel LHX3 mutation, which is associated with combined pituitary hormone deficiency including ACTH deficiency, short neck, and sensorineural hearing loss.\n'
p12695
sg4
(lp12696
(dp12697
g7
I58
sg8
VP18509
p12698
sg10
I26
sg11
Vcombined pituitary hormone
p12699
sg13
I3
sa(dp12700
g7
I18
sg8
g15
sg10
I4
sg11
VLHX3
p12701
sg13
I1
sa(dp12702
g7
I106
sg8
VP01189
p12703
sg10
I4
sg11
VACTH
p12704
sg13
I1
sasg20
(lp12705
(dp12706
g7
I139
sg23
VC0018784
p12707
sg10
I26
sg11
Vsensorineural hearing loss
p12708
sg13
I3
sa(dp12709
g7
I77
sg23
VC0599750
p12710
sg10
I18
sg11
Vhormone deficiency
p12711
sg13
I2
sa(dp12712
g7
I106
sg23
VC0342388
p12713
sg10
I15
sg11
VACTH deficiency
p12714
sg13
I2
sasa(dp12715
g2
S'So-called stress hormones, like adrenocorticotropic hormone, cortisol, and antidiuretic hormone, are released concomitant with nausea and vomiting in motion sickness, but do not seem to be involved in the aetiology of motion sickness.\n'
p12716
sg4
(lp12717
(dp12718
g7
I32
sg8
VP01189
p12719
sg10
I27
sg11
Vadrenocorticotropic hormone
p12720
sg13
I2
sasg20
(lp12721
(dp12722
g7
I150
sg23
VC0026603
p12723
sg10
I15
sg11
Vmotion sickness
p12724
sg13
I2
sa(dp12725
g7
I127
sg23
VC0027498
p12726
sg10
I19
sg11
Vnausea and vomiting
p12727
sg13
I3
sa(dp12728
g7
I150
sg23
VC0026603
p12729
sg10
I15
sg11
Vmotion sickness
p12730
sg13
I2
sasa(dp12731
g2
S'MMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47 IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspecific Interstitial Pneumonia (iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared using the Mann-Whitney U test.\n'
p12732
sg4
(lp12733
(dp12734
g7
I0
sg8
VP03956
p12735
sg10
I5
sg11
VMMP-1
p12736
sg13
I1
sasg20
(lp12737
(dp12738
g7
I101
sg23
VC0085786
p12739
sg10
I28
sg11
VUsual Interstitial Pneumonia
p12740
sg13
I3
sa(dp12741
g7
I151
sg23
VC1290344
p12742
sg10
I34
sg11
VNonspecific Interstitial Pneumonia
p12743
sg13
I3
sa(dp12744
g7
I236
sg23
VC0036202
p12745
sg10
I11
sg11
Vsarcoidosis
p12746
sg13
I1
sa(dp12747
g7
I131
sg23
VC0085786
p12748
sg10
I3
sg11
VUIP
p12749
sg13
I1
sasa(dp12750
g2
S'This activity is regulated by such inhibitors as metalloprvteinase 1 tissue inhibitor and cystatin C. The comparative analysis was applied concerning matrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor and cystatin C--indicators of conditions of the "proteolysis-antiproteolysis" system in the bronchoalveolar secretion of patients with chronic obstructive lung disease, bronchial asthma and pneumonia.\n'
p12751
sg4
(lp12752
(dp12753
g7
I90
sg8
VP01034
p12754
sg10
I10
sg11
Vcystatin C
p12755
sg13
I2
sa(dp12756
g7
I150
sg8
VP03956
p12757
sg10
I74
sg11
Vmatrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor
p12758
sg13
I8
sa(dp12759
g7
I90
sg8
VP01034
p12760
sg10
I10
sg11
Vcystatin C
p12761
sg13
I2
sasg20
(lp12762
(dp12763
g7
I394
sg23
VC0004096
p12764
sg10
I16
sg11
Vbronchial asthma
p12765
sg13
I2
sa(dp12766
g7
I415
sg23
VC0032285
p12767
sg10
I9
sg11
Vpneumonia
p12768
sg13
I1
sa(dp12769
g7
I360
sg23
VC0024117
p12770
sg10
I32
sg11
Vchronic obstructive lung disease
p12771
sg13
I4
sasa(dp12772
g2
S'To observe the effects of Dureping Injection on the contents of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the lung tissue of mice with pneumonia of influenza virus infection.\n'
p12773
sg4
(lp12774
(dp12775
g7
I64
sg8
VP14780
p12776
sg10
I26
sg11
Vmatrix metalloproteinase-9
p12777
sg13
I2
sa(dp12778
g7
I92
sg8
VP14780
p12779
sg10
I5
sg11
VMMP-9
p12780
sg13
I1
sa(dp12781
g7
I103
sg8
VP01033
p12782
sg10
I46
sg11
Vtissue inhibitor of matrix metalloproteinase-1
p12783
sg13
I5
sa(dp12784
g7
I151
sg8
VP01033
p12785
sg10
I6
sg11
VTIMP-1
p12786
sg13
I1
sasg20
(lp12787
(dp12788
g7
I204
sg23
VC0021400
p12789
sg10
I9
sg11
Vinfluenza
p12790
sg13
I1
sa(dp12791
g7
I191
sg23
VC0032285
p12792
sg10
I9
sg11
Vpneumonia
p12793
sg13
I1
sa(dp12794
g7
I214
sg23
VC0042769
p12795
sg10
I15
sg11
Vvirus infection
p12796
sg13
I2
sasa(dp12797
g2
S"We developed a Korean version of the NPI-Q (KNPI-Q) and compared subitems with those of the Korean version of the NPI (KNPI) in 63 dementia patients; 47 patients had been diagnosed with Alzheimer's disease with dementia, 8 with vascular dementia, and 8 with dementia with Lewy body disease.\n"
p12798
sg4
(lp12799
(dp12800
g7
I44
sg8
g15
sg10
I6
sg11
VKNPI-Q
p12801
sg13
I1
sa(dp12802
g7
I15
sg8
g15
sg10
I27
sg11
VKorean version of the NPI-Q
p12803
sg13
I5
sasg20
(lp12804
(dp12805
g7
I131
sg23
VC0497327
p12806
sg10
I8
sg11
Vdementia
p12807
sg13
I1
sa(dp12808
g7
I186
sg23
VC1521724
p12809
sg10
I19
sg11
VAlzheimer's disease
p12810
sg13
I2
sa(dp12811
g7
I131
sg23
VC0497327
p12812
sg10
I8
sg11
Vdementia
p12813
sg13
I1
sa(dp12814
g7
I131
sg23
VC0497327
p12815
sg10
I8
sg11
Vdementia
p12816
sg13
I1
sa(dp12817
g7
I272
sg23
VC0752347
p12818
sg10
I17
sg11
VLewy body disease
p12819
sg13
I3
sa(dp12820
g7
I228
sg23
VC0011269
p12821
sg10
I17
sg11
Vvascular dementia
p12822
sg13
I2
sasa(dp12823
g2
S'All patients received the Korean version of the Mini-Mental State Examination and the Clinical Dementia Rating within 1 month of the KNPI-Q.\n'
p12824
sg4
(lp12825
(dp12826
g7
I133
sg8
g15
sg10
I6
sg11
VKNPI-Q
p12827
sg13
I1
sasg20
(lp12828
(dp12829
g7
I95
sg23
VC0497327
p12830
sg10
I8
sg11
VDementia
p12831
sg13
I1
sasa(dp12832
g2
S'The KNPI-Q is a reliable and brief instrument that can be employed for screening in the evaluation of neuropsychiatric symptoms of dementia and associated caregiver distress.\n'
p12833
sg4
(lp12834
(dp12835
g7
I4
sg8
g15
sg10
I6
sg11
VKNPI-Q
p12836
sg13
I1
sasg20
(lp12837
(dp12838
g7
I131
sg23
VC0497327
p12839
sg10
I8
sg11
Vdementia
p12840
sg13
I1
sasa(dp12841
g2
S'The cognitive function of each sub-domain, functional impairments, depressive symptoms, and caregiver burden were assessed using the dementia version of Seoul Neuropsychological Screening Battery (SNSB-D), Barthel Index for Daily Living Activities (ADL), Seoul-Instrumental Activities of Daily Living (S-IADL), the Clinical Dementia Rating Sum of Box (CDR-SB), the Global Deterioration Scale (GDS), the Korean version of the Neuropsychiatric Inventory (K-NPI), and the 15-item Geriatric Depression Scale.\n'
p12842
sg4
(lp12843
(dp12844
g7
I352
sg8
VP51861
p12845
sg10
I6
sg11
VCDR-SB
p12846
sg13
I1
sa(dp12847
g7
I315
sg8
VP51861
p12848
sg10
I35
sg11
VClinical Dementia Rating Sum of Box
p12849
sg13
I6
sasg20
(lp12850
(dp12851
g7
I324
sg23
VC0497327
p12852
sg10
I8
sg11
VDementia
p12853
sg13
I1
sa(dp12854
g7
I133
sg23
VC0497327
p12855
sg10
I8
sg11
Vdementia
p12856
sg13
I1
sa(dp12857
g7
I487
sg23
VC0011581
p12858
sg10
I10
sg11
VDepression
p12859
sg13
I1
sa(dp12860
g7
I67
sg23
VC0086132
p12861
sg10
I19
sg11
Vdepressive symptoms
p12862
sg13
I2
sasa(dp12863
g2
S'Our primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).\n'
p12864
sg4
(lp12865
sg20
(lp12866
(dp12867
g7
I117
sg23
VC0497327
p12868
sg10
I8
sg11
VDementia
p12869
sg13
I1
sasa(dp12870
g2
S'The patients were also evaluated using the Korean version of the Severe Impairment Battery (SIB-Ko), Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), Barthel Activities of Daily Living (B-ADL), the Korean version of the Instrumental Activities of Daily Living (K-IADL), the Korean version of the Neuropsychiatric Inventory (K-NPI) and the Functional Assessment Staging (FAST).\n'
p12871
sg4
(lp12872
sg20
(lp12873
(dp12874
g7
I72
sg23
VC0684336
p12875
sg10
I10
sg11
VImpairment
p12876
sg13
I1
sa(dp12877
g7
I110
sg23
VC0497327
p12878
sg10
I8
sg11
VDementia
p12879
sg13
I1
sasa(dp12880
g2
S'The aim of this study is to develop the Korean version of the NPI (K-NPI) and to test its reliability and usefulness in dementia patients.\n'
p12881
sg4
(lp12882
sg20
(lp12883
(dp12884
g7
I120
sg23
VC0497327
p12885
sg10
I8
sg11
Vdementia
p12886
sg13
I1
sasa(dp12887
g2
S'Total K-NPI scores correlated positively with dementia severity assessed with the Korean Mini-Mental State Examination.\n'
p12888
sg4
(lp12889
sg20
(lp12890
(dp12891
g7
I46
sg23
VC0497327
p12892
sg10
I8
sg11
Vdementia
p12893
sg13
I1
sasa(dp12894
g2
S'The K-NPI, whose reliability and competency are comparable to those of the original version, may be a reliable and useful tool for measuring neuropsychiatric disturbances in Korean dementia patients.\n'
p12895
sg4
(lp12896
sg20
(lp12897
(dp12898
g7
I181
sg23
VC0497327
p12899
sg10
I8
sg11
Vdementia
p12900
sg13
I1
sasa(dp12901
g2
S'Bone and cartilage and their disorders are addressed under the following headings: functions of bone; normal and abnormal bone remodeling; osteopetrosis and osteoporosis; epithelial-mesenchymal interaction, condensation and differentiation; osteoblasts, markers of bone formation, osteoclasts, components of bone, and pathology of bone; chondroblasts, markers of cartilage formation, secondary cartilage, components of cartilage, and pathology of cartilage; intramembranous and endochondral bone formation; RUNX genes and cleidocranial dysplasia (CCD); osterix; histone deacetylase 4 and Runx2; Ligand to receptor activator of NFkappaB (RANKL), RANK, osteoprotegerin, and osteoimmunology; WNT signaling, LRP5 mutations, and beta-catenin; the role of leptin in bone remodeling; collagens, collagenopathies, and osteogenesis imperfecta; FGFs/FGFRs, FGFR3 skeletal dysplasias, craniosynostosis, and other disorders; short limb chondrodysplasias; molecular control of the growth plate in endochondral bone formation and genetic disorders of IHH and PTHR1; ANKH, craniometaphyseal dysplasia, and chondrocalcinosis; transforming growth factor beta, Camurati-Engelmann disease (CED), and Marfan syndrome, types I and II; an ACVR1 mutation and fibrodysplasia ossificans progressiva; MSX1 and MSX2: biology, mutations, and associated disorders; G protein, activation of adenylyl cyclase, GNAS1 mutations, McCune-Albright syndrome, fibrous dysplasia, and Albright hereditary osteodystrophy; FLNA and associated disorders; and morphological development of teeth and their genetic mutations.\n'
p12902
sg4
(lp12903
(dp12904
g7
I562
sg8
VP56524
p12905
sg10
I21
sg11
Vhistone deacetylase 4
p12906
sg13
I3
sa(dp12907
g7
I704
sg8
g15
sg10
I4
sg11
VLRP5
p12908
sg13
I1
sa(dp12909
g7
I1217
sg8
g15
sg10
I5
sg11
VACVR1
p12910
sg13
I1
sa(dp12911
g7
I1284
sg8
VP35548
p12912
sg10
I4
sg11
VMSX2
p12913
sg13
I1
sa(dp12914
g7
I1045
sg8
g15
sg10
I5
sg11
VPTHR1
p12915
sg13
I1
sa(dp12916
g7
I1037
sg8
g15
sg10
I3
sg11
VIHH
p12917
sg13
I1
sa(dp12918
g7
I627
sg8
VP19838
p12919
sg10
I8
sg11
VNFkappaB
p12920
sg13
I1
sa(dp12921
g7
I1275
sg8
VP28360
p12922
sg10
I4
sg11
VMSX1
p12923
sg13
I1
sa(dp12924
g7
I1379
sg8
VP84996
p12925
sg10
I5
sg11
VGNAS1
p12926
sg13
I1
sa(dp12927
g7
I1171
sg8
VP01137
p12928
sg10
I3
sg11
VCED
p12929
sg13
I1
sa(dp12930
g7
I588
sg8
g15
sg10
I5
sg11
VRunx2
p12931
sg13
I1
sa(dp12932
g7
I847
sg8
VP22607
p12933
sg10
I5
sg11
VFGFR3
p12934
sg13
I1
sa(dp12935
g7
I1052
sg8
g15
sg10
I4
sg11
VANKH
p12936
sg13
I1
sa(dp12937
g7
I1143
sg8
VP01137
p12938
sg10
I26
sg11
VCamurati-Engelmann disease
p12939
sg13
I2
sa(dp12940
g7
I1110
sg8
VP18075
p12941
sg10
I31
sg11
Vtransforming growth factor beta
p12942
sg13
I4
sa(dp12943
g7
I750
sg8
VP41159
p12944
sg10
I6
sg11
Vleptin
p12945
sg13
I1
sa(dp12946
g7
I724
sg8
VP35222
p12947
sg10
I12
sg11
Vbeta-catenin
p12948
sg13
I1
sa(dp12949
g7
I1361
sg8
VP51828
p12950
sg10
I16
sg11
Vadenylyl cyclase
p12951
sg13
I2
sa(dp12952
g7
I651
sg8
g15
sg10
I15
sg11
Vosteoprotegerin
p12953
sg13
I1
sa(dp12954
g7
I637
sg8
g15
sg10
I5
sg11
VRANKL
p12955
sg13
I1
sasg20
(lp12956
(dp12957
g7
I1016
sg23
VC0019247
p12958
sg10
I17
sg11
Vgenetic disorders
p12959
sg13
I2
sa(dp12960
g7
I157
sg23
VC0029456
p12961
sg10
I12
sg11
Vosteoporosis
p12962
sg13
I1
sa(dp12963
g7
I862
sg23
VC0334044
p12964
sg10
I10
sg11
Vdysplasias
p12965
sg13
I1
sa(dp12966
g7
I522
sg23
VC0008928
p12967
sg10
I23
sg11
Vcleidocranial dysplasia
p12968
sg13
I2
sa(dp12969
g7
I1422
sg23
VC0259779
p12970
sg10
I17
sg11
Vfibrous dysplasia
p12971
sg13
I2
sa(dp12972
g7
I810
sg23
VC0029434
p12973
sg10
I23
sg11
Vosteogenesis imperfecta
p12974
sg13
I2
sa(dp12975
g7
I547
sg23
VC0008928
p12976
sg10
I3
sg11
VCCD
p12977
sg13
I1
sa(dp12978
g7
I1058
sg23
VC0265292
p12979
sg10
I27
sg11
Vcraniometaphyseal dysplasia
p12980
sg13
I2
sa(dp12981
g7
I1091
sg23
VC0553730
p12982
sg10
I17
sg11
Vchondrocalcinosis
p12983
sg13
I1
sa(dp12984
g7
I318
sg23
VC0677042
p12985
sg10
I9
sg11
Vpathology
p12986
sg13
I1
sa(dp12987
g7
I1445
sg23
VC2931404
p12988
sg10
I34
sg11
VAlbright hereditary osteodystrophy
p12989
sg13
I3
sa(dp12990
g7
I1037
sg23
VC0342384
p12991
sg10
I3
sg11
VIHH
p12992
sg13
I1
sa(dp12993
g7
I1143
sg23
VC0011989
p12994
sg10
I26
sg11
VCamurati-Engelmann disease
p12995
sg13
I2
sa(dp12996
g7
I139
sg23
VC0029454
p12997
sg10
I13
sg11
Vosteopetrosis
p12998
sg13
I1
sa(dp12999
g7
I1396
sg23
VC0242292
p13000
sg10
I24
sg11
VMcCune-Albright syndrome
p13001
sg13
I2
sa(dp13002
g7
I318
sg23
VC0677042
p13003
sg10
I9
sg11
Vpathology
p13004
sg13
I1
sa(dp13005
g7
I207
sg23
VC0233656
p13006
sg10
I12
sg11
Vcondensation
p13007
sg13
I1
sa(dp13008
g7
I924
sg23
VC0343284
p13009
sg10
I17
sg11
Vchondrodysplasias
p13010
sg13
I1
sa(dp13011
g7
I1236
sg23
VC0016037
p13012
sg10
I37
sg11
Vfibrodysplasia ossificans progressiva
p13013
sg13
I3
sa(dp13014
g7
I1181
sg23
VC0024796
p13015
sg10
I15
sg11
VMarfan syndrome
p13016
sg13
I2
sa(dp13017
g7
I874
sg23
VC0010278
p13018
sg10
I16
sg11
Vcraniosynostosis
p13019
sg13
I1
sa(dp13020
g7
I1171
sg23
VC0011989
p13021
sg10
I3
sg11
VCED
p13022
sg13
I1
sasa(dp13023
g2
S'Genome-wide analysis showed an association of asthma in Russians with the polymorphic loci of gene MUC19 (12q12) encoding gel-forming mucin 19.\n'
p13024
sg4
(lp13025
(dp13026
g7
I122
sg8
g15
sg10
I20
sg11
Vgel-forming mucin 19
p13027
sg13
I3
sa(dp13028
g7
I94
sg8
g15
sg10
I18
sg11
Vgene MUC19 (12q12)
p13029
sg13
I3
sasg20
(lp13030
(dp13031
g7
I46
sg23
VC0004096
p13032
sg10
I6
sg11
Vasthma
p13033
sg13
I1
sasa(dp13034
g2
S'Seven polymorphic loci of gene MUC19 (rs1492313, rs2588401, rs2588402, rs2638863, rs2638864, rs1352940, and rs2933373), which are in close linkage disequilibrium among themselves and rs2933346, are associated with asthma with the same p-value (p = 4.96 x 10(-6)).\n'
p13035
sg4
(lp13036
(dp13037
g7
I31
sg8
g15
sg10
I5
sg11
VMUC19
p13038
sg13
I1
sasg20
(lp13039
(dp13040
g7
I214
sg23
VC0004096
p13041
sg10
I6
sg11
Vasthma
p13042
sg13
I1
sa(dp13043
g7
I147
sg23
VC0394006
p13044
sg10
I14
sg11
Vdisequilibrium
p13045
sg13
I1
sasa(dp13046
g2
S'According to our data, the association of polymorphic variants of gene MUC19 with asthma has not been previously identified in any study.\n'
p13047
sg4
(lp13048
(dp13049
g7
I71
sg8
g15
sg10
I5
sg11
VMUC19
p13050
sg13
I1
sasg20
(lp13051
(dp13052
g7
I82
sg23
VC0004096
p13053
sg10
I6
sg11
Vasthma
p13054
sg13
I1
sasa(dp13055
g2
S'Our results indicate the important role of polymorphic variants of gene MUC19 in the formation of a predisposition to the development of asthma in individuals of Russian ethnicity.\n'
p13056
sg4
(lp13057
(dp13058
g7
I72
sg8
g15
sg10
I5
sg11
VMUC19
p13059
sg13
I1
sasg20
(lp13060
(dp13061
g7
I137
sg23
VC0004096
p13062
sg10
I6
sg11
Vasthma
p13063
sg13
I1
sasa(dp13064
g2
S'To detect the mucin gene (MUC2, MUC5AC, MUC5B, MUC18 and MUC19) expression in the nasal polyps, allergic rhinitis (AR) and the normal nasal mucosa in human.\n'
p13065
sg4
(lp13066
(dp13067
g7
I26
sg8
g15
sg10
I4
sg11
VMUC2
p13068
sg13
I1
sa(dp13069
g7
I47
sg8
VP43121
p13070
sg10
I5
sg11
VMUC18
p13071
sg13
I1
sa(dp13072
g7
I14
sg8
g15
sg10
I10
sg11
Vmucin gene
p13073
sg13
I2
sa(dp13074
g7
I57
sg8
g15
sg10
I5
sg11
VMUC19
p13075
sg13
I1
sasg20
(lp13076
(dp13077
g7
I96
sg23
VC2607914
p13078
sg10
I17
sg11
Vallergic rhinitis
p13079
sg13
I2
sa(dp13080
g7
I115
sg23
VC2607914
p13081
sg10
I2
sg11
VAR
p13082
sg13
I1
sa(dp13083
g7
I82
sg23
VC0027430
p13084
sg10
I12
sg11
Vnasal polyps
p13085
sg13
I2
sasa(dp13086
g2
S'It indicates that the secretion of MUC19 in allergic rhinitis was on high level.\n'
p13087
sg4
(lp13088
(dp13089
g7
I35
sg8
g15
sg10
I5
sg11
VMUC19
p13090
sg13
I1
sasg20
(lp13091
(dp13092
g7
I44
sg23
VC2607914
p13093
sg10
I17
sg11
Vallergic rhinitis
p13094
sg13
I2
sasa(dp13095
g2
S'We aimed to assess the impact of hypocretin deficiency on attentional functioning by comparing performances on the attention network test (ANT) of narcoleptic patients with hypocretin deficiency (narcolepsy type 1-NT1) versus patients without hypocretin deficiency (narcolepsy type 2-NT2) and healthy controls.\n'
p13096
sg4
(lp13097
(dp13098
g7
I33
sg8
VP50336
p13099
sg10
I10
sg11
Vhypocretin
p13100
sg13
I1
sa(dp13101
g7
I33
sg8
VP50336
p13102
sg10
I10
sg11
Vhypocretin
p13103
sg13
I1
sa(dp13104
g7
I33
sg8
VP50336
p13105
sg10
I10
sg11
Vhypocretin
p13106
sg13
I1
sasg20
(lp13107
(dp13108
g7
I196
sg23
VC0027404
p13109
sg10
I10
sg11
Vnarcolepsy
p13110
sg13
I1
sa(dp13111
g7
I196
sg23
VC0027404
p13112
sg10
I10
sg11
Vnarcolepsy
p13113
sg13
I1
sasa(dp13114
g2
S'A randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.\n'
p13115
sg4
(lp13116
(dp13117
g7
I173
sg8
VP01350
p13118
sg10
I7
sg11
Vgastrin
p13119
sg13
I1
sa(dp13120
g7
I227
sg8
g15
sg10
I12
sg11
VReg receptor
p13121
sg13
I2
sasg20
(lp13122
(dp13123
g7
I21
sg23
VC0456909
p13124
sg10
I5
sg11
Vblind
p13125
sg13
I1
sa(dp13126
g7
I64
sg23
VC0011854
p13127
sg10
I15
sg11
Vtype 1 diabetes
p13128
sg13
I3
sasa(dp13129
g2
S'In the A(1)AR agonist area, clinical candidates have been discovered for the following conditions: atrial arrhythmias (tecadenoson, selodenoson and PJ-875); Type II diabetes and insulin sensitizing agents (GR79236, ARA, RPR-749, and CVT-3619); and angina (BAY 68-4986).\n'
p13130
sg4
(lp13131
(dp13132
g7
I178
sg8
VP01308
p13133
sg10
I7
sg11
Vinsulin
p13134
sg13
I1
sasg20
(lp13135
(dp13136
g7
I99
sg23
VC0085611
p13137
sg10
I18
sg11
Vatrial arrhythmias
p13138
sg13
I2
sa(dp13139
g7
I157
sg23
VC0011860
p13140
sg10
I16
sg11
VType II diabetes
p13141
sg13
I3
sa(dp13142
g7
I248
sg23
VC0002962
p13143
sg10
I6
sg11
Vangina
p13144
sg13
I1
sa(dp13145
g7
I233
sg23
VC0240912
p13146
sg10
I3
sg11
VCVT
p13147
sg13
I1
sasa(dp13148
g2
S'The treatment of type II diabetes using A(1)AR agonists in the clinic has met with limited success due to cardiovascular side effects and a well-defined desensitization of full agonists in human trials (GR79236, ARA, and RPR 749).\n'
p13149
sg4
(lp13150
sg20
(lp13151
(dp13152
g7
I17
sg23
VC0011860
p13153
sg10
I16
sg11
Vtype II diabetes
p13154
sg13
I3
sasa(dp13155
g2
S'Reg protein acts as an autocrine/paracrine growth factor to induce beta-cell replication via the Reg receptor and ameliorates experimental diabetes.\n'
p13156
sg4
(lp13157
(dp13158
g7
I97
sg8
g15
sg10
I12
sg11
VReg receptor
p13159
sg13
I2
sa(dp13160
g7
I0
sg8
VP05451
p13161
sg10
I11
sg11
VReg protein
p13162
sg13
I2
sasg20
(lp13163
(dp13164
g7
I139
sg23
VC0011849
p13165
sg10
I8
sg11
Vdiabetes
p13166
sg13
I1
sasa(dp13167
g2
S'We have demonstrated in vitro and in vivo that the exogenous addition of rat and human Reg gene products, Reg/REG proteins, induced beta-cell replication via the Reg receptor and thereby ameliorated experimental diabetes.\n'
p13168
sg4
(lp13169
(dp13170
g7
I87
sg8
VP05451
p13171
sg10
I3
sg11
VReg
p13172
sg13
I1
sa(dp13173
g7
I81
sg8
VP05451
p13174
sg10
I23
sg11
Vhuman Reg gene products
p13175
sg13
I4
sa(dp13176
g7
I162
sg8
g15
sg10
I12
sg11
VReg receptor
p13177
sg13
I2
sa(dp13178
g7
I110
sg8
VP05451
p13179
sg10
I3
sg11
VREG
p13180
sg13
I1
sasg20
(lp13181
(dp13182
g7
I212
sg23
VC0011849
p13183
sg10
I8
sg11
Vdiabetes
p13184
sg13
I1
sasa(dp13185
g2
S'From the regenerating islet-derived cDNA library we isolated Reg (Regenerating Gene) and demonstrated that Reg protein induces beta-cell replication via the Reg receptor and ameliorates experimental diabetes.\n'
p13186
sg4
(lp13187
(dp13188
g7
I107
sg8
VP05451
p13189
sg10
I11
sg11
VReg protein
p13190
sg13
I2
sa(dp13191
g7
I61
sg8
VP05451
p13192
sg10
I3
sg11
VReg
p13193
sg13
I1
sa(dp13194
g7
I157
sg8
g15
sg10
I12
sg11
VReg receptor
p13195
sg13
I2
sasg20
(lp13196
(dp13197
g7
I199
sg23
VC0011849
p13198
sg10
I8
sg11
Vdiabetes
p13199
sg13
I1
sasa(dp13200
g2
S'Genomic DNA was isolated from patients with hypopituitarism to amplify and sequence eight pituitary specific transcription factors (HESX1, LHX3, LHX4, OTX2, PITX2, POU1F1, PROP1, and SIX6).\n'
p13201
sg4
(lp13202
(dp13203
g7
I132
sg8
g15
sg10
I5
sg11
VHESX1
p13204
sg13
I1
sa(dp13205
g7
I172
sg8
g15
sg10
I5
sg11
VPROP1
p13206
sg13
I1
sa(dp13207
g7
I145
sg8
g15
sg10
I4
sg11
VLHX4
p13208
sg13
I1
sa(dp13209
g7
I164
sg8
VP28069
p13210
sg10
I6
sg11
VPOU1F1
p13211
sg13
I1
sa(dp13212
g7
I151
sg8
VP32243
p13213
sg10
I4
sg11
VOTX2
p13214
sg13
I1
sa(dp13215
g7
I157
sg8
g15
sg10
I5
sg11
VPITX2
p13216
sg13
I1
sa(dp13217
g7
I139
sg8
g15
sg10
I4
sg11
VLHX3
p13218
sg13
I1
sa(dp13219
g7
I183
sg8
g15
sg10
I4
sg11
VSIX6
p13220
sg13
I1
sa(dp13221
g7
I90
sg8
VP19883
p13222
sg10
I40
sg11
Vpituitary specific transcription factors
p13223
sg13
I4
sasg20
(lp13224
(dp13225
g7
I44
sg23
VC0020635
p13226
sg10
I15
sg11
Vhypopituitarism
p13227
sg13
I1
sasa(dp13228
g2
S'Rat insulinoma INS-1E cells and mouse beta-TC3 cells stably expressing Gadd45b were generated.\n'
p13229
sg4
(lp13230
(dp13231
g7
I0
sg8
VP01308
p13232
sg10
I21
sg11
VRat insulinoma INS-1E
p13233
sg13
I3
sa(dp13234
g7
I71
sg8
g15
sg10
I7
sg11
VGadd45b
p13235
sg13
I1
sasg20
(lp13236
(dp13237
g7
I15
sg23
VC1533172
p13238
sg10
I3
sg11
VINS
p13239
sg13
I1
sa(dp13240
g7
I4
sg23
VC0021670
p13241
sg10
I10
sg11
Vinsulinoma
p13242
sg13
I1
sasa(dp13243
g2
S'To define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the contribution of possible oligogenic inheritance, we aimed to comprehensively sequence 17 known ALS genes in 391 ALS patients from the United States.\n'
p13244
sg4
(lp13245
sg20
(lp13246
(dp13247
g7
I66
sg23
VC0002736
p13248
sg10
I3
sg11
VALS
p13249
sg13
I1
sa(dp13250
g7
I66
sg23
VC0002736
p13251
sg10
I3
sg11
VALS
p13252
sg13
I1
sa(dp13253
g7
I35
sg23
VC0002736
p13254
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p13255
sg13
I3
sa(dp13256
g7
I66
sg23
VC0002736
p13257
sg10
I3
sg11
VALS
p13258
sg13
I1
sasa(dp13259
g2
S'High nuclear ATF2 expression was mainly observed in translocation-associated and/or spindle cell sarcomas including synovial sarcoma, desmoplastic small round cell tumor, endometrial stromal sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and solitary fibrous tumor.\n'
p13260
sg4
(lp13261
(dp13262
g7
I0
sg8
VP15336
p13263
sg10
I17
sg11
VHigh nuclear ATF2
p13264
sg13
I3
sasg20
(lp13265
(dp13266
g7
I134
sg23
VC0281508
p13267
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p13268
sg13
I5
sa(dp13269
g7
I171
sg23
VC0206630
p13270
sg10
I27
sg11
Vendometrial stromal sarcoma
p13271
sg13
I3
sa(dp13272
g7
I84
sg23
VC0205945
p13273
sg10
I21
sg11
Vspindle cell sarcomas
p13274
sg13
I3
sa(dp13275
g7
I116
sg23
VC0039101
p13276
sg10
I16
sg11
Vsynovial sarcoma
p13277
sg13
I2
sa(dp13278
g7
I277
sg23
VC1266119
p13279
sg10
I22
sg11
Vsolitary fibrous tumor
p13280
sg13
I3
sa(dp13281
g7
I52
sg23
VC0040715
p13282
sg10
I13
sg11
Vtranslocation
p13283
sg13
I1
sa(dp13284
g7
I200
sg23
VC3179349
p13285
sg10
I41
sg11
Vgastrointestinal stromal tumor, malignant
p13286
sg13
I4
sa(dp13287
g7
I242
sg23
VC0751689
p13288
sg10
I29
sg11
Vperipheral nerve sheath tumor
p13289
sg13
I4
sasa(dp13290
g2
S'SIRT1 immunoreactivity was reviewed in a series of 164 soft tissue tumors including alveolar soft part sarcoma, angiomyolipoma, clear cell sarcoma, desmoid/fibromatosis, desmoplastic small round cell tumor, Ewing sarcoma, gastrointestinal stromal tumor, glomus tumor, leiomyoma, leiomyosarcoma, lipoma, liposarcoma, malignant peripheral nerve sheath tumor, nodular fasciitis, osteosarcoma, rhabdomyosarcoma, schwannoma, solitary fibrous tumor, synovial sarcoma, undifferentiated pleomorphic sarcoma, and Wilms tumor.\n'
p13291
sg4
(lp13292
(dp13293
g7
I0
sg8
g15
sg10
I5
sg11
VSIRT1
p13294
sg13
I1
sasg20
(lp13295
(dp13296
g7
I444
sg23
VC0039101
p13297
sg10
I16
sg11
Vsynovial sarcoma
p13298
sg13
I2
sa(dp13299
g7
I420
sg23
VC1266119
p13300
sg10
I22
sg11
Vsolitary fibrous tumor
p13301
sg13
I3
sa(dp13302
g7
I462
sg23
VC1704218
p13303
sg10
I36
sg11
Vundifferentiated pleomorphic sarcoma
p13304
sg13
I3
sa(dp13305
g7
I390
sg23
VC0035412
p13306
sg10
I16
sg11
Vrhabdomyosarcoma
p13307
sg13
I1
sa(dp13308
g7
I408
sg23
VC0027809
p13309
sg10
I10
sg11
Vschwannoma
p13310
sg13
I1
sa(dp13311
g7
I254
sg23
VC0017653
p13312
sg10
I12
sg11
Vglomus tumor
p13313
sg13
I2
sa(dp13314
g7
I268
sg23
VC0023267
p13315
sg10
I9
sg11
Vleiomyoma
p13316
sg13
I1
sa(dp13317
g7
I156
sg23
VC0016048
p13318
sg10
I12
sg11
Vfibromatosis
p13319
sg13
I1
sa(dp13320
g7
I207
sg23
VC0553580
p13321
sg10
I13
sg11
VEwing sarcoma
p13322
sg13
I2
sa(dp13323
g7
I112
sg23
VC0206633
p13324
sg10
I14
sg11
Vangiomyolipoma
p13325
sg13
I1
sa(dp13326
g7
I376
sg23
VC0029463
p13327
sg10
I12
sg11
Vosteosarcoma
p13328
sg13
I1
sa(dp13329
g7
I128
sg23
VC0206651
p13330
sg10
I18
sg11
Vclear cell sarcoma
p13331
sg13
I3
sa(dp13332
g7
I148
sg23
VC0079218
p13333
sg10
I7
sg11
Vdesmoid
p13334
sg13
I1
sa(dp13335
g7
I120
sg23
VC3489413
p13336
sg10
I6
sg11
Vlipoma
p13337
sg13
I1
sa(dp13338
g7
I303
sg23
VC0023827
p13339
sg10
I11
sg11
Vliposarcoma
p13340
sg13
I1
sa(dp13341
g7
I170
sg23
VC0281508
p13342
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p13343
sg13
I5
sa(dp13344
g7
I84
sg23
VC0206657
p13345
sg10
I26
sg11
Valveolar soft part sarcoma
p13346
sg13
I4
sa(dp13347
g7
I222
sg23
VC0238198
p13348
sg10
I30
sg11
Vgastrointestinal stromal tumor
p13349
sg13
I3
sa(dp13350
g7
I55
sg23
VC0037579
p13351
sg10
I18
sg11
Vsoft tissue tumors
p13352
sg13
I3
sa(dp13353
g7
I504
sg23
VC0027708
p13354
sg10
I11
sg11
VWilms tumor
p13355
sg13
I2
sa(dp13356
g7
I279
sg23
VC0023269
p13357
sg10
I14
sg11
Vleiomyosarcoma
p13358
sg13
I1
sa(dp13359
g7
I357
sg23
VC0410005
p13360
sg10
I17
sg11
Vnodular fasciitis
p13361
sg13
I2
sa(dp13362
g7
I316
sg23
VC0751690
p13363
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p13364
sg13
I5
sasa(dp13365
g2
S'Pathologic diagnosis of CD117-negative GISTs can be facilitated with the application of a panel of immunohistochemical markers, including DOG-1 and WT-1.\n'
p13366
sg4
(lp13367
(dp13368
g7
I138
sg8
g15
sg10
I5
sg11
VDOG-1
p13369
sg13
I1
sa(dp13370
g7
I24
sg8
VP10721
p13371
sg10
I20
sg11
VCD117-negative GISTs
p13372
sg13
I2
sasg20
(lp13373
(dp13374
g7
I39
sg23
VC0238198
p13375
sg10
I5
sg11
VGISTs
p13376
sg13
I1
sasa(dp13377
g2
S'In this study, WT-1 immunoreactivity was explored in 97 gastrointestinal stromal tumours (GISTs).\n'
p13378
sg4
(lp13379
sg20
(lp13380
(dp13381
g7
I56
sg23
VC0238198
p13382
sg10
I32
sg11
Vgastrointestinal stromal tumours
p13383
sg13
I3
sa(dp13384
g7
I90
sg23
VC0238198
p13385
sg10
I5
sg11
VGISTs
p13386
sg13
I1
sasa(dp13387
g2
S'The expression of WT-1 was compared with other immunohistochemical markers of GIST and the association with clinicopathological features was also evaluated.\n'
p13388
sg4
(lp13389
(dp13390
g7
I78
sg8
VP10721
p13391
sg10
I4
sg11
VGIST
p13392
sg13
I1
sasg20
(lp13393
(dp13394
g7
I78
sg23
VC1847319
p13395
sg10
I4
sg11
VGIST
p13396
sg13
I1
sasa(dp13397
g2
S'All 97 GISTs were positive for WT-1 and the staining intensity was strong in 59 (60.8%), moderate in 28 (28.9%) and weak in 10 cases (10.3%).\n'
p13398
sg4
(lp13399
sg20
(lp13400
(dp13401
g7
I7
sg23
VC0238198
p13402
sg10
I5
sg11
VGISTs
p13403
sg13
I1
sasa(dp13404
g2
S'Although the biological roles of WT-1 in GIST are still unknown, our findings might provide a rationale for immunotherapy targeting WT-1 and a therapeutic solution to the challenge of imatinib-resistant GISTs.\n'
p13405
sg4
(lp13406
sg20
(lp13407
(dp13408
g7
I203
sg23
VC0238198
p13409
sg10
I5
sg11
VGISTs
p13410
sg13
I1
sa(dp13411
g7
I41
sg23
VC0238198
p13412
sg10
I4
sg11
VGIST
p13413
sg13
I1
sasa(dp13414
g2
S'WT-1 immunoreactivity in gastrointestinal stromal tumor (GIST) was currently not known.\n'
p13415
sg4
(lp13416
sg20
(lp13417
(dp13418
g7
I57
sg23
VC0238198
p13419
sg10
I4
sg11
VGIST
p13420
sg13
I1
sa(dp13421
g7
I25
sg23
VC0238198
p13422
sg10
I30
sg11
Vgastrointestinal stromal tumor
p13423
sg13
I3
sasa(dp13424
g2
S'We, therefore, investigated the expression of WT-1 in GIST in comparison to other soft tissue tumors by immunohistochemistry and Western blot analysis.\n'
p13425
sg4
(lp13426
sg20
(lp13427
(dp13428
g7
I54
sg23
VC1847319
p13429
sg10
I4
sg11
VGIST
p13430
sg13
I1
sa(dp13431
g7
I82
sg23
VC0037579
p13432
sg10
I18
sg11
Vsoft tissue tumors
p13433
sg13
I3
sasa(dp13434
g2
S'We found that all 28 cases (100%) of GIST are positive for WT-1, diffusely (&gt;75%, 3+) in 13 (46.4%) cases, moderately (26% to 75%, 2+) in 13 (46.4%) cases, and focally (5% to 25%, 1+) in 2 (7.2%) cases.\n'
p13435
sg4
(lp13436
(dp13437
g7
I37
sg8
VP10721
p13438
sg10
I4
sg11
VGIST
p13439
sg13
I1
sasg20
(lp13440
(dp13441
g7
I37
sg23
VC1847319
p13442
sg10
I4
sg11
VGIST
p13443
sg13
I1
sasa(dp13444
g2
S'The significance of cytoplasmic expression of WT-1 in GIST and some smooth muscle tumors is unclear and warrant further investigation.\n'
p13445
sg4
(lp13446
sg20
(lp13447
(dp13448
g7
I68
sg23
VC0206658
p13449
sg10
I20
sg11
Vsmooth muscle tumors
p13450
sg13
I3
sa(dp13451
g7
I54
sg23
VC1847319
p13452
sg10
I4
sg11
VGIST
p13453
sg13
I1
sasa(dp13454
g2
S'The potential roles of WT-1 in the diagnosis and treatment of GIST were discussed.\n'
p13455
sg4
(lp13456
sg20
(lp13457
(dp13458
g7
I62
sg23
VC1847319
p13459
sg10
I4
sg11
VGIST
p13460
sg13
I1
sasa(dp13461
g2
S'This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.\n'
p13462
sg4
(lp13463
(dp13464
g7
I69
sg8
VP29401
p13465
sg10
I15
sg11
Vtyrosine kinase
p13466
sg13
I2
sa(dp13467
g7
I367
sg8
VP01116
p13468
sg10
I3
sg11
Vras
p13469
sg13
I1
sasg20
(lp13470
(dp13471
g7
I39
sg23
VC1261473
p13472
sg10
I7
sg11
Vsarcoma
p13473
sg13
I1
sa(dp13474
g7
I172
sg23
VC0334459
p13475
sg10
I23
sg11
Vcongenital fibrosarcoma
p13476
sg13
I2
sa(dp13477
g7
I200
sg23
VC0206628
p13478
sg10
I20
sg11
Vmesoblastic nephroma
p13479
sg13
I2
sa(dp13480
g7
I380
sg23
VC0162678
p13481
sg10
I17
sg11
Vneurofibromatosis
p13482
sg13
I1
sa(dp13483
g7
I104
sg23
VC0238198
p13484
sg10
I30
sg11
Vgastrointestinal stromal tumor
p13485
sg13
I3
sa(dp13486
g7
I39
sg23
VC1261473
p13487
sg10
I7
sg11
Vsarcoma
p13488
sg13
I1
sa(dp13489
g7
I323
sg23
VC0039082
p13490
sg10
I8
sg11
Vsyndrome
p13491
sg13
I1
sa(dp13492
g7
I259
sg23
VC0281508
p13493
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p13494
sg13
I5
sa(dp13495
g7
I136
sg23
VC0334121
p13496
sg10
I34
sg11
Vinflammatory myofibroblastic tumor
p13497
sg13
I3
sa(dp13498
g7
I222
sg23
VC0392784
p13499
sg10
I31
sg11
Vdermatofibrosarcoma protuberans
p13500
sg13
I2
sasa(dp13501
g2
S'An additional 80 endometrial cancer patients were studied for RAB32 methylation and MSI status.\n'
p13502
sg4
(lp13503
(dp13504
g7
I62
sg8
g15
sg10
I5
sg11
VRAB32
p13505
sg13
I1
sasg20
(lp13506
(dp13507
g7
I84
sg23
VC0920269
p13508
sg10
I3
sg11
VMSI
p13509
sg13
I1
sa(dp13510
g7
I17
sg23
VC0476089
p13511
sg10
I18
sg11
Vendometrial cancer
p13512
sg13
I2
sasa(dp13513
g2
S'In contrast, RAB32 methylation occurred in only 1 of 80 endometrial cancers, including 20 MSI-H, 8 MSI-L and 52 MSS tumors.\n'
p13514
sg4
(lp13515
(dp13516
g7
I13
sg8
g15
sg10
I5
sg11
VRAB32
p13517
sg13
I1
sasg20
(lp13518
(dp13519
g7
I112
sg23
VC0024814
p13520
sg10
I3
sg11
VMSS
p13521
sg13
I1
sa(dp13522
g7
I116
sg23
VC0027651
p13523
sg10
I6
sg11
Vtumors
p13524
sg13
I1
sa(dp13525
g7
I90
sg23
VC0920269
p13526
sg10
I3
sg11
VMSI
p13527
sg13
I1
sa(dp13528
g7
I56
sg23
VC0476089
p13529
sg10
I19
sg11
Vendometrial cancers
p13530
sg13
I2
sa(dp13531
g7
I90
sg23
VC0920269
p13532
sg10
I3
sg11
VMSI
p13533
sg13
I1
sasa(dp13534
g2
S'We conclude that although RAB32 methylation is rare in endometrial cancers, it is strongly associated with hMLH1 hypermethylation and MSI in gastric adenocarcinomas.\n'
p13535
sg4
(lp13536
(dp13537
g7
I107
sg8
VP40692
p13538
sg10
I5
sg11
VhMLH1
p13539
sg13
I1
sa(dp13540
g7
I26
sg8
g15
sg10
I5
sg11
VRAB32
p13541
sg13
I1
sasg20
(lp13542
(dp13543
g7
I134
sg23
VC0920269
p13544
sg10
I3
sg11
VMSI
p13545
sg13
I1
sa(dp13546
g7
I55
sg23
VC0476089
p13547
sg10
I19
sg11
Vendometrial cancers
p13548
sg13
I2
sa(dp13549
g7
I149
sg23
VC0001418
p13550
sg10
I15
sg11
Vadenocarcinomas
p13551
sg13
I1
sasa(dp13552
g2
S'Panel, consisting of 16 new potential markers for early and differentiated diagnosis of prostatic gland cancer, was identified: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY and LRRC58.\n'
p13553
sg4
(lp13554
(dp13555
g7
I177
sg8
g15
sg10
I9
sg11
VLOC440944
p13556
sg13
I1
sa(dp13557
g7
I199
sg8
VP51788
p13558
sg10
I5
sg11
VCLCN2
p13559
sg13
I1
sa(dp13560
g7
I245
sg8
VP27816
p13561
sg10
I4
sg11
VMAP4
p13562
sg13
I1
sa(dp13563
g7
I238
sg8
g15
sg10
I5
sg11
VCAND2
p13564
sg13
I1
sa(dp13565
g7
I222
sg8
g15
sg10
I5
sg11
VLMCD1
p13566
sg13
I1
sa(dp13567
g7
I229
sg8
g15
sg10
I7
sg11
VFAM19A4
p13568
sg13
I1
sa(dp13569
g7
I162
sg8
g15
sg10
I6
sg11
VCTDSPL
p13570
sg13
I1
sa(dp13571
g7
I128
sg8
g15
sg10
I7
sg11
VBHLHE40
p13572
sg13
I1
sa(dp13573
g7
I187
sg8
g15
sg10
I5
sg11
VSETD5
p13574
sg13
I1
sa(dp13575
g7
I258
sg8
g15
sg10
I6
sg11
VLRRC58
p13576
sg13
I1
sa(dp13577
g7
I137
sg8
g15
sg10
I5
sg11
VFOXP1
p13578
sg13
I1
sa(dp13579
g7
I194
sg8
VP40337
p13580
sg10
I3
sg11
VVHL
p13581
sg13
I1
sa(dp13582
g7
I206
sg8
g15
sg10
I7
sg11
VOSBPL10
p13583
sg13
I1
sa(dp13584
g7
I170
sg8
VP61328
p13585
sg10
I5
sg11
VFGF12
p13586
sg13
I1
sa(dp13587
g7
I155
sg8
g15
sg10
I5
sg11
VITGA9
p13588
sg13
I1
sa(dp13589
g7
I214
sg8
g15
sg10
I6
sg11
VZNF860
p13590
sg13
I1
sasg20
(lp13591
(dp13592
g7
I104
sg23
VC0006826
p13593
sg10
I6
sg11
Vcancer
p13594
sg13
I1
sa(dp13595
g7
I194
sg23
VC0019562
p13596
sg10
I3
sg11
VVHL
p13597
sg13
I1
sasa(dp13598
g2
S'However, there is little information about the involvement of MAP4 in human cancer.\n'
p13599
sg4
(lp13600
(dp13601
g7
I62
sg8
VP27816
p13602
sg10
I4
sg11
VMAP4
p13603
sg13
I1
sasg20
(lp13604
(dp13605
g7
I76
sg23
VC0006826
p13606
sg10
I6
sg11
Vcancer
p13607
sg13
I1
sasa(dp13608
g2
S'Here we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells.\n'
p13609
sg4
(lp13610
(dp13611
g7
I18
sg8
VP27816
p13612
sg10
I4
sg11
VMAP4
p13613
sg13
I1
sasg20
(lp13614
(dp13615
g7
I48
sg23
VC2699153
p13616
sg10
I8
sg11
Vinvasion
p13617
sg13
I1
sa(dp13618
g7
I94
sg23
VC0006826
p13619
sg10
I6
sg11
Vcancer
p13620
sg13
I1
sasa(dp13621
g2
S'The fusion between echinoderm microtubule-associated protein 4 (EML4) and anaplastic lymphatic tumor kinase (ALK) rearrangement is present in approximately 5% of non-small cell lung cancer (NSCLC) patients.\n'
p13622
sg4
(lp13623
(dp13624
g7
I74
sg8
g15
sg10
I33
sg11
Vanaplastic lymphatic tumor kinase
p13625
sg13
I4
sa(dp13626
g7
I19
sg8
g15
sg10
I43
sg11
Vechinoderm microtubule-associated protein 4
p13627
sg13
I4
sa(dp13628
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13629
sg13
I1
sa(dp13630
g7
I109
sg8
g15
sg10
I3
sg11
VALK
p13631
sg13
I1
sasg20
(lp13632
(dp13633
g7
I162
sg23
VC0007131
p13634
sg10
I26
sg11
Vnon-small cell lung cancer
p13635
sg13
I4
sa(dp13636
g7
I190
sg23
VC0007131
p13637
sg10
I5
sg11
VNSCLC
p13638
sg13
I1
sa(dp13639
g7
I95
sg23
VC0027651
p13640
sg10
I5
sg11
Vtumor
p13641
sg13
I1
sasa(dp13642
g2
S'##### ##########4 (echinoderm microtubule-associated protein 4, EML4) ######### (anaplastic lymphatic tumor kinase, ALK) ##############5%####### (non-small cell lung cancer, NSCLC) ###, ########## (epidermal growth factor receptor, EGFR) #K-ras##################EML4-ALK#####NSCLC####ALK######, ###########80%, ##############NSCLC##EML4-ALK#######, ########################### (immunohistochemistry, IHC) ##EML4-ALK##############, ###############, #######"#######"####### ##Pubmed################, #######2015#2#25#, ################, ######meta####, #############"###"###### (fluorescence in situ hybridization, FISH) #########, ########IHC############# ##11#####meta##, EML4-ALK############3,234#, ##### (diagnositic odds ratio, DOR) #1,135.00 (95%CI: 337.10-3,821.46) ############  (summary receiver operating characteristic curve, SROC) ####0.992,3 (SEAUC=0.003,2) , Q*####0.964,4 (SEQ*=0.008,7) ### #####IHC###EML4-ALK#########, ##########, ##############, #########.\n'
p13643
sg4
(lp13644
(dp13645
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13646
sg13
I1
sa(dp13647
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13648
sg13
I1
sa(dp13649
g7
I30
sg8
VP27816
p13650
sg10
I32
sg11
Vmicrotubule-associated protein 4
p13651
sg13
I3
sa(dp13652
g7
I116
sg8
g15
sg10
I3
sg11
VALK
p13653
sg13
I1
sa(dp13654
g7
I239
sg8
VP01116
p13655
sg10
I5
sg11
VK-ras
p13656
sg13
I1
sa(dp13657
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13658
sg13
I1
sa(dp13659
g7
I116
sg8
g15
sg10
I3
sg11
VALK
p13660
sg13
I1
sa(dp13661
g7
I198
sg8
VP01133
p13662
sg10
I32
sg11
Vepidermal growth factor receptor
p13663
sg13
I4
sa(dp13664
g7
I116
sg8
g15
sg10
I3
sg11
VALK
p13665
sg13
I1
sa(dp13666
g7
I116
sg8
g15
sg10
I3
sg11
VALK
p13667
sg13
I1
sa(dp13668
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13669
sg13
I1
sa(dp13670
g7
I116
sg8
g15
sg10
I3
sg11
VALK
p13671
sg13
I1
sa(dp13672
g7
I116
sg8
g15
sg10
I3
sg11
VALK
p13673
sg13
I1
sa(dp13674
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13675
sg13
I1
sa(dp13676
g7
I64
sg8
g15
sg10
I4
sg11
VEML4
p13677
sg13
I1
sasg20
(lp13678
(dp13679
g7
I146
sg23
VC0007131
p13680
sg10
I26
sg11
Vnon-small cell lung cancer
p13681
sg13
I4
sa(dp13682
g7
I174
sg23
VC0007131
p13683
sg10
I5
sg11
VNSCLC
p13684
sg13
I1
sa(dp13685
g7
I174
sg23
VC0007131
p13686
sg10
I5
sg11
VNSCLC
p13687
sg13
I1
sa(dp13688
g7
I102
sg23
VC0027651
p13689
sg10
I5
sg11
Vtumor
p13690
sg13
I1
sa(dp13691
g7
I174
sg23
VC0007131
p13692
sg10
I5
sg11
VNSCLC
p13693
sg13
I1
sasa(dp13694
g2
S'Based on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY, and LRRC58.\n'
p13695
sg4
(lp13696
(dp13697
g7
I258
sg8
VP51788
p13698
sg10
I5
sg11
VCLCN2
p13699
sg13
I1
sa(dp13700
g7
I318
sg8
g15
sg10
I6
sg11
VLRRC58
p13701
sg13
I1
sa(dp13702
g7
I281
sg8
g15
sg10
I5
sg11
VLMCD1
p13703
sg13
I1
sa(dp13704
g7
I187
sg8
g15
sg10
I7
sg11
VBHLHE40
p13705
sg13
I1
sa(dp13706
g7
I196
sg8
g15
sg10
I5
sg11
VFOXP1
p13707
sg13
I1
sa(dp13708
g7
I253
sg8
VP40337
p13709
sg10
I3
sg11
VVHL
p13710
sg13
I1
sa(dp13711
g7
I246
sg8
g15
sg10
I5
sg11
VSETD5
p13712
sg13
I1
sa(dp13713
g7
I288
sg8
g15
sg10
I7
sg11
VFAM19A4
p13714
sg13
I1
sa(dp13715
g7
I229
sg8
VP61328
p13716
sg10
I5
sg11
VFGF12
p13717
sg13
I1
sa(dp13718
g7
I221
sg8
g15
sg10
I6
sg11
VCTDSPL
p13719
sg13
I1
sa(dp13720
g7
I304
sg8
VP27816
p13721
sg10
I4
sg11
VMAP4
p13722
sg13
I1
sa(dp13723
g7
I214
sg8
g15
sg10
I5
sg11
VITGA9
p13724
sg13
I1
sa(dp13725
g7
I265
sg8
g15
sg10
I7
sg11
VOSBPL10
p13726
sg13
I1
sa(dp13727
g7
I297
sg8
g15
sg10
I5
sg11
VCAND2
p13728
sg13
I1
sa(dp13729
g7
I273
sg8
g15
sg10
I6
sg11
VZNF860
p13730
sg13
I1
sa(dp13731
g7
I236
sg8
g15
sg10
I9
sg11
VLOC440944
p13732
sg13
I1
sasg20
(lp13733
(dp13734
g7
I82
sg23
VC0600139
p13735
sg10
I15
sg11
Vprostate cancer
p13736
sg13
I2
sa(dp13737
g7
I125
sg23
VC0033578
p13738
sg10
I15
sg11
Vprostate tumors
p13739
sg13
I2
sa(dp13740
g7
I171
sg23
VC0001807
p13741
sg10
I14
sg11
Vaggressiveness
p13742
sg13
I1
sa(dp13743
g7
I156
sg23
VC0006826
p13744
sg10
I10
sg11
Vmalignancy
p13745
sg13
I1
sa(dp13746
g7
I253
sg23
VC0019562
p13747
sg10
I3
sg11
VVHL
p13748
sg13
I1
sasa(dp13749
g2
S'We also analyzed gene expression of MAP4 in 34 patients with bladder cancer using immunohistochemical staining assay.\n'
p13750
sg4
(lp13751
(dp13752
g7
I36
sg8
VP27816
p13753
sg10
I4
sg11
VMAP4
p13754
sg13
I1
sasg20
(lp13755
(dp13756
g7
I61
sg23
VC0699885
p13757
sg10
I14
sg11
Vbladder cancer
p13758
sg13
I2
sasa(dp13759
g2
S'We used cAMP elevators and small interfering RNA of MAP4 here, found that both of them can potently inhibit the invasion and the migration of bladder cancer cells by disrupting microtubule (MT) cytoskeleton.\n'
p13760
sg4
(lp13761
(dp13762
g7
I52
sg8
VP27816
p13763
sg10
I4
sg11
VMAP4
p13764
sg13
I1
sasg20
(lp13765
(dp13766
g7
I112
sg23
VC2699153
p13767
sg10
I8
sg11
Vinvasion
p13768
sg13
I1
sa(dp13769
g7
I142
sg23
VC0699885
p13770
sg10
I14
sg11
Vbladder cancer
p13771
sg13
I2
sasa(dp13772
g2
S'Consistently, the bladder cancer grade is positively correlated with the protein level of MAP4.\n'
p13773
sg4
(lp13774
(dp13775
g7
I90
sg8
VP27816
p13776
sg10
I4
sg11
VMAP4
p13777
sg13
I1
sasg20
(lp13778
(dp13779
g7
I18
sg23
VC0699885
p13780
sg10
I14
sg11
Vbladder cancer
p13781
sg13
I2
sasa(dp13782
g2
S'Our results indicated that the cAMP/PKA signaling pathway might inhibit bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics, which could be exploited for the therapy of invasive bladder cancer.\n'
p13783
sg4
(lp13784
(dp13785
g7
I114
sg8
VP27816
p13786
sg10
I4
sg11
VMAP4
p13787
sg13
I1
sa(dp13788
g7
I36
sg8
VP17612
p13789
sg10
I3
sg11
VPKA
p13790
sg13
I1
sasg20
(lp13791
(dp13792
g7
I87
sg23
VC2699153
p13793
sg10
I13
sg11
Vcell invasion
p13794
sg13
I2
sa(dp13795
g7
I72
sg23
VC0699885
p13796
sg10
I14
sg11
Vbladder cancer
p13797
sg13
I2
sa(dp13798
g7
I195
sg23
VC0859917
p13799
sg10
I23
sg11
Vinvasive bladder cancer
p13800
sg13
I3
sasa(dp13801
g2
S'Irritable bowel syndrome symptoms consistently improved after 3 weeks of LFD, and significantly more participants reported symptom relief in response to placebo (80%) than FOS (30%).\n'
p13802
sg4
(lp13803
sg20
(lp13804
(dp13805
g7
I25
sg23
VC1457887
p13806
sg10
I7
sg11
Vsymptom
p13807
sg13
I1
sa(dp13808
g7
I0
sg23
VC0022104
p13809
sg10
I24
sg11
VIrritable bowel syndrome
p13810
sg13
I3
sasa(dp13811
g2
S'Children with congenital esophageal atresia (EA) and tracheoesophageal fistula (TEF) have chronic respiratory symptoms including recurrent pneumonia, wheezing and persistent cough.\n'
p13812
sg4
(lp13813
sg20
(lp13814
(dp13815
g7
I25
sg23
VC0014850
p13816
sg10
I18
sg11
Vesophageal atresia
p13817
sg13
I2
sa(dp13818
g7
I163
sg23
VC0562483
p13819
sg10
I16
sg11
Vpersistent cough
p13820
sg13
I2
sa(dp13821
g7
I80
sg23
VC0040588
p13822
sg10
I3
sg11
VTEF
p13823
sg13
I1
sa(dp13824
g7
I129
sg23
VC0694550
p13825
sg10
I19
sg11
Vrecurrent pneumonia
p13826
sg13
I2
sa(dp13827
g7
I45
sg23
VC0014850
p13828
sg10
I2
sg11
VEA
p13829
sg13
I1
sa(dp13830
g7
I150
sg23
VC0043144
p13831
sg10
I8
sg11
Vwheezing
p13832
sg13
I1
sa(dp13833
g7
I53
sg23
VC0040588
p13834
sg10
I25
sg11
Vtracheoesophageal fistula
p13835
sg13
I2
sa(dp13836
g7
I98
sg23
VC0037090
p13837
sg10
I20
sg11
Vrespiratory symptoms
p13838
sg13
I2
sasa(dp13839
g2
S'Adult patients experiencing symptoms of cough and recurrent aspiration pneumonia should be evaluated for congenital TEF.\n'
p13840
sg4
(lp13841
sg20
(lp13842
(dp13843
g7
I50
sg23
VC0747651
p13844
sg10
I30
sg11
Vrecurrent aspiration pneumonia
p13845
sg13
I3
sa(dp13846
g7
I40
sg23
VC0010200
p13847
sg10
I5
sg11
Vcough
p13848
sg13
I1
sasa(dp13849
g2
S'Our patient underwent primary repair of OA/TEF malformations, which was later complicated by pneumonia and a recurrent TEF.\n'
p13850
sg4
(lp13851
sg20
(lp13852
(dp13853
g7
I93
sg23
VC0032285
p13854
sg10
I9
sg11
Vpneumonia
p13855
sg13
I1
sa(dp13856
g7
I47
sg23
VC0000768
p13857
sg10
I13
sg11
Vmalformations
p13858
sg13
I1
sasa(dp13859
g2
S'These findings suggest that a relatively small increase in plasma TNF-Alfa, and decreases in urine TNF-Alfa, GM-CSF, and IL-15 from just before to just after the diagnosis of pneumonia could be markers for an increased risk of PUs in individuals with pneumonia after traumatic SCI.\n'
p13860
sg4
(lp13861
(dp13862
g7
I121
sg8
VP40933
p13863
sg10
I5
sg11
VIL-15
p13864
sg13
I1
sa(dp13865
g7
I93
sg8
VP01375
p13866
sg10
I14
sg11
Vurine TNF-Alfa
p13867
sg13
I2
sa(dp13868
g7
I109
sg8
VP04141
p13869
sg10
I6
sg11
VGM-CSF
p13870
sg13
I1
sa(dp13871
g7
I66
sg8
VP01375
p13872
sg10
I3
sg11
VTNF
p13873
sg13
I1
sasg20
(lp13874
(dp13875
g7
I175
sg23
VC0032285
p13876
sg10
I9
sg11
Vpneumonia
p13877
sg13
I1
sa(dp13878
g7
I175
sg23
VC0032285
p13879
sg10
I9
sg11
Vpneumonia
p13880
sg13
I1
sasa(dp13881
g2
S'The study aimed to investigate the innate cytokine interleukin-15 (IL-15) as a marker of disease severity.A prospective single-centre observational study was conducted in a university-affiliated paediatric teaching hospital, comparing children (0-18 months) hospitalised for viral bronchiolitis, those admitted to the paediatric intensive care unit with severe disease and healthy age-matched controls.\n'
p13882
sg4
(lp13883
(dp13884
g7
I67
sg8
VP40933
p13885
sg10
I5
sg11
VIL-15
p13886
sg13
I1
sa(dp13887
g7
I42
sg8
VP13236
p13888
sg10
I23
sg11
Vcytokine interleukin-15
p13889
sg13
I2
sasg20
(lp13890
(dp13891
g7
I275
sg23
VC0006274
p13892
sg10
I19
sg11
Vviral bronchiolitis
p13893
sg13
I2
sasa(dp13894
g2
S'Peripheral blood mononuclear cell (PBMC) IL-15 mRNA expression was significantly higher in those with moderate severity bronchiolitis compared with controls and those with severe disease.\n'
p13895
sg4
(lp13896
(dp13897
g7
I11
sg8
VP40933
p13898
sg10
I40
sg11
Vblood mononuclear cell (PBMC) IL-15 mRNA
p13899
sg13
I6
sasg20
(lp13900
(dp13901
g7
I120
sg23
VC0006271
p13902
sg10
I13
sg11
Vbronchiolitis
p13903
sg13
I1
sasa(dp13904
g2
S'Targets of de-regulated miRNA were differentially expressed in bronchiolitis, including JAK3, STAT5A and NFKB1 on the IL-15 signalling pathway.IL-15 is associated with disease severity in children hospitalised with viral bronchiolitis.\n'
p13905
sg4
(lp13906
(dp13907
g7
I88
sg8
VP52333
p13908
sg10
I4
sg11
VJAK3
p13909
sg13
I1
sa(dp13910
g7
I118
sg8
VP40933
p13911
sg10
I30
sg11
VIL-15 signalling pathway.IL-15
p13912
sg13
I3
sa(dp13913
g7
I105
sg8
VP19838
p13914
sg10
I5
sg11
VNFKB1
p13915
sg13
I1
sa(dp13916
g7
I94
sg8
VP42229
p13917
sg10
I6
sg11
VSTAT5A
p13918
sg13
I1
sasg20
(lp13919
(dp13920
g7
I215
sg23
VC0006274
p13921
sg10
I19
sg11
Vviral bronchiolitis
p13922
sg13
I2
sa(dp13923
g7
I63
sg23
VC0006271
p13924
sg10
I13
sg11
Vbronchiolitis
p13925
sg13
I1
sasa(dp13926
g2
S'The present study aimed to investigate the role of Interleukin 15 (IL-15) in protein degradation in skeletal muscle mediated by the ubiquitin-proteasome pathway (UPP) in a rat model of chronic obstructive pulmonary disease (COPD).\n'
p13927
sg4
(lp13928
(dp13929
g7
I132
sg8
VP62979
p13930
sg10
I9
sg11
Vubiquitin
p13931
sg13
I1
sa(dp13932
g7
I51
sg8
VP40933
p13933
sg10
I14
sg11
VInterleukin 15
p13934
sg13
I2
sa(dp13935
g7
I67
sg8
VP40933
p13936
sg10
I5
sg11
VIL-15
p13937
sg13
I1
sasg20
(lp13938
(dp13939
g7
I185
sg23
VC0024117
p13940
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13941
sg13
I4
sa(dp13942
g7
I224
sg23
VC0024117
p13943
sg10
I4
sg11
VCOPD
p13944
sg13
I1
sasa(dp13945
g2
S'Patients with SWA were older at seizure diagnosis than those with SA (p=0.04), were less often referred for evaluation of seizures or epilepsy (p=0.04), and were referred faster for VEM, despite SWA were significantly less likely to include motor manifestations (p=0.0004).\n'
p13946
sg4
(lp13947
sg20
(lp13948
(dp13949
g7
I122
sg23
VC0036572
p13950
sg10
I8
sg11
Vseizures
p13951
sg13
I1
sa(dp13952
g7
I32
sg23
VC0036572
p13953
sg10
I7
sg11
Vseizure
p13954
sg13
I1
sa(dp13955
g7
I134
sg23
VC0014544
p13956
sg10
I8
sg11
Vepilepsy
p13957
sg13
I1
sa(dp13958
g7
I241
sg23
VC1334804
p13959
sg10
I20
sg11
Vmotor manifestations
p13960
sg13
I2
sasa(dp13961
g2
S'We suggest that patients with SWA have a unique epilepsy syndrome.\n'
p13962
sg4
(lp13963
sg20
(lp13964
(dp13965
g7
I57
sg23
VC0039082
p13966
sg10
I8
sg11
Vsyndrome
p13967
sg13
I1
sa(dp13968
g7
I48
sg23
VC0014544
p13969
sg10
I8
sg11
Vepilepsy
p13970
sg13
I1
sasa(dp13971
g2
S'Achilles tendon (T) and Hoffmann (H) reflexes were evoked during spike and wave activity (SWA) in 6 patients with generalized epilepsy, selected on the basis of their photosensitivity.\n'
p13972
sg4
(lp13973
sg20
(lp13974
(dp13975
g7
I167
sg23
VC0393720
p13976
sg10
I16
sg11
Vphotosensitivity
p13977
sg13
I1
sa(dp13978
g7
I114
sg23
VC0014548
p13979
sg10
I20
sg11
Vgeneralized epilepsy
p13980
sg13
I2
sasa(dp13981
g2
S'Partial epilepsy after shunting manifested itself in 15 patients, but this did not correlate with the side of the shunt or with the side of the SWA in the EEG.\n'
p13982
sg4
(lp13983
sg20
(lp13984
(dp13985
g7
I0
sg23
VC0014547
p13986
sg10
I16
sg11
VPartial epilepsy
p13987
sg13
I2
sasa(dp13988
g2
S'We hypothesized that the NDI may be due to of severe hypokalemia induced tubular dysfunction.\n'
p13989
sg4
(lp13990
sg20
(lp13991
(dp13992
g7
I25
sg23
VC1563705
p13993
sg10
I3
sg11
VNDI
p13994
sg13
I1
sasa(dp13995
g2
S'Previously, we reported an increase of V1aR mRNA and a decrease of V2R mRNA in the collecting ducts under chronic metabolic acidosis.\n'
p13996
sg4
(lp13997
(dp13998
g7
I39
sg8
VP37288
p13999
sg10
I9
sg11
VV1aR mRNA
p14000
sg13
I2
sa(dp14001
g7
I67
sg8
VP30518
p14002
sg10
I8
sg11
VV2R mRNA
p14003
sg13
I2
sasg20
(lp14004
(dp14005
g7
I114
sg23
VC0220981
p14006
sg10
I18
sg11
Vmetabolic acidosis
p14007
sg13
I2
sasa(dp14008
g2
S'Patients with moderate to severe nonproliferative diabetic retinopathy (NPDR) had POBF 18% higher than the control (mean OBF, 943 microL/min).\n'
p14009
sg4
(lp14010
sg20
(lp14011
(dp14012
g7
I26
sg23
VC0730278
p14013
sg10
I44
sg11
Vsevere nonproliferative diabetic retinopathy
p14014
sg13
I4
sasa(dp14015
g2
S'Among PRP-treated subjects with PDR, ocular blood flow was 22% below the control (mean OBF, 619 microL/min), and 34% less than moderate to severe nonproliferative diabetic retinopathy.\n'
p14016
sg4
(lp14017
(dp14018
g7
I6
sg8
g15
sg10
I3
sg11
VPRP
p14019
sg13
I1
sasg20
(lp14020
(dp14021
g7
I139
sg23
VC0730278
p14022
sg10
I44
sg11
Vsevere nonproliferative diabetic retinopathy
p14023
sg13
I4
sa(dp14024
g7
I32
sg23
VC1845050
p14025
sg10
I3
sg11
VPDR
p14026
sg13
I1
sasa(dp14027
g2
S'Diabetic patients with no retinopathy or mild NPDR had OBF indistinguishable from the control (785 vs. 797 microL/min).\n'
p14028
sg4
(lp14029
sg20
(lp14030
(dp14031
g7
I26
sg23
VC0035309
p14032
sg10
I11
sg11
Vretinopathy
p14033
sg13
I1
sasa(dp14034
g2
S'POBF is unaffected early in diabetic retinopathy, but increases significantly in eyes with moderate to severe NPDR.\n'
p14035
sg4
(lp14036
sg20
(lp14037
(dp14038
g7
I28
sg23
VC0011884
p14039
sg10
I20
sg11
Vdiabetic retinopathy
p14040
sg13
I2
sa(dp14041
g7
I103
sg23
VC0730278
p14042
sg10
I11
sg11
Vsevere NPDR
p14043
sg13
I2
sasa(dp14044
g2
S'These experimental data represent the largest published assessment of POBF in NPDR.\n'
p14045
sg4
(lp14046
sg20
(lp14047
sa(dp14048
g2
S'POBF in the patients with non-exudative and exudative age related macular degeneration (AMD) was investigated.\n'
p14049
sg4
(lp14050
sg20
(lp14051
(dp14052
g7
I88
sg23
VC0242383
p14053
sg10
I3
sg11
VAMD
p14054
sg13
I1
sa(dp14055
g7
I54
sg23
VC0242383
p14056
sg10
I32
sg11
Vage related macular degeneration
p14057
sg13
I4
sasa(dp14058
g2
S'The POBF increased but was still below normal levels at the NPDR stage, and then increased to an above normal level in the PPDR/PDR stage of diabetic retinopathy.\n'
p14059
sg4
(lp14060
sg20
(lp14061
(dp14062
g7
I141
sg23
VC0011884
p14063
sg10
I20
sg11
Vdiabetic retinopathy
p14064
sg13
I2
sa(dp14065
g7
I61
sg23
VC1845050
p14066
sg10
I3
sg11
VPDR
p14067
sg13
I1
sasa(dp14068
g2
S'Right before and one month after this fourth vaccine dose, the avidity of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn) was determined using 1.5 M ammonium thiocyanate as dissociating agent.\n'
p14069
sg4
(lp14070
(dp14071
g7
I209
sg8
g15
sg10
I3
sg11
VPrn
p14072
sg13
I1
sa(dp14073
g7
I198
sg8
g15
sg10
I9
sg11
Vpertactin
p14074
sg13
I1
sa(dp14075
g7
I115
sg8
g15
sg10
I2
sg11
VDT
p14076
sg13
I1
sa(dp14077
g7
I140
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14078
sg13
I2
sa(dp14079
g7
I97
sg8
g15
sg10
I16
sg11
Vdiphtheria toxin
p14080
sg13
I2
sa(dp14081
g7
I157
sg8
g15
sg10
I2
sg11
VPT
p14082
sg13
I1
sasg20
(lp14083
(dp14084
g7
I162
sg23
VC1704429
p14085
sg10
I25
sg11
Vfilamentous hemagglutinin
p14086
sg13
I2
sa(dp14087
g7
I189
sg23
VC1704429
p14088
sg10
I3
sg11
VFHA
p14089
sg13
I1
sa(dp14090
g7
I140
sg23
VC0043167
p14091
sg10
I9
sg11
Vpertussis
p14092
sg13
I1
sa(dp14093
g7
I120
sg23
VC0039614
p14094
sg10
I7
sg11
Vtetanus
p14095
sg13
I1
sa(dp14096
g7
I97
sg23
VC0012546
p14097
sg10
I10
sg11
Vdiphtheria
p14098
sg13
I1
sasa(dp14099
g2
S'Immunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially available enzyme-linked immunosorbent assays (ELISA).\n'
p14100
sg4
(lp14101
(dp14102
g7
I18
sg8
g15
sg10
I3
sg11
VIgG
p14103
sg13
I1
sa(dp14104
g7
I97
sg8
g15
sg10
I9
sg11
Vpertactin
p14105
sg13
I1
sa(dp14106
g7
I108
sg8
g15
sg10
I3
sg11
VPrn
p14107
sg13
I1
sa(dp14108
g7
I0
sg8
g15
sg10
I16
sg11
VImmunoglobulin G
p14109
sg13
I2
sa(dp14110
g7
I59
sg8
g15
sg10
I2
sg11
VPT
p14111
sg13
I1
sa(dp14112
g7
I42
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14113
sg13
I2
sasg20
(lp14114
(dp14115
g7
I42
sg23
VC0043167
p14116
sg10
I9
sg11
Vpertussis
p14117
sg13
I1
sa(dp14118
g7
I64
sg23
VC1704429
p14119
sg10
I25
sg11
Vfilamentous hemagglutinin
p14120
sg13
I2
sa(dp14121
g7
I114
sg23
VC0039614
p14122
sg10
I7
sg11
Vtetanus
p14123
sg13
I1
sa(dp14124
g7
I139
sg23
VC0012546
p14125
sg10
I10
sg11
Vdiphtheria
p14126
sg13
I1
sa(dp14127
g7
I91
sg23
VC1704429
p14128
sg10
I3
sg11
VFHA
p14129
sg13
I1
sasa(dp14130
g2
S'We have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn).\n'
p14131
sg4
(lp14132
(dp14133
g7
I185
sg8
g15
sg10
I2
sg11
VPT
p14134
sg13
I1
sa(dp14135
g7
I237
sg8
g15
sg10
I3
sg11
VPrn
p14136
sg13
I1
sa(dp14137
g7
I143
sg8
g15
sg10
I2
sg11
VDT
p14138
sg13
I1
sa(dp14139
g7
I226
sg8
g15
sg10
I9
sg11
Vpertactin
p14140
sg13
I1
sa(dp14141
g7
I168
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14142
sg13
I2
sa(dp14143
g7
I125
sg8
g15
sg10
I16
sg11
Vdiphtheria toxin
p14144
sg13
I2
sasg20
(lp14145
(dp14146
g7
I148
sg23
VC0039614
p14147
sg10
I7
sg11
Vtetanus
p14148
sg13
I1
sa(dp14149
g7
I190
sg23
VC1704429
p14150
sg10
I25
sg11
Vfilamentous hemagglutinin
p14151
sg13
I2
sa(dp14152
g7
I168
sg23
VC0043167
p14153
sg10
I9
sg11
Vpertussis
p14154
sg13
I1
sa(dp14155
g7
I217
sg23
VC1704429
p14156
sg10
I3
sg11
VFHA
p14157
sg13
I1
sa(dp14158
g7
I125
sg23
VC0012546
p14159
sg10
I10
sg11
Vdiphtheria
p14160
sg13
I1
sasa(dp14161
g2
S'Immunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT) and diphtheria toxoid (DT) were measured using commercially available ELISA tests.\n'
p14162
sg4
(lp14163
(dp14164
g7
I18
sg8
g15
sg10
I3
sg11
VIgG
p14165
sg13
I1
sa(dp14166
g7
I97
sg8
g15
sg10
I9
sg11
Vpertactin
p14167
sg13
I1
sa(dp14168
g7
I108
sg8
g15
sg10
I3
sg11
VPrn
p14169
sg13
I1
sa(dp14170
g7
I0
sg8
g15
sg10
I16
sg11
VImmunoglobulin G
p14171
sg13
I2
sa(dp14172
g7
I59
sg8
g15
sg10
I2
sg11
VPT
p14173
sg13
I1
sa(dp14174
g7
I42
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14175
sg13
I2
sasg20
(lp14176
(dp14177
g7
I42
sg23
VC0043167
p14178
sg10
I9
sg11
Vpertussis
p14179
sg13
I1
sa(dp14180
g7
I64
sg23
VC1704429
p14181
sg10
I25
sg11
Vfilamentous hemagglutinin
p14182
sg13
I2
sa(dp14183
g7
I114
sg23
VC0039614
p14184
sg10
I7
sg11
Vtetanus
p14185
sg13
I1
sa(dp14186
g7
I138
sg23
VC0012546
p14187
sg10
I10
sg11
Vdiphtheria
p14188
sg13
I1
sa(dp14189
g7
I91
sg23
VC1704429
p14190
sg10
I3
sg11
VFHA
p14191
sg13
I1
sasa(dp14192
g2
S'Antibody geometric mean concentrations (GMCs) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (Prn) were measured with commercial ELISA tests in samples taken preceding maternal vaccination and one month afterwards, at delivery and from the cord blood, and in infants before and 1 month after the primary series of 3 pertussis containing hexavalent vaccines.\n'
p14193
sg4
(lp14194
(dp14195
g7
I155
sg8
g15
sg10
I3
sg11
VPrn
p14196
sg13
I1
sa(dp14197
g7
I144
sg8
g15
sg10
I9
sg11
Vpertactin
p14198
sg13
I1
sa(dp14199
g7
I85
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14200
sg13
I2
sa(dp14201
g7
I102
sg8
g15
sg10
I2
sg11
VPT
p14202
sg13
I1
sasg20
(lp14203
(dp14204
g7
I301
sg23
VC0035334
p14205
sg10
I4
sg11
Vcord
p14206
sg13
I1
sa(dp14207
g7
I135
sg23
VC1704429
p14208
sg10
I3
sg11
VFHA
p14209
sg13
I1
sa(dp14210
g7
I85
sg23
VC0043167
p14211
sg10
I9
sg11
Vpertussis
p14212
sg13
I1
sa(dp14213
g7
I85
sg23
VC0043167
p14214
sg10
I9
sg11
Vpertussis
p14215
sg13
I1
sa(dp14216
g7
I68
sg23
VC0012546
p14217
sg10
I10
sg11
Vdiphtheria
p14218
sg13
I1
sa(dp14219
g7
I54
sg23
VC0039614
p14220
sg10
I7
sg11
Vtetanus
p14221
sg13
I1
sa(dp14222
g7
I107
sg23
VC1704429
p14223
sg10
I26
sg11
Vfilamentous haemagglutinin
p14224
sg13
I2
sa(dp14225
g7
I63
sg23
VC0039614
p14226
sg10
I2
sg11
VTT
p14227
sg13
I1
sa(dp14228
g7
I80
sg23
VC0012546
p14229
sg10
I2
sg11
VDT
p14230
sg13
I1
sasa(dp14231
g2
S'Immunoglobulin G (IgG) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous hemaglutinin (FHA) and pertactin (Prn) were measured using commercial ELISA tests, at baseline, 1 month after maternal vaccination, at delivery, and in infants from cord blood and before and after the primary series (EPI: month 2-3-4) of a pertussis containing vaccine.\n'
p14232
sg4
(lp14233
(dp14234
g7
I18
sg8
g15
sg10
I3
sg11
VIgG
p14235
sg13
I1
sa(dp14236
g7
I79
sg8
g15
sg10
I2
sg11
VPT
p14237
sg13
I1
sa(dp14238
g7
I0
sg8
g15
sg10
I16
sg11
VImmunoglobulin G
p14239
sg13
I2
sa(dp14240
g7
I62
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14241
sg13
I2
sa(dp14242
g7
I119
sg8
g15
sg10
I9
sg11
Vpertactin
p14243
sg13
I1
sa(dp14244
g7
I130
sg8
g15
sg10
I3
sg11
VPrn
p14245
sg13
I1
sasg20
(lp14246
(dp14247
g7
I62
sg23
VC0043167
p14248
sg10
I9
sg11
Vpertussis
p14249
sg13
I1
sa(dp14250
g7
I45
sg23
VC0012546
p14251
sg10
I10
sg11
Vdiphtheria
p14252
sg13
I1
sa(dp14253
g7
I62
sg23
VC0043167
p14254
sg10
I9
sg11
Vpertussis
p14255
sg13
I1
sa(dp14256
g7
I57
sg23
VC0012546
p14257
sg10
I2
sg11
VDT
p14258
sg13
I1
sa(dp14259
g7
I31
sg23
VC0039614
p14260
sg10
I7
sg11
Vtetanus
p14261
sg13
I1
sa(dp14262
g7
I84
sg23
VC1704429
p14263
sg10
I24
sg11
Vfilamentous hemaglutinin
p14264
sg13
I2
sa(dp14265
g7
I110
sg23
VC1704429
p14266
sg10
I3
sg11
VFHA
p14267
sg13
I1
sa(dp14268
g7
I261
sg23
VC0035334
p14269
sg10
I4
sg11
Vcord
p14270
sg13
I1
sa(dp14271
g7
I40
sg23
VC0039614
p14272
sg10
I2
sg11
VTT
p14273
sg13
I1
sa(dp14274
g7
I313
sg23
VC0267963
p14275
sg10
I3
sg11
VEPI
p14276
sg13
I1
sasa(dp14277
g2
S'Anti-Pertussis Toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxin (TT) and diphtheria toxin (DT) antibodies were measured by ELISA.\n'
p14278
sg4
(lp14279
(dp14280
g7
I100
sg8
g15
sg10
I32
sg11
Vdiphtheria toxin (DT) antibodies
p14281
sg13
I4
sa(dp14282
g7
I22
sg8
g15
sg10
I2
sg11
VPT
p14283
sg13
I1
sa(dp14284
g7
I71
sg8
g15
sg10
I3
sg11
VPrn
p14285
sg13
I1
sa(dp14286
g7
I60
sg8
g15
sg10
I9
sg11
Vpertactin
p14287
sg13
I1
sa(dp14288
g7
I0
sg8
g15
sg10
I20
sg11
VAnti-Pertussis Toxin
p14289
sg13
I2
sasg20
(lp14290
(dp14291
g7
I5
sg23
VC0043167
p14292
sg10
I9
sg11
VPertussis
p14293
sg13
I1
sa(dp14294
g7
I54
sg23
VC1704429
p14295
sg10
I3
sg11
VFHA
p14296
sg13
I1
sa(dp14297
g7
I77
sg23
VC0039614
p14298
sg10
I7
sg11
Vtetanus
p14299
sg13
I1
sa(dp14300
g7
I27
sg23
VC1704429
p14301
sg10
I25
sg11
Vfilamentous hemagglutinin
p14302
sg13
I2
sa(dp14303
g7
I100
sg23
VC0012546
p14304
sg10
I10
sg11
Vdiphtheria
p14305
sg13
I1
sasa(dp14306
g2
S'Geometric mean titers were not different after prebiotic supplementation at 5 months, Ptx (37/44 EU/ml), FHA (78/96 EU/ml), Prn (78/80 EU/ml), Diphtheria (0.40/0.57 IU/ml), Tetanus (0.74/0.99 IU/ml) and Hib (0.35/0.63 myg/ml), and at 12 months Ptx (55/66 EU/ml), FHA (122/119 EU/ml), Prn (116/106 Eu/ml), Diphtheria (0.88/1.11 IU/ml), Tetanus (1.64/1.79 IU/ml) and Hib (2.91/2.55 myg/ml).\n'
p14307
sg4
(lp14308
(dp14309
g7
I124
sg8
g15
sg10
I3
sg11
VPrn
p14310
sg13
I1
sasg20
(lp14311
(dp14312
g7
I173
sg23
VC0039614
p14313
sg10
I7
sg11
VTetanus
p14314
sg13
I1
sa(dp14315
g7
I105
sg23
VC1704429
p14316
sg10
I3
sg11
VFHA
p14317
sg13
I1
sa(dp14318
g7
I105
sg23
VC1704429
p14319
sg10
I3
sg11
VFHA
p14320
sg13
I1
sa(dp14321
g7
I173
sg23
VC0039614
p14322
sg10
I7
sg11
VTetanus
p14323
sg13
I1
sa(dp14324
g7
I143
sg23
VC0012546
p14325
sg10
I10
sg11
VDiphtheria
p14326
sg13
I1
sa(dp14327
g7
I143
sg23
VC0012546
p14328
sg10
I10
sg11
VDiphtheria
p14329
sg13
I1
sasa(dp14330
g2
S'This multiplex immunoassay (MIA) can simultaneously determine levels of specific mouse serum IgG antibodies to P antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), and combined fimbria type 2 and 3 antigens (Fim2/3) and to diphtheria toxin (Dtx) and tetanus toxin (TT) in a single well.\n'
p14331
sg4
(lp14332
(dp14333
g7
I199
sg8
g15
sg10
I3
sg11
VPtx
p14334
sg13
I1
sa(dp14335
g7
I249
sg8
VP07333
p14336
sg10
I6
sg11
VFim2/3
p14337
sg13
I1
sa(dp14338
g7
I138
sg8
g15
sg10
I8
sg11
VP.69 Prn
p14339
sg13
I2
sa(dp14340
g7
I81
sg8
g15
sg10
I26
sg11
Vmouse serum IgG antibodies
p14341
sg13
I4
sa(dp14342
g7
I111
sg8
VP01893
p14343
sg10
I25
sg11
VP antigens P.69 pertactin
p14344
sg13
I4
sa(dp14345
g7
I264
sg8
g15
sg10
I16
sg11
Vdiphtheria toxin
p14346
sg13
I2
sa(dp14347
g7
I209
sg8
VP01893
p14348
sg10
I38
sg11
Vcombined fimbria type 2 and 3 antigens
p14349
sg13
I7
sa(dp14350
g7
I282
sg8
g15
sg10
I3
sg11
VDtx
p14351
sg13
I1
sa(dp14352
g7
I182
sg8
g15
sg10
I15
sg11
Vpertussis toxin
p14353
sg13
I2
sasg20
(lp14354
(dp14355
g7
I182
sg23
VC0043167
p14356
sg10
I9
sg11
Vpertussis
p14357
sg13
I1
sa(dp14358
g7
I264
sg23
VC0012546
p14359
sg10
I10
sg11
Vdiphtheria
p14360
sg13
I1
sa(dp14361
g7
I176
sg23
VC1704429
p14362
sg10
I3
sg11
VFHA
p14363
sg13
I1
sa(dp14364
g7
I149
sg23
VC1704429
p14365
sg10
I25
sg11
Vfilamentous hemagglutinin
p14366
sg13
I2
sa(dp14367
g7
I291
sg23
VC0039614
p14368
sg10
I7
sg11
Vtetanus
p14369
sg13
I1
sasa(dp14370
g2
S'Our recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.\n'
p14371
sg4
(lp14372
(dp14373
g7
I63
sg8
VP59768
p14374
sg10
I4
sg11
VGNG2
p14375
sg13
I1
sa(dp14376
g7
I58
sg8
VP59768
p14377
sg10
I4
sg11
VGng2
p14378
sg13
I1
sa(dp14379
g7
I32
sg8
VP59768
p14380
sg10
I24
sg11
VG protein Gamma2 subunit
p14381
sg13
I4
sasg20
(lp14382
(dp14383
g7
I90
sg23
VC0025202
p14384
sg10
I18
sg11
Vmalignant melanoma
p14385
sg13
I2
sasa(dp14386
g2
S'Our recent study also showed that reduced GNG2 alone augmented proliferation of malignant melanoma cells.\n'
p14387
sg4
(lp14388
(dp14389
g7
I42
sg8
VP59768
p14390
sg10
I4
sg11
VGNG2
p14391
sg13
I1
sasg20
(lp14392
(dp14393
g7
I80
sg23
VC0025202
p14394
sg10
I18
sg11
Vmalignant melanoma
p14395
sg13
I2
sa(dp14396
g7
I63
sg23
VC0334094
p14397
sg10
I13
sg11
Vproliferation
p14398
sg13
I1
sasa(dp14399
g2
S'To our knowledge, however, there is no evidence showing an effect of Gng2/GNG2 alone on metastasis of any cancers including malignant melanoma.\n'
p14400
sg4
(lp14401
(dp14402
g7
I69
sg8
VP59768
p14403
sg10
I4
sg11
VGng2
p14404
sg13
I1
sa(dp14405
g7
I74
sg8
VP59768
p14406
sg10
I4
sg11
VGNG2
p14407
sg13
I1
sasg20
(lp14408
(dp14409
g7
I106
sg23
VC0006826
p14410
sg10
I7
sg11
Vcancers
p14411
sg13
I1
sa(dp14412
g7
I88
sg23
VC0027627
p14413
sg10
I10
sg11
Vmetastasis
p14414
sg13
I1
sa(dp14415
g7
I124
sg23
VC0025202
p14416
sg10
I18
sg11
Vmalignant melanoma
p14417
sg13
I2
sasa(dp14418
g2
S'In his study, we first prepared GNG2-overexpressed SK-Mel28 human malignant melanoma cells, in which GNG2 protein expression level was undetectably low.\n'
p14419
sg4
(lp14420
(dp14421
g7
I32
sg8
VP59768
p14422
sg10
I4
sg11
VGNG2
p14423
sg13
I1
sa(dp14424
g7
I101
sg8
VP59768
p14425
sg10
I12
sg11
VGNG2 protein
p14426
sg13
I2
sasg20
(lp14427
(dp14428
g7
I66
sg23
VC0025202
p14429
sg10
I18
sg11
Vmalignant melanoma
p14430
sg13
I2
sasa(dp14431
g2
S'Migration and invasion activities of the GNG2-overexpressed malignant melanoma cells were suppressed up to 1/10th, with decreased activity of focal adhesion kinase (FAK).\n'
p14432
sg4
(lp14433
(dp14434
g7
I165
sg8
g15
sg10
I3
sg11
VFAK
p14435
sg13
I1
sa(dp14436
g7
I142
sg8
g15
sg10
I21
sg11
Vfocal adhesion kinase
p14437
sg13
I3
sa(dp14438
g7
I41
sg8
VP59768
p14439
sg10
I4
sg11
VGNG2
p14440
sg13
I1
sasg20
(lp14441
(dp14442
g7
I60
sg23
VC0025202
p14443
sg10
I18
sg11
Vmalignant melanoma
p14444
sg13
I2
sa(dp14445
g7
I120
sg23
VC0086439
p14446
sg10
I18
sg11
Vdecreased activity
p14447
sg13
I2
sa(dp14448
g7
I14
sg23
VC2699153
p14449
sg10
I8
sg11
Vinvasion
p14450
sg13
I1
sa(dp14451
g7
I148
sg23
VC0001511
p14452
sg10
I8
sg11
Vadhesion
p14453
sg13
I1
sasa(dp14454
g2
S'Taken together, our results suggest that overexpression of GNG2 alone inhibits metastasis in human malignant melanoma cells with decreased FAK activity.\n'
p14455
sg4
(lp14456
(dp14457
g7
I139
sg8
g15
sg10
I3
sg11
VFAK
p14458
sg13
I1
sa(dp14459
g7
I59
sg8
VP59768
p14460
sg10
I4
sg11
VGNG2
p14461
sg13
I1
sasg20
(lp14462
(dp14463
g7
I79
sg23
VC0027627
p14464
sg10
I10
sg11
Vmetastasis
p14465
sg13
I1
sa(dp14466
g7
I99
sg23
VC0025202
p14467
sg10
I18
sg11
Vmalignant melanoma
p14468
sg13
I2
sasa(dp14469
g2
S'Thus, GNG2 might be a candidate of molecular targets of prevention and therapy for metastasis of malignant melanoma.\n'
p14470
sg4
(lp14471
(dp14472
g7
I6
sg8
VP59768
p14473
sg10
I4
sg11
VGNG2
p14474
sg13
I1
sasg20
(lp14475
(dp14476
g7
I83
sg23
VC0027627
p14477
sg10
I10
sg11
Vmetastasis
p14478
sg13
I1
sa(dp14479
g7
I97
sg23
VC0025202
p14480
sg10
I18
sg11
Vmalignant melanoma
p14481
sg13
I2
sasa(dp14482
g2
S'Our recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.\n'
p14483
sg4
(lp14484
(dp14485
g7
I63
sg8
VP59768
p14486
sg10
I4
sg11
VGNG2
p14487
sg13
I1
sa(dp14488
g7
I58
sg8
VP59768
p14489
sg10
I4
sg11
VGng2
p14490
sg13
I1
sa(dp14491
g7
I32
sg8
VP59768
p14492
sg10
I24
sg11
VG protein Gamma2 subunit
p14493
sg13
I4
sasg20
(lp14494
(dp14495
g7
I90
sg23
VC0025202
p14496
sg10
I18
sg11
Vmalignant melanoma
p14497
sg13
I2
sasa(dp14498
g2
S'At present, however, there is no evidence showing an effect of Gng2/GNG2 alone on cancer biology.\n'
p14499
sg4
(lp14500
(dp14501
g7
I68
sg8
VP59768
p14502
sg10
I4
sg11
VGNG2
p14503
sg13
I1
sa(dp14504
g7
I63
sg8
VP59768
p14505
sg10
I4
sg11
VGng2
p14506
sg13
I1
sasg20
(lp14507
(dp14508
g7
I82
sg23
VC0006826
p14509
sg10
I6
sg11
Vcancer
p14510
sg13
I1
sasa(dp14511
g2
S'The purpose of this study was to examine the biological significance of GNG2 in human malignant melanoma cells.\n'
p14512
sg4
(lp14513
(dp14514
g7
I72
sg8
VP59768
p14515
sg10
I4
sg11
VGNG2
p14516
sg13
I1
sasg20
(lp14517
(dp14518
g7
I86
sg23
VC0025202
p14519
sg10
I18
sg11
Vmalignant melanoma
p14520
sg13
I2
sasa(dp14521
g2
S'Levels of proliferation and activities of signal transduction molecules were examined in both GNG2-overexpressed and -depleted human malignant melanoma cells.\n'
p14522
sg4
(lp14523
(dp14524
g7
I94
sg8
VP59768
p14525
sg10
I4
sg11
VGNG2
p14526
sg13
I1
sasg20
(lp14527
(dp14528
g7
I10
sg23
VC0334094
p14529
sg10
I13
sg11
Vproliferation
p14530
sg13
I1
sa(dp14531
g7
I133
sg23
VC0025202
p14532
sg10
I18
sg11
Vmalignant melanoma
p14533
sg13
I2
sasa(dp14534
g2
S'Proliferation of GNG2-overexpressed SK-Mel28 human malignant melanoma cells was suppressed with decreased c-SRC and AKT activities and increased p21(Cip/WAF1) expression level in vitro.\n'
p14535
sg4
(lp14536
(dp14537
g7
I153
sg8
VP38936
p14538
sg10
I4
sg11
VWAF1
p14539
sg13
I1
sa(dp14540
g7
I106
sg8
VP12931
p14541
sg10
I5
sg11
Vc-SRC
p14542
sg13
I1
sa(dp14543
g7
I17
sg8
VP59768
p14544
sg10
I4
sg11
VGNG2
p14545
sg13
I1
sa(dp14546
g7
I116
sg8
g15
sg10
I3
sg11
VAKT
p14547
sg13
I1
sa(dp14548
g7
I145
sg8
VP42857
p14549
sg10
I3
sg11
Vp21
p14550
sg13
I1
sa(dp14551
g7
I149
sg8
g15
sg10
I3
sg11
VCip
p14552
sg13
I1
sasg20
(lp14553
(dp14554
g7
I51
sg23
VC0025202
p14555
sg10
I18
sg11
Vmalignant melanoma
p14556
sg13
I2
sa(dp14557
g7
I0
sg23
VC0334094
p14558
sg10
I13
sg11
VProliferation
p14559
sg13
I1
sasa(dp14560
g2
S'In contrast, proliferation of GNG2-depleted A375P human malignant melanoma cells was enhanced with increased c-SRC and AKT activities and decreased p21(Cip/WAF1) expression level in vitro.\n'
p14561
sg4
(lp14562
(dp14563
g7
I152
sg8
g15
sg10
I3
sg11
VCip
p14564
sg13
I1
sa(dp14565
g7
I156
sg8
VP38936
p14566
sg10
I4
sg11
VWAF1
p14567
sg13
I1
sa(dp14568
g7
I109
sg8
VP12931
p14569
sg10
I5
sg11
Vc-SRC
p14570
sg13
I1
sa(dp14571
g7
I119
sg8
g15
sg10
I3
sg11
VAKT
p14572
sg13
I1
sa(dp14573
g7
I148
sg8
VP42857
p14574
sg10
I3
sg11
Vp21
p14575
sg13
I1
sa(dp14576
g7
I30
sg8
VP59768
p14577
sg10
I4
sg11
VGNG2
p14578
sg13
I1
sasg20
(lp14579
(dp14580
g7
I13
sg23
VC0334094
p14581
sg10
I13
sg11
Vproliferation
p14582
sg13
I1
sa(dp14583
g7
I56
sg23
VC0025202
p14584
sg10
I18
sg11
Vmalignant melanoma
p14585
sg13
I2
sasa(dp14586
g2
S'We demonstrated for the first time that increased protein expression level of GNG2 alone inhibits proliferation of malignant melanoma cells in vitro and in vivo, suggesting that GNG2 could be a novel molecular target for malignant melanoma therapy.\n'
p14587
sg4
(lp14588
(dp14589
g7
I78
sg8
VP59768
p14590
sg10
I4
sg11
VGNG2
p14591
sg13
I1
sa(dp14592
g7
I78
sg8
VP59768
p14593
sg10
I4
sg11
VGNG2
p14594
sg13
I1
sasg20
(lp14595
(dp14596
g7
I115
sg23
VC0025202
p14597
sg10
I18
sg11
Vmalignant melanoma
p14598
sg13
I2
sa(dp14599
g7
I98
sg23
VC0334094
p14600
sg10
I13
sg11
Vproliferation
p14601
sg13
I1
sa(dp14602
g7
I115
sg23
VC0025202
p14603
sg10
I18
sg11
Vmalignant melanoma
p14604
sg13
I2
sasa(dp14605
g2
S'Gng2 transcript expression levels in a malignant melanoma were less than 1/10 of the level in a benign tumor.\n'
p14606
sg4
(lp14607
(dp14608
g7
I0
sg8
VP59768
p14609
sg10
I15
sg11
VGng2 transcript
p14610
sg13
I2
sasg20
(lp14611
(dp14612
g7
I96
sg23
VC0086692
p14613
sg10
I12
sg11
Vbenign tumor
p14614
sg13
I2
sa(dp14615
g7
I39
sg23
VC0025202
p14616
sg10
I18
sg11
Vmalignant melanoma
p14617
sg13
I2
sasa(dp14618
g2
S'The difference in Gng2 transcript expression levels between benign tumors and malignant melanomas was greatest among all of the G protein Gamma subunits examined in this study.\n'
p14619
sg4
(lp14620
(dp14621
g7
I18
sg8
VP59768
p14622
sg10
I15
sg11
VGng2 transcript
p14623
sg13
I2
sa(dp14624
g7
I128
sg8
g15
sg10
I24
sg11
VG protein Gamma subunits
p14625
sg13
I4
sasg20
(lp14626
(dp14627
g7
I60
sg23
VC0086692
p14628
sg10
I13
sg11
Vbenign tumors
p14629
sg13
I2
sa(dp14630
g7
I78
sg23
VC0025202
p14631
sg10
I19
sg11
Vmalignant melanomas
p14632
sg13
I2
sasa(dp14633
g2
S'Moreover, protein expression levels of Gng2 were decreased in malignant melanomas compared with those in benign melanocytic tumors in RET-mice.\n'
p14634
sg4
(lp14635
(dp14636
g7
I39
sg8
VP59768
p14637
sg10
I4
sg11
VGng2
p14638
sg13
I1
sasg20
(lp14639
(dp14640
g7
I124
sg23
VC0027651
p14641
sg10
I6
sg11
Vtumors
p14642
sg13
I1
sa(dp14643
g7
I62
sg23
VC0025202
p14644
sg10
I19
sg11
Vmalignant melanomas
p14645
sg13
I2
sasa(dp14646
g2
S'Analysis of human malignant melanomas also showed reduced GNG2 protein expression levels in five human malignant melanoma cell lines compared with the expression levels in normal human epithelial melanocytes (NHEM).\n'
p14647
sg4
(lp14648
(dp14649
g7
I58
sg8
VP59768
p14650
sg10
I12
sg11
VGNG2 protein
p14651
sg13
I2
sasg20
(lp14652
(dp14653
g7
I18
sg23
VC0025202
p14654
sg10
I19
sg11
Vmalignant melanomas
p14655
sg13
I2
sa(dp14656
g7
I18
sg23
VC0025202
p14657
sg10
I18
sg11
Vmalignant melanoma
p14658
sg13
I2
sasa(dp14659
g2
S'Thus, we demonstrated for the first time that Gng2/GNG2 expression levels are reduced in malignant melanoma, suggesting that GNG2 could be a novel biomarker for malignant melanoma.\n'
p14660
sg4
(lp14661
(dp14662
g7
I46
sg8
VP59768
p14663
sg10
I4
sg11
VGng2
p14664
sg13
I1
sa(dp14665
g7
I51
sg8
VP59768
p14666
sg10
I4
sg11
VGNG2
p14667
sg13
I1
sa(dp14668
g7
I51
sg8
VP59768
p14669
sg10
I4
sg11
VGNG2
p14670
sg13
I1
sasg20
(lp14671
(dp14672
g7
I89
sg23
VC0025202
p14673
sg10
I18
sg11
Vmalignant melanoma
p14674
sg13
I2
sa(dp14675
g7
I89
sg23
VC0025202
p14676
sg10
I18
sg11
Vmalignant melanoma
p14677
sg13
I2
sasa(dp14678
g2
S'Several DNA repair enzymes are essential for comprehensive neural repair mechanisms after stroke, including PolBeta and NEIL3 for neurogenesis, APE1 for white matter repair, Gadd45b for axonal regeneration, and DNA-PKs for neurovascular remodeling.\n'
p14679
sg4
(lp14680
(dp14681
g7
I144
sg8
VP27695
p14682
sg10
I4
sg11
VAPE1
p14683
sg13
I1
sa(dp14684
g7
I120
sg8
g15
sg10
I5
sg11
VNEIL3
p14685
sg13
I1
sa(dp14686
g7
I174
sg8
g15
sg10
I7
sg11
VGadd45b
p14687
sg13
I1
sa(dp14688
g7
I8
sg8
g15
sg10
I18
sg11
VDNA repair enzymes
p14689
sg13
I3
sa(dp14690
g7
I211
sg8
g15
sg10
I7
sg11
VDNA-PKs
p14691
sg13
I1
sasg20
(lp14692
(dp14693
g7
I90
sg23
VC0038454
p14694
sg10
I6
sg11
Vstroke
p14695
sg13
I1
sa(dp14696
g7
I215
sg23
VC0265449
p14697
sg10
I3
sg11
VPKs
p14698
sg13
I1
sasa(dp14699
g2
S'The aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER.\n'
p14700
sg4
(lp14701
(dp14702
g7
I83
sg8
g15
sg10
I4
sg11
VTFF3
p14703
sg13
I1
sasg20
(lp14704
(dp14705
g7
I115
sg23
VC0476089
p14706
sg10
I18
sg11
Vendometrial cancer
p14707
sg13
I2
sasa(dp14708
g2
S'We evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue.\n'
p14709
sg4
(lp14710
(dp14711
g7
I46
sg8
g15
sg10
I4
sg11
VTFF3
p14712
sg13
I1
sasg20
(lp14713
(dp14714
g7
I17
sg23
VC0476089
p14715
sg10
I22
sg11
Vendometrial carcinomas
p14716
sg13
I2
sasa(dp14717
g2
S'1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas.\n'
p14718
sg4
(lp14719
(dp14720
g7
I0
sg8
g15
sg10
I6
sg11
V1-TFF3
p14721
sg13
I1
sasg20
(lp14722
(dp14723
g7
I42
sg23
VC0699748
p14724
sg10
I12
sg11
Vpathogenesis
p14725
sg13
I1
sa(dp14726
g7
I65
sg23
VC0476089
p14727
sg10
I22
sg11
Vendometrial carcinomas
p14728
sg13
I2
sasa(dp14729
g2
S'2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type.\n'
p14730
sg4
(lp14731
(dp14732
g7
I28
sg8
g15
sg10
I4
sg11
VTFF3
p14733
sg13
I1
sasg20
(lp14734
(dp14735
g7
I66
sg23
VC0206687
p14736
sg10
I22
sg11
Vendometrioid carcinoma
p14737
sg13
I2
sa(dp14738
g7
I150
sg23
VC0027651
p14739
sg10
I5
sg11
Vtumor
p14740
sg13
I1
sasa(dp14741
g2
S'3-TFF3(+) seems to forecast a good prognosis in type I endometrial carcinomas.\n'
p14742
sg4
(lp14743
(dp14744
g7
I0
sg8
g15
sg10
I6
sg11
V3-TFF3
p14745
sg13
I1
sasg20
(lp14746
(dp14747
g7
I55
sg23
VC0476089
p14748
sg10
I22
sg11
Vendometrial carcinomas
p14749
sg13
I2
sasa(dp14750
g2
S'Based on our data, TFF3 expression in endometrial cancer deserves further investigation.\n'
p14751
sg4
(lp14752
(dp14753
g7
I19
sg8
g15
sg10
I4
sg11
VTFF3
p14754
sg13
I1
sasg20
(lp14755
(dp14756
g7
I38
sg23
VC0476089
p14757
sg10
I18
sg11
Vendometrial cancer
p14758
sg13
I2
sasa(dp14759
g2
S'We evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray.\n'
p14760
sg4
(lp14761
(dp14762
g7
I101
sg8
VP06401
p14763
sg10
I21
sg11
Vprogesterone receptor
p14764
sg13
I2
sa(dp14765
g7
I129
sg8
VP01344
p14766
sg10
I54
sg11
Vinsulin-like growth factor II mRNA - binding protein 3
p14767
sg13
I9
sa(dp14768
g7
I225
sg8
g15
sg10
I4
sg11
VTFF3
p14769
sg13
I1
sa(dp14770
g7
I76
sg8
VP03372
p14771
sg10
I18
sg11
Voestrogen receptor
p14772
sg13
I2
sa(dp14773
g7
I196
sg8
g15
sg10
I27
sg11
Vintestinal trefoil factor 3
p14774
sg13
I4
sa(dp14775
g7
I185
sg8
g15
sg10
I4
sg11
VIMP3
p14776
sg13
I1
sa(dp14777
g7
I124
sg8
VP06401
p14778
sg10
I2
sg11
VPR
p14779
sg13
I1
sasg20
(lp14780
(dp14781
g7
I17
sg23
VC0476089
p14782
sg10
I22
sg11
Vendometrial carcinomas
p14783
sg13
I2
sasa(dp14784
g2
S'We recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.\n'
p14785
sg4
(lp14786
(dp14787
g7
I28
sg8
g15
sg10
I4
sg11
VTFF3
p14788
sg13
I1
sa(dp14789
g7
I33
sg8
g15
sg10
I4
sg11
VIMP3
p14790
sg13
I1
sasg20
(lp14791
(dp14792
g7
I85
sg23
VC0476089
p14793
sg10
I21
sg11
Vendometrial carcinoma
p14794
sg13
I2
sasa(dp14795
g2
S'By RT-PCR we have confirmed complete FAM107A downregulation in laryngeal cancer cell lines (15/15) and primary tumors (21/21) and this finding was further supported by FAM107A protein immunohistochemistry (15/15).\n'
p14796
sg4
(lp14797
(dp14798
g7
I37
sg8
g15
sg10
I7
sg11
VFAM107A
p14799
sg13
I1
sasg20
(lp14800
(dp14801
g7
I63
sg23
VC0595989
p14802
sg10
I16
sg11
Vlaryngeal cancer
p14803
sg13
I2
sa(dp14804
g7
I103
sg23
VC0677930
p14805
sg10
I14
sg11
Vprimary tumors
p14806
sg13
I2
sasa(dp14807
g2
S'Downregulated in renal cell carcinoma 1 (DRR1) has important roles in tumor cell growth, neuron survival and spine formation, and was recently shown to bind actin.\n'
p14808
sg4
(lp14809
(dp14810
g7
I41
sg8
g15
sg10
I4
sg11
VDRR1
p14811
sg13
I1
sa(dp14812
g7
I0
sg8
g15
sg10
I39
sg11
VDownregulated in renal cell carcinoma 1
p14813
sg13
I6
sasg20
(lp14814
(dp14815
g7
I17
sg23
VC2931882
p14816
sg10
I22
sg11
Vrenal cell carcinoma 1
p14817
sg13
I4
sa(dp14818
g7
I70
sg23
VC0027651
p14819
sg10
I5
sg11
Vtumor
p14820
sg13
I1
sasa(dp14821
g2
S'In addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells.\n'
p14822
sg4
(lp14823
(dp14824
g7
I13
sg8
g15
sg10
I4
sg11
VDRR1
p14825
sg13
I1
sa(dp14826
g7
I22
sg8
g15
sg10
I6
sg11
VCOMMD1
p14827
sg13
I1
sa(dp14828
g7
I44
sg8
VP24385
p14829
sg10
I9
sg11
Vcyclin D1
p14830
sg13
I2
sasg20
(lp14831
(dp14832
g7
I91
sg23
VC0334094
p14833
sg10
I13
sg11
Vproliferation
p14834
sg13
I1
sa(dp14835
g7
I71
sg23
VC0599156
p14836
sg10
I10
sg11
Vtransition
p14837
sg13
I1
sa(dp14838
g7
I108
sg23
VC0027819
p14839
sg10
I13
sg11
Vneuroblastoma
p14840
sg13
I1
sasa(dp14841
g2
S'Consistent with these facts, low expressions of DRR1 were associated with tumorigenesis of human neuroblastoma and its mouse model.\n'
p14842
sg4
(lp14843
(dp14844
g7
I48
sg8
g15
sg10
I4
sg11
VDRR1
p14845
sg13
I1
sasg20
(lp14846
(dp14847
g7
I74
sg23
VC0007621
p14848
sg10
I13
sg11
Vtumorigenesis
p14849
sg13
I1
sa(dp14850
g7
I97
sg23
VC0027819
p14851
sg10
I13
sg11
Vneuroblastoma
p14852
sg13
I1
sasa(dp14853
g2
S'This study has thus revealed a novel nuclear complex of F-actin, DRR1 and COMMD1 that is involved in NF-KB degradation and cell cycle suppression in neuroblastoma cells.\n'
p14854
sg4
(lp14855
(dp14856
g7
I65
sg8
g15
sg10
I4
sg11
VDRR1
p14857
sg13
I1
sa(dp14858
g7
I74
sg8
g15
sg10
I6
sg11
VCOMMD1
p14859
sg13
I1
sasg20
(lp14860
(dp14861
g7
I134
sg23
VC0221103
p14862
sg10
I11
sg11
Vsuppression
p14863
sg13
I1
sa(dp14864
g7
I149
sg23
VC0027819
p14865
sg10
I13
sg11
Vneuroblastoma
p14866
sg13
I1
sasa(dp14867
g2
S'The aim of the present study was to analyze the expression level of FAM107A gene, a TSG located in 3p21.1, in lung cancer tumors and in tumor adjacent normal lung samples.\n'
p14868
sg4
(lp14869
(dp14870
g7
I68
sg8
g15
sg10
I12
sg11
VFAM107A gene
p14871
sg13
I2
sa(dp14872
g7
I84
sg8
g15
sg10
I21
sg11
VTSG located in 3p21.1
p14873
sg13
I4
sasg20
(lp14874
(dp14875
g7
I122
sg23
VC0027651
p14876
sg10
I6
sg11
Vtumors
p14877
sg13
I1
sa(dp14878
g7
I110
sg23
VC0684249
p14879
sg10
I11
sg11
Vlung cancer
p14880
sg13
I2
sa(dp14881
g7
I122
sg23
VC0027651
p14882
sg10
I5
sg11
Vtumor
p14883
sg13
I1
sasa(dp14884
g2
S'Promoter methylation of FAM107A gene was confirmed only in the minority of NSCLCs.\n'
p14885
sg4
(lp14886
(dp14887
g7
I24
sg8
g15
sg10
I12
sg11
VFAM107A gene
p14888
sg13
I2
sasg20
(lp14889
sa(dp14890
g2
S'We recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).\n'
p14891
sg4
(lp14892
(dp14893
g7
I117
sg8
g15
sg10
I7
sg11
VFam107A
p14894
sg13
I1
sa(dp14895
g7
I111
sg8
g15
sg10
I4
sg11
VDRR1
p14896
sg13
I1
sa(dp14897
g7
I39
sg8
VP48506
p14898
sg10
I29
sg11
Vglucocorticoid-regulated gene
p14899
sg13
I2
sasg20
(lp14900
(dp14901
g7
I88
sg23
VC0007134
p14902
sg10
I20
sg11
Vrenal cell carcinoma
p14903
sg13
I3
sasa(dp14904
g2
S'In human, FAM107A termed TU3A/DRR1 has been reported as a candidate tumor suppressor gene which expression is downregulated in several types of cancer, however no studies have investigated the other family protein, FAM107B.\n'
p14905
sg4
(lp14906
(dp14907
g7
I215
sg8
g15
sg10
I7
sg11
VFAM107B
p14908
sg13
I1
sa(dp14909
g7
I10
sg8
g15
sg10
I7
sg11
VFAM107A
p14910
sg13
I1
sa(dp14911
g7
I30
sg8
g15
sg10
I4
sg11
VDRR1
p14912
sg13
I1
sa(dp14913
g7
I25
sg8
g15
sg10
I4
sg11
VTU3A
p14914
sg13
I1
sasg20
(lp14915
(dp14916
g7
I68
sg23
VC0027651
p14917
sg10
I5
sg11
Vtumor
p14918
sg13
I1
sa(dp14919
g7
I144
sg23
VC0006826
p14920
sg10
I6
sg11
Vcancer
p14921
sg13
I1
sasa(dp14922
g2
S'Down-regulated in renal cell carcinoma 1 (DRR1) is mapped at 3p21.1, and is a candidate tumor suppressor gene.\n'
p14923
sg4
(lp14924
(dp14925
g7
I0
sg8
g15
sg10
I40
sg11
VDown-regulated in renal cell carcinoma 1
p14926
sg13
I6
sa(dp14927
g7
I42
sg8
g15
sg10
I4
sg11
VDRR1
p14928
sg13
I1
sasg20
(lp14929
(dp14930
g7
I88
sg23
VC0027651
p14931
sg10
I5
sg11
Vtumor
p14932
sg13
I1
sa(dp14933
g7
I18
sg23
VC2931882
p14934
sg10
I22
sg11
Vrenal cell carcinoma 1
p14935
sg13
I4
sasa(dp14936
g2
S'DRR1 was poorly expressed in established cancer cell lines, including neuroblastoma cells, whereas strong expression was observed in normal cells.\n'
p14937
sg4
(lp14938
(dp14939
g7
I0
sg8
g15
sg10
I4
sg11
VDRR1
p14940
sg13
I1
sasg20
(lp14941
(dp14942
g7
I41
sg23
VC0006826
p14943
sg10
I6
sg11
Vcancer
p14944
sg13
I1
sa(dp14945
g7
I70
sg23
VC0027819
p14946
sg10
I13
sg11
Vneuroblastoma
p14947
sg13
I1
sasa(dp14948
g2
S'A neuroblastoma model, MYCN transgenic mice, revealed that DRR1 protein was expressed in the celiac ganglion 2 weeks after birth when neuroblast hyperplasia was also observed; however, there was no longer any expression of DRR1 protein in tumors originating from the ganglion 8 weeks after birth.\n'
p14949
sg4
(lp14950
(dp14951
g7
I59
sg8
g15
sg10
I12
sg11
VDRR1 protein
p14952
sg13
I2
sa(dp14953
g7
I23
sg8
VP04198
p14954
sg10
I4
sg11
VMYCN
p14955
sg13
I1
sa(dp14956
g7
I59
sg8
g15
sg10
I12
sg11
VDRR1 protein
p14957
sg13
I2
sasg20
(lp14958
(dp14959
g7
I100
sg23
VC1258666
p14960
sg10
I8
sg11
Vganglion
p14961
sg13
I1
sa(dp14962
g7
I2
sg23
VC0027819
p14963
sg10
I13
sg11
Vneuroblastoma
p14964
sg13
I1
sa(dp14965
g7
I239
sg23
VC0027651
p14966
sg10
I6
sg11
Vtumors
p14967
sg13
I1
sa(dp14968
g7
I100
sg23
VC1258666
p14969
sg10
I8
sg11
Vganglion
p14970
sg13
I1
sa(dp14971
g7
I145
sg23
VC0020507
p14972
sg10
I11
sg11
Vhyperplasia
p14973
sg13
I1
sasa(dp14974
g2
S'Together, our data indicate that DRR1 protein is expressed in normal cells, particularly in the nervous system during embryogenesis, is involved in neuronal cell survival, and is downregulated during neuroblastoma carcinogenesis.\n'
p14975
sg4
(lp14976
(dp14977
g7
I33
sg8
g15
sg10
I12
sg11
VDRR1 protein
p14978
sg13
I2
sasg20
(lp14979
(dp14980
g7
I214
sg23
VC0596263
p14981
sg10
I14
sg11
Vcarcinogenesis
p14982
sg13
I1
sa(dp14983
g7
I96
sg23
VC0027769
p14984
sg10
I7
sg11
Vnervous
p14985
sg13
I1
sa(dp14986
g7
I200
sg23
VC0027819
p14987
sg10
I13
sg11
Vneuroblastoma
p14988
sg13
I1
sasa(dp14989
g2
S'TU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).\n'
p14990
sg4
(lp14991
(dp14992
g7
I0
sg8
g15
sg10
I4
sg11
VTU3A
p14993
sg13
I1
sasg20
(lp14994
(dp14995
g7
I91
sg23
VC0007134
p14996
sg10
I20
sg11
Vrenal cell carcinoma
p14997
sg13
I3
sa(dp14998
g7
I66
sg23
VC0027651
p14999
sg10
I5
sg11
Vtumor
p15000
sg13
I1
sa(dp15001
g7
I113
sg23
VC0007134
p15002
sg10
I3
sg11
VRCC
p15003
sg13
I1
sasa(dp15004
g2
S'Recently, down-regulation of TU3A expression has been reported not only in RCC but also in other types of cancers.\n'
p15005
sg4
(lp15006
(dp15007
g7
I29
sg8
g15
sg10
I4
sg11
VTU3A
p15008
sg13
I1
sasg20
(lp15009
(dp15010
g7
I106
sg23
VC0006826
p15011
sg10
I7
sg11
Vcancers
p15012
sg13
I1
sa(dp15013
g7
I75
sg23
VC0007134
p15014
sg10
I3
sg11
VRCC
p15015
sg13
I1
sasa(dp15016
g2
S'Furthermore, we observed promoter hyper-methylation of TU3A in several types of cancer cell lines and primary cancers of the bladder and testis.\n'
p15017
sg4
(lp15018
(dp15019
g7
I55
sg8
g15
sg10
I4
sg11
VTU3A
p15020
sg13
I1
sasg20
(lp15021
(dp15022
g7
I110
sg23
VC0006826
p15023
sg10
I7
sg11
Vcancers
p15024
sg13
I1
sa(dp15025
g7
I80
sg23
VC0006826
p15026
sg10
I6
sg11
Vcancer
p15027
sg13
I1
sasa(dp15028
g2
S'To our knowledge, the present study is the first to demonstrate the epigenetic inactivation of TU3A in human cancers.\n'
p15029
sg4
(lp15030
(dp15031
g7
I95
sg8
g15
sg10
I4
sg11
VTU3A
p15032
sg13
I1
sasg20
(lp15033
(dp15034
g7
I109
sg23
VC0006826
p15035
sg10
I7
sg11
Vcancers
p15036
sg13
I1
sa(dp15037
g7
I79
sg23
VC0544461
p15038
sg10
I12
sg11
Vinactivation
p15039
sg13
I1
sasa(dp15040
g2
S'The findings of this study warrant further study to investigate the role of TU3A methylation in cancer development.\n'
p15041
sg4
(lp15042
(dp15043
g7
I76
sg8
g15
sg10
I4
sg11
VTU3A
p15044
sg13
I1
sasg20
(lp15045
(dp15046
g7
I96
sg23
VC0006826
p15047
sg10
I6
sg11
Vcancer
p15048
sg13
I1
sasa(dp15049
g2
S'The aim of this study was to examine the association between GCK, GCKR, FADS1, DGKB/TMEM195 and CDKAL1 gene polymorphisms and the development of gestational diabetes.\n'
p15050
sg4
(lp15051
(dp15052
g7
I66
sg8
g15
sg10
I4
sg11
VGCKR
p15053
sg13
I1
sa(dp15054
g7
I84
sg8
g15
sg10
I7
sg11
VTMEM195
p15055
sg13
I1
sa(dp15056
g7
I96
sg8
g15
sg10
I11
sg11
VCDKAL1 gene
p15057
sg13
I2
sa(dp15058
g7
I61
sg8
VP35557
p15059
sg10
I3
sg11
VGCK
p15060
sg13
I1
sasg20
(lp15061
(dp15062
g7
I145
sg23
VC0085207
p15063
sg10
I20
sg11
Vgestational diabetes
p15064
sg13
I2
sasa(dp15065
g2
S'Background Familial hemiplegic migraine type 3 is a monogenic subtype of migraine caused by missense mutations in the neuronal voltage-gated sodium channel gene SCN1A, with 10 different mutations reported so far.\n'
p15066
sg4
(lp15067
(dp15068
g7
I118
sg8
VP29475
p15069
sg10
I48
sg11
Vneuronal voltage-gated sodium channel gene SCN1A
p15070
sg13
I6
sasg20
(lp15071
(dp15072
g7
I31
sg23
VC0149931
p15073
sg10
I8
sg11
Vmigraine
p15074
sg13
I1
sa(dp15075
g7
I11
sg23
VC0338484
p15076
sg10
I28
sg11
VFamilial hemiplegic migraine
p15077
sg13
I3
sasa(dp15078
g2
S'Results In both pedigrees, we identified SCN1A mutation p.F1499L, which has been previously associated with familial hemiplegic migraine type 3 and elicited repetitive daily blindness.\n'
p15079
sg4
(lp15080
(dp15081
g7
I41
sg8
VP35498
p15082
sg10
I23
sg11
VSCN1A mutation p.F1499L
p15083
sg13
I3
sasg20
(lp15084
(dp15085
g7
I174
sg23
VC0456909
p15086
sg10
I9
sg11
Vblindness
p15087
sg13
I1
sa(dp15088
g7
I108
sg23
VC0338484
p15089
sg10
I28
sg11
Vfamilial hemiplegic migraine
p15090
sg13
I3
sasa(dp15091
g2
S'Conclusion Like a substantial proportion of other familial hemiplegic migraine type 3 mutations, p.F1499L affects the intracellular linker between domains III and IV of SCN1A, which seems to be a mutational hot-spot.\n'
p15092
sg4
(lp15093
(dp15094
g7
I169
sg8
VP35498
p15095
sg10
I5
sg11
VSCN1A
p15096
sg13
I1
sasg20
(lp15097
(dp15098
g7
I50
sg23
VC0338484
p15099
sg10
I28
sg11
Vfamilial hemiplegic migraine
p15100
sg13
I3
sasa(dp15101
g2
S'A genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures.\n'
p15102
sg4
(lp15103
(dp15104
g7
I112
sg8
VP50993
p15105
sg10
I6
sg11
VATP1A2
p15106
sg13
I1
sa(dp15107
g7
I120
sg8
VP35498
p15108
sg10
I5
sg11
VSCN1A
p15109
sg13
I1
sa(dp15110
g7
I130
sg8
VP01893
p15111
sg10
I13
sg11
VCACNA1A genes
p15112
sg13
I2
sasg20
(lp15113
(dp15114
g7
I232
sg23
VC0009952
p15115
sg10
I16
sg11
Vfebrile seizures
p15116
sg13
I2
sa(dp15117
g7
I69
sg23
VC0338484
p15118
sg10
I28
sg11
Vfamilial hemiplegic migraine
p15119
sg13
I3
sa(dp15120
g7
I219
sg23
VC0014544
p15121
sg10
I8
sg11
Vepilepsy
p15122
sg13
I1
sasa(dp15123
g2
S'Mutations in three genes (CACNA1A, ATP1A2, and SCN1A) have been found to cause FHM.\n'
p15124
sg4
(lp15125
(dp15126
g7
I35
sg8
VP50993
p15127
sg10
I6
sg11
VATP1A2
p15128
sg13
I1
sa(dp15129
g7
I47
sg8
VP35498
p15130
sg10
I5
sg11
VSCN1A
p15131
sg13
I1
sasg20
(lp15132
(dp15133
g7
I79
sg23
VC1832894
p15134
sg10
I3
sg11
VFHM
p15135
sg13
I1
sasa(dp15136
g2
S'Among these, nine SCN1A gene mutations were reported to cause familial hemiplegic migraine type 3 (FHM3).\n'
p15137
sg4
(lp15138
(dp15139
g7
I62
sg8
VP35498
p15140
sg10
I35
sg11
Vfamilial hemiplegic migraine type 3
p15141
sg13
I5
sa(dp15142
g7
I99
sg8
VP35498
p15143
sg10
I4
sg11
VFHM3
p15144
sg13
I1
sa(dp15145
g7
I18
sg8
VP35498
p15146
sg10
I10
sg11
VSCN1A gene
p15147
sg13
I2
sasg20
(lp15148
(dp15149
g7
I62
sg23
VC1864987
p15150
sg10
I35
sg11
Vfamilial hemiplegic migraine type 3
p15151
sg13
I5
sa(dp15152
g7
I99
sg23
VC1864987
p15153
sg10
I4
sg11
VFHM3
p15154
sg13
I1
sasa(dp15155
g2
S'Method The clinical manifestations of a Chinese FHM family were recorded and all coding exons and flanking intronic regions of the CACNA1A, ATP1A2, and SCN1A genes were tested for mutations.\n'
p15156
sg4
(lp15157
(dp15158
g7
I140
sg8
VP50993
p15159
sg10
I6
sg11
VATP1A2
p15160
sg13
I1
sa(dp15161
g7
I152
sg8
VP35498
p15162
sg10
I11
sg11
VSCN1A genes
p15163
sg13
I2
sasg20
(lp15164
(dp15165
g7
I48
sg23
VC1832894
p15166
sg10
I3
sg11
VFHM
p15167
sg13
I1
sasa(dp15168
g2
S'Conclusion The identification of a novel mutation in the SCN1A gene in the Chinese population may further aid in the understanding of FHM genetics.\n'
p15169
sg4
(lp15170
(dp15171
g7
I57
sg8
VP35498
p15172
sg10
I10
sg11
VSCN1A gene
p15173
sg13
I2
sasg20
(lp15174
(dp15175
g7
I134
sg23
VC1832894
p15176
sg10
I3
sg11
VFHM
p15177
sg13
I1
sa(dp15178
g7
I35
sg23
VC2985438
p15179
sg10
I14
sg11
Vnovel mutation
p15180
sg13
I2
sasa(dp15181
g2
S"Mutations in four genes have been identified in familial hemiplegic migraine (FHM), from which CACNA1A (FHM type 1) and SCN1A (FHM type 3) code for neuronal voltage-gated calcium or sodium channels, respectively, while ATP1A2 (FHM type 2) encodes the Alfa2 isoform of the Na(+),K(+)-ATPase's catalytic subunit, thus classifying FHM primarily as an ion channel/ion transporter pathology.\n"
p15182
sg4
(lp15183
(dp15184
g7
I219
sg8
VP50993
p15185
sg10
I6
sg11
VATP1A2
p15186
sg13
I1
sa(dp15187
g7
I120
sg8
VP35498
p15188
sg10
I5
sg11
VSCN1A
p15189
sg13
I1
sa(dp15190
g7
I283
sg8
VP38606
p15191
sg10
I6
sg11
VATPase
p15192
sg13
I1
sasg20
(lp15193
(dp15194
g7
I78
sg23
VC1832894
p15195
sg10
I3
sg11
VFHM
p15196
sg13
I1
sa(dp15197
g7
I78
sg23
VC1832894
p15198
sg10
I3
sg11
VFHM
p15199
sg13
I1
sa(dp15200
g7
I376
sg23
VC0677042
p15201
sg10
I9
sg11
Vpathology
p15202
sg13
I1
sa(dp15203
g7
I78
sg23
VC1832894
p15204
sg10
I3
sg11
VFHM
p15205
sg13
I1
sa(dp15206
g7
I48
sg23
VC0338484
p15207
sg10
I28
sg11
Vfamilial hemiplegic migraine
p15208
sg13
I3
sa(dp15209
g7
I78
sg23
VC1832894
p15210
sg10
I3
sg11
VFHM
p15211
sg13
I1
sa(dp15212
g7
I78
sg23
VC1832894
p15213
sg10
I3
sg11
VFHM
p15214
sg13
I1
sasa(dp15215
g2
S'Moreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura.\n'
p15216
sg4
(lp15217
(dp15218
g7
I44
sg8
VP35498
p15219
sg10
I5
sg11
VSCN1A
p15220
sg13
I1
sa(dp15221
g7
I32
sg8
VP50993
p15222
sg10
I6
sg11
VATP1A2
p15223
sg13
I1
sasg20
(lp15224
(dp15225
g7
I134
sg23
VC1832894
p15226
sg10
I3
sg11
VFHM
p15227
sg13
I1
sa(dp15228
g7
I160
sg23
VC0154723
p15229
sg10
I18
sg11
Vmigraine with aura
p15230
sg13
I3
sa(dp15231
g7
I104
sg23
VC0338484
p15232
sg10
I28
sg11
Vfamilial hemiplegic migraine
p15233
sg13
I3
sasa(dp15234
g2
S'The FHM3 subtype is caused by mutations in SCN1A, which is also the most frequent epilepsy gene encoding the voltage-gated Na+ channel NaV1.1.\n'
p15235
sg4
(lp15236
(dp15237
g7
I123
sg8
VP37088
p15238
sg10
I18
sg11
VNa+ channel NaV1.1
p15239
sg13
I3
sa(dp15240
g7
I43
sg8
VP35498
p15241
sg10
I5
sg11
VSCN1A
p15242
sg13
I1
sa(dp15243
g7
I4
sg8
VP35498
p15244
sg10
I12
sg11
VFHM3 subtype
p15245
sg13
I2
sasg20
(lp15246
(dp15247
g7
I82
sg23
VC0014544
p15248
sg10
I8
sg11
Vepilepsy
p15249
sg13
I1
sa(dp15250
g7
I4
sg23
VC1864987
p15251
sg10
I4
sg11
VFHM3
p15252
sg13
I1
sasa(dp15253
g2
S'The aim of this study was to explore the clinical, genetic and pathogenetic features of a pure FHM3 family.\n'
p15254
sg4
(lp15255
(dp15256
g7
I95
sg8
VP35498
p15257
sg10
I11
sg11
VFHM3 family
p15258
sg13
I2
sasg20
(lp15259
(dp15260
g7
I95
sg23
VC1864987
p15261
sg10
I4
sg11
VFHM3
p15262
sg13
I1
sasa(dp15263
g2
S'Results and conclusions We identified a novel SCN1A (p.Leu1624Pro) mutation in a pure FHM family with notably early-onset attacks at mean age of 7.\n'
p15264
sg4
(lp15265
(dp15266
g7
I46
sg8
VP35498
p15267
sg10
I5
sg11
VSCN1A
p15268
sg13
I1
sasg20
(lp15269
(dp15270
g7
I86
sg23
VC1832894
p15271
sg10
I3
sg11
VFHM
p15272
sg13
I1
sasa(dp15273
g2
S'L1624P locates in S3 of domain IV, the same domain as two of four known pure FHM3 mutations.\n'
p15274
sg4
(lp15275
(dp15276
g7
I77
sg8
VP35498
p15277
sg10
I4
sg11
VFHM3
p15278
sg13
I1
sasg20
(lp15279
(dp15280
g7
I77
sg23
VC1864987
p15281
sg10
I4
sg11
VFHM3
p15282
sg13
I1
sasa(dp15283
g2
S'Similar to the known FHM3 mutations, this novel mutation predicts hyperexcitability of GABAergic inhibitory neurons.\n'
p15284
sg4
(lp15285
(dp15286
g7
I21
sg8
VP35498
p15287
sg10
I14
sg11
VFHM3 mutations
p15288
sg13
I2
sasg20
(lp15289
(dp15290
g7
I21
sg23
VC1864987
p15291
sg10
I4
sg11
VFHM3
p15292
sg13
I1
sa(dp15293
g7
I42
sg23
VC2985438
p15294
sg10
I14
sg11
Vnovel mutation
p15295
sg13
I2
sasa(dp15296
g2
S'Sixty patients with migraine without aura (MO) or with different types of migraine with aura (MA), including sporadic hemiplegic, familial hemiplegic, and probable familial hemiplegic, were screened for mutations in the four genes previously linked with different types of migraine (ATP1A2, CACNA1A, SCN1A, and KCNK18).\n'
p15297
sg4
(lp15298
(dp15299
g7
I300
sg8
VP35498
p15300
sg10
I5
sg11
VSCN1A
p15301
sg13
I1
sa(dp15302
g7
I283
sg8
VP50993
p15303
sg10
I6
sg11
VATP1A2
p15304
sg13
I1
sa(dp15305
g7
I311
sg8
g15
sg10
I6
sg11
VKCNK18
p15306
sg13
I1
sasg20
(lp15307
(dp15308
g7
I94
sg23
VC0154723
p15309
sg10
I2
sg11
VMA
p15310
sg13
I1
sa(dp15311
g7
I20
sg23
VC0338480
p15312
sg10
I21
sg11
Vmigraine without aura
p15313
sg13
I3
sa(dp15314
g7
I20
sg23
VC0149931
p15315
sg10
I8
sg11
Vmigraine
p15316
sg13
I1
sa(dp15317
g7
I43
sg23
VC0338480
p15318
sg10
I2
sg11
VMO
p15319
sg13
I1
sa(dp15320
g7
I74
sg23
VC0154723
p15321
sg10
I18
sg11
Vmigraine with aura
p15322
sg13
I3
sasa(dp15323
g2
S'One novel mutation in SCN1A, encoding Alfa subunit of sodium channel, causing amino acid change M1500V localized to a region encoding inactivation loop between transmembrane domains III and IV of the channel, was detected in a female FHM patient.\n'
p15324
sg4
(lp15325
(dp15326
g7
I22
sg8
VP35498
p15327
sg10
I5
sg11
VSCN1A
p15328
sg13
I1
sasg20
(lp15329
(dp15330
g7
I234
sg23
VC1832894
p15331
sg10
I3
sg11
VFHM
p15332
sg13
I1
sa(dp15333
g7
I134
sg23
VC0544461
p15334
sg10
I12
sg11
Vinactivation
p15335
sg13
I1
sa(dp15336
g7
I4
sg23
VC2985438
p15337
sg10
I14
sg11
Vnovel mutation
p15338
sg13
I2
sasa(dp15339
g2
S'The presence of SCN1A mutations and absence of mutations in ATP1A2 or CACNA1A suggest that the Polish patients represent FHM type 3.\n'
p15340
sg4
(lp15341
(dp15342
g7
I16
sg8
VP35498
p15343
sg10
I15
sg11
VSCN1A mutations
p15344
sg13
I2
sa(dp15345
g7
I60
sg8
VP50993
p15346
sg10
I6
sg11
VATP1A2
p15347
sg13
I1
sasg20
(lp15348
(dp15349
g7
I121
sg23
VC1832894
p15350
sg10
I3
sg11
VFHM
p15351
sg13
I1
sasa(dp15352
g2
S'Mutations of the voltage gated Na(+) channel Na(V)1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).\n'
p15353
sg4
(lp15354
(dp15355
g7
I55
sg8
VP35498
p15356
sg10
I5
sg11
VSCN1A
p15357
sg13
I1
sasg20
(lp15358
(dp15359
g7
I104
sg23
VC0014544
p15360
sg10
I10
sg11
Vepilepsies
p15361
sg13
I1
sa(dp15362
g7
I164
sg23
VC0338484
p15363
sg10
I7
sg11
VFHM-III
p15364
sg13
I1
sa(dp15365
g7
I134
sg23
VC0338484
p15366
sg10
I28
sg11
Vfamilial hemiplegic migraine
p15367
sg13
I3
sasa(dp15368
g2
S'A mutation causing FHM type 3 (FHM3) has been identified in SCN1A encoding the Nav1.1 Na(+) channel.\n'
p15369
sg4
(lp15370
(dp15371
g7
I60
sg8
VP35498
p15372
sg10
I5
sg11
VSCN1A
p15373
sg13
I1
sa(dp15374
g7
I19
sg8
VP35498
p15375
sg10
I10
sg11
VFHM type 3
p15376
sg13
I3
sa(dp15377
g7
I79
sg8
VP35498
p15378
sg10
I12
sg11
VNav1.1 Na(+)
p15379
sg13
I2
sa(dp15380
g7
I31
sg8
VP35498
p15381
sg10
I4
sg11
VFHM3
p15382
sg13
I1
sasg20
(lp15383
(dp15384
g7
I19
sg23
VC1864987
p15385
sg10
I10
sg11
VFHM type 3
p15386
sg13
I3
sa(dp15387
g7
I31
sg23
VC1864987
p15388
sg10
I4
sg11
VFHM3
p15389
sg13
I1
sasa(dp15390
g2
S'In particular, we investigate the dynamical repertoire from normal spiking (milliseconds) to spreading depression and anoxic depolarization (tens of seconds) and show that FHM3 mutations render gray matter tissue more vulnerable to spreading depression despite opposing effects associated with action potential generation.\n'
p15391
sg4
(lp15392
(dp15393
g7
I172
sg8
VP35498
p15394
sg10
I4
sg11
VFHM3
p15395
sg13
I1
sasg20
(lp15396
(dp15397
g7
I172
sg23
VC1864987
p15398
sg10
I4
sg11
VFHM3
p15399
sg13
I1
sa(dp15400
g7
I103
sg23
VC0011581
p15401
sg10
I10
sg11
Vdepression
p15402
sg13
I1
sa(dp15403
g7
I103
sg23
VC0011581
p15404
sg10
I10
sg11
Vdepression
p15405
sg13
I1
sasa(dp15406
g2
S'PAR2 gene expression correlated positively with transcript levels of IL-8, IL-1Beta as well mucosal SLPI levels in H. pylori-infected patients (r: 0.47-0.84; p &lt; .0001), whereas no correlation was found with the degree of gastritis.\n'
p15407
sg4
(lp15408
(dp15409
g7
I0
sg8
VP55085
p15410
sg10
I4
sg11
VPAR2
p15411
sg13
I1
sa(dp15412
g7
I75
sg8
VP01584
p15413
sg10
I8
sg11
VIL-1Beta
p15414
sg13
I1
sasg20
(lp15415
(dp15416
g7
I225
sg23
VC0017152
p15417
sg10
I9
sg11
Vgastritis
p15418
sg13
I1
sasa(dp15419
g2
S'Mucosal levels of Secretory Leukocyte Protease Inhibitor (SLPI) are specifically reduced in relation to H. pylori-induced gastritis.\n'
p15420
sg4
(lp15421
sg20
(lp15422
(dp15423
g7
I122
sg23
VC0017152
p15424
sg10
I9
sg11
Vgastritis
p15425
sg13
I1
sasa(dp15426
g2
S'In contrast to other diseases, SLPI seems not to have a regulatory role for Progranulin in H. pylori-mediated gastritis.\n'
p15427
sg4
(lp15428
sg20
(lp15429
(dp15430
g7
I110
sg23
VC0017152
p15431
sg10
I9
sg11
Vgastritis
p15432
sg13
I1
sasa(dp15433
g2
S'SLPI expression is generally induced during inflammation; however, Helicobacter pylori-mediated gastritis is associated with significantly decreased antral SLPI levels.\n'
p15434
sg4
(lp15435
(dp15436
g7
I0
sg8
VP03973
p15437
sg10
I4
sg11
VSLPI
p15438
sg13
I1
sasg20
(lp15439
(dp15440
g7
I44
sg23
VC0021368
p15441
sg10
I12
sg11
Vinflammation
p15442
sg13
I1
sa(dp15443
g7
I96
sg23
VC0017152
p15444
sg10
I9
sg11
Vgastritis
p15445
sg13
I1
sasa(dp15446
g2
S'SLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n=13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n=18), autoimmune (n=11), lymphocytic gastritis (n=26) and H. pylori-negative controls (n=17).\n'
p15447
sg4
(lp15448
sg20
(lp15449
(dp15450
g7
I190
sg23
VC0443146
p15451
sg10
I10
sg11
Vautoimmune
p15452
sg13
I1
sa(dp15453
g7
I209
sg23
VC1283271
p15454
sg10
I21
sg11
Vlymphocytic gastritis
p15455
sg13
I2
sasa(dp15456
g2
S'In comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P&lt;0.001), whereas epithelial SLPI expression was not affected in NSAID-enhanced and autoimmune gastritis either in the antrum or corpus, respectively.\n'
p15457
sg4
(lp15458
(dp15459
g7
I42
sg8
VP03973
p15460
sg10
I4
sg11
VSLPI
p15461
sg13
I1
sa(dp15462
g7
I169
sg8
VP12830
p15463
sg10
I15
sg11
Vepithelial SLPI
p15464
sg13
I2
sasg20
(lp15465
(dp15466
g7
I101
sg23
VC1283271
p15467
sg10
I21
sg11
Vlymphocytic gastritis
p15468
sg13
I2
sa(dp15469
g7
I235
sg23
VC0017154
p15470
sg10
I20
sg11
Vautoimmune gastritis
p15471
sg13
I2
sasa(dp15472
g2
S'Both the H. pylori-mediated and lymphocytic gastritis revealed a significantly lower expression of SLPI in infiltrating immune cells (P&lt;0.01), whereas immune cells infiltrating the corpus in autoimmune gastritis showed higher SLPI levels than the immune cells of other groups (P&lt;0.03).\n'
p15473
sg4
(lp15474
(dp15475
g7
I99
sg8
VP03973
p15476
sg10
I4
sg11
VSLPI
p15477
sg13
I1
sasg20
(lp15478
(dp15479
g7
I32
sg23
VC1283271
p15480
sg10
I21
sg11
Vlymphocytic gastritis
p15481
sg13
I2
sa(dp15482
g7
I194
sg23
VC0017154
p15483
sg10
I20
sg11
Vautoimmune gastritis
p15484
sg13
I2
sa(dp15485
g7
I107
sg23
VC0332448
p15486
sg10
I12
sg11
Vinfiltrating
p15487
sg13
I1
sa(dp15488
g7
I107
sg23
VC0332448
p15489
sg10
I12
sg11
Vinfiltrating
p15490
sg13
I1
sasa(dp15491
g2
S'Antral SLPI levels were inversely correlated with inflammatory scores of antrum-predominant gastritis.\n'
p15492
sg4
(lp15493
sg20
(lp15494
(dp15495
g7
I92
sg23
VC0017152
p15496
sg10
I9
sg11
Vgastritis
p15497
sg13
I1
sasa(dp15498
g2
S'Pharmacological inhibition of different signaling pathways and genetic knockdown of Notch-2 further revealed JNK as an upstream effector of Notch-2 in TGF-Beta1-mediated renal fibrosis.\n'
p15499
sg4
(lp15500
(dp15501
g7
I109
sg8
VP53779
p15502
sg10
I3
sg11
VJNK
p15503
sg13
I1
sa(dp15504
g7
I151
sg8
VP01137
p15505
sg10
I9
sg11
VTGF-Beta1
p15506
sg13
I1
sa(dp15507
g7
I84
sg8
g15
sg10
I7
sg11
VNotch-2
p15508
sg13
I1
sa(dp15509
g7
I84
sg8
g15
sg10
I7
sg11
VNotch-2
p15510
sg13
I1
sasg20
(lp15511
(dp15512
g7
I170
sg23
VC0151650
p15513
sg10
I14
sg11
Vrenal fibrosis
p15514
sg13
I2
sasa(dp15515
g2
S'Consistently, we also demonstrated that administration of TSA or a Gamma-secretase inhibitor RO4929097 in the mouse model of unilateral ureteral obstruction significantly ameliorated renal fibrosis through suppression of the JNK/Notch-2 signaling activation.\n'
p15516
sg4
(lp15517
(dp15518
g7
I229
sg8
g15
sg10
I7
sg11
VNotch-2
p15519
sg13
I1
sa(dp15520
g7
I225
sg8
VP53779
p15521
sg10
I3
sg11
VJNK
p15522
sg13
I1
sasg20
(lp15523
(dp15524
g7
I136
sg23
VC0041956
p15525
sg10
I20
sg11
Vureteral obstruction
p15526
sg13
I2
sa(dp15527
g7
I183
sg23
VC0151650
p15528
sg10
I14
sg11
Vrenal fibrosis
p15529
sg13
I2
sa(dp15530
g7
I206
sg23
VC0221103
p15531
sg10
I11
sg11
Vsuppression
p15532
sg13
I1
sasa(dp15533
g2
S'Although, renal abnormalities are considered an integral part of the HJCYS, published reports on ESRD are scarce.\n'
p15534
sg4
(lp15535
sg20
(lp15536
(dp15537
g7
I69
sg23
VC0917715
p15538
sg10
I5
sg11
VHJCYS
p15539
sg13
I1
sa(dp15540
g7
I97
sg23
VC0022661
p15541
sg10
I4
sg11
VESRD
p15542
sg13
I1
sasa(dp15543
g2
S'Here we show that Notch2 prevents podocyte loss and nephrosis.\n'
p15544
sg4
(lp15545
(dp15546
g7
I18
sg8
g15
sg10
I6
sg11
VNotch2
p15547
sg13
I1
sasg20
(lp15548
(dp15549
g7
I52
sg23
VC0027720
p15550
sg10
I9
sg11
Vnephrosis
p15551
sg13
I1
sasa(dp15552
g2
S'Administration of a Notch2 agonistic monoclonal antibody ameliorates proteinuria and glomerulosclerosis in a mouse model of nephrosis and focal segmental glomerulosclerosis.\n'
p15553
sg4
(lp15554
(dp15555
g7
I20
sg8
g15
sg10
I6
sg11
VNotch2
p15556
sg13
I1
sasg20
(lp15557
(dp15558
g7
I138
sg23
VC0017668
p15559
sg10
I34
sg11
Vfocal segmental glomerulosclerosis
p15560
sg13
I3
sa(dp15561
g7
I85
sg23
VC0178664
p15562
sg10
I18
sg11
Vglomerulosclerosis
p15563
sg13
I1
sa(dp15564
g7
I124
sg23
VC0027720
p15565
sg10
I9
sg11
Vnephrosis
p15566
sg13
I1
sasa(dp15567
g2
S'Hence, specific activation of Notch2 rescues damaged podocytes and activating Notch2 may represent a novel clinical strategy for the amelioration of nephrosis and glomerulosclerosis.\n'
p15568
sg4
(lp15569
(dp15570
g7
I30
sg8
g15
sg10
I6
sg11
VNotch2
p15571
sg13
I1
sa(dp15572
g7
I30
sg8
g15
sg10
I6
sg11
VNotch2
p15573
sg13
I1
sasg20
(lp15574
(dp15575
g7
I149
sg23
VC0027720
p15576
sg10
I9
sg11
Vnephrosis
p15577
sg13
I1
sa(dp15578
g7
I163
sg23
VC0178664
p15579
sg10
I18
sg11
Vglomerulosclerosis
p15580
sg13
I1
sasa(dp15581
g2
S'To investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN).\n'
p15582
sg4
(lp15583
(dp15584
g7
I95
sg8
g15
sg10
I5
sg11
Vhes-1
p15585
sg13
I1
sa(dp15586
g7
I88
sg8
g15
sg10
I6
sg11
VNotch2
p15587
sg13
I1
sasg20
(lp15588
(dp15589
g7
I95
sg23
VC0206141
p15590
sg10
I3
sg11
Vhes
p15591
sg13
I1
sa(dp15592
g7
I181
sg23
VC0022658
p15593
sg10
I11
sg11
Vnephropathy
p15594
sg13
I1
sasa(dp15595
g2
S'The role of NOTCH2 and JAG1 in formation of proximal nephron structures and podocytes might explain the observed phenotypes of renal dysplasia and proteinuria in patients with Alagille syndrome, and renal tubular acidosis may be the result of JAG1 expression in the collecting ducts.\n'
p15596
sg4
(lp15597
(dp15598
g7
I12
sg8
g15
sg10
I6
sg11
VNOTCH2
p15599
sg13
I1
sa(dp15600
g7
I23
sg8
VP78504
p15601
sg10
I4
sg11
VJAG1
p15602
sg13
I1
sa(dp15603
g7
I23
sg8
VP78504
p15604
sg10
I4
sg11
VJAG1
p15605
sg13
I1
sasg20
(lp15606
(dp15607
g7
I127
sg23
VC0266313
p15608
sg10
I15
sg11
Vrenal dysplasia
p15609
sg13
I2
sa(dp15610
g7
I199
sg23
VC0001126
p15611
sg10
I22
sg11
Vrenal tubular acidosis
p15612
sg13
I3
sa(dp15613
g7
I176
sg23
VC0085280
p15614
sg10
I17
sg11
VAlagille syndrome
p15615
sg13
I2
sasa(dp15616
g2
S'The oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.\n'
p15617
sg4
(lp15618
(dp15619
g7
I110
sg8
VP35218
p15620
sg10
I18
sg11
Vcarbonic anhydrase
p15621
sg13
I2
sa(dp15622
g7
I130
sg8
VP35218
p15623
sg10
I2
sg11
VCA
p15624
sg13
I1
sasg20
(lp15625
(dp15626
g7
I48
sg23
VC0333519
p15627
sg10
I13
sg11
Vdental caries
p15628
sg13
I2
sasa(dp15629
g2
S'Streptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.\n'
p15630
sg4
(lp15631
(dp15632
g7
I101
sg8
VP35218
p15633
sg10
I29
sg11
VBeta-class carbonic anhydrase
p15634
sg13
I3
sasg20
(lp15635
(dp15636
g7
I62
sg23
VC0333519
p15637
sg10
I13
sg11
Vdental caries
p15638
sg13
I2
sasa(dp15639
g2
S'A carbonic anhydrase (CA, EC 4.2.1.1) denominated PgiCA, belonging to the Gamma-class, from the oral pathogenic bacteria Porphyromonas gingivalis, the main causative agent of periodontitis, was investigated for its inhibition profile with sulfonamides and one sulfamate.\n'
p15640
sg4
(lp15641
(dp15642
g7
I22
sg8
VP35218
p15643
sg10
I2
sg11
VCA
p15644
sg13
I1
sa(dp15645
g7
I2
sg8
VP35218
p15646
sg10
I18
sg11
Vcarbonic anhydrase
p15647
sg13
I2
sasg20
(lp15648
(dp15649
g7
I175
sg23
VC0031099
p15650
sg10
I13
sg11
Vperiodontitis
p15651
sg13
I1
sasa(dp15652
g2
S'Recently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation.\n'
p15653
sg4
(lp15654
(dp15655
g7
I130
sg8
VP12524
p15656
sg10
I5
sg11
Vc-myc
p15657
sg13
I1
sa(dp15658
g7
I96
sg8
VP19447
p15659
sg10
I12
sg11
VXPB helicase
p15660
sg13
I2
sa(dp15661
g7
I86
sg8
VP32780
p15662
sg10
I5
sg11
VTFIIH
p15663
sg13
I1
sasg20
(lp15664
(dp15665
g7
I192
sg23
VC0027651
p15666
sg10
I5
sg11
Vtumor
p15667
sg13
I1
sa(dp15668
g7
I96
sg23
VC0268136
p15669
sg10
I3
sg11
VXPB
p15670
sg13
I1
sasa(dp15671
g2
S'In XPB cells carrying mutant TFIIH, loop formation failed and the serum response was abnormal; RNAi depletion of FIR similarly disabled c-myc regulation.\n'
p15672
sg4
(lp15673
(dp15674
g7
I113
sg8
g15
sg10
I3
sg11
VFIR
p15675
sg13
I1
sa(dp15676
g7
I136
sg8
VP12524
p15677
sg10
I5
sg11
Vc-myc
p15678
sg13
I1
sa(dp15679
g7
I29
sg8
VP32780
p15680
sg10
I5
sg11
VTFIIH
p15681
sg13
I1
sasg20
(lp15682
(dp15683
g7
I3
sg23
VC0268136
p15684
sg10
I3
sg11
VXPB
p15685
sg13
I1
sa(dp15686
g7
I22
sg23
VC0596988
p15687
sg10
I6
sg11
Vmutant
p15688
sg13
I1
sasa(dp15689
g2
S'Recently, an interaction between FUSE-binding protein-interacting repressor (FIR) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and might be important for suppressing tumor formation.\n'
p15690
sg4
(lp15691
(dp15692
g7
I130
sg8
VP12524
p15693
sg10
I5
sg11
Vc-myc
p15694
sg13
I1
sa(dp15695
g7
I77
sg8
g15
sg10
I3
sg11
VFIR
p15696
sg13
I1
sa(dp15697
g7
I96
sg8
VP19447
p15698
sg10
I12
sg11
VXPB helicase
p15699
sg13
I2
sa(dp15700
g7
I86
sg8
VP32780
p15701
sg10
I5
sg11
VTFIIH
p15702
sg13
I1
sa(dp15703
g7
I33
sg8
g15
sg10
I42
sg11
VFUSE-binding protein-interacting repressor
p15704
sg13
I3
sasg20
(lp15705
(dp15706
g7
I189
sg23
VC0027651
p15707
sg10
I5
sg11
Vtumor
p15708
sg13
I1
sa(dp15709
g7
I96
sg23
VC0268136
p15710
sg10
I3
sg11
VXPB
p15711
sg13
I1
sasa(dp15712
g2
S'Here, XPB and XPD mutations are shown to block transcription activation by the FUSE Binding Protein (FBP), a regulator of c-myc expression, and repression by the FBP Interacting Repressor (FIR).\n'
p15713
sg4
(lp15714
(dp15715
g7
I189
sg8
g15
sg10
I3
sg11
VFIR
p15716
sg13
I1
sa(dp15717
g7
I101
sg8
g15
sg10
I3
sg11
VFBP
p15718
sg13
I1
sa(dp15719
g7
I122
sg8
VP12524
p15720
sg10
I5
sg11
Vc-myc
p15721
sg13
I1
sa(dp15722
g7
I6
sg8
VP19447
p15723
sg10
I3
sg11
VXPB
p15724
sg13
I1
sa(dp15725
g7
I14
sg8
VP18074
p15726
sg10
I3
sg11
VXPD
p15727
sg13
I1
sa(dp15728
g7
I79
sg8
g15
sg10
I20
sg11
VFUSE Binding Protein
p15729
sg13
I3
sa(dp15730
g7
I162
sg8
g15
sg10
I25
sg11
VFBP Interacting Repressor
p15731
sg13
I3
sasg20
(lp15732
(dp15733
g7
I14
sg23
VC0268138
p15734
sg10
I3
sg11
VXPD
p15735
sg13
I1
sa(dp15736
g7
I6
sg23
VC0268136
p15737
sg10
I3
sg11
VXPB
p15738
sg13
I1
sasa(dp15739
g2
S"The repression domain of FIR targeted only TFIIH's p89/XPB helicase, required at several stages in transcription, but not factors required for promoter selection.\n"
p15740
sg4
(lp15741
(dp15742
g7
I55
sg8
VP19447
p15743
sg10
I12
sg11
VXPB helicase
p15744
sg13
I2
sa(dp15745
g7
I25
sg8
g15
sg10
I3
sg11
VFIR
p15746
sg13
I1
sa(dp15747
g7
I43
sg8
VP32780
p15748
sg10
I5
sg11
VTFIIH
p15749
sg13
I1
sasg20
(lp15750
(dp15751
g7
I55
sg23
VC0268136
p15752
sg10
I3
sg11
VXPB
p15753
sg13
I1
sasa(dp15754
g2
S'To investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).\n'
p15755
sg4
(lp15756
sg20
(lp15757
(dp15758
g7
I243
sg23
VC0011615
p15759
sg10
I2
sg11
VAD
p15760
sg13
I1
sa(dp15761
g7
I210
sg23
VC0033860
p15762
sg10
I9
sg11
Vpsoriasis
p15763
sg13
I1
sa(dp15764
g7
I195
sg23
VC0037274
p15765
sg10
I13
sg11
Vskin diseases
p15766
sg13
I2
sa(dp15767
g7
I224
sg23
VC0011615
p15768
sg10
I17
sg11
Vatopic dermatitis
p15769
sg13
I2
sasa(dp15770
g2
S'IL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis.\n'
p15771
sg4
(lp15772
sg20
(lp15773
(dp15774
g7
I132
sg23
VC0033860
p15775
sg10
I9
sg11
Vpsoriasis
p15776
sg13
I1
sasa(dp15777
g2
S'Using skin samples from patients with mycosis fungoides (n = 21), healthy volunteers (n = 17), and individuals with atopic dermatitis (n = 17) and psoriasis (n = 9), we found IL32 mRNA expression significantly higher in mycosis fungoides samples than in samples from benign inflammatory skin diseases, and its expression increases with disease progression.\n'
p15778
sg4
(lp15779
(dp15780
g7
I175
sg8
VP24001
p15781
sg10
I9
sg11
VIL32 mRNA
p15782
sg13
I2
sasg20
(lp15783
(dp15784
g7
I116
sg23
VC0011615
p15785
sg10
I17
sg11
Vatopic dermatitis
p15786
sg13
I2
sa(dp15787
g7
I38
sg23
VC0026948
p15788
sg10
I17
sg11
Vmycosis fungoides
p15789
sg13
I2
sa(dp15790
g7
I336
sg23
VC0242656
p15791
sg10
I19
sg11
Vdisease progression
p15792
sg13
I2
sa(dp15793
g7
I147
sg23
VC0033860
p15794
sg10
I9
sg11
Vpsoriasis
p15795
sg13
I1
sa(dp15796
g7
I38
sg23
VC0026948
p15797
sg10
I17
sg11
Vmycosis fungoides
p15798
sg13
I2
sa(dp15799
g7
I287
sg23
VC0037274
p15800
sg10
I13
sg11
Vskin diseases
p15801
sg13
I2
sasa(dp15802
g2
S'Immunofluorescence staining demonstrated that IL-32 was expressed in AD lesional skin, whereas it was present in neither skin biopsy specimens from healthy donors nor in lesional skin from patients with psoriasis.\n'
p15803
sg4
(lp15804
sg20
(lp15805
(dp15806
g7
I203
sg23
VC0033860
p15807
sg10
I9
sg11
Vpsoriasis
p15808
sg13
I1
sasa(dp15809
g2
S'In this study, the expression profile of ASPP2 in choriocarcinoma was examined in comparison with normal placentas and hydatidiform moles, the latter being a type of GTD that carries malignant potential.\n'
p15810
sg4
(lp15811
(dp15812
g7
I41
sg8
g15
sg10
I5
sg11
VASPP2
p15813
sg13
I1
sasg20
(lp15814
(dp15815
g7
I50
sg23
VC0008497
p15816
sg10
I15
sg11
Vchoriocarcinoma
p15817
sg13
I1
sa(dp15818
g7
I119
sg23
VC0020217
p15819
sg10
I18
sg11
Vhydatidiform moles
p15820
sg13
I2
sasa(dp15821
g2
S'Downregulation of ASPP2 messenger RNA and protein was demonstrated in choriocarcinoma by quantitative PCR and immunohistochemistry.\n'
p15822
sg4
(lp15823
(dp15824
g7
I18
sg8
g15
sg10
I31
sg11
VASPP2 messenger RNA and protein
p15825
sg13
I5
sasg20
(lp15826
(dp15827
g7
I70
sg23
VC0008497
p15828
sg10
I15
sg11
Vchoriocarcinoma
p15829
sg13
I1
sasa(dp15830
g2
S'ASPP2-transfected choriocarcinoma cells (JEG-3 and JAR) showed an increase in apoptosis and a decrease in cell migration as detected by TdT-mediated dUTP nick end labeling and wound healing assays, respectively, illustrating the complex action of ASPP2 on cell functions other than programmed cell death.\n'
p15831
sg4
(lp15832
(dp15833
g7
I0
sg8
g15
sg10
I5
sg11
VASPP2
p15834
sg13
I1
sa(dp15835
g7
I0
sg8
g15
sg10
I5
sg11
VASPP2
p15836
sg13
I1
sa(dp15837
g7
I136
sg8
VP04053
p15838
sg10
I3
sg11
VTdT
p15839
sg13
I1
sasg20
(lp15840
(dp15841
g7
I18
sg23
VC0008497
p15842
sg10
I15
sg11
Vchoriocarcinoma
p15843
sg13
I1
sasa(dp15844
g2
S'Taken together, we demonstrated a loss of tumor-suppressive ASPP2 in choriocarcinoma with effects on cell migration and apoptosis.\n'
p15845
sg4
(lp15846
(dp15847
g7
I60
sg8
g15
sg10
I5
sg11
VASPP2
p15848
sg13
I1
sasg20
(lp15849
(dp15850
g7
I69
sg23
VC0008497
p15851
sg10
I15
sg11
Vchoriocarcinoma
p15852
sg13
I1
sa(dp15853
g7
I42
sg23
VC0027651
p15854
sg10
I5
sg11
Vtumor
p15855
sg13
I1
sasa(dp15856
g2
S'No correlation between erythrocyte TDP concentration and transketolase activity and/or alpha-ETK was observed in ESRD patients, either before or 10 h after administration.\n'
p15857
sg4
(lp15858
(dp15859
g7
I57
sg8
VP29401
p15860
sg10
I13
sg11
Vtransketolase
p15861
sg13
I1
sa(dp15862
g7
I87
sg8
VP51813
p15863
sg10
I9
sg11
Valpha-ETK
p15864
sg13
I1
sasg20
(lp15865
(dp15866
g7
I113
sg23
VC0022661
p15867
sg10
I4
sg11
VESRD
p15868
sg13
I1
sasa(dp15869
g2
S'Scores for VEGF, TIMP-1, TIMP-3, SLPI and PAI-1 were all increased in OA compared with PM, and higher scores were associated with greater chondropathy.\n'
p15870
sg4
(lp15871
(dp15872
g7
I42
sg8
VP05121
p15873
sg10
I5
sg11
VPAI-1
p15874
sg13
I1
sa(dp15875
g7
I25
sg8
VP35625
p15876
sg10
I6
sg11
VTIMP-3
p15877
sg13
I1
sa(dp15878
g7
I17
sg8
VP01033
p15879
sg10
I6
sg11
VTIMP-1
p15880
sg13
I1
sa(dp15881
g7
I33
sg8
VP03973
p15882
sg10
I4
sg11
VSLPI
p15883
sg13
I1
sasg20
(lp15884
(dp15885
g7
I138
sg23
VC0007302
p15886
sg10
I12
sg11
Vchondropathy
p15887
sg13
I1
sasa(dp15888
g2
S'Concentrations of the plasminogen activators pro-urokinase, tissue plasminogen activator, plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), plasminogen, and fibrin split product D-dimer in synovial fluid (SF) and blood plasma of 29 patients with rheumatoid arthritis (RA) were compared with the concentrations of 18 patients with spondyloarthropathy (SpA).\n'
p15889
sg4
(lp15890
(dp15891
g7
I132
sg8
VP05121
p15892
sg10
I5
sg11
VPAI-1
p15893
sg13
I1
sa(dp15894
g7
I60
sg8
VP00747
p15895
sg10
I28
sg11
Vtissue plasminogen activator
p15896
sg13
I3
sa(dp15897
g7
I22
sg8
VP00747
p15898
sg10
I11
sg11
Vplasminogen
p15899
sg13
I1
sa(dp15900
g7
I22
sg8
VP00747
p15901
sg10
I36
sg11
Vplasminogen activators pro-urokinase
p15902
sg13
I3
sa(dp15903
g7
I90
sg8
VP00747
p15904
sg10
I40
sg11
Vplasminogen activator inhibitors 1 and 2
p15905
sg13
I6
sa(dp15906
g7
I167
sg8
VP22087
p15907
sg10
I6
sg11
Vfibrin
p15908
sg13
I1
sa(dp15909
g7
I142
sg8
VP05120
p15910
sg10
I5
sg11
VPAI-2
p15911
sg13
I1
sasg20
(lp15912
(dp15913
g7
I278
sg23
VC0003873
p15914
sg10
I2
sg11
VRA
p15915
sg13
I1
sa(dp15916
g7
I361
sg23
VC0949691
p15917
sg10
I3
sg11
VSpA
p15918
sg13
I1
sa(dp15919
g7
I340
sg23
VC0949691
p15920
sg10
I19
sg11
Vspondyloarthropathy
p15921
sg13
I1
sa(dp15922
g7
I256
sg23
VC0003873
p15923
sg10
I20
sg11
Vrheumatoid arthritis
p15924
sg13
I2
sasa(dp15925
g2
S'Besides myeloperoxidase (MPO), which was used as the gold standard in differentiating AML from other type of ALs, the most specific markers for AML in our study were CD14 and CD64 (99.5 and 95.6%).\n'
p15926
sg4
(lp15927
(dp15928
g7
I8
sg8
VP05164
p15929
sg10
I15
sg11
Vmyeloperoxidase
p15930
sg13
I1
sa(dp15931
g7
I166
sg8
VP08571
p15932
sg10
I4
sg11
VCD14
p15933
sg13
I1
sa(dp15934
g7
I25
sg8
VP05164
p15935
sg10
I3
sg11
VMPO
p15936
sg13
I1
sasg20
(lp15937
(dp15938
g7
I86
sg23
VC0023467
p15939
sg10
I3
sg11
VAML
p15940
sg13
I1
sa(dp15941
g7
I109
sg23
VC0002736
p15942
sg10
I3
sg11
VALs
p15943
sg13
I1
sa(dp15944
g7
I86
sg23
VC0023467
p15945
sg10
I3
sg11
VAML
p15946
sg13
I1
sasa(dp15947
g2
S'They were characterized as follows: (1) disease onset with initial signs/symptoms due to intractable otitis media with effusion or granulation, which did not respond to ordinary treatments such as antibiotics and insertion of tympanic ventilation tubes, followed by progressive hearing loss; (2) predominantly female (73%) and older (median age: 68 years); (3) predominantly myeloperoxidase (MPO)-ANCA-positive (60%), followed by proteinase 3 (PR3)-ANCA-positive (19%) and both ANCAs-negative (16%); (4) frequently observed accompanying facial palsy (36%) and hypertrophic pachymeningitis (28%); and (5) disease often involving lung (35%) and kidney (26%) lesions.\n'
p15948
sg4
(lp15949
(dp15950
g7
I430
sg8
VP63123
p15951
sg10
I12
sg11
Vproteinase 3
p15952
sg13
I2
sa(dp15953
g7
I444
sg8
VP63123
p15954
sg10
I3
sg11
VPR3
p15955
sg13
I1
sa(dp15956
g7
I375
sg8
VP05164
p15957
sg10
I15
sg11
Vmyeloperoxidase
p15958
sg13
I1
sa(dp15959
g7
I392
sg8
VP05164
p15960
sg10
I3
sg11
VMPO
p15961
sg13
I1
sasg20
(lp15962
(dp15963
g7
I537
sg23
VC0015469
p15964
sg10
I12
sg11
Vfacial palsy
p15965
sg13
I2
sa(dp15966
g7
I101
sg23
VC0029883
p15967
sg10
I26
sg11
Votitis media with effusion
p15968
sg13
I4
sa(dp15969
g7
I278
sg23
VC0011053
p15970
sg10
I12
sg11
Vhearing loss
p15971
sg13
I2
sa(dp15972
g7
I560
sg23
VC0948402
p15973
sg10
I28
sg11
Vhypertrophic pachymeningitis
p15974
sg13
I2
sasa(dp15975
g2
S'Effects of zolpidem were wide ranging (eg, improvement on the JFK Coma Recovery Scale-Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale) and generally lasted 1 to 4 hours before the participant returned to baseline.\n'
p15976
sg4
(lp15977
sg20
(lp15978
(dp15979
g7
I66
sg23
VC0009421
p15980
sg10
I4
sg11
VComa
p15981
sg13
I1
sa(dp15982
g7
I166
sg23
VC0393593
p15983
sg10
I8
sg11
VDystonia
p15984
sg13
I1
sa(dp15985
g7
I107
sg23
VC0030567
p15986
sg10
I17
sg11
VParkinson Disease
p15987
sg13
I2
sasa(dp15988
g2
S'The altered tissue steroid concentrations in endometriosis were in line with the expression of various steroidogenic enzymes in the lesions, of which HSD3B2 showed constantly high expression, whereas CYP11A1 expression was low.\n'
p15989
sg4
(lp15990
(dp15991
g7
I200
sg8
VP05108
p15992
sg10
I7
sg11
VCYP11A1
p15993
sg13
I1
sa(dp15994
g7
I150
sg8
VP26439
p15995
sg10
I6
sg11
VHSD3B2
p15996
sg13
I1
sasg20
(lp15997
(dp15998
g7
I45
sg23
VC0014175
p15999
sg10
I13
sg11
Vendometriosis
p16000
sg13
I1
sasa(dp16001
g2
S"Type III groups together 10 autoimmune diseases (autoimmune thyroid disease, myasthenia and/or thymoma, Sjoegren's syndrome, pernicious anaemia, idiopathic thrombocytopaenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune haemolytic anaemia, systemic lupus erythematosus) for which a genetic predisposition (phenotype HLA B8 and/or DR3 or DR5) seems to be an important factor.\n"
p16002
sg4
(lp16003
(dp16004
g7
I202
sg8
VP01308
p16005
sg10
I7
sg11
Vinsulin
p16006
sg13
I1
sasg20
(lp16007
(dp16008
g7
I49
sg23
VC0178468
p16009
sg10
I26
sg11
Vautoimmune thyroid disease
p16010
sg13
I3
sa(dp16011
g7
I271
sg23
VC0024141
p16012
sg10
I28
sg11
Vsystemic lupus erythematosus
p16013
sg13
I3
sa(dp16014
g7
I183
sg23
VC0001403
p16015
sg10
I17
sg11
VAddison's disease
p16016
sg13
I2
sa(dp16017
g7
I202
sg23
VC0011854
p16018
sg10
I26
sg11
Vinsulin-dependent diabetes
p16019
sg13
I2
sa(dp16020
g7
I230
sg23
VC0042900
p16021
sg10
I8
sg11
Vvitiligo
p16022
sg13
I1
sa(dp16023
g7
I95
sg23
VC0040100
p16024
sg10
I7
sg11
Vthymoma
p16025
sg13
I1
sa(dp16026
g7
I28
sg23
VC0004364
p16027
sg10
I19
sg11
Vautoimmune diseases
p16028
sg13
I2
sa(dp16029
g7
I77
sg23
VC0947912
p16030
sg10
I10
sg11
Vmyasthenia
p16031
sg13
I1
sa(dp16032
g7
I104
sg23
VC1527336
p16033
sg10
I19
sg11
VSjoegren's syndrome
p16034
sg13
I2
sa(dp16035
g7
I156
sg23
VC0857305
p16036
sg10
I25
sg11
Vthrombocytopaenic purpura
p16037
sg13
I2
sa(dp16038
g7
I125
sg23
VC0002892
p16039
sg10
I18
sg11
Vpernicious anaemia
p16040
sg13
I2
sa(dp16041
g7
I240
sg23
VC0002880
p16042
sg10
I29
sg11
Vautoimmune haemolytic anaemia
p16043
sg13
I3
sasa(dp16044
g2
S'A significant increase in the frequency of HLA DR5 antigen was observed in patients with ARC mainly in purpura thrombocytopenic patients.\n'
p16045
sg4
(lp16046
(dp16047
g7
I43
sg8
VP30486
p16048
sg10
I15
sg11
VHLA DR5 antigen
p16049
sg13
I3
sasg20
(lp16050
(dp16051
g7
I103
sg23
VC0857305
p16052
sg10
I24
sg11
Vpurpura thrombocytopenic
p16053
sg13
I2
sa(dp16054
g7
I89
sg23
VC0001857
p16055
sg10
I3
sg11
VARC
p16056
sg13
I1
sasa(dp16057
g2
S'Genome-wide pathway analysis with the dysregulated genes after overexpression of either of the two miRs in MCF-7 breast cancer cell identified the "Cancer"- and "Cell signaling"-related pathway as the top pathway for miR-204 and miR-211, respectively.\n'
p16058
sg4
(lp16059
(dp16060
g7
I217
sg8
g15
sg10
I7
sg11
VmiR-204
p16061
sg13
I1
sa(dp16062
g7
I229
sg8
g15
sg10
I7
sg11
VmiR-211
p16063
sg13
I1
sasg20
(lp16064
(dp16065
g7
I148
sg23
VC0006826
p16066
sg10
I6
sg11
VCancer
p16067
sg13
I1
sa(dp16068
g7
I113
sg23
VC0678222
p16069
sg10
I13
sg11
Vbreast cancer
p16070
sg13
I2
sasa(dp16071
g2
S'In addition, a high association was observed between miR-204 and miR-211 expression in breast cancer tissue.\n'
p16072
sg4
(lp16073
(dp16074
g7
I53
sg8
g15
sg10
I7
sg11
VmiR-204
p16075
sg13
I1
sa(dp16076
g7
I65
sg8
g15
sg10
I7
sg11
VmiR-211
p16077
sg13
I1
sasg20
(lp16078
(dp16079
g7
I87
sg23
VC0678222
p16080
sg10
I13
sg11
Vbreast cancer
p16081
sg13
I2
sasa(dp16082
g2
S'To shed light on their roles of miR-211 in breast cancer, the expression of miR-211 was examined by real-time RT-PCR in breast cancer and normal tissues.\n'
p16083
sg4
(lp16084
sg20
(lp16085
(dp16086
g7
I43
sg23
VC0678222
p16087
sg10
I13
sg11
Vbreast cancer
p16088
sg13
I2
sa(dp16089
g7
I43
sg23
VC0678222
p16090
sg10
I13
sg11
Vbreast cancer
p16091
sg13
I2
sasa(dp16092
g2
S'MiR-211 is significantly downregulated in breast cancer.\n'
p16093
sg4
(lp16094
(dp16095
g7
I0
sg8
g15
sg10
I3
sg11
VMiR
p16096
sg13
I1
sasg20
(lp16097
(dp16098
g7
I42
sg23
VC0678222
p16099
sg10
I13
sg11
Vbreast cancer
p16100
sg13
I2
sasa(dp16101
g2
S'MiR-211 re-expression suppressed cell growth, cell cycle, migration, and invasion in triple-negative breast cancer (TNBC) cell line MDA-MB231.\n'
p16102
sg4
(lp16103
(dp16104
g7
I0
sg8
g15
sg10
I3
sg11
VMiR
p16105
sg13
I1
sasg20
(lp16106
(dp16107
g7
I101
sg23
VC0678222
p16108
sg10
I13
sg11
Vbreast cancer
p16109
sg13
I2
sa(dp16110
g7
I73
sg23
VC2699153
p16111
sg10
I8
sg11
Vinvasion
p16112
sg13
I1
sasa(dp16113
g2
S'The expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified.\n'
p16114
sg4
(lp16115
(dp16116
g7
I94
sg8
g15
sg10
I7
sg11
VmiR-92a
p16117
sg13
I1
sa(dp16118
g7
I124
sg8
g15
sg10
I7
sg11
VmiR-10b
p16119
sg13
I1
sa(dp16120
g7
I103
sg8
g15
sg10
I7
sg11
VmiR-205
p16121
sg13
I1
sa(dp16122
g7
I86
sg8
g15
sg10
I6
sg11
VmiR-21
p16123
sg13
I1
sa(dp16124
g7
I142
sg8
g15
sg10
I10
sg11
VmiR-146a/b
p16125
sg13
I1
sa(dp16126
g7
I58
sg8
g15
sg10
I7
sg11
VmiR-206
p16127
sg13
I1
sa(dp16128
g7
I188
sg8
g15
sg10
I6
sg11
VmiR-22
p16129
sg13
I1
sa(dp16130
g7
I75
sg8
g15
sg10
I9
sg11
VmiR-27a/b
p16131
sg13
I1
sa(dp16132
g7
I154
sg8
g15
sg10
I7
sg11
VmiR-335
p16133
sg13
I1
sa(dp16134
g7
I172
sg8
g15
sg10
I7
sg11
VmiR-211
p16135
sg13
I1
sa(dp16136
g7
I67
sg8
g15
sg10
I6
sg11
VmiR-31
p16137
sg13
I1
sa(dp16138
g7
I163
sg8
g15
sg10
I7
sg11
VmiR-204
p16139
sg13
I1
sa(dp16140
g7
I112
sg8
g15
sg10
I10
sg11
VmiR-125a/b
p16141
sg13
I1
sa(dp16142
g7
I209
sg8
g15
sg10
I6
sg11
VmiR-17
p16143
sg13
I1
sa(dp16144
g7
I133
sg8
g15
sg10
I7
sg11
VmiR-155
p16145
sg13
I1
sa(dp16146
g7
I196
sg8
g15
sg10
I7
sg11
VmiR-126
p16147
sg13
I1
sa(dp16148
g7
I181
sg8
g15
sg10
I5
sg11
VmiR-7
p16149
sg13
I1
sasg20
(lp16150
(dp16151
g7
I220
sg23
VC0678222
p16152
sg10
I13
sg11
Vbreast cancer
p16153
sg13
I2
sasa(dp16154
g2
S'Quantitative RT-PCR analysis confirmed that miR-135b, miR-192, miR-194 and miR-211 were significantly up-regulated in radiation-induced mammary cancer compared with spontaneous cancer and normal mammary tissue.\n'
p16155
sg4
(lp16156
(dp16157
g7
I54
sg8
g15
sg10
I7
sg11
VmiR-192
p16158
sg13
I1
sa(dp16159
g7
I44
sg8
g15
sg10
I8
sg11
VmiR-135b
p16160
sg13
I1
sasg20
(lp16161
(dp16162
g7
I144
sg23
VC0006826
p16163
sg10
I6
sg11
Vcancer
p16164
sg13
I1
sa(dp16165
g7
I144
sg23
VC0006826
p16166
sg10
I6
sg11
Vcancer
p16167
sg13
I1
sasa(dp16168
g2
S'The HBD/LD ratio in the measles patients two to three days after the onset of rash was significantly lower than that in control subjects (P less than 0.001).\n'
p16169
sg4
(lp16170
sg20
(lp16171
(dp16172
g7
I78
sg23
VC0015230
p16173
sg10
I4
sg11
Vrash
p16174
sg13
I1
sa(dp16175
g7
I24
sg23
VC0025007
p16176
sg10
I7
sg11
Vmeasles
p16177
sg13
I1
sa(dp16178
g7
I4
sg23
VC1840321
p16179
sg10
I3
sg11
VHBD
p16180
sg13
I1
sasa(dp16181
g2
S'UC treatment obviously reduced the expression levels of IL-2, IFN-Gamma, NF-KBp65, ICAM-1 and VEGF and increased inhibitory kappa B alpha (IKB-Alfa) expression in the grafts, where no obvious inflammatory cell infiltration or corneal neovascularization was found.\n'
p16182
sg4
(lp16183
(dp16184
g7
I56
sg8
VP60568
p16185
sg10
I4
sg11
VIL-2
p16186
sg13
I1
sa(dp16187
g7
I83
sg8
VP05362
p16188
sg10
I6
sg11
VICAM-1
p16189
sg13
I1
sa(dp16190
g7
I139
sg8
VP25963
p16191
sg10
I8
sg11
VIKB-Alfa
p16192
sg13
I1
sa(dp16193
g7
I62
sg8
VP01579
p16194
sg10
I9
sg11
VIFN-Gamma
p16195
sg13
I1
sasg20
(lp16196
(dp16197
g7
I192
sg23
VC0302158
p16198
sg10
I30
sg11
Vinflammatory cell infiltration
p16199
sg13
I3
sa(dp16200
g7
I226
sg23
VC0085109
p16201
sg10
I26
sg11
Vcorneal neovascularization
p16202
sg13
I2
sasa(dp16203
g2
S'In contrast, none of other patients with MFM had necklace CBs except for one patient with reducing body myopathy.\n'
p16204
sg4
(lp16205
sg20
(lp16206
(dp16207
g7
I104
sg23
VC0026848
p16208
sg10
I8
sg11
Vmyopathy
p16209
sg13
I1
sasa(dp16210
g2
S'Among the serums assessed, MMA levels showed a positive correlation to TNSr and KNPQ in the IPD patients with peripheral neuropathy (TNSr r = 0.882, p &lt; 0.001, KNPQ r = 0.710, p = 0.004), while Vitamin B12 and homocysteine showed no statistically significant correlation.\n'
p16211
sg4
(lp16212
sg20
(lp16213
(dp16214
g7
I27
sg23
VC0276096
p16215
sg10
I3
sg11
VMMA
p16216
sg13
I1
sa(dp16217
g7
I110
sg23
VC0031117
p16218
sg10
I21
sg11
Vperipheral neuropathy
p16219
sg13
I2
sasa(dp16220
g2
S"The serum MMA positively correlated with the severity of neuropathic pain and this can be used as a useful marker in assessment of peripheral neuropathy in Parkinson's disease.\n"
p16221
sg4
(lp16222
sg20
(lp16223
(dp16224
g7
I10
sg23
VC0276096
p16225
sg10
I3
sg11
VMMA
p16226
sg13
I1
sa(dp16227
g7
I131
sg23
VC0031117
p16228
sg10
I21
sg11
Vperipheral neuropathy
p16229
sg13
I2
sa(dp16230
g7
I57
sg23
VC0027796
p16231
sg10
I16
sg11
Vneuropathic pain
p16232
sg13
I2
sa(dp16233
g7
I156
sg23
VC0030567
p16234
sg10
I19
sg11
VParkinson's disease
p16235
sg13
I2
sasa(dp16236
g2
S'Functional vitamin B12 deficiency, defined by elevated levels of the B12-dependent metabolites, methylmalonic acid (MMA), and/or homocysteine, despite normal B12 values, may cause neuropathy and is associated with disorders linked to increased oxidative stress.\n'
p16237
sg4
(lp16238
sg20
(lp16239
(dp16240
g7
I244
sg23
VC0242606
p16241
sg10
I16
sg11
Voxidative stress
p16242
sg13
I2
sa(dp16243
g7
I11
sg23
VC0042847
p16244
sg10
I22
sg11
Vvitamin B12 deficiency
p16245
sg13
I3
sa(dp16246
g7
I116
sg23
VC0276096
p16247
sg10
I3
sg11
VMMA
p16248
sg13
I1
sa(dp16249
g7
I180
sg23
VC0442874
p16250
sg10
I10
sg11
Vneuropathy
p16251
sg13
I1
sa(dp16252
g7
I96
sg23
VC0276096
p16253
sg10
I18
sg11
Vmethylmalonic acid
p16254
sg13
I2
sasa(dp16255
g2
S'CDC6 and GDF-9 expressions in 108 gallbladder adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues were detected using immunohistochemistry (IHC).\n'
p16256
sg4
(lp16257
(dp16258
g7
I0
sg8
g15
sg10
I4
sg11
VCDC6
p16259
sg13
I1
sa(dp16260
g7
I9
sg8
VP09466
p16261
sg10
I5
sg11
VGDF-9
p16262
sg13
I1
sasg20
(lp16263
(dp16264
g7
I66
sg23
VC0262493
p16265
sg10
I18
sg11
Vgallbladder polyps
p16266
sg13
I2
sa(dp16267
g7
I46
sg23
VC0001418
p16268
sg10
I15
sg11
Vadenocarcinomas
p16269
sg13
I1
sa(dp16270
g7
I89
sg23
VC0085694
p16271
sg10
I21
sg11
Vchronic cholecystitis
p16272
sg13
I2
sasa(dp16273
g2
S'We demonstrated that positive CDC6 and GDF-9 expressions were significantly higher in adenocarcinomas than that in peritumoral tissues, polyps, and chronic cholecystitis (p &lt; 0.01).\n'
p16274
sg4
(lp16275
(dp16276
g7
I30
sg8
g15
sg10
I4
sg11
VCDC6
p16277
sg13
I1
sa(dp16278
g7
I39
sg8
VP09466
p16279
sg10
I5
sg11
VGDF-9
p16280
sg13
I1
sasg20
(lp16281
(dp16282
g7
I148
sg23
VC0085694
p16283
sg10
I21
sg11
Vchronic cholecystitis
p16284
sg13
I2
sa(dp16285
g7
I136
sg23
VC0032584
p16286
sg10
I6
sg11
Vpolyps
p16287
sg13
I1
sa(dp16288
g7
I86
sg23
VC0001418
p16289
sg10
I15
sg11
Vadenocarcinomas
p16290
sg13
I1
sasa(dp16291
g2
S'Previously, we identified MFAP4 as a serum biomarker candidate for hepatic fibrosis and cirrhosis in hepatitis C patients.\n'
p16292
sg4
(lp16293
(dp16294
g7
I26
sg8
VP55083
p16295
sg10
I5
sg11
VMFAP4
p16296
sg13
I1
sasg20
(lp16297
(dp16298
g7
I67
sg23
VC0239946
p16299
sg10
I16
sg11
Vhepatic fibrosis
p16300
sg13
I2
sa(dp16301
g7
I88
sg23
VC0023890
p16302
sg10
I9
sg11
Vcirrhosis
p16303
sg13
I1
sa(dp16304
g7
I101
sg23
VC0019196
p16305
sg10
I11
sg11
Vhepatitis C
p16306
sg13
I2
sasa(dp16307
g2
S'The aim of the present study was to elucidate the potential of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate (F0-F2) and severe fibrosis stages and cirrhosis (F3 and F4, Desmet-Scheuer scoring system).\n'
p16308
sg4
(lp16309
(dp16310
g7
I63
sg8
VP55083
p16311
sg10
I5
sg11
VMFAP4
p16312
sg13
I1
sasg20
(lp16313
(dp16314
g7
I196
sg23
VC0023890
p16315
sg10
I9
sg11
Vcirrhosis
p16316
sg13
I1
sa(dp16317
g7
I86
sg23
VC0239946
p16318
sg10
I16
sg11
Vhepatic fibrosis
p16319
sg13
I2
sa(dp16320
g7
I94
sg23
VC0016059
p16321
sg10
I8
sg11
Vfibrosis
p16322
sg13
I1
sasa(dp16323
g2
S'Linear and logistic multivariate regression analyses were performed and nonparametric receiver operating characteristic-curves for cirrhosis were used to estimate cut-off points for pMFAP4.\n'
p16324
sg4
(lp16325
sg20
(lp16326
(dp16327
g7
I131
sg23
VC0023890
p16328
sg10
I9
sg11
Vcirrhosis
p16329
sg13
I1
sasa(dp16330
g2
S'Microfibrillar-associated protein 4 (MFAP4) is a systemic biomarker that is significantly elevated in samples from patients suffering from hepatic cirrhosis.\n'
p16331
sg4
(lp16332
(dp16333
g7
I0
sg8
VP55083
p16334
sg10
I35
sg11
VMicrofibrillar-associated protein 4
p16335
sg13
I3
sa(dp16336
g7
I37
sg8
VP55083
p16337
sg10
I5
sg11
VMFAP4
p16338
sg13
I1
sasg20
(lp16339
(dp16340
g7
I124
sg23
VC0683278
p16341
sg10
I9
sg11
Vsuffering
p16342
sg13
I1
sa(dp16343
g7
I139
sg23
VC0023890
p16344
sg10
I17
sg11
Vhepatic cirrhosis
p16345
sg13
I2
sasa(dp16346
g2
S'Tropomyosin and MFAP-4 demonstrated high serum levels in patients with hepatic cirrhosis of different causes.\n'
p16347
sg4
(lp16348
(dp16349
g7
I0
sg8
VP07951
p16350
sg10
I11
sg11
VTropomyosin
p16351
sg13
I1
sasg20
(lp16352
(dp16353
g7
I71
sg23
VC0023890
p16354
sg10
I17
sg11
Vhepatic cirrhosis
p16355
sg13
I2
sasa(dp16356
g2
S'A quantitative analysis of MFAP-4 serum levels in a large number of patients showed MFAP-4 as novel candidate biomarker with high diagnostic accuracy for prediction of nondiseased liver versus cirrhosis [area under receiver operating characteristic curve (AUC) = 0.97, P &lt; 0.0001] as well as stage 0 versus stage 4 fibrosis (AUC = 0.84, P &lt; 0.0001), and stages 0 to 3 versus stage 4 fibrosis (AUC = 0.76, P &lt; 0.0001).\n'
p16357
sg4
(lp16358
sg20
(lp16359
(dp16360
g7
I318
sg23
VC0016059
p16361
sg10
I8
sg11
Vfibrosis
p16362
sg13
I1
sa(dp16363
g7
I318
sg23
VC0016059
p16364
sg10
I8
sg11
Vfibrosis
p16365
sg13
I1
sa(dp16366
g7
I193
sg23
VC0023890
p16367
sg10
I9
sg11
Vcirrhosis
p16368
sg13
I1
sasa(dp16369
g2
S'Low CRF had PARs of 9.3% and 10.5% for cancer mortality in subjects who had overweight and obesity, respectively.\n'
p16370
sg4
(lp16371
(dp16372
g7
I4
sg8
VP06850
p16373
sg10
I3
sg11
VCRF
p16374
sg13
I1
sasg20
(lp16375
(dp16376
g7
I4
sg23
VC0022661
p16377
sg10
I3
sg11
VCRF
p16378
sg13
I1
sa(dp16379
g7
I39
sg23
VC0006826
p16380
sg10
I6
sg11
Vcancer
p16381
sg13
I1
sa(dp16382
g7
I76
sg23
VC1561826
p16383
sg10
I22
sg11
Voverweight and obesity
p16384
sg13
I3
sasa(dp16385
g2
S'The population attributable risks (PARs) were 0.41, 0.40 and 0.38 for total, CVD and cancer mortality, accordingly.\n'
p16386
sg4
(lp16387
sg20
(lp16388
(dp16389
g7
I85
sg23
VC0006826
p16390
sg10
I6
sg11
Vcancer
p16391
sg13
I1
sa(dp16392
g7
I77
sg23
VC0007222
p16393
sg10
I3
sg11
VCVD
p16394
sg13
I1
sasa(dp16395
g2
S'Mean EARs for lung cancer were 17.5 cases per 10,000 persons per year (PY) and 10.1 PY.\n'
p16396
sg4
(lp16397
sg20
(lp16398
(dp16399
g7
I14
sg23
VC0684249
p16400
sg10
I11
sg11
Vlung cancer
p16401
sg13
I2
sasa(dp16402
g2
S'Mean EARs for breast cancer were 8.2 PY and 2.8 PY.\n'
p16403
sg4
(lp16404
sg20
(lp16405
(dp16406
g7
I14
sg23
VC0678222
p16407
sg10
I13
sg11
Vbreast cancer
p16408
sg13
I2
sasa(dp16409
g2
S'In addition, through activation of G-protein-coupled protease activated receptors (PARs) TF induces cell signaling that is related to cancer, angiogenesis and inflammation.\n'
p16410
sg4
(lp16411
(dp16412
g7
I83
sg8
g15
sg10
I4
sg11
VPARs
p16413
sg13
I1
sa(dp16414
g7
I35
sg8
VP63123
p16415
sg10
I46
sg11
VG-protein-coupled protease activated receptors
p16416
sg13
I4
sasg20
(lp16417
(dp16418
g7
I134
sg23
VC0006826
p16419
sg10
I6
sg11
Vcancer
p16420
sg13
I1
sa(dp16421
g7
I159
sg23
VC0021368
p16422
sg10
I12
sg11
Vinflammation
p16423
sg13
I1
sasa(dp16424
g2
S'PARs are implicated in a wide range of diseases, such as cancer and inflammation.\n'
p16425
sg4
(lp16426
(dp16427
g7
I0
sg8
g15
sg10
I4
sg11
VPARs
p16428
sg13
I1
sasg20
(lp16429
(dp16430
g7
I57
sg23
VC0006826
p16431
sg10
I6
sg11
Vcancer
p16432
sg13
I1
sa(dp16433
g7
I68
sg23
VC0021368
p16434
sg10
I12
sg11
Vinflammation
p16435
sg13
I1
sasa(dp16436
g2
S'Thrombin-induced activation of protease-activated receptors (PARs) represents a link between inflammation and cancer.\n'
p16437
sg4
(lp16438
(dp16439
g7
I61
sg8
g15
sg10
I4
sg11
VPARs
p16440
sg13
I1
sa(dp16441
g7
I31
sg8
VP63123
p16442
sg10
I28
sg11
Vprotease-activated receptors
p16443
sg13
I2
sa(dp16444
g7
I0
sg8
VP00734
p16445
sg10
I8
sg11
VThrombin
p16446
sg13
I1
sasg20
(lp16447
(dp16448
g7
I93
sg23
VC0021368
p16449
sg10
I12
sg11
Vinflammation
p16450
sg13
I1
sa(dp16451
g7
I110
sg23
VC0006826
p16452
sg10
I6
sg11
Vcancer
p16453
sg13
I1
sasa(dp16454
g2
S'Frozen tunica vaginalis specimens from patients with adult-onset primary hydrocele testis and control male nonhydrocele patients were subjected to Western blot analysis for the detection of AQP1 and AQP3 proteins.\n'
p16455
sg4
(lp16456
(dp16457
g7
I190
sg8
VP29972
p16458
sg10
I4
sg11
VAQP1
p16459
sg13
I1
sa(dp16460
g7
I199
sg8
g15
sg10
I13
sg11
VAQP3 proteins
p16461
sg13
I2
sasg20
(lp16462
(dp16463
g7
I73
sg23
VC1720771
p16464
sg10
I16
sg11
Vhydrocele testis
p16465
sg13
I2
sa(dp16466
g7
I14
sg23
VC0750103
p16467
sg10
I9
sg11
Vvaginalis
p16468
sg13
I1
sasa(dp16469
g2
S'AQP1 protein expression in the tunica vaginalis was significantly higher in patients with adult-onset hydrocele testis than in the controls.\n'
p16470
sg4
(lp16471
(dp16472
g7
I0
sg8
VP29972
p16473
sg10
I4
sg11
VAQP1
p16474
sg13
I1
sasg20
(lp16475
(dp16476
g7
I38
sg23
VC0750103
p16477
sg10
I9
sg11
Vvaginalis
p16478
sg13
I1
sa(dp16479
g7
I102
sg23
VC1720771
p16480
sg10
I16
sg11
Vhydrocele testis
p16481
sg13
I2
sasa(dp16482
g2
S'The densities of AQP1-expressing capillaries and lymphatic vessels were similar between the tunica vaginalis of the controls and those of hydrocele patients.\n'
p16483
sg4
(lp16484
(dp16485
g7
I17
sg8
VP29972
p16486
sg10
I4
sg11
VAQP1
p16487
sg13
I1
sasg20
(lp16488
(dp16489
g7
I99
sg23
VC0750103
p16490
sg10
I9
sg11
Vvaginalis
p16491
sg13
I1
sa(dp16492
g7
I138
sg23
VC1720771
p16493
sg10
I9
sg11
Vhydrocele
p16494
sg13
I1
sasa(dp16495
g2
S'In conclusion, overexpression of the AQP1 protein in individual capillary endothelial cells of the tunica vaginalis may contribute to the development of adult-onset primary noncommunicating hydrocele testis as another aquaporin-related disease.\n'
p16496
sg4
(lp16497
(dp16498
g7
I218
sg8
VP30301
p16499
sg10
I9
sg11
Vaquaporin
p16500
sg13
I1
sa(dp16501
g7
I37
sg8
VP29972
p16502
sg10
I12
sg11
VAQP1 protein
p16503
sg13
I2
sasg20
(lp16504
(dp16505
g7
I190
sg23
VC1720771
p16506
sg10
I16
sg11
Vhydrocele testis
p16507
sg13
I2
sa(dp16508
g7
I106
sg23
VC0750103
p16509
sg10
I9
sg11
Vvaginalis
p16510
sg13
I1
sasa(dp16511
g2
S'There are very few reports in the published literature of abdominal aortic aneurysm in patient with situs inversus totalis, all of whom underwent open aneurysm repair.\n'
p16512
sg4
(lp16513
sg20
(lp16514
(dp16515
g7
I100
sg23
VC0037221
p16516
sg10
I14
sg11
Vsitus inversus
p16517
sg13
I2
sa(dp16518
g7
I58
sg23
VC0162871
p16519
sg10
I25
sg11
Vabdominal aortic aneurysm
p16520
sg13
I3
sa(dp16521
g7
I75
sg23
VC0002940
p16522
sg10
I8
sg11
Vaneurysm
p16523
sg13
I1
sasa(dp16524
g2
S'The authors describe a case of successfully repaired abdominal aortic aneurysm with a false aneurysm of the right external iliac artery in situs inversus totalis.\n'
p16525
sg4
(lp16526
sg20
(lp16527
(dp16528
g7
I139
sg23
VC0037221
p16529
sg10
I14
sg11
Vsitus inversus
p16530
sg13
I2
sa(dp16531
g7
I53
sg23
VC0162871
p16532
sg10
I25
sg11
Vabdominal aortic aneurysm
p16533
sg13
I3
sa(dp16534
g7
I86
sg23
VC1510412
p16535
sg10
I14
sg11
Vfalse aneurysm
p16536
sg13
I2
sasa(dp16537
g2
S'The surgical management of patients with abdominal aortic aneurysm in situs inversus totalis is discussed.\n'
p16538
sg4
(lp16539
sg20
(lp16540
(dp16541
g7
I41
sg23
VC0162871
p16542
sg10
I25
sg11
Vabdominal aortic aneurysm
p16543
sg13
I3
sa(dp16544
g7
I70
sg23
VC0037221
p16545
sg10
I14
sg11
Vsitus inversus
p16546
sg13
I2
sasa(dp16547
g2
S'Collectively, the MLN CD11b- CD103+ PD-L1High DC subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-Beta activation.\n'
p16548
sg4
(lp16549
(dp16550
g7
I121
sg8
VP12872
p16551
sg10
I4
sg11
VMLNs
p16552
sg13
I1
sa(dp16553
g7
I18
sg8
VP12872
p16554
sg10
I27
sg11
VMLN CD11b- CD103+ PD-L1High
p16555
sg13
I4
sa(dp16556
g7
I173
sg8
VP18075
p16557
sg10
I8
sg11
VTGF-Beta
p16558
sg13
I1
sasg20
(lp16559
(dp16560
g7
I121
sg23
VC0026691
p16561
sg10
I4
sg11
VMLNs
p16562
sg13
I1
sasa.